ASCO 2024
5890 abstracts
Abstract
First-line treatment of fecal microbiota transplantation for immune-mediated colitis.Org: University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center,
Abstract
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.Org: Netherlands Cancer Institute (NKI-AVL), The Netherlands Cancer Institute, Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals,
Abstract
Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).Org: University of Bielefeld, Medical University of Graz, Department of Radiation Oncology, University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany,
Abstract
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD,
Abstract
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.Org: AstraZeneca, Winship Cancer Institute, Department of Thoracic Oncology, Kanagawa Cancer Center, Kanagawa Cancer Center, Cancer Center Clínica Universidad de Navarra, Madrid, Spain,
Abstract
ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).Org: Sarah Cannon Research Institute/Tennessee Oncology, Jilin Cancer Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Federal State Budgetary Institution “N. N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Beijing Cancer Hospital,
Abstract
First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses.Org: Roche Products Ltd., Genentech, Roche Products Limited, German Breast Group, Centre for Haematology and Oncology Bethanien,
Abstract
Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.Org: Dana-Farber Cancer Institute, University of Wisconsin, University of California Irvine, University of Colorado Denver Department of Radiation Oncology, Perlmutter Cancer Center, NYU Langone Health,
Abstract
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.Org: Institut Català D'Oncologia, IDIBELL, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Abstract
Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).Org: Kanagawa Cancer Center, Fukushima Medical University, School of Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), National Cancer Center Hospital East, Kashiwa, Japan, Department of Breast Surgery, Shizuoka General Hospital,
Abstract
Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.Org: SOLTI Cancer Research Group, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Vall d’Hebron Institute of Oncology,
Abstract
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Org: Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
Impact of hormone receptor status and tumor subtypes on clinical behavior and outcomes of breast cancer in young BRCA carriers.Org: Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, Genoa, Italy, Academic Trials Promoting Team, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium, U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy, Department of Medical Oncology, Universite Paris Cité, Institut Curie, Paris, France, Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).Org: Winship Cancer Institute, Emory University, Atlanta, GA, USA, Cancer Research and Biostatistics, University of Kansas Medical Center, ASCO,
Abstract
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.Org: Yale Cancer Center, Yale School of Medicine, Emory University School of Medicine, Nashville Breast Center, Dallas Surgical Group,
Abstract
Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.Org: Exact Sciences Corporation, CRAB, Rabin Medical Center, Public Health Sciences Division, Department of Breast Medical Oncology,
Abstract
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).Org: University of Milan and European Institute of Oncology, IRCCS, Fudan University Shanghai Cancer Center, Division of Medical Oncology, National Cancer Centre of Singapore, National Cancer Center Hospital East, Kashiwa, Japan, Latin American Cooperative Oncology Group (LACOG),
Abstract
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.Org: Winship Cancer Institute of Emory University, IRCCS Ospedale San Raffaele, Sarah Cannon Research Institute/Tennessee Oncology, Lifespan Cancer Institute, Legorreta Cancer Center at Brown University,
Abstract
Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul National University Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Department of Hematology-Oncology,
Abstract
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.Org: Dana-Farber Cancer Institute, University of Chicago Medicine, UNC Lineberger Comprehensive Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Emory University Hospital,
Abstract
A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.Org: Department of Surgery Oncology and Gastroenterology, University of Padua, Padova, MO, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV, Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy, Azienda Unità Sanitaria Locale-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Reggio Emilia, Italy, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom,
Abstract
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.Org: University of California, San Diego Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Winship Cancer Institute of Emory University,
Abstract
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.Org: Yonsei University College of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Gangnam Severance Hospital, Seoul St. Mary's Hospital,
Abstract
ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Malden, MA,
Abstract
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).Org: Peter MacCallum Cancer Centre, Melbourne, Australia, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, UT Southwestern Simmons Comprehensive Cancer Center, Lifespan Cancer Institute, Legorreta Cancer Center at Brown University,
Abstract
Shareable artificial intelligence to extract cancer outcomes from electronic health records.Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Dana-Farber Cancer Institute, Boston, MA, USA, Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY, Dana-Farber Cancer Institute, Boston, MA, Dana-Farber Cancer Institute,
Abstract
Efficacy of eSyM: Acute care utilization among patients with cancer who do versus do not report ePROs.Org: Dana-Farber Cancer Institute, MaineHealth Cancer Care, Lifespan Cancer Institute, WVU Cancer Institute, Baptist Cancer Center,
Abstract
An AI-assisted navigation approach for patients with radiographic suspicion of new pancreas cancer.Org: Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health Cancer Institute, Cold Spring Harbor Laboratory, Division of Surgery, Northwell Health Cancer Institute,
Abstract
Prescription drug monitoring program mandates and opioid prescriptions received by patients dying of cancer.Org: Weill Cornell Medicine, University of Alabama at Birmingham, Albert Einstein College of Medicine, The University of Texas MD Anderson Cancer Center, Harvard Pilgrim Health Care Institute,
Abstract
Payor denial after prior authorization request for long-acting pain medication: Provider and patient perspectives.Org: Memorial Sloan Kettering Cancer Center, University of Rochester, The University of North Carolina at Chapel Hill, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center,
Abstract
High deductible health plans and survival among cancer survivors.Org: Department of Radiation Oncology, Washington University School of Medicine in St. Louis, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Costs of Care, Boston, University of Minnesota Masonic Cancer Center, University of California, San Francisco,
Abstract
Implementing financial toxicity and health-related social risks screening and referral.Org: School of Social Work, The University of North Carolina at Chapel Hill, Chapel Hill, NC, NYU Langone Health, Mineola, NY,
Abstract
Early integrated rehabilitation and vocational rehabilitation in 435 patients with breast cancer: A comparison between the intervention group and control group in a prospective study.Org: Institute of Oncology Ljubljana, Community Health Centre Vrhnika, Community Health Centre Ljubljana, Faculty of Sport, University Medical Center Ljubljana,
Abstract
State mandatory paid medical leave policies and cancer stage at diagnosis in US adults.Org: Saint Louis University School of Medicine, Washington University School of Medicine in St. Louis, Memorial Sloan Kettering Cancer Center, American Cancer Society, Washington University School of Medicine,
Abstract
National implementation of an AI-based virtual dietitian for patients with cancer.Org: Savor Health LLC., Perelman School of Medicine, The University of North Carolina at Chapel Hill,
Abstract
Ensuring precision medicine for veterans with lung cancer: A randomized clinical trial.Org: Morehouse School of Medicine, Atlanta, GA, Stanford University School of Medicine, Stanford, CA, Medical Services,
Abstract
Geriatric assessment in older patients with non-small cell lung cancer: Insights from a cluster-randomized, phase III trial—ENSURE-GA study (NEJ041/CS-Lung001).Org: St. Marianna University School of Medicine, Kagawa University Faculty of Medicine, Teine Keijinnkai Hospital, NHO Hamada Medical Center, Tokyo Metropolitan Institute for Geriatrics and Gerontology,
Abstract
Acute care and overall survival results of a randomized trial of a virtual health intervention during routine cancer treatment.Org: Memorial Sloan Kettering Cancer Center, University of Washington School of Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA,
Abstract
A randomized study comparing electronic patient-reported outcome (ePRO) monitoring with routine follow-up during trastuzumab deruxtecan treatment in patients with metastatic breast cancer (PRO-DUCE study).Org: Department of Breast Surgery, Kansai Medical University Hospital, Osaka, Japan, Center for Clinical Science, National Center for Global Health and Medicine, Tokyo, Japan, Department of Oncology, Sagara Hospital, Kagoshima, Japan, Department of Medical Oncology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan, Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan,
Abstract
Evaluation of a complex survivorship intervention incorporating electronic patient-reported outcomes in early stage breast and gynecologic cancer: Results from the Linking You to Support and Advice (LYSA) randomized controlled trial.Org: Cancer Research @UCC, CUH/UCC Cancer Centre, CUH/UCC Cancer Centre & Cancer Trials Ireland, Cork University Hospital Group, Cancer Trials Ireland,
Abstract
The impact of self-reported social determinants of health (SDOH) on patient engagement and symptom burden across a remote patient monitoring (RPM) pathway in 42 European hospitals.Org: Cancer Survivorship Program, INSERM 981, Gustave Roussy, Villejuif, France, INSERM Unit 981, Gustave Roussy Cancer Center, Villejuif, France, Patient Pathway Division,
Abstract
Associations of social determinants of health with avoidance of information, treatment receipt, and physician mistrust for women with breast cancer.Org: Dana-Farber Brigham Cancer Center, Dana-Farber Cancer Institute, Boston Medical Center, Boston University, Survey and Data Management Core,
Abstract
Social vulnerability and clinical trial enrollment: The next frontier of health equity.Org: Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Vizient Clinical Database Inc, New Brunswick, NJ, Irving,
Abstract
N2M2/NOA-20: Phase I/IIa umbrella trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.Org: University of Heidelberg, NCT Heidelberg, Heidelberg University Hospital, Department of Neurology and Hematology-Oncology, Department of Neuroradiology,
Abstract
Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Alliance Statistics and Data Management Center, Mayo Clinic Rochester,
Abstract
Niraparib efficacy in patients with newly-diagnosed glioblastoma: Clinical readout of a phase 0/2 "trigger" trial.Org: Ivy Brain Tumor Center at Barrow Neurological Institute, Ivy Brain Tumor Center,
Abstract
Efficacy and safety of the vebreltinib in patients with previously treated, secondary glioblastoma/IDH mutant glioblastoma with PTPRZ1-METFUsion GENe (FUGEN): A randomised, multicentre, open-label, phase II/III trial.Org: Beijing Neurosurgical Institute, Capital Medical University, Department of Neurosurgery, Prince of Wales Hospital, Beijing Tiantan Hospital, The First Affiliated Hospital of Zhengzhou University,
Abstract
Survival outcomes associated with first-line PCV or temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma.Org: Paris Brain Institute (ICM), Service de Neurologie 2 Mazarin, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, AP-HP, Sorbonne Université, Lyon HCL,
Abstract
Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.Org: Berry Consultants, LLC, Global Coalition for Adaptive Research, Hunstman Cancer Institute at the University of Utah, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA,
Abstract
A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL).Org: Dana-Farber Cancer Institute, DFCI/PCC Fellowship Program - Attendings, Massachusetts General Hospital, Kite Pharma, Division of Neuroradiology,
Abstract
High-dose almonertinib in treatment-naïve EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis.Org: Zhejiang Cancer Hospital, Hangzhou Yirui Pharmaceutical Technology, China National Biotec Group, Zhejiang Hospital, Department of Thoracic Medical Oncology,
Abstract
Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases.Org: Miami Cancer Institute, Baptist Health South Florida, Northwestern Medicine Cancer Center Warrenville, Northwestern Medicine Proton Center, CHUM,
Abstract
Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial.Org: Memorial Sloan Kettering Cancer Center, Royal Marsden NHS Foundation Trust, The Christie NHS Foundation Trust and University of Manchester, University of Pittsburgh Medical Center (UPMC), Duke Cancer Institute,
Abstract
Claudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial.Org: Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Beijing Cancer Hospital, Beijing, China, Department of Gastrointestinal Oncology, Beijing Cancer Hospital, Beijing, China, Peking University Cancer Hospital and Institute, Beijing, China,
Abstract
A potential best-in-class BCMA-CD19 bispecific CART with advanced safety by self-inhibiting IFNG signaling during CRS.Org: Celledit, The Third Affiliated Hospital of Southern Medical University, The First Affiliated Hospital of University of Science and Technology of China, The Second Xiangya Hospital of Central South University,
Abstract
A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.Org: Memorial Sloan Kettering Cancer Center, Division of Gynecologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, University of Cincinnati Cancer Center, START Midwest, Grand Rapids, MI,
Abstract
First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma.Org: Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Medical Oncology Department, Hospital Universitario 12 De Octubre, Hospital Clinic of Barcelona, Hospital Clinic i Provincial de Barcelona,
Abstract
Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.Org: EpicentRx, Clinical Trials Innovations, Cleveland Clinic Lerner College of Medicine,
Abstract
Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.Org: Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, University of Chicago, Chicago, IL, Department of Medicine, Division of Hematology and Oncology, The Medical College of Wisconsin, Milwaukee, WI, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Mary Crowley Cancer Research, Dallas, TX, AdventHealth Cancer Institute, Orlando, FL, Sarah Cannon Research Institute, Nashville, TN, St. Jude Crosson Cancer Institute/Providence Medical Foundation, Fullerton, CA, Fort Wayne Medical Oncology - West Jefferson Office, Fort Wayne, IN, Scholar Rock Inc., Cambridge, MA, Scholar Rock, Cambridge, MA, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Michigan, University of Chicago, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Division of Hematology and Oncology,
Abstract
First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC).Org: Merck Santé S.A.S., Merck Specialities Pvt. Ltd., Merck Institute of Pharmacometrics, The Healthcare Business of Merck KGaA, Next Oncology Virginia and Virginia Cancer Specialists,
Abstract
First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.Org: START Midwest, Grand Rapids, MI, Memorial Sloan Kettering Cancer Center, University Hospitals Seidman Cancer Center and Case Western Reserve University, Yale School of Medicine, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.Org: Memorial Sloan Kettering Cancer Center, Fudan University Shanghai Cancer Center, University of California Irvine, the First Affiliated Hospital, Zhejiang, University School of Medicine, Shanghai Medical College, Fudan University,
Abstract
Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).Org: King's College London, Imperial College, University College London Cancer Institute, University College London Hospital NHS Trust and Great Ormond Street Hospital, Kinghorn Cancer Centre,
Abstract
First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.Org: KSQ Therapeutics, Cambridge, MA, Roche Pharma Research and Early Development, Roche Innovation Center, Dana-Farber Cancer Institute, Hackensack University Medical Center,
Abstract
A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.Org: National Cancer Center Hospital East, Chiba, Japan, Samsung Medical Center, Seoul, seoul, South Korea, NEXT Oncology, San Antonio, TX, National Cancer Center Hospital, Tokyo, Japan, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.Org: Massachusetts General Hospital, Department of Experimental Therapeutics, National Cancer Center Hospital East, National Cancer Center Hospital East, Kashiwa, Japan, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Memorial Sloan Kettering Cancer Center,
Abstract
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.Org: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Second Department of Thoracic Tumors, Peking University Cancer Hospital, Department of Medical Oncology, Harbin Medical University Cancer Hospital, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology,
Abstract
Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: A prospective multicentric randomized trial (TRANSMET).Org: Assistance Publique - Hôpitaux de Paris (APHP), University Paris-Saclay, Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy, Service de Chirurgie HPB Transplantation, Hopital Haut Leveque,
Abstract
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW.Org: Bristol Myers Squibb, Cancer Research SA, Fondazione Policlinico Universitario A. Gemelli IRCCS, Institut Paoli-Calmettes, Marseille, France, Instituto Catalán de Oncología,
Abstract
Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study.Org: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, West China Hospital, Sichuan University,
Abstract
FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses.Org: Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Klinik Dr. Hancken GmbH,
Abstract
Acquired gene alteration patterns and post-progression survival: PARADIGM study analysis.Org: National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, Disaster Medical Center, Tokyo, Japan, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).Org: David Geffen School of Medicine at UCLA, University of California, Los Angeles, Seoul National University Hospital, Korea University Anam Hospital, Korea University College of Medicine,
Abstract
Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial.Org: Amsterdam UMC location VUMC, Amsterdam UMC, location Vrije Universiteit, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Medisch centrum Leeuwarden,
Abstract
Primary outcome analysis of the ORCHESTRA trial: A randomized phase III trial of additional tumor debulking to first-line palliative systemic therapy for patients with multiorgan metastatic colorectal cancer.Org: Radboud UMC, Erasmus Medical Center, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Amsterdam UMC location VUMC, Erasmus MC Cancer Institute,
Abstract
NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.Org: University College Hospital-London, NHS Foundation Trust, University College London Cancer Institute, The Christie NHS Foundation Trust, University of Leeds,
Abstract
A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174).Org: University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, Dana-Farber Cancer Institute, Boston, MA,
Abstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA).Org: Rush University Medical Center, NRG Oncology SDMC/ACR, Mount Sinai Medical Center, University of Maryland, Baltimore, MD, Brown University School of Medicine-Rhode Island Hospital,
Abstract
Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): Results from a randomized phase II trial.Org: University College London Cancer Institute, Cholangiocarcinoma Foundation, University of Manchester and The Christie NHS Foundation Trust, Hammersmith Hospital, Imperial College London,
Abstract
International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).Org: Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Los Angeles, CA, Seoul National University Hospital, Seoul, South Korea,
Abstract
Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575/RENAISSANCE phase III trial.Org: Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Frankfurter Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Third Department of Internal Medicine, Klinikum Rechts der Isar,
Abstract
Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.Org: Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Veneto Institute of Oncology IOV–IRCCS, Azienda Ospedaliero Universitaria Santa Maria della Misericordia, Ospedale Santa Maria delle Croci,
Abstract
Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.Org: Department of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada, Department of Medical Oncology, The Sidney Kimmel Cancer Center at Johns Hopkins, Cancer Convergence Institute, Bloomberg-Kimmel Institute, Baltimore, MD, Ontario Institute for Cancer Research, Toronto, ON, Canada, Northwell Health Cancer Institute, Lake Success, NY, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD,
Abstract
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.Org: University Medical Center Mainz, University Grenoble Alpes, CHU Grenoble Alpes, Institute for Advanced Biosciences, Kindai University Faculty of Medicine, Osaka-Sayama, Japan,
Abstract
Effects of immune-enhancing nutrition on radical cystectomy outcomes: Primary results from the randomized phase III double-blind clinical trial (S1600).Org: University of Kansas Medical Center, Kansas City, KS, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center, Seattle, WA,
Abstract
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).Org: Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Université Paris-Sud, Université Paris-Saclay, Netherlands Cancer Institute,
Abstract
Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.Org: Pfizer Inc., Fred Hutchinson Cancer Center, Barts Cancer Institute, University of Colorado Anschutz Medical Campus, Gustave Roussy Cancer Center,
Abstract
Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.Org: Memorial Sloan Kettering Cancer Center, University of Bari "A. Moro" and Policlinico Consorziale, Kyushu University, Texas Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea,
Abstract
Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).Org: Merck & Co., Inc., Rahway, NJ, MSD UK, London, United Kingdom, Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, London, United Kingdom, Vanderbilt-Ingram Cancer Center,
Abstract
Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.Org: Gustave Roussy Cancer Center, Université Paris Saclay, Paris, France, Royal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science,
Abstract
Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC).Org: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Georgetown-Lombardi Comprehensive Cancer Center, Bristol Myers Squibb, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center,
Abstract
Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.Org: Euromed service, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, The University of Texas MD Anderson Cancer Center, British Columbia Cancer Agency, Asan Medical Center,
Abstract
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Barts Cancer Institute,
Abstract
CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer.Org: Massachusetts General Hospital Cancer Center and Harvard Medical School, Institut Català d’Oncologia–Bellvitge Institute for Biomedical Research, Studienpraxis Urologie, Asan Medical Center, Hospital Universitario Gregorio Marañón,
Abstract
Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore).Org: Memorial Sloan Kettering Cancer Center, Carolina Urologic Research Center and GenesisCare US, British Columbia Cancer Agency (BCCA), Veterans Prostate Cancer Awareness, Novartis Pharmaceuticals Corporation,
Abstract
EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL).Org: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy, Department of Urology and Research Program in Systems Oncology, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland, Instituto Valenciano de Oncologia, Valencia, Spain, Astellas Pharma Inc., Northbrook, IL, Pfizer Inc., New York, NY,
Abstract
Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.Org: University of Kansas Medical Center, Mayo Clinic, Mayo Clinic Cancer Center, Washington University in St. Louis, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute,
Abstract
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).Org: Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Duke University Medical Center, Duke University Department of Biostatistics and Bioinformatics,
Abstract
Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore.Org: Memorial Sloan Kettering Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, Institut Gustave Roussy, University Hospital Essen,
Abstract
Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).Org: University of Wisconsin Carbone Cancer Center, Madison, WI, Dana-Farber Cancer Institute, Boston, MA, University of Wisconsin,
Abstract
A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.Org: Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Princess Margaret Cancer Center, Toronto, ON, Canada, Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal, QC, Canada, University of Western Ontario, London, ON, Canada, Manitoba Prostate Cancer, University of Manitoba, Winnipeg, MB, Canada, CancerCare Manitoba, Winnipeg, MB, Canada, McGill University Health Center, Montreal, QC, Canada, Department of Urology, Dalhousie University, Halifax, NS, Canada, Queen's University, Kingston, ON, Canada, St. Josephs Healthcare, McMaster University, Hamilton, ON, Canada, Northern Alberta Urology Clinic, Edmonton, AB, Canada, Princess Margaret Cancer Centre, Toronto, ON, Canada, Princess Margaret Cancer Centre - University Health Network, Toronto, ON, Canada, University Health Network, Toronto, ON, Canada, Ottawa Hospital, Ottawa, ON, Canada, CIUSSS de l'Estrie – CHUS (Hôpital Fleurimont), Sherbrooke, QC, Canada, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, St. Vincent's Hospital Sydney, Sydney, NSW, Australia, Princess Margaret Cancer Centre, University Health Network, Toronto Allergy and Asthma Centre, Oncotelic,
Abstract
MANCAN2: A multicentre randomised controlled trial of self-help cognitive behavioural therapy (CBT) to manage hot flush and night sweats (HFNS) symptoms in patients with prostate cancer receiving androgen deprivation therapy (ADT).Org: Southampton Clinical Trials Unit, University of Southampton, University Hospital Southampton NHS Foundation Trust, Turning Point Therapeutics, Guys and St Thomas NHS Foundation Trust,
Abstract
Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.Org: Bradford Hill Clinical Research Center, Erasmus MC Cancer Institute, Centre Georges-François Leclerc, Dijon, France, Arturo Lopez Perez Foundation Oncology Institute, Institut régional du Cancer de Montpellier (ICM),
Abstract
Trends in phase 3 gynecological clinical trials of targeted therapies: Study oversight and pharmaceutical involvement in the past 12 years.Org: California Pacific Medical Center Research Institute, San Francisco, CA, Stanford University Medical Center, Palo Alto Medical Foundation,
Abstract
Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/GOG-0724.Org: The University of Texas MD Anderson Cancer Center, The The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.Org: Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Auckland City Hospital and University of Auckland, Auckland, New Zealand,
Abstract
Endometrial cancer and obesity trends in the United States in the 21st century.Org: UC Irvine Health, Pingtung Veterans General Hospital, University of California, Irvine Medical Center, California Pacific Medical Center Research Institute, San Francisco, CA, Stanford University Medical Center,
Abstract
Long-term survival outcomes for hormonal therapy in premenopausal patients with clinical stage I endometrial cancer.Org: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY, Duke University Trent Center for Bioethics Humanities and History of Medicine, Durham, NC, Icahn School of Medicine at Mount Sinai, New York, NY, Columbia University Mailman School of Public Health, New York, NY, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Massachusetts General Hospital, Boston, MA,
Abstract
Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.Org: Lifespan Cancer Institute, Rhode Island Hospital, Providence, RI, Women and Infants Hospital of Rhode Island, University of Illinois at Chicago,
Abstract
Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.Org: GEICO, Arcagy-Gineco, NSGO-CTU, SAKK, BGOG,
Abstract
Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial.Org: Nantes Université, CRCI2NA, UMR 1307 Inserm-UMR 6075 CNRS, Breast, Gynecology and Reconstructive Surgery Unit, Institut Curie, University Hospitals Leuven, Leuven Cancer Institute, and BGOG,
Abstract
Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.Org: Sun Yat-sen University Cancer Center, Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, Department of Oncology, National Taiwan University Hospital, Affiliated Hospital of Guizhou Medical University,
Abstract
Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial.Org: Department of Radiation Oncology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China, Department of Oncology, the Affiliated Hospital of North Sichuan Medical College, Nanchong, China, Department of Oncology, Wuzhou Red Cross Hospital, Wuzhou, China, Department of Radiation Oncology, Hainan General Hospital, Haikou, China, Department of Oncology, Liuzhou People's Hospital, Liuzhou, China,
Abstract
Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).Org: Gustave Roussy Cancer Center, The Institute of Cancer Research/The Royal Marsden Hospital, City of Hope Comprehensive Cancer Center Department of Medical Oncology and Therapeutics Research, ISA Pharmaceuticals B.V., Regeneron Pharmaceuticals, Inc.,
Abstract
A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).Org: H. Lee Moffitt Cancer Center and Research Institute, Washington University School of Medicine, University of Washington School of Medicine, Massachusetts General Hospital, Harvard Medical School, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center,
Abstract
HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results.Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, University of Kansas Medical Center, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Cleveland Clinic Lerner College of Medicine,
Abstract
Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC).Org: The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Baylor College of Medicine, Mayo Hosp, Memorial Sloan Kettering Cancer Center,
Abstract
Intra-treatment hypoxia directed major radiation de-escalation as definitive treatment for human papillomavirus-related oropharyngeal cancer.Org: Memorial Sloan Kettering Cancer Center, New York, NY, Miami Cancer Institute, Miami, FL, Hartford Health Care,
Abstract
A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.Org: Department of Medicine, University of Chicago, Johns Hopkins Medicine, University of Pennsylvania, Emory University Winship Cancer Institute, Hollings Cancer Center,
Abstract
Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.Org: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer,
Abstract
Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.Org: Versiti Blood Research Institute, Division of Hematology and Oncology, Medical College of Wisconsin, Imperial College London, Royal North Shore Hospital, Singapore General Hospital, Duke-NUS Medical School,
Abstract
Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.Org: Memorial Sloan Kettering Cancer Center, Medical University of Silesia, Hematology Ward, S. Eugenio Hospital, The University of Texas MD Anderson Cancer Center,
Abstract
Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.Org: City of Hope National Medical Center, CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center,
Abstract
Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study.Org: Autolus Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, The David and Etta Jonas Center for Cellular Therapy, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute,
Abstract
Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.Org: Institute of Hematology and Blood Disease Hospital, CAMS & PUMC, Tianjin, China, Henan Cancer Hospital, Zhengzhou, China, The Second Hospital of HeBei Medical University, Shijiazhuang, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Institute of Hematology and Oncology, Harbin the First Hospital, Harbin, China,
Abstract
Frailty risk assessment and impact on acute myeloid leukemia outcomes (FRAIL-AML): A population-based study from Ontario, Canada.Org: Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, ICES, North York, ON, Canada,
Abstract
A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia.Org: The University of Texas MD Anderson Cancer Center, Department of Leukemia, Centre Hospitalier Régional Universitaire de Nîmes, Hopital Cochin, Groupement des Hôpitaux de l'Institut Catholique de Lille,
Abstract
Upfront allo-HSCT after intensive chemotherapy for untreated aggressive ATL: JCOG0907, a single-arm, phase 3 trial.Org: Department of Health Sciences, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan, Saitama Medical University, Hidaka-Gun, Japan, Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan, National Cancer Center Hospital, Tokyo, Japan, National Cancer Center Hospital, Chuo-Ku, Japan,
Abstract
CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma.Org: Cancer Center Clínica Universidad de Navarra, Madrid, Spain, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,
Abstract
Safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells.Org: Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Center for Cellular Immunotherapies, Department of Biostatistics, Epidemiology, and Informatics,
Abstract
Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.Org: Mayo Clinic, Memorial Sloan Kettering Cancer Center, Cleveland Clinic Lerner College of Medicine, The Ohio State University - Division of Hematology, Washington University School of Medicine,
Abstract
Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.Org: The University of Texas MD Anderson Cancer Center, Maria Skłodowska-Curie National Research Institute of Oncology, General University Hospital in Prague, Charles University Hospital and Faculty of Medicine, Wrocław Medical University,
Abstract
Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.Org: F. Hoffmann-La Roche Ltd, Roche Products Ltd., City of Hope National Medical Center, Humanitas University and IRCCS Humanitas Research Hospital, Centre Hospitalier Universitaire de Lille,
Abstract
Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).Org: University of Lille, CHU Lille - Hopital Huriez, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Service d'Hématologie et Thérapie Cellulaire,
Abstract
Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).Org: Université de Poitiers et Centre Hospitalier Universitaire de Poitiers, INSERM U1313 and CIC 1082, Poitiers, France, Hôpital Haut Leveque, University Hospital, Pessac, France, ECSTRA, Centre de Recherche en Epidémiologie et Statistiques, INSERM UMR 1153, Paris, France, Lille University Hospital, Lille, France, CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France,
Abstract
Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.Org: Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona, Spain, Hematology Department, University Hospital Hôtel-Dieu, Nantes, France, National and Kapodistrian University of Athens, Athens, Greece, Ankara University, Ankara, Turkey, CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France,
Abstract
DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).Org: Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer (IBMCC-USAL, CSIC), Medical University of Lodz, Samodzielny Publiczny Szpital Kliniczny,
Abstract
Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis.Org: University of Alabama at Birmingham, University Medical Center Hamburg-Eppendorf, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Vrije Universiteit Amsterdam, Stanford University School of Medicine,
Abstract
Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.Org: Saint-Louis Hospital, APHP, University Paris Cité, Paris and Saint Cloud, France,
Abstract
Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).Org: Centre Hospitalier Universitaire de Nantes, Ankara University, University of Athens, School of Medicine, Showa University, Memorial Sloan Kettering Cancer Center,
Abstract
All-oral triplet iberdomide, ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D.Org: Centre Hospitalier Universitaire de Nantes, Centre Hospitalier Universitaire de Poitiers, Vendée Departmental Hospital Centre, Hopital Cote de Nacre, Hematology Department, University Cancer Institute IUCT oncopôle, Toulouse, France,
Abstract
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.Org: Division of Hematology, Mayo Clinic, Rochester, MN, Stanford University Medical Center, Palo Alto, CA, University of Kansas Medical Center, Kansas City, KS, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.Org: South Australian Health and Medical Research Institute, Universitätsklinikum Jena, Akita University Hospital, The University of Texas MD Anderson Cancer Center, University of Chicago,
Abstract
Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy.Org: Massachusetts General Hospital, Boston, MA, Harvard Medical School, The Ohio State University Wexner Medical Center, Columbus, OH,
Abstract
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.Org: University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), Swiss Group for Clinical Cancer Research (SAKK), Department of Internal Medicine III with Hematology,
Abstract
Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.Org: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital),
Abstract
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.Org: St. Vincent’s Hospital, The Catholic University of Korea, Haematology Unit, Royal Adelaide Hospital, Sungkyunkwan University School of Medicine,
Abstract
BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).Org: National Cancer Center Hospital, Tokyo, Japan, Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China, Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Respiratory Medicine and Infectious Disease, Niigata University Medical & Dental Hospital, Niigata, Japan, Biological Therapy Oncology, Tianjin Cancer Hospital, Tianjin, China,
Abstract
Feasibility and safety of neoadjuvant nivolumab and chemotherapy for resectable diffuse pleural mesotheliomas: Results of a prospective pilot study.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial.Org: Sun Yat-sen University Cancer Center, Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Sun Yat-sen University, Shenzhen People’s Hospital, Tianjin Medical University Cancer Institute and Hospital,
Abstract
Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).Org: Klinik für Pneumologie - Evangelische Lungenklinik Berlin Buch, Berlin, Germany, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, Federal State Budgetary Institution “N. N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation, Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy,
Abstract
Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC): Data from ALINA.Org: Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, Gustave Roussy and Paris Saclay University, Faculty of Medicine, Villejuif / Kremlin-Bicêtre, France, Samsung Medical Center, Seoul, South Korea, Asan Medical Center, Seoul, South Korea,
Abstract
A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091).Org: Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, The First People's Hospital of Foshan,
Abstract
Taiwan national lung cancer early detection program for heavy smokers and non-smokers with family history of lung cancer.Org: National Taiwan University College of Medicine, Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Health Promotion Administration, Taipei, Health Promotion Administration, Ministry of Health and Welfare, Taiwan, Health Promotion Administration, Ministry of Health and Welfare, Taiwan (R.O.C),
Abstract
ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.Org: Gustave Roussy Cancer Center, Biostatistics Unit, Hopital Cochin, Chi Creteil, Centre François Baclesse,
Abstract
Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.Org: Sun Yat-sen University Cancer Center, Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Jilin Cancer Hospital, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine,
Abstract
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.Org: Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, Medical Oncology, Regional University Hospital of Málaga, Málaga, Spain, Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, Paris-Saclay University, Gustave Roussy Cancer Center, Villejuif, France,
Abstract
NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).Org: Memorial Sloan Kettering Cancer Center, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Washington University School of Medicine in St. Louis, Washington University School of Medicine,
Abstract
Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.Org: Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Thoracic Medicine Department 1, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Yunnan Cancer Hospital, Kunming, China, Sun Yat-sen University Cancer Center, Guang Zhou, China,
Abstract
BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.Org: Royal Marsden Hospital NHS Foundation Trust, Medical Oncology Service, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), National and Kapodistrian University of Athens,
Abstract
Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.Org: Bristol Myers Squibb, Oncosite Centro de Pesquisa Clínica em Oncologia, Puerta de Hierro University Hospital, Madrid, Spain, Dana-Farber Cancer Institute, Boston, MA, USA, McGill University Health Centre, Montreal, QC, Canada,
Abstract
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.Org: Hospital Universitario 12 de Octubre, Madrid, Spain, Hospital Universitari i Politécnic La Fe de Valencia, Valencia, Spain, Henry Dunant Hospital Center, Athens, Greece, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain, Asklepios Lung Clinic, German Center for Lung Research (DZL), Munich-Gauting, Germany,
Abstract
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.Org: Pfizer Inc., European Institute of Oncology IRCCS, National Cancer Center Hospital East, Kashiwa, Japan, Guangdong Lung Cancer Institute, Tennessee Oncology, PLLC,
Abstract
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.Org: Princess Margaret Cancer Centre, Wakayama Medical University, Wakayama, Japan, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Jilin Cancer Hospital, Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research,
Abstract
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study.Org: University Hospital (UKSH), Campus Kiel, Department of Dermatology, Kiel, Germany, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland, Fondazione IRCCS - Istituto Nazionale dei Tumori (INT), Milano, Italy, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Woolloongabba, QLD, Australia, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy,
Abstract
A randomised, controlled, multicentre trial of imiquimod versus radiotherapy for lentigo maligna.Org: Melanoma Institute Australia, The University of Sydney, Chris O'Brien Lifehouse, Icon Cancer Centre, Faculty of Medicine and Health, The University of Sydney,
Abstract
Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048.Org: Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy, University Hospital Zurich, Zürich, Switzerland, CEPCM, Dermatology and Skin Cancer Department, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille, France, Linear Clinical Research, Nedlands, Western Australia, Australia, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,
Abstract
Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.Org: Orlando Health Cancer Institute, First Department of Medicine, National and Kapodistrian University of Athens, Cooper University Hospital, Norris Comprehensive Cancer Center,
Abstract
Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.Org: University Hospital Zurich, Aix-Marseille University CHU Timone, Hôpital de la Timone, Department of Cancer Medicine, Gustave Roussy Cancer Centre, Gustave Roussy Cancer Campus,
Abstract
Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM).Org: The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA, HCA Healthcare global Sarah Cannon Research Institute, London, United Kingdom, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, University of Chicago, Comprehensive Cancer Center, Chicago, IL, Jefferson Medical College, Philadelphia, PA,
Abstract
Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy.Org: Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Mayo Clinic, Rochester, MN, USA, University of Rochester, Rochester, NY, Massachusetts General Hospital, Marblehead, MA, Dana-Farber Cancer Institute, Boston, MA, USA,
Abstract
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases.Org: University Hospital Schleswig-Holstein, University Hospital Heidelberg, Skin Cancer Center, University Hospital Leipzig, University Hospital Carl Gustav Carus, Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases,
Abstract
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).Org: Gustave Roussy Cancer Campus, EORTC Headquarters, Université Clermont Auvergne, Dermato-Oncology and CIC AP-HP Hôpital Saint Louis, Université de Versailles-Saint Quentin en Yvelines,
Abstract
Efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring NTRK or ROS1 fusions.Org: Roche Products Ltd., Genentech, Memorial Sloan Kettering Cancer Center, Hopp Children’s Cancer Center Heidelberg (KiTZ), Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
Abstract
Phase IB study of tovorafenib for children with relapsed/recurrent low-grade gliomas and other MAPK pathway activated tumors.Org: Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Children's Hospital of Philidelphia, St. Louis Children's Hospital, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, Massachusetts General Hospital,
Abstract
Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial.Org: Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Memorial Sloan Kettering Cancer Center, FLENI,
Abstract
Impact of an objective scoring system on initiation of therapy in patients with International Neuroblastoma Risk Group Staging System (INRGSS) stage MS neuroblastoma: A report from the Children’s Oncology Group.Org: Children's Hospital Colorado, Aurora, CO, Children's Oncology Group Statistics and Data Center, University of Florida, Baylor College of Medicine, Children's Hospital of Philadelphia, Roswell Park Cancer Institute Department of Cancer Prevention and Population Sciences,
Abstract
A pilot study of post-consolidation chemoimmunotherapy for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group.Org: University of Chicago Medical Center, Chicago, IL, Children's Oncology Group Statistics and Data Center, University of Florida, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, Children's Oncology Group Statistics & Data Center, Department of Biostatistics & Data Science,
Abstract
Preliminary experience of ex-vivo expanded allogeneic universal donor TGFβi NK cell infusions in combination with irinotecan, temozolomide, and dinutuximab in patients with relapsed or refractory neuroblastoma: The Allo - STING trial.Org: Nationwide Children's Hosp, Columbus, OH, OHB Neonatology, Nationwide Childrens Hospital, Nationwide Children's Hospital,
Abstract
Outcome of children and young adults with localized extremity rhabdomyosarcoma treated on Children's Oncology Group trials.Org: CancerCare Manitoba, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, The Ohio State University James Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Cincinnati Children's Hospital Medical Center,
Abstract
Radiation dose escalation and local control for intermediate-risk rhabdomyosarcoma on ARST1431: A report from the Children’s Oncology GroupOrg: Memorial Sloan Kettering Cancer Center, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, The Hospital for Sick Children, Cincinnati Children's Hospital Medical Center, University of Pennsylvania,
Abstract
RMS13: A phase II trial using risk adapted focal proton beam radiation and/or surgery with the addition of maintenance chemotherapy in intermediate risk rhabdomyosarcoma.Org: St. Jude Children's Research Hospital, Department of Radiation Oncology, University of Florida College of Medicine Jacksonville, Cook Children's Medical Center, Department of Radiation Oncology, University of Florida College of Medicine Jacksonville,
Abstract
Uptake of germline cancer genetic services in a randomized trial of remote telehealth services as compared to usual care: A report from the Childhood Cancer Survivor Study (CCSS).Org: University of Chicago Pritzker School of Medicine, Fox Chase Cancer Center, University of Pennsylvania, Columbia University Mailman School of Public Health, New York, NY, Duke University Medical Center,
Abstract
A stepped wedge trial of a healthcare provider–focused intervention to increase human papillomavirus (HPV) vaccine initiation among survivors of childhood cancer.Org: Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, NC, Emory University, Atlanta, GA, USA, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, Emory University and Children's Healthcare of Atlanta, Atlanta, GA,
Abstract
Communicating cardiovascular health information and improving coordination with primary care: A Childhood Cancer Survivor Study randomized trial.Org: Fred Hutchinson Cancer Center, St. Jude Children's Research Hospital, University of Washington School of Medicine, Division of Haematology/Oncology, The Hospital for Sick Children, The Hospital for Sick Children,
Abstract
Access for adolescents and young adults with hard-to-cure cancer to PROFYLE: The pan-Canadian precision oncology pipeline.Org: The Children's Hospital of Eastern Ontario, The Hospital for Sick Children, Tom Baker Cancer Centre, CancerCare Manitoba,
Abstract
CINSARC score use in pediatric non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) in the Children’s Oncology Group (COG) studies ARST0332 and ARST1321.Org: Children's Hospital of Philadelphia, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Children's Oncology Group Statistics and Data Center, University of Florida, Massachusetts General Hospital, Seattle Children's Hospital,
Abstract
Comparison of immunoglobulin high-throughput sequencing MRD in bone marrow and peripheral blood in pediatric B-ALL: A report from the Children's Oncology Group AALL1731.Org: Adaptive Biotechnologies, Baylor College of Medicine, Servier Pharmaceuticals, Perlmutter Cancer Center, New York University Langone Health, University of Washington School of Medicine,
Abstract
Vincristine (VCR) pharmacokinetics (PK) in infants dosed using a body surface area (BSA) banded dosing table and in older children dosed based on BSA: A pediatric early phase clinical trial network study (PEPN22P1).Org: Children's Hospital Colorado, Aurora, CO, Children's Hospital of Philadelphia, Children's Oncology Group Statistics and Data Center, University of Florida, Texas Children's Cancer and Hematology Center, Institute for Clinical and Translational Research, Baylor College of Medicine,
Abstract
Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) registry results.Org: Dana-Farber Cancer Institute, Boston Children's Hospital Cancer and Blood Disorders Center, Memorial Sloan Kettering Cancer Center, University of Colorado Denver, Children's Mercy Hospital,
Abstract
Brigatinib monotherapy in children with R/R ALK+ ALCL, IMT, or other solid tumors: Results from the BrigaPED (ITCC-098) phase 1 study.Org: Princess Máxima Center for Pediatric Oncology, Erasmus MC-Sophia Children’s Hospital, University Medical Center Hamburg-Eppendorf, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Children University Hospital,
Abstract
Effect of polygenic risk score for clinically significant prostate cancer in a screening program: The BARCODE 1 study results.Org: Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Institute of Cancer Research, The Institute of Cancer Research, Royal Marsden NHS Foundation Trust,
Abstract
Evaluation of a polygenic risk score as a predictor of early onset triple-negative breast cancer in Black women.Org: Cleveland Clinic Lerner College of Medicine, Myriad Genetics, Inc.,
Abstract
Breast cancer polygenic risk score and patient survival outcomes in the Pathways study.Org: Roswell Park Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Division of Research, Kaiser Permanente Northern California, Buffalo, NY,
Abstract
Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study.Org: IRCCS Ospedale Policlinico San Martino-University of Genova, Genoa, Italy, IRCCS Ospedale Policlinico San Martino, Genova, Italy, AOU Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy, Institut Jules Bordet and Université Libre de Bruxelles (U.L.B), Brussels, Belgium, Department of Medical Oncology, Universite Paris Cité, Institut Curie, Paris, France,
Abstract
Association between rare pathogenic variants in established cancer risk genes and the diagnosis of single and multiple common cancers: A UK Biobank study.Org: Duke Cancer Institute Center for Prostate and Urologic Cancers and Department of Medicine, Duke University School of Medicine, Durham, NC, NorthShore University HealthSystem Research Institute, Evanston, IL,
Abstract
Menopausal hormone therapy and ovarian and endometrial cancers: Long-term follow-up of the Women’s Health Initiative randomized trials.Org: The Lundquist Research Institute, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, Fred Hutchinson Cancer Research Center, Kaiser Permanente Southern California, Albert Einstein College of Medicine,
Abstract
Effects of HPV vaccination on the development of HPV-related cancers: A retrospective analysis of a United States-based cohort.Org: Department of Otolaryngology, University of Pittsburgh, Thomas Jefferson University, Departments of Otolaryngology and Clinical/Experimental Pharmacology - Thomas Jefferson University, Jefferson Kimmel Cancer Center at Jefferson Health, Department of Otolaryngology, Thomas Jefferson University, Philadelphia, PA,
Abstract
Comparative risk of obesity-related cancer with glucagon-like protein-1 receptor agonists vs. bariatric surgery in patients with BMI ≥ 35.Org: Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, Population Health and Equity Research Institute,
Abstract
Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.Org: Memorial Sloan Kettering Cancer Center, Chris O'Brien Lifehouse, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Medical Oncology and Sarcoma Center, Dana-Farber Cancer Institute,
Abstract
StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs).Org: University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, Leuven, Belgium, Oregon Health & Science University, Portland, OR, University of Miami – Sylvester Comprehensive Cancer Center, Miami, FL, Medical Oncology Department, Hospital Universitario Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain, Universitaetsklinikum Essen - Westdeutsches Tumorzentrum (WTZ) (West German Cancer Center), Essen, Germany,
Abstract
Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma.Org: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Fudan University Shanghai Cancer Center, The Affliated Cancer Hospital of Zhengzhou University,
Abstract
SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.Org: UPMC Hillman Cancer Center, Mayo Clinic Rochester, Melanoma Institute Australia, University of Sydney and Sydney Cancer Centre, Chris O'Brien Lifehouse,
Abstract
Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), myxoid liposarcoma (MLPS) and de-differentiated liposarcoma (DDLPS): A single-arm phase 2 trial.Org: Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China,
Abstract
ImmunoSarc II master trial (phase II of sunitinib and nivolumab): Results from the dedifferentiated chondrosarcoma (DDCS) cohort—A GEIS, ISG and UCL study.Org: University College London Hospital NHS Trust and Great Ormond Street Hospital, Health Research Institute-Fundación Jiménez Díaz University Hospital, Autonomous University of Madrid (IIS-FJD, UAM), IRCCS Istituto Ortopedico Rizzoli, Hospital Universitario Miguel Servet,
Abstract
ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma.Org: Musculoskeletal Tumor Center, Peking University People's Hospital, Tianjin Medical University Cancer Institute and Hospital, Department of Musculoskeletal Oncology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,
Abstract
SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES).Org: Children's Hospital of Philadelphia, Mayo Clinic, Department of Population Health Sciences, Weill Cornell Medicine, Children’s Hospital Los Angeles,
Abstract
Multi-site randomized trial of stepped palliative care (PC) for patients with advanced lung cancer.Org: Massachusetts General Hospital, Division of Hematology and Oncology/Department of Medicine, Boston, MA, Harvard Medical School, University of Pennsylvania,
Abstract
A mobile app–based program for facilitating advance care planning discussions between patients with advanced cancer and oncologists: A randomized controlled trial (J-SUPPORT 2104).Org: Institute for Cancer Control, National Cancer Center Hospital East, Kashiwa, Japan, Division of Survivorship Research, Division of Behavioral Sciences, Japanese Organisation for Research and Treatment of Cancer,
Abstract
BE-a-PAL: A cluster-randomized trial of algorithm-based default palliative care referral among patients with advanced cancer.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Perelman School of Medicine at the University of Pennsylvania, Tennessee Oncology, PLLC,
Abstract
Randomized trial of a multimodal intervention to enhance sexual function and quality of life (QOL) in hematopoietic stem cell transplant (HSCT) survivors.Org: Massachusetts General Hospital, Fox Chase Cancer Center, Lifespan Cancer Institute, Dana-Farber Cancer Institute/Mass General Brigham, Division of Hematology and Oncology/Department of Medicine,
Abstract
Risk prediction model for taxane-induced peripheral neuropathy (TIPN) in patients with early-stage cancer receiving taxane therapy: SWOG S1714.Org: Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, SWOG Statistics and Data Management Center/Fred Hutchinson Cancer Research Center, University of Michigan Rogel Cancer Center, University of Michigan College of Pharmacy,
Abstract
Walking dose required to achieve a clinically meaningful reduction in cancer-related fatigue among patients with breast cancer receiving chemotherapy: A URCC NCORP nationwide prospective cohort study.Org: James P. Wilmot Cancer Center, University of Rochester Medical Center, University of Rochester School of Medicine & Dentistry, University of Rochester, Providence Cancer Institute,
Abstract
Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.Org: Mayo Clinic Department of Radiation Oncology, Rochester, MN, Mayo Clinic, Phoenix, AZ, Division of Hematology & Medical Oncology,
Abstract
Primary outcomes of the enhanced, EHR-facilitated cancer symptom control (E2C2) cluster-randomized, stepped wedge, pragmatic trial.Org: Mayo Clinic Department of Pediatric and Adolescent Medicine, Mayo Clinic, Indiana University School of Medicine and Regenstrief Institute, Yale University School of Medicine, National Cancer Institute/National Institutes of Health,
Abstract
Results from a randomised, open-label trial of a multimodal intervention (exercise, nutrition and anti-inflammatory medication) plus standard care versus standard care alone to attenuate cachexia in patients with advanced cancer undergoing chemotherapy.Org: Cancer Clinic, St. Olavs Hospital, Trondheim University Hospital, Department of clinical and molecular medicine, Faculty of Medicine and Health Sciences,
Abstract
Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.Org: Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, Personalis, Inc., The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research and Ralph Lauren Centre for Breast Cancer Research,
Abstract
Comprehensive clinical characteristics and ctDNA mutational profile analysis of endocrine resistance/sensitivity to adjuvant ET therapy in luminal breast cancer from the GEICAM/2014-03_RegistEM registry.Org: Instituto Valenciano de Oncología (IVO), GEICAM Spanish Breast Cancer Group, Hospital Universitario de Donostia-BioDonostia, Complejo Hospitalario Universitario a Coruña (CHUAC), Hospital Universitario de Canarias,
Abstract
On-treatment (tx) dynamic circulating tumor DNA changes (∆ctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA-3 (ML-3).Org: BC Cancer - Vancouver Centre, Novartis Pharmaceuticals Corporation, Novartis Institutes for BioMedical Research, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori Regina Elena,
Abstract
Discriminating subtypes in advanced breast cancer with ctDNA methylation profiling.Org: The Institute of Cancer Research, London, United Kingdom, Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, United Kingdom, ICR, London, United Kingdom, University College London Hospitals NHS Foundation Trust, London, United Kingdom, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom,
Abstract
Cost-utility of geriatric assessment (GA) in older adults with cancer: A model-based economic evaluation of four randomized controlled trials (RCTs).Org: University of Toronto, University Health Network, Lawrence S. Bloomberg Faculty of Nursing, Princess Margaret Cancer Centre,
Abstract
Geriatric assessment-directed supportive care intervention (GAIN-S)-implementation via telehealth in a lower-resourced community.Org: City of Hope National Medical Center, Duarte, CA, CanSino Biologics, City of Hope National Comprehensive Cancer Center, City of Hope Comprehensive Cancer Center,
Abstract
Geriatric assessment and management with question prompt list using a web-based application for elderly patients with cancer to communicate aging-related concerns: A randomized clinical trial (J-SUPPORT 2101 study).Org: National Cancer Center Hospital East, Kashiwa, Japan, IMSUT Hospital, University of Tokyo, Shizuoka Cancer Center, Nagoya City University Graduate School of Medical Sciences,
Abstract
Primary treatment modification strategies among older adults with advanced cancer.Org: University of Rochester Medical Center, University of Rochester, The University of North Carolina at Chapel Hill, University of Rochester School of Medicine and Dentistry, James P. Wilmot Cancer Center,
Abstract
Effect of war on radiotherapy in Ukraine and how to help.Org: Stanford University School of Medicine, Spizhenko Clinic, The University of Sydney, National Cancer Institute/National Institutes of Health, LISOD Clinic,
Abstract
Quality of life for older patients with metastatic cancer in Brazil: A telehealth-based geriatric assessment and supportive care intervention (GAIN-S).Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), City of Hope Comprehensive Cancer Center, University of Oklahoma Health Sciences Center, Massachusetts General Hospital, National Institute of Medical Sciences and Nutrition Salvador Zubirán,
Abstract
Accuracy of a mobile sensor-based system for the detection of chemotherapy toxicity in older adults with cancer.Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, University Health Network, Benemerita Universidad Autónoma de Puebla, Princess Margaret Cancer Centre,
Abstract
Longitudinal tumor-wide sampling of glioblastoma reveals diverse genomic drivers of the earliest clonal expansion at diagnosis and recurrence.Org: University of California Irvine, San Francisco Medical Center,
Abstract
Utility of circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) for prognosis of patients with recurrent high grade glioma.Org: Memorial Sloan Kettering Cancer Center, Harvard Medical School, Weill Cornell Medicine, NYU Langone Health, Department of Pathology and Laboratory Medicine,
Abstract
Efficacy and biomarker analysis of phase 2 (P2) and window-of-opportunity (WoO) cohorts of patients with recurrent glioblastoma (rGBM) treated with ST101, an inhibitor of the transcription factor C/EBPβ.Org: Columbia University Irving Medical Center, New York, NY, USA, Sapience Therapeutics, Sapience Therapeutics, Inc., Columbia University Medical Center, BioForum Ltd.,
Abstract
Pre-clinical modeling of navtemadlin pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in glioblastoma, IDH-wildtype.Org: Mayo Clinic, University of Minnesota, Brigham and Women's Hospital, Harvard Medical School,
Abstract
Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials.Org: Personalis, Inc., Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO),
Abstract
CD8 radiomics signature to assess inter-lesion spatial heterogeneity and cold liver lesions in advanced non-small cell lung cancers treated with durvalumab.Org: Gustave Roussy Cancer Center, Department of Radiation Oncology, Université Paris-Saclay, UMR 1030, ImmunoRadAI,
Abstract
High-dimensional longitudinal immune profiling uncovers a dual role of the CXCL9/CXCR3, CXCL13/CXCR5, and CCL11/CCL3 axis in the coupling of immune-related adverse events to immune checkpoint inhibitor response.Org: CHUV, Lausanne University Hospital, Department of Oncology, National Taiwan University Hospital, University of Lausanne, University Hospital of Lausanne,
Abstract
Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.Org: Medical University of Gdańsk, Gdańsk, Poland, International Centre for Thoracic Cancers (CICT), Gustave Roussy Cancer Center, Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine,
Abstract
Performance characteristics of a tissue-agnostic genome-wide methylome enrichment MRD assay for head and neck malignancies.Org: Princess Margaret Cancer Centre, University Health Network, Adela, Inc., Foster City, CA, Toronto, ON, Canada,
Abstract
Personalized cell-free tumor DNA analysis for patients with HNSCC: Liquid biopsy for minimal residual disease detection in head and neck squamous cell carcinoma (LIONESS).Org: The Bradfield Centre, NeoGenomics Laboratories, Inc.,
Abstract
Circulating tumor cells and tumor DNA in patients with resectable colorectal liver metastases: The MIRACLE.Org: Erasmus MC Cancer Institute, Erasmus University Medical Center, Albert Schweitzer Hospital, IJsselland Hospital, Amphia Hospital,
Abstract
Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS).Org: Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, The Third Hospital of Shandong Province, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Yantai Yuhuangding Hospital,
Abstract
A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study.Org: Peking University Cancer Hospital & Institute, Henan Cancer Hospital, Fudan University Shanghai Cancer Center, Fujian Provincial Cancer Hospital, Zhejiang Cancer Hospital,
Abstract
Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study.Org: Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, GCP center, West China Hospital, Sichuan University, Chengdu, China, Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, Department of Oncology, Zhejiang Cancer Hospital, Hangzhou, China, Department of Hepato-Pancreato-Biliary & Gastric Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China,
Abstract
A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort.Org: Chongqing University Cancer Hospital, Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, China, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, State Key Laboratory of Biotherapy,
Abstract
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).Org: AstraZeneca, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dana-Farber Cancer Institute,
Abstract
A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer.Org: Memorial Sloan Kettering Cancer Center, Interventional Radiology Service,
Abstract
Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.Org: Yale University School of Medicine and Yale Cancer Center, Dana Farber Cancer Institute – ECOG-ACRIN Biostatistics Center, Johns Hopkins University, University of Pennsylvania Medical Center, University of Maryland Marlene and Stewart Greenebaum Cancer Center,
Abstract
Prospective validation of ctHPVDNA for detection of minimal residual disease and prediction of recurrence in patients with HPV-associated head and neck cancer treated with surgery.Org: Harvard Medical School, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Massachusetts General Hospital, Mass Eye and Ear/Mass Gen Hospital, Harvard University,
Abstract
Neoadjuvant sintilimab and platinum-doublet chemotherapy followed by transoral robotic surgery for HPV-associated resectable oropharyngeal cancer: Single-arm, phase II trial.Org: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Gansu Provincial Cancer Hospital,
Abstract
Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.Org: University of Pittsburgh Medical Center Hillman Cancer Center, Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Aichi Cancer Center Hospital, Memorial Sloan Kettering Cancer Center, University of Ulsan College of Medicine,
Abstract
Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.Org: Memorial Sloan Kettering Cancer Center, Duke University Medical Center, Vall d’Hebron University Hospital/VHIO, Institut Català d'Oncologia L´Hospitalet, Ramón y Cajal University Hospital,
Abstract
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.Org: Sichuan Cancer Hospital and Institute, Chengdu, China, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, France; Cancer Research Center of Lyon (INSERM 1052, CNRS 5286), Lyon, France; Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France, Institut de Cancérologie de l'Ouest, Saint-Herblain, France, Hospital Universitario Son Espases, Mallorca, Spain, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy,
Abstract
KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.Org: Candiolo Cancer Institute, FPO-IRCCS, IOR, Dexeus University Hospital, IRCCS Azienda Ospedaliero Universitaria Bologna,
Abstract
International medical graduates (IMG) representation at international oncology conference meetings.Org: Roswell Park Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Gazi University Faculty of Medicine, University of Arkansas for Medical Sciences,
Abstract
Going back home: Understanding the challenges of international medical graduates (IMGs) in oncology.Org: University of Miami Sylvester Comprehensive Cancer Center, Capital Health, University of California, San Francisco, NYU Langone Health, Mayo Clinic,
Abstract
Depicting oncologists' perceptions and knowledge of global disparities in conflicts of interest reporting: The ONCOTRUST-1 study.Org: Faculty of Medical Sciences, University Mohammed VI Polytechnic, National Institute of Oncology. Istenhegyi Géndiagnosztika Private Health Center Oncology Clinic, Evercare Hospital Dhaka, Kenyatta University Teaching,
Abstract
Molecular characterization of patients with localized Ewing sarcoma targeting discrete prognostic groups: A report from the Children’s Oncology Group.Org: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston Children's Hospital, Children's Oncology Group Statistics and Data Center, University of Florida, Cleveland Clinic Lerner College of Medicine,
Abstract
Prospective evaluation of pre-treatment ctDNA burden in localized osteosarcoma to identify patients with inferior outcomes: A report from the LEOPARD study.Org: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Massachusetts General Hospital, Aflac Cancer Center/Children's Healthcare of Atlanta, Children's Hospital & Clinics Minnesota, Cedars-Sinai Medical Center,
Abstract
Impact of ATRX loss on survival and immune microenvironment in multiple sarcoma subtypes.Org: The University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
AI virtual patient navigation to promote re-engagement of U.S. inner city patients nonadherent with colonoscopy appointments: A quality improvement initiative.Org: Montefiore Einstein Comprehensive Cancer Center, MyndYou,
Abstract
Multimodal artificial intelligence models from baseline histopathology to predict prognosis in HR+ HER2- early breast cancer: Subgroup analysis.Org: University Hospital LMU Munich, Medical School Hannover, West German Study Group, Breast Unit, Charité-Universitätsmedizin Berlin,
Abstract
Real-world and clinical trial validation of a deep learning radiomic biomarker for PD-(L)1 immune checkpoint inhibitor response in stage IV NSCLC.Org: Onc.AI, Pfizer Inc., Department of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital,
Abstract
Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial.Org: University of Colorado Cancer Center, Sheba Medical Center, Department of Thoracic Oncology, Kanagawa Cancer Center, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, N.P. Napalkov St. Petersburg City Cancer Center,
Abstract
Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, Jiangsu Province Hospital, Nanjing, China, Hunan Cancer Hospital, Changsha, China, Shandong Cancer Hospital and Institute, Jinan, China, Zhejiang Cancer Hospital, Hangzhou, China,
Abstract
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).Org: University of Chicago, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, University of Chicago Medical Center, Chicago, IL, Division of Hematology and Medical Oncology, University of Colorado School of Medicine,
Abstract
The potential role of serial circulating tumor DNA (ctDNA) testing after upfront surgery to guide adjuvant chemotherapy for early stage pancreatic cancer: The AGITG DYNAMIC-Pancreas trial.Org: Northern Health, Peter MacCallum Cancer Centre, Melbourne, Australia, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne, VIC, Australia,
Abstract
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial.Org: Department of Medical Oncology, Peter MacCallum Cancer Centre and Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, MD, Melanoma Institute Australia, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia, Center for Cancer Prevention and Early Detection, City of Hope, Phoenix, AZ, Eastern Health & Epworth Healthcare & Eastern Health Clinical School, Monash University, Melbourne, Australia,
Abstract
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).Org: Princess Margaret Cancer Centre, Ankara University, University Hospital Brno, General Hospital Evangelismos, Athens, Greece, St. Vincent's Hospital Melbourne,
Abstract
Patterns of depressive symptoms among survivors of early-stage breast cancer (BC).Org: INSERM, EFS UFC, UMR1098, RIGHT, University of Franche-Comté, Besançon, France, Gustave Roussy Cancer Center, Bordeaux Population Health, Unicancer, Jean Godinot Cancer Institute,
Abstract
Patient and caregiver experience with the hope and prognostic uncertainty of immunotherapy: A qualitative study.Org: Massachusetts General Hospital, Massachusetts General Brigham Salem Hospital, University of Miami Health System,
Abstract
Hope drives quality of life in patients with brain metastases, but the hope center remains elusive: An analysis of NRG-CC003.Org: Sharei Zedek Hospital, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, Northwestern Medicine Cancer Center Warrenville, Northwestern Medicine Proton Center, Baptist Health South Florida,
Abstract
Final analysis of 2-THE-TOP: A phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma.Org: Department of Neurological Surgery, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, University of Florida Department of Neurosurgery, University of Southern California Department of Neurological Surgery,
Abstract
Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.Org: Massachusetts General Hospital Cancer Center, Northwestern Memorial Hospital, Chicago, IL, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Massachusetts General Hospital,
Abstract
Association of matrix metalloproteinase 2 (MMP2) baseline plasma level to objective response (OR), progression free survival (PFS), and overall survival (OS) and changes under treatment in patients treated with bevacizumab (Bev) for recurrent high-grade glioma (HGG).Org: University Hospital Timone, Marseille, France, Aix Marseille University, Marseille, France, Assistance Publique–Hôpitaux de Paris, Paris, France, Medical Oncology 1, Venetian Institute of Oncology-IRCCS, Padua, Padua, Italy, Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), Neurologie 2, Paris, France,
Abstract
Blood alterations preceding clinical manifestation of glioblastoma.Org: Medical University of Vienna, Department of Psychiatry and Human Behavior, University of California, Irvine, Danube Hospital, Institute of Neurology, Comprehensive Cancer Center Erlangen-EMN,
Abstract
The role of amide proton transfer imaging in detecting active malignant glioma.Org: The Johns Hopkins University School of Medicine, Johns Hopkins University School of Medicine, F. M. Kirby Research Center for Functional Brain Imaging,
Abstract
Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03.Org: Vall d’Hebron University Hospital/VHIO, Vall d'Hebron Institute of Oncology, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group,
Abstract
Real world experience of trastuzumab deruxtecan for the treatment of metastatic breast cancer in the UK.Org: Royal Free London NHS Foundation Trust, The Christie NHS Foundation Trust, Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Guys' and St Thomas' NHS Trust, Belfast Health and Social Care Trust,
Abstract
Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.Org: Sarah Cannon Research Institute/Tennessee Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Abstract
Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study.Org: Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China, Harbin Medical University Cancer Hospital, Harbin, China, Chongqing University Cancer Hospital, Chonqqing, China, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center,
Abstract
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.Org: Memorial Sloan Kettering Cancer Center, University of Vermont Cancer Center, Université Libre de Bruxelles (ULB), Institut Jules Bordet, Université Libre de Bruxelles, Medical Oncology Department,
Abstract
Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial.Org: Hospital del Mar, Barcelona, Spain, CIBERONC-ISCIII, Biovica International AB, Hospital Clínico Universitario de Valencia, INCLIVA-Biomedical Research Institute,
Abstract
Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2- metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial.Org: Sysmex Inostics Gmbh, Sysmex Inostics, Inc., GEICAM Spanish Breast Cancer Group, Cancer Trials Ireland, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) ,
Abstract
Myosteatosis on computed tomography as a predictor of therapeutic response to CDK4/6 inhibitors plus aromatase inhibitors in patients with advanced breast cancer.Org: Yonsei University College of Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Endocrine Research Institute, Severance Hospital, Division of Medical Oncology, National Cancer Center Singapore,
Abstract
The subgroup analysis by age and geriatric assessment in a phase III study comparison of trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study).Org: National Center for Global Health and Medicine, Shimane University Hospital, Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Clinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan,
Abstract
Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study.Org: Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy, Precision Medicine Unit in Senology Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy, Precision Medicine in Senology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Fondazione Pascale, Naples, Italy, Sapienza University of Rome, Medical Oncology Department, Policlinico Umberto I, Roma, Italy,
Abstract
Multiple alternative splicing of HER2 transcripts and exon skipping with potential consequences on function and antibody-based therapy.Org: Genomic Testing Cooperative, John Theurer Cancer Center at Hackensack Meridian Health, John Theurer Cancer Center, Breast and GYN Divisions, John Theurer Cancer Center, Hackensack University Medical Center,
Abstract
Safety and efficacy of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: An updated systematic review and meta-analysis of clinical trials.Org: The Frank H. Netter M.D. School of Medicine at Quinnipiac University, Bridgeport, CT, BronxCare Health System, The Bronx, NY, Samaritan Medical Centre,
Abstract
[68Ga]Ga-ABY-025 PET in HER2-positive breast cancer: Benefits and pitfalls in staging of axillary disease.Org: Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, Radiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden, Affibody AB, Stockholm, Sweden, Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden,
Abstract
Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan.Org: Miami Cancer Institute, Baptist Health South Florida, Guardian Research Network,
Abstract
Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC).Org: Mayo Clinic, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, University of Michigan, Duke University Medical Center/Duke Cancer Institute,
Abstract
A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling.Org: City of Hope Comprehensive Cancer Center, Translational Genomics Research Institute (TGen North), Cedars-Sinai Medical Center,
Abstract
Differential genomic profiling of the progesterone receptor (PR) negative and estrogen receptor (ER) low metastatic breast cancer subtypes through circulating tumor DNA: A TNBC-like disease subtype?Org: Department of Medicine (DMED), University of Udine, Aviano, Italy, Washington University in St. Louis, St. Louis, MO, Universita degli Studi di Udine, Udine, Italy, Weill Cornell Medicine, New York, NY, Massachusetts General Hospital Cancer Center, Boston, MA,
Abstract
CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer.Org: Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Repare Therapeutics, Saint-Laurent, QC, Canada, Repare Therapeutics, Cambridge, MA, University of Milan and European Institute of Oncology, IRCCS, Milan, Italy,
Abstract
Testing patterns and prevalence of PIK3CA, AKT1, and PTEN alterations among patients (pts) with HR+/HER2- metastatic breast cancer (mBC) in the US.Org: AstraZeneca, Gaithersburg, MD, MD Anderson Cancer Center, PLC, Cambridge University Hospitals NHS Foundation Trust,
Abstract
Utility of circulating tumor DNA (ctDNA) to inform treatment of patients with metastatic breast cancer.Org: Foundation Medicine, Inc., Cambridge, MA, Allegheny Health Network Cancer Institute at Allegheny General Hospital, Weill Cornell Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD,
Abstract
Evaluating metrics of circulating tumor DNA response and progression using a high sensitivity tumor-agnostic assay in metastatic HR+/HER2- breast cancer receiving endocrine therapy and a CDK4/6-inhibitor.Org: Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Department of Medical Biophysics, University of Toronto,
Abstract
The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast.Org: BostonGene Corporation, BostonGene Corp., The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, BostonGene, Corp.,
Abstract
Kinome reprogramming as a therapeutic opportunity in ESR1 fusion driven breast cancer but not in gynecologic cancers.Org: Caris Life Sciences Research and Development, Tempero Bio, Azidus Brasil, Caris Life Sciences, Phoenix Tissue Repair,
Abstract
Deciphering the global landscape of breast cancer in 38 OECD countries from 1990-2019: A benchmarking global analysis.Org: All India Institute of Medical Sciences (AIIMS), Surat Municipal Institute of Medical Education and Research (SMIMER), Smt. NHL Municipal Medical College, Punjab Institute of Medical Sciences, Sterling Hospitals,
Abstract
A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer.Org: Fudan University Shanghai Cancer Center, The Second Hospital of Dalian Medical University, Harbin Medical University Cancer Hospital, Liaoning Cancer Hospital & Institute, Shenyang, China, Hunan Cancer Hospital,
Abstract
Efficacy of alpelisib (ALP) + fulvestrant (FUL) with rational use of metformin (MET) in patients with HR+/HER2- advanced breast cancer (ABC).Org: SBIH Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM, Moscow, Russian Federation, Saint Petersburg State University, Saint Petersburg, Russian Federation, SPbGU, Saint Petersburg, Russian Federation, Department of Antitumor Drug Therapy, Clinical Oncologic Dispensary, Krasnodar, Russian Federation,
Abstract
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trial.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Harbin Medical University Cancer Hospital,
Abstract
H3B-6545 + palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).Org: Royal Marsden NHS Foundation Trust, Saint Luke's Cancer Institute, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarah Cannon Research Institute/Tennessee Oncology, Eisai,
Abstract
LEONARDA-2: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2- advanced or metastatic breast cancer.Org: Genor Biopharma Co.,Ltd., Genor Biopharma, Genor Biopharma Co.,Ltd., Shanghai, China, Genor Biopharma Co., Ltd., Beijing, China,
Abstract
Comparison of expert treatment recommendations versus community healthcare providers: Analysis from an online decision support tool for metastatic breast cancer.Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute/Tennessee Oncology, Emory University at Winship Cancer Institute, Clinical Care Options, LLC,
Abstract
Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.Org: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Breast Surgery, Jiangxi Cancer Hospital, Nanchang, China, Hunan Cancer Hospital, Changsha, China, Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China,
Abstract
Impact of prior anticancer treatments on palbociclib (PAL) clinical outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) in real-world settings.Org: Texas Oncology-Baylor Charles A. Sammons Cancer Center, The US Oncology Network, Mid-Illinois Hematology & Oncology Associates, Alabama Oncology, Novant Health Oncology Specialists,
Abstract
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC).Org: Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, MA, USA, Massachusetts General Hospital, Florida Cancer Specialists/Sarah Cannon Research Institute, University of Virginia, Charlottesville, VA, USA, Memorial Sloan Kettering Cancer Center,
Abstract
Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Bireociclib plus fulvestrant for advanced HR+/HER2- breast cancer progressing after endocrine therapy: Interim analysis of a phase 3 trial (BRIGHT-2).Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Harbin Medical University Cancer Hospital, Harbin, China, Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China,
Abstract
Interim analysis (IA) of the giredestrant (G) + everolimus (EVERO) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC).Org: Linear Clinical Research & University of Western Australia, Harry Perkins Institute for Medical Research, F. Hoffmann-La Roche Ltd, Genentech, SOLTI Cancer Research Group,
Abstract
Genomic alterations (GA) in ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) patients (pts) with metastatic breast cancer (MBC): Co-occurrence and prevalence along treatment course.Org: Foundation Medicine, Inc., Cambridge, MA, Winship Cancer Institute of Emory University,
Abstract
Development of a multiparametric prognostic score based on PAM50, in patients with HR+/HER2- advanced breast cancer (aBC) treated with endocrine therapy (ET) plus cyclin dependent kinase 4 and 6 inhibitors (CDKi), within the CDK-PREDICT (SOLTI-1801) study and HCB cohort.Org: SOLTI Cancer Research Group, August Pi i Sunyer Biomedical Research Institute, Hospital Clínic de Barcelona, IDIBAPS, Biomedical Research Institute INCLIVA, Hospital Universitario 12 de Octubre Research Institute,
Abstract
Comprehensive analysis of TROP2, PD-L1, stromal (s)TILs, and HER2 expression patterns in patients (pts) with metastatic HR+HER2- breast cancer.Org: Dana-Farber Cancer Institute, University of Milan and European Institute of Oncology, IRCCS, Brigham and Women's Hospital, University of Milano, European Institute of Oncology, Division of Early Drug Development, European Institute of Oncology,
Abstract
Effect and acceptability of jasmine compound essential oil for premenopausal breast cancer survivors suffering from genitourinary syndrome of menopause: A prospective interventional study.Org: Cancer Hospital of China Medical University, Institute of Oncology Ljubljana, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute,
Abstract
Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study.Org: Sarah Cannon Research Institute/Tennessee Oncology, Asan Medical Center, Samsung Medical Center, Menarini Group, Hospital Universitario 12 de Octubre,
Abstract
Efficacy of subsequent treatments after disease progression on CDK4/6 inhibitors therapy in patients with hormone receptor-positive metastatic breast cancer: A Kaplan-Meier derived individual-patient data meta-analysis.Org: Faculdade de Medicina da Universidade de São Paulo, Massachusetts General Hospital Cancer Center, Federal University of Minas Gerais (UFMG), Case Western Reserve University School of Medicine, Penn State University College of Medicine,
Abstract
Novel epigenomic liquid biopsy assay to predict estrogen receptor (ER) status and to infer ER pathway activation in breast cancer.Org: Dana-Farber Cancer Institute, Precede Biosciences, Harvard Medical School,
Abstract
Real-world treatment outcomes in patients with HR+ HER2- advanced breast cancer treated with CDK4/6 inhibitors and endocrine therapy.Org: Military Institute of Medicine-National Research Institute, Department of Oncology, National Taiwan University Hospital, Department of Clinical Oncology, Queen Elizabeth Hospital, Breast Unit, Lower Silesian Oncology Centre,
Abstract
Nationwide real-world practice pattern and clinical data of palbociclib in patients with HR(+), HER2(-) metastatic breast cancer (KCSG BR21-15).Org: Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Seoul, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study.Org: Baylor University Medical Center, Texas Oncology, The US Oncology Network, International Breast Cancer Center (IBCC), Quironsalud Group,
Abstract
Survival outcome prediction of breast carcinomas on whole-slide histopathology images using deep learning.Org: DiaDeep, IHP Group, Loire-Atlantique/Vendée Cancer Registry, Institut de Cancerologie de l'Ouest,
Abstract
Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC).Org: Guardant Health, Inc., Guardant Health, Sarah Cannon Research Institute/Tennessee Oncology, Winship Cancer Institute of Emory University, Massachusetts General Hospital Cancer Center,
Abstract
Economic impact of longer treatment duration in first-line for HR+/HER2- metastatic breast cancer: A retrospective analysis.Org: Genentech, Genesis Research, Ellison Institute of Technology,
Abstract
Real-world treatment patterns, healthcare resource utilization and costs of care among newly-diagnosed patients with HR+/HER2- metastatic breast cancer.Org: Ellison Institute of Technology, Genentech, Genesis Research,
Abstract
Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2- metastatic breast cancer: A machine learning approach.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study.Org: David Geffen School of Medicine at UCLA, University of California Irvine, Jonsson Comprehensive Cancer Center, Los Angeles, CA, Gilead Sciences, Inc.,
Abstract
Impact of use of antibody drug conjugates on the prognostic outcome of patients with HR+ve/HER2-ve MBC: Results from a real world dataset.Org: Mediclinic City Hospital, TriNetX Europe,
Abstract
Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.Org: Dana-Farber Cancer Institute, Yale School of Medicine, University of Pittsburgh Medical Center (UPMC), Yale Cancer Center, Harvard Medical School,
Abstract
Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response.Org: Memorial Sloan Kettering Cancer Center, Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, European Institute of Oncology IRCCS, Breast Service, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
Prospective, randomized trial on efficacy and safety of cryotherapy and cryocompression therapy as prevention of chemotherapy-induced peripheral neuropathy.Org: Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria, Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria,
Abstract
A phase 1 study of liposomal irinotecan in patients with advanced breast cancer.Org: Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Harbin Medical University Cancer Hospital, Harbin, China, Department of Breast, Henan Cancer Hospital, Zhengzhou, China, Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China,
Abstract
Utidelone plus bevacizumab for the treatment of HER2-negative breast cancer brain metastases (U-BOMB): A multicenter, single-arm phase II study.Org: Department of Breast, Henan Cancer Hospital, Zhengzhou, China, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, Department of Medical Oncology, General Hospital of Ningxia Medical University, China, Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Cancer Center, Sun Yat-sen University, Guangzhou, China,
Abstract
SurvivorCHIP: Evaluation of clonal hematopoiesis in women treated for breast cancer.Org: Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Case Western Reserve University School of Medicine,
Abstract
Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies.Org: University of California, San Francisco, Miami Cancer Institute, Baptist Health South Florida, Mayo Clinic, Rush University Medical Center,
Abstract
Results and exploratory biomarker analyses of a phase II study CHANGEABLE: Combination of HX008 and niraparib in germ-line-mutated metastatic breast cancer.Org: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, China, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan.Org: Memorial Sloan Kettering Cancer Center, SUNY Downstate Medical Center, Lombardi Comprehensive Cancer Center, Georgetown University, Lombardi Comprehensive Cancer Center,
Abstract
Utility of axillary surgery in patients with de novo metastatic breast cancer undergoing surgery of the primary site.Org: Fox Chase Cancer Center, Biostatistics and Bioinformatics Core, Temple University Health System,
Abstract
SV-BR-1-GM after progression on ADC in patients with metastatic breast cancer.Org: Hoag Cancer Center, Newport Beach, CA, Sylvester Comprehensive Cancer Center, University of Miami Health System, BriaCell Therapeutics Corp., Morehouse School of Medicine, Mayo Clinic Florida,
Abstract
Efficacy and safety of erdafitinib in adults with breast cancer and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial.Org: Hospital Privado de la Comunidad de Mar del Plata, Buenos Aires, Argentina, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany, Vall d’Hebron Barcelona Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain, Department of Cancer Medicine and INSERM U981, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France, Department of Oncology, AK Altona, Asklepios Tumourzentrum Hamburg, Hamburg, Germany,
Abstract
Phase I clinical trial of MUC1-targeted CAR-T cells with PD-1-knockout in the treatment of advanced breast cancer.Org: Guangzhou Anjie Biomedical Technology Co. Ltd, Sun Yat-sen Memorial Hospital, Sun Yat-sen University Cancer Center,
Abstract
Exosomal HMGB1 educate PD-L1+-tumor associated macrophages via glycometabolic reprogramming to induce lung-tropic metastasis of triple negative breast cancer.Org: The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China, Bengbu Medical College, Bengbu, China, Dalian Medical University,
Abstract
Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results.Org: Los Angeles Cancer Network, Inova Schar Cancer Institute, Northwest Medical Specialties, Virginia Oncology Associates, Valkyrie Clinical Trials, Inc,
Abstract
Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC).Org: Yale New Haven Hospital, New Haven, CT, Upstate University Hospital, Syracuse, NY, SUNY Upstate University Hospital,
Abstract
Racial disparities among triple negative breast cancer clinical trial enrollees between 2010-2023.Org: New York Medical College, Valhalla, Nykode Therapeutics, Albert Einstein College of Medicine, Bronx, NY,
Abstract
Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial.Org: Memorial Sloan Kettering Cancer Center, University of Washington School of Medicine and Fred Hutchinson Cancer Center, University of Pittsburgh, Washington University School of Medicine, Kaplan Hospital,
Abstract
Novel HLA-Ilo/HLA-IIhi phenotype and immune evasion in triple-negative breast cancer.Org: Labcorp Oncology, OmniSeq Inc. (Labcorp), Roswell Park Comprehensive Cancer Center, Duke University Medical Center, Duke Cancer Institute,
Abstract
Interaction between VEGF-A and immune checkpoint targets in triple-negative breast cancer and mechanisms of immune evasion and tumor progression.Org: Labcorp Oncology, Roswell Park Comprehensive Cancer Center, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
Comparison of tumor immune microenvironments (TIMEs) between primary and metastatic sites (Mets) in triple-negative breast cancer (TNBC).Org: Cedars-Sinai Medical Center, City of Hope National Medical Center, Washington University in St. Louis, Allegheny Health Network Cancer Institute, Tempus AI,
Abstract
Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial.Org: Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Hospital Universitario Ramón y Cajal,
Abstract
Real-world immune-related adverse events in patients with early triple negative breast cancer who received pembrolizumab.Org: Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Wesleyan University, Department of Breast Medical Oncology, Division of Cancer Medicine,
Abstract
Prognosis and tumor-infiltrating lymphocytes (TILs) in estrogen receptor (ER)-low metastatic breast cancer (MBC): Analysis from a large multi-institutional cohort and the TONIC phase II trial with nivolumab.Org: University of Padova, Istituto Oncologico Veneto IRCCS, Fondazione IRCCS INT, Milan, Italy, Netherlands Cancer Institute, University Hospital of Modena,
Abstract
Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.Org: International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Medica Scientia Innovation Research (MEDSIR), Oncoclínicas&Co,
Abstract
Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Dana-Farber Cancer Institute, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Immune related adverse events in patients with breast cancer and autoimmune disease treated with immunotherapy.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Massachusetts General Hospital, Department of Radiation Oncology, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey.Org: Yale University School of Medicine, Yale Cancer Center, Yale School of Medicine,
Abstract
Tucatinib and trastuzumab for previously treated HER2−mutated metastatic breast cancer (SGNTUC−019): A phase 2 basket study.Org: The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Istituto Europeo di Oncologia, IRCCS and University of Milano, Aichi Cancer Center Hospital, Seoul National University Hospital,
Abstract
Detection of TROP2: Ushering in a new choice in the treatment of patients with special types of invasive breast cancer.Org: Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, The Fourth Hospital of Hebei Medical University, Shijiazhuang Yiling Pharmaceutical, China National Biotec Group,
Abstract
CREB5 as an essential transcription and tumorigenic regulator in basal-like breast and prostate cancer.Org: University of Minnesota, Rush University Medical College, Harvard Medical School, University of Minnesota Masonic Cancer Center,
Abstract
A single center retrospective cohort study of patients with metastatic breast cancer and leptomeningeal disease: Updated survival data and subgroup analyses by breast cancer subtype.Org: University of California Irvine, UCSF Breast Care Center, UCSF Medical Center, Helen Diller Family Comprehensive Cancer Center, Department of Radiation Oncology,
Abstract
Transcriptomic analysis of cAMP/PKA/CREB signaling in invasive lobular breast cancer.Org: Washington University School of Medicine, University of Pittsburgh,
Abstract
Updated safety and antitumor activity of BB-1701 from study 101 in the multiple dose level cohort of patients with locally advanced/metastatic HER2-low expressing breast cancer.Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Jiangsu Province Hospital, Nanjing, China, Linyi Cancer Hospital, Linyi, China, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, China,
Abstract
Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: A SEER-Medicare analysis.Org: Pfizer AB, Pfizer Inc., RTI Health Solutions, University of Pittsburgh, University of California Irvine,
Abstract
Financial toxicity in patients with metastatic breast cancer on trastuzumab deruxtecan (T-DXd).Org: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, School of Social Work, The University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, NYU Grossman Long Island School of Medicine, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center,
Abstract
Real-world tumor BRCA testing patterns and PARP inhibitor use in HER2-negative metastatic breast cancer.Org: Mayo Clinic, Rochester, MN, AstraZeneca, Gaithersburg, MD,
Abstract
Molecular and immunological characterization of androgen receptor expression in different breast cancer subtypes.Org: Norris Comprehensive Cancer Center, Keck School of Medicine, Caris Life Sciences, City of Hope National Medical Center, Department of Population and Public Health Sciences,
Abstract
Identification of HER2 ultra-low based on an artificial intelligence (AI)-powered HER2 subcellular quantification from HER2 immunohistochemistry images.Org: Lunit Inc., Department of Pathology, Samsung Medical Center, Department of Pathology, Kyung Hee University Hospital, Digital Medicine Society (DiMe), Samsung Medical Center,
Abstract
Male breast cancer survival in Mexico between 2007 and 2016: A retrospective cohort.Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Institute of Public Health and Center for Stroke Research, Charité—Universitätsmedizin Berlin, INCMNSZ,
Abstract
The impact of COVID-19 and missed diagnosis of breast cancer.Org: Palo Alto Medical Foundation Research Institute, Palo Alto, CA, Pingtung Veterans General Hospital, Pingtung, Taiwan, California Pacific Medical Center Research Institute, San Francisco, CA,
Abstract
Disparities in stage at presentation for disaggregated Asian American, Native Hawaiian, and Pacific Islander (AANHPI) groups with breast cancer.Org: University of Pennsylvania, Harvard University, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, University of Rochester, University of Pittsburgh,
Abstract
ctDNA monitoring for breast cancer at high risk of recurrence: Interim analysis of JCOG1204A1.Org: Department of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Japan, Breast Medical Oncology Department, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan, National Defense Medical College Hospital, Tokorozawa, Japan, Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan, Department of Breast Care, Saitama Medical Center, Saitama, Japan,
Abstract
Clinical relevance of clinical treatment score post 5 years (CTS5) in HR-positive, HER2-positive breast cancer: An exploratory analysis from the HERA trial.Org: Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul National University Hospital, Division of Medical Oncology, National Cancer Center Singapore,
Abstract
Patient factors associated with chemotherapy modifications: Results from the Optimal Breast Cancer Chemotherapy Dosing (OBCD) study.Org: Memorial Sloan Kettering Cancer Center, Kaiser Permanente Washington Health Research Institute, Rogel Cancer Center, University of Michigan, The Permanente Medical Group Consulting Services, Kaiser Permanente Division of Research,
Abstract
Estimating benefit from dose dense adjuvant chemotherapy for early breast cancer in the PANTHER randomized phase 3 trial.Org: Karolinska Institutet and Karolinska University Hospital, Comprehensive Cancer Center, Medical University of Vienna, Karolinska Institutet, Helios Klinikum Berlin-Buch, IIIrd Medical Department, Paracelsus Medical University,
Abstract
Associations between HIV infection status, psychosocial factors, and adjuvant endocrine therapy adherence among South African women with early-stage breast cancer.Org: Yale Cancer Center, Yale School of Medicine, University of Witwatersrand Faculty of Health Sciences, University of Miami Health System, University Witwatersrand Faculty Health Sciences,
Abstract
Impact of young age at diagnosis on survival outcomes in patients with early breast cancer according to tumor subtype: Pooled analysis of 5 randomized clinical trials from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM).Org: Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova, Genova, Italy, Genoa, IT, Italy, Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Istituto Nazionale Tumori Napoli IRCCS "Fondazione Pascale", Napoli, Italy, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy, Department of Medicine (DAME), University of Udine; Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Udine, Italy, Precision Medicine Unit in Senology Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy, IRCCS Sacro Cuore Don Calabria, Negrar Di Valpolicella, Italy, Clinical Oncology Department, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, Genoa, Italy and Academic Trials Promoting Team, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium, IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy, Medical Research Council at UCL, London, United Kingdom, Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova and Medical Oncology Department, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy, Clinical Oncology Department, IRCCS Ospedale Policlinico San Martino Genoa, Genova, Italy, University of Genova, Genova, Italy, IRCCS Ospedale Policlinico San Martino, Istituto Nazionale Tumori Napoli IRCCS Fondazione Pascale, Napoli, Italy, University Federico II,
Abstract
Use of chemotherapy and loco-regional therapy for stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study.Org: National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany, Geschäftsstelle Qualitätskonferenzen bei der Klinischen Landesregisterstelle Baden-Württemberg GmbH, Krebsregister Baden-Württemberg, Stuttgart, Germany, Breast Cancer Center, Klinik St. Elisabeth, Heidelberg, Germany, Department of Obstetrics and Gynecology, University Hospital of Schleswig Holstein, Campus Lübeck, Lübeck, Germany, National Center for Tumor Diseases (NCT),
Abstract
Adjuvant chemotherapy guided by an integrated mRNA–lncRNA signature in triple-negative breast cancer (BCTOP-T-A01): A randomized, open-label, multicenter phase 3 trial.Org: Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Fudan University Shanghai Cancer Center, Shanghai, China, Chongqing Cancer Hospital, Chongqing, China, Northern Jiangsu People's Hospital, Yangzhou, China,
Abstract
Benefit of perioperative chemotherapy in the patients with loco-regional recurrence of HR-positive HER2-negative breast cancer: A multi-institutional retrospective cohort study.Org: Breast Medical Oncology Department, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Fukushima Medical University, School of Medicine, Department of Breast Oncology, Cancer Hospital of Xinjiang Medical University, Urumuqi, China, Research Institute for Radiation Biology and Medicine,
Abstract
Improving patient understanding of GEP test results (IMPARTER4): An RCT.Org: Brighton & Sussex Medical School, University of Sussex, School of Medicine, Showa University, Keele University, Brighton and Sussex Medical School,
Abstract
Identification of patients with DCIS with low-risk clinicopathology who benefit from radiation therapy with and without endocrine therapy after breast-conserving surgery assessed with the 7-gene biosignature.Org: Nashville Breast Center, Cleveland Clinc, Michigan Healthcare Professionals, University of Colorado Denver, Washington University School of Medicine,
Abstract
Breast Cancer Index re-stratifies 21-gene assay risk groups for late distant recurrence and extended endocrine therapy benefit: Results from the BCI Registry Study.Org: University of Illinois Chicago, bioTheranostics, A Hologic Company, Hologic, San Diego State University Department of Biology, San Diego, CA,
Abstract
RNA-Seq based gene expression profiling of baseline and on-treatment breast tumors to predict response to HER2-directed therapy, without chemotherapy (TBCRC026).Org: Cancer Research @UCC, Cork, Ireland, Lineberger Comprehensive Center, Chapel Hill, NC, University of California, San Francisco, CA, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD,
Abstract
PARPi eligibility amongst women with newly diagnosed invasive breast cancer enrolled in the GREAT universal genetic testing study.Org: McGill University Health Center, Jewish General Hospital Stroll Cancer Prevention Centre, Montréal, QC, Canada, McGill University Department of Human Genetics, Montreal, QC, Canada,
Abstract
Dose-dense adjuvant chemotherapy in patients with HER2-low early breast cancer: An exploratory analysis of the GIM2 trial.Org: Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Clinical Oncology Department, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Department of Clinical Medicine and Surgery, Università Federico II, Napoli, Italy, Medical Oncology Department, ASL FR, Frosinone, Italy, Precision Medicine Unit in Senology Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy,
Abstract
Updated SEER database study of 21-gene assay to assess breast cancer–specific mortality and benefit of chemotherapy by race and ethnicity.Org: Genomic Health Inc, Department of Biostatistics & Data Science, UPMC Hillman Cancer Center, Exact Sciences Corporation, National Cancer Institute/National Institutes of Health,
Abstract
Cost consequence model of the MammaPrint (70-gene signature) and 21-gene signature in patients with primary HR+HER2-, N1 early-stage breast cancer in Germany.Org: Agendia BV, Department of Gynecology and Obstetrics, Women's Hospital St. Louise, St. Josefs, St. Vincenz-Krankenhaus GmbH,
Abstract
Predicting completion of endocrine therapy for older patients with early-stage breast cancer.Org: NYU Langone Medical Center, Perlmutter Cancer Center, New York University Langone Health, NYU Langone Health,
Abstract
Sexual health and therapy adherence of hormone-sensitive breast cancer survivors on maintenance endocrine therapy: The SHE-CAN project in Toronto, Canada.Org: Mount Sinai Hospital-Breast Medical Oncology, Women's College Hospital,
Abstract
Patient-reported provider communication skills and adherence to recommended treatment in breast cancer.Org: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Duke University Medical Center, School of Social Work, The University of North Carolina at Chapel Hill, Breastcancer.org, Schools of Medicine and Public Health, University of California, Los Angeles,
Abstract
Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13).Org: Dana-Farber Cancer Institute, Mayo Clinic, Medical University of Vienna, Washington University School of Medicine, The University of Texas MD Anderson Cancer Center,
Abstract
Predicting epirubicin response in Danish patients with breast cancer.Org: Aida Oncology, Dragor, Denmark, JADBio, Crete, Greece, Raven Biosciences,
Abstract
Cancer outcomes from a real-world cohort of patients eligible for adjuvant CDK4/6 inhibitors but without genomic risk for chemotherapy: A GBECAM multicenter retrospective study.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Hospital Moinhos de Vento, Sírio Libanês Hospital, Hospital Sírio-Libanês, A.C. Camargo Cancer Center,
Abstract
Short-term risk of recurrence in patients (pts) with HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): A meta-analysis.Org: Analysis Group, Inc., Novartis Pharmaceuticals Corporation, University Hospital Erlangen, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Relevance of timing intake of everolimus (EVE) combined with adjuvant endocrine therapy (ET) in patients (pts) with high-risk early breast cancer: Results of a sub-study of the UCBG-UNIRAD trial.Org: Surgery Department, Institut Curie, Saint Cloud, France, Universite Paris Cite, Residual Tumor and Response to Treatment, U932 Immunity and Cancer,
Abstract
An initial experience of robot-assisted breast conserving surgery: A multicenter study of the Korea Robot-Endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG).Org: Samsung Changwon Hospital, Department of Surgery, Soonchunhyang University College of Medicine, Kosin University Gospel Hospital, Pusan National University Yangsan Hospital, Yonsei University College of Medicine,
Abstract
Clinical outcomes of patients with HER2-positive microinvasive breast cancer.Org: Department of Oncology, National Taiwan University Hospital, Asan Medical Center, University of Ulsan College of Medicine, Division of Breast Surgery, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
Artificial intelligence algorithms for recurrence risk score prediction in early-stage breast cancer: A multicenter study of 437 cases.Org: Cukurova University Medical Oncology, Acibadem University, Ege University, Department of Medical Oncology, Koç University Faculty of Medicine, Johns Hopkins Anadolu Health Center Hospital,
Abstract
Clinical-pathological characteristics associated with multigene assay risk scores, and prognostic impact of multigene risk scores in patients with invasive lobular carcinoma.Org: Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Seoul, South Korea, Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Division of Breast Surgery, Department of Surgery, Asan Medical Center, Ulsan University, College of Medicine, Seoul, South Korea, Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Seoul, South Korea, Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Division of Breast Surgery, Department of Surgery, Asan Medical Center, Ulsan University, College of Medicine, Seoul, South Korea, Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
Impact of CYP2D6 polymorphisms on adverse events in patients with breast cancer treated with tamoxifen: Insights from an early dose escalation trial in CYP2D6 poor metabolizers.Org: Oncology Department, San Cecilio University Hospital, Granada, Spain, Oncology Department, Hospital Provincial de Castellón, Castellon De La Plana, Spain, Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada; Biosanitary Research Institute of Granada (ibs.GRANADA), Granada, Spain,
Abstract
Effects of plant-based diet (PBD) and exercise therapy (Ex) on weight and body composition in patients with primary hormone receptor (HR) positive breast cancer: A phase 2 randomized controlled trial.Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham,
Abstract
Impact of circulating tumor DNA (ctDNA) surveillance on clinical care for patients with stage I-III breast cancer: Findings from a multi-institutional study.Org: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, Massachusetts General Hospital, Harvard Medical School, Washington University in St. Louis, Natera, Inc.,
Abstract
Safety run-in phase of the multi-epitope HER2 peptide vaccine in combination with trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy.Org: Mayo Clinic Florida, Mayo Clinic, Mayo Clinic Alliance Statistics and Data Center, Mayo Clinic Department of Pediatric and Adolescent Medicine,
Abstract
Prognostic value of Oncotype recurrence score (RS) and Mammaprint (MP) in premenopausal patients with hormone positive (HR+) breast cancer (BC) with low genomic risk, stratified by race: A study of the National Cancer Database (NCDB).Org: Medical University of South Carolina, SUNY Upstate University Hospital, State University of New York Upstate Medical University,
Abstract
Long-term oncologic outcome of breast-conserving surgery in breast cancer with BRCA 1/2 mutation (ON-BRCA II, KoREa-BSG 06).Org: Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV, Dongtan Sacred Heart Hospital, Hallym University, Division of Breast Surgery, Samsung Medical Center,
Abstract
Deep learning-based quantitative assessment of tumor-infiltrating lymphocytes from hematoxylin and eosin-stained slides in triple-negative breast cancer: A prognostic study.Org: Biomy Inc., Center of Development of Advanced Diagnostics, Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Department of Preventive Medicine, Graduate School of Medicine, Osaka University,
Abstract
Radiogenomics of homologous recombination deficiency (HRD) in breast cancer: Radiomics-based image biomarker for HRD.Org: Genome Insight Inc., Bucheon St. Mary's Hospital, Samsung Medical Center, Genome Insight, Inc., Sungkyunkwan University School of Medicine,
Abstract
Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030.Org: Dana-Farber Cancer Institute, 4D Path Inc., Vanderbilt University Medical Center, University of Pittsburgh, O'Neal Comprehensive Cancer Center at UAB,
Abstract
Ki67 as a prognostic factor in male breast cancer (male BC): Results from a large GEICAM Spanish cohort of male BC.Org: Gipuzkoa Cancer Unit- OSID/Onkologikoa-Osakidetza, GEICAM Spanish Breast Cancer Group, Hospital Universitario de Basurto, Hospital Clínico Universitario de Valencia, Institut Català d’Oncologia Hospitalet- Hospital Moises Broggi,
Abstract
Postpartum breast cancer: Analysis of factors related to pregnancy and identification of differential prognostic markers.Org: Medical Oncology Department, University Reina Sofia Hospital, Maimónides Biomedical Research Institute of Córdoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)–H. Universitario Reina Sofía, Universidad de Córdoba, GEICAM Spanish Breast Cancer Group,
Abstract
Association of tumor-infiltrating lymphocytes (TILs) and immune signatures with PAM50 intrinsic subtyping hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of two multicentric neoadjuvant trials.Org: University of Padua School of Medicine, University of Padova, Veneto Institute of Oncology IOV-IRCCS, Reveal Genomics Srl, Istituto Oncologico Veneto IRCCS,
Abstract
Association of circulating T lymphocytes and their functional states with pathologic complete response (pCR) in breast cancer (BC). A prospective Italian study.Org: University of Eastern Piedmont, University of Piemonte Orientale Amedeo Avogadro, AOU Maggiore della Carità, Università del Piemonte Orientale - Dipartimento di Medicina Traslazionale - DIMET, Novara, Italy,
Abstract
Molecular profiling after short-term preoperative endocrine therapy to identify oestrogen receptor positive (ER+)/HER2+ early breast tumours with favourable prognosis.Org: Institute of Cancer Research, London, United Kingdom, Royal Marsden Hospital, London, United Kingdom, The Institute of Cancer Research, London, United Kingdom, The Institue of Cancer Research, London, United Kingdom, The Institute of Cancer Research, Sutton, United Kingdom,
Abstract
Evaluating the association between radiomic features on breast MRI and dormant tumor cell presence in the SURMOUNT trial.Org: Columbia University Medical Center, Hospital of the University of Pennsylvania, University of Pennsylvania, Perelman Center for Advanced Medicine, Center for Biomedical Image Computing and Analytics (CBICA),
Abstract
A blind validation of a deep-learning solution providing HER2, ER, and PR results from H&E-stained breast cancer specimens.Org: Panakeia Technologies Limited, Leeds Institute of Molecular Medicine, NHS Leeds Teaching Hospitals Trust, University of Leeds,
Abstract
The landscape of the intestinal microbiome amongst patients with newly diagnosed invasive breast cancer (BC) and ductal carcinoma in situ (DCIS).Org: Dana-Farber Cancer Institute, Department of Biostatistics & Data Science, Microbiome Analysis Core, Harvard T.H. Chan School of Public Health, Harvard Medical School,
Abstract
Impact of race/ethnicity on the MammaPrint genomic assay risk and prognosis in early breast cancer (EBC): A National Cancer Database (NCDB) analysis.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Tisch Cancer Institute, Mount Sinai Hospital-Breast Medical Oncology,
Abstract
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the Recurrence Score in node-positive breast cancer: Independent validation in the PACS-01 trial.Org: Exact Sciences Corporation, Gustave Roussy Cancer Center, Centre Léon Bérard, R&D Unicancer, Alliance for Clinical Trials in Oncology,
Abstract
Relationship of adaptive subtyping and tumour heterogeneity of treatment response to neoadjuvant therapy in hormone receptor–positive HER2-negative early breast cancer: PENELOPE-B.Org: GBG Forschungs GmbH, German Breast Group, Helios Klinikum Berlin-Buch, Roswell Park Comprehensive Cancer Center, Penn Medicine Abramson Cancer Center,
Abstract
Adjunctive statistical standardization of quantitated adjuvant ER and PgR in CCTG MA.27.Org: Ontario Institute for Cancer Research, Toronto, ON, Canada, MASS General Hospital BHX-1, Mayo Clinic Department of Oncology, Progendis, Caris Life Sciences,
Abstract
Monitoring ctDNA dynamics in early breast cancer using a novel ultra-sensitive tumor-informed structural variant approach combining whole-genome sequencing and multiplex dPCR.Org: Lund University, SAGA Diagnostics, Skåne University Hospital, Lund University,
Abstract
Predicting response to neoadjuvant therapy (NAT) in patients (pts) with early-stage breast cancer (BC) using circulating tumor DNA (ctDNA) testing.Org: Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Natera, Inc.,
Abstract
Nectin-4 expression in primary breast cancer and associated clinical outcomes.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Broad Institute of Harvard and MIT, Massachusetts General Hospital, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Artificial intelligence (AI) –powered H&E whole-slide image (WSI) analysis to predict recurrence in hormone receptor positive (HR+) early breast cancer (EBC).Org: Oncology Therapeutic Development, Lunit Inc.,
Abstract
The immunomodulatory impacts of endocrine therapy on host immunity in early-stage hormone receptor positive, HER2 negative breast cancer.Org: Dana-Farber Cancer Institute, Duke Cancer Institute, Duke University Medical Center, The University of North Carolina at Chapel Hill, UT Southwestern Medical Center,
Abstract
Correlation of hormone receptor positive HER2-negative/MammaPrint high-2 breast cancer with triple negative breast cancer: Results from gene expression data from the ISPY2 trial.Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale University School of Medicine, Bioinformatics Support Program,
Abstract
Clinical application of novel mobile AI solution for real-time detection and differential diagnosis in breast ultrasound: The first prospective feasibility study.Org: Hogukro 807, Shin Kong Wu Ho-Su Memorial Hospital,
Abstract
Memory mayhem: Hormone therapy causing brain fog in patients with DCIS.Org: SUNY Upstate Medical University, Syracuse, NY, Nykode Therapeutics, SUNY Upstate University Hospital, SUNY Upstate Medical Center,
Abstract
Patient-reported outcomes in N1 breast cancer: A phase III trial comparing whole-breast to whole-breast plus regional irradiation after taxane-based chemotherapy (KROG 1701).Org: Samsung Medical Center, Chonnam National University Medical School and CNU Hwasun Hospital, Asan Medical Center, Soonchunhyang University Hospital, Gil Medical Center,
Abstract
Radiofrequency ablation without excision for breast cancer: 5-year results of ipsilateral breast tumor recurrence-free survival in the RAFAELO study (NCCH1409).Org: NHO Tokyo Med Ctr, National Cancer Center Hospital East, Kashiwa, Japan, Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Hokkaido University Hospital Cancer Center, Gunma Prefectural Cancer Center,
Abstract
Radar reflectors for marking of target lymph nodes in patients receiving neoadjuvant chemotherapy for breast cancer: A subgroup analysis of the prospective AXSANA (EUBREAST-03) trial.Org: University Hospital of Schleswig Holstein, Klinikum Esslingen, University Hospital Rostock, Karolinska Institutet, Capio St. Göran’s Hospital,
Abstract
A retrospective look: Industry partnership and transparency in phase III randomized clinical trials of breast cancer targeted therapies across two decades.Org: California Pacific Medical Center Research Institute, San Francisco, CA, Center for Health Systems Research, Sutter Health, Stanford University Medical Center, Palo Alto Medical Foundation,
Abstract
Patient-derived tumor cell clusters (PTC) guiding-neoadjuvant therapy of HER2-positive breast cancer: A prospective randomized phase II clinical trial.Org: Zhejiang Cancer Hospital, Hangzhou, China,
Abstract
Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.Org: Duke Cancer Institute, University of California, San Francisco, University of Utah, University of California, Davis Comprehensive Cancer Center, University of Chicago Medicine,
Abstract
Evolution and prognostic significance of HER-2 changes from primary to residual disease in patients with HER-2–negative breast cancer receiving neoadjuvant chemotherapy.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital,
Abstract
Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.Org: University of Chicago Medicine, University of Chicago, University of California, San Francisco Department of Medicine, University of California, San Francisco Department of Surgery, University of California, San Francisco,
Abstract
Harnessing cell-free orphan non-coding RNAs as a predictive measure of long-term survival in neoadjuvant breast cancer therapy.Org: Exai Bio Inc., UCSF Comprehensive Cancer Center, University of California, San Francisco, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV, Department of Laboratory Medicine,
Abstract
Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial.Org: International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, Jersey City (New Jersey, USA),
Abstract
Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial.Org: Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria, Austrian Breast and Colorectal Cancer Study Group, Wien, Austria, Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Vienna, Austria, Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria, Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria,
Abstract
Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial.Org: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, DFCI/PCC Fellowship Program - Attendings, Personalis, Inc.,
Abstract
Prediction of pCR with pretreatment MRI radiomics in triple negative breast cancer treated with neoadjuvant chemo-immunotherapy.Org: Institut Curie, Paris, France, Institut Curie, Paris and St Cloud, France, Institut Curie, Saint Cloud, France, Institut Curie, Paris and Saint Cloud, France, Institut Curie, Paris and Saint-Cloud, France,
Abstract
Multiomic factor analysis for pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial.Org: West German Study Group, Moenchengladbach, Germany, Queen Mary University of London, London, United Kingdom, Medical School Brandenburg, Institute for Biometrics and Registry Research, Neuruppin, Neuruppin, Germany,
Abstract
Pathological complete response (pCR) association with a novel homologous recombination deficiency HRD signature (HRDsig) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (Tx).Org: Cancer Center, Stanford, Palo Alto, CA, Foundation Medicine, Inc., San Diego, CA, Foundation Medicine, Inc., Cambridge, MA, SUNY Upstate Medical University, Syracuse, NY, Foundation Medicine, Inc., Boston, MA,
Abstract
An MRI-based multi-parameter clinical decision support system (NeoMDSS) for early prediction of pathological complete response after the first cycle of neoadjuvant therapy in breast cancer: A multi-center prospective observational cohort study.Org: Cancer Center Clínica Universidad de Navarra, Madrid, Spain, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangdong Academy of Medical Sciences, Southern Medical University, Department of Vascular Surgery,
Abstract
Evaluating gut microbiome as a biomarker of pathological complete response in patients with early locally advanced triple negative breast cancer (LA TNBC): A pilot study.Org: H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, MCC Physicians, Duke University Medical Center, Duke Cancer Institute,
Abstract
Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.Org: Mayo Clinic, University of California Irvine, UCSF Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Alliance for Clinical Trials in Oncology,
Abstract
Personalized neoadjuvant strategy in ER positive and HER2 negative breast cancer to increase BCS rate (PLATO): A prospective, multicenter, phase II clinical trial.Org: Seoul National University Hospital, Seoul National University College of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul National University Bundang Hospital,
Abstract
Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: A randomized phase II study (METIS).Org: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Cancer Center, Sun Yat-sen University, Guangzhou, China, Shantou Central Hospital, Shantou, China,
Abstract
Pathological complete response to predict long term outcomes in the I-SPY2 TRIAL.Org: Masonic Cancer Center, University of Minnesota, University of California Irvine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco,
Abstract
Predictive biomarkers for pathological complete response in early-stage triple negative breast cancer following neoadjuvant chemotherapy.Org: Instituto do Câncer do Estado de São Paulo (ICESP), Universidade de São Paulo, Grupo Dasa,
Abstract
Evaluating the efficacy of neoadjuvant endocrine therapy in HER2 low vs. HER2 negative breast cancer: An NCBD analysis.Org: Department of Oncology/Hematology, Loma Linda University Medical Center, City of Hope National Cancer Center, City of Hope National Medical Center,
Abstract
Ten-year outcomes of targeted axillary surgery after neoadjuvant chemotherapy in breast cancer.Org: Kyungpook National University Hospital, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV, Kyungpook National University School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital,
Abstract
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).Org: University of California, San Francisco, Mayo Clinic, University of Chicago Medical Center, Chicago, IL, Winship Cancer Institute of Emory University, Hunstman Cancer Institute at the University of Utah,
Abstract
Trends, patterns, and outcomes of neoadjuvant chemotherapy (NACT) use among patients with early invasive triple negative breast cancer (TNBC).Org: The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX,
Abstract
Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): Primary analysis of a prospective, multicenter, response-adapted study.Org: Second Hospital of Shandong University, Jinan, China, Affiliated Hospital of Jining Medical University, Jining, China, Binzhou Medical University Hospital, Binzhou, China, Linyi Cancer Hospital, Linyi, China, Liaocheng People's Hospital, Liaocheng, China,
Abstract
Clinical outcomes and efficacy of HER2-targeted therapy in breast cancer with uncommon in situ hybridization (ISH) patterns or discordant immunohistochemistry (IHC).Org: Department of Public Health Sciences, Section of Infectious Diseases and Global Health, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, University of Chicago Medicine, Center for Data Intensive Science at the University of Chicago,
Abstract
Automated prediction of response to neoadjuvant chemotherapy from digitized H&E slides of pre-treatment core needle biopsies in germline BRCA carriers with HER2-negative breast cancer (TBCRC 031).Org: Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Dana-Farber Cancer Institute, 4D Path Inc.,
Abstract
The predictive value of the mature B cell signature in early Her2-positive breast cancer treated with neoadjuvant therapy.Org: National Taiwan University Hospital, National Taiwan University College of Medicine,
Abstract
Survival outcomes and treatment patterns by tumor subtype (TS) in stage III inflammatory and non-inflammatory breast cancer (BC).Org: Dana-Farber Cancer Institute/Harvard Medical School, Grupo Oncológico Cooperativo del Sur, Brigham and Women's Hospital, Tufts Medical Center/Tufts University, Michigan State University,
Abstract
Phase II study of neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant stage III triple negative breast cancer (TNBC): BCT1702—Survival results.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Breast Cancer Trials - Australia and New Zealand, NHMRC Clinical Trials Centre, Monash Health, Bentleigh East, VIC, Australia, Macarthur Cancer Therapy Center,
Abstract
Node marking techniques and targeted axillary dissection in patients with cN1 disease undergoing neoadjuvant chemotherapy: Analysis of initial 500 participants in the ATNEC trial.Org: Royal Derby Hospital, University of Warwick, Aberdeen Royal Infirmary, Royal Cornwall Hospitals NHS Trust, Queen Elizabeth Hospital,
Abstract
Circulating tumor DNA detection after neoadjuvant chemotherapy and prediction of distant relapse free survival, local recurrence, and distant recurrence in triple-negative breast cancer in the TRICIA study.Org: Lady Davis Institute of the Jewish General Hospital, Jewish General Hospital Stroll Cancer Prevention Centre, Montreal, QC, Canada, Canada, Jewish General Hospital-Sir Mortimer B. Davis Jewish General Hospital,
Abstract
Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in patients with HER2 low/ultra-low/null metastatic breast cancer.Org: University of Hawaii Cancer Center, The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center,
Abstract
Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd).Org: Stanford University Medical Center, University of Miami Health System, Stanford University School of Medicine, Medical Oncology Department, Ramón y Cajal University Hospital, Levine Cancer Institute, Atrium Heath,
Abstract
An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).Org: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, Mayo Clinic, Miami Cancer Institute, Baptist Health South Florida, NW Medical Specialties,
Abstract
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).Org: The University of Texas MD Anderson Cancer Center, US Oncology Research/Maryland Oncology Hematology, Norton Healthcare, New York Presbyterian, Northwest Medical Specialties,
Abstract
INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC).Org: Genentech, Product Development Data Science, F. Hoffmann-La Roche Ltd., F. Hoffmann-La Roche Ltd, Roche Products Ltd., Product Development Oncology, F. Hoffmann-La Roche Ltd.,
Abstract
AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.Org: Centre Hospitalier De L Ardenne, Libramont-Chevigny, Belgium, Hospital Universitario Arnau de Vilanova; GEICAM Spanish Breast Cancer Group, Lleida, Spain, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, START Madrid - Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, The Oncology Institute, Whittier, CA,
Abstract
Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study.Org: Institut Català D'Oncologia, IDIBELL, L’Hospitalet, Hospital Universitario Marques de Valdecilla, Hospital Vithas Málaga,
Abstract
Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation.Org: Pangaea Oncology, Breast Oncology Institute, Sermonix Pharmaceuticals, Mayo Clinic, Medical Oncology,
Abstract
First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.Org: Vall d’Hebron University Hospital/VHIO, Vall d'Hebron Institute of Oncology, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Instituto Valenciano de Oncología,
Abstract
International phase 3 clinical trial evaluating PF-07220060 plus fulvestrant in patients with HR+/HER2− advanced/metastatic breast cancer with progression after a prior CDK4/6 inhibitor.Org: Dana-Farber Cancer Institute, Institut Jules Bordet, Université Libre de Bruxelles, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Centro de Pesquisa Clínica Hospital São Lucas da PUCRS,
Abstract
pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2– locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant (adj) endocrine therapy (ET).Org: Winship Cancer Institute of Emory University, Dana-Farber Cancer Institute, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, University Hospital Erlangen, Hospital Alemán,
Abstract
TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.Org: Stanford University School of Medicine, University of Colorado Health Cancer Care, Huntsman Cancer Institute, START San Antonio, Pfizer Inc.,
Abstract
Implementing geriatric assessment for dose optimization of CDK 4/6 inhibitors in older breast cancer patients (IMPORTANT trial): A pragmatic randomized-controlled trial.Org: Örebro University Hospital, Santo Stefano Hospital, General Hospital of Patras St. Andrews, Akershus University Hospital (Ahus), Papageorgiou General Hospital,
Abstract
ECLECTIC: 18F-fluoroestradiol PET and circulating biomarkers to guide the choice of the second line therapy for ER+, HER2- metastatic breast cancer: A phase 3 trial.Org: Institut Curie, Saint Cloud, France, Paris and Saint Cloud, France, Centre Oscar Lambret, Lille University Hospital,
Abstract
Innovation of the first-line strategy optimized as abemaciclib with endocrine therapy based on the ESR1 mutation of ctDNA for patients with HR-positive HER2-negative advanced metastatic breast cancer (JBCRG-M08; AMBER study).Org: Osaka University Hospital, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Nagoya University Hospital,
Abstract
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors.Org: Gustave Roussy Cancer Center, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology, Clinical Oncology Department, IRCCS Ospedale Policlinico San Martino Genoa, Genova, Italy, IRCCS Ospedale Policlinico San Martino Genoa,
Abstract
INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Winship Cancer Institute of Emory University, Seoul National University Hospital, IRCCS Ospedale San Raffaele,
Abstract
Study of the Bria-IMT regimen and CPI vs physicians' choice in advanced metastatic breast cancer (BRIA-ABC).Org: University of Washington School of Medicine and Fred Hutchinson Cancer Center, Mayo Clinic Florida, University of Pittsburgh, Hoag Cancer Center, Newport Beach, CA, Morehouse School of Medicine,
Abstract
TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, Dana-Farber Cancer Institute, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC,
Abstract
Clinical utility of ctDNA as a tool to detect triple-negative breast cancer relapses: The CUPCAKE trial.Org: Institut Curie, Saint Cloud, France, Institut Bergonie, Centre Jean Perrin, Centre Léon Bérard, Institut Paoli Calmettes,
Abstract
Phase I/II study of stereotactic radiation and sacituzumab govitecan with zimberelimab in the management of metastatic triple negative breast cancer with brain metastases.Org: H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, Prince of Wales Hospital,
Abstract
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).Org: Roswell Park Comprehensive Cancer Center, Buffalo, NY,
Abstract
TOPOLOGY: A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.Org: Institut Curie, Saint Cloud, France, Hopital Privé des Cotes d'Armor, Paris and Saint-Cloud, Medical Oncology Department and D3i, Paris and Saint Cloud,
Abstract
Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer (MBC) with a somatic BRCA1/2 mutation identified in a cell-free DNA or tumor tissue genotyping assay.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, The University of Texas MD Anderson Cancer Center, Emory University School of Medicine, Massachusetts General Hospital,
Abstract
Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (OPBC-03/SAKK 23/16/IBCSG 57-18/ABCSG-53/GBG-101-TAXIS).Org: University Hospital Basel and Faculty of Medicine University of Basel, Basel, Switzerland, Hamad Medical Corporation, Department of Oncoplastic Breast Surgery, Doha, Qatar, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland, Breast Center Zurich, Zurich, Switzerland, Canton Hospital Münsterlingen, Münsterlingen, Switzerland,
Abstract
A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009.Org: Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health, University of Pittsburgh School of Public Health, University of Pittsburgh Medical Center (UPMC),
Abstract
A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008.Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, Women and Infants Hospital of Rhode Island,
Abstract
Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT trial.Org: Cancer Research @UCC, Brown University - ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Saint Vincent Hospital Cancer Center Green Bay, University of Alabama at Birmingham Comprehensive Cancer Center,
Abstract
Prospective evaluation of the breast microbiome and tumor microenvironment-related biomarkers of response to neoadjuvant systemic therapy in triple negative breast cancer.Org: Cancer Research @UCC, CUH/UCC Cancer Centre, HRB Clinical Research Facility, School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute,
Abstract
Assessing the feasibility and cost-effectiveness of all oral adjuvant chemotherapy (cyclophosphamide, methotrexate, capecitabine) in high-risk hormone receptor positive breast cancer.Org: University of Illinois Hospital & Health Sciences System, University of Illinois Chicago, Stanford University School of Medicine,
Abstract
Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in patients with breast cancer with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01.Org: Greenwich LifeSciences, Stafford, TX, Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine,
Abstract
Abemaciclib dose escalation to maintain intensity (ADE-MI).Org: University of Illinois Hospital & Health Sciences System, University of Illinois Chicago, University of Illinois at Chicago, University of Illinois Chicago College of Pharmacy,
Abstract
RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE).Org: Medstar Georgetown University Hospital-Lombardi Comprehensive Cancer Center, Lombardi Cancer Center Georgetown University, Regional Cancer Care Associates, Cantex Pharmaceuticals, Georgetown University Medical Center,
Abstract
The SURVIVE study: Liquid biopsy guided surveillance after intermediate- to high-risk early breast cancer.Org: Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany, Department of Women's Health, University of Tübingen, Tübingen, Germany, Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany, Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany,
Abstract
CINDERELLA clinical trial: Using artificial intelligence–driven healthcare to enhance breast cancer locoregional treatment decisions.Org: Breast Unit, Champalimaud Research and Clinical Centre, Champalimaud Foundation, Breast Cancer Radiation Therapy Unit, CEAUL - Centro de Estatística e Aplicações, Faculdade de Ciências, Universidade de Lisboa,
Abstract
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer.Org: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), Department of Biostatistics, University of Pittsburgh School of Public Health, St. Luke’s University Health Network Cancer Center, Orlando Health Cancer Institute, The Ohio State University Comprehensive Cancer Center,
Abstract
MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/iBRA-NET).Org: University Hospital Schleswig-Holstein Campus Lübeck, Breast Cancer Center, Affiliated Cancer Hospital of Chongqing University, Chongqing, China, Die Filderklinik, University of Ulm, Aberdeen Breast Unit,
Abstract
A pilot study of early PET and biomarker dynamics in patients with stage 2 and 3 triple negative breast cancer treated with neoadjuvant response-adapted chemotherapy with pembrolizumab (NeoADAPT).Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Radiology at Johns Hopkins,
Abstract
Neoadjuvant dalpiciclib, exemestane, and goserelin in premenopausal women with HR-positive, HER2-negative breast cancer: A prospective, multicenter, randomized two-group, non-controlled phase 2 clinical trial.Org: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Hemay Pharmaceutical, China National Biotec Group, Tianjian,
Abstract
A phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR- positive HER-2 negative breast cancer: DARLING-02.Org: The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Affiliated Hospital of Hebei Engineering University, Handan, China, First Hospital of Qinhuangdao, Qinhuangdao, China, Qinhuangdao Maternal and Child Health Hospital, Qinhuangdao, China,
Abstract
Clinical validation of image-based AI predictive biomarkers for precision neoadjuvant triple-negative breast cancer treatment (PEAR-TNBC).Org: Ourotech Ltd t/a Pear Bio, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Manchester University Foundation Trust, Barts Cancer Centre,
Abstract
A window-of-opportunity (WOO) trial of giredestrant +/- LHRHa vs anastrozole+LHRHa in premenopausal women with ER+/HER2- early breast cancer (EBC; IBCSG 67-22; PREcoopERA).Org: European Institute of Oncology, Milan, Italy, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center, Boston, MA, Peter MacCallum Cancer Centre, Melbourne, Australia, European Institute of Oncology IRCCS, and University of Milan, Milano, Italy, Breast Unit, Helios University Clinic, University Witten-Herdecke, Wuppertal, Germany,
Abstract
NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC).Org: University of Kansas Medical Center, ZAS Hospitals, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, University of Kansas Cancer Center,
Abstract
Neoadjuvant targeted therapy in early resectable HER2-mutant lobular breast cancer.Org: Vanderbilt-Ingram Cancer Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, UT Southwestern Simmons Comprehensive Cancer Center,
Abstract
Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV.Org: LMU University Hospital Munich, Interdisciplinary Breast Center, Rotkreuz-Clinics Munich, West German Study Group, Ev. Hospital Bethesda,
Abstract
ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.Org: Dana-Farber Cancer Institute/Harvard Medical School, Mayo Clinic, Department of Biostatistics & Data Science, The University of North Carolina at Chapel Hill, The University of Texas MD Anderson Cancer Center,
Abstract
Assessing patient engagement levels in clinical cancer research: Development of a novel evaluation tool and comparison between eastern and western countries.Org: Div of Int'l Health Policy Research, National Cancer Center Japan, Tokyo, Japan, Cliniques Universitaires Saint-Luc, Brussels, Belgium, Independent Consultant/Expert, Louvain-La-Neuve, Belgium, Faculty of International Liberal Arts, Juntendo University, Tokyo, Japan, Japan Agency for Medical Research and Development, Tokyo, Japan, Pancreatic Cancer Action Network, Tokyo, Japan, Chiba University, Chiba-Shi Inage-Ku, Japan, Novartis Pharma K.K., Tokyo, Japan, Efgcp, Wezembeek-Oppem, Belgium, Department of International Clinical Development, National Cancer Center Hospital, Tokyo, Japan, Int'l Health Policy Research, National Cancer Center Japan, Tokyo, Japan,
Abstract
Multi-stakeholder, intentional outreach for improving representative recruitment in Pragmatica–Lung (SWOG S2302).Org: Atrium Health Wake Forest Baptist Comprehensive Cancer Center - Levine Cancer Institute, Charlotte, NC, SWOG Statistical Center, Fred Hutchinson Cancer Center, Seattle, WA, Cedars-Sinai Medical Center, Los Angeles, CA, Dartmouth Cancer Center, Lebanon, NH, Lahey Hospital and Medical Center, Burlington, MA,
Abstract
Data-driven strategies for enhancing diversity in oncology clinical trials: Optimization of eligibility criteria.Org: Flatiron Foundation Medicine Insights Lab, New York, NY, Emory University, Atlanta, GA, USA, Atlanta, GA, Genentech Inc.,
Abstract
Impact of the COVID-19 pandemic mitigation strategies on cancer treatment trials: A meta-analysis of industry and NCI studies.Org: SWOG Statistics and Data Management Center/Fred Hutchinson Cancer Research Center, Seattle, WA, Friends of Cancer Research, Washington, DC, ASCO, Alexandria, VA, Wake Forest University School of Medicine, Winston-Salem, NC, Massachusetts General Hospital, Boston, MA, USA,
Abstract
Approaches to engaging participants in a national cancer genomics research network.Org: The Ohio State University College of Medicine, University of New Mexico Comprehensive Cancer Center, University of Colorado School of Medicine,
Abstract
Evaluation of the study of control arms in randomized clinical trials of cancer.Org: Brown University School of Medicine-Rhode Island Hospital, Memorial Sloan Kettering Cancer Center, Yale University School of Medicine, Saint Louis University School of Medicine, UNC Lineberger Comprehensive Cancer Center,
Abstract
The science of getting published: Key factors influencing publication in pediatric oncology.Org: Immune Oncology Research Institute, Yerevan, Armenia, Yeolyan Hematology and Oncology Center, Armenia,
Abstract
Improving clinical trial performance using adult-learning methods.Org: Department of Clinical Strategy and Solutions, Vaniam Group LLC, Chicago, IL,
Abstract
Underrepresentation of Asian Americans, Native Hawaiians, and other Pacific Islanders (AA & NHPI) in cancer clinical trials that led to FDA approvals in 2010-2022.Org: Center for Drug Evaluation and Research, Oncology Center of Excellence, U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health,
Abstract
Current diagnostic guidelines and perpetuation of inequities in ovarian cancer: A National Cancer Database study.Org: University of Pennsylvania, University of Pennsylvania Perelman School of Medicine,
Abstract
Post-market study requirements and associations with timely submission and regulatory action for oncology drugs receiving accelerated approval, 2011-2023.Org: University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Perelman School of Medicine, Carey Law School,
Abstract
Project Facilitate: An analysis of the increased utilization in the oncology single patient expanded access pathway.Org: U.S. Food and Drug Administration, Oncology Center of Excellence, Silver Spring, MD, Office of the Commissioner,
Abstract
Mind the gap: Estimating the opportunity lost due to the gap between FDA and EMA cancer drug approvals.Org: Lifespan Cancer Institute, Brown University School of Medicine-Rhode Island Hospital, Rhode Island Hospital, Stanford University School of Medicine, The University of Texas MD Anderson Cancer Center,
Abstract
The oncology care model and initiation of systemic therapy for cancer.Org: Harvard Medical School, Brigham and Women's Hospital, Department of Health Care Policy, Dana-Farber Cancer Institute, Dartmouth Cancer Center, Lebanon, NH,
Abstract
Examining the financial landscape of cancer: An analysis of debt and bankruptcy among patients in Massachusetts (2010-2019).Org: Brigham and Women's Hospital, Boston, MA, Beth Israel Deaconess Medical Center, BIDMC,
Abstract
Supplemental Nutrition Assistance Program (SNAP) policy changes and mammography use in the United States.Org: St. Louis University School of Medicine, University of Alabama at Birmingham, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Department of Surveillance and Health Equity Science, American Cancer Society, Department of Radiation Oncology, Washington University School of Medicine in St. Louis,
Abstract
Caregivers and legal barriers: Navigating care of a family member diagnosed with cancer.Org: Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Triage Cancer, University of Alabama at Birmingham,
Abstract
A two-decade trend analysis of in-hospital outcomes and racial/ethnic disparities among hospitalized patients with lung cancer in the United States.Org: Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, MedStar Union Memorial Hospital, Department of Public Health Sciences, University of Chicago, Department of Dermatology,
Abstract
Impact of boarding time on in-hospital mortality in patients with cancer presenting to the emergency department.Org: The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Historic redlining, modern neighborhood structures, and mortality in children, adolescents, and young adults with cancer.Org: University of Washington, Seattle, WA, University of California, San Francisco, San Francisco, CA, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, San Diego State University Department of Biology, San Diego, CA, Fred Hutchinson Cancer Center, Seattle, WA,
Abstract
Characteristics and pregnancy outcomes of pregnant women by cancer diagnosis status.Org: Komodo Health, San Francisco Medical Center, CanSino Biologics, New York City, Nykode Therapeutics,
Abstract
Diet quality and cardiometabolic risk factors among breast cancer survivors in the Pathways Study.Org: Division of Research, Kaiser Permanente Northern California, Fred Hutchinson Cancer Research Center, University of Washington Medical Center,
Abstract
Comorbid opioid use disorder and resource utilization outcomes in patients with neoplasm-related pain: A population analysis.Org: Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, MedStar Union Memorial Hospital, Department of Public Health Sciences, University of Chicago, University of Benin,
Abstract
The impact of multiple pharmacy use on medication adherence in individuals with colorectal cancer.Org: CVS Health,
Abstract
Development and validation of point-of-care mobile solution to guide the diagnosis of malnutrition: A multicenter, prospective cohort study.Org: West China Hospital, Chengdu Origen Biotechnology, China National Biotec Group, Sichuan University,
Abstract
Relationship between receipt of combined axillary dissection and nodal irradiation and age.Org: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Yale University,
Abstract
Electronic patient-reported outcome measures (E-Proms): Results of the H2020 CAPABLE project for patients with metastatic renal cell cancer (mRCC).Org: Dept. of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy, Division of Medical Oncology, AOU Consorziale Policlinico di Bari, Bari, Italy, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy, Dept of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy, University of Pavia,
Abstract
Examining 1-year mortality risk among patients with malignant melanoma undergoing immune checkpoint inhibitor therapy with a history of cannabis use.Org: Fairfield Medical Center, Lancaster, OHB Neonatology, West Virginia University School of Medicine, Morgantown,
Abstract
Association of frailty assessed by a ten-item frailty index (FI-CGA-10) with health-related quality of life in older adults with cancer.Org: Geriatric Oncology Service, NHO Kyushu Cancer Center, Fukuoka University, Department of Biostatistics & Data Science, Yamaguchi University Graduate School of Medicine,
Abstract
Geographic distribution and accessibility of clinic trials for advanced-stage pancreatic cancer in the United States: A focus on rural and minority health disparities.Org: University of North Dakota, Gundersen Lutheran Health System Inc, Medical College of Wisconsin - Green Bay, University of Kansas School of Medicine,
Abstract
Clinical applicability of guideline-recommended molecular targets and genome-targeted cancer therapies.Org: Hospital de la Santa Creu i Sant Pau, Brigham and Women's Hospital, Brigham and Women's Hospital and Harvard Medical School,
Abstract
Administrative burden of establishing health care coverage for the uninsured and its impact on timely access to care.Org: UT Southwestern Medical Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Rutgers-RWJBarnabas Health,
Abstract
The annual cost of cancer screening in the U.S.Org: National Cancer Institute/National Institutes of Health, University of California Irvine, San Diego School of Medicine, University of California, San Diego School of Medicine,
Abstract
Advancing breast cancer care for underserved women: A study of the Pink Ribbon Mammogram Program in Oakland County.Org: Trinity Health Oakland Hospital/Wayne State University, Trinity Health Oakland Hospital/Wayne State University School of Medicine, Ross University School of Medicine,
Abstract
Cancer care service use intensity in Medicare Advantage versus traditional Medicare.Org: Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center, McDermott+ Consulting, University of Minnesota, George Mason University, Manassas, VA,
Abstract
Assessing the true cost of cancer screening: Comparing hospital prices to claims remittance data for common cancer screening tests at top-ranked US hospitals.Org: Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Tennessee Oncology, PLLC, Owen Graduate School of Management,
Abstract
Financial toxicity during pediatric cancer therapy: A qualitative analysis.Org: University of Washington School of Medicine, Seattle Children's Hospital, Fred Hutchinson Cancer Center,
Abstract
Overlapping and non-overlapping indications for checkpoint inhibitors in the US.Org: Brigham and Women's Hospital, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center,
Abstract
Association of characteristics of cancer, patient, and county with telemedicine services use: Impact of the waiver of reimbursement restrictions on telemedicine.Org: University of Nebraska Medical Center, Baystate Medical Center and University of Massachusetts-Baystate, University of Chicago, University of Massachusetts-Baystate,
Abstract
Opioid prescribing trends and pain scores among adult patients with cancer in a large health system.Org: Yale School of Medicine, Mayo Clinic, Oncology Center of Excellence, U.S. Food and Drug Administration, Cancer Outcomes, Public Policy and Effectiveness Research Center,
Abstract
In search of strategies to mitigate financial toxicity in survivorship care: A survey of 347 head and neck cancer survivors.Org: School of Medicine, Showa University, University of California Irvine, Schools of Medicine and Public Health, University of California, Los Angeles, Public Health Vaccines,
Abstract
Prospective iterative data visualization (DV) study to enhance health literacy in prostate cancer (PC).Org: University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, ZERO Prostate Cancer, Alexandria, VA,
Abstract
National survey of patient perspectives on medication costs among co-pay assistance recipients with cancer.Org: University of Oklahoma Health Sciences Center, Oklahoma City, Okyo Pharma, Fox Chase Cancer Center, Philadelphia, PA,
Abstract
Oral cancer drug repositories: Challenges and solutions.Org: Bangalore Medical College And Research Institute, Yale University, Yale School of Medicine, Yale-New Haven Hospital,
Abstract
System-level variation in evidence-based multidisciplinary cancer care delivery.Org: Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV, University of Alabama at Birmingham, American College of Surgeons, Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham,
Abstract
Trends in pharmaceutical industry payments to US cancer centers, 2014-2021.Org: Memorial Sloan Kettering Cancer Center, US Digital Corps, US General Services Administration, DELFI Diagnostics, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
Accelerating cancer research trial startup in the community setting: A quality-improvement study.Org: TriHealth Cancer Institute, TriHealth Cancer Institute - Montgomery, Cincinnati, OH, Montgomery, OH,
Abstract
Inpatient burden and clinical outcomes of cytokine release syndrome in patients with cancer: A National Inpatient Sample study.Org: NYU Grossman School of Medicine, Southern Illinois University School of Medicine,
Abstract
Health-related quality of life (HRQoL) and symptoms in LIBRETTO-431 patients with RET fusion-positive advanced non-small-cell lung cancer (NSCLC).Org: Shanghai Pulmonary Hospital, Shanghai, China, AOU San Luigi, University of Torino, Hospital Ramón y Cajal, University Hospitals KU Leuven,
Abstract
Trends in NCCN enforcement of financial conflict of interest policies for guidelines panelists.Org: Memorial Sloan Kettering Cancer Center, DELFI Diagnostics, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, Yale University School of Medicine, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
Healthcare spending after a cancer diagnosis among working-aged adults.Org: University of Minnesota, University of Colorado Cancer Center, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, American Cancer Society,
Abstract
Disrupting how we recruit to cancer clinical trials.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Columbia University Medical Center, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Department of Biostatistics & Data Science,
Abstract
Cost trends in standard-of-care cancer treatments, 2017-2021.Org: New York Presbyterian/Weill Cornell Medical Center, Memorial Sloan Kettering Cancer Center, University of Chicago, Harris School of Public Policy, Yale University School of Medicine, DELFI Diagnostics,
Abstract
Risk prediction model for acute care use among patients with advanced cancer on clinical trials.Org: Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Fred Hutchinson Cancer Research Center, SWOG Statistics and Data Management Center/Fred Hutchinson Cancer Research Center,
Abstract
Trends in prices of checkpoint inhibitors in the US, 2016-2023.Org: Brigham and Women's Hospital, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center,
Abstract
Effect of multi-cancer early detection screening on late-stage cancers: A modeling study.Org: Value Analytics Labs, LLC, Exact Sciences Corporation, Memorial Sloan Kettering Cancer Center, Medical University of South Carolina, London School of Hygiene & Tropical Medicine,
Abstract
Impact of race and ethnicity on financial toxicity in patients with genitourinary cancers.Org: Corewell Health System - Beaumont University Hospital, William Beaumont University Hospital, Royal Oak, MI, Miami Cancer Institute, Baptist Health South Florida,
Abstract
Clinicians’ perspectives on the Telehealth Serious Illness Care Program for older adults with myeloid malignancies.Org: University of Rochester School of Medicine & Dentistry, Rochester, NY, University of Rocheser Medical Center, University of Rochester, University of Rochester Medical Center,
Abstract
Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023.Org: Brown University/Legorreta Cancer Center, Dana-Farber Cancer Institute, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, University of Kansas Medical Center,
Abstract
Access barriers and cost of varenicline for smoking cessation: A national comparative analysis of Medicare standalone part D and Medicare Advantage plan.Org: Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, University of Texas Southwestern Medical Center, Dallas, TX, Peking Union Medical College Hospital, Beijing, China, Texas Christian Univerisity, Fort-Worth, TX,
Abstract
Performance of a trained large language model to provide clinical trial recommendation in a head and neck cancer population.Org: Memorial Sloan Kettering Cancer Center, Columbia University, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Cost-effectiveness of a circulating tumor fraction molecular biomarker for treatment response monitoring.Org: Tempus AI, Perelman School of Medicine at the University of Pennsylvania, Abramson Cancer Center, Ochsner Health Center, Johns Hopkins University,
Abstract
Options for evaluating communication strategies in treatment and clinical trial discussions.Org: University of Wisconsin, Dana-Farber Cancer Institute, Madison, WI, Boston, MA,
Abstract
Adopting combination machine learning models could reduce hospital length of stay for oncology patients.Org: Integra Connect, West Palm Beach, Flare Therapeutics, Bengaluru, Indiana University School of Medicine,
Abstract
Association between financial fragility and treatment patterns in multiple myeloma.Org: Fred Hutchinson Cancer Center, Seattle, WA,
Abstract
Use of artificial intelligence (Al) in augmenting prior authorisation process for financial support in hemato-lymphoid malignancies: Joint project of Navya Al and Indian Cancer Society Cancer Cure Fund (ICS-CCF).Org: Tata Memorial Centre, Bone Marrow Transplant Unit, Advance Centre for Treatment, Research and Education in Cancer, Indian Cancer Society,
Abstract
Impact of lung biomarker testing on out-of-pocket costs for metastatic non-small cell lung cancer.Org: Northwestern University, University of Michigan,
Abstract
Post-acute care facility utilization and outcomes among Medicare beneficiaries undergoing inpatient cancer surgery.Org: Massachusetts General Hospital, Harvard Medical School, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Dana-Farber Cancer Institute,
Abstract
Cost-effectiveness of short-course radiotherapy versus long-course chemoradiation in organ preservation for locally advanced rectal cancer.Org: Department of Radiation Medicine and Applied Sciences, University of California San Diego, Duke Health Systems, The University of North Carolina at Chapel Hill,
Abstract
Effects of prehab or rehabilitation on upper extremity disability and quality of life after breast cancer surgery.Org: Select Medical, Mechanicsburg, PA, Baylor Scott and White Health, Grapevine, TX, K. R. Love Quantitative Consulting and Collaboration QCC,
Abstract
Multilevel factors associated with delays to neoadjuvant chemotherapy among young adults with operable breast cancer.Org: Columbia University School of Nursing, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Columbia University Irving Medical Center, New York, NY, USA,
Abstract
Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.Org: The University of Texas MD Anderson Cancer Center, Yale School of Medicine,
Abstract
Enhancing the patient journey to clinical trial enrollment with navigation to optimize accrual: A pilot study for a pragmatic multicentre, stepped wedge, cluster randomized controlled trial (The CTN Pilot Trial).Org: University of Windsor, University of Manitoba, Clinical Trials Navigator, Western University, University of Western Ontario,
Abstract
Disparities in stereotactic radiosurgery practice patterns for treatment of brain metastases: A large national cancer database study.Org: Stanford Cancer Institute, University of California San Francisco School of Medicine, Division of Oncology, Children’s Hospital of Philadelphia, Veterans Affairs Palo Alto Health Care System,
Abstract
Implementation and preliminary efficacy of a risk stratification system +/- patient-reported outcomes monitoring for patients with hospital-diagnosed advanced lung cancer.Org: The University of North Carolina at Chapel Hill, UNC Eshelman School of Pharmacy, Lineberger Comprehensive Cancer Center, Division of Oncology, Children’s Hospital of Philadelphia, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA,
Abstract
Evaluating disparities in receptor status, overall survival, and time to hormone therapy among women with breast cancer.Org: Stanford Cancer Institute, Palo Alto, CA, University of Nevada Las Vegas, Las Vegas, NV, Stanford University School of Medicine,
Abstract
Sociodemographic differences in suicide/intentional self-harm among cancer survivors versus the general United States population.Org: University of Iowa College of Public Health, Henry Ford Health System, Department of Radiation Oncology, Washington University School of Medicine in St. Louis, Duke University Medical Center,
Abstract
Quality of life and testosterone recovery after androgen deprivation therapy in patients with high-risk prostate cancer: Long-term data from a phase III trial.Org: Centre Hospitalier Universitaire de Sherbrooke, CHU de Québec - Université Laval, Centre Hospitalier Universitaire de Montréal, Hôpital Maisonneuve-Rosemont de Montréal, Centre de Santé et de Services Sociaux de Chicoutimi,
Abstract
Association of cancer survivors’ experience of care with financial toxicity: Results from a national survey.Org: National Cancer Institute/National Institutes of Health, Flinders University, Queensland University of Technology,
Abstract
Risk of significant functional impairment across cancer diagnosis and care continuum.Org: Dept. of Physical Therapy and Human Movement Sciences, Northwestern University Feinberg School of Medicine, Dept. of Medical Social Sciences, Northwestern University, Department of Medical Social Sciences,
Abstract
Associations of symptom burden with patient-reported outcomes (PROs) and clinical outcomes among early-phase cancer clinical trial (EP-CT) participants.Org: University of Oklahoma Health Sciences Center, Massachusetts General Hospital, Brigham and Women's Hospital, Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, MA, USA,
Abstract
Real-world assessment of treatment-related symptoms and associated burden among African American and Caucasian patients receiving chemotherapy in the US.Org: Carevive Systems Inc., Parexel, Genentech Inc.,
Abstract
Patient-reported outcomes corresponding to most common symptomatic adverse events in lung cancer clinical trials.Org: Oncology Center of Excellence, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Oncologic Diseases, Office of New Drugs,
Abstract
Impact of clinical response and AEs on health-related quality of life (HRQoL) in patients (pts) with R/R large B-cell lymphoma (LBCL): Pooled data from 4 lisocabtagene maraleucel (liso-cel) trials.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Evidera PPD, Bethesda, Bristol Myers Squibb,
Abstract
Relationship between cognitive and emotional domains of prognostic awareness with quality of life and psychological distress in patients with advanced cancer.Org: The Warren Alpert Medical School of Brown University, University of Massachusetts Chan Medical School, Massachusetts General Hospital, Harvard Medical School, Brigham and Women’s Hospital,
Abstract
Feasibility and utilization of electronic patient-reported outcome measures for lung cancer in routine clinical care.Org: Takeda Development Center Americas, Inc., Lexington, MA, USA, Takeda Pharmaceutical Company Limited, Osaka, Japan, Carevive Systems, Inc., Piedmont Research Strategies,
Abstract
SPPADE symptom prevalence and severity in a diverse sample of patients living with metastatic cancers.Org: Mayo Clinic, Indiana University School of Medicine, Regenstrief Institute, Mayo Clinic Florida, National Cancer Institute/National Institutes of Health,
Abstract
Health-related quality of life (QoL) in randomized phase III trials in oncology: Association between results of QoL, results of primary endpoint and drug approval.Org: Department of Oncology, Ivrea Community Hospital, ASL-TO4, Ivrea (Turin), Italy, Department of Oncology, University of Turin, Città della Salute e della Scienza di Torino, Turin, Italy, Department of Oncology , University of Turin, A.O.Ordine Mauriziano, Turin, Italy, Department of Oncology, University of Turin, AO Ordine Mauriziano, Turin, Italy, Royal Marsden Hospital, Renal and Melanoma Unit, London, United Kingdom,
Abstract
Symptom management through electronic patient-reported outcome (ePRO)-based intervention in patients with breast cancer treated with abemaciclib: Primary results from the LIBRA study, a phase II randomized controlled trial.Org: Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Keio University School of Medicine, Keio University School of Medicine General Surgery, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Department of Breast Medical Oncology, Japanese Foundation for Cancer Research,
Abstract
Comparative patient-reported tolerability (PRT): A multiplicity-controlled analysis of LIBRETTO-531, a randomized controlled trial (RCT) in medullary thyroid cancer (MTC).Org: Sidney Kimmel Cancer Center at Thomas Jefferson University, Thomas Jefferson University Hospital, Center for Head and Neck Cancers, Massachusetts General Hospital, Medical Oncology Department. Vall Hebron University Hospital,
Abstract
Reasons for unmet care needs in older adults with cancer: Analyses from the 2015–2019 National Health and Aging Trends Study.Org: University of Rocheser Medical Center, Rochester, NY, University of Rochester School of Medicine and Dentistry, University of Rochester Medical Center, James P. Wilmot Cancer Center,
Abstract
Evaluation of drug tolerability as a function of toxicity and quality of life in patients enrolled on I-SPY2.Org: University of California, San Francisco Department of Surgery, University of California, San Francisco, Susan G. Komen, UCSF Breast Science Advocacy Core, Mayo Clinic - Department of Surgical Oncology,
Abstract
Neuropathy trajectory informed by algorithm-based alerts from remote symptom monitoring (RSM) tool in breast cancer practice.Org: Cleveland Clinic Lerner College of Medicine, Carevive Systems Inc., Carevive Systems, Inc., Mayfield Heights, North Miami,
Abstract
The pre-operative window of endocrine therapy to inform radiation therapy decisions (POWER) trial: Baseline patient beliefs about breast cancer and endocrine therapy.Org: University of Virginia, Charlottesville, VA, USA,
Abstract
A descriptive patient-reported outcomes (PROs) analysis of KEYNOTE-412 to understand head and neck symptom burden.Org: Merck & Co., Inc., Gustave Roussy Cancer Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Yale University School of Medicine, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Association of patient-reported experience of care with cancer clinical trial participation.Org: National Cancer Institute/National Institutes of Health, ImStem Biotechnology,
Abstract
Social determinants of health and patient reported outcomes in lung cancer survivors.Org: Mayo Clinic, Department of Pediatric and Adolescent Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Department of Quantitative Health Sciences, Mayo Clinic Arizona,
Abstract
Change in financial toxicity during early-phase cancer clinical trial (EP-CT) participation.Org: Massachusetts General Hospital, Brigham and Women's Hospital, University of Oklahoma Health Sciences Center, Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, MA, USA, The University of Oklahoma Stephenson Cancer Center,
Abstract
Evaluating the feasibility of a Mobile Audio Companion (Elly) to reduce anxiety and to improve patient-reported outcomes among patients with cancer.Org: Cedars-Sinai Medical Center, Cedars-Sinai Medical Center, Los Angeles, CA,
Abstract
Cost-utility analysis of a supervised exercise program for patients with metastatic breast cancer in the PREFERABLE-EFFECT randomized controlled trial (RCT).Org: University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht University, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT) Heidelberg,
Abstract
Age-normed patient-reported outcome measures among cancer survivors.Org: Henry Ford Health System, Henry Ford Hospital,
Abstract
EROS: Engendering reproductive health within oncologic survivorship—ECOG-ACRIN E1Q11 paradoxical provision of reproductive health.Org: Cook County Hospital, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP, SHCC MU-NCORP,
Abstract
If you build it, they will come: Success of the EROS (Engendering Reproductive Health Within Oncologic Survivorship)—ECOG-ACRIN E1Q11 in recruitment of minority patients.Org: Cook County Hospital, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP, SHCC MU-NCORP,
Abstract
Viral hepatitis screening in patients with early breast cancer receiving cancer therapy: A quality improvement initiative.Org: The University of Texas Health Science Center at Houston, The University of Texas MD Anderson Cancer Center,
Abstract
Impact of transitions of care nurse navigation on post-discharge follow-up.Org: Sidney Kimmel Cancer Center at Thomas Jefferson University, Jefferson Health, Jefferson Kimmel Cancer Center at Jefferson Health, Sidney Kimmel Cancer Center - Jefferson Health,
Abstract
Implementation of standardized electronic documentation of goals of care discussions to improve cancer care.Org: University of California, San Diego Medical Center, Moores Cancer Center at UC San Diego Health, Cleveland Clinic Lerner College of Medicine, Endocrinology and Metabolism Institute, Doris A. Howell Palliative Care Service,
Abstract
Improving quality of oncology (onc) documentation and enhancing structured data collection using a standardized onc note template.Org: UW Health, University of Wisconsin Carbone Cancer Center, University of Wisconsin, University of Wisconsin School of Medicine and Public Health, Mayo Clinic Cancer Center,
Abstract
Comprehensive molecular pathology review service to reduce barriers to precision oncology in rural eastern North Carolina.Org: East Carolina University Health, Brody School of Medicine at East Carolina University,
Abstract
Enhancing inpatient chemo/immunotherapy stewardship: A novel scoring rubric approach to optimize utilization and reduce costs.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Health System,
Abstract
Examining the relationship between ECOG performance status and immunotherapy outcomes: Insights from real-world data analysis.Org: SUNY Upstate Medical University,
Abstract
Association between comorbidity clusters and mortality in patients with cancer: A machine learning analysis of data from the US National Health and Nutrition Examination Survey 1999–2018.Org: School of Pharmacy and Pharmaceutical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Sanatorium & Hospital, China National Biotec Group,
Abstract
Unstructured EMR data hold the key to oncology studies: Methods for validating NLP-extracted phenotypes from EMR notes.Org: IQVIA, Boston Pharmaceuticals, MaaT Pharma, South Bend, Intercept Pharmaceuticals,
Abstract
Commercial health plan spending on oncology drugs approved via the accelerated approval pathway and later withdrawn from the market.Org: UnitedHealthcare, Minnetonka, Optum, Eden Prairie,
Abstract
Time-to-diagnosis and peri-diagnostic healthcare utilization between screen- and non-screen detected cancers: Evidence from SEER-Medicare.Org: Exact Sciences Corporation, Curta, Inc., Curta Inc, Exact Sciences Corp., Mayo Clinic,
Abstract
Analysis of healthcare provider management of immune-related adverse events and concordance with NCCN Guidelines.Org: Clinical Care Options, LLC, University of Washington School of Medicine, Fred Hutchinson Cancer Center,
Abstract
Linking an early access program (EAP) to the National Health Data System (NHDS) in France and assessing its performances and potential biases.Org: Artificial Intelligence And Cancers Association, French National Cancer Institute, OncoReal, AstraZeneca France, Paris, France,
Abstract
Inpatient healthcare utilization in the first year following a childhood cancer diagnosis: A population-based analysis.Org: University of Washington School of Medicine, Fred Hutchinson Cancer Center,
Abstract
Racial/ethnic differences in incidence of squamous cell carcinoma in California.Org: Sutter Sacramento Medical Center, SIMR Biotech Pty Ltd,
Abstract
Association of enrollment in Medicare Advantage plans versus fee-for-service in patients with a late-stage diagnosis of gynecologic cancer.Org: Emory University, Atlanta, GA, USA, Rollins School of Public Health, Atlanta, GA, Georgia Center for Cancer Statistics, Winship Cancer Institute of Emory University,
Abstract
Estimating adult cancer cachexia prevalence and impact on survival in the US: Real-world data analysis.Org: OHSU Knight Cancer Institute, Duke Cancer Institute, Duke University Medical Center, James P. Wilmot Cancer Center, University of Rochester Medical Center,
Abstract
Demographics and survival outcomes of stage IV male breast cancer: A retrospective analysis of SEER database.Org: University of Arkansas for Medical Sciences, University of Arkansas Medical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, University of Arkansas for Medical Sciences, Littlerock, AR, University of Arkansas Medical Sciences, Little Rock, AR,
Abstract
Knowledge, attitudes, and current practices toward lung cancer palliative care management in China: A national survey.Org: Chongqing University Cancer Hospital, Chongqing Cancer Hospital,
Abstract
Breaking through barriers: Unraveling challenges in clinical trial participation among oncologic patients in a developing country.Org: Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil,
Abstract
Pulmonary toxicities in patients (pts) with metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd): The Mayo Clinic experience.Org: Mayo Clinic, Rochester, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Mayo Clinic Florida, Jacksonville,
Abstract
Ambulatory teclistamab administration in patients with relapsed/refractory multiple myeloma.Org: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University,
Abstract
End of life (EOL) care in head and neck squamous cell carcinoma (HNSCC) compared to other solid tumors (OST) in Washington (WA) State.Org: Fred Hutchinson Cancer Center, Seattle Gummy Company, Wave Life Sciences, Department of Otolaryngology, University of Pittsburgh, Head and Neck Surgery,
Abstract
Timing of EGFR or ALK inhibitor initiation and survival among patients with advanced NSCLC.Org: Department of Thoracic Oncology, Kanagawa Cancer Center, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Impact of carboplatin and cisplatin shortages on treatment patterns in patients with metastatic solid tumors.Org: Flatiron Health, San Francisco, CA,
Abstract
Mutated KRAS as a promising target in pancreas cancer: PURPLE registry data to inform real-world incidence and prognostic significance and to aid trial recruitment.Org: Northern Health, Peter MacCallum Cancer Centre, Melbourne, Australia, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne Health,
Abstract
Incorporating precision oncology in everyday clinical practice: First two years of comprehensive genomic profiling (CGP) testing experience in Croatia.Org: Department of Oncology, University Hospital Center Split, Department of Oncology and Nuclear Medicine, Sestre Milosrdnice University Hospital Center, Department of Oncology, University Hospital Center Zagreb, Department of Radiotherapy and Oncology, University Hospital Center Osijek, Department of Medical Oncology, Division of Medical Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Center,
Abstract
Developing a deep learning algorithm to support decision making for the classification of microsatellite instability (MSI) in cancer, using artificial intelligence (AI).Org: Alexander Fleming Institute, Instituto Tecnológico Universitario Buenos Aires, Instituto Tecnologico Buenos Aires, Instituto Privado de Oncología Alexander Fleming Buenos Aires,
Abstract
Differences in baseline characteristics and healthcare costs among insured patients with advanced cancer with vs without clinical trial participation.Org: Optum, Eden Prairie, MN, Illumina, Inc., San Diego, CA,
Abstract
Medicare reimbursement trends of biological reference agents and their biosimilars.Org: US Oncology Research, The Woodlands, Txinno Bioscience, McKesson, The US Oncology Network,
Abstract
Real-world outcomes in patients with biomarker-selected early-stage non-small cell lung cancer.Org: Henry Ford Health System, Genentech,
Abstract
Real-world duration of interruptions in imaging and endocrine therapy (ET) after pregnancy in early-stage estrogen receptor (ER) positive breast cancer (BC).Org: Stanford Health Care, Stanford Hospital and Clinics, Stanford University School of Medicine, Stanford Comprehensive Cancer Institute,
Abstract
Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL).Org: BeiGene, Kaiser Permanente Northern California, Division of Research,
Abstract
Insights from C-CAT repository: A novel approach to identifying appropriate patient populations for anticancer drug development using the clinicogenomic nationwide database in Japan.Org: National Cancer Center Research Institute, National Cancer Center Hospital East, Kashiwa, Japan, Division of Genome Biology, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Experimental Therapeutics, National Cancer Center Hospital East,
Abstract
Impact of protein energy malnutrition on hospitalized patients with lung cancer: A United States population-based cohort study.Org: Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Jefferson-Einstein Hospital, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Albert Einstein Healthcare Network, Philadelphia, PA,
Abstract
Genomic landscape and therapeutic implications in advanced solid cancers: KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors, KCSG AL-22-09).Org: Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, National Cancer Center Hospital East, Kashiwa, Japan, Goyang-Si, South Korea, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy,
Abstract
Understanding trends of US breast cancer hospitalization, mortality and costs using the National Inpatient Sample database.Org: MedStar Georgetown Cancer Institute, Yale University, Harvard T.H. Chan School of Public Health, NYU Langone Health, Dow University of Health Sciences,
Abstract
Integration of a machine learning model-generated surgical risk score into the EHR and preoperative workflow.Org: City of Hope National Medical Center, Duarte, CA, CanSino Biologics, City of Hope National Comprehensive Cancer Center,
Abstract
Therapy-related myeloid neoplasm risk score (TMNRS): A convenient clinical score for TMN risk assessment at presentation in adult patients (pts) with cancer.Org: Department of Hematology and Medical Oncology at Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Roswell Park Comprehensive Cancer Center, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine,
Abstract
The benefit of chart curation of electronic health record (EHR) data: Comparing data completeness between curated and structured data.Org: Integra Connect PrecisionQ, Integra Connect,
Abstract
Trends in mortality from secondary malignancy in the United States, 1999-2019.Org: The Ohio State University James Cancer Center, Dow University of Health Sciences, University of Toledo, UNC Nash General Hospital, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA,
Abstract
Surgical outcomes for non-small cell lung carcinoma by race and surgical facility types in the United States.Org: Mayo Clinic, Mitchell Cancer Institute, University of South Alabama,
Abstract
Effect of real-time data-driven physician engagement on appropriate precision oncology testing.Org: Diaceutics, Parsippany, NJ, Utah Tech University, St. George's University of London,
Abstract
Geographic and sociodemographic variations in disease burden, epidemiological trends, and risk factors of early-onset lung cancer: A global analysis.Org: Department of Thoracic Oncology and Surgery, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine,
Abstract
Census tract–level social determinants of health and variability in stage at diagnosis of bladder, breast, and non-small cell lung cancers.Org: Swedish Cancer Institute, Syapse, Merck & Co., Inc., H. Lee Moffitt Cancer Center and Research Institute, The University of Texas MD Anderson Cancer Center,
Abstract
Treatment trends for metastatic urothelial carcinoma across eight Mexican centers: A global oncology perspective.Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Instituto Nacional de Cancerologia, Centro Medico Nacional XX de Noviembre, Hospital Universitario "Dr. José Eleuterio González",
Abstract
Retrospective analysis: Does 5-FU dose adjustment per DPYD mutation status affect toxicity?Org: SUNY Upstate Medical University, Tata Memorial Centre, Hinduja Hospital, Tata Memorial Hospital,
Abstract
Outcomes of liver transplant recipients with pretransplant malignancies: Insights from a single institution’s experience.Org: University of Minnesota, Houston Methodist Cancer Center, Houston Methodist Hospital, Houston Methodist Neal Cancer Center, Missouri City,
Abstract
Effect of combination of genomic variation–based machine learning and clinical pathology on accurate diagnosis of tumors: Lung adenocarcinoma and lung squamous cell carcinoma.Org: Nanhai People's Hospital, the Second School of Clinical Medicine, Southern Medical University, Foshan, China, The Second Hospital of Tianjin Medical University,
Abstract
Biomarker testing and targeted therapy use among patients with non-small cell lung cancer in the United States: An analysis using a physician notes real-world database.Org: Amplity Health, Langhorne, PainReform,
Abstract
A deep learning–enabled workflow to estimate real world progression-free survival in patients with metastatic breast cancer.Org: nference, nference Labs, Mayo Clinic,
Abstract
Long-term cardiovascular outcomes in survivors of 20 adult solid tumors: Large population-based matched cohort study.Org: Levine Cancer Institute, Atrium Health Levine Cancer Institute, King Faisal Specialist Hospital & Research Center,
Abstract
Assessing secular trends in lung cancer stage in the United States community oncology setting from 2013 to 2023.Org: Ontada, Boston, MA,
Abstract
Intra-read analysis of radiologists in the setting of blinded independent central review of oncology studies.Org: Clario, Charlottesville, VA,
Abstract
Rethinking the impact of pretransplant malignancy on eligibility for double lung transplantation (DLT): An analysis of 23,291 recipients.Org: Feinberg School of Medicine, Northwestern University, Chicago, IL,
Abstract
Clinical trial participation and end-of-life care among older adults: A multi-center longitudinal observational cohort analysis of 121,717 patients with cancer.Org: Sarah Cannon Research Institute (SCRI), SCRI Oncology Partners, The US Oncology Network, Texas Oncology,
Abstract
Impact on biomarker documentation in community oncology by optimizing clinical decision support.Org: McKesson Specialty Health, The US Oncology Network, The Woodlands, TX,
Abstract
Impact of social determinants of health on health-related quality of life in cancer survivors.Org: University of Maryland School of Medicine, Department of Epidemiology and Public Health, Greenebaum Comprehensive Cancer Center,
Abstract
New-onset atrial fibrillation, cardiovascular outcomes and all-cause mortality in patients with newly diagnosed cancer: A large population-based matched cohort study.Org: Apex Institute of Medical Science, Levine Cancer Institute, King Faisal Specialist Hospital & Research Center, Levine Cancer Institute, Atrium Health, Charlotte, NC,
Abstract
Comparative analysis of actionable gene reporting in targeted panels versus comprehensive NGS testing for solid tumor samples.Org: NeoGenomics Laboratories, Inc., Aliso Viejo, CA, Durham, NC, Fort Myers, FL, San Diego, CA,
Abstract
Time to treatment initiation: An assessment of trends in delays in patients with lung cancer across Missouri.Org: University of Missouri Hospital, Missouri Cancer Registry and Research Center, Department of Public Health and Primary Care, College of Health Sciences University of Missouri, MU Institute for Data Science and Informatics,
Abstract
Disparities in frontline treatment and overall survival in the era of targeted tyrosine kinase inhibitor therapy for chronic myeloid leukemia: 2004-2021.Org: University of Utah, Huntsman Cancer Institute,
Abstract
Geographic and racial disparities in bi-specific antibodies trials access for diffuse large B-cell lymphoma.Org: H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Danbury Hospital, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center,
Abstract
Medicaid expansion and cancer stage at diagnoses during the COVID-19 pandemic in the United States.Org: American Cancer Society, Department of Surveillance and Health Equity Science, American Cancer Society,
Abstract
Importance of information-seeking styles among patients with cancer pre- and post-treatment: A URCC NCORP Research Base study.Org: University of Rocheser Medical Center, Rochester, NY, James P. Wilmot Cancer Center, University of Rochester Medical Center, University of Rochester,
Abstract
Identifying states for targeted alloHCT access initiatives using social vulnerability, physician density, and unmet need.Org: University of Maryland School of Public Health, NMDP,
Abstract
Cancer clinical trial participation in socioeconomically vulnerable patients: A risk model to aid in targeted interventions.Org: Arnold Ventures, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Research Center,
Abstract
Identifying modifiable risk factors to improve immigrant breast cancer screening in the United States.Org: Memorial Sloan Kettering Cancer Center, Washington University School of Medicine in St. Louis, NYU Grossman School of Medicine, American Cancer Society,
Abstract
Patterns of screening and access to care in women diagnosed with breast cancer in a safety-net system.Org: UT Southwestern Medical Center, University of Texas MD Anderson Cancer Center,
Abstract
Unveiling the cost-effectiveness of CDK4/6 inhibitors in treating patients with HR+/HER2- metastatic breast cancer: A closer look at nonmedication expenses.Org: UVA Comprehensive Cancer Center, University of Virginia, Charlottesville, VA, USA, Duke University Medical Center/Duke Cancer Institute,
Abstract
The positive impact of Medicaid expansion on melanoma stage at presentation.Org: City of Hope Comprehensive Cancer Center, City of Hope Medical Center, City of Hope National Comprehensive Cancer Center, City of Hope Cancer Center, City of Hope National Medical Center,
Abstract
Impact of age on clinical trial availability for AYAs with cancer: A time-trend analysis.Org: Cancer and Blood Disease Institute, Children's Hospital Los Angeles Department of Pediatrics, Rush University Medical Center, The University of Texas MD Anderson Cancer Center,
Abstract
A unique model: Partnership between community oncology and pharma for clinical trial enrichment.Org: Texas Oncology, Mirati Therapeutics, Texas Oncology PA, Texas Oncology Tyler, Texas Oncology - Baylor Charles A. Sammons Cancer Center,
Abstract
Unveiling the interplay of social factors in cancer survivorship: A comprehensive social determinants of health (SDOH) profile analysis.Org: Tsinghua University, Beijing InnoCare Pharma Tech, China National Biotec Group, University of Oklahoma Health Sciences Center, Oklahoma City,
Abstract
Navigating disparities: Insights from a colorectal cancer screening program in federally qualified community healthcare centers.Org: Horizons: South Georgia's Cancer Coalition, Albany, GA, Augusta University, Augusta, GA, Georgia Cancer Center, Augusta University,
Abstract
Trends in the providers’ uptake of advance care planning from 2016 to 2021.Org: University of California Davis, Sacramento, CA, UT Southwestern Medical Center, University of Virginia School of Medicine, Charlottesville, VA,
Abstract
The influence of access to care on radiation therapy utilization among older women with breast cancer.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Institute for Healthcare Delivery Science, Tisch Cancer Institute, Department of Population Health Science and Policy, Memorial Sloan Kettering Cancer Center,
Abstract
Time to treatment initiation of lung cancer and contributing factors from 2015-2020 utilizing Surveillance, Epidemiology and End Results program database.Org: RWJBH Rutgers Health Community Medical Center,
Abstract
Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program study.Org: VA Puget Sound Health Care System, Veterans Healthcare Administration, Corporal Michael Crescenz VA Medical Center, Genetic Support Foundation, VA Million Veteran Program,
Abstract
Symptoms reported by patients using an ePRO compared with those reported to nurses via telephone triage.Org: Advicenne Pharma, Canopy Care, Northwest Medical Specialties, Highlands Oncology Group, Cancer Specialists of North Florida,
Abstract
Trend and burden of cancer related hospitalizations in the US: Insights from a National Inpatient Sample Database analysis.Org: University of Vermont Medical Center, Roswell Park Comprehensive Cancer Center, University of California, Riverside, Corewell Health William Beaumont University Hospital, Miami Cancer Institute,
Abstract
Food for cancer health equity: The impact of a culturally tailored food voucher intervention on food insecurity among Latinx patients with cancer.Org: Division of Oncology, Stanford University School of Medicine, Stanford, CA, Pacific Cancer Care, Monterey, CA, University of California San Francisco School of Medicine, San Francisco, CA,
Abstract
Clinical impact and financial feasibility of remote oncology pharmacists' roles in community oncology practices.Org: McKesson, The US Oncology Network, The Woodlands, TX,
Abstract
The future is now: Implementation of standard of care, preemptive pharmacogenomic testing in patients with gastrointestinal cancers.Org: UCHealth, University of Colorado Anschutz Medical Campus, University of Colorado School of Medicine, University of Colorado Cancer Center, Division of Medical Oncology, National Cancer Center Singapore,
Abstract
Activating HR+/HER2- and triple-negative breast cancer care teams and their patients in shared decision-making.Org: PRIME Education, LLC, Miami Cancer Institute, Baptist Health South Florida,
Abstract
The acceptability of hospital-at-home for persons living with cancer and their caregivers.Org: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center,
Abstract
Feasibility and satisfaction level of caregivers with telemedicine in childhood cancer: A mixed-methods study.Org: All India Institute of Medical Sciences (AIIMS), New Delhi, India, Indiana University School of Medicine, All India Institute of Medical Sciences,
Abstract
The impact of admitting ward on resource utilization and outcomes among hospitalized cancer survivors.Org: Princess Margaret Cancer Centre, University of Toronto, Division of General Internal Medicine, St Michael's Hospital, Unity Health - St Michael's Hospital,
Abstract
Clinical utility and accessibility of functional precision medicine for relapsed/refractory pediatric and adult cancers.Org: First Ascent Biomedical, Florida International University, Cleveland Clinic Florida, University of Miami Health System, Nicklaus Children's Hospital,
Abstract
Using machine learning for targeted advance care planning (ACP) conversations in patients with cancer: A quality improvement initiative.Org: Duke University School of Medicine, Atrium Health Levine Cancer Institute, Patient Safety and Quality, Duke University Health System, Business Transformation,
Abstract
TriHealth Cancer Institute’s collaboration with the Tempus AI TIME program impact on clinical trial operations and enrollment.Org: TriHealth Cancer Institute, Tempus AI,
Abstract
A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Illumina Inc., Fortrea Inc.,
Abstract
Deep learning vs traditional breast cancer risk assessment models: Are we offering supplemental services to those who benefit the most?Org: Massachusetts General Hospital,
Abstract
Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board.Org: NHMRC Clinical Trials Centre, The University of Sydney, Garvan Institute of Medical Research, Prince of Wales Hospital, The NHMRC Clinical Trials Centre,
Abstract
Efficient site selection for clinical trials using simulated annealing.Org: ConcertAI, Cambridge, MA,
Abstract
Performance of an artificial intelligence/machine learning model designed to identify hospitalized patients with cancer who could benefit from timely specialized palliative care delivery.Org: Mayo Clinic, University of Michigan Medical School,
Abstract
Using an artificial intelligence platform to enhance cancer detection rates in primary care.Org: C the Signs, Imperial College,
Abstract
Large language models to evaluate racial discrepancies in performance status assignment.Org: University of California Irvine, University of California, San Francisco Medical Center,
Abstract
Clinical and sociodemographic factors associated with digital health literacy in patients with non-Hodgkin lymphoma or colorectal carcinoma.Org: Hackensack Meridian School of Medicine, Center for Discovery & Innovation, Hackensack Meridian Health, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack University Medical Center,
Abstract
Adaptively learning visual model of surgical resection images via coarse-to-fine–grained strategy for pathological invasiveness prediction in indeterminate stage IA lung adenocarcinoma.Org: Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, The School of Computer Science and Technology, Harbin Institute of Technology, Shenzhen, China, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, Guangdong Provincial People's Hospital, Guangzhou, China, The First Clinical Medical College, Guangdong Medical University, Zhanjiang, China,
Abstract
Integrating 4 Methods (In4M) to evaluate physical function in patients with cancer: Results of a comprehensive digital health study.Org: Mayo Clinic, U.S. Food and Drug Administration, Yale University, Fight Colorectal Cancer, Arlington, VA, CancerHacker Lab,
Abstract
Artificial intelligence (AI) content detection in ASCO scientific abstracts from 2021 to 2023.Org: University of Chicago, ASCO,
Abstract
Effect of a learning-based approach using the echo-signals obtained by a single-unit transducer on detection of breast tumors.Org: L'imagin Inc, Seoul National University Hospital, Seoul National University College of Medicine, Department of Transdisciplinary Medicine, Seoul Metropolitan Government Seoul National University,
Abstract
Association of symptom severity, anxiety, and health literacy with portal usage among patients with cancer.Org: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Northwestern University, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Department of Medical Social Sciences,
Abstract
Continuous remote monitoring of performance status in patients with NSCLC through fitness tracker–derived life-log data.Org: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Samsung Medical Center, Sungkyunkwan University School of Medicine, AI Graduate School,
Abstract
AI-enabled digital test to predict disease recurrence for patients with early-stage invasive breast cancer and performance in a MammaPrint low-risk cohort from the Netherlands with a median 6-year follow-up.Org: Icahn Mount Sinai School of Medicine, Miami, FL, Laboratory of Pathology, Dordrecht, Netherlands, PreciseDx,
Abstract
Digital health program for patients with cancer to support self-management: A retrospective real-world analysis.Org: Landspitali - The National University Hospital of Iceland, Sidekick Health, Berlin, Germany, Sidekick Health, Kopavogur, Iceland,
Abstract
Outcomes of very young women and adolescent (VYWAA) with breast cancer (BC) in rural and urban Saskatchewan: A population-based cohort study.Org: McGill University Health Center, University of Saskatchewan, Saskatoon Cancer Centre, Saskatchewan Cancer Agency, Allan Blair Cancer Center,
Abstract
Real world study of racial disparities associated with toxicities of sacituzumab govitecan.Org: Penn State Cancer Institute, Hershey, PA, Institute for Computational and Data Sciences, University Park, PA, Clinical and Translational Sciences Institute,
Abstract
National and state models for relationships between social vulnerability and mammography rates.Org: Wayne State University School of Medicine, Detroit, MI, Millennium Pharmaceuticals, Department of Oncology, National Taiwan University Hospital, College of Medicine, University of the Philippines - Manila,
Abstract
Inequities in timely treatment (Tx) initiation for patients (pts) with acute myeloid leukemia (AML) treated in a predominantly community setting in the United States (US).Org: Genentech, The James Cancer Center, The Ohio State University Comprehensive Cancer Center, University of Chicago, AbbVie Inc.,
Abstract
Dissecting racial/ethnic disparities in non-small cell lung cancer staging at diagnosis: Intra-ethnic and geographic differences.Org: Division of Epidemiology & Population Health Sciences, Department of Public Health Sciences, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System,
Abstract
Lessons learned from a genetic counseling randomized clinical trial: Implications for recruiting individuals identifying as Asians in research.Org: University of California, San Francisco, Department of Medicine, School of Medicine, San Francisco, CA, University of California, San Francisco, Department of Psychiatry, School of Medicine, San Francisco, CA, University of California, San Francisco, Departments of Medicine and Epidemiology and Biostatistics, San Francisco, CA, Division of Hematology Oncology, Department of Medicine, University of California-San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, CA,
Abstract
Geographic disparities in brachytherapy accessibility for cervical cancer.Org: The Catholic University of Korea, Seoul National University Hospital, South Korea,
Abstract
Racial disparities in the immunotherapeutic outcomes of patients with non-small cell lung cancer (NSCLC): An in-depth systematic review and meta-analysis.Org: University of Hawaii Internal Medicine Residency Program, Texas Tech University Health Sciences Center School of Medicine, Department of Medicine, Weiss Memorial Hospital, Department of Medicine, Albert Einstein Healthcare Network, Department of Internal Medicine, St. Elizabeth’s Medical Center,
Abstract
Association of immune checkpoint inhibitor introduction and changes in survival disparities by health insurance coverage among individuals newly diagnosed with advanced cancers in the US.Org: American Cancer Society, Emory University School of Public Health, Department of Surveillance and Health Equity Science, American Cancer Society, Emory University, Rollins School of Public Health,
Abstract
Pharmacokinetics (PK) and pharmacogenomics (PGx) of ribociclib (ribo) in Black patients with metastatic breast cancer (mBC): The LEANORA study.Org: Georgetown University Medical Center, Washington, DC, Tufts Medical Center/Tufts University, Boston, MA, National Cancer Institute/National Institutes of Health,
Abstract
Examining disparities in the receipt of curative treatment for hepatocellular cancer (HCC): A multicenter retrospective study from 2016-2023.Org: Trinity Health Oakland Hospital/Wayne State University, University of Connecticut, Trinity Health Oakland Hospital/Wayne State University School of Medicine, Ross University School of Medicine,
Abstract
Association between social determinants of health and time to treatment for newly diagnosed multiple myeloma.Org: Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Taussig Cancer Institute, Case Western Reserve University School of Medicine,
Abstract
Improving lung cancer health equity by applying deep learning to low dose CT screening of minority and disadvantaged patients.Org: University of Illinois at Chicago Cancer Center, University of Illinois at Chicago College of Medicine, Division of Medical Oncology, University of Illinois Hospital and Health Sciences System, University of Illinois College of Medicine,
Abstract
Demographics of cancer screening in Providence’s homeless population.Org: Rhode Island Hospital, Legorreta Cancer Center, Brown University School of Medicine-Rhode Island Hospital, Providence, RI, Brown Physicians Inc,
Abstract
Post mastectomy reconstruction choice: Do race and ethnicity play a role?Org: Mount Sinai West, The Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Medical Center,
Abstract
Rapid survey assessment: Barriers and facilitators to mammogram completion in English and Spanish-speaking patients in a federally qualified health center (FQHC) setting.Org: University of Chicago, Tapestery 360, University of Chicago Medical Center, Chicago, IL,
Abstract
WITHDRAWN: Palliative care utilization and disparities in deceased patients with breast cancer in U.S. hospitals: A retrospective study.Org: Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Community Hospital of San Bernardino, Trumbull Regional Medical Center, Western Reserve, University of California Irvine,
Abstract
Identifying eligibility criteria that perpetuate race/ethnic disparities in acute myeloid leukemia (AML) clinical trial participation.Org: Dana-Farber Cancer Institute, University of Chicago Medicine, University of Chicago Medical Center, Chicago, IL, University of Chicago, University of Illinois at Chicago,
Abstract
Use of surgery for de novo metastatic breast cancer (mBC).Org: Stanford Hospital and Clinics, Stanford University School of Medicine, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, University of California, San Francisco,
Abstract
Trends in location of death for individuals with pediatric cancer in the United States.Org: University of Pittsburgh, Yale College, Stanford School of Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, NYC Health + Hospitals/Elmhurst,
Abstract
Association of food insecurity with reduced cancer screening rates.Org: NYU Long Island School of Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Division of Oncology-Hematology, Perlmutter Cancer Center, New York University Langone Health, NYU Langone Hospital,
Abstract
Disparities in the initial presentation of melanoma across two socioeconomically diverse New York City neighborhoods.Org: Rutgers NJMS, NYU Langone Health, New York Medical College,
Abstract
Racial disparities and survival outcome of patients with locally advanced cervix cancer in the international randomised phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).Org: NHMRC Clinical Trials Centre, The University of Sydney, Louisiana State University Health Sciences Center, Department of Gynecologic Oncology, University of California, Los Angeles,
Abstract
Occurrence of cancer in people with intellectual disabilities in Germany.Org: University of Bielefeld, Central Research Institute for Ambulatory Health Care in Germany, German Cancer Society, Ulm University Hospital, Evangelisches Krankenhaus Königin Elisabeth Herzberge gGmbH,
Abstract
Racial disparities in presentation and survival for lobular breast cancer.Org: University of Galway, Galway University Hospital, Ireland, Womens College Hospital, Toronto Allergy and Asthma Centre,
Abstract
Long term impact of COVID-19 pandemic on mammographic breast cancer screening.Org: Mayo Clinic, Department of Quantitative Health Sciences, Mayo Clinic Arizona, Department of Statistics, Mayo Clinic Scottsdale,
Abstract
Persistent poverty impacts survival and National Comprehensive Cancer Network guideline-concordant care for patients with melanoma.Org: The Ohio State University College of Medicine, The Ohio State University Wexner Medical Center, The Ohio State University James Cancer Center,
Abstract
Disparity in oncology therapy access and differences in clinical pathological features and outcomes in indigenous population lung cancer (LC): A retrospective study from Martinique.Org: CHU Martinique, Gustave Roussy Cancer Center, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Paris Saclay University,
Abstract
Racial, ethnic, and regional influences on national patterns of mammographic screening for breast cancer.Org: Scripps Cancer Center, San Diego, CA,
Abstract
Racial/ethnic representation and disparities in preclinical cancer models.Org: BC Cancer - Vancouver Centre, The University of Texas MD Anderson Cancer Center, Adesh Institute of Medical Science and Research, McMaster University and Juravinski Cancer Centre, Government Medical College,
Abstract
Racial/ethnic inequities in care for patients with advanced endometrial cancer: What’s structural racism and social determinants of health got to do with it?Org: Flatiron Health, San Francisco, CA,
Abstract
Exploring health disparities in prostate cancer through circulating tumor DNA analysis.Org: Indiana University School of Medicine, Indiana University Simon Comprehensive Cancer Center,
Abstract
Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).Org: Mayo Clinic, NYU Langone Health, H. Lee Moffitt Cancer Center and Research Institute, The University of Texas MD Anderson Cancer Center, University of California Irvine,
Abstract
Unveiling inequities in representation: Racial disparities in supportive care breast cancer clinical trial enrollment.Org: University of California, San Francisco,
Abstract
Global disparities in immunotherapy clinical trials: A comprehensive analysis of low- and middle-income countries over the past decade.Org: Immune Oncology Research Institute, Yerevan State Medical University, Yerevan State Medical University after M. Heratsi, Immune Oncology Research Center, Yeolyan Hematology and Oncology Center,
Abstract
Decentralized trial recruitment methods to facilitate broad coverage across urban and rural counties for a blood-based test in early colorectal cancer detection.Org: Science 37, Culver City, Freenome Holdings Inc., South San Francisco, New York University School of Medicine,
Abstract
Assessing survival effects of persistent poverty and payer status in non-elderly adults with lung or breast cancer.Org: National Cancer Institute/National Institutes of Health, Rockville, MD,
Abstract
The effect of a multilevel community health worker-led intervention on patient knowledge and receipt of precision medicine: Updated findings from a randomized clinical trial.Org: Division of Oncology, Stanford University School of Medicine, Stanford, CA, Northwestern, Chicago, IL, Pacific Cancer Care, Monterey, CA, Ravenswood Family Health Center, Palo Alto, CA, Stanford University - School of Medicine, Palo Alto, CA,
Abstract
Role of social determinants burden on outcomes and survival for AYAs with cancer.Org: University Hospitals Cleveland Medical Center, University Hospitals Center for Clinical Research, Case Western Reserve University School of Medicine, Angie Fowler Chair in Adolescent & Young Adult Cancer Research, Angie Fowler AYA Cancer Institute,
Abstract
Colorectal cancer and the heart: Uncovering the beat of racial disparities in MACCE.Org: Landmark Medical Center, New York Medical College, Department of Oncology, National Taiwan University Hospital, Mayo Clinic,
Abstract
Association of socioeconomic status with aggressive end-of-life care in patients with cancer before and during the COVID-19 pandemic.Org: University Health Network (UHN), University of Toronto, Queen's University Belfast, Princess Margaret Cancer Centre, Department of Biostatistics & Data Science,
Abstract
The impacts of area-level social deprivation on overall survival in patients receiving immune-checkpoint inhibitors (ICI) treatments: A retrospective cohort study.Org: The Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center, Department of Biomedical Informatics, The Ohio State University College of Medicine,
Abstract
Predicting therapeutic clinical trial enrollment for underrepresented patients in neuro-oncology using supervised machine learning.Org: University of California, San Francisco, San Francisco, CA, University of California, San Francisco, School of Medicine, San Francisco, CA, Dana-Farber Cancer Institute, Boston, MA, USA, Mayo Clinic, Phoenix, AZ,
Abstract
Disparities in breast cancer prevention initiatives at a comprehensive cancer center: Who are we serving?Org: Indiana University School of Medicine, Indiana University Health, Indiana University Simon Comprehensive Cancer Center,
Abstract
Exploring disparities in palliative care utilization among hospitalized patients with hepatocellular carcinoma: A retrospective cohort study.Org: Harlem Hospital Center, New York, NY,
Abstract
Association of single nucleotide polymorphisms (SNPs) in inflammatory pathways with breast cancer (BC) risk: A multi-ethnic scoping review.Org: Massachusetts General Hospital, University of Michigan,
Abstract
A nationwide analysis of demographic and treatment patterns in admissions for malignant pleural effusions from 2016-2020.Org: John H. Stroger, Jr. Hospital of Cook County, John H. Stroger Jr. Hospital of Cook County, John H Stroger, Jr. Hospital of Cook County,
Abstract
Challenges and solutions to recruiting diverse populations to oncology clinical trials: A mixed-methods study of clinical research coordinators.Org: University of California, San Francisco,
Abstract
Potentially inappropriate medications and their association with frailty, unplanned hospitalizations, and mortality in patients with cancer treated in the national U.S. Veterans Affairs Healthcare System.Org: VA Boston Healthcare System, Brigham and Women's Hospital, VA Greater Los Angeles Healthcare System, Massachusetts Veterans Epidemiology Research and Information Center, Harvard Medical School,
Abstract
Current trends of clinical trials for older patients with cancer: A systematic review.Org: Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Université Libre de Bruxelles, International Drug Development Institute, University of Medicine 'I. Hatieganu' Cluj Napoca,
Abstract
Diagnostic test use and time to cancer diagnosis in Medicare recipients.Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Medicus Economics, LLC, Cleveland Clinic Lerner College of Medicine,
Abstract
Effect of a 12-week remote exercising program (ExIOnc) on quality of life and symptoms of older patients with cancer in Brazil.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), São Paulo, Brazil, Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Brasília, Brazil, Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Porto Alegre, Brazil, City of Hope National Medical Center, Duarte, CA, UPMC Hillman Cancer Center, Pittsburgh, PA,
Abstract
Accelerated epigenetic aging and risk of chemotoxicity in older adults with early breast cancer.Org: City of Hope National Medical Center, City of Hope Comprehensive Cancer Center, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Start low, go slow: A systematic review and meta-analysis of upfront tailored treatment dosing in older adults with advanced cancer.Org: University of Pennsylvania, Penn Medicine Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania,
Abstract
Analyzing correlates for cervical cancer awareness in Mauritania, Madagascar, and Benin from the Demographic Health Survey (DHS): 2017-2022.Org: Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA, Uganda Cancer Institute, Kampala, Uganda,
Abstract
Assessment of endocrine therapy adherence in a nurse-led cancer survivorship clinic: Results from the Linking You to Support and Advice (LYSA) trial.Org: Cancer Research @UCC, College of Medicine and Health, University College Cork, CUH/UCC Cancer Centre, Cork University Hospital Group, CUH/UCC Cancer Centre & Cancer Trials Ireland,
Abstract
Multi-cancer early detection (MCED) test performance in cancer survivors.Org: Dana-Farber Cancer Institute, GRAIL, LLC, a subsidiary of Illumina, Inc.,
Abstract
Evaluating the utility of routine survivorship exams in breast cancer: Modality of detection of recurrence in a prospective cohort study.Org: San Francisco Medical Center, Kaiser Permanente Northern California, Division of Research, Department of Hematology Oncology, Kaiser Permanente,
Abstract
Facilitating adaptive coping with fear of recurrence among breast cancer survivors: Feasibility and acceptability outcomes from a three-arm randomized controlled trial.Org: Indiana University School of Medicine, Fred Hutchinson Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center,
Abstract
The use of telehealth in a large community oncology practice prior to and during the COVID-19 pandemic.Org: IntrinsiQ Specialty Solutions, Carroltton, Txinno Bioscience, Florida Cancer Specialists and Research Institute, Ocala, FL, Fort Myers, FL,
Abstract
Patient satisfaction with cancer care delivery through telemedicine at a comprehensive cancer center across three years during and after the COVID-19 pandemic.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Quality of telehealth-provided cancer care in VA.Org: Duke University Medical Center, Durham, NC, Durham VA Medical Center, Michigan State University College of Human Medicine, East Lansing, MI,
Abstract
Mobile health–supported comprehensive intervention model (CIMmH) improved physical fitness of patients with esophageal cancer after esophagectomy: Prospective randomized controlled trial.Org: Department of Thoracic Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, Department of Radiological diagnosis, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Department of Clinical Nutrition, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Telehealth consultations and recruitment trends in clinical trials: A retrospective analysis at investigational cancer therapeutics, a dedicated phase I department at The University of Texas MD Anderson Cancer Center.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Investigational Cancer Therapeutics Department, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Chemotherapy Care Companion: Enhancing cancer care through digital remote monitoring.Org: Ochsner Health System, Oschner Health System, Ochsner Health Center, Ochsner Medical Center,
Abstract
Patient-reported experience with an immunotherapy telehealth platform.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University,
Abstract
Cost-effectiveness of an oral THC: CBD cannabis extract for secondary prevention of refractory, chemotherapy-induced nausea and vomiting.Org: The University of Sydney, Chris O'Brien Lifehouse, NHMRC Clinical Trials Centre,
Abstract
Implementing fragmentomics into real world screening interventions to evaluate clinical utility among individuals with elevated risk for lung cancer (FIRSTLUNG) L301.Org: DELFI Diagnostics, Duke University Department of Anesthesiology, Delfi Diagnostics, Inc.,
Abstract
Establishing a protocol to increase racial/ethnic minority enrollment on an active radiation oncology randomized clinical trial.Org: Johns Hopkins University School of Medicine, Johns Hopkins Bloomberg School of Public Health, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation,
Abstract
Breaking barriers for cancer clinical trials: A multi-tiered interventional approach to boost racial and ethnic minority participation in early-phase studies.Org: Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Keck School of Medicine,
Abstract
A new model to enhance enrollment of diverse participants to therapeutic clinical trials.Org: Golgi, Inc, Lexington, KY, Boston, MA, Yale Cancer Center, Yale School of Medicine,
Abstract
Developing behavioral intervention to support molecular testing of patients with biliary tract cancer.Org: Georgetown University, Lombardi Comprehensive Cancer Center, Lewis Katz School of Medicine, Center for Discovery & Innovation, Hackensack Meridian Health,
Abstract
A phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI).Org: Columbia University Irving Medical Center, New York, NY, USA, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Montefiore Einstein Comprehensive Cancer Center, Perlmutter Cancer Center, New York University Langone Health, NYU Langone Health,
Abstract
GUIAR: Promoting lung cancer screening in Hispanic head and neck cancer survivors.Org: University of Miami Sylvester Comprehensive Cancer Center, Dana-Farber Cancer Institute, University of Miami Health System,
Abstract
Serial testing to assess cognitive function in patients with cancer being treated with immunotherapy.Org: Indiana University School of Medicine, Indiana University Melvin and Simon Comprehensive Cancer Center,
Abstract
A phase II randomized double-blind placebo-controlled study of fisetin to improve physical function in frail older breast cancer survivors (TROFFi).Org: City of Hope National Medical Center, City of Hope National Comprehensive Cancer Center, University of California, Los Angeles, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Linking in with advice and supports for men impacted by metastatic cancer: The LIAM Mc trial (NCT05946993).Org: Cancer Research @UCC, College of Medicine and Health, University College Cork, University College Cork, Cork, Ireland, Cork University Hospital Group,
Abstract
Neuro-oncology anywhere: A decentralized approach to clinical trials in brain tumors and beyond.Org: Mayo Clinic, Rochester, MN,
Abstract
Dual-agent immunotherapy for prevention of melanoma brain metastases: A real-world analysis of 8686 patients.Org: Penn State Milton S. Hershey Medical Center, Hershey, PA, Penn State College of Medicine, University Park, PA, University of Toronto,
Abstract
Clinical and molecular features and survival in thyroid cancer with brain metastases.Org: University of Toronto, Princess Margaret Cancer Centre, University Health Network, Princess Margaret Cancer Center, Department of Medical Oncology and Hematology,
Abstract
Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases.Org: Cancer Research UK & UCL Cancer Trials Centre, Tohoku Medical Megabank Organization, Taiho Pharmaceutical Co. Ltd, Helsinn Healthcare,
Abstract
Barriers to accrual and enrollment in brain tumor trials.Org: Dana-Farber Cancer Institute, Massachusetts General Hospital, University of California Irvine, The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center School of Nursing,
Abstract
SHADOW study: Comparison of conventional clinical follow-up with clinician led video follow-up in newly diagnosed patients with intermediate and high grade glioma receiving adjuvant temozolomide therapy.Org: Tata Memorial Centre, Tata Memorial Hospital, Actrec Tata Memorial Centre,
Abstract
Blood baseline neutrophil count to predict bevacizumab efficacy in glioblastoma.Org: Georges-Francois Leclerc Cancer Center, Georges François Leclerc Cancer Center – UNICANCER, Dijon, France, CHU Dijon, Centre GF Leclerc, University Hospital (CHU) - Department of Medical Oncology,
Abstract
ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using FMISO PET and MRI.Org: Massachusetts General Hospital, Brown University School of Medicine-Rhode Island Hospital, University of Washington School of Medicine, Wake Forest University Department of General Internal Medicine, Icahn School of Medcn At Mount Sinai,
Abstract
Effect of breast cancer receptor subtypes and CSF cytology status on survival for patients with leptomeningeal disease.Org: Vassar Brothers Medical Center, Nuvance Health, Rochester General Hospital, James P. Wilmot Cancer Center, University of Rochester Medical Center,
Abstract
Radiosurgery to 5 or more newly diagnosed brain metastases in the systemic therapy era.Org: The University of Texas MD Anderson Cancer Center, New York City, Txinno Bioscience, Houston, TX, Brody School of Medicine at East Carolina University,
Abstract
Tumor reactive T cells from the cerebrospinal fluid of patients with leptomeningeal disease from melanoma.Org: H. Lee Moffitt Cancer Center and Research Institute, Department of Immuno-Oncology,
Abstract
Genomic biomarkers of CNS-specific outcomes in patients with breast cancer brain metastases.Org: Brown University School of Medicine-Rhode Island Hospital, Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Albert Einstein College of Medicine,
Abstract
Real-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis.Org: Yale University,
Abstract
Efficacy of intrathecal delivery of peptide-pulsed type 1 conventional dendritic cell vaccine for the treatment of breast cancer-associated leptomeningeal disease in preclinical models.Org: H. Lee Moffitt Cancer Center and Research Institute, Roswell Park Comprehensive Cancer Center,
Abstract
Novel non-invasive method for measuring intracranial pressure for drug delivery and other neurologic disorders.Org: Northwestern Memorial Hospital, Chicago, IL, Chicago, IL, Northwestern Medicine Group, Stanford Cancer Center GI Surgical Oncology, Palo Alto, CA,
Abstract
Identification of pharmaceutics with selective activity against melanoma-associated leptomeningeal disease using patient-derived circulating tumor cells.Org: H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Evaluation of survival outcomes in patients with solid organ cancer with brain metastasis treated with exacta encylopedic tumor analysis based treatments.Org: Medical College of Wisconsin and WIN Consortium, Sir H N Reliance Foundation Hospital and Research Centre, Orange County Neurosurgical Associates, Datar Cancer Genetics, Datar Cancer Genetics Limited,
Abstract
PD-L1, tumor mutational burden (TMB) and long-term survival in patients with non-small cell lung cancer (NSCLC) and brain metastases.Org: Brigham and Women's Hospital, Yale Cancer Center, Brigham and Women's Hospital/Dana-Farber Cancer Institute,
Abstract
Development of clinically accessible nomograms to predict risk of brain metastases at baseline and follow-up in patients with non-small cell lung cancer.Org: Penn State College of Medicine, University of Toronto, John Hopkins University, Arizona College of Osteopathic Medicine, Penn State Hershey Medical Center,
Abstract
Tumor treating fields (TTFields) therapy in patients with glioblastoma: Long-term survival results from TTFields in Germany in routine clinical care (TIGER) study.Org: General Hospital Aschaffenburg-Alzenau, University Hospital Tübingen, University Hospital Erlangen, University Hospital Cologne, University Hospital Essen,
Abstract
A phase I trial on the intra- and post-operative intracranial administration of ipilimumab and nivolumab in patients with recurrent high-grade glioma.Org: Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), CellCarta,
Abstract
Pharmacological targeting of lipid metabolism by a first-in-class SREBP-targeted degrader to treat glioblastoma.Org: MEDIFIC Inc., MEDIFIC lnc,
Abstract
Outcomes and immune response after peptide vaccination targeting human cytomegalovirus antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma.Org: Day One Biopharmaceuticals, The Preston Robert Tisch Brain Tumor Center,
Abstract
Retrospective study of ivosidenib for patients with recurrent IDH mutant gliomas.Org: University of Pittsburgh, University of Pittsburgh Cancer Institute, UPMC Cancer Center - Hillman Cancer Center,
Abstract
CDKN2A deletion and radiation sensitivity in IDH-mutant astrocytomas.Org: MGH Brain Tumor Center, Massachusetts General Hospital, Department of Neurosurgery, Prince of Wales Hospital,
Abstract
INB-200: Fully enrolled phase 1 study of gene-modified autologous gamma-delta (γδ) T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ).Org: In8bio, Inc, In8bio, In8Bio, Inc., University of Alabama at Birmingham Comprehensive Cancer Center,
Abstract
Expand and pull: A new treatment paradigm for glioblastoma using a long-acting recombinant interleukin-7 and oncolytic viral therapy.Org: Washington University School of Medicine in St. Louis, Washington University School of Medicine, Washington University in St. Louis, NeoImmuneTech, Inc.,
Abstract
Targeting glioma stem cells with thyroid hormone suppression: Phase 1/2 trial of methimazole in patients with progressive grade 4 gliomas.Org: Cleveland Clinic Lerner College of Medicine,
Abstract
Out-of-pocket cost modeling of adjuvant radiation therapy duration in standard-of-care treatment of glioblastoma across Medicaid and Medicare plans.Org: Case Western Reserve University School of Medicine, Department of Radiation Oncology, University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center,
Abstract
Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482 + pembrolizumab (pembro) in patients with recurrent inoperable glioblastoma (GBM).Org: Seoul National University Hospital, Asan Medical Center, University of Ulsan College of Medicine, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack University Medical Center,
Abstract
The TAC-GReD trial: The combination of talazoparib and carboplatin in DNA damage repair deficient recurrent high-grade glioma.Org: Department of Clinical Oncology, Queen Elizabeth Hospital, LKS Faculty of Medicine, University of Hong Kong, Department of Neurosurgery, Prince of Wales Hospital, Prince of Wales Hospital,
Abstract
Can targeting TSP-1 with gabapentin enhance survival in glioblastoma? A 20-year retrospective cohort study.Org: University of California, San Francisco, San Francisco, CA, University of California, San Francisco, School of Medicine, San Francisco, CA, Miami Cancer Institute, Miami, FL,
Abstract
Safety and efficacy of CyberKnife radiosurgery plus anlotinib hydrochloride in patients with recurrent glioblastoma: A prospective phase II single-arm study.Org: CyberKnife Center, Department of Neurosurgery, Prince of Wales Hospital, Huashan Hospital, Shanghai Medical College, Fudan University, Fudan University Shanghai Cancer Center, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
Distribution and mutational landscape of inherited cancer susceptibility syndromes in central nervous system tumors.Org: Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Phase I clinical trial of 64Cu-ATSM for malignant brain tumors.Org: Department of Diagnostic and Interventional Radiology, Kanagawa Cancer Center Hospital, Yokohama, Japan, Department of Neurosurgery and Neuro-Oncology, National Cancer Center Research Institute, Tokyo, Japan, Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan, Department of Neurosurgery, Kanagawa Cancer Center Hospital, Yokohama, Japan, Department of Neurosurgery and Neuro-Oncology, Tokyo, Japan,
Abstract
Glioma monitoring via longitudinal intracranial cerebrospinal fluid cell-free DNA.Org: Mayo Clinic, Predicine Inc., Predicine, Inc., Department of Neurologic Surgery, Department of Neurology and Hematology-Oncology,
Abstract
Phase 1 LITESPARK-001 study of belzutifan in advanced solid tumors: Results of the glioblastoma cohort.Org: Wake Forest University Department of General Internal Medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, University of Miami Health System, Sarah Cannon Research Institute at Tennessee Oncology DDU, South Texas Accelerated Research Therapeutics (START),
Abstract
Cost-effectiveness of dabrafenib plus trametinib in BRAFV600E-mutant pediatric low-grade glioma: A microsimulation study.Org: The Hospital for Sick Children, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital, University of Alberta, University of Toronto,
Abstract
A phase II, open label, single arm study of nivolumab for recurrent or progressive IDH mutant gliomas with prior exposure to alkylating agents.Org: Columbia University Irving Medical Center, New York, NY, USA, Dana-Farber Cancer Institute, Miami Cancer Institute, Baptist Health South Florida, Rhode Island Hospital,
Abstract
Initial results from phase I trial of a novel oncolytic adenovirus Ad-TD-nsIL12 in recurrent glioblastoma connecting to ventricular system.Org: Sanbo Brain Hospital, Capital Medical University, Beijing, China, Centre for Cancer Biomarkers & Biotherapeutics, Barts Cancer Institute,
Abstract
Zotiraciclib for newly diagnosed or recurrent glioblastoma: Updated outcome and biomarker analysis.Org: University Hospital Zurich, Brain Tumor Centre, University of Zurich, EORTC Headquarters, Institute of Neuropathology,
Abstract
Phase IIb randomized, blinded, controlled trial evaluating neoadjuvant PD-1 blockade combined with A2B5+ glioma stem-like cell lysate-loaded DC vaccine in recurrent glioblastoma (IDH1/2 -).Org: Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China, Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shang Hai, China, Shanghai Medsyin Biopharma Co., Ltd., Shang Hai, China, St. John's Cancer Institute, Santa Monica, CA, Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China,
Abstract
Development and validation of a clinical risk score for postoperative outcome in newly diagnosed glioblastoma: A report of the RANO Resect group.Org: Department of Neurosurgery, Ludwig-Maximilians-University, Munich, Germany, Department of Neurosurgery & Division of Neuro-Oncology, University of San Francisco, San Francisco, CA, Department of Neurosurgery, McGovern Medical School at UT Health Houston, Houston, TX, Department of Neurosurgery, University of Freiburg, Freiburg, Germany, Department of Neurosurgery, University of Cologne, Cologne, Germany,
Abstract
Primary intracranial germ cell tumors in adolescents and adults: Results of an international, multicenter, retrospective cohort study.Org: Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany, University Medicine Charité, Berlin, Germany, University Hospital Zurich, Zurich, Switzerland, Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Kantonsspital Luzern, Lucerne, Switzerland,
Abstract
Safety and efficacy of B7-H3 targeting CAR-T cell therapy for patients with recurrent GBM.Org: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China, Fuzhou Tcelltech Biological Science and Technology Inc., Fuzhou, China, Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, Yale Cancer Center, New Haven, CT,
Abstract
Multi-institutional study of reirradiation for recurrent high grade glioma.Org: Alexander T. Augusta Military Medical Center, Wake Forest Baptist Health, Wake Forest School of Medicine, Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Department of Radiation Oncology, Washington University School of Medicine in St. Louis,
Abstract
Enrichment of glioblastoma tumor microenvironment in a GZMK+ T cell population.Org: IRCCS Humanitas Research Hospital, Rozzano, Italy, Laboratory of Translational Immunology, Department of Biomedical Sciences, Humanitas University,
Abstract
Deciphering pediatric low-grade glioma trajectories: Deep learning–based volumetrics for patients under surveillance.Org: Brigham and Women's Hospital, Division of Neuroradiology, Perelman School of Medicine, University of Pennsylvania, Department of Radiology,
Abstract
Interim report of a phase 2 study of sonodynamic therapy (SDT) using SONALA-001 together with MR-guided low-intensity focused ultrasound (MRgFUS) in children with diffuse intrinsic pontine glioma (DIPG).Org: Children's National Hospital, Washington, DC, University of California Irvine, Nicklaus Children's Hospital, Trecona Limited, SonALAsense,
Abstract
Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results.Org: Division of Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Tennessee Oncology, PLLC, Sarah Cannon Research Institute, Nashville, TN, Sarah Cannon Research Institute at HealthONE, Denver, CO, NEXT Oncology Virginia, Fairfax, VA,
Abstract
A phase 0/1 trigger trial of BDTX-1535 in patients with recurrent high-grade glioma (HGG) with EGFR alterations or fusions.Org: Ivy Brain Tumor Center at Barrow Neurological Institute,
Abstract
PK-PD-efficacy modeling of brigimadlin in MDM2-amplified glioblastoma.Org: Mayo Clinic, University of Minnesota, Boehringer Ingelheim,
Abstract
A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).Org: Miami Cancer Institute, Baptist Health South Florida, Cleveland Clinic Lerner College of Medicine, Department of Internal Medicine, William Beaumont University Hospital, The University of North Carolina at Chapel Hill,
Abstract
Small extracellular vesicles as a novel liquid biopsy approach for glioblastoma.Org: Atrium Health Wake Forest Baptist Medical Center, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC,
Abstract
Intracranial hemorrhage in glioblastoma: Incidence, risk factors, and outcome.Org: Kantonsspital Aarau, Univ. Lille, CHU Lille - Hopital Huriez, Lillometrics, University Hospital of Zurich,
Abstract
A phase II study of plerixafor combined with whole brain radiation therapy (WBRT) for patients with newly diagnosed glioblastoma.Org: Stanford University School of Medicine, Stanford Cancer Institute Palo Alto, Stanford Cancer Center GI Surgical Oncology, Stanford Cancer Institue, The University of Texas MD Anderson Cancer Center,
Abstract
Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma.Org: The University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology, Department of Biostatistics & Data Science, Department of Radiation Oncology, University of California Irvine,
Abstract
A novel liquid biopsy assay with an 88% detection rate of genomic alterations across CNS tumors.Org: BillionToOne, Inc., Department of Translational Neurosciences, Pacific Neuroscience Institute and Saint John’s Cancer Institute at Providence Saint John’s Health Center, Saint John’s Cancer Institute at Providence Saint John’s Health Center,
Abstract
Pre-treatment immune biomarkers of pembrolizumab efficacy in patients with glioblastoma treated with standard of care.Org: Baylor College of Medicine, Oregon Health & Science University, Oregon Healthy Authority Health Promotion and Chronic Disease Prevention Section, Lake Oswego, OR, Providence Brain and Spine Institute,
Abstract
Phase 2 study of bizaxofusp, an IL-4R targeted toxin payload, in nonresectable recurrent GBM: Comparison of overall survival with contemporaneous eligibility-matched and propensity score balanced external control arm.Org: Medicenna Therapeutics Inc., Hospital of the University of Pennsylvania, University of Texas Health San Antonio Cancer Center, Medicenna Therapeutics, St. Michael's Hospital and University of Toronto,
Abstract
Therapeutic insights for the aggressive subset of high-grade gliomas (HGG) driven by chromosome 1q32 MDM4-containing amplicon and unmethylated MGMT.Org: Legorreta Cancer Center at Brown University, Brown University School of Medicine-Rhode Island Hospital, University of Minnesota, Sarah Cannon Research Institute/Tennessee Oncology, Brown Unversity School of Medicine-Rhode Island Hospital,
Abstract
Racial/ethnic disparities in healthcare utilization, post-operative outcomes, and overall survival for IDH-wildtype glioblastoma stratifying by MGMT promoter methylation status.Org: University of Minnesota System, University of Minnesota Medical Center,
Abstract
Unraveling the immunologic vulnerabilities of diffuse hemispheric glioma, H3 G34-mutant.Org: University of Minnesota, Caris Life Sciences, Duke University Medical Center, The Preston Robert Tisch Brain Tumor Center, Miami Cancer Institute,
Abstract
NFKBIA deletions reshape the epigenome antithetical to the IDH mutation and indication of prognosis in diffuse gliomas.Org: University of Alabama at Birmingham School of Medicine, Institut Mar d'Investigacions Mèdiques, NRG Oncology and The University of Florida Health Cancer Center, The Ohio State University James Cancer Center,
Abstract
Global, national, and regional burden of brain and central nervous system cancer in youth under 20 from 1990-2019: A benchmarking analysis.Org: All India Institute of Medical Sciences (AIIMS), Mamata Medical College, Bukovinian State Medical University, Government Medical College and Hospital, Christian Medical College Ludhiana,
Abstract
Evaluating Ki67 and Oncotype DX Breast Recurrence Score during neoadjuvant treatment with letrozole/abemaciclib or chemotherapy in patients with highly proliferative HR+/HER2- breast cancer participating in the GEICAM CARABELA trial.Org: Spanish Breast Cancer Group, Málaga,
Abstract
A 16 year-retrospective study of refractory meningiomas: Prognostic factors and systemic treatments.Org: Centre Hospitalier de l'Université de Montréal (CHUM)-Notre Dame, Montréal, QC, Canada,
Abstract
Marrow-ablative consolidation chemotherapy (HDCT) to decrease the development of choroid plexus carcinoma (CPC) specific relapse in high-risk TP53-mutated (germline or somatic) young children with newly diagnosed CPC.Org: St. Christopher's Hospital for Children, Alberta Children's Hospital, Children's Hospital of Michigan, Hospital Pablo Tobon Uribe, Hospital San Vicente Fundacion,
Abstract
Real-world monitoring and treatment patterns in von Hippel-Lindau (VHL) disease-associated central nervous system hemangioblastomas (CNS-Hb).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Analysis Group, Inc., Merck Sharp & Dohme, Merck & Co., Inc.,
Abstract
A phase 3 randomized controlled trial of post-surgical stereotactic radiotherapy versus surgically targeted radiation therapy with GammaTile for treatment of newly diagnosed metastatic brain tumors.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL).Org: Mayo Clinic-Florida, MD Anderson Cancer Center Madrid, Curis Inc,
Abstract
Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial.Org: Med. Univ. of Vienna, Hospital Professor Doutor Fernando Fonseca EPE, Arnau de Vilanova University Hospital,
Abstract
VAMANA: A phase 2 study of low-dose bevacizumab plus CCNU in relapsed/recurrent glioblastoma.Org: Tata Memorial Center, Tata Memorial Hospital and ACTREC, Homi Bhabha National Institute, Homi Bhaba National Institute,
Abstract
A multicenter phase 1 trial of tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2–positive breast cancer (TUTOR).Org: Miami Neuroscience Institute,
Abstract
A prospective, multicenter trial of low-intensity focused ultrasound (LIFU) for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE).Org: Sunnybrook Hospital, InSightec Inc, Cornell University, Bel Air, Sunnybrook Research Institute,
Abstract
A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC).Org: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Roswell Park Comprehensive Cancer Center, Buffalo, NY, Memorial Sloan Kettering Cancer Center,
Abstract
A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION).Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida,
Abstract
A phase II, multicenter, prospective study of sacituzumab govitecan in recurrent glioblastoma.Org: The University of Texas Health Science Center at San Antonio, Texas Oncology in Austin, Mays Cancer Center, UT Health Science Center at San Antonio,
Abstract
Azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II CAN-201 NDG trial design.Org: Spanish National Cancer Research Center (CNIO), Barcelona Translational Genomics and Targeted Therapeutics in Solid Tumors Group,
Abstract
Longitudinal stereotactic injections of oncolytic immunoactivating rQNestin34.5v.2 (CAN-3110) with concomitant biopsies for “-omic” analyses in recurrent glioblastoma (GBM).Org: Center for Neuro-Oncology, Dana-Farber Cancer Institute,
Abstract
A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE).Org: Overlook Medical Center, Neuro-Oncology at Roswell Park Cancer Institute, Northwell Health Neurosurgery at Lenox Hill Hospital,
Abstract
Phase 1 dose-finding study to evaluate safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma.Org: Centre for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, Department of Neurosurgery, LMU University Hospital, LMU Munich, Liège University Hospital, Department of Neurology and Wilhelm Sander-Therapy Unit, University Hospital Regensburg, Division of Clinical Neuro-Oncology, Department of Neurology, University Hospital Bonn,
Abstract
The anti-tumor immune response of radiotherapy combined with anti-CD200R1 in hepatocellular carcinoma.Org: The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
A phase 1/2 dose escalation and expansion study of sonodynamic therapy with SONALA-001 in combination with Exablate 4000 Type 2.0 MR-guided focused ultrasound in patients with progressive or recurrent glioblastoma (rGBM).Org: NYU Medical Center-Perlmutter Cancer Center,
Abstract
DIET2TREAT: A randomized, multi-center, phase 2 trial of a ketogenic diet vs standard dietary guidance in combination with standard-of-care treatment for patients with newly diagnosed glioblastoma.Org: Providence Saint John’s Health Center, Santa Monica, CA, Milwaukee, WI, Cedars-Sinai Cancer,
Abstract
First-in-human study of ZGGS18, a dual specific antibody targeting VEGF and TGF-β, as monotherapy in patients with advanced solid tumors.Org: ChangSha TaiHe Hospital, Shulan (Hangzhou) Hospital, Deyang People's Hospital, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Anhui Provincal Hospital,
Abstract
Phase 1 study of multiple intracerebral doses of a neural stem cell-based oncolytic virotherapy for treatment of recurrent high-grade gliomas.Org: Citi of Hope, City of Hope Beckman Research Institute, Ciry of Hope,
Abstract
A phase I/II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0028 in patients with advanced solid tumors.Org: Huaota Biopharma Co., Ltd., Huaota Biopharm Co., Ltd.,
Abstract
Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.Org: University of Okahoma Health Sciences Center,
Abstract
Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors.Org: South Texas Accelerated Research Therapeutics, San Antonio, TX, Austin Health, Heidelberg, Australia, Monash Health and Monash University, Melbourne, VIC, Australia, Monash Medical Centre, Southern Health, Clayton, QLD, Australia, Carolina BioOncology Institute, Huntersville, NC,
Abstract
Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors.Org: City of Hope Comprehensive Cancer Center, Duarte, CA, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of (South), Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, ABL Bio, Gyeonggi-Do, South Korea,
Abstract
Phase I dose escalation trial of the first-in-class TNFR2 agonist monoclonal antibody, HFB200301, in monotherapy and in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in adult patients with advanced solid tumors.Org: Hospital Clínico Universitario de Valencia, HiFiBiO Therapeutics Inc.,
Abstract
Effects of pre-treatment on odds of immune-related adverse events.Org: Department of Social Sciences and Health Policy,
Abstract
A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma.Org: Phase I Clinical Trial Ward of Medical Oncology Center, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC).Org: Janusz Korczak Provincial Specialist Hopsital, Institute of Cancer Research at the Royal Marsden, Phase 1 Clinical Trial Unit, NEXT Oncology, Hospital Universitario Quirón Salud, Early Phase Clinial Trials Unit, Maria Sklodowska-Curie National Research Institute of Oncology,
Abstract
Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial.Org: Department of Pulmonary Diseases, Erasmus MC, Rotterdam, Netherlands, Medical Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain, Clinical Research Unit, Military Hospital Begin, Saint-Mandé, France, Hopital Morvan CHU de Brest, Brest, France, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland,
Abstract
Development of NTX-472, a formulated mRNA therapy targeting CD20, CD19, and CD47, for treatment of B-cell lymphoma.Org: Nutcracker Therapeutics, Emeryville, CA,
Abstract
Updated results on the bispecific PSMAxCD3 antibody CC-1 for treatment of prostate cancer.Org: Clinical Collaboration Unit Translational Immunology, Cluster of Excellence iFIT (EXC2180), Bicony Therapeutics Gmbh, NCT Trial Center and Department of Internal Medicine V and Internal Medicine VI, Charité Comprehensive Cancer Center and Department of Hematology,
Abstract
Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.Org: Hematology Oncology Association of the Treasure Coast,
Abstract
A phase I monotherapy dose escalation study of HFB301001, a novel next generation OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors.Org: Department of Hematology and Oncology, Mayo Clinic Florida, Greenebaum Comprehensive Cancer Center, University of Maryland, Vall d'Hebrón Institute of Oncology, HiFiBiO Therapeutics Inc.,
Abstract
The role of obesity on outcomes of adoptive cellular therapy in solid tumors.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Biostatistics, Indiana University School of Medicine, Indianapolis, IN, Department of Investigational Cancer Therapeutics,
Abstract
A phase I study to evaluate the safety and tolerability of JCXH-211 (a self-replicating mRNA encoding IL-12) intratumoral injection in patients with malignant solid tumors: Results from the phase Ia dose escalation.Org: Immorna Biotherapeutics,
Abstract
Use of IL-3RB to mediate antitumor effect of CAR-T cells through the JAK-STAT signaling pathway.Org: Thoracic Oncology Ward, Institute of Medical Technology, Peking University Health Science Center, Beijing NA,
Abstract
A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.Org: Merck and Co Inc, NextCure Inc,
Abstract
Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors.Org: Jackson Memorial Hospital, Providence Portland Medical Center,
Abstract
Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors.Org: Department of Early Clinical Development, Kyoto University Graduate School of Medicine, Kyoto, Japan, Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan, Department of Experimental Therapeutics, Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Tregs, gMDSCs, and levels of soluble MICA as prognostic biomarkers for combined NEO-201 and pembrolizumab.Org: Women’s Malignancies Branch, Precision Biologics, Inc., Thoracic and Gastrointestinal Malignancies Branch,
Abstract
Randomized phase IIb trial of a CMV vaccine immunotherapeutic candidate (VBI-1901) in recurrent glioblastomas.Org: Dana-Farber Cancer Institute and Harvard Medical School,
Abstract
Updated results on multiple antigens stimulating cellular therapy (MASCT-I) in metastatic urothelial carcinoma: A randomized, open-label, phase I trial.Org: HRYZ Biotech Co. Ltd.,
Abstract
Phase 1 study of GT101 as an autologous tumor infiltrating lymphocyte (TIL) therapy in advanced solid tumors.Org: The Fifth Medical Centre of Chinese PLA General Hospital, Department of Pulmonary Neoplasm Internal Medicine, Fifth Medical Center of Chinese PLA General Hospital, Gynecological Oncology Center, Chongqing University Cancer Hospital, Phase I Clinical Trial Center, Chongqing University Cancer Hospital,
Abstract
Effect of novel autologous immune training platform on end-stage patients with cancer.Org: Department of Oncology, Royal Brisbane and Women’s Hospital, Southern Oncology Clinical Research Organisation, Greenslopes Hospital, Clinical Research South Australia, Alloplex Biotherapeutics, Inc.,
Abstract
Exploring the safety and efficacy of GT201 as a first-in-class autologous tumor-infiltrating lymphocyte monotherapy in advanced solid tumors.Org: Oncology Department, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China, Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China, The First Affiliated Hospital of Suzhou University, Suzhou, China, The First Affiliated Hospital of Soochow University, Suzhou, China, Department of Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China,
Abstract
Effect of CD22-directed CAR-T cells secreting anti-CD19 T cell engagers on control of leukemia progression compared to tandem anti-CD19/CD22 CAR-T cells.Org: Cancer Immunotherapy Unit (UNICA), Josep Carreras Leukaemia Research Institute, Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense,
Abstract
IOV-3001, a modified interleukin-2 fusion protein, for potential use in tumor-infiltrating lymphocyte cell therapy regimens.Org: Iovance Biotherapeutics, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
A first-in-human study of CRISPR/Cas9-engineered tumor infiltrating lymphocytes (TILs) product GT316 as monotherapy in advanced solid tumors.Org: Shanghai Tenth People's Hospital,
Abstract
Non-clinical evidence supporting the upcoming CLD-201 clinical trial: Cell-based oncolytic virotherapy for multiple solid tumors.Org: Calidi Biotherapeutics, StemVac GmbH,
Abstract
Constructing adverse event timelines for patients receiving CAR-T therapy using large language models.Org: University California, UCSF Cardiovascular Research Institute,
Abstract
Gender disparity in chimeric antigen receptor T-cell therapy utilization and outcomes in the United States.Org: Nassau University Medical Center, University of Massachusetts Chan Medical School - Baystate,
Abstract
Transforming tumor immune microenvironments with a novel systemic enveloped oncolytic virotherapy targeting all tumor sites.Org: Calidi Biotherapeutics, StemVac GmbH, Bernried,
Abstract
Non-clinical evaluation of NT-175, an autologous T cell product engineered to express an HLA-A*02:01-restricted TCR targeting TP53 R175H and resistant to TGF-b inhibition.Org: Santa Monica,
Abstract
Effect of placental circulating T cells expressing CD16 on multiple hematological and solid tumor cancers through combination with various monoclonal antibodies.Org: Celularity Inc.,
Abstract
Chimeric antigen receptor T-cell therapy in B-cell malignancies and DNA-methylation–based biological aging.Org: University of Missouri at Columbia, University of Missouri Columbia,
Abstract
Erythrocyte-αPD-1 conjugates overcome resistance to checkpoint blockade immunotherapy: A first-in-human study.Org: Westlake University, Zhejiang Province People’s Hospital, School of Life Sciences, Institute of Basic Medical Sciences, Westlake Institute for Advanced Study,
Abstract
Antagonizing vasoactive intestinal peptide (VIP) receptors with Muc16CD-directed armored CAR T cells for pancreatic cancer.Org: Achieve Clinics,
Abstract
Circulating metabolic profiling as a biomarker for immune checkpoint blockade efficacy.Org: National Research Council Canada (NRC), Halifax, NS,
Abstract
Combinatorial cellular therapy in pediatric solid tumors with natural killer (NK) and genetically engineered myeloid cells (GEMys).Org: National Institutes of Health Clinical Center, National Cancer Institute, Molecular Imaging Branch,
Abstract
Soluble mesothelin neutralizes mesothelin antibody-based therapies.Org: Mayo Clinic, National Cancer Institute, Vilnius, Lithuania,
Abstract
Proteogenomic profiling of clonal hematopoiesis in the solid tumor microenvironment.Org: Queen's University Belfast, Princess Margaret Cancer Center,
Abstract
Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors.Org: GENINUS Inc.,
Abstract
Effect of indoximod-based chemo-immunotherapy in patients with pediatric brain tumors on activation and clonal proliferation of a circulating population of early non-exhausted stem-like CD8+ T cells whose on-treatment expansion is predictive of long-term outcome.Org: Lumos Pharma, Inc.,
Abstract
Use of a tissue-free epigenomic circulating tumor DNA (ctDNA) assay for quantification of tumor fraction (TF) and association with outcomes from RADIOHEAD real-world advanced pan-cancer cohort.Org: Parker Institute for Cancer Immunotherapy,
Abstract
CD4 effector T cell expansion to identify objective responses to the CD40 agonist mitazalimab in combination with modified FOLFIRINOX (mFFX) as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC) in the OPTIMIZE-1 study.Org: Hospital of the University of Pennsylvania, Alligator Bioscience,
Abstract
Investigating peripheral blood biomarkers of immune checkpoint inhibitor associated fatigue.Org: Johns Hopkins University School of Medicine, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, F. Hoffmann-La Roche AG, Genentech,
Abstract
A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers.Org: OncoHost LTD, Thomas Jefferson University Methodist Hospital, Center for Immune-Oncology,
Abstract
Targeting a non-canonical STING signaling pathway in T cells to improve antitumor immunity.Org: The University of North Carolina at Chapel Hill, Chapel Hill, NC, NC Medical Research,
Abstract
Impact of microbiota specific circulating memory T cells in response to immunotherapy.Org: University of Verona, Oncology Section, Gustave Roussy, Université Paris Saclay, Gustave Roussy Cancer Campus (GRCC), bioMérieux, Gustave Roussy Cancer Campus (GRCC), ClinicObiome,
Abstract
Identification of molecular subtypes for integrated multi-omics analysis for use in guiding precision medicine in hepatocellular carcinoma.Org: Xiangya Hospital of Central South University, Changsha, China, Changsha, Hunan Center hospital, China National Biotec Group,
Abstract
Characterization of T-cell receptor repertoire and correlation with tumor mutational landscape in lung cancer.Org: HaploX Biotechnology, Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Chengdu, China,
Abstract
Novel method (MAXIM) uses deep learning model to impute missing stains in multiplex images (mIF).Org: National Cancer Insititute, National Institute of Allergy and Infectious Diseases,
Abstract
Efficacy, safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in a phase Ib dose expansion in resistant NSCLC, melanoma, and GI malignancy.Org: UCI Health, Horizon Oncology & Research Center,
Abstract
Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors.Org: Department of Medical Oncology UMC Utrecht, Utrecht, Netherlands, Schlieren, Switzerland,
Abstract
SH2B3 mutation as a potential resistance mechanism to oncolytic virus therapy.Org: Yale New Haven Hospital, Yale School of Medicine,
Abstract
Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200, in patients with advanced solid tumors.Org: The Lifespan Cancer Institute, Tan Tock Seng Hospital, Lee Kong Chian/NTU,
Abstract
Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation.Org: China Medical University Hospital, NGM Biopharmaceuticals, Inc.,
Abstract
Preliminary results of a phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors.Org: Atlantic Health System, Carol G Simon Cancer Center, Barbara Ann Karmanos Cancer Institute, Detroit, Wayne State University, Barbara Ann Karmanos Cancer Center,
Abstract
Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study.Org: Tongji University, Nanchang,
Abstract
Safety and activity of Diakine DK210 (EGFR), a next generation tumor-targeted IL2 x IL10 dual immunocytokine, in patients with advanced cancer: Initial results of the phase 1 first-in-human trial.Org: NEXT Virginia,
Abstract
Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.Org: University of Western Australia & Linear Clinical Research, Monash Medical Centre, Biokinetic, Parc Taulí Institute of Research and Innovation I3PT, Maria Sklodowska Curie National Research Institute of Oncology,
Abstract
Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL-3 inhibitor, in patients with advanced malignancies.Org: Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Storm Therapeutics Ltd.,
Abstract
Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3).Org: UTEC Hospital Clínico San Carlos, START Madrid - CIOCC, Waltham,
Abstract
EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.Org: Grey Wolf Therapeutics, Southern Oncology Clinical Research Unit Pty Ltd., START Barcelona, University Hospital Fundación Jiménez Diaz, Olivia Newton-John Cancer Wellness & Research Centre,
Abstract
A first‑in‑human phase 1a dose‑escalation study of BGB‑15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti‑PD‑1 antibody) in patients (pts) with advanced solid tumors.Org: Ashford Cancer Centre Research, Glandore, Australia, BeiGene USA, Inc., San Mateo, CA, BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene UK, Ltd., London, United Kingdom,
Abstract
Phase 1/2 study of XTX202, a tumor-activated IL-2βγ, in advanced solid tumors.Org: Division of Hematology and Medical Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Washington Cancer Institute/Georgetown-Lombardi Comprehensive Cancer Center, HealthPartners and Regions Hospital, Xilio Therapeutics, Inc,
Abstract
A phase I/II study to evaluate the safety, pharmacokinetics, and efficacy of PRJ1-3024 in patients with advanced solid tumors.Org: Department of Gastrooncology, Beijing Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Zhuhai Yufan Biotechnologies Co, Ltd,
Abstract
Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcγRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1.Org: Department of Hematology, Oncology and Radiation Physics, Skane University Hospital Comprehensive Cancer Center, Lund, Sweden, Karolinska Comprehensive Cancer Center, Stockholm, Sweden, OU Health Stephenson Cancer Center, Oklahoma City, OK, Sahlgrenska University Hospital, Gothenburg, Sweden, Health Partners, Saint Paul, MN,
Abstract
Targeting GARP–TGF-β1 with livmoniplimab plus anti–PD-1 budigalimab to remodel the immunosuppressive tumor microenvironment.Org: North Chicago,
Abstract
Phase I dose-escalation and cohort expansion study of the anti-BTLA antibody, tifcemalimab, in combination with toripalimab (anti-PD-1) in heavily pretreated patients (pts) with advanced malignancies.Org: Weill Cornell Medicine/NewYork-Presbyterian Hospital,
Abstract
Initial results from a first-in-human phase 1 study of SNS-101 (pH-selective anti-VISTA antibody) alone or in combination with cemiplimab in patients with advanced solid tumors.Org: West Valley City, San Antonio, TX,
Abstract
Correlation of baseline ENPP1 and cGAS expression in advanced solid tumors with intratumoral immune activation and clinical outcomes after treatment with the first-in-class oral ENPP1 inhibitor RBS2418, alone or in combination with pembrolizumab.Org: HonorHealth Research and Innovation Institute, Center for Cancer and Blood Disorders, Med Onc / Hem Consultants,
Abstract
A first-in-human, phase 1/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: Initial results from dose escalation.Org: Yonsei Cancer Center and Severance Hospital, Suwon, South Korea,
Abstract
The gut microbial characteristics and underlying mechanisms of patients with different clinical prognoses from immunotherapy by landmark analysis.Org: Department of Gastroenterology, Key Laboratory of Gut Microbiota Translational Medicine Research, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, China, Medical Research Center, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing, China, Department of Gastroenterology, Key Laboratory of Gut Microbiota Translational Medicine Research, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China,
Abstract
Examining response to immunotherapy in clear-cell renal cell carcinoma using baseline serum metabolic signatures.Org: ReviveMed Inc.,
Abstract
IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors.Org: Department of Urology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Florida Cancer Specialists & Research Institute, Sarah Cannon Research Institute and Sidney Kimmel Cancer Center, Thomas Jefferson University,
Abstract
Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors.Org: Horizon Oncology Research LLC, University of Utah Health, The University of Sydney Medical School, BioAtla Inc.,
Abstract
Tislelizumab first-line (1L) gastric/gastroesophageal junction cancer (G/GEJ) treatment efficacy on patient-reported outcome (PRO)-based symptom endpoints adjusting for informative missing data bias: Results from RATIONALE 305.Org: The Psychometrics Team, Sheridan, WY, BeiGene (Beijing) Co., Ltd, San Mateo, CA,
Abstract
Pharmacokinetic (PK) and pharmacodynamic (PD) findings from a phase 1b study of ATR inhibitor tuvusertib + anti-PD-L1 avelumab in patients with advanced unresectable solid tumors.Org: New Experimental Therapeutics (NEXT), San Antonio, TX, New Experimental Therapeutics (NEXT), Hospital Universitario Quirónsalud, Barcelona, Spain, New Experimental Therapeutics (NEXT), Hospital Universitario Quirónsalud, Madrid, Spain, The Healthcare Business of Merck KGaA, Darmstadt, Germany, Merck Specialities Pvt. Ltd., (an affiliate of Merck KGaA, Darmstadt, Germany), Bangalore, India,
Abstract
Correlative and spatial biomarker analysis of a phase 1/2b study to evaluate pepinemab in combination with pembrolizumab for first-line treatment of patients with recurrent or metastatic head and neck cancer.Org: Vaccinex, Inc, Zuckerberg Cancer Center, California Cancer Associates for Research and Excellence, Cancer Care of Western North Carolina,
Abstract
A phase 1 study of the small-molecule PD-L1 inhibitor INCB099280 in select advanced solid tumors: Updated safety, efficacy, and pharmacokinetics (PK) results.Org: Early Phase Trials Unit, Institut Bergonié, Bordeaux, France,
Abstract
Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors.Org: Cancer Center of Jinling Hospital, Nanjing Chinese Medicine University, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Gynecologic Oncology Department, Linyi Cancer Hospital, Anyang Tumor Hospital,
Abstract
TransCon IL-2 β/γ alone or in combination with pembrolizumab, standard of care chemotherapy or TransCon TLR7/8 agonist in advanced/metastatic solid tumors: Updated results of the phase 1/2 IL Believe study.Org: Gabrail Cancer and Research Center, Cancer Research South Australia,
Abstract
Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials.Org: Division of Surgery and Cancer, Imperial College, London, United Kingdom, Campus Bio-Medico University, Rome, Italy, University Campus Bio-Medico of Rome, Roma, Italy, Institute for Research in Biomedicine, Faculty of Biomedical Sciences, Universita della Svizzera Italiana, Bellinzona, Switzerland, Evergrande Center for Immunologic Diseases, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Mass General Brigham, Boston, MA,
Abstract
Phase 1 trial of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in monotherapy and combination with pembrolizumab in patients with advanced solid tumors.Org: Medical Oncology Associates, Hope Cancer Center of East Texas,
Abstract
Impact of concurrent antibiotics on survival with immunotherapy in metastatic colorectal and pancreatic cancer.Org: BC Cancer-Vancouver Centre, Canadian Cancer Trials Group, Queen's University Belfast, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada, Princess Margaret Cancer Centre,
Abstract
BGB-A317-212: A multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors.Org: Jiangsu Cancer Hospital, Peking University First Hospital, Zhejiang Provincial People's Hospital, The First Affiliated Hospital of Nanchang University Branch Donghu, The People's Hospital of Guangxi Zhuang Autonomous Region,
Abstract
Impact of body mass index (BMI) on survival outcomes in patients with cancer treated with immune checkpoint inhibitors (ICPI): A systematic review and meta analysis.Org: Karachi Medical and Dental College, SGRD Institute of Medical Sciences & Research,
Abstract
PD-L1 immunohistochemistry in gastric cancer: Comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays.Org: Toho University Graduate School of Medicine, University Clinic of Mainz,
Abstract
Lung-MAP S1800D: A phase II/III study of N-803 (ALT-803) plus pembrolizumab versus standard of care in participants with stage IV or recurrent non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy.Org: Winship Cancer Institute at Emory University,
Abstract
Modulation of lipid metabolism associated with response to metronomic capecitabine plus camrelizumab in patients with refractory gastrointestinal cancer: A prospective, single-center, exploratory trial.Org: Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China, Department of Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China,
Abstract
Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with previously treated metastatic non-small cell lung cancer (NSCLC) or cutaneous melanoma (SGN35-033): Overall survival.Org: Blue Ridge Cancer Care, Oncology Hematology Care, Inc.,
Abstract
A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors.Org: H. Lee Moffitt Cancer Center and Research Institute, Barbara Ann Karmanos Cancer Institute, Mary Crowley Cancer Research, Sarah Cannon Research Institute/Tennessee Oncology, NeoImmuneTech, Inc.,
Abstract
Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.Org: Roswell Park Comprehensive Cancer Center, University of California, San Diego Center for Advanced Laboratory Medicine, Moores Cancer Center, UC San Diego Health, Dartmouth Cancer Center, Lebanon, NH, Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC,
Abstract
The efficacy of immune checkpoint inhibitors in patients with cancer with pseudoprogression.Org: Novokuznetsk State Institute of Postgraduate Medical Education, Russian Medical Academy of Continuous Professional Education, City Clinical Cancer Hospital No. 1, Moscow City Clinical Cancer Hospital No. 1, Moscow Center for Rehabilitation,
Abstract
A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab.Org: Earle A Chiles Research Institute, Werewolf Therapeutics Inc, Cogitars GmbH,
Abstract
Pharmacodynamic (PD) and immunophenotyping analyses of ATR inhibitor (ATRi) tuvusertib + ATM inhibitor (ATMi) lartesertib in a phase Ib study in patients with advanced unresectable solid tumors.Org: New Experimental Therapeutics (NEXT), Merck Serono Ltd.,
Abstract
Evaluation of the tumor microenvironment in African American and non-Hispanic White patients with non-small cell lung cancer associated with PD-L1 expression or the presence of tertiary lymphoid structures.Org: Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, Washington University School of Medicine in St. Louis, St. Louis, MO,
Abstract
A phase 2a safety run-in and preliminary efficacy study of liposomal gemcitabine (FF-10832) in combination with pembrolizumab in patients with advanced solid tumors.Org: Atlantic Hematology Oncology, Morristown Medical Center, Morristown, NJ, FUJIFILM Pharmaceuticals USA, FUJIFILM Corporation,
Abstract
Use of CRTAM expression as a predictive biomarker for immune checkpoint blockade in a pan-cancer cohort.Org: School of Integrative and Global Majors, WIN Consortium,
Abstract
Identification of a predictive phosphoproteomic signature of response to atezolizumab and bevacizumab (AB) in patients with advanced hepatocellular carcinoma (aHCC).Org: Institute of Liver Studies, Kinomica Limited,
Abstract
Endogenous retrotransposable elements as a novel predictive biomarker of response to immunotherapy.Org: Princess Alexandra Hospital & University of CanadaQueensland,
Abstract
PERIO-02: Phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion +/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.Org: Department of Interventional Radiology,
Abstract
A distinct dimension of immunotherapeutic biomarker: Beyond immune infiltration and tumor antigenicity.Org: Zhongshan School of Medicine,
Abstract
AI based PD-L1 CPS quantifier software to identify more patients for checkpoint therapy in gastric cancer at pathologist-level interobserver concordance.Org: Sammamish, WA,
Abstract
Safety and preliminary efficacy of EIK1001 in combination with atezolizumab in participants with advanced solid tumors.Org: Eikon Therapeutics, Inc.,
Abstract
Genomic instability in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/ IFCT1301 trial.Org: Centrale Supelec, Office of Biostatistics and Epidemiology, Centre Hospitalier Universitaire de Clermont-Ferrand - Hôpital Gabriel Montpied, CHITS Toulon Sainte Musse, Université Paul Sabatier,
Abstract
Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.Org: University of Arkansas for Medical Sciences (UAMS), Little Rock, AR,
Abstract
AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease–positive pancreatic and colorectal cancer.Org: Northwell Heath, University of Florida Health Cancer Center, Weill Cornell Medicine, Englander Institute of Precision Medicine, NewYork-Presbyterian Hospital,
Abstract
Development of an mRNA therapeutic vaccine for virally driven Merkel cell carcinoma.Org: Yale School of Medicine, Yale Cancer Center,
Abstract
Detection of immune-related adverse events among hospitalized patients using large language models.Org: Harvard Medical School, Massachusetts General Hospital, Brigham and Women's Hospital/Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Oregon Health and Science University,
Abstract
Efficacy and safety of recombinant human adenovirus type 5 (H101) combined with immune checkpoint inhibitors (ICIs) in patients with liver metastatic gastric cancer: A prospective multicenter phase II study (the TROJAN 021 study).Org: Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai Jiaotong University School of Medicine,
Abstract
Triple M overlap syndrome (TMOS): Evaluating immune checkpoint inhibitor-related overlap syndrome of myocarditis, myositis and myasthenia gravis using an international pharmacovigilance database.Org: Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, Jordan University of Science and Technology, Irbid, Jordan, Saudi Food and Drug Authority, Pharmacovigilance Department, Riyadh, Saudi Arabia, Allegheny Health Network Cancer Institute at Allegheny General Hospital, Pittsburgh, PA, Morehouse School of Medicine, Atlanta, GA, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, Stanford Cancer Institute, Pao Alto, CA, Rheumatology and Clinical Immunology Section, Internal Medicine Department, The University of Texas MD Anderson Cancer Center, Houston, TX, Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA, Vanderbilt University Medical Center, Nashville, TN, Yale Cancer Center, New Haven, CT, Saudi Food and Drug Authority, Pharmacovigilance Division, Riyadh, Saudi Arabia,
Abstract
Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors.Org: L&L Biopharma Co. LTD., Thoracic Cancer Institute, Tongji University School of Medicine,
Abstract
Comprehensive whole genome and transcriptome analysis of patients with advanced solid tumor treated with immune checkpoint inhibitor therapy in the pan-cancer cohorts from the Marathon of Hope Cancer Centres Network Study (MOHCCN).Org: Princess Alexandra Hospital & University of Queensland, Woolloongabba, Australia, Toronto, Canada,
Abstract
Single cell sequencing reveals T follicular helper cells as the link between combination ICI therapy and the development of increased IRAEs.Org: Rosalind Franklin Medical School, UCLA Geffen School of Medicine, UCLA David Geffen School of Medicine, USC Keck School of Medicine,
Abstract
Primary analysis of a phase 1/2 study of LM-101: An anti-SIRPα antibody as a single agent in patients with advanced malignancies.Org: Collaborative Innovation Center of Cancer Medicine,
Abstract
Updated safety, efficacy, pharmacokinetics, and biomarkers from the phase 1 study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors.Org: College of Pharmacy, Chungnam National University,
Abstract
The impact of COVID-19 mRNA vaccines on immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors.Org: Department of Oncology/Hematology, Loma Linda University Medical Center, AdventHealth Orlando,
Abstract
19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.Org: MH Egeszsegugyi Kozpont, Budapest, Hungary, Centre for Cancer Immunology, University of Southampton, Southampton, United Kingdom, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom, PRA Health Sciences, Budapest, Hungary, University of Southampton, Southampton, United Kingdom,
Abstract
Development of a novel risk stratification model for immune-related adverse events for patients with advanced melanoma and non-small cell lung cancer treated with immune checkpoint inhibitors.Org: Cumming School of Medicine,
Abstract
Can immune therapy prevent pre-clinical cancer from progression? The impact of immune therapy on secondary cancer incidence.Org: Cleveland Clinic Taussig Cancer Center, Cleveland Clinic, Lerner Research Institute; Center for Immunotherapy & Precision Immuno-Oncology,
Abstract
Tocilizumab for advanced non-small cell lung cancer with concomitant inflammatory cachexia: A single-centre study.Org: Department of Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Patient experience with immuno-oncology-induced cytokine release syndrome: Developing a conceptual model of symptoms and their impacts on patients' lives.Org: Gentilly, Reading,
Abstract
Comprehensive analysis of TMB, TNB, and HLA via NGS sequencing in a large cohort of Chinese pan-cancer patients.Org: Oncology Department of Wuxi Traditional Chinese Medicine Hospital, Cancer Institute of Jiangsu University, Affiliated Hospital of Jiangsu University, MEDx (Suzhou) Translational Medicine Co., Ltd., Translational Medicine Center,
Abstract
Intravenous delivery of oncolytic adenovirus TILT-123 results in systemic tumor transduction and accumulation of lymphocytes.Org: Cancer Gene Therapy Group, Docrates Cancer Center, National Center for Cancer Immune Therapy, Digital Microscopy and Molecular Pathology Unit, Institute for Molecular Medicine Finland,
Abstract
The impact of proton-pump inhibitor use on the incidence and severity of gastrointestinal toxicity to checkpoint inhibition.Org: The University of Texas Health Sciences Center, The University of Texas Health Science Center at Houston, McGovern Medical School,
Abstract
A phase I open-label study of a novel IL-2Rβ/γ cytokine agonist, LTC004, in patients with advanced or metastatic solid tumors.Org: The Affiliated Hospital of Hebei University, The First Affiliated Hospital Bengbu Medical University,
Abstract
A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results.Org: Institut Català d’Oncologia-IDIBELL, Regeneron Pharmaceutials, Inc.,
Abstract
Correlations between first cycle toxicity and overall survival in patients with rare cancers treated with immune checkpoint inhibitors (NCI/SWOG S1609).Org: University of Washington/Fred Hutchinson Cancer Center and SWOG Statistics and Data Management Center, Seattle, WA, UC San Diego Moores Cancer Center, La Jolla, CA, Northwestern University, Chicago, IL, National Cancer Institute/National Institutes of Health, Bethesda, MD, Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA,
Abstract
Safety and efficacy of immune checkpoint inhibitors (ICI) in patients (pts) with pre-existing neurologic autoimmune diseases (NAID) and Parkinson's disease.Org: Campus Bio Medico University of Rome, Department of Surgery and Cancer Imperial College London, Department of Biotechnology and Applied Clinical Sciences University of L'Aquila,
Abstract
A multi-centre, single arm, phase 2 trial of pembrolizumab in treatment-naïve patients with carcinoma of unknown primary site.Org: Edmonton, AB, Canada, University of Ottawa, The Ottawa Hospital Regional Cancer Centre,
Abstract
Phase 1 study of ASP1002, a bispecific antibody targeting claudin 4 (CLDN4) and CD137, in patients with locally advanced (LA) or metastatic solid tumors that express CLDN4.Org: Northbrook, IL,
Abstract
Transcriptome-based response predictor to identify potential responders among patients with negative standard markers for response to immune checkpoint blockers.Org: Pangea Biomed, NIH-National Cancer Institute, Cancer Data Science Laboratory,
Abstract
Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Division of Cancer Medicine, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
A phase 2, multicenter study of TILs treatment in advanced tumors with alterations in the SWI/SNF complex: The TILTS study.Org: Early Drug Development Unit, HM Sanchinarro University Hospital, Institut Catala D' Oncologia, Bellvitge Biomedical Research Institute (IDIBELL), Departamento de Ciencias Médicas Básicas, Universidad San Pablo-CEU, CEU Universities,
Abstract
An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT‑112 in human leukocyte antigen-C*08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation.Org: Hoag Memorial Hospital Presbyterian, Newport Beach, CA, Texas Oncology–Baylor Charles A. Sammons Cancer Center, Dallas, TX, Providence Cancer Institute EACRI,
Abstract
Preliminary results of a phase 1, first-in-human, dose escalation study of the anti-CCR8 cytolytic antibody, CHS-114 (formerly SRF114) in patients with advanced solid tumors.Org: Washington University School of Medicine in St Louis, Coherus Biosciences, Surface Oncology,
Abstract
Genetic drivers of severe skin toxicity with immune checkpoint inhibitors (ICIs) in Asian patients.Org: Chugai Pharmaceutical Co., Ltd.,
Abstract
Phase I trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO).Org: Duke University Cancer Institute, Louisiana State University School of Medicine,
Abstract
A phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors.Org: Department of Advanced Medical Development, Boehringer Ingelheim Pharmaceuticals, Inc., Nippon Boehringer Ingelheim Co., Ltd.,
Abstract
Binary oncolytic adenovirus in combination with HER2-specific autologous CAR VST for treatment of advanced HER2-positive solid tumors (VISTA).Org: Cell and Gene Therapy, Baylor College of Medicine Division of Diabetes Endocrinology and Metabolism, Baylor College of Medicine Division of Pediatrics,
Abstract
ATTAINMENT: A phase Ib trial of MDX-124, a first-in-class annexin-A1 targeting antibody, alone and in combination with anti-cancer treatments, in patients with advanced solid tumors.Org: The Clatterbridge Cancer Centre, Medannex Ltd, Liverpool Clinical Trials Centre, Liverpool Experimental Cancer Medicine Centre,
Abstract
First-in-human autologous CAR-T for metastatic breast cancers to target growth factor receptor MUC1*.Org: Minerva Biotechnologies, City of Hope Comprehensive Cancer Center, Cedars-Sinai Medical Center, University of Washington and Fred Hutchinson Cancer Research Centre, City of Hope National Medical Center,
Abstract
Fecal microbiota transplantation combined with anti-PD-(L)1 inhibitors as first-line maintenance therapy for advanced gastric and non small cell lung cancer.Org: The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, China, Changzhou Second People’s Hospital, Changzhou, China,
Abstract
A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.Org: City of Hope Comprehensive Cancer Center, Duarte, CA, Washington University School of Medicine in St Louis, St. Louis, MO, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
DUET-01: A first-in-human, phase 1/2 study of BOXR1030 in patients with advanced glypican-3-positive solid tumors.Org: Froedtert and the Medical College of Wisconsin Workforce Health, Milwaukee, WI, SOTIO Biotech Inc., Boston, MA, SOTIO Biotech a.s., Prague, Czech Republic, SOTIO Biotech AG, Basel, Switzerland, Texas Oncology–Baylor Charles A. Sammons Cancer Center, Dallas, TX,
Abstract
ATHENA: A phase 1/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced/recurrent hepatocellular carcinoma (HCC).Org: Trinity College Dublin, Oregon Health Sciences University, University of Pittsburg Medical Center,
Abstract
Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).Org: Department of Medical Oncology, Amsterdam UMC, START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Medical Oncology Department, Catalan Institute of Cancer (ICO), Cancer Immunotherapy Group (CIT), Bellvitge Biomedical Research Institute (IDIBELL) —OncoBell, Early Phase Drug Development Program START Madrid-CIOCC, Centro Integral Oncológico Clara Campal,
Abstract
A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors.Org: Division of Hematology/Oncology, University of Cincinnati Cancer Center,
Abstract
A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280, an investigational B7-H3 x CD3ε conditional bispecific redirected activation (COBRA) T-cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors.Org: Takeda Development Center Americas, Inc. (TDCA),
Abstract
A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors.Org: Ankyra Therapeutics, National Cancer Institute, Vilnius, Lithuania, UPMC Hillman Cancer Center,
Abstract
A phase 1, multi-center, safety, feasibility, and preliminary efficacy study evaluating a single dose of UNO101 in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies.Org: Soroka - Clalit and Ben Gurion University Medical Center, Beer Sheva, Israel, Beyond Cancer, Rehovot, Israel,
Abstract
The FIPO23 trial: First-in-human phase I/II study of XON7 in advanced solids tumors.Org: Hôpital Foch,
Abstract
First-in-human phase I/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18.2 and 4-1BB, in patients with advanced solid tumors.Org: First Affiliated Hospital of Nanchang University, Department of Medical Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University,
Abstract
A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.Org: Department of Stem Cell Transplantation and Cellular Therapy,
Abstract
Two phase 2A clinical trials to evaluate the safety and efficacy of IMSA101 in combination with radiotherapy and checkpoint inhibitors in oligometastatic and oligoprogressive solid tumor malignancies.Org: MetroHealth Cancer Center, University of Wisconsin Madison, Cleveland VA,
Abstract
Combination therapy with the oncolytic virus CF33-CD19 and blinatumomab for the treatment of advanced solid tumors.Org: City of Hope National Comprehensive Cancer Center, Imugene,
Abstract
Phase I, open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors.Org: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Limited,
Abstract
Phase I trial of CRD3874-SI, a systemically administered STING agonist, in patients with advanced solid tumors.Org: Memorial Sloan Kettering Cancer Center - Fellowship (GME Office), Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center,
Abstract
EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).Org: A2 Biotherapeutics, Inc., H. Lee Moffitt Cancer Center and Research Institute, Mayo Clinic, NYU Langone Health, New York, NY, Washington University in St. Louis,
Abstract
A first-in-human phase I study of ATG-031, anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM).Org: Antengene Corporation Co., Ltd,
Abstract
A phase 1/2 study of BDC-3042, a novel dectin-2 agonistic antibody, in patients with advanced cancers.Org: Next Oncology Virginia and Virginia Cancer Specialists, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Dana-Farber Cancer Institute, Stanford University School of Medicine,
Abstract
A phase 1 dose-escalation and expansion study of an intratumorally administered dual STING agonist (ONM-501) alone and in combination with cemiplimab in patients with advanced solid tumors and lymphomas.Org: University of Pittsburgh Medical Center (UPMC), The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, UPMC Hillman Cancer Center, UT Southwestern Medical Center, OncoNano Medicine Inc.,
Abstract
A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors.Org: NextGen Oncology,
Abstract
EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).Org: Agoura Hills,
Abstract
A phase 1 trial in progress for in situ immunomodulation with CDX-301, radiation therapy, poly-ICLC, and CDX-1140 in patients with unresectable and metastatic solid tumors.Org: Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, University of Southern California Marshall School of Business, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Division of Oncology, Rambam health care, Haifa, Israel,
Abstract
Phase 1 study of AM003, a novel individualized immunotherapy, in a basket of advanced solid tumors.Org: Aummune, Institute of Oncology Angel H Roffo, Sheba Medical Center, Or-Yeuda,
Abstract
A phase I pilot study of personalized neoantigen peptide-based vaccine in combination with pembrolizumab in advanced solid tumors (PNeoVCA).Org: Mayo Clinic Florida, Mayo Clinic,
Abstract
FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.Org: Department of Peptide-based Immunotherapy, Institute of Immunology,
Abstract
A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors.Org: Institute Gustave Roussy and Paris Saclay University, Dermatology Department Hospital Center University De Lille, Department of Dermatology Comprehensive Cancer Center, Westdeutsches Tumorzentrum University Hospital Essen & Research Alliance Ruhr & Research Center One Health University Duisburg-Essen, Department of Medical Oncology Dana-Farber Cancer Institute,
Abstract
The anti-CD20 antibody-drug conjugates TRS005 in relapse/refractory CD20-positive B-cell non-Hodgkin lymphoma: A multicenter, open-label, single-arm, phase I study.Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Cancer Center/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Henan Provincial Cancer Hospital, Henan Cancer Hospital, Zhengzhou University, Tianjin Medical university cancer institute & Hospital,
Abstract
A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.Org: Scientia Clinical Research Limited, North Shore Hematology Oncology Associates, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Shanghai Cancer Hospital of Fudan University, CStone Pharmaceuticals Co. Ltd.,
Abstract
Phase 1 study (NCT04931823) of CPO100 (albumin bound docetaxel) in patients with advanced solid tumors.Org: Comp Cancer Ctr of Nevada, UCLA- Santa Monica, Comprehensive Cancer Centers of Nevada, Carolina BioOnology Institute,
Abstract
A phase 1/1b, first-in-human, multi-part study of DF6215, an engineered IL-2Rα-active agonist, to investigate the safety, tolerability, pharmacokinetics, and biological and clinical activity in patients with advanced solid tumors.Org: PASO Medical,
Abstract
Clinical landscape of precision oncology for rare cancers among diverse Asian populations: Insights from the MASTER KEY registry.Org: Department of International Clinical Development, National Cancer Center Hospital, Tokyo, Japan, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Division of Clinical Cancer Genomics, Hokkaido University Hospital, Hokkaido, Japan, Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan,
Abstract
Repurposing ibrutinib for chemo-immunotherapy in a phase 1b study of ibrutinib with indoximod plus metronomic cyclophosphamide and etoposide for patients with childhood brain cancer.Org: Lumos Pharma, Inc. (formerly NewLink Genetics Corporation),
Abstract
Safety and efficacy of biosimilar TDM-1: A real world retrospective study.Org: Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad,
Abstract
A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.Org: School of Medicine, Tongji University, Jinan Central Hospital, Shandong University, Zhongshan Hospital, Fudan University, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Nanyang Medical College First Affiliated Hospital,
Abstract
Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types.Org: University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, Universitätsmedizin Mannheim, Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, University of Washington Medicine,
Abstract
Dose optimization and exposure-response analyses to support optimal dose of ABBV-400, a novel C-met–targeting antibody drug conjugate, in patients with metastatic colorectal cancer (mCRC).Org: AbbVie Deutschland GmbH & Co. KG,
Abstract
A blind retrospective analysis of a novel predictive marker to ICB response in NSCLC, calculated directly from histopathological slides.Org: Pangea Biomed,
Abstract
YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial.Org: Summit Cancer Centers, BRCR Global, Karmanos Cancer Center,
Abstract
Comparison of primary versus metastatic tumor tissue sources when designing panels for whole genome–based tumor-informed ctDNA assays in clear cell renal cell carcinoma.Org: Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, Myriad Genetics, Inc., Salt Lake City, UT,
Abstract
Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study.Org: Pindara Private Hospital/Ramsay Health, Oncology Chemotherapy Department, First Affiliated Hospital of Zhejiang University School of Medicine, Tumor Hospital, Sunshine Coast University Private Hospital,
Abstract
Evaluation of the safety, pharmacokinetics, and efficacy of JSKN003 in patients with advanced solid tumors: A phase I/II clinical study.Org: Department of Breast Surgery, Sun Yat-sen Memorial Hospital, 2nd Hospital, Zhejiang University School of Medicine, Department of Medical Oncology, Xuzhou Central Hospital,
Abstract
Safety and efficacy of JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study.Org: Blacktown Hospital, Hollywood Private Hospital, Liverpool Hospital, Alphamab Oncology Ltd.,
Abstract
Immune-phenotyping of peripheral blood mononuclear cells from patients with early triple-negative breast cancer: Identification of a systemic immunosuppressive CD3+ CD4+ CD39+ Treg subset.Org: University of Pretoria, Medical Oncology Centre of Rosebank, The Medical Oncology Centre of Rosebank,
Abstract
An open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors (CLINCH).Org: Cancer Center, West China Hospital, Sichuan University, Cabrini Health Limited, Antengene Therapeutics Ltd.,
Abstract
High-sensitive multi-cancers early detection for 8 cancer types by cell-free DNA targeted methylation sequencing: A retrospective cohort study.Org: Sun Yat Sen University Cancer Center, Laboratory of Oncology in South China, Geneplus-Beijing Institute, Geneplus-Beijing Insititute, Department of Colorectal Surgery,
Abstract
Association of KRAS G12D vs. G12V circulating tumor DNA variant allele fraction and real-world overall survival in metastatic non-small cell lung and colorectal cancers.Org: University of Pennsylvania, Guardant Health Inc.,
Abstract
Presence of molecular residual disease after pathologic complete response among patients with inflammatory breast cancer.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Breast Medical Oncology Department, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan, The University of Texas M.D. Anderson Cancer Center,
Abstract
Relationship between dynamic changes in circulating tumor fraction and real-world imaging with real-world survival in patients with solid tumors treated with immunotherapy.Org: Tempus AI, Tempus Labs, Inc., Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Washington University School of Medicine in St. Louis,
Abstract
The design, preclinical study and phase I dose escalation plan of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment.Org: Hangzhou HighField Biopharmaceuticals Corporation, Zhejiang University, School of Pharmacy,
Abstract
Early clues in the battle against advanced gastric cancer: How plasma ctDNA signals the effectiveness of PD-1 inhibitors with chemotherapy.Org: Gastric Cancer Center, The First Affiliated Hospital with Nanjing Medical University,
Abstract
Phase Ia/Ib trial on the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).Org: Division of Medical Oncology, Hyogo Cancer Center, Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Department of Clinical Oncology, St. Marianna University School of Medicine, Clinical Research Center, Kindai University Hospital, Kindai University Hospital Cancer Center,
Abstract
Classification of HER2 status across multiple cancers using epigenomic profiles from a novel liquid biopsy assay.Org: Precede Biosciences, Boston Pharmaceuticals, MaaT Pharma, Dana-Farber Cancer Institute, DFCI/PCC Fellowship Program - Attendings,
Abstract
Using cell-free RNA in monitoring immune system and the demonstration of significant systemic deficiency in lymphoid and myeloid biomarkers in patients with cancer.Org: John Theurer Cancer Center at Hackensack University,
Abstract
Personalized circulating tumor DNA for minimal residual disease and dynamic assessment in patients undergoing neoadjuvant chemotherapy for breast cancer: Preliminary analysis from MSK-LINC.Org: Babraham Research Park,
Abstract
Enhancing cancer detection through AI-driven high content analysis of circulating tumor cells.Org: Nashik, Datar Cancer Genetics Pvt Ltd, Datar Cancer Genetics Inc, Morrisville, Medanta Medicity,
Abstract
Paired matched normal sequencing to accurately identify somatic clonal hematopoiesis mutations (CHm) in solid tumor tissue and plasma specimens.Org: Eurofins Viracor Biopharma, Lenexa,
Abstract
Discovery of long non-coding RNA biomarkers for prognosis in pediatric acute lymphoblastic leukemia.Org: UMass Chan Medical School, Population and Quantitative Health Sciences,
Abstract
ctDNA as a biomarker in phase II study of tepotinib in advanced solid cancers with MET exon 14 skipping mutation or amplification (KCSG AL19-17).Org: Chungbuk Univeristy Hospital, Chungbuk University College of Medicine, Inje University College of Medicine, Pusan National University School of Medicine, Chonnam National University Hwasun Hospital,
Abstract
Clinical impact of molecular profiling in the national prospective cohort Solving Unknown Primary Cancer (SUPER) study.Org: University of Melbourne Centre for Cancer Research, Department of Clinical Pathology, Westmead Institute for Medical Research, Andrew Love Cancer Centre, South West Healthcare,
Abstract
Characterization of molecular response and progression in patients with metastatic HR+/HER2- breast cancer receiving endocrine therapy and CDK4/6 inhibitors using a high-sensitivity tumor-informed assay.Org: Division of Medical Oncology & Hematology,
Abstract
Correlation of ctDNA and radiographic imaging features derived from 18F-FDG PET/CT for patients with metastatic melanoma treated with immunotherapy.Org: Australian Centre for Quantitative Imaging, AIQ Solutions, Centre for Precision Health and School of Medical and Health Sciences, Department Nuclear Medicine, Clinical Cancer Research,
Abstract
Association of complementing circulating tumor DNA and circulating tumor cells load on stable and progressive disease in treated patients.Org: OneCell Dx, Mumbai Oncocare Centre, MOC Cancer Care & Research Centre, Omega Hospital, HCG Cancer Care,
Abstract
RNA-based fusion testing in gastrointestinal (GI) carcinomas: A single-institution experience.Org: Center for Integrated Diagnostics,
Abstract
Effect of breast tissue density on cell-free orphan non-coding RNAs secreted by breast cancers.Org: Renown Health-Pennington Cancer Institute,
Abstract
Analytical validation of the Labcorp Plasma Complete test to enable precision oncology through solid tumor liquid biopsy comprehensive genomic profiling.Org: Wake Forest Comprehensive Cancer Center and Department of Pathology,
Abstract
Development, comparative study, and external validation of a new deep learning model for predicting genome-wide gene expression from histopathology slides.Org: Medical University of Bialystok,
Abstract
Development of a serum miRNA panel for detection of early stage non-small cell lung cancer.Org: Miracle Biotechnology Inc., National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Southern University of Science and Technology,
Abstract
Non-invasive colorectal cancer detection using multimodal deep learning ensemble classifier.Org: GC Genome, Yongin, South Korea, GC Genome, Yongin-Si, South Korea, GC Genome, Yongin, Gyeonggi-do, South Korea, GC Genome, Yongin-Si, Gyeonggi-do, South Korea, Genece Health, San Diego, CA,
Abstract
Nature and distribution of methyl thioadenosine phosphorylase (MTAP) genomic loss in human tumors.Org: Vita-Salute San Raffaele University,
Abstract
Therapeutic implications of phosphoproteomics in molecular cancer diagnostics.Org: Technical University of Munich (TUM), Hopp Children's Cancer Center (KiTZ),
Abstract
Utility of [18F]FDG PET/CT in predicting pathological complete response to neoadjuvant therapy in breast cancer: A prospective study.Org: IRCCS - Humanitas Research Hospital,
Abstract
Development and validation of mFISHseq: A diagnostic test using multiplexed RNA-FISH–guided laser capture microdissection RNA sequencing.Org: Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany, MultiplexDX, Bratislava, Slovakia, Institute of Clinical Biochemistry and Diagnostics, University Hospital, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Králové, Czech Republic, Wellcome Centre for Cell Biology, University of Edinburgh, Edinburgh, United Kingdom, The Biomedical Research Institute of Málaga, Malaga, Spain, Laboratory for RNA Molecular Biology, The Rockefeller University, New York, NY, Precede Biosciences, Boston, MA, Breast and Imaging Center, Memorial Sloan Kettering, New York, NY, Department of Internal Medicine Hematology Oncology, University of Heidelberg, Heidelberg, Germany,
Abstract
Assessing the value of repeat next generation testing in patients with non-small cell lung cancer: A retrospective review.Org: University of California, Irvine, Orange, CA,
Abstract
A highly sensitive, low input, and automated assay for molecular residual disease detection (MRD) using whole-genome sequencing (WGS).Org: Illumina, Inc.,
Abstract
Clinical validation of Northstar Select, a novel liquid biopsy assay for comprehensive genomic profiling of solid tumors.Org: BillionToOne, Inc.,
Abstract
CUPCOMP: A multi-site UK trial in carcinoma of unknown primary: A comparison across tissue and liquid biomarkers.Org: Cancer Research UK National Biomarker Centre, Royal United Hospitals Bath NHS Foundation Trust, Torbay and South Devon NHS Foundation Trust, Velindre University NHS Trust, Clatterbridge Centre for Oncology NHS Foundation Trust,
Abstract
Polyploid circulating stromal cells in blood to identify invasive solid tumors and to prognosticate for highly aggressive cancer subtypes.Org: Creatv MicroTech, Inc., Fred & Pamela Buffett Cancer Center, Department of Surgery, Medical College of Wisconsin, Gunma University, Desai Sethi Urology Institute at the University of Miami and Sylvester Comprehensive Cancer Center,
Abstract
A novel MRI-based tumor-targeting theragnostic agent: Magnetoelectric nanoparticles in an in vivo murine KRAS/P53 pancreatic flank tumor model.Org: Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Cancer Physiology/Clinical Science Laboratory, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Department of Gastroenterology Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Department of Immuno-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Department of Diagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL,
Abstract
A pan-cancer analysis of SMARCA4 alterations and the unique clinicogenomic characteristics associated with SMARCA4 mutation types.Org: Memorial Sloan Kettering Cancer Center, AstraZeneca, Early Drug Development Group,
Abstract
Focus on human epidermal growth factor receptor 2 (HER2) positive metastatic colorectal cancer (HER2+ mCRC): A real world retrospective analysis.Org: Fondazione Policlinico Universitario Agostino Gemelli – IRCCS, 'Tor Vergata' Clinical Center, University of Rome, UOC Oncologia, Ospedale Santa Maria Goretti,
Abstract
Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer.Org: Compass Oncology/US Oncology Network, Accutar Biotechnology Inc.,
Abstract
A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation.Org: University of California, Irvine Chao Family Comprehensive Cancer Center, Division of Cancer Treatment and Diagnosis National Cancer Institute,
Abstract
A phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): Results of dose escalation.Org: National Cancer Institute-Cancer Therapy Evaluation Program, Cullgen, Inc.,
Abstract
Long-term efficacy, safety and PK data of TH1902 (sudocetaxel zendusortide) in solid tumors: A novel SORT1-targeting peptide-drug-conjugate (PDC).Org: Barbara Ann Karmanos Cancer Center, Mary Crowley Cancer Research Center, Pennsylvania Cancer Specialists and Research Institute,
Abstract
A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).Org: Mayo Clinic, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Atlantic Health System, Carol G Simon Cancer Center, Morristown, NJ, Department of Hematology and Oncology, Mayo Clinic Florida, Robert H. Lurie Comprehensive Cancer Center of Northwestern University,
Abstract
Contribution of the microbiome to differential drug efficacy and clinical trial outcomes between the US and Japan.Org: BioCorteX Inc.,
Abstract
Standard atezolizumab leads to severe overexposure in real-world patients with lung cancer: How far could we go in extending dosing intervals and saving money?Org: COMPO Centre de Recherche en Cancérologie de Marseille Inserm U1068 CNRS, CRCM, Hôpital Nord, SMARTc Centre de Recherche en Cancérologie de Marseille Inserm U1068, Multidisciplinary Oncology and Therapeutic Innovations,
Abstract
Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update.Org: Frauenshuh Cancer Center, Nimbus Therapeutics, Florida Cancer Affiliates, Honor Health Research Institute,
Abstract
Breaking from the paradigm of antibody-drug conjugates: Evaluation of clinical pharmacokinetics and safety of bicycle toxin conjugates (BTCs).Org: Bicycle Therapeutics, BicycleTx Ltd,
Abstract
Final results of a first-in-human phase I dose escalation trial of daily oral zelenirstat, a n-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas.Org: BC Cancer Centre for Lymphoid Cancer, Pacylex Pharmaceuticals, Inc.,
Abstract
An exploratory study on prediction of risk for abemaciclib-induced interstitial lung disease or hepatotoxicity by specific human leukocyte antigen alleles.Org: Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, Department of Breast Medical Oncology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan, Department of Breast Surgery, Shizuoka General Hospital, Shizuoka, Japan, Department of Breast Surgery, Kansai Rosai Hospital, Amagasaki, Japan,
Abstract
Prevalence of recreational and medical cannabis products in Veterans and their interactions with cancer directed pharmacological treatment.Org: University of Tennessee Health Science Center, University of Tennessee of Health Science Center, Kirkland Cancer Center, Baptist Memorial Hospital - Collierville, Lt. Col. Luke Weathers Jr. VA Medical Center,
Abstract
Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients (pts) with advanced solid tumors or hematologic malignancies.Org: IRCCS University Hospital of Bologna, Cancer Center Clinica Universidad de Navarra,
Abstract
Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.Org: Advanced Molecular Imaging and Therapy, Hoag Family Cancer Institute and University of Southern California, Hunstman Cancer Hospital, University of Utah Health, University of Kentucky, Markey Cancer Center, Department of Medical Oncology, Mercy Medical Center,
Abstract
Alectinib in pediatric patients with solid or CNS tumors harboring ALK-fusions: Emerging pharmacokinetic data from the iMATRIX alectinib phase I/II open-label, multi-center study.Org: Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Copenhagen University Hospital - Rigshospitalet, Hospital Universitari I Politecnic La Fe,
Abstract
Multi-ethnic genome-wide association study to identify a novel locus for susceptibility to immune-related adverse events from immune checkpoint inhibitors.Org: Department of Haematology Oncology, National University Cancer Institute Singapore, Department of Haematology-Oncology, Rheumatology Division, National University Hospital,
Abstract
Targeting rare variants of a pan-cancer target: The landscape of BRAF non-v600 mutations and BRAF fusions from 172,005 adult patients with cancer.Org: Trinity St. James's Cancer Institute,
Abstract
Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Investigational Cancer Therapeutics,
Abstract
Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors.Org: Henry Ford Cancer Hospital, Northwestern University - McGaw Medical Center,
Abstract
Efficacy and safety of FCN-159, a MEK1/2 inhibitor in pediatric participants with neurofibromatosis type 1: Results from a phase 2 trial.Org: The Children's Hospital of Zhejiang University School of Medicine, NanFang Hospital of Southern Medical University, Shanghai Ninth People's Hospital, Shanghai Fosun Pharmaceutical Industrial Development CO., Ltd.,
Abstract
Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study.Org: Bayer HealthCare Pharmaceuticals, Inc., Bayer Pharmaceuticals, Inc., PPD, part of Thermo Fisher Scientific, Bayer HealthCare SAS,
Abstract
First-in-human study of TQB3617, a BET inhibitor in patients with relapsed/refractory hematologic malignancies.Org: Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China, Department of Hematology, Beijing TongRen Hospital, Capital Medical University, Beijing, China, Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Nanjing, China,
Abstract
First-in-human study of simmitinib, a novel tyrosine kinase inhibitor targeting FGFR1-3, KDR and CSF-1R.Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China, Harbin Medical University Cancer Hospital, Harbin, China, The Second Affiliated Hospital of Anhui Medical University, Hefei, China, Chongqing University Cancer Hospital, Chongqing, China, Phase I Clinical Trial Center, Chongqing University Cancer Hospital, Chongqing, China, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, Henan Cancer Hospital, Zhengzhou, China, Shandong Provincial Institute of Cancer Prevention and Treatment, Jinan, China, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China, Fujian Provincial Cancer Hospital, Fuzhou, China, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Yunnan Cancer Hospital, Yunnan, China, First Affiliated Hospital Of Gannan Medical University, Ganzhou, China, CSPC Pharmaceutical Group Limited, Shijiazhuang, China, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Safety, efficacy and pharmacokinetics of VC004, a highly selective next-generation pan-TRK inhibitor, in patients with locally advanced/metastatic solid tumors.Org: Jiangsu Vcare PharmaTech Co., Ltd.,
Abstract
Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor.Org: Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan, Tohoku University Hospital, Miyagi, Japan, National Center for Global Health and Medicine, Tokyo, Japan, NHO Shikoku Cancer Center, Ehime, Japan, Showa University, Tokyo, Japan,
Abstract
Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H.Org: Division of Medical Oncology, Duke University Medical Center, Duke Cancer Institute, Durham, NC, Dana-Farber Cancer Institute, Boston, MA, Columbus Oncology and Hematology Associates, Columbus, OH, Medical College of Wisconsin, Milwaukee, WI, National Cancer Institute, Bethesda, MD, Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, National Institutes of Health, Bethesda, MD, National Cancer Institute Mouse Cancer Genetics Program, Frederick, MD, City of Hope, Duarte, CA, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, National Cancer Institute Center for Bioinformatics, Rockville, MD, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, University of Pennsylvania Department of Medicine, Philadelphia, PA, Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, Massachusetts General Hospital, Boston, MA,
Abstract
FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS or NF1 mutations: A phase 1B dose-expansion study.Org: Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Beijing Cancer Hospital, Beijing, China, West China Hospital, Sichuan University, Chengdu, China, Jiangsu Province Hospital, Nanjing, Jiangsu, China, Sun Yat-Sen University Cancer Center, Guangzhou, China, Fudan University Shanghai Cancer Center; Shanghai Medical College, Fudan University, Shanghai, China, Fujian Cancer Hospital, Fuzhou, China, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Fudan University Shanghai Cancer Center, Shanghai, China, West China Hospital of Sichuan University, Chengdu, China, Shanghai Fosun Pharmaceutical Industrial Development CO., Ltd., Shanghai, China,
Abstract
Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer and glioblastoma multiforme.Org: BioTheryX, San Diego State University Department of Biology, San Diego, CA, CanSino Biologics,
Abstract
First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC.Org: Centro Oncologico International,
Abstract
The microtubule-destabilizing agent AUS_001 as a candidate for glioblastoma therapy.Org: Australis Pharmaceuticals, Inc., Kiyatec, Inc., College of Medicine and Public Health, Adelaide Medical School, The University of Adelaide,
Abstract
Efficacy and safety of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC): Results from a multicenter, single-arm, phase II study.Org: Department of Medical Oncology, Shanghai Pulmonary Hospital, Cancer Institute, Tongji University School of Medicine, Shanghai, China, Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, Lung Cancer and Gastrointestinal Unit, Department of Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Shandong Cancer Hospital, Jinan, China, Department of Respiratory Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China, Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China, Clinical Trial Center, West China Hospital, Sichuan University, Chengdu, China, Harbin Medical University Cancer Hospital, Harbin, China, Department of Thoracic Tumor Radiotherapy Ward 2, Jiangxi Cancer Hospital, Nanchang, China, Department of Radiation Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China, Tianjin Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China, Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, China, Department of Medical Oncology, the First Affiliated Hospital of Xiamen University, Xiamen, China, Department of Thoracic Oncology II, Peking University Cancer Hospital and Institute, Beijing, China, Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China, Department of Respiratory Medicine, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, Department of Clinical Medicine, Shouyao Holdings (Beijing) Co., Ltd, Beijing, China, Oncology Department, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China,
Abstract
The genomic, transcriptomic, and immunologic landscape of TEM8 (ANTXR1) in small-cell lung cancer (SCLC).Org: Hunstman Cancer Hospital,
Abstract
A phase Ib/IIa study of DX1002, a novel drug in patients with pretreated advanced hepatocellular carcinoma: Efficacy and safety analysis.Org: Shanghai Tenth People’s Hospital, Tongji University School of Medicine,
Abstract
MyTACTIC: Activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkers.Org: US Medical Affairs Oncology,
Abstract
Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors.Org: Memorial Sloan Kettering Cancer Center, Foundation Medicine, Inc., Cambridge, MA,
Abstract
A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma.Org: Cyclacel Ltd,
Abstract
BY101921: Restoring interferon signaling and anti-tumor immunity through PARP7 inhibition.Org: Chengdu Baiyu Pharmaceutical Co., Ltd.,
Abstract
Ipatasertib in patients with AKT1/2/3 mutation-positive (AKTmut) tumors: TAPISTRY study.Org: Henry Ford Cancer Institute/Henry Ford Health, Department of Medical Oncology and Therapeutics Research, Hoffmann-La Roche Ltd,
Abstract
Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors.Org: Durarte, Cedars-Sinai Cancer Institute, City of Hope Orange County Lennar Foundation Center, Virginia Cancer Specialists (VCS) Research Institute, Community Regional Cancer Care - East,
Abstract
Artificial intelligence (AI) -powered H&E whole-slide image (WSI) analysis of tertiary lymphoid structure (TLS) to predict response to immunotherapy in non-small cell lung cancer (NSCLC).Org: Ascension Saint Francis Hospital,
Abstract
On the right TRACK: Providing comprehensive genomic profiling (CGP) and molecular tumor board (MTB) for patients (pts) with rare cancers.Org: TargetCancer Foundation, Center for Personalized Cancer Therapy, Avera Cancer Care Institute, Rutgers New Jersey Medical School, Medical Acquisition, Inc.,
Abstract
Efficacy and safety of olaparib in patients with tumors harboring alterations in homologous recombination repair pathway associated genes: Results from the Drug Rediscovery Protocol.Org: Department of Medical Oncology, Erasmus Medical Cancer Institute, Rotterdam, Netherlands, Radboud University Medical Center, Nijmegen, Netherlands, Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands, Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands, Department of medical oncology, Leiden University Medical Center, Leiden, Netherlands,
Abstract
A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies.Org: UH Cleveland Medical Center, Department Of Medicine, Norwalk Hospital, Nuvance Health, CMO Consulting, Inc., Henry Ford Cancer Institute, Henry Ford Health,
Abstract
Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors.Org: State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine,
Abstract
PAS-004: A novel macrocyclic MEK inhibitor to inhibit cancer cell growth in vitro and tumor growth in mouse xenograft studies.Org: Cheminpharma,
Abstract
Cold-inducible RNA-binding protein as a context-specific functional mediator of breast cancer metastasis.Org: Université Montreal,
Abstract
Preclinical characterization of HBW-012-E, a novel, potent, selective, safe, and orally active KRAS G12D inhibitor with superior pharmacokinetic (PK) properties and anti-tumor efficacy.Org: Chengdu Hyperway Pharmaceuticals,
Abstract
Nivolumab plus ipilimumab (N+I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.Org: Sutter Cancer Research Consortium, City of Hope Chicago,
Abstract
Safety, tolerability, pharmacokinetics and clinical activity of AST-3424, an AKR1C3-activated bis-alkylating moiety prodrug, in subjects with advanced solid tumors in China: A phase I dose-escalation study.Org: Ascentawits Pharmaceuticals, Ltd, Shenzhen, China, Ascentawits Pharmaceuticals, Ltd, Foster City, CA, Ascentawits Pharmaceuticals Ltd, Shenzhen, China,
Abstract
Diversity in B7-H3/CD276 expression across cancer types: Exploring a dynamic novel immune checkpoint.Org: University of California, San Diego, Moores Cancer Center, La Jolla, CA, Labcorp Oncology, Buffalo, NY, Labcorp Oncology, Durham, NC, Division of Surgical Oncology, Department of Surgery, Center for Personalized Cancer Therapy, University of California, San Diego, La Jolla, CA,
Abstract
Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, ASCO, Alexandria, VA,
Abstract
Ex vivo assessment of cellular mass response for personalized therapy selection of hyperthermic intraperitoneal chemotherapy (HIPEC) agents.Org: Travera, Medford, MA,
Abstract
Role of dynamic ctDNA monitoring in cervical and anal epidermoid carcinomas under curative chemoradiation.Org: Instituto D'Or de Pesquisa e Ensino (IDOR), Institituto do Câncer do Estado de São Paulo, Instituto do Câncer do Estado de São Paulo - Faculdade de Medicina da Universida,
Abstract
Phase II study to evaluate safety and efficacy of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors (KCSG AL20-17).Org: Division of Hematology/Oncology, Department of Internal Medicine Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital; Cancer Research Institute, Seoul National University, Jongno-Gu, South Korea, Division of Hematology and Oncology, Department of Internal Medicine, National Cancer Center, Goyang, South Korea, Division of Hematology and Oncology, Department of Internal Medicine, National Cancer Center, Goyang-Si, South Korea, Division of Hematology/Oncology, Department of Internal Medicine Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea, Republic of (South), Korea University Anam Hospital, Seoul, South Korea, Division of Hematology and Oncology, Department of Internal Medicine, Chungnam National University College of Medicine, Chungnam National University Hospital, Daejeon, South Korea, Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, Deparment of Medical Oncology, Yonsei Unviersity College of Medicine, Gangnam Severance Hospital, Seoul, South Korea, Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, South Korea, Division of Hematology-Oncology, Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, South Korea, Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea,
Abstract
Single cell characterization of persistent cells upon immunotherapy treatment in colorectal and endometrial tumors: The SERPENTINE trial.Org: Hospital Unviersitario Vall d'Hebron, CNAG, Omniscope, AstraZeneca R&D Boston, Vall d’Hebron Hospital Campus and Institute of Oncology (VHIO),
Abstract
Expression of metabolic genes associated with changes in brain structure across the lifespan affects patients (pts) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance).Org: New Brunswick, NJ,
Abstract
Identification of a patient tissue-based phosphorylation site as a biomarker for epidermal growth factor receptor (EGFR) activity in non-small cell lung cancer.Org: Indivumed Therapeutics, INDIVUMED GMBH,
Abstract
Molecularly matched therapies identified by comprehensive genomic profiling before the first-line setting to provide alternative treatment outcomes in patients with solid tumors: 1-year follow-up of the prospective FIRST-Dx study.Org: Toyama University Hospital, Tokyo Medical and Dental University, Aichi Cancer Center Research Institute,
Abstract
Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2 or ERBB3 amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.Org: Michigan Cancer Research Consortium, City of Hope - Chicago, Division of Hematology and Oncology, Department of Medicine, O’Neal Comprehensive Cancer Center of University of Alabama at Birmingham, Heersink School of Medicine, Intermountain Healthcare, Cancer Research Consortium of West Michigan,
Abstract
The pathway alteration load as a pan-cancer determinant of outcome of targeted therapies: Results from the Drug Rediscovery Protocol (DRUP).Org: Department of Molecular Oncology & Immunology, Netherlands Cancer Institute (Netherlands), Hartwig Medical Foundation, Erasmus Medical Cancer Institute, Department of Biometrics,
Abstract
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Final results of the investigator-initiated phase II BEAVER trial.Org: Department of Laboratory Medicine and Pathobiology,
Abstract
The immunological milieu of oropharyngeal squamous cell carcinoma (OPC) according to HPV and smoking status and its influence on prognosis.Org: Universidade de Sao Paulo, FMUSP,
Abstract
Comprehensive characterization of ERBB2 genomic alterations in lung cancer.Org: Plantsville,
Abstract
Clinical and molecular characterization of AXL in colorectal cancer: CALGB (Alliance)/SWOG 80405 and real-world data.Org: West Virginia University Cancer Institute, Mary Babb Randolph Cancer Center, Department of Bioengineering,
Abstract
Biomarker discordance after neoadjuvant systemic therapy and associated patterns of recurrence.Org: Loma Linda University Department of Internal Medicine, Loma Linda University Health, Loma Linda University of Medicine,
Abstract
Comprehensive molecular profiling of newly diagnosed advanced, high-grade ovarian cancer: Unveiling BRCA1/2 mutations and genomic instability scores to advocate for public insurance coverage of genetic testing—Insights from the Hellenic Society of Medical Oncology (HeSMO) national program.Org: Hellenic Society of Medical Oncology,
Abstract
Results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Investigational Cancer Therapeutics, Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan, Division of Cancer Medicine, Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan,
Abstract
A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors.Org: University of Missouri - Kansas City School of Medicine, Department of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston,
Abstract
A phase 1 study of HRS-1167 (M9466), a highly selective PARP1 inhibitor, in patients (pts) with advanced solid tumors.Org: Liaoning Cancer Hospital&Institute, The Second Hospital of Shanxi Medical University, Shanxi Provincial Cancer Hospital,
Abstract
Clinicopathologic and genomic characteristics of patients with advanced ovarian, breast, and prostate cancer treated with poly (ADP-ribose) polymerase inhibitors (PARPi) in a real-world setting.Org: Cleveland Clinic Brunswick Urgent Care, Center for Immunotherapy and Precision Immuno-Oncology,
Abstract
A randomized, double-blind, study to evaluate the efficacy, pharmacodynamics, safety and immunogenicity of FKS518 proposed biosimilar to denosumab with the originator in postmenopausal women with osteoporosis (LUMIADE-3 study).Org: Center for Clinical and Basic Research AS,
Abstract
Total toxicity burden as a practical tool to quantify the overall severity of multiple adverse events in clinical trials.Org: Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Hospital Universitario de Ramon y Cajal, Madrid, Spain, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, Hospital Santa Creu i Sant Pau, Barcelona, Spain,
Abstract
Clinical update related to the first-in-human trial of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate.Org: Hebei University Affiliated Hospital, Affiliated Cancer Hospital of Harbin Medical University, Jiamusi Cancer and Tuberculosis Hospital, Phase I Clinical Trials Center, CSPC Pharmaceutical Group Limited,
Abstract
Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.Org: The University of Texas HSC at San Antonio Cancer Therapy and Research Center,
Abstract
An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).Org: START San Antonio, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Mayo Clinic Cancer Center, Beth Israel Deaconess Medical Center, START Mountain Region,
Abstract
Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial.Org: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy, Department of Clinical and Molecular Medicine, Oncology Unit, Sant’ Andrea University Hospital, Sapienza University of Rome, Roma, Italy, Dipartimento di Eccellenza in Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Napoli UOC PATOLOGIA CLINICA - Ospedale San Giovanni Addolorata, Roma, Rome, Italy, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy,
Abstract
Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met–targeting antibody-drug conjugate, in select advanced solid tumor indications.Org: Technion Israel Institue of Technology,
Abstract
A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.Org: Virginia Cancer Specialists and NEXT Oncology, Stephenson Cancer Center and Sarah Cannon Research Institute, OnCusp Therapeutics, Inc., Navigate BioConsulting,
Abstract
A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1.Org: Huntsman Cancer Institute at University of Utah Health, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute,
Abstract
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics of VIP943 monotherapy in patients with advanced CD123+ hematologic malignancies.Org: SCRI at TriStar Centennial, The University of Texas MD Anderson Cancer Institute,
Abstract
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer.Org: Adelaide Cancer Center, ICON Cancer Care, Austin, TX, Adelaide Cancer Center, Brisbane, Australia,
Abstract
Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC).Org: Geffen School of Medicine, Weill Cornell Medical Center, Toranomon Hospital Kajigaya,
Abstract
Study of ELU001, a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors.Org: Mayo Clinic Department of Medical Oncology,
Abstract
HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors.Org: Università Milano-Bicocca,
Abstract
A multi-center, open-label phase 1/1b dose finding, safety, and pharmacokinetic study of MBRC-101, an Anth-EphA5 monomethyl auristatin (MMAE) antibody drug conjugate, in advanced refractory solid tumors.Org: MBrace Therapeutics, Inc,
Abstract
A modular, open-label, phase I/IIa study to evaluate the safety, tolerability, pharmacokinetics (PKs) and anti-tumour activity of a first-in-class (FIC) specific dUTPase inhibitor CV6-168 combined with anti-cancer treatments in patients (pts) with advanced malignancies.Org: Newcastle University and Northern Centre for Cancer Care, University of Sheffield, CV6 Therapeutics (NI) Ltd, Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust,
Abstract
A first-in-human, phase 1 study evaluating oral TACC3 inhibitor, AO-252, in advanced solid tumors.Org: A2A Pharmaceuticals, Inc., Oklahoma City, OK,
Abstract
A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.Org: FogPharma,
Abstract
A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of TT125-802 in patients with advanced solid tumors.Org: NEXT Madrid- Universitary Hospital Quironsalud Madrid, Hospital Quiron Salud - NEXT Oncology, University Hospital Lausanne (CHUV) and Lausanne University, Vall d'Hebron Hospital,
Abstract
Selpercatinib in non-MTC, RET-mutated tumors: Efficacy in MEN-associated and other tumors.Org: Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy, Royal North Shore Hospital, St. Leonards, NSW, Australia, Multidisciplinary Oncology & Therapeutic Innovations, Hôpitaux Universitaires de Marseille Timone, Marseille, France, Department of Respiratory Medicine, Nagoya University Graduate school of Medicine, Nagoya, Japan, The Ohio State University Comprehensive Cancer Center, Columbus, OH,
Abstract
177Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin: The phase 3 randomized LEVEL, GETNE-T2217 trial.Org: Imas12, UCM, Hospital Universitario Central de Asturias, ISPA, University Clinical Hospital of Santiago de Compostela,
Abstract
CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors.Org: Global Medicines Development,
Abstract
An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations (SEACRAFT-1).Org: Next Oncology Virginia and Virginia Cancer Specialists, Sarah Cannon Research Institute/Tennessee Oncology, University of California Irvine, Comprehensive Cancer Centers of Nevada, Washington University School of Medicine in St Louis,
Abstract
PRIMROSE: A modular phase 1/2a study of AZD3470, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP deficient advanced solid tumors.Org: ERC Chromatin Remodeling, Institut Gustav Roussy,
Abstract
A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation.Org: Sarah Cannon Research Institute/Tennessee Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Duke University Medical Center, Huntsman Cancer Institute, University of Utah,
Abstract
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799544 (ARRY-134) as a single agent and in combination with PF-07799933 BRAF dimer inhibitor, in participants 16 years and older with advanced solid tumors.Org: Chercheur clinicien centre de recherche CHU de Québec, Department of Medical Oncology, McGill University Health Centre, Division of Neuro-Oncology, NewYork-Presbyterian/Columbia University Medical Center,
Abstract
A phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer.Org: MD Community Health Network, Department of Internal Medicine, Division of Hematology/Oncology,University of Michigan Rogel Cancer Center,
Abstract
A phase 1 study of the BET inhibitor ZEN003694 in combination with the MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast cancer (NCI number 10449).Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, National Cancer Institute, Rockville, MD, National Cancer Institute, Cancer Therapy Evaluation Program, Rockville, MD,
Abstract
First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors.Org: Stevenage, Uxbridge, Texas Oncology–San Antonio Babcock Next Oncology,
Abstract
Phase II study of enasidenib in IDH2-mutated malignant sinonasal and skull base tumors.Org: Radiology and Imaging Services, Sinonasal and Skull Base Tumor Program,
Abstract
A pan-tumor prospective translational, Irish study, investigating the association of gut microbiome (GM) diversity with pathological complete response (pCR) after neoadjuvant treatment in early stage breast, rectal, and esophageal cancers.Org: Beaumont RSCI Cancer Centre, Beaumont RCSI Cancer Centre, Royal College of Surgeons of Ireland, Beaumont RCSI Cancer Center, Royal College of Surgeons in Ireland,
Abstract
A first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors.Org: Oncology Virginia,
Abstract
IAM1363-01: A phase 1/1b study of a selective and brain-penetrant HER2 inhibitor for HER2-driven solid tumors.Org: Iambic Clinical Advisory Board,
Abstract
Pilot study of CBX-12 pharmacodynamics in patients with advanced solid tumors.Org: Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, Cancer Therapy Evaluation Program, Division of Cancer Treatment & Diagnosis, National Cancer Institute of the National Institutes of Health, Bethesda, MD, Clinical Pharmacodynamic Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD,
Abstract
Spatially resolved multi-region proteomics for prediction of clinical outcome in deficient mismatch repair metastatic colorectal cancer treated with PD-1 blockade.Org: Gastrointestinal Research Unit, Center for Cell Signaling in Gastroenterology,
Abstract
Uncovering actionable genetic alterations and immune predictive biomarkers for anal squamous cell carcinomas in the era of immunotherapy: PD-L1 and beyond.Org: Division of Hematology and Oncology, Department of Medicine, University of Pittsburg Medical Center, and UPMC Hillman Cancer Center, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center,
Abstract
Candidate molecular alterations associated with potential resistance in KRAS G12D gastrointestinal cancers.Org: Mayo Clinic, Guardant Health Inc., Guardant Health, Inc.,
Abstract
Phase 1/2 study of FMC-376 an oral KRAS G12C dual inhibitor in participants with locally advanced unresectable or metastatic solid tumors (PROSPER).Org: Frontier Medicines, START San Antonio, Next Oncology Virginia and Virginia Cancer Specialists, START Mountain Region,
Abstract
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in combination with gemcitabine and docetaxel in non-small cell and small cell lung cancers.Org: Department of Oncology, Washington University School of Medicine, Siteman Cancer Center, Washington University School of Medicine, Polaris Pharmaceuticals Inc., Division of Medical Oncology, Washington University in St. Louis,
Abstract
Characterization of necroptosis activators in colorectal cancer.Org: West Virginia University Cancer Institute and the Mary Babb Randolph Cancer Center, Institute for Quantitative and Computational Biosciences,
Abstract
A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors.Org: Sarah Cannon Research Institute/Tennessee Oncology, Baylor University Medical Center, Texas Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Sidney Kimmel Cancer Center at Thomas Jefferson University,
Abstract
A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors.Org: AdventHealth Cancer Institute, START Mountain Region, Sarah Cannon Research Institute at HealthONE, Sarah Cannon Research Institute/Tennessee Oncology, START San Antonio,
Abstract
Highly prognostic signature for stage II colon cancer from the TOSCA trial: The PROSIT study.Org: IEO, European Institute of Oncology IRCCS, Medical Oncology Unit 1, Universita Di Genova, Medical Oncology 1, Istituto Oncologico Veneto, IOV - IRCCS, Istituto di Ricerche Farmacologiche Mario Negri,
Abstract
Preliminary results correlating post-operative ctDNA status with disease-free survival in patients with stage II (high risk)/III colorectal cancer in the BNT000-001 epidemiology study.Org: BioNTech Diagnostics GmbH,
Abstract
Financial toxicity and unmet essential needs in patients with gastrointestinal cancer.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Memorial Sloan Kettering Cancer Center, School of Social Work, The University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China,
Abstract
Upstream regulation of neurotransmitter signaling genes in metastatic colorectal cancer (mCRC) patients: Data from CALGB/SWOG 80405 trial (Alliance) and MONSTAR-SCREEN-2.Org: Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, Lawrence J. Ellison Institute for Transformative Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of RAS wild-type (WT) metastatic colorectal cancer (mCRC): Pooled analysis of the randomized trials FIRE-1, FIRE-3, XELAVIRI, and PanaMa.Org: Staedtische Kliniken Neuss Lukaskrankenhaus Gmbh, Klinikum Magdeburg GGMBH, Klinikum Bayreuth GmbH, Onkologische Schwerpunktpraxis,
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP): Outcomes and adverse events in patients with solid tumors.Org: Pancreas Centre BC, Department of Pathology & Laboratory Medicine Vancouver General Hospital, British Columbia Cancer Research Centre, Providence Health - St. Paul's Hospital,
Abstract
Cost-effectiveness analysis of later-line treatments for refractory metastatic colorectal cancer.Org: Medical Oncology and Therapeutics, City of Hope/AccessHope,
Abstract
Multi-modal artificial intelligence enhanced systematic colorectal cancer pathology evaluation.Org: Western Connecticut Health Network-Danbury Hospital, Southern Taiwan University of Science and Technology, UConn School of Medicine, University of Washington Fred Hutchinson Cancer Center,
Abstract
Patients with early-onset metastatic colorectal cancer as an emerging distinctive clinical and molecular phenomenon.Org: University of Cagliari, Oncology and Gastroenterology, Veneto Institute of Oncology IOV - IRCCS, AOU - Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Università Politecnica delle Marche,
Abstract
AGITG MONARCC: A randomized phase 2 study of panitumumab monotherapy and panitumumab (pan) plus 5 fluorouracil (FU) as first-line therapy for RAS and BRAF wild type metastatic colorectal cancer—A trial by the Australasian Gastro-Intestinal Trials Group (AGITG).Org: NHMRC Clinical Trial Centre, Shoalhaven District Memorial Hospital, Flinders Medical Centre, Australasian Gastro-Intestinal Trials Group, Sunshine Hospital,
Abstract
Early versus conventional adjuvant chemotherapy in stage III colon cancer: A multicenter, randomized, open-label, phase 3 trial.Org: Division of Colon and Rectum, Department of Surgery, College of Medicine, Yeungnam University, Colorectal Cancer Centre, Kyungpook National University Medical Centre, School of Medicine, Kyungpook National University, Department of Oncology/Hematology, Kyungpook National University Medical Center, Kyungpook National University School of Medicine, Department of Oncology/Haematology, Kyungpook National University Medical Centre, Kyungpook National University School of Medicine, Department of Surgery, School of Medicine, Dongsan Medical Centre, Keimyung University,
Abstract
Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC).Org: University of Colorado Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Colorado Anschutz Medical Campus, Inova Schar Cancer Institute,
Abstract
The role of metastasectomy in patients with early onset metastatic colorectal cancer.Org: Padua, Ancona,
Abstract
Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort.Org: Department of Gastrointestinal Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston, TX, Guardant Health, Redwood City, CA, Guardant Health, Inc., Redwood City, CA,
Abstract
A phase II clinical trial of metformin combined with FOLFIRI plus bevacizumab as second-line therapy in patients with RAS-mutant metastatic colorectal cancer.Org: Zhongshan, China,
Abstract
The molecular landscape of PIWIL1 expression in colorectal adenocarcinoma (CRC).Org: Washington University in St. Louis, Siteman Cancer Center, Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center,
Abstract
Spatial patterns in the tumor immune microenvironment as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab+FOLFOX induction in RAS wildtype (wt) metastatic colorectal cancer (mCRC): PanaMa (AIO KRK0212) trial.Org: Munich Hospital Neuperlach, Dr Hancken Hospital, DKTK, German Cancer Research Centre (DKFZ), University Hospital, LMU Munich,
Abstract
Efficacy and safety of fruquintinib plus trifluridine/tipiracil (TAS-102) as third-line treatment in patients with metastatic colorectal adenocarcinoma: Results from a single arm, phase 2, multicenter study.Org: Department of Oncology, Liwan District People's Hospital of Guangzhou, Guangzhou, China, Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China,
Abstract
Survival impact of KRAS mutation in metastatic colorectal cancer (mCCR) under first-line treatment.Org: Oncoclinicas&Co - Medica Scientia Innovation Research (MedSir),
Abstract
Prognostic impact of HER family expressions for metastatic colorectal cancer (mCRC): SCRUM-Japan MONSTAR-SCREEN-2 and CALGB/SWOG 80405 trial (Alliance) international collaboration.Org: Gifu University Hospital, Osaka General Medical Center,
Abstract
Correlation of circulating tumor DNA and recurrence in patients with metastatic colorectal cancer with no evidence of disease: An open-label, prospective, phase II study.Org: Burning Rock Biotech, Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center,
Abstract
Guanylate cyclase 2C (GUCY2C; GUC) expression and the tumor immune microenvironment (TIME) in gastrointestinal (GI) cancers.Org: Comprehensive Cancer Center Innsbruck,
Abstract
The tumor immune microenvironment features and their prognostic value in rectal and sigmoid colon signet-ring cell carcinoma.Org: Chinese Academy of Medical Sciences & Peking Union Medical College,
Abstract
Neoadjuvant chemotherapy with FOLFOXIRI plus lateral lymph nodes dissection for the treatment of resectable rectal cancer with lateral lymph node metastasis: A single-arm, investigator-initiated, phase II trial.Org: State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, Comprehensive Third Ward, Cancer Institute & Hospital,
Abstract
Real-world use of anti-EGFR therapy in metastatic colorectal cancer.Org: University of Colorado Cancer Center, Aurora, CO, Compugen,
Abstract
Effect of p16 immunohistochemical expression (exp) on irinotecan in metastatic colorectal cancer (mCRC): A translational analysis of the TRIBE and TRIBE2 studies.Org: CdC Poliambulanza, AULSS8 Berica,
Abstract
Clinicopathological characteristics and survival in metastatic colorectal cancer with short-form APC mutations.Org: Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Genomic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
A phase II study to evaluate the efficacy and safety of fruquintinib combined with tislelizumab and hepatic artery infusion chemotherapy (HAIC) for advanced colorectal cancer liver metastases: An updated analysis of survival.Org: Liver Surgery Department, Department of Traditional Chinese Medicine/ Integrative Oncology,
Abstract
A phase 2 study evaluating response and biomarkers in patients with microsatellite stable (MSS) advanced colorectal cancer (CRC) treated with nivolumab/relatlimab.Org: Bloomberg-Kimmel Institute for Cancer Immunotherapy,
Abstract
Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: First effectiveness data of the European multi-centric, multi-national, non-interventional study—BERING-CRC.Org: Landeskrankenhaus Feldkirch, Claraspital, Luebecker Onkologische Schwerpunktpraxis,
Abstract
Efficacy of FOLFIRI plus bevacizumab versus FOLFIRI plus cetuximab in RAS-mutant metastatic colorectal cancer: Final update on patients with RAS-mutant metastatic colorectal cancer treated in FIRE-3.Org: Gesundheitszentrum St. Marien GmbH, Department of Hematology and Oncology, Klinikum Bayreuth GmbH, Practice for Medical Oncology, Frankfurt Institute of Clinical Cancer Research, Krankenhaus Nordwest, University Cancer Center Germany, Städtische Kliniken Neuss,
Abstract
A phase II clinical evaluation of radiofrequency ablation (RFA) combined with regorafenib and toripalimab in patients with colorectal cancer with liver metastases.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites.Org: Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, Beth Israel Deaconess Medical Center, Boston, MA,
Abstract
Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase 1 TriComB study.Org: Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Oncology Unit 1, Department of Medical Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy, Phase 1 Unit, Clinical Pharmacology Center for Drug Experimentation, Pisa University Hospital, Pisa, Italy, Oncology Unit 1, Veneto Institute of Oncology - IRCCS, Padua, Italy,
Abstract
Updated results and subgroup analysis by presence of liver metastases of a phase I/II study of the EP4 antagonist vorbipiprant with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC).Org: Monza, Italy, Rottapharm Biotech and University of Milan - Bicocca, Molecular Immunology Unit, Experimental Oncology Department,
Abstract
Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC).Org: Memorial Sloan Kettering Cancer Center,
Abstract
Comparing the efficacy and safety of HepaSphere drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy versus hepatic arterial infusion chemotherapy alone in unresectable colorectal liver metastases.Org: Department of Interventional Therapy,
Abstract
Extent of lymphadenectomy for surgical management of right-sided colon cancer: Multicenter, open label, randomized, controlled trial.Org: Colorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, The First Affiliated Hospital of Harbin Medical University, Harbin, China, Xuanwu Hospital, Capital Medical University, Beijing, China, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China,
Abstract
Phase Ib/II trial of hepatic arterial infusion chemotherapy in combination with fruquintinib for refractory unresectable colorectal cancer liver metastases.Org: Department of Interventional Therapy,
Abstract
New drugs to prevent oxaliplatin-induced peripheral neuropathy: A double-blind, randomized study.Org: Nippon Medical School Hospital, Kansai Rosai Hospital, Fukui-ken Saiseikai Hospital, Hyogo Medical University, Toyama Prefectural Central Hospital,
Abstract
Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study.Org: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
Updated survival results of BBCAPX-II: Sintilimab combined with bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.Org: Key Laboratory of Cancer Prevention and Intervention, Zhejiang University College of Medicine, Colorectal Surgery and Oncology,
Abstract
Irinotecan plus anlotinib or further in combination with penpulimab as second-line treatment of metastatic colorectal cancer (ZL-IRIAN).Org: Shangai,
Abstract
Evaluating the potential of micronuclei DNA from erythrocytes for early detection or recurrence risk prediction of colorectal cancer.Org: Department of Colorectal Surgery and Oncology, Wenzhou Central Hospital, Wenzhou, China, Timing BioTech, Zhejiang Provincial Hospital of Chinese Medicine,
Abstract
A phase 1, open-label, dose escalation, and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in patients with HLA-A*0201-positive disease and WT1-positive recurrent/metastatic cancers.Org: Carol G Simon Cancer Center,
Abstract
First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.Org: Shanghai Henlius Biotech Inc.,
Abstract
Neoadjuvant chemotherapy with atezolizumab, bevacizumab, and FOLFOX for patients with unresectable colorectal liver metastases: A translational pilot study.Org: Seoul, NA,
Abstract
Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: Updated results of a multicenter, single-arm, phase 2 trial.Org: The Central Hospital of Xiao Gan, Xiantao First People’s Hospital, Jianghan Oilfield General Hospital, Xiang Yang Central Hospital, Hubei University of Art and Science,
Abstract
Microbiome signature, immune landscape and global methylation in early onset colorectal cancer.Org: Pelotonia Institute for Immuno-Oncology, The Ohio State Comprehensive Cancer Center, Center for Biostatistics,
Abstract
Long-term outcomes of ablation versus surgery in patients with colorectal lung oligometastasis: A retrospective cohort study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Early [18F]FDG PET/CT response evaluation after a single dose of anti-EGFR therapy as a predictive biomarker for treatment benefit in patients with advanced colorectal cancer.Org: Cancer Centre Amsterdam, Radboud Medical Center,
Abstract
Deciphering tumor microenvironment dynamics in HER2-amplified refractory metastatic colorectal cancer in the TRIUMPH trial.Org: Hiroshima University Hospital, Department of Surgery, NHO, Osaka National Hospital, Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Department of Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center,
Abstract
A phase II trial of alternating mXELOX/mXELIRI plus bevacizumab (BEV) as first-line treatment for metastatic colorectal cancer (mCRC).Org: The Second Hospital of Nanjing,
Abstract
Staged resection versus simultaneous resection for conversion surgery for initially unresectable colorectal liver metastasis: A prospective cohort study.Org: Zhongshan Hospital, Fudan University, Shanghai, China,
Abstract
Time to target TIM-3 in colorectal cancer: TIM-3 expression to predict survival outcomes in patients in CALGB (Alliance)/SWOG 80405.Org: Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business, Los Angeles Medical Center, Keck School of Medicine of the University of Southern California, Department of Population and Public Health Sciences,
Abstract
Genomic alterations in early-onset versus average-onset stage IV colorectal cancer.Org: Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Vanderbilt University Medical Center, Natera, Inc., Vanderbilt-Ingram Cancer Center,
Abstract
Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2.Org: Medical Oncology Service. Hospital G. U. Gregorio Marañón. IiSGM. Universidad Complutense, Allina Health Cancer Institute, Poitiers University Hospital and University of Poitiers, HUTCHMED Limited,
Abstract
Impact of GABA pathway genes expression on first-line treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance).Org: Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, University of Southern California Marshall School of Business, Department of Population and Public Health Sciences, University of Wisconsin Carbone Cancer Center,
Abstract
Impact of colorectal liver metastases (CRLM) in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in the phase 3 SUNLIGHT trial.Org: Université Paris-Cité (Paris Descartes), Georges Pompidou European Hospital, SIRIC CARPEM, Taiho Oncology Inc., Servier International Research Institute,
Abstract
Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in patients (pts) with pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A translational analysis of the TRIPLETE trial.Org: Azienda Ospedaliera Universitaria Pisana, Veneto Institute of Oncology - IRCCS, San Bortolo General Hospital, CRO Aviano, Fondazione Poliambulanza,
Abstract
Artemin and immune checkpoint inhibitor (ICI) efficacy in metastatic colorectal cancer (mCRC): A correlative analysis of the Canadian Cancer Trials Group (CCTG) CO.26 trial.Org: Princess Margaret Cancer Centre, University Health Network, Genome Sciences Centre, BCCA, The Ottawa Hospital Cancer Centre, Oregon Health & Science University,
Abstract
Efficacy and safety of combination therapy with binimetinib, encorafenib, and cetuximab for BRAF non-V600E mutated metastatic colorectal cancer: Results from a phase 2 BIG BANG trial (EPOC1703).Org: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Japan, Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan, Aichi Cancer Center Hospital, Nagoya, Japan, Department of Gastrointestinal and Medical Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan,
Abstract
Iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors: A single-arm, multicenter, pivotal, phase II study.Org: West China School of Medicine/West China Hospital of Sichuan University, The First Affiliated Hospital of Kunming Medical University, Affiliated Tumor Hospital, Guangzhou Medicine University, Cental Hospital Affiliated to Shandong First Medical University, Affiliated Hospital of Jiangnan University (Wuxi Fourth People's Hospital),
Abstract
Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES study).Org: Fondazione Policlinico Universitario "A. Gemelli" - IRCCS - UOC Oncologia Medica, Roma, Italy, Medical Oncology, Azienda Ospedaliera ARNAS Garibaldi, Catania, Italy, Medical Oncology Deparment, Istituto Europeo di Oncologia – IRCCS, Milan, Italy, Clinical Sperimental Abdominal Oncology Unit, Istituto Nazionale Tumori – IRCCS Fondazione G. Pascale, Napoli, Italy, Oncology Unit, Fondazione Casa Sollievo della Sofferenza – IRCCS, San Giovanni Rotondo, Italy,
Abstract
Exploratory biomarker analysis for predicting treatment effects of aflibercept in the VELOUR trial.Org: Swiss Institute of Bioinformatics, Docrates Cancer Hospital Helsinki, Katholieke University Leuven, Geneva University Hospitals,
Abstract
Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: An open-label, single-arm, multicenter phase II study.Org: The Second Affiliated Hospital of Zhejiang University School of Medicine,
Abstract
Association of circulating DNA with recurrence in CRS-HIPEC patients with colorectal and appendiceal peritoneal carcinomatosis: Insights from a phase II randomized trial.Org: Kansas University Cancer Center,
Abstract
A multicenter single-arm phase II study examining the efficacy of TNT for locally advanced rectal cancer: ENSEMBLE-2.Org: Akita Red Cross Hospital, Akita, Japan, Department of Digestive and General Surgery, Faculty of Medicine, University of the Ryukyus, Nakagami-Gun Nishihara-Cho, Japan, Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan, Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan, Department of Gastroenterological Surgery and Pediatric Surgery, Gifu University Graduate School of Medicine, Nishinomiya, Japan,
Abstract
Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX).Org: Stanford University Hospital and Clinics,
Abstract
Combined impact of primary tumor molecular profile and location in the relapse pattern of early-stage, microsatellite stable colorectal cancer.Org: Memorial Sloan Kettering Cancer Center,
Abstract
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study.Org: Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Department of Medical Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China, First Chest Radiotherapy Department, Hunan Cancer Hospital, Changsha, China, Phase I Center, ShanDong Cancer Hospital, Jinan, China, Oncology Chemotherapy Department, Anhui Provincial Hospital, Hefei, China,
Abstract
A phase II open‐label study with atezolizumab (atezo) in combination with bevacizumab (bev) in patients (pts) with advanced chemotherapy-resistant colorectal cancer (CRC) and MSI‐like molecular signature: The MoTriColor Consortium CT3 study.Org: Milano, MI, Italy, Napoli, Italy, Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, L?Hospitalet De Llobregat,
Abstract
Prognostic and predictive value of ctDNA-based MRD and actionable biomarkers in patients with resectable colorectal cancer: CIRCULATE-Japan GALAXY.Org: National Cancer Center Hospital East, Kashiwa, Japan, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan, The Committee of Hereditary Colorectal Cancer of the Japanese Society for Cancer of the Colon and Rectum, Sendai City Medical Center Sendai Open Hospital, Hyogo Medical University,
Abstract
Tumor microbiota, consensus molecular subtype and survival in colon adenocarcinoma.Org: Molecular Oncology Lab, INGEMM, Functional Genomics Center Zurich, Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII,
Abstract
Korean Society of Coloproctology trial of consolidation chemotherapy for locally advanced mid or low rectal cancer after neoadjuvant concurrent chemoradiotherapy: KONCLUDE multicenter radomized trial.Org: Department of Surgery, School of Medicine, Dongsan Medical Centre, Keimyung University, Daegu, South Korea, Wonkwang University Hospital, Iksan, South Korea, Department of Surgery, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Busan, South Korea, Department of Surgery, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, South Korea,
Abstract
Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases.Org: Compugen Ltd., Compugen USA Inc.,
Abstract
Comparative analysis of first-line therapy with fruquintinib plus chemotherapy versus standard therapy in advanced metastatic colorectal cancer (mCRC): A prospective cohort study compared with propensity score matching (PSM) cohort.Org: Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China, Huangshi Central Hospital of Hubei Province, Huangshi, China, Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China, Hubei Cancer Hosp, Wuhan, China, Department of Abdominal Oncology, Hubei Cancer Hospital, Wuhan, China,
Abstract
Real-world ctDNA testing patterns, associated biomarkers and sites of metastasis in early stage colorectal cancer.Org: Flatiron Health, San Francisco, CA,
Abstract
Efficacy of fadraciclib (CYC065), a novel dual CDK2/9 inhibitor, on patient-derived models of colorectal cancer.Org: Cyclacel Pharmaceuticals Inc,
Abstract
Characteristics of patients (pts) with disease relapse despite absence of molecular residual disease (MRD) after resection of colorectal oligometastases (CRM): Implications from PRECISION study.Org: Guardant Health Japan Corp.,
Abstract
Circulating tumor DNA as a predictive biomarker for pathologic response after treatment with neoadjuvant immunotherapy for localized dMMR/MSI-H colorectal cancer.Org: Department of Hematopathology,
Abstract
A multi-center study for colorectal cancer early detection among patients with high-risk disease using a cell-free fragmentomics assay.Org: Guangdong Cardiovascular Institute, General Hospital of Eastern Military Command, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc.,
Abstract
Neoadjuvant long-course chemoradiation plus PD1 blockade for locally advanced rectal cancer: Results of a phase 2, open-label, randomized controlled trial.Org: Beijing Friendship Hospital, Xuanwu Hospital, Beijing Chaoyang Hospital, Beijing Hospital,
Abstract
Individualized tumor-informed circulating tumor DNA analysis for molecular residual disease detection in predicting recurrence and efficacy of adjuvant chemotherapy in colorectal cancer.Org: State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, Burning Rock Biotech, Guangzhou, China,
Abstract
Survival and patient-reported outcomes of real-world patients with high-risk stage II and stage III colon cancer after 3 versus 6 months of adjuvant CAPOX.Org: Department of Research and Development,
Abstract
Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): Primary outcome of a multicenter randomized controlled trial.Org: Southwest Hospital Army Medical University, The First Medical Center PLA General Hospital, The Affiliated Hospital of Qingdao Zhejiang University, Changhai Hospital Naval Medical University, Ruijin Hospital Shanghai Jiao Tong University School of Medicine,
Abstract
Longitudinal clinical performance of a novel tumor-naive minimal residual disease assay in patients with resected stage II and III colorectal cancer: A subset analysis from the GALAXY study in CIRCULATE-Japan.Org: Tempus AI, Chicago, IL, Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Japan, Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University Hospital, Fukuoka, Japan,
Abstract
Clinical validation of a novel circulating tumor DNA methylation assay for predicting recurrence of colorectal cancer in patients with curative-intent surgery by monitoring minimal residual disease.Org: Gencurix Inc.,
Abstract
Phase II study of neoadjuvant short-course radiotherapy combined with CAPEOX plus envafolimab in patients with microsatellite stable locally advanced rectal cancer: Updated results of PRECAM study.Org: Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou Shengting Medical Technology Co., Ltd, Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences,
Abstract
Clinical outcomes and impact of mismatch repair deficiency (dMMR) in patients with pT4N0 colon cancer (CC): Data from a large, consecutive, multicenter, real-world cohort.Org: Tor Vergata' Clinical Center, IFOM ETS - The AIRC Institute of Molecular Oncology, Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Molecular Medicine,
Abstract
Clinical validation of Histotype Px Colorectal in patients in a U.S. colon cancer cohort.Org: DoMore Diagnostics,
Abstract
Postoperative positron emission tomography–computed tomography (PET-CT) in patients (Pts) with pathological stage III colon cancer (CC): Results from the first prospective validation study.Org: Affiliated to the Sackler Faculty of Medicine, Tel Aviv, Israel,
Abstract
Contrasting comprehensive genomic profiles of adenocarcinomas of the appendix in younger versus older patients.Org: Ronald Reagan UCLA Medical Center,
Abstract
A novel, noninvasive, multimodal screening test for the early detection of precancerous lesions and colorectal cancers using an artificial intelligence–based algorithm.Org: Mainz Biomed Germany GmbH, Department of Gastroenterology, Hepatology & Nutrition, Landshut Hospital, Medical Clinic I,
Abstract
PREVECOL, a predictive model for early detection of colorectal cancer and precancerous lesions in liquid biopsy.Org: Advanced Marker Discovery, S.L. (AMADIX),
Abstract
Allele-specific KRAS mutations as prognostic biomarkers in mucinous adenocarcinoma of the appendix and colorectal cancer.Org: Jordan University of Science and Technology, Mut’ah University,
Abstract
Randomized study to assess colonic microbiome changes in response to energy drink consumption (ROSANNA trial).Org: University of Florida/UF Health Cancer Center,
Abstract
Longitudinal circulating tumor DNA monitoring in predicting response to short-course neoadjuvant radiotherapy in locally advanced rectal cancer: Data from a phase III clinical trial (UNION).Org: Department of Innovative Technology, Shanghai Tongshu Biotechnology Research Institute,
Abstract
A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating tumor DNA (ctDNA): TACT-D.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, Guardant Health, Inc., Redwood City, CA,
Abstract
Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study.Org: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Pierre Fabre Laboratories,
Abstract
STELLAR-303: A randomized phase 3 study of zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated metastatic colorectal cancer.Org: Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC,
Abstract
A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy compared to synthetic control cohort: Results from the MD Anderson INTERCEPT program.Org: MD Anderson Hematology/Oncology Fellowship,
Abstract
Adjuvant chemotherapy with mFOLFOXIRI versus mFOLFOX6 in MRD-positive stage II-III colorectal cancer.Org: Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, SYSU, Guangzhou, China, The Sixth Affiliated hospital, Sun Yat-sen University, Guangzhou, China, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Third Affiliated Hospital of Kunming Medical University, Kunming, China, Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China,
Abstract
MIRACLE1: Phase II study of radiotherapy followed by CapeOx and tirelizumab as first-line treatment in MSS rectal cancer with synchronous resectable liver/lung metastases.Org: Department of Cancer Prevention,
Abstract
The NEO-RT trial: A phase 3 randomized trial of neoadjuvant chemotherapy, excision and observation versus chemoradiotherapy for early rectal cancer, CCTG CO.32.Org: Roswell Park Comprehensive Cancer Institute,
Abstract
Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur).Org: Billings Clinic Cancer Center,
Abstract
IL33-ST2 axis as a diagnostic and therapeutic biomarker in nivolumab therapy for advanced gastric cancer.Org: Keio University Hospital,
Abstract
Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Hadassah Medical Center, City of Hope Comprehensive Cancer Center, AbbVie Inc., North Chicago, IL, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).Org: NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, NSABP Foundation, Inc., UPMC Hillman Cancer Center, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC,
Abstract
Non-colorectal GI malignancies in the young: Incidence trends, demographic disparities, and survival analysis.Org: University of South Dakota,
Abstract
Adjuvant chemotherapy in clinical local advanced CRC following preoperational therapies and pT0-3N0M0 diagnosis (CANWATCH).Org: Kunming, China,
Abstract
SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.Org: The Miriam Hospital,
Abstract
Total neoadjuvant therapy with split-course hypofraction radiotherapy combined with CAPOX and envafolimab followed by local excision for locally advanced very low rectal cancer (TRACE-LE): An open-label, single-arm, multicenter, phase II trial.Org: Department of Colorectal Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China, Union Hospital Medical College, Huazhong University of Science and Technology, Wuhan, China, Longyan Affiliated Hospital, Fujian Medical University, Longyan, China, Fujian Provincial Cancer Hospital, Fuzhou, China, Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, People’s Republic of China, Fuzhou, China, Department of Colorectal Surgery, Fujian Medical University Union Hospital, Fuzhou, China,
Abstract
Clinical impact of oncogenic KRAS dosage variation in pancreatic cancer.Org: Seongnam, South Korea,
Abstract
Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, phase II study.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Union Hospital Medical College,
Abstract
Efficacy and safety of chidamide in combination with serplulimab and standard third-line treatments in advanced colorectal cancer: A single arm, exploratory phase 2 trial.Org: The First Affiliated Hospital of Suzhou University, Suzhou, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Affiliated Hospital of Soochow University,
Abstract
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, UPMC Hillman Cancer Center, NSABP Foundation, Inc. Pathology Lab,
Abstract
BreAK CRC, a first-in-human phase I/II trial of STC-1010, a new allogenic cancer vaccine for advanced or metastatic unresectable colorectal cancer.Org: Centre Hospitalier Universitaire de Poitiers, Poitiers, France, Department of Clinical Research, Centre Léon Bérard, Lyon, France, 4 rue Eric de Cromières, Clermont-Ferrand, France, Brenus Pharma, Clermont-Ferrand, France, Medical Oncology Department, Centre Georges-François Leclerc, University of Bourgogne Franche-Comté, Dijon, France,
Abstract
REPROGRAM-02: A phase II-III study evaluating an induction treatment with regorafenib and metronomic chemotherapy before the second line chemotherapy in metastatic colorectal cancer.Org: University of Besançon, Etablissement Français du Sang Bourgogne Franche-Comté, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Hôpital Henri-Mondor, AP-HP - Université de Paris Est,
Abstract
T cell receptor and immune gene expression pharmacodynamics for durvalumab monotherapy and in combination with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma (uHCC).Org: Oncology R&D, AstraZeneca, Gaithersburg, MD, Oncology R&D, AstraZeneca, Waltham, MA,
Abstract
Longitudinal circulating tumor DNA (ctDNA) analysis during treatment (Tx) of locally advanced resectable (LAR) gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ADENOCA): The PLAGAST prospective biomarker study.Org: Hôpital Européen Georges Pompidou, Université de Paris, Natera, Inc., Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, Center de Recherche des Cordeliers,
Abstract
FGF19-FGFR4 axis as the inaugural target for determining the efficacy of advanced esophageal cancer treatment.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Nanfang Hospital, Southern Medical University,
Abstract
Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO.Org: Oncology Unit Santa Maria delle Croci Hospital, Cardinale G Panico, Azienda Toscana Nord Ovest, University Hospital of Pisa,
Abstract
Ultra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer.Org: Duke University Medical Center, Durham, NC, Personalis, Inc., Menlo Park, CA, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
A phase II study of radiotherapy combined with docetaxel, cisplatin, and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer.Org: Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan, Tohoku University Graduate School of Medicine, Sendai, Japan,
Abstract
RNA expression-based hypoxia score as a prognostic and predictive biomarker in hepatocellular carcinoma.Org: JC Walter Jr Center for Transplantation and Sherrie and Alan Conover Center for Liver Disease and Transplantation,
Abstract
Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial.Org: Rinku General Medical Center, Tokyo Medical and Dental University Hospital, Osaka National Hospital, Osaka Prefectural General Medical Center, Izumi City General Hospital,
Abstract
Circulating immune protein biomarkers of early response and resistance in patients with metastatic HER-2–negative esophagogastric cancer (mEGC) treated with pembrolizumab and chemotherapy.Org: Olink Proteomics AB,
Abstract
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649.Org: Johannes-Gutenberg University Clinic, Mainz, Germany, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing, China, Clinica San Carlos de Apoquindo, Pontificia Universidad Católica, Santiago, Chile, Fundacion Arturo López Pérez, Providencia, Chile, Klinika Onkologii i Radioterapii, Narodowy Instytut Onkologii, Warszawa, Poland,
Abstract
Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up.Org: Maria Sklodowska-Curie National Cancer Research Institute,
Abstract
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648.Org: Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Institute of Cancer of São Paulo, University of São Paulo, Ono Pharmaceutical Company Ltd.,
Abstract
A phase 1 study to evaluate the safety and preliminary efficacy of minnelide given alone or in combination with paclitaxel in advanced gastric cancer.Org: Minneamrita Therapeutics, Samsung Medical Center, University of Miami School of Medicine, Sungkyunkwan University School of Medicine,
Abstract
Association of ERBB2 extrachromosomal DNA (ecDNA) with first-line HER2-targeted treatment outcomes in advanced esophagogastric adenocarcinoma (EGC).Org: Weill Cornell Medical Center/NewYork-Presbyterian, Department of Epidemiology & Biostatistics,
Abstract
Efficacy of EpCAM CAR-T IMC001 in advanced gastric cancers.Org: Suzhou Immunofoco Biotechnology Co., Ltd, Suzhou, China,
Abstract
Perioperative chemotherapy for patients with gastric cancer with microsatellite instability or deficient mismatch repair: A systematic review and meta-analysis.Org: Department of Biotherapy,
Abstract
Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.Org: Digestive Oncology, University Hospitals Gasthuisberg, Leuven, and KU Leuven, Leuven, Belgium, Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan, Center for Immuno-Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, Center of Oncology of the Lublin Region St Jana z Dukli, Lublin, Poland, Astellas Pharma Global Development, Inc., Northbrook, IL,
Abstract
Overall survival results from the phase 2 NIVOFGFR2 study of first-line nivolumab plus CAPOX in patients with FGFR2-positive, PD-L1-positive metastatic gastric cancer.Org: Bureau for Cancer Research - BUCARE, Todua Clinic, Tashkent State Dental Institute,
Abstract
Phase 1b study of futibatinib plus pembrolizumab with or without chemotherapy in patients with esophageal carcinoma: Updated results of antitumor activity.Org: Department of Gastroenterological Surgery, Gunma Prefectural Cancer Center, Gunma, Japan, Department of Gastroenterological and Pediatric Surgery, Gifu University Hospital, Gifu-Shi, Japan, Department of Gastroenterological Surgery, Tokai University School of Medicine, Isehara, Japan, Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki-Shi, Japan,
Abstract
Updated results and biomarker analyses from the phase 2 trial of nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEJA).Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Chinese Academy of Medical Science and Peking Union Medical College,
Abstract
Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study.Org: University Hospital Marqués de Valdecilla, IDIVAL, Santander, Spain, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil, Pontifica Catholic University of Chile, Santiago, Chile, IMAT-Oncomedica, Monteria, Colombia, Trinity St. James Cancer Institute, Dublin, Ireland,
Abstract
Effect of phosphoproteomic subtyping of gastric cancer on chemotherapy and guidance of targeted cancer therapy.Org: Institute for Protein Research, IMSUT Hospital, The Institute of Medical Science, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Center for Drug Design Research,
Abstract
Real-world data in Japan for the variants in homologous recombination gene on the etiology of gastric cancer in younger and older patients.Org: Department of Clinical Genomic Medicine, Okayama University Hospital, Okayama, Japan, Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan, Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama-Shi, Japan,
Abstract
Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.Org: The State Key Laboratory of Pharmaceutical Biotechnology, China Pharmaceutical University, Clinical Cancer Institute of Nanjing University, Department of Thoracic and Cardiovascular Surgery,
Abstract
An exploratory analysis of the genetic alteration associated with early-onset gastric and colorectal cancer using a large-scale nationwide database of Japan (C-CAT).Org: Cancer Institute Hospital, Japanese Foundation for Cancer Research,
Abstract
Safety and efficacy results from the phase I/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18.2+/HER2- locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.Org: FutureGen Biopharmaceutical (Beijing) Co, Beijing, Beijing, China, Futuregen Biopharmaceutical (Beijing) Co., Ltd, Beijing, China, FutureGen Biopharmaceutical (Beijing) Co., Beijing, China,
Abstract
First-line regorafenib with nivolumab and FOLFOX or CapeOX in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: A single-arm, phase Ib/II trial (REGONIVOCTx, EPOC2104).Org: National Cancer Center Hospital East, Kashiwa, Japan, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba, Japan,
Abstract
Phase II randomized study of maintenance therapy with regorafenib (REGO) versus placebo after first-line platinum and fluoropyrimidines-based chemotherapy in HER2 negative locally advanced/metastatic gastric (GC) or gastroesophageal junction (GEJ) cancer: Results of a-MANTRA study (GOIRC-05-2016).Org: Reggio Emilia, Potenza, Italy - Reggio Emilia, Vimercate, Experimental Clinical Abdominal Oncology Unit,
Abstract
Comparative outcomes of esophageal stent placement in patients with esophageal cancer: A prospective study of 183 cases.Org: Maimonides Medical Center, SUNY Downstate University Hospital,
Abstract
Efficacy and safety of the combination of tisleizumab with chemoradiotherapy in oligorecurrence esophageal squamous cell carcinoma: A prospective phase II study.Org: Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Neoadjuvant therapy using PD-1 inhibitor plus chemotherapy with different intervals between chemotherapy cycles for locally advanced gastric or gastroesophageal junction cancer: A randomized phase 2 study.Org: Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hospital, Department of Immunology and Oncology, Clínica Universidad de Navarra, Henan Cancer Hosptal, Surgical Oncology, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University,
Abstract
Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.Org: 900 Hospital of the Joint Logistics Support Force, The First Affiliated Hospital of Anhui Medical University,
Abstract
First-line osemitamab (TST001) plus nivolumab and capox for advanced g/GEJ cancer (TranStar102): Results of cohort G from a phase I/IIa study.Org: Fujian Cancer Hospital, Fuzhou, China, Medical Oncology Department of Gastrointestinal Cancer, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, China, Department of Gastrointestinal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Central Hospital Affiliated to Shandong First Medical University; Jinan Central Hospital, Shandong University, Jinan, China, Affiliated Hospital Zhejiang University, Hangzhou, China,
Abstract
Paclitaxel oral solution versus paclitaxel injection as second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial.Org: Ruijin Hospital, Shanghai Jiaotong University School of Medicine,
Abstract
Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202.Org: Kashiwa, Japan, Cape Coral, FL, Bothell, WA,
Abstract
Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.Org: Gradyate School of Medicine, Department of Radiation Oncology and Image-Applied Therapy, Department of Therepeutic Oncology, Department of Clinical Trial Promotion, Clinical Trial Promotion Department,
Abstract
Validation of PD-L1 as a predictive biomarker of response in operable gastroesophageal adenocarcinoma: A meta-analysis and meta-regression of neoadjuvant chemoimmunotherapy trials.Org: Institute of Applied Health Research,
Abstract
Whole transcriptome analysis to reveal epithelial-mesenchymal transition after neoadjuvant therapy with or without additional anti-EGFR treatment: Subgroup analysis of esophageal squamous cell carcinomas of the SAKK 75/08 and the EORTC AIO POWER study.Org: Institute of Pathology and Molecular Pathology, Kepler University Hospital Linz, Evang. Klinkien Essen-Mitte,
Abstract
Multi-region exome sequencing to determine the origin of esophageal spindle-cell squamous cell carcinoma.Org: Kanghui Biotech lnc., Shenyang, China,
Abstract
Multicenter randomized phase II study of short course FOLFOX + nivolumab (Nivo) followed by maintenance Nivo +/- radiation (RT) in the first line treatment of metastatic or unresectable gastroesophageal adenocarcinoma (mGEA).Org: Omaha, NE, NewYork-Presbyterian/Weill Cornell Medicine, UNMC,
Abstract
Safety and feasibility of esophagectomy following neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: Analysis of two phase 2 clinical trials.Org: Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Zhejiang Key Laboratory of Radiation Oncology,
Abstract
Neoadjuvant dual checkpoint inhibition followed by immune-chemoradiation in patients with resectable gastric adenocarcinoma.Org: Department of Gastroenterology, Hepatology, and Nutrition University of Texas MD Anderson Cancer Center,
Abstract
Neoadjuvant S-1 plus cisplatin-based chemoradiotherapy compared with surgery alone for locally advanced gastric cancer: Randomized, phase II trial.Org: SongDang Institute for Cancer Research,
Abstract
A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastric cancer: Efficacy and safety analysis (BOLD-100-001).Org: Bold Therapeutics Inc., Translational Research in Oncology,
Abstract
Neoadjuvant/adjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585.Org: Chonnam National University Medical School, Hwasun, South Korea, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy, Universidad de La Frontera, James Lind Cancer Research Center, Temuco, Chile, National Cheng Kung University, Tainan, Taiwan, CHU Brest–Institut de Cancerologie et d’Hematologie ARPEGO Network, Brest, France,
Abstract
Preoperative nivolumab plus SOX in patients with locally advanced gastric or gastro-esophageal junction cancer: A phase 2, single-arm trial.Org: Department of Gastric Surgery, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences,
Abstract
Conversion surgery for tislelizumab combined chemotherapy for T4a/N3 esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study.Org: Department of Endoscopy, Department of Esophageal Minimal Invasive Surgery,
Abstract
Long-term survival comparison of adjuvant FLOT versus XELOX chemotherapy for locally advanced gastric cancer in a large real-world cohort.Org: Lanzhou University Second Hospital, Lanzhou, China, Lanzhou University Second Hospitai, Lanzhou, China,
Abstract
Prediction for major pathologic response after neoadjuvant tislelizumab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma by RNA sequencing: A single-arm, phase II trial.Org: Daping Hospital, Army Medical University,
Abstract
Comparing toripalimab combined with chemoradiotherapy versus chemoradiotherapy alone for locally advanced esophageal squamous cell carcinoma: A multicenter, open-label, randomized phase II clinical trial.Org: Department of Thoracic Radiotherapy, Hangzhou Institute of Medicine (HIM), The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Lishui Municipal Central Hospital, Zhejiang Province Taizhou Hospital,
Abstract
68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) for detecting occult peritoneal metastasis in locally advanced gastric cancer: A single-center prospective cohort study.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Hospital, Sichuan University, Chengdu, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Distinct tumor microbiome and metabolomic profiles to inform responses of patients with esophageal cancer to neoadjuvant chemoradiotherapy and immunotherapy.Org: Johns Hopkins Medical Institutes, Esophageal Institute, Johns Hopkins Medical Institutions, Allegheny Health Network Cardiovascular Institute, Allegheny General Hospital,
Abstract
The use of micronuclei DNA from erythrocytes for the detection of early-stage gastrointestinal cancers.Org: Hangzhou China, The Fifth People's Hospital of Yuhang District,
Abstract
CLDN18/CLDN18.2 IHC assay comparison (SP455, 43-14A, EPR19202) and co-prevalence expression with other biomarkers in gastric carcinoma.Org: Roche Tissue Diagnostics,
Abstract
Neoadjuvant chemotherapy with albumin-bound paclitaxel plus cisplatin and capecitabine for locally advanced esophageal squamous cell carcinoma: A prospective phase II trial.Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College,
Abstract
A phase III trial comparing 5-FU plus cisplatin (CF) versus CF plus docetaxel or radiotherapy as neoadjuvant treatment for locally advanced esophageal cancer: 5-year follow-up from JCOG1109.Org: Shizuoka General Hospital, Kochi Health Sciences Center,
Abstract
Perioperative PD-1 antibody tislelizumab plus chemotherapy for locally advanced gastro-oesophageal junction cancer: A prospective, nonrandomized, open-label, phase II trial.Org: Melanoma and Sarcoma Medical Oncology Unit,
Abstract
Neoadjuvant toripalimab plus chemotherapy followed by concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (GASTO 1071).Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center Gansu Hospital, Department of Traditional Chinese Medicine/ Integrative Oncology,
Abstract
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study.Org: Zhongshan Hospital of Fudan University, Shanghai, China, Seoul National University Hospital, Cancer Research Institute, Seoul, South Korea, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
A prospective phase 2 single-arm study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (Keypoint-1).Org: Division of Thoracic Surgery,
Abstract
Neoadjuvant immunotherapy (PD-1) combined with chemotherapy for locally advanced thoracic esophageal carcinoma (EC): A single-arm, open-label, phase II study.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China,
Abstract
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).Org: Maria Skłodowska-Curie National Research Institute and Oncology Centre, Hôtel-Dieu de Québec, Clinical Hospital “RZHD-Medicine”, Chi Mei Medical Center,
Abstract
SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial.Org: Department of Hepatobiliary Pancreatic and Splenic Surgery, Baoji Central Hospital, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, The First Affiliated Hospital of Bengbu Medical University,
Abstract
Survival outcomes with adjuvant immunotherapy after hepatic resection in patients with intermediate/advanced (BCLC stage B/C) hepatocellular carcinoma: Insights from a propensity-matched multicenter study.Org: Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai, China, Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Navy Medical University, Shanghai, China, Department of Hepatobiliary Surgery, Affiliated Hospital of Nantong University, Nantong, China, Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial People’s Hospital, Hangzhou, China, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China,
Abstract
ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy.Org: Taipei, Taiwan, Sutter/California Pacific Medical Center, Nanjing Bayi Hospital, Nanjing, Jiangsu, China, Ibaraki, Japan,
Abstract
Predictors of short-term death and long-term survival in advanced hepatocellular carcinoma (HCC) treated with contemporary tyrosine kinase inhibitors (TKI) or immunotherapy: A multicenter analysis from the HCC-CHORD consortium.Org: Nova Scotia Cancer Center, Princess Margaret Cancer Centre and University of Toronto,
Abstract
Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC).Org: Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Prince of Wales Hospital, Department of Clinical Oncology, The Chinese University of Hong Kong, Amsterdam UMC, University of Amsterdam, Department of Medical Oncology, ENETS Center of Excellence, Cancer Center Amsterdam, Gastroenterology, Hepatology, Infectious Diseases and Endocrinology Department, Hannover Medical School,
Abstract
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Lishui Central Hospital, Akeso Biopharma, Inc., Zhongshan, China,
Abstract
Genomic signature analysis and survival outcomes in cholangiocarcinoma (CCA) using oncology research information exchange network (ORIEN) database.Org: Department of Translational Genomics, Univeristy of Iowa Hospitals and Clinics, Aster Insights,
Abstract
Atezolizumab plus bevacizumab (A+B) as first-line systemic therapy for advanced hepatocellular carcinoma (HCC): A multi-institution analysis of patient outcomes based on Child Pugh (CP) and ALBI liver function.Org: Mayo Clinic, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center,
Abstract
Neoadjuvant immuno-chemo-radiotherapy in operable esophageal and gastroesophageal junction adenocarcinoma with carboplatin, paclitaxel plus radiotherapy and avelumab (anti-PDL1 antibody): Neo-CREATE trial.Org: Wollongong Hospital, Genesis Care, Bowel Health Service,
Abstract
Impact of hepatitis B virus (HBV) infection on efficacy and safety in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC).Org: Amsterdam UMC, University of Amsterdam, ENETS Center of Excellence, Cancer Center Amsterdam, Charite Campus Charite Mitte,
Abstract
Impact of CTNNB1 alterations on outcomes in patients with hepatocellular carcinoma (HCC).Org: Caris Life Sciences, Irving, TX, Mayo Clinic Scottsdale,
Abstract
Hepatic artery infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for initial unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus: A prospective, single-arm phase II trial.Org: The First Affiliated Hospital of Chongqing Medical University,
Abstract
Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study.Org: Saint-Luc University Clinics, Brussels, Belgium, Eugène Marquis Center, Rennes, France, Claude Huriez Hospitals, Lille University Hospital, Lille, France, Ghent University Hospital, Ghent, Belgium, CR UK Liverpool Experimental Cancer Medicine Centre and Clatterbridge Cancer Centre, Liverpool, United Kingdom,
Abstract
Characterizing outcomes of biliary tract cancers (BTC) with β-catenin (CTNNB1) alterations.Org: Irving, TX, O’Neal Comprehensive Cancer Center of University of Alabama at Birmingham, Heersink School of Medicine,
Abstract
Genomic and transcriptomic biomarkers of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancer.Org: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milano), Italy, CHA University School of Medicine, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, CHA Bundang Medical Center, Department of Surgery, Brigham and Women's Hospital, Boston, MA,
Abstract
Stereotactic body radiotherapy (SBRT) combined with transcatheter arterial chemoembolization (TACE) and tyrosine kinase inhibitors (TKIs) versus TACE and TKIs alone for unresectable hepatocellular carcinoma (uHCC) with portal vein tumor thrombus (PVTT): A randomized controlled trial.Org: State Key Laboratory of Biotherapy and Cancer Center, Department of Liver Transplantation Center, Division of Liver Surgery, Laboratory of Liver Surgery, Collaborative Innovation Center of Biotherapy,
Abstract
Clinical outcomes from a phase I clinical trial of a novel oncolytic virus VG161 in patients with hepatocellular carcinoma (HCC) refractory after 2 prior lines of therapy including checkpoint inhibitors (CPI).Org: CNBG-Virogin Biotech (Shanghai) Co.,Ltd., Liver Cancer Institute, Zhongshan Hospital, Fudan University,
Abstract
Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): Exploratory analyses from KEYNOTE-240.Org: University Croix-Rousse Hospital, University Hospital of Lyon, Lyon, France, Istinye University, Istanbul, Turkey, Purpan Hospital, Toulouse, France, Chinese University of Hong Kong, Hong Kong, China, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada,
Abstract
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.Org: Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany, Chinese University of Hong Kong, Hong Kong, China, Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China, Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, China, Department of Interventional Radiology, Hunan Cancer Hospital, Changsha, China, Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, China, Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China, Department of General Surgery, Anhui Provincial Hospital, Hefei, China, Department of Medical Oncology, Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, China, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Liver Cancer Center, Guangzhou, China, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, State Autonomous Budgetary Healthcare Institution, Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan, Ufa, Russian Federation, Department of Infectious Disease and Hepatology, Wroclaw Medical University, and Centrum Badań Klinicznych P.Napora, Wroclaw, Poland, Department of Liver and Pancreas Gland Oncosurgery, Communal Non-profit Enterprise "Regional Center of Oncology", Kharkiv, Ukraine, Jiangsu Hengrui Pharmaceuticals, Co., Ltd, Shanghai, China, National Taiwan University Hospital, Taipei, Taiwan, Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, Cancer Center of Nanjing, Jinling Hospital, Nanjing, China,
Abstract
Efficacy and safety of envafolimab plus lenvatinib combined with TACE in initially unresectable hepatocellular carcinoma: An open-label, single-arm, phase II study.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, China,
Abstract
Atezolizumab + bevacizumab versus lenvatinib as first-line systemic therapy for treatment of hepatocellular carcinoma in a real-world population: Outcomes from the HCC CHORD database.Org: Halifax, NS, Canada, Winnipeg, MB, Canada,
Abstract
A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer: Efficacy and safety analysis (BOLD-100-001).Org: Translational Research in Oncology, Canada,
Abstract
Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies.Org: The People's Liberation Army 81 Hospital, University Hospital Gasthuisberg, Bristol Haematology and Oncology Centre, Statistics & Decision Sciences, Janssen China R&D Center, Chi-Mei Medical Center,
Abstract
Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).Org: Liver Cancer Institute, Department of Hepatic Surgery II, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Department of Hepatic Surgery V, Center of Hepato-Pancreato-Biliary Surgery,
Abstract
Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04).Org: Center for Cancer Biostatistics, University of Michigan School of Public Health,
Abstract
Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging.Org: The Johns Hopkins Hospital, The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Enable Medicine,
Abstract
Adjuvant S-1 vs. observation for resected biliary tract cancer: 5-year follow-up of the JCOG1202/ASCOT.Org: Department of Medical Oncology, Tochigi Cancer Center, National Cancer Center Hospital East, Tochigi, Japan, Japan Clinical Oncology Group Operations Office, Clinical Research Support Office, National Cancer Center Hospital, Chuo-Ku, Japan, Japan Clinical Oncology Group Operations Office, Clinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan, Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan, Department of Surgery, Kansai Medical University, Hirakata, Japan,
Abstract
Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (SHATA-001).Org: Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China,
Abstract
Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: A prospective, single-arm, phase II trial.Org: Eastern Hepatobiliary Surgery Hospital, Naval Medical University, National Center for Liver Cancer,
Abstract
Utilization of tumor-informed circulating tumor DNA in detecting minimal residual disease and guiding adjuvant therapy in liver cancer.Org: Department of Liver Surgery and Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Zhongshan-BGI Precision Medical Center, BGI-shanghai,
Abstract
PD-1 inhibitor (sintilimab) and lenvatinib plus TACE-HAIC as conversion therapy for initially unresectable HCC: A single-arm, phase 2 clinical trial (PLATIC).Org: Department of Liver Surgery,
Abstract
Bone metastases and skeletal related events in patients with gastrointestinal neuroendocrine tumors.Org: St. Agnes Health Care, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University,
Abstract
Updated results from venous infusion chemotherapy (VIC) plus apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.Org: Department of Hepatobiliary Surgery,
Abstract
Overall survival outcomes of phase II GECCOR-GB trial, a multicentre trial of adjuvant adjuvant gemcitabine plus cisplatin (GC) and capecitabine with concurrent capecitabine radiotherapy (Cape-RT) for operated gallbladder cancer (GBC).Org: Mahamana Pandit Madan Mohan Malviya Cancer Centre, Homi Bhabha Cancer Hospital & Research Centre,
Abstract
Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.Org: Liver Unit and HPB Oncology Area, Clínica Universidad de Navarra and CIBEREHD, Pamplona, Spain, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY, Cancer Center of Nanjing, Jinling Hospital, Nanjing, China, Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China, Department of Diagnostic Radiology, National Cancer Center, Chuo-Ku, Tokyo, Japan,
Abstract
Cabozantinib plus atezolizumab in patients with advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II trial (CABATEN / GETNE-T1914).Org: University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario 12 de Octubre, Imas12, UCM, Hospital Universitario La Paz, IdiPAZ, Hospital Universitario Central de Asturias, ISPA, Catalan Institute of Oncology (ICO-Badalona) Germans Trias i Pujol University Hospital,
Abstract
OPTIMIZE-1 primary analysis: Safety, efficacy and biomarker results of a phase 1b/2 study combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).Org: Institut De Cancerologie De Lorraine,
Abstract
Prognostic value of circulating tumor DNA testing in surgically resected pancreatic cancer.Org: New York Harbour Veterans Healthcare System, Manhattan VA/NYU,
Abstract
Differences in genomic and transcriptomic landscapes of human papillomavirus (HPV)–positive neuroendocrine neoplasms and HPV-positive carcinoma.Org: Loma Linda University Health| School of Medicine, Wayne State University/Karmanos Cancer Center, Division of Hematology/Oncology, University of California, Division of Gynecologic Oncology, Department of Oncology, Karmanos Cancer Institute, Division of Gynecologic Oncology, The University of Cincinnati Cancer,
Abstract
Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study.Org: IRCCS Policlinico San Martino and DiMI, Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Uniklinikum Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Oncologia Clinica e Sperimentale Sarcomi e Tumori Rari, Istituto Nazionale Tumori IRCCS, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University Graduate School,
Abstract
The clinical utility of plasma cell-free DNA (cfDNA) in NET-02: Randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).Org: CRUK Manchester Institute, Leeds Institute of Clinical Trials Research, Newcastle Hospital NHS Foundation Trust, Leeds Teaching Hospitals NHS Trust, CRUK Cancer Biomarker Centre,
Abstract
Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort.Org: Princess Margaret Cancer Centre, University Health Network, University of Toronto, 23andMe, Jasper Therapeutics,
Abstract
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3.Org: Florida Cancer Specialists North Division, Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), IPSEN Bioinnovation Limited, Università degli studi di Verona and Azienda Ospedaliera Universitaria Integrata,
Abstract
Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC).Org: Yale Cancer Center, Foundation Medicine, Inc., Cambridge, MA, Perlmutter Cancer Center, NYU Langone Health,
Abstract
Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.Org: Affiliated Zhenjiang Hospital of Jiangsu University, National Institute of Healthcare Data Science,
Abstract
Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205).Org: Virginia Mason Hospital and Medical Center, Verastem Oncology,
Abstract
Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody MK-0482 + pembrolizumab + gemcitabine + nab-paclitaxel (Gem/Nab-P) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).Org: Ramat Gan, Hadassah Hebrew - University Medical Center, Jerusalem, Medical Oncology and Immunotherapy, Siena,
Abstract
Somatic mismatch repair deficiency in pancreas cancer (PC): Immune checkpoint blockade (ICB) outcomes and exploratory genomic analyses.Org: Icahn School of Medicine at Mount Sinai Morningside-West,
Abstract
A randomised phase 2 study of liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxalipalatin versus nab-paclitaxel plus gemcitabine in unresectable locally advanced or metastatic pancreatic cancer.Org: Liaoning Cancer Hospital, Shenyang, China, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Yunnan Cancer Hospital, Yunnan, China, CSPC Ouyi Pharmaceutical Technology (Shijiazhuang) Co.,Ltd, Shijiazhuang, China,
Abstract
Effect of ctDNA whole-exome sequencing in pancreatic adenocarcinoma on prognostic value, actionable alterations, and organ tropisms in metastatic disease.Org: University of Valencia, Instituto Carlos III,
Abstract
Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma.Org: 1440 Foundation,
Abstract
FG-M108 plus nab-paclitaxel and gemcitabine (AG) as first-line (1L) treatment for patients with Claudin-18.2 (CLDN18.2) positive locally advanced unresectable or metastatic pancreatic cancer (PC): Preliminary results from the phase 1b study.Org: Phase I Clinical Trials Center, The First Hospital of China Medical University,
Abstract
Primary prophylaxis with pegylated-granulocyte colony-stimulating factor for patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: A randomized phase II trial.Org: Haeundae Paik Hospital,
Abstract
A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC).Org: Epworth Medical Centre, New Zealand Clinical Research-Auckland, Rotorua Hospital, Blacktown Cancer and Haematology Centre, Beijing Tsinghua Changgung Hospital,
Abstract
Association of BRCA1/2 pathogenic variants with primary tumor location and metastatic organotropism in pancreatic adenocarcinoma.Org: University of Pennsylvania - Perelman School of Medicine,
Abstract
Impact on chemotherapy induced peripheral neuropathy of nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in patients with pancreatic cancer, with supportive mouse model data.Org: Department of Hematology, Oncology and Cancer Immunology, Medical Oncology Department-CHU Sart-Tilman, Department of Oncology. Experimental Cancer Therapy Unit, Hospital of LUHS Kauno Klinikos, Institute for Molecular Bioscience, The University of Queensland,
Abstract
Integrated genomic and transcriptomic analysis to predict FOLFIRINOX response in metastatic pancreatic ductal adenocarcinoma.Org: Amsterdam UMC, Center for Experimental Molecular Medicine,
Abstract
Serial circulating tumor DNA monitoring for predicting treatment response and prognosis in patients with pancreatic cancer.Org: Seoungnam, South Korea,
Abstract
Phase II study of pirfenidone combined with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.Org: Department of Pancreatobiliary Surgery,
Abstract
Post-progression therapies and outcomes for patients with advanced, BRCA-related pancreatic cancer after receipt of PARP inhibitors: A national retrospective cohort study.Org: UT Southwestern Medical Center, Penn Medicine Abramson Cancer Center, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center,
Abstract
Treatment landscape, outcome and quality of life in patients with pancreatic cancer: IKF642/PARAGON study.Org: Outpatient Clinics for Hematology and Oncology, Onkozentrum Dresden/Freiberg/Meissen, St. Bernward Krankenhaus, Marienhospital Stuttgart, Universität Greifswald,
Abstract
Clinical utility and outcomes associated with mutations detection in liquid biopsy for patients with pancreatic ductal adenocarcinoma: Real-world data evidence from a single institution.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Gastrointestinal Radiation Oncology, University of Texas MD Anderson Cancer Center,
Abstract
Molecular landscape and site of metastasis in PDAC.Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Caris Life Sciences, Irving, TX, Dana-Farber Cancer Institute, Sidney Kimmel Medical College of Thomas Jefferson University, Thomas Jefferson University,
Abstract
Comparative effectiveness of NALIRIFOX vs. FOLFIRINOX in pancreatic cancer.Org: University of Southern California Marshall School of Business, Medical Oncology and Therapeutics, City of Hope/AccessHope,
Abstract
GATA6 expression in advanced pancreatic ductal adenocarcinoma (PDAC) as a prognostic and predictive biomarker in the Canadian COMPASS trial and the Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS.Org: Chirurgia Digestiva, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Wallace McCain Center for Pancreatic Cancer,
Abstract
Neoadjuvant fractionated versus hypofractionated chemoradiotherapy in resectable and borderline resectable pancreatic cancer.Org: Kettering Laboratory Complex, University of Cincinnati Medical Center,
Abstract
Neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma (PDAC) with germline DNA damage repair (DDR) mutations: A dual institution retrospective study.Org: Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA,
Abstract
Does non-alcoholic fatty liver disease increase the risk for pancreatic cancer? A multi-center retrospective cohort study.Org: University of Illinois College of Medicine Peoria (UICOMP), Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center,
Abstract
Independent blinded validation of a novel blood-based early pancreatic cancer detection test.Org: Wholomics GmbH, Ried Im Innkreis, Austria, Amsterdam UMC, Center for Experimental Molecular Medicine, Amsterdam, Netherlands, Department of Surgery, Amsterdam University Medical Center, Amsterdam, Netherlands,
Abstract
Tislelizumab combined with gemcitabine and albumin paclitaxel as preoperative therapy for patients with borderline resectable pancreatic cancer: A prospective, single-arm, phase II trial.Org: The Second Affiliated Hospital of Army Military Medical University, Chongqing, China,
Abstract
ETCTN 10366: A phase 1 study of DNA-PK inhibitor peposertib in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma.Org: NewYork-Presbyterian/Weill Cornell Medical Center,
Abstract
KRAS mutations allelic frequency dynamics using plasma extracellular vesicles: Association with survival outcomes in localized pancreatic adenocarcinoma.Org: Captis Diagnostics, Inc, Department of Biomedical Engineering, Carnegie Mellon University, Department of Pathology, University of Pittsburgh, Department of Medical Oncology, University of Pittsburgh,
Abstract
Predicting real-world overall survival for post-operative pancreatic ductal adenocarcinoma: An ASCO CancerLinQ Discovery analysis.Org: University of Wisconsin - Madison, University of Wisconsin–Madison,
Abstract
Perioperative fuzuloparib plus mFOLFIRINOX for resectable pancreatic adenocarcinoma: A phase 1 study.Org: Pancreatic Disease Center, Shanghai Jiao Tong University School of Medicine,
Abstract
Adjuvant mFOLFIRINOX (mFFX) for resected pancreatic cancer (PC): Long term clinical and genomic outcomes.Org: Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland, Icahn School of Medicine at Mount Sinai Morningside-West, New York, NY, Mount Sinai Hospital, New York, NY, SUNY Downstate, Brooklyn, NY, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Extracellular (EC) Mucin5AC (MUC5AC) detection after neoadjuvant therapy (NAT) and the risk of recurrence in resected pancreatic ductal adenocarcinoma (R-PDA).Org: James Cancer Center,
Abstract
Fragmentomics of cell-free DNA as a sensitive biomarker for early detection of pancreatic cancer.Org: Pancreas Center,
Abstract
Durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer (PDAC): Long-term outcomes and correlative insights.Org: USF Health Morsani College of Medicine, St. Vincent’s University Hospital,
Abstract
A phase I/II open-label clinical trial of CPI-613 in combination with modified FOLFIRINOX in patients with locally advanced (LAPC) or borderline resectable pancreatic cancer (BRPC).Org: Department of Nursing University Hospitals Seidman Cancer Center, Department of Nursing, University Hospitals Seidman Cancer Center / Case Western Comprehensive Cancer Center, University Hospitals, Case Medical Center - Seidman Cancer Center, Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Department of Surgery, University Hospitals Seidman Cancer Center,
Abstract
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.Org: New York University, Grossman School of Medicine, New York University, School of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
Early-onset appendiceal adenocarcinoma (EOAA): 10-year experience from a single center.Org: Yale University Medical Center, University of Chicago Hospitals,
Abstract
KRAS mutations and their prognostic implications in appendiceal cancers.Org: Caris Life Sciences, Irving, TX, Norris Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ,
Abstract
Association between activating GNAS mutations and outcomes with chemotherapy in metastatic appendiceal adenocarcinoma.Org: Yale Univesity Medical Center, University of Chicago Hospitals,
Abstract
Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings.Org: Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University,
Abstract
Protein expression of claudin 18.2, Nectin-4, HER-3, and PD-L1 in small bowel adenocarcinoma: Exploring potential targets of antibody drugs.Org: Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
ESORES-Trial: Surgery as needed versus surgery on principle in patients with postneoadjuvant clinical complete tumor response of esophageal cancer.Org: University Freiburg Medical Center, Department of General- and Visceral Surgery, Freiburg, Germany, Endowed Professorship Self-Help Research, Comprehensive Cancer Center, Medical Center and Faculty of Medicine - University of Freiburg, Freiburg, Germany,
Abstract
A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors.Org: National Cancer Center East, Daiichi Sankyo Ltd.,
Abstract
A randomized, open-label phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF633/DANTE trial, a trial of AIO in collaboration with SAKK.Org: University Cancer Center Germany, St. Anna Hospital Herne, RKH-Clinics Ludwigsburg, University Hospital Ulm, Charité-University madicine Berlin,
Abstract
Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical trial.Org: Tianjin's Clinical Research Center for Cancer, Radiation Oncology Key Laboratory of Sichuan Province, University of Electronic Science and Technology of China, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University,
Abstract
Safety of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in patients (pts) with biliary tract cancer with peritoneal metastases.Org: City of Hope Comprehensive Cancer Center, Duarte, CA, CanSino Biologics,
Abstract
GEMINI-Gastric: A phase 2 study of novel treatment combinations in patients with locally advanced unresectable or metastatic gastric cancers.Org: Chang Gung Memorial Hospital at Linkou and Chang Gung University, Seoul National University Graduate School, AstraZeneca Global R&D (China) Co., AstraZeneca Pharmaceutical Co.,
Abstract
A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with Caprin-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.Org: Charles A. Sammons Cancer Center, Baylor University Medical Center at Dallas, Loma Linda University School of Medicine, Toray Industries, Inc.,
Abstract
GEMINI-Hepatobiliary: A phase 2 study of novel first-line immuno-oncology-based treatments in patients with advanced hepatobiliary cancers.Org: NTUH Cancer Hospital, B2F Samsung Comprehensive Cancer Center, Jiangsu, China, Shatin, Hong Kong,
Abstract
Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.Org: Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain, Yale University School of Medicine, New Haven, CT, Sheba Medical Center, Ramat Gan, and Tel Aviv University, Tel Aviv, Israel, Rambam Medical Center, Haifa, Israel, HonorHealth Research Institute, Scottsdale, AZ,
Abstract
A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations.Org: University of Texas Southwestern Medical School, The University of Chicago Medicine Comprehensive Cancer Center, The University of Edinburgh, Cancer Research UK Beatson Institute, CR-UK Beatson Institute & MRC Centre for Inflammation Research,
Abstract
An open-label, multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.Org: Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Replimune, Inc., Clinical Cooperation Unit Virotherapy, German Cancer Center Research Center (DKFZ),
Abstract
Apatinib and camrelizumab plus Intravenous FOLFOX or hepatic arterial infusion chemotherapy with FOLFOX for advanced HCC: A multicenter, prospective, randomized phase III trial.Org: Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan, China, Sun Yat-sen Memorial Hospital, Sun Yat-sen University Cancer Center Gansu Hospital, Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma.Org: Weill Medical College at Cornell University, Liver Oncology and Therapeutic Innovation Unit, AP-HP-Hôpital Beaujon, Clichy, France, Department of Oncology, National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan, Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Department of Medicine, Section of Hematology and Oncology, University of Chicago,
Abstract
TOURMALINE: A phase 3b study of durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer.Org: Vall d’Hebron Institute of Oncology (VHIO); Vall d’Hebron University Hospital, Statistics, DaneStat Consulting Limited, Oncology Business Unit Medical, AstraZeneca, Oncology Biostatistics Unit, AstraZeneca, Global Medical Affairs, AstraZeneca,
Abstract
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.Org: University of Wisconsin, Carbone Cancer Center, Madison, WI, Wigen Biomedicine Technology (Shanghai), University of Wisconsin Carbone Cancer Center,
Abstract
Apatinib and camrelizumab plus hepatic arterial infusion with oxaliplatin and 5-fluorouracil vs. apatinib and camrelizumab as the first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A randomized multi-center clinical trial.Org: Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China,
Abstract
Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma.Org: Weill Medical College at Cornell University,
Abstract
Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial.Org: The Ohio State University Wexner Medical Center and Comprehensive Cancer Center, Trinity Health IHA Medical Group,
Abstract
A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma.Org: Servier Pharmaceuticals LLC,
Abstract
REPLACE: A phase III, randomized, open-label trial to evaluate the safety and efficacy of regorafenib and pembrolizumab versus locoregional therapy (LRT) with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma (HCC) with beyond up-to-7 criteria.Org: IDIBAPS, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain, Institució Catalana d’Estudis Avançats (ICREA), Barcelona, Spain, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, Translatoinal Research in Oncology (TRIO), Montevideo, Uruguay, Translational Research in Oncology (TRIO), Edmonton, AB, Canada,
Abstract
Phase II study of neoadjuvant durvalumab and tremelimumab in combination with gemcitabine and cisplatin in patients with intrahepatic cholangiocarcinoma that is borderline resectable or resectable with high risk for recurrence.Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health,
Abstract
A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01.Org: Mayo Clinic Comprehensive Cancer Center, IRCCS San Raffaele Hospital, UCL Cancer Institute, Cedars-Sinai Medical Center, Memorial Sloan Kettering Cancer Center,
Abstract
Phase 1 study to evaluate safety and preliminary efficacy of padeliporfin vascular targeted photodynamic therapy (VTP) in patients with locally advanced (LA) unresectable pancreatic ductal adenocarcinoma (PDAC).Org: Division of Vascular & Interventional Radiology, Department of Radiological Sciences, Orange, CA, Ness Ziona, Israel, Steba/Impact Biotech,
Abstract
Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, AK Altona, Asklepios Tumourzentrum Hamburg, Oncolytics Biotech, Calgary, AB, Canada,
Abstract
A phase II randomized control trial of triapine plus lutetium 177 DOTATATE versus lutetium 177 DOTATATE alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors.Org: Markey Cancer Center, University of Kentucky HealthCare,
Abstract
SWOG S2012: Randomized phase II/III trial of first line platinum (P)/etoposide (E) with or without atezolizumab (NSC #783608) in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC).Org: Department of Thoracic/Head and Neck Medical Oncology,
Abstract
A randomized, multi-center, phase 2 study of ivaltinostat (Ival) plus capecitabine (Cape) versus capecitabine alone in the maintenance setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).Org: Clinical Research Alliance, LSU School of Medicine, CG Pharmaceuticals Inc.,
Abstract
METAPANC, intensified treatment in patients with oligometastatic pancreatic cancer: Multimodal surgical treatment versus systemic chemotherapy alone—A prospective randomized controlled multicenter phase III trial.Org: Amsterdam UMC Location University of Amsterdam, University Hospital Essen West German Cancer Center,
Abstract
CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-naïve pancreatic adenocarcinoma.Org: Brown University/Lifespan Cancer Institute,
Abstract
Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM).Org: Department of Quantitative Science Research, Mount Sinai Comprehensive Cancer Center, University of California, San Diego Moores Cancer Center, Inova Fairfax Medical Campus, Department of Medicine, Section of Hematology and Oncology, University of Chicago,
Abstract
Targeting replication stress in pancreatic cancer: A phase II trial investigating azenosertib in combination with gemcitabine in second-line advanced pancreatic cancer.Org: Dana-Farber Cancer Institute, Boston, MA, Massachusetts General Hospital,
Abstract
VIRAGE: A phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine plus/minus VCN-01 in patients with metastatic pancreatic cancer.Org: Vall d´Hebrón Institute of Oncology (VHIO),
Abstract
Association of machine learning (ML)–derived histological features with transcriptomic molecular subtypes in advanced renal cell carcinoma (RCC).Org: PathAI, Dana-Farber/Harvard Cancer Center, Path AI,
Abstract
Sequential neoadjuvant chemotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.Org: Atrium Health Wake Forest University Baptist Medical Center,
Abstract
Impact of Latino ethnicity on the gut microbiome composition of patients with metastatic renal cell cancer (mRCC).Org: Department of Immunology, Roswell Park Comprehensive Cancer Center, Translational Genomics Institute,
Abstract
A phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.Org: Center for Hematology Oncology, US Oncology Research/Texas Oncology-Tyler,
Abstract
Multi-omics analyses and molecular subtypes to provide potential therapeutic implications in fumarate hydratase-deficient renal cell carcinoma.Org: Sichuan Clinical Research Center for Kidney and Urologic Diseases,
Abstract
Comparing the somatic, germline, and immune landscapes of upper tract urothelial carcinoma (UTUC) and UC of the bladder (UCB).Org: University of California, San Diego Health, Tempus AI, University of California, Irvine Medical Center, Cleveland Clinic Taussig Cancer Institute, University of Washington, Fred Hutchinson Cancer Center,
Abstract
CA-62: A new biomarker for the detection of early-stage renal cell carcinoma.Org: UCM Technologies Inc., Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, IM Sechenov First Moscow State Medical University, Pacific Biosciences Research Centre,
Abstract
A phase I/II study of intraperitoneal (IP) paclitaxel (PTX) in patients with metastatic appendiceal adenocarcinoma.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, Txinno Bioscience,
Abstract
Phase 2 randomized study of rintatolimod following FOLFIRINOX in patients with locally advanced pancreatic adenocarcinoma.Org: AIM ImmunoTech, Inc.,
Abstract
A phase II study of cadonilimab plus mFOLFIRINOX as induction therapy for locally advanced pancreatic adenocarcinoma (LAPC).Org: Nanjing, China, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital,
Abstract
Sintilimab plus axitinib for advanced fumarate hydratase-deficient renal cell carcinoma: A multi-center, open-label, single-arm, phase II study (SAFH).Org: Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Department of Radiology, West China Hospital, Sichuan University, Chengdu, China, Department of Urology, Southwest Hospital, Army Medical University, Chongqing, Chengdu, China, The First Affiliated Hospital of Kunming Medical University, Kunming, China,
Abstract
Comparison of TKI and CPI strategies as first-line treatment of patients with advanced renal cell carcinoma: Real-world outcome data from the German research platform CARAT.Org: University Clinic Erlangen, Münster University Medical Center, Clinic for Internal Medicine (Tumor Research) and Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Gemeinschaftspraxis für Hämatologie und Onkologie,
Abstract
Changes in treatment (Rx) patterns and attrition rates in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).Org: University of Utah/Huntsman Cancer Institute,
Abstract
Lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial.Org: University Hospital Essen, Memorial Sloan Kettering Cancer Center, Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Department of Urology and Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany, Medical University of Vienna,
Abstract
Tumor evolution of brain-specific tropism in metastatic renal cell carcinoma.Org: JHU, Johns Hopkins Brain Tumor Group, Sidney Kimmel Cancer Center at Johns Hopkins, The James Buchanan Brady Urological Institute,
Abstract
Matched tissue and circulating tumor DNA (ctDNA) analysis in renal cell carcinoma (RCC): Results from a multimodal real-world database.Org: University of Miami Sylvester Comprehensive Cancer Center/Jackson Health System, School of Medicine, University of California, San Diego,
Abstract
Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti-PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl) pretreated patients (pts) with advanced or metastatic renal cell cancer (mRCC): Results from the multi-stage phase 1-2 INNATE trial.Org: University of Florida Department of Medicine/Division of Hematology/Oncology, Department of Medicine, Division of Hematology and Oncology, The Medical College of Wisconsin, Division of Hematology/Oncology, Department of Internal Medicine, Henry Ford Cancer, Joe Arrington Cancer Research and Treatment Center, Oncology Consultants,
Abstract
First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma (RCC): An international multi-center study.Org: Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, Dana-Farber Cancer Institute, Boston, MA, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, Rogel Comprehensive Cancer Center, Ann Arbor, MI, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, Tom Baker Cancer Centre, University of Calgary, Alberta, Canada, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic, City of Hope Comprehensive Cancer Center, Duarte, CA, Genitourinary Medical Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Campus Biomedico, Roma, Italy, University Hospital of Parma, Fontevivo, Italy, Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, United Kingdom, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Vanderbilt University Medical Center, Nashville, TN, Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC).Org: Medical Oncology, Vall d'Hebron Institute of Oncology, Division of Medical Oncology, National Cancer Centre Singapore,
Abstract
Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study.Org: University of Miami Hospital and Clinics, Cancer Research Services, New York Oncology Hematology, Moscow City Clinical Oncology Hospital No. 1, Alexandra General Hospital,
Abstract
Preliminary results from a phase II clinical study of first-line drugs combined with stereotactic body radiotherapy (SBRT) in the treatment of oligoprogressive renal cell carcinoma.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China,
Abstract
Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial.Org: Fundación Cancer - Fuca, Hospital Sirio Libanes, Instituto Medico Rio IV, Centro de Investigación Clínica Bradford Hill, Erasto Gaertner Hospital,
Abstract
Health-related quality of life (HRQoL) with nivolumab (NIVO) subcutaneous (SC) or intravenous (IV) in patients (pts) with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior therapy in the phase 3 CheckMate 67T trial.Org: Roswell Park Comprehensive Cancer Center, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Bristol Myers Squibb, Adelphi Mill, Adelphi Values,
Abstract
Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Yale Cancer Center, Yale School of Medicine,
Abstract
Belzutifan plus lenvatinib (len) for Chinese patients (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Preliminary results of cohort 1 of the phase 1 LITESPARK-010 study.Org: The Affiliated Hospital of Nanjing University Medical School, MSD (China) Co., Ltd.,
Abstract
Camrelizumab plus apatinib for advanced renal cell carcinoma patients after first-line tyrosine kinase inhibitor treatment failure: A multicenter phase II trial.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Medical Imaging, Nuclear Medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Department of General Internal Medicine,
Abstract
A phase I/II study of talazoparib and axitinib in patients with advanced clear cell renal cell carcinoma.Org: Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University,
Abstract
Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, DFCI/PCC Fellowship Program - Attendings, Yale Cancer Center,
Abstract
Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC).Org: Hackensack, NJ, University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center,
Abstract
A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Indiana University Simon Comprehensive Cancer Center, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, University of Chicago, Chicago, IL, Department of Medicine, Division of Hematology and Oncology, The Medical College of Wisconsin, Milwaukee, WI, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Mary Crowley Cancer Research, Dallas, TX, AdventHealth Cancer Institute, Orlando, FL, Sarah Cannon Research Institute, Nashville, TN, St. Jude Crosson Cancer Institute/Providence Medical Foundation, Fullerton, CA, Fort Wayne Medical Oncology - West Jefferson Office, Fort Wayne, IN, Scholar Rock Inc., Cambridge, MA, Scholar Rock, Cambridge, MA, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
Examination of irAE and treatment discontinuation irAE in patients with RCC with T effector phenotype.Org: Vindhya Data Science,
Abstract
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs).Org: Winship Cancer Institute of Emory University, Emory University, Atlanta, GA, USA, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Association between circulating cytokines expression patterns and outcomes to immune-checkpoint (ICI)–based regimens in metastatic renal cell carcinoma (mRCC).Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,
Abstract
Applying genomic analysis to refine unclassified renal cell carcinoma.Org: Department Medicine, Ankara University School of Medicine,
Abstract
Genomic landscape of metastatic clear cell renal cell carcinoma (mccRCC): A retrospective real-world analysis from Flatiron Health (FH)-Foundation Medicine, Inc. (FMI) clinico-genomic database (CGDB).Org: AOU Consorziale Policlinico di Bari, Interdisciplinary Department of Medicine, AdRes Health Economics and Outcome Research, Roche SpA, University of Bari ‘Aldo Moro’,
Abstract
Impact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC).Org: Miyarisan Pharmaceutical Co., Ltd., Saitama, Japan,
Abstract
Identification of prognostic genomic biomarkers in metastatic clear cell renal cell carcinoma (mccRCC): An analysis of the large retrospective real world clinico-genomic data from Flatiron Health (FH)-Foundation Medicine, Inc. (FMI) clinico-genomic database (CGDB).Org: Interdisciplinary Department of Medicine, University of Bari ‘Aldo Moro’, AdRes Health Economics and Outcome Research, University of Bari ‘Aldo Moro’ and AOU Policlinico di Bari,
Abstract
Disparate outcomes among Latino and non-Hispanic White (NHW) patients with metastatic clear cell renal cell carcinoma (mccRCC).Org: University of California, San Diego, Department of Urology,
Abstract
Association of immune-related adverse events, inflammatory biomarkers, and clinical outcomes in patients treated with ICIs for advanced renal cell carcinoma.Org: Winship Cancer Institute of Emory University, Emory University, Atlanta, GA, USA, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Emory University School of Medicine,
Abstract
Biomarker analysis of zanzalintinib in clear cell renal cell carcinoma from STELLAR-001.Org: APHP Hôpital Européen Georges Pompidou and Université Paris Cité, Charles University and Thomayer University Hospital, Institut de Cancérologie Gustave Roussy,
Abstract
Unraveling the gene expression signatures with associated clinical outcomes in papillary renal cell carcinoma.Org: Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, Center for Prostate Disease Research (CPDR),
Abstract
Treatment outcomes of brain metastasis from primary renal cell carcinoma in United States: A National Cancer Database analysis.Org: King Edward Medical University, Grant Government Medical College, Miami Cancer Insitute,
Abstract
Comparative effectiveness of first-line (1L) ipilimumab plus nivolumab (Ipi + Nivo) versus immune checkpoint inhibitors + tyrosine kinase inhibitors (ICI + TKI) in patients (pts) with intermediate or poor (I/P) risk metastatic clear cell renal cell carcinoma (mccRCC).Org: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, Huntsman Cancer Institute at the University of Utah, University of Utah/Huntsman Cancer Institute,
Abstract
Impact of obesity on immune-related adverse events and tyrosine kinase inhibitor side effects in patients with metastatic renal cell carcinoma (mRCC).Org: Roswell Park Cancer Institute, Buffalo, NY, Buffalo, IL, Roswell Park Comprehensive Cancer Center,
Abstract
Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39.Org: University of California Irvine Medical Center, Santa Creu i Sant Pau Hospital, Seattle Cancer Care Alliance, IDIVAL, Barts Cancer Centre QMUL,
Abstract
Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden.Org: St Bartholomew’s Hospital, Centre Jean Bernard, Yamagata University Faculty of Medicine, Englander Institute for Precision Medicine, Meyer Cancer Center,
Abstract
Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)—2-year event-free survival and safety data for Cohort H.Org: University Hospitals Case Medical Center, Piedmont Cancer Institute, P.C.,
Abstract
Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39.Org: Barts Cancer Centre, QMUL, London, United Kingdom, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY, Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent and Center for Oncological Research (CORE), Integrated Personalised and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium, Charing Cross Hospital, London, United Kingdom, University of California, Los Angeles Medical Center, Los Angeles, CA,
Abstract
Age and other criteria influencing nontreatment of patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a physician survey in five European countries (Eu5).Org: Precision Value and Health, Nova Southeastern College of Pharmacy,
Abstract
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.Org: Jagiellonian University Medical College Hospital, Kraków, N.N Blokhin National Medical Research Center of Oncology, Reinier de Graaf Gasthuis, Delft,
Abstract
Analyzing disparities in socioeconomic factors, clinical characteristics, and outcomes in bladder cancer: Insights from the National Cancer Database (NCDB).Org: Inova Schar Cancer Institute, Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University, Georgetown University Medical School,
Abstract
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with histological subtypes.Org: INSERMU981, Billerica, Darmstadt,
Abstract
Correlation of peripheral blood monocytic myeloid-derived suppressor cells (M-MDSC) and T-cell receptor (TCR) dynamics with clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with nivolumab (NIVO).Org: Memorial Sloan Kettering Cancer Center, Adaptive Phage Therapeutics, Genitourinary Oncology Service, Weill Cornell Medical College University,
Abstract
Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC).Org: Vasgene Therapeutics, Inc, Newark, NJ, Orlando, FL,
Abstract
Inferring PDL-1 status from H&E images using digital pathology to identify patients responsive to anti-PD(L)-1 immuno-oncology therapy for bladder cancer trials.Org: J&J Innovative Medicine, J&J Innovative Medicine, San Diego, CA, J&J Innovative Medicine, Raritan, NJ, J&J Innovative Medicine, Spring House, PA, Johnson & Johnson Innovative Medicine, Cambridge, MA, Research & Development,
Abstract
Response and outcomes with immune checkpoint inhibitor (ICI) in patients (pts) with urothelial carcinoma (UC) and subtype histology (SH).Org: NYC Health + Hospitals/Jacobi, Attiko Hospital, Marqués de Valdecilla Universitary Hospital,
Abstract
Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB).Org: James P. Wilmot Cancer Center - Pluta, University of Rochester Medical Center, Memorial Sloan Kettering Cancer Center, Genitourinary Oncology Service, Weill Cornell Medical College University,
Abstract
Multi-omic analysis of the prognostic and predictive value of LAG3 expression in urothelial carcinoma.Org: Department of Genitourinary Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of Virginia Comprehensive Cancer Center, Department of Translational Genomics, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Department of Surgical Oncology, Roswell Park Cancer Institute, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center,
Abstract
Disparities in trends in bladder cancer mortality between urban and rural patients: A 2000-2020 analysis.Org: Cleveland Medical Center, University Hospitals and Case Western Reserve University, University Hospitals of Seidman Cancer Center/Case Comprehensive Cancer Center,
Abstract
FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro).Org: Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Greenberg Bladder Cancer Institute,
Abstract
A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).Org: Cancer Therapy Evaluation Program - National Cancer Institute,
Abstract
Updated results from a phase II study of penpulimab plus anlotinib as first-line therapy in metastatic urothelial cancer (mUC).Org: Medical Ethics Committee of Chinese PLA General Hospital, the First Medical Center of Chinese PLA General Hospital,
Abstract
Tumor-specific MHC class II upregulation associated with response to anti-PD-L1 therapy in patients with urothelial cancer.Org: Antwerpen,
Abstract
Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results.Org: Memorial Sloan Kettering Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center,
Abstract
Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression.Org: School of Life Science and Technology, Tonji Univesity,
Abstract
SOGUG-Vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer.Org: Toledo, Spain, Santiago De Compostela, Spain, Sevilla, Spain, Oviedo, Spain, Huelva, Spain,
Abstract
Longitudinal analysis of circulating tumor DNA in localized and metastatic urothelial cancer.Org: University of Oklahoma College of Medicine, Department of Medical Oncology & Experimental Therapeutics, San Diego Health,
Abstract
Landscape analysis and oncologic outcomes in advanced urothelial carcinoma (UC) by NECTIN4 RNA expression.Org: University of California, San Diego, Moores Cancer Center, La Jolla, CA, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Caris Life Sciences, Irving, TX, Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida,
Abstract
Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC).Org: Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, Ziauddin Medical University, Karachi, Pakistan, Canyon Vista Medical Center, Sierra Vista, AZ, University of Arizona, Tucson, AZ, Rashid Latif Medical College, Lahore, Pakistan,
Abstract
ERBB2 mutations and association with molecular phenotype in urothelial carcinoma.Org: Dana-Farber Cancer Institute, Yale University School of Medicine, Yale School of Medicine, Yale Cancer Center, Yale University,
Abstract
Combined high-resolution H3K27ac epigenomic and single-cell transcriptional profiling as a signature predictive of response to neoadjuvant immune checkpoint inhibitors (ICI) in urothelial cancer (UC).Org: CFCE, Servicio de Urología, Hospital Universitario de Bellvitge, Irsicaixa - IGTP,
Abstract
A multi-institutional observer study of AI-aided oncologists' performance on treatment response assessment of bladder cancer.Org: Penn State Cancer Institute, University of Michigan, University of Iowa Holden Comprehensive Cancer Center, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan,
Abstract
Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim analysis of the atezobladderpreserve phase II trial (SOGUG-2017-A-IEC(VEJ)-4).Org: Medical Oncology Department-Complejo Hospitalario Universitario de Ourense, Hospital Universitari Parc Taulí, HU Sant Joan de Reus, Hospital Universitario San Cecilio, Medical Oncology Department, Fundació Althaia,
Abstract
Tumor fraction and copy number burden from urinary cell-free tumor DNA (utDNA) to predict minimal residual disease prior to repeat-transurethral resection in high-risk non-muscle invasive bladder cancer (HR-NMIBC).Org: Oschner Medical Center, Northwestern University, Department of Urology, Feinberg School of Medicine,
Abstract
A phase II clinical trial of toripalimab combined with cisplatin plus gemcitabine chemotherapy as neoadjuvant treatment for muscle-invasive bladder cancer.Org: Affiliated Hospital of Medical School, Nanjing University,
Abstract
Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).Org: Memorial Sloan Kettering Cancer Center, Barts Cancer Institute, Queen Mary University of London, Genitourinary Oncology Service, Weill Cornell Medical College University,
Abstract
Phase II trial of intravesical camrelizumab in BCG-unresponsive high-risk non-muscle invasive bladder cancer.Org: Tong Ji University,
Abstract
FGFR3-mutated urothelial carcinoma of bladder and upper tract including ureter and renal pelvis: A comparative genomic profiling study.Org: Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Medicine, Division of Hematology/Oncology, University of Washington, Fred Hutchinson Cancer Center, Department of Pathology, SUNY Upstate Medical University,
Abstract
Outcomes of patients with bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer who demonstrated nonresponse to pembrolizumab in KEYNOTE-057: A post hoc analysis.Org: MSD Netherlands,
Abstract
Differentiating between adrenocortical carcinoma and pheochromocytoma by radiomics features at CT: A multi-institutional retrospective study.Org: State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Zhongshan School of Medicine,
Abstract
Cost effectiveness analysis of nadofaragene firadenovec for the treatment of high-risk, bacillus Calmette-Guerin–unresponsive, non-muscle invasive bladder cancer from a US third-party payer perspective.Org: Analysis Group Inc.,
Abstract
Clinical efficacy and biomarker analysis of pre-operative ipilimumab plus nivolumab in stage III urothelial cancer: The NABUCCO trial update.Org: Netherlands Cancer Institute, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, University Medical Center Utrecht,
Abstract
Final results of CORE-001: A phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.Org: Division of Urology, Perelman School of Medicine at the University of Pennsylvania, BCG Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chesapeake Urology, Spokane Urology,
Abstract
Prognostic factors of relapse in surgically resected small cell neuroendocrine carcinomas of the urothelial tract (SCNEC-URO).Org: Department of Internal Medicine, University of Michigan, Division of Pathology and Laboratory Medicine,
Abstract
Survival outcomes of small cell variant bladder cancer: Analysis from nationwide study.Org: Wyckoff Heights Medical Center,
Abstract
Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma.Org: James J. Peters VAMC, Genitourinary Malignancies Branch, NCI, National Institutes of Child Health and Human Development, Clinical Pharmacology Program,
Abstract
Updated interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma.Org: Winship Cancer Institute of Emory University, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA,
Abstract
Comparing treatment modalities for T2N0M0 muscle invasive bladder cancer: A propensity score analysis with the National Cancer Database.Org: Weston Hospital, Maroone Cancer Center,
Abstract
FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors.Org: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Carbone Cancer Center, University of Wisconsin, Madison, WI, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL,
Abstract
Phase 2 trial for sequential treatment of high dose cabozantinib (CABO) or CABO plus nivolumab (NIVO) on/after progression on CABO monotherapy in advanced renal cell carcinoma (RCC): Seq-Cabo.Org: Peter O’Donnell Jr. School of Public Health,
Abstract
NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).Org: NRG Oncology Statistics and Data Management Center, Philadelphia, PA, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, University Hospitals Seidman Cancer Center, Cleveland, OH, Massachusetts General Hospital, Harvard Medical School, Boston, MA, Radiology School of Medicine, University of California, San Francisco, San Francisco, CA,
Abstract
PRadR: PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer, a multicentric phase I/II.Org: Institut de Recherche en Cancérologie de Montpellier, Inserm U1296, Department of Nuclear Medicine, Grenoble Alpes University Hospital, Nuclear Medicine Department, Centre Jean Perrin, UNIV Lyon-Université Claude Bernard Lyon 1,
Abstract
Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study.Org: Barts Health NHS Trust Saint Bartholomew’s Hospital,
Abstract
Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
Phase 2 study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma (RCC): FORTUNE trial.Org: Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI,
Abstract
Enfortumab vedotin plus pembrolizumab in the treatment of locally advanced or metastatic bladder cancer of variant histology: A phase II study.Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Department of Pathology, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University, Atlanta, GA,
Abstract
Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587).Org: University of California, San Diego (UCSD), Hematology/Oncology, Weill Cornell Medicine, Pelotonia Institute for Immuno-Oncology and Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center,
Abstract
Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).Org: IRCCS San Raffaele Hospital and Scientific Institute, Division of Hematology/Oncology, UCLA David Geffen School of Medicine,
Abstract
Effect of antibiotic, proton pump inhibitor, H2 blocker, metformin and statin use on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting.Org: John D. Dingell VA Hospital,
Abstract
Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO).Org: Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, AdventHealth Cancer Institute, The Lank Center for Genitourinary Oncology,
Abstract
Prevalence of HER3 expression in prostate adenocarcinoma and its clinicopathological characteristics.Org: The Edward P. Evans Foundation Precision Oncology Center of Excellence, Washington DC VA Medical Center, George Washington University Milken Institute School of Public Health, Department of Biostatistics and Bioinformatics, George Washington University Milken Institute School of Public Health,
Abstract
68Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study.Org: Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) IRCCS, Meldola, Italy,
Abstract
SOGUG-NEOWIN: A phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations.Org: University of Sheffield, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy Département d'Organisation du Parcours Patient, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,
Abstract
A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2.Org: University Paris Saclay,
Abstract
INSIGHT-005: A new stratum of the explorative, open-labeled, phase I INSIGHT study to evaluate the feasibility and safety, as well as preliminary efficacy, of subcutaneous injections with IMP321 (eftilagimod alpha) in combination with PD-L1 inhibitor (avelumab) for metastatic or unresectable locally advanced urothelial carcinoma (UC)—IKF-s614.Org: Universitätsklinik Tübingen, Klinik für Urologie, University Medical Center of the Johannes Gutenberg-University Mainz, Hematology Oncology Practice Eppendorf (HOPE), University Cancer Center Hamburg (UCCH),
Abstract
Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO.Org: University of Southampton Faculty of Medicine, Action on Bladder Cancer, Veracyte, Inc, Decipher Biosciences,
Abstract
ENLIGHTED phase 3 study: Efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) for treatment of low-grade upper tract urothelial cancer (LG UTUC).Org: Carolina Urologic Research Center and GenesisCare US, Steba/Impact Biotech, Weizmann Institute of Science, Memorial Sloan Kettering Cancer Center,
Abstract
NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring.Org: Division of Oncology/Unit of Urology, Urological Research Institute, Urology Unit,
Abstract
Safety and immunological effects of ablative radiotherapy followed by pembrolizumab in patients with advanced adrenocortical carcinoma.Org: Memorial Sloan Kettering Cancer Center, New York, NY, Department of Epidemiology & Biostatistics,
Abstract
A phase II multicenter study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors (E-VIRTUE).Org: Genitourinary Malignancies Branch, CCR, NCI, NIH, Bethesda, MD, Laboratory of Pathology, CCR, NCI, NIH, Bethesda, MD, Urologic Oncology Branch, CCR, NCI, NIH, Bethesda, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, Biostatistics and Data Management Section, OCD, NCI, NIH, Bethesda, MD,
Abstract
Evaluation of homologous recombination repair (HRR) status in metastatic prostate cancer by next-generation sequencing and functional tissue-based immunofluorescence assays.Org: Urology Department, Cancer Genomics Group, Radiotherapy Oncology Department, Hospital ALTHAIA, Hospital de Granollers,
Abstract
A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (LASER).Org: Genitourinary Malignancies Branch, NCI,
Abstract
SMART: A phase II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer.Org: Genitourinary Malignancies Branch, CCR, NCI, NIH, Bethesda, MD, New York University Grossman School of Medicine, New York, NY, Urologic Oncology Branch, CCR, NCI, NIH, Bethesda, MD, Radiology and Imaging Sciences, CCR, NCI, NIH, Bethesda, MD, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD,
Abstract
A phase 1/2 study of EG-70 (detalimogene voraplasmid) intravesical monotherapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.Org: EnGene Inc.,
Abstract
A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design.Org: Davis Comprehensive Cancer Center, Swog Gu Bladder Patient Advocate,
Abstract
Discovery of a novel non-negative matrix factorization (NMF)-based homologous recombination deficiency (HRD) score and subsequent exploration in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).Org: Pfizer Oncology Global Medical Affairs,
Abstract
Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS.Org: Divisions of Medical Oncology and Urology, Bayer Consumer Care AG,
Abstract
Dissecting the significance of ACP1 gene alterations in prostate cancer (PCa).Org: Cleveland Clinc, Caris Life Sciences, Irving, TX, Caris life sciences and the University of South Carolina, Huntsman Cancer Institute, Miami Cancer Institute - Baptist Health South Florida,
Abstract
Clinical and genomic landscape of neuroendocrine prostate cancer (NEC) vs. prostate adenocarcinoma (AdenoK).Org: Huntsman Cancer Institute - University of Utah,
Abstract
Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).Org: Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, The Urology Center of Colorado, National Center for Tumor Diseases (NCT), Heidelberg University Hospital,
Abstract
PHAROS, a real-world multi-country European study on patients with high-risk localised and locally advanced prostate cancer receiving radical treatment.Org: Janssen-Cilag SAS,
Abstract
Exploration of circulating tumor cell (CTC) conversion and CTC0 as prognostic biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).Org: AZ Groeninge, European Health Centre, Otwock & Postgraduate Medical Education Center,
Abstract
Association between body mass index and physical activity among prostate cancer survivors.Org: University of North Dakota School of Medicine and Health Sciences,
Abstract
Metastatic pure seminomas with early relapse: Prognostic roles of high dose chemotherapy and surgery of residual disease.Org: Institut de Cancérologie Jean Godinot, University Hospital St André,
Abstract
Impact of mental health illness (MHI) prior to prostate cancer (PC) diagnosis (Dx) on treatment (Tx) received and PC outcomes.Org: Wellstar MCG Health/Georgia Cancer Center, Durham VA Health Care System, Durham Veterans Affairs Health Care System, University of Texas Medical Branch at Galveston,
Abstract
Adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study.Org: The First Affiliated Hospital of Xi'an Jiaotong University,
Abstract
Predictors of long-term prostate cancer mortality in men continuing prostate-specific antigen screening after age 70.Org: Department of Radiation Oncology, Rogel Cancer Center,
Abstract
Utilization patterns and outcomes of radiotherapy for patients with germ cell tumor relapsing with brain metastases, with a focus on stereotactic radiosurgery.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Prognostic reclassification and survival outcomes in intermediate- and poor-risk nonseminomatous germ cell tumors (NSGCT).Org: Advanced Centre for Treatment, Research and Education in Cancer (ACTREC),
Abstract
Longitudinal evaluation of circulating tumor DNA (ctDNA) as a prognostic biomarker to detect minimal residual disease (MRD) in testicular cancer.Org: Department of Urology, Icahn School of Medicine at Mount Sinai,
Abstract
Management of relapsed stage I nonseminomatous germ-cell tumor with retroperitoneal only relapse.Org: Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University Simon Comprehensive Cancer Center, Indiana University – Purdue University Indianapolis,
Abstract
Management of progressive brain metastases in patients (pts) with relapsed germ-cell tumor (GCT) treated with salvage high-dose chemotherapy (HDCT).Org: Indiana University Simon Cancer Center,
Abstract
Post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic pure seminoma.Org: Department of Urology, University Hospital Cologne, Cologne, Germany, Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, Department of Urology, University Hospital, Duesseldorf, Germany, Department of Urology, University Hospital of Cologne, Cologne, Germany, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany,
Abstract
Real-world evidence of overall survival (OS) and treatment patterns of patients (pts) with testicular germ cell tumors (GCT) receiving palliative chemotherapy in the United States.Org: Memorial Sloan Kettering Cancer Center, New York, NY, BioNTech, New Kensignton, PA, Analysis Group, Inc.,
Abstract
Multicenter analysis of high-dose chemotherapy (HDCT) regimens for the treatment of patients (pts) with recurrent germ cell tumors (GCTs).Org: City of Hope Comprehensive Cancer Center, UCLA Medical Center, UC Davis Comprehensive Cancer Center, Department of Medical Oncology and Therapeutics Research, University of California, Davis Comprehensive Cancer Center,
Abstract
High dose chemotherapy in male patients with germ cell cancer: A population-based study by the SWENOTECA group.Org: Department of Immunology, Genetics & Pathology, Uppsala University, Uppsala, Sweden, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden, Department of Oncology, Oslo University Hospital, Oslo, Norway, The Cancer Clinic, St. Olavs University Hospital, Trondheim, Norway, Department of Oncology, Skåne University Hospital, Lund, Sweden,
Abstract
Long term cardiovascular adverse outcomes in testicular cancer survivors: Real-world U.S. population-based study.Org: University of Pennsylvania, Conshohocken, Abramson Cancer Center, Indian University Simon Comprehensive Cancer Center, University Medical Center Groningen,
Abstract
Survival associated with chemotherapy and prognostic biomarkers in penile cancer at a reference hospital in the Northeast Brazil from 2000 to 2021.Org: Hospital Haroldo Juaçaba, Instituto do Câncer do Ceará, Ceará Cancer Institute,
Abstract
Implications of HPV infection on survival outcomes in patients with penile squamous cell carcinoma: Insights from a nationwide study.Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Miami, FL, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, William Beaumont University Hospital,
Abstract
Molecular and clinical correlates of high PSMA/FOLH1 mRNA expression in primary and metastatic prostate cancer (PC).Org: The Medical College of Wisconsin, Department of Medicine, Division of Hematology and Oncology,
Abstract
Association of tumor genetics with outcomes in patients (pts) with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617.Org: Oncologia D'Or,
Abstract
A phase 1, multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors.Org: Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, Coherent Biopharma, Suzhou, China,
Abstract
Albumin-bound paclitaxel, cisplatin, and bleomycin combination with tislelizumab for stage IV squamous cell carcinoma of the penis without surgical indications: A single-arm, single-center prospective phase II clinical study.Org: Cancer Hospital of HuanXing ChaoYang District Beijing,
Abstract
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Secondary analysis of the SPARTAN trial.Org: Division of Urology and Surgical Oncology, Guy's, King's, and St. Thomas' Hospitals,
Abstract
Fractionated docetaxel (D) and radium 223 (Ra223) in metastatic castration-resistant prostate cancer (CRPC): A modular phase I trial.Org: The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute,
Abstract
Patient-reported outcomes (PROs) for rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC): An analysis of the CHART randomized, open-label, phase 3 trial.Org: Department of Urology Surgery, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Department of Urology, Sun Yat-sen University Cancer Center, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, The Second Affiliated Hospital of Xi'an Jiaotong University, The First Affiliated Hospital of the Army Medical University,
Abstract
Real-world comparative effectiveness and cardiovascular safety of enzalutamide versus abiraterone amongst older men diagnosed with metastatic castration-resistant prostate cancer.Org: University of Illinois-Chicago, University of Illinois- Chicago,
Abstract
Real-world baseline treatment patterns and overall survival (rwOS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in the United States.Org: ConcertAI, LLC,
Abstract
PLATIPARP: A phase 2 study of induction docetaxel and carboplatin followed by maintenance rucaparib in treatment of patients with mCRPC with homologous recombination DNA repair deficiency.Org: Fred Hutchinson Cancer Center, Division of Hematology & Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, University of Washington/Fred Hutch Cancer Center, Department of Laboratory Medicine and Pathology, University of Washington,
Abstract
Matching-adjusted indirect comparisons (MAICs) of talazoparib plus enzalutamide (TALA+ENZA) versus olaparib plus abiraterone and prednisone/prednisolone (OLAP+AAP) for first-line (1L) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair mutations (HRRm)/BRCAm.Org: EVERSANA, Burlington, ON, Canada,
Abstract
BRCA1/2 reversion mutations (BRCArev) in advanced prostate cancer in the absence of prior PARP inhibitor (PARPi) therapy.Org: Foundation Medicine, Inc., Cambridge, MA, Cedars-Sinai Medical Center, SUNY Upstate Medical University, University of California, San Diego Health,
Abstract
Race and decisional conflict about genetic testing in patients with advanced prostate cancer.Org: Henry Ford Hospital, Henry Ford Health System, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Henry Ford Cancer Institute, Detroit, MI,
Abstract
Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).Org: Severance Hospital Yonsei University Health System, University of Auckland, Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, National Yang Ming Chiao Tung University,
Abstract
Association of genomic alterations with clinical outcomes following lutetium-177-PSMA vipivotide tetraxetan in men with metastatic castrate-resistant prostate cancer.Org: Solove Research Institute,
Abstract
Biomarker assessment and pharmacology of HP518, an AR PROTAC degrader from the phase 1 dose-escalation study in patients with metastatic castration-resistant prostate cancer (mCRPC).Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Border Medical Oncology Research Unit, Albury Wodonga Regional Cancer Centre & Rural Medical School, Albury Campus, University of New South Wales, Albury-Wodonga, NSW, Australia, Department of Clinical Medicine and Surgery, Università Federico II, Napoli, Italy, Chris O'Brien Lifehouse, The Alfred Hospital,
Abstract
Development of a machine learning model to predict overall survival results from randomized clinical trials of patients with metastatic prostate cancer.Org: Janssen Research and Development La Jolla, Research & Development, Johnson and Johnson Innovative Medicine, Johnson & Johnson Medical China,
Abstract
Site versus central read discrepancy rates in PCWG3 evaluation for progression.Org: Clario, Philadelphia, PA, PainReform,
Abstract
Plasma tumour DNA dynamics and circulating subclones patterns in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel in a prospective biomarker trial (NCT03381326).Org: UCL Cancer Institute, London, United Kingdom, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori", Meldola, Italy, Department of Cellular, Computational and Integrative Biology - University of Trento, Trento, Italy, Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, Italy, Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy,
Abstract
METRADS-P vs. RECIST/PCWG criteria to detect disease progression in metastatic castration-resistant prostate cancer (mCRPC).Org: Clinical Trials and Statistics Unit, Fondazione Policlinico Gemelli IRCCS,
Abstract
Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC).Org: Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, Private Medical Institution, Euromed service, St Petersburg, Russian Federation, START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain, Department Of Medicine, Norwalk Hospital, Nuvance Health, Norwalk, CT, Pfizer Inc., Collegeville, PA,
Abstract
ODM-209, a CYP 11A1 inhibitor in patients with mCRPC: Results from the STESIDES phase 1 study.Org: Rigshospitalet University Hospital of Copenhagen, HUCH, Finland, Tampere University Hospital (TAYS), Espoo,
Abstract
A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC).Org: University of California Medical Center, Departments of Radiology and Biomedical Imaging, Pharmaceutical Chemistry, Radiology and Biomedical Imaging,
Abstract
Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).Org: Department of Theranostics and Nuclear Medicine, Cancer Imaging, Prostate Cancer Theranostics and Imaging Centre of Excellence, Perth, Western Australia, Australia, ANZUP Cancer Clinical Trials Group,
Abstract
Dynamic androgen receptor alterations (ARa) ctDNA profiles and clinical outcomes in metastatic prostate cancer (mPC).Org: University of San Diego,
Abstract
Race and association between ADT and adverse events.Org: Department of Computational Biomedicine,
Abstract
Rezvilutamide (REZ) plus docetaxel (DOC) in patients (pts) with chemo-naïve metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone (ABI).Org: Clinical Trial Center and National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, China, Department of Urology Surgery, Hunan Cancer Hospital, Changsha, China, Uro-Oncology, Chongqing University Cancer Hospital, Chongqing, China, Urological Oncology, Sichuan Cancer Hospital, Chengdu, China, Urinary Surgery, The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University, Chongqing, China,
Abstract
Rapid and deep prostate-specific antigen (PSA) response to apalutamide plus ADT and survival in metastatic castration-sensitive prostate cancer (mCSPC) in real world practice in the US (OASIS Project).Org: Department of Global Real-World Evidence, Janssen Pharmaceuticals LLC, Janssen Pharmaceuticals Inc, Department of Janssen Data Science,
Abstract
Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).Org: Monash University Eastern Health Clinical School, Monash Cancer Centre, Sydney Adventist Hospital, Mater Misercordiae University Hospital, Guy's, King's, and St. Thomas' Hospitals, and Sarah Cannon Research Institute,
Abstract
The effect of ACEi/ARB on survival outcome of patients with mCRPC treated with abiraterone.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China, The Sixth Affiliated Hospital of Sun Yat-Sen, Guangzhou, China,
Abstract
Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study.Org: Huntsman Cancer Institute at the University of Utah, SWOG Statistics and Data Management Center, Seattle, WA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, University of Kentucky, Lexington, KY,
Abstract
Validation of a digital pathology-based multimodal artificial intelligence model in oliogmetastatic castration-sensitive prostate cancer, including in patients from the STOMP and ORIOLE phase II randomized clinical trials.Org: Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD Anderson Cancer Center, New Brunswick, NJ,
Abstract
Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).Org: Centre for Integrative Biology, Department of Cellular, Computational and Integrative Biology,
Abstract
Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).Org: Chesapeake Urology Research Associates, Duke Cancer Network,
Abstract
Prognostic value of baseline circulating tumor DNA (ctDNA) tumor fraction (TF) in metastatic hormone-sensitive prostate cancer (mHSPC).Org: Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Foundation Medicine, Inc., Cambridge, MA, Cambridge, MA,
Abstract
Treatment outcomes for patients with Ga68-PSMA-PET prostate cancer (PC) with or without conventional imaging correlates.Org: The University of Texas Southwestern Medical Center,
Abstract
Resources to address challenges in first-line treatment intensification in metastatic castration-sensitive prostate cancer (mCSPC): A discrete choice experiment.Org: Department of Urology and Department of Population Health, NYU Langone Health, New York, NY, Throughline Strategy, Toronto, ON, Canada, Birmingham City University, Birmingham, United Kingdom,
Abstract
EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL).Org: Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Memorial Sloan Kettering Cancer Center, Vancouver Prostate Centre, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori,
Abstract
Abiraterone with discontinuation of gonadotropin-releasing hormone (GnRH) analogues in patients (pts) with metastatic prostate cancer (PC): A single arm, phase II study.Org: Montefiore Medical Center Department of Surgery,
Abstract
Prognostic validation of a digital pathology-based multi-modal artificial intelligence (MMAI) biomarker in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the CHAARTED trial (ECOG-ACRIN EA3805).Org: University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, University College London, London, United Kingdom, South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, SA, Australia,
Abstract
PROact: A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in patients with metastatic hormone sensitive prostate cancer with HRR gene mutation.Org: Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Institute of Urology, Nanjing University, Nanjing, China,
Abstract
Hematologic toxicity in 177lu-PSMA-617 treatment for mCRPC: Unraveling the impact of PSMA PET bone tumor volume (PSMA-bTTV).Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center, Division of Hematology & Oncology,
Abstract
Whole exome correlates in metastatic hormone sensitive prostate cancer (mHSPC): Results from E3805 CHAARTED.Org: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, University College London Cancer Institute, South Australian Immunogenomics Cancer Institute, University of Adelaide,
Abstract
Impact of alterations in tumor suppressor genes (TSG-alt) on survival outcomes in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC) receiving androgen deprivation therapy (ADT) with androgen receptor pathway inhibition (ARPI) or docetaxel.Org: Huntsman Cancer Insititute,
Abstract
Association of androgen receptor gene expression signature and ARV7 with clinical outcome in metastatic hormone-sensitive prostate cancer.Org: Catalan Institute of Oncology-Badalona, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Applied Research Group in Oncology (B-ARGO), Germans Trias I Pujol Research Institute,
Abstract
Post-progression survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide or placebo: Post hoc analysis of ARASENS.Org: Bayer Ltd, Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain,
Abstract
Therapeutic strategy for targeting recurrent oncogenic kinase gene fusions in prostate cancer.Org: Caris Life Sciences Research and Development, Caris Life Sciences, Irving, TX,
Abstract
Sexual health outcomes in sexual minority vs. heterosexual men after prostate radiotherapy.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, Medical College of Wisconsin, Division of Infectious Diseases,
Abstract
Clinical characteristics and treatment patterns of patients with high-risk localized prostate cancer (HR LPC) treated with radical prostatectomy (RP) and perioperative hormonal therapy (HT) in Japan, South Korea, and Taiwan.Org: Akita University Graduate School of Medicine, Regional Medical Affairs, Johnson & Johnson Innovative Medicine Asia Pacific, Janssen China Research & Development, IQVIA Real-World Solutions Asia-Pacific,
Abstract
A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC).Org: Froedtert & Medical College of Wisconsin, Department of Neurobiology and Anatomy,
Abstract
Impact of pre-treatment MRI capsular involvement and extraprostatic extension on metastasis free and overall survival in localized prostate cancer.Org: Duke Cancer Center,
Abstract
Independent blinded validation of an AI-based digital histology classifier for prostate cancer recurrence and metastasis risk prediction.Org: Glickman Urological & Kidney Institute, PathomIQ, Inc., Center for Urologic Oncology, Department of Urology and Tisch Cancer Institute, Cleveland Clinic Glickman Urology and Kidney Institute,
Abstract
Immunologic effects of B cell depletion on T cells in high-risk prostate cancer.Org: University of California, San Diego Center for Advanced Laboratory Medicine, MaineHealth Cancer Care,
Abstract
Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL).Org: American College of Radiology, Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Minnesota Oncology Hematology PA - Maplewood, CentraCare Health System, Marin Cancer Institute,
Abstract
Prognostic impact of residual cancer burden (RCB) on long-term outcomes after neoadjuvant (neo) androgen receptor pathway inhibitor (ARPI) and radical prostatectomy (RP) for high-risk localized prostate cancer (HRLPC): A pooled analysis of phase 2 trials.Org: Dana-Farber Cancer Institute, Indiana University – Purdue University Indianapolis, Department of Data Sciences, Beth Israel Deaconess Medical Center, University of California Irvine,
Abstract
Germline gene-specific associations in a large prostate cancer cohort.Org: Invitae Corporation, Division of Hematology & Oncology, University of Washington & Fred Hutchinson Cancer Center,
Abstract
Mutational burden among patients with metastatic prostate cancer differs by race in 3 key genes: An analysis of genomic and clinical data from the AACR Project GENIE biopharma collaborative in cBioPortal.Org: Florida A&M University,
Abstract
Socio-economic disparities in prostate cancer hospitalizations and outcomes across the United States.Org: Lincoln Medical and Mental Health Center, University of Benin Teaching Hospital,
Abstract
COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy.Org: XCancer Omaha, Urology San Antonio, Tower Urology, New Mexico Cancer Center, Carolina Urologic Research Center and Atlantic Urology Clinics,
Abstract
Willingness of patients with biochemically recurrent prostate cancer (BCR) with positive 18F-dcfpyl PET/CT PSMA to monitor without treatment.Org: Molecular Imaging Program,
Abstract
Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease.Org: Saint Louis VA Medical Center, University of Massachusetts Lowell, St. Louis Veterans Affairs Medical Center,
Abstract
A phase II trial of enfortumab vedotin for locally advanced and metastatic squamous cell carcinoma of the penis.Org: Mayo Clinic Rochester, Rochester, MN, Mayo Clinic Arizona, Mayo Clinic Florida, Mayo Clinic Alliance Statistics and Data Center, Mayo Clinic,
Abstract
Informed decision-making about germline testing among Veterans with advanced prostate cancer (APC): A mixed-methods study.Org: San Francisco VA Health Care System, San Francisco VA Medical Center,
Abstract
A randomized phase 2 trial in progress of flexible and extended dosing of 177Lu-PSMA-617 molecular radioligand therapy in mCRPC (FLEX-MRT).Org: Department of Nuclear Medicine, School of Medicine, and Klinikum Rechts der Isar, Technical University of Munich, Department of Medicine Statistics Core (DOMStat), Department of Medicine's Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine,
Abstract
SAVE: A prospective, single-arm, single-center clinical study of disitamab vedotin in combination with toripalimab in patients with advanced penile cancer that has progressed or is intolerant to cisplatin chemotherapy.Org: Affiliated Cancer Hospital of Chongqing University,
Abstract
A phase 1b study of PSCA CAR T cells plus or minus radiation for the treatment of patients with PSCA+ metastatic castration-resistant prostate cancer.Org: Michelson Center for Convergent Bioscience,
Abstract
A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC).Org: Catalan Institute of Cancer (ICO), Celcuity, Inc., Département Interdisciplinaire D’organisation Du Parcours Patient (DIOPP),
Abstract
Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).Org: British Columbia Cancer Agency (BCCA), Vancouver Cancer Centre, Vancouver, BC, Canada, Huntsman Cancer Institute, Salt Lake City, UT, Cancer Institute Center for Prostate and Urologic Cancer, Duke University Medical Center, Durham, NC, Urologicum Duisburg, Duisburg, Germany, Centre Hospitalier de Quimper, Institut de Cancérologie de Cornouaille (ICC), Brest, France, Kagawa University, Kagawa, Japan, Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey, Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, AstraZeneca, Gaithersburg, MD, AstraZeneca, Cambridge, United Kingdom, Peter MacCallum Cancer Centre, Melbourne, Australia,
Abstract
CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy: Phase 3 MK-5684-003 trial.Org: Fred Hutchinson Cancer Center, University of Washington and Fred Hutchinson Cancer Research Centre, Merck & Co., Inc., Rahway, NJ, University of Minnesota Masonic Cancer Center, Minneapolis, MN,
Abstract
LIBERTAS: A degendered and transgender-inclusive phase 3 study of apalutamide (APA) plus intermittent vs continuous androgen deprivation therapy (ADT) in participants (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).Org: Janssen Research & Development, Brisbane, CA, Hospital Aranda de la Parra, Guanajuato, Mexico, West China Hospital of Sichuan University, Sichuan, China, NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, NY, Janssen Research & Development, Titusvillle, NJ,
Abstract
Veterans Affairs seamless phase II/III randomized trial of standard systemic therapy with or without PET-directed local therapy for oligometastatic prostate cancer (VA STARPORT).Org: Hines VA, Hines, IL, Houston VA Medical Center, Richmond, VA, Radiation Oncology Service,
Abstract
A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101).Org: Wayne State University, Detroit, MI, Montefiore Einstein Cancer Center, Bronx, NY, Roger Maris Cancer Center, Fargo, ND, University of California, San Diego, La Jolla, CA, Icahn School of Medicine at Mount Sinai,Tisch Cancer Institute, New York, NY,
Abstract
A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.Org: Oncternal Therapeutics, Inc.,
Abstract
CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA: Phase 3 MK-5684-004 study.Org: Roanoke, University Hospital Freiburg,
Abstract
TRAMP study: A phase 2 trial of tumor necrosis factor-α blockade and AR inhibition in men with CRPC.Org: Division of Hematology & Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Fred Hutchinson Cancer Research Center,
Abstract
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer.Org: Mayo Clinic Rochester, Rochester, MN, Clarity Pharmaceuticals, XCancer Omaha, Omaha, NE, Washington University in St. Louis, Mayo Clinic,
Abstract
Darolutamide plus androgen-deprivation therapy in patients with high-risk biochemical recurrence of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).Org: Universitätsklinikum rechts der Isar, Technical University Munich, Carolina Urologic Research Center and Genesis Care/Atlantic Urology Clinics, Loos, France, Espoo, Finland, Institut Gustave Roussy, University of Paris Saclay,
Abstract
A randomized phase II study of ADT + abiraterone versus ADT + abiraterone + docetaxel in patients with low-volume metastatic hormone-sensitive prostate cancer.Org: Northwestern University, Feinberg School of Medicine,
Abstract
Debunking the frailty-sarcopenia-ADT axis in metastatic prostate cancer with multicomponent exercise: The FIERCE trial.Org: Roslindale, MA, Massachusetts Institute of Technology,
Abstract
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.Org: GenesisCare, Fort Myers, FL, Telix Pharmaceuticals (Innovations),
Abstract
Randomized PROSTATE-IQ trial to reduce ADT treatment burden for patients with biochemical recurrence after prostatectomy.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
Unveiling the unique identity of clear-cell endometrial cancer (CCEC): A comprehensive comparative analysis with ovarian counterpart and other endometrial subtypes.Org: Service de Génétique des Tumeurs,
Abstract
A phase 2 randomized trial of neoadjuvant enoblituzumab versus standard of care in men with high-risk localized prostate cancer: The help elucidate and attack longitudinally (HEAT) prostate cancer randomized study.Org: Division of Biostatistics and Bioinformatics,
Abstract
A phase 1 safety and feasibility study of intratumoral placement of bicalutamide implants combined with radiotherapy for localized prostate cancer.Org: Molecular Imaging Branch, Radiation Oncology Branch, Center for Interventional Oncology, San Carlos,
Abstract
CLARIFY: Positron emission tomography using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy (a phase 3 diagnostic study).Org: Atlantic Urology Clinics,
Abstract
Combination of cemiplimab and ISA101b vaccine for the treatment of recurrent/metastatic HPV16 cervical cancer.Org: Catholic University of Rome, Clínica de Neoplasias Litoral, University Hospital of Leuven, Leuven Cancer Institute, Barretos Cancer Hospital,
Abstract
Value of ctDNA-based molecular residual disease (MRD) in evaluating the adjuvant therapy effect in ovarian cancer.Org: Shenzhen Center,
Abstract
ALADDIN: Evaluation of darolutamide addition to androgen deprivation therapy and radiation therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases.Org: Georges Pompidou European Hospital, Pôle santé Léonard de Vinci, Centre d’oncologie et radiothérapie, ROC37, Finisterian Center of Radiotherapy and Oncology,
Abstract
A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune).Org: Department of Urology, University of California, San Diego,
Abstract
Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: Clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts.Org: Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China, Jiangsu Cancer Hospital, Nanjing, China, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi 'an, China, Zhejiang Provincial People’s Hospital, Hangzhou, China, The First people's Hospital of Changde, Changde, China,
Abstract
Specific vaginal and gut microbiome and the anti-tumor effect of butyrate in women with cervical cancer.Org: Kanghui Biotech lnc.,
Abstract
Efficacy and safety of enlonstobart (SG001), a PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer: A multicenter, single-arm, open-label, phase II study.Org: CSPC zhongqi pharmaceutical technology Co. Ltd.,
Abstract
Precision oncology for rare gynecologic malignancies: Integrating molecular tumor boards and real-time treatment matching.Org: Joint Department of Medical Imaging (University of Toronto), Genome Diagnostics,
Abstract
Nimotuzumab in combination with radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma: Results from a prospective, multicenter, open-label, single-arm trial.Org: Zhangzhou Hospital Affiliated to Fujian Medical University, The First Affiliated Hospital of Xi’an Jiaotong University, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Yantai Yuhunagding Hospital, The Affiliated Hospital of Southwest Medical University,
Abstract
A single-arm, phase II trial assessing the combination of AK105 and anlotinib in first-line treatment for persistent, recurrent, or metastatic cervical cancer.Org: The First Affiliated Hospital of Zhengzhou University, Zhengzhou Gensciences, China National Biotec Group,
Abstract
Evaluation of the effectiveness and safety of disitamab vedotin in HER2-expressing 2L recurrent or metastatic cervical cancer (r/mCC): Interim results of RC48-C018.Org: Union Hospital Tong Ji Medical Huazhong University Science And Technology, Shanghai, China, Qilu Hospital of Shandong University, Jinan, China, The First Affiliated Hospital of Xi 'an Jiaotong University, Xian, China, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China, Yunnan Cancer Hospital, Kunming, Kunming, China,
Abstract
Prognostic analysis of nimotuzumab combined with concurrent chemoradiotherapy in locally advanced cervical cancer: A multicenter real-world study.Org: The Second Xiangya Hospital of Central South University, Changsha, China, Changde Hospital, Xiangya School of Medicine, Changde, China, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China, The Central Hospital of Yongzhou, Yongzhou, China,
Abstract
Cervical cancer disparities in stage at presentation for disaggregated Asian Americans, Native Hawaiians, and Pacific Islanders.Org: University of the Philippines, Stanford Medicine, University of the Philippines - Manila, Memorial Sloan Kettering Cancer Center Department of Radiation Oncology,
Abstract
Beneath the surface: Exploring stress and bias in cervical cancer screening compliance.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, Weill Cornell Medical College University,
Abstract
Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.Org: Broward Health, Genmab US, Inc.,
Abstract
Molecular characterization of cervical cancer histological subtypes: The VENUS study.Org: Genome Diagnostics,
Abstract
Neoadjuvant chemo-immunotherapy following concurrent immuno-chemoradiotherapy and immune-maintenance therapy as primary treatment for locally advanced cervical cancer: A prospective, single-arm, phase 2 trial.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
Maximizing cervical cancer prevention in safety-net settings of care: Resources from the Federal Cervical Cancer Collaborative for provider and patient engagement.Org: US Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), Office of Women’s Health, Division of Cancer Epidemiology and Genetics, Office of Research on Women's Health,
Abstract
It takes a village: The impact of social and environmental factors on cervical cancer screening.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, Weill Cornell Medical College University,
Abstract
Clinico-molecular predictors of exceptional response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).Org: Ile de France,
Abstract
The efficacy of recombinant human adenovirus type 5 (H101) intra-tumor therapy in persistent/recurrent/metastatic gynecological cancer and the exploration of changes in tumor microenvironment.Org: The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China,
Abstract
Use of cell-free DNA from ascites to identify variants and tumour evolution in a cohort of patients with advanced ovarian cancer.Org: The Royal Hospital for Women,
Abstract
Differences in physical and emotional distress amongst patients undergoing neoadjuvant chemotherapy versus surgery for advanced ovarian cancer: Patient-reported outcomes at diagnosis.Org: Mayo Clinic, Rochester, MN,
Abstract
Avelumab with axitinib in persistent or recurrent cervical cancer after platinum-based chemotherapy (ALARICE study).Org: Department of Obstetrics and Gynaecology, Pokfulam, Yaumatei, Pamela Youde Nethersole Eastern Hospital, Chai Wan,
Abstract
Efficacy and safety of cadonilimab plus anti-EGFR monoclonal antibody as de-chemotherapy regimen in persistent, recurrent, or metastatic gynecologic cancer.Org: The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China,
Abstract
Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer.Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Pelvic ultrasound-based deep learning models for accurate diagnosis of ovarian cancer: Retrospective multicenter study.Org: Aemasue Corperation, Korean University Medical Center, Anam hospital,
Abstract
Tumor-informed ctDNA as an objective marker for postoperative residual disease in epithelial ovarian cancer.Org: Klinikum Starnberg, SAGA Diagnostics AB,
Abstract
Neoadjuvant combination treatment of olaparib and pembrolizumab for patients with HRD-positive advanced ovarian cancer.Org: Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan, Department of Gynecology, NHO Shikoku Cancer Center, Matsuyama, Japan, Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan, Department of Gynecology, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Evaluation of a novel extracellular vesicle (EV) based ovarian cancer (OC) screening test in asymptomatic postmenopausal women.Org: Mercy BioAnalytics, Inc., MRC Clinical Trials Unit,
Abstract
Using artificial intelligence-powered evidence-based molecular decision-making for improved outcomes in ovarian cancer.Org: Predictive Oncology,
Abstract
Phase 1 study of BAT8006, a folate receptor α antibody drug conjugate with strong bystander effect, in subjects with advanced solid tumors.Org: Phase I Clinical Research Center, Bio-Thera Solutions, Ltd, Biothera Solution Ltd, Bio-Thera Solution. Co., Ltd.,
Abstract
Efficacy, safety, and biomarkers of neoadjuvant niraparib monotherapy in homologous recombination deficiency (HRD) advanced ovarian cancer: A prospective, multicenter, phase II, single-arm NANT study.Org: Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, China, Department of Gynecological Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Shandong University, Jinan, China,
Abstract
Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets.Org: Centre Hospitalier Lyon Sud, Pierre-Benite, GINECO, Paris, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy, EA3738 Ciblage Thérapeutique en Oncologie, Oullins, UCBL EA3738 CICLY, Oullins,
Abstract
The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?Org: GSK, Flatiron Health, San Francisco, CA,
Abstract
A phase I single-arm, open-label trial of engineering tumor-infiltrating lymphocytes with membrane-bound IL-7 for recurrent ovarian cancer.Org: Department of Obstetrics and Gynecology, Shanghai Tenth People's Hospital, Shanghai, China, Shanghai Juncell Therapeutics Co., Ltd., Shanghai, China, Department of Radiology, Shanghai Tenth People's Hospital, Shanghai, China,
Abstract
Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.Org: GOG Foundation, National Cancer Center Korea, Hospital Universitario Virgen de Valme, Department of Cancer and Blood, Limited Liability Company MedPomosch,
Abstract
The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study.Org: Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,
Abstract
Overall survival (OS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance monotherapy: Update from the L-MOCA trial.Org: Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Department of Gynecologic Oncology, Cancer Hospital of The University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China, Department of Gynecologic Oncology, Anhui Provincial Cancer Hospital, Hefei, China, Department of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan, China, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China,
Abstract
First-in-human, phase I study of CBP-1008, a first-in-class bispecific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors.Org: Peking University School of Oncology, Harbin Medical University Caner Hospital, Beijing Obstertrics and Gynecology Hospital,
Abstract
PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.Org: TILT Biotherapeutics, Mayo Clinic, Docrates Cancer Center, Cancer Gene Therapy Group, Merck & Co., Inc.,
Abstract
Systematic review of frailty assessment in ovarian cancer studies.Org: Library and Information Services,
Abstract
Hospital challenges faced by frail patients with ovarian cancer and the adverse outcomes: A nationwide study.Org: Upstate Medical University, Brooklyn, NY, Nuvance Health/Vassar Brothers Medical Center, Poughkeepsie, NY, Lake Erie College of Osteopathic Medicine,
Abstract
Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery.Org: Department of Gynecologic Oncology & Reproductive Medicine, University of Texas at Austin,
Abstract
Anlotinib plus hormone therapy in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II study.Org: Xin Hua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Renji Hospital, Shanghai Jiaotong University School of Medicine,
Abstract
Beacon: A phase II study of bevacizumab, atezolizumab, and cobimetinib in patients with recurrent, platinum resistant, high grade serous ovarian cancer.Org: The Royal Women’s Hospital, Cancer Immunology Research,
Abstract
A phase II study of anlotinib plus albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or peritoneal carcinomar (A-Plus trial): Updated efficacy and safety.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,
Abstract
Association of physical activity with self-reported quality of life after primary chemotherapy for ovarian cancer.Org: University of Texas at Arlington,
Abstract
Real-world biomarker testing, treatment patterns and outcomes in a US cohort of patients with advanced ovarian cancer.Org: AstraZeneca Pharmaceuticals LP,
Abstract
Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates.Org: UMR981 Institut Gustave Roussy, Confluent Private Hospital, Hôpital Cochin, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité,
Abstract
Evaluation of prognostic and predictive values of bespoke circulating tumor DNA assay in patients with advanced epithelial ovarian cancer.Org: BGI Genomics, BGI-Shenzhen, Tianjin Medical Laboratory, BGI-Tianjin,
Abstract
Role of the receptor for advanced glycation end products (RAGE) in blood as a potential biomarker for progression to olaparib: A post hoc analysis of patients with platinum-resistant ovarian cancer (PROC) treated in the ROLANDO-GEICO 1601 trial.Org: Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain, Laboratory of Translational Oncology, Program in Solid Tumors, Cima-Universidad de Navarra, Cancer Center Clínica Universidad de Navarra CCUN, Navarra Institute for Health Research IdISNA, Department of Pathology, Anatomy & Physiology, Navarra University, Pamplona, Spain,
Abstract
An evaluation of cell-free tumor DNA from 20 mL of peritoneal fluid for homologous recombination deficiency (HRD) testing in newly diagnosed ovarian cancer (OC).Org: Gustave Roussy Institute, Villejuif, France, France, Institut Gustave Roussy, Gustave Roussy Cancer Center,
Abstract
Artificial intelligence to predict homologous recombination deficiency in ovarian cancer from whole-slide histopathological images.Org: Institut de Cancerologie de l'Ouest, Saint-Herblain, France, Pathology Department, IHP Group,
Abstract
Molecular profiling of plasma from matched NCI-MATCH gynecological cancers.Org: Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research,
Abstract
Intratumoral Ral-binding protein 1 (RalBP1) expression as a potential predictor of bevacizumab treatment efficacy in patients with ovarian cancer.Org: Department of Obstetrics and Gynecology and Comprehensive Cancer Center Munich, Klinikum der Universität München,
Abstract
Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic ovarian cancer: Results from a multi-center multi-country phase 1/2a expansion cohort.Org: Cohen Children's Medical Center,
Abstract
Evaluation of a novel signature for PARP inhibitor sensitivity prediction using real-world data.Org: Zephyr AI, Mclean, VA,
Abstract
Molecular and immune characterization of squamous cell ovarian cancers for identification of therapeutic targets.Org: Rutgers Robert Wood Johnson Medical School Department of Obstetrics and Gynecology,
Abstract
Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) trial: Mirvetuximab soravtansine (MIRV) vs. investigator’s choice chemotherapy (ICC) in older patients with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression.Org: Istituto Europeo Oncologia, Community Health Network, Inc, Wielkopolskie Centrum Onkologii, Department of Obstetrics and Gynecology, Faculty of Medicine,
Abstract
Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer.Org: Department of Physiology and Pharmacology, Faculty of Medicine, Tel-Aviv University, Department of Physiology and Pharmacology, Faculty of Medicine, Tel Aviv University,
Abstract
Targeting the CD47/TSP-1 axis: A promising strategy for patients with ovarian cancer (OC) that relapses on PARP inhibitors (PARPi).Org: Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Apmonia Therapeutics, CNRS UMR 7369 MEDyC - Reims University,
Abstract
Germline genetic profiles of women with ovarian malignancies: A Myriad Collaborative Research Registry study.Org: University of California, Los Angeles, David Geffen School of Medicine,
Abstract
Characterization of long-term survivors from four clinical trials examining patients with folate receptor alpha–positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine.Org: University Hospital Leuven, Leuven Cancer Institute and BGOG, Department of Medical Oncology, Clínica Universidad de Navarra, Bon Secours Hospital Cork and Cancer Trials Ireland, Heilbronn Women's Clinic, US Oncology Research, Texas Oncology and Gynecologic Oncology Group (GOG) Foundation,
Abstract
Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC).Org: Dana-Farber Cancer Institute, Guardant Health Inc., Brigham and Women's Hospital/Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Massachusetts General Hospital,
Abstract
Comparison of the clinical and genomic profiles of endometrial cancer in Appalachian and non-Appalachian patients.Org: Biostatistics and Bioinformatics Shared Resource Facility, John P. Murtha Cancer Center, Uniformed Services University and Walter Reed National Military Medical Center,
Abstract
Efficacy of niraparib in patients with advanced ovarian cancer: A meta-analysis of randomized controlled trials.Org: Federal University of the State of Rio de Janeiro, Rio De Janeiro, Faculdade Santa Marcelina, University of Brasilia, University of South Santa Catarina,
Abstract
Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer: FLORA-4 study.Org: Department of OB/GYN, Duke Cancer Institute of Duke University Health System, CanariaBio, Inc,
Abstract
Characterization of ESR1 mutations in endometrial and ovarian cancers.Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, Johns Hopkins Kimmel Cancer Center, Caris Life Sciences, Irving, TX,
Abstract
Phase 3 dose selection for selinexor in TP53wt endometrial cancer based on exposure-response analysis.Org: Copenhagen University Hospital Rigshospitalet, CEEGOG and First Faculty of Medicine, Charles University and General University Hospital in Prague, Gynecologic Oncology Group (GOG) Foundation, Karyopharm Therapeutics Inc.,
Abstract
Efficacy and safety of combination therapy with envafolimab and lenvatinib in patients with endometrial cancer after failure of first-line platinum-based therapy.Org: Ganzhou Cancer Hospital, Department of Gynecologic Oncology, Fujian Provincial Cancer Hospital, Yueyang Central Hospital, Department of Clinical Development, 3D Medicines Inc.,
Abstract
Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by BRCA1/BRCA2 mutation (BRCAm) status.Org: UZ Leuven and BGOG, Cliniques Universitaires Saint-Luc and BGOG, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, FirstHealth Moore Regional Hospital, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, and GOG Foundation (GOG-F),
Abstract
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium.Org: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Northwestern Memorial Hospital, Chicago, IL, Chicago, IL, Il-Yang Pharmaceuticals, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Real-world treatment patterns and outcomes by mismatch repair/microsatellite instability (MMR/MSI) status in patients (pts) with advanced endometrial cancer (aEC), 2018-2023.Org: Flatiron Health, Inc.,
Abstract
Outcomes of reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.Org: Kaiser Permanente San Diego, Kaiser Permanente National Drug Use Management,
Abstract
Assessing the risk of uterine serous carcinoma in survivors of triple-negative breast cancer: Is BRCA1 the link?Org: Meigs Division of Gynecologic Oncology, Vincent Department of Obstetrics & Gynecology,
Abstract
Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.Org: Minnesota Oncology, Maplewood, MN, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, FirstHealth Moore Regional Hospital, Pinehurst, NC, Oklahoma Cancer Specialists and Research Institute, Tulsa, OK, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea,
Abstract
Neoadjuvant chemotherapy versus primary surgery in patients with stage III/IV endometrial cancer: A National Cancer Database study.Org: Jefferson Health- Abington Hospital, Abington Hospital-Jefferson Health, Division of Biostatistics, Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Division of Biostatistics, Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Hanjani Institute for Gynecologic Oncology,
Abstract
Cadonilimab plus lenvatinib in patients with advanced endometrial cancer: A multicenter, single-arm, phase II trial.Org: The Third Affiliated Hospital Kunming Medical University,
Abstract
Prognostic value of PORTEC-3 molecular markers by disease risk in a real-world early endometrial cancer cohort.Org: AstraZeneca UK Limited,
Abstract
Endometrial carcinoma in Black vs Asian women: Racial disparities and opportunities to improve survival in 219,301 patients in the USA.Org: Brookdale University Hospital and Medical Center, One Brooklyn Health/Brookdale University Hospital and Medical Center, Brookdale University Hospital & Medical Center,
Abstract
Benmelstobart (TQB2450) combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent, or metastatic endometrial cancer: A multicohort, open label, multicenter, phase II clinical trial (TQB2450-II-08).Org: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Department of Gynecology Oncology, Tianjin Central Hospital of Gynecology Obstetrics, Gynecologic Radiation Department, Zhejiang Cancer Hospital, Beijing Chao-Yang Hospital,Capital Medical University, Oncology Department, Beijing Luhe Hospital, Capital Medical University,
Abstract
HER2 expression in a molecularly characterized cohort of patients with endometrial cancer (EC): SPECTRUM study.Org: Clinical Biostatistics Unit,
Abstract
Exploring the tumor microenvironment (TME) in patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) undergoing immune checkpoint inhibitor (ICI) therapy: Proteomic insights into immune resistance mechanisms.Org: Biognosys, Schlieren, Switzerland,
Abstract
Prognostic assessment of simple hysterectomy versus radical/modified radical hysterectomy in clinically apparent stage II endometrial cancer: A multi-center cohort study.Org: Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China, Qilu Hospital of Shandong University, Shandong, China, Qilu Hospital of Shandong University, Jinan, China,
Abstract
The molecular landscape of pembrolizumab and lenvatinib treatment in endometrial cancer.Org: Caris Life Sciences, Irving, TX, Washington University School of Medicine in St Louis, University of Cincinnati College of Medicine, Winship Cancer Institute of Emory University,
Abstract
Efficacy of olaparib combined to metronomic cyclophosphamide and metformin in patients with recurrent advanced/metastatic endometrial by molecular subtypes: ENDOLA phase I/II trial.Org: Gustave-Roussy Cancer Campus, Centre Antoine-Lacassagne, Pole Santé Publique, Pharmacie, URCC,
Abstract
Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial.Org: Department of Oncology, Odense University Hospital, Willis-Knighton Cancer Center, Gynecologic Oncology Associates, Department of Gynaecology, Obstetrics, and Neonatology, General University Hospital in Prague, Division of Gynecologic Oncology, McGill University Health Centre,
Abstract
Post hoc analysis of progression-free survival (PFS) and overall survival (OS) by mechanism of mismatch repair (MMR) protein loss in patients with endometrial cancer (EC) treated with dostarlimab plus chemotherapy in the RUBY trial.Org: AMITA Health Adventist Medical Center, Indiana University Health & Simon Cancer Center, Hungarian National Institute of Oncology, Soroka University Medical Center, OLV Hospital,
Abstract
Analysis of healthcare provider treatment of advanced endometrial cancer and concordance with expert recommendations in 2023 vs 2022.Org: David Geffen School of Medicine at the University of California,
Abstract
Combined uterine and colorectal screening: A call for action.Org: University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, Stanford University, Stanford, CA, California Pacific Medical Center Research Institute, San Francisco, CA, Women's Health Integrated Research Center at Inova Health System, Annandale, VA, Women’s Health Integrated Research Center at Inova Health System, Department of Defense Gynecologic Cancer Center of Excellence, Annandale, VA, Stanford University Medical Center, Palo Alto, CA, Pingtung Veterans General Hospital, Pingtung, South Korea, California Pacific Medical Center Research Institute, San Francisco, CA, Center for Health Systems Research, Stanford University Medical Center, Stanford, CA, Palo Alto Medical Foundation,
Abstract
Endometrial cancer (EC) by ERBB2 amplification (ERBB2amp) status: Differences in molecular subtypes, ancestry, and real-world outcomes.Org: Texas Oncology-The Woodlands,
Abstract
Prospective evaluation of the effect of 3 days of post-chemotherapy dexamethasone on patient reported symptoms in gynecologic oncology patients treated with carboplatin and paclitaxel.Org: Drexel University, Magee-Womens Hospital of UPMC,
Abstract
Germline genetic profiles of women with uterine cancer: A Myriad Collaborative Research Registry study.Org: California Pacific Medical Center Research Institute, San Francisco, CA, Kaiser Permanente Oakland Medical Center, University of California Irvine, David Geffen School of Medicine at UCLA, Stanford University Medical Center, Stanford, CA,
Abstract
Rising trends in HPV (+) & HPV (-) vulvar cancers among US non-Hispanic White and Hispanic White females 50 years and older.Org: Touro College of Osteopathic Medicine, Stony Brook Medicine, Northwell Staten Island University Hospital, Staten Island University Hospital,
Abstract
Disparities in ovarian and uterine cancer in relation to the development of novel therapeutics.Org: California Pacific Medical Center Research Institute, San Francisco, CA, University of California Irvine, Center for Health Systems Research, Stanford University Medical Center, Stanford, CA, Palo Alto Medical Foundation,
Abstract
SB221: A proof-of-concept study to assess the combination of SON-1010 (IL12-FHAB) and atezolizumab in patients with platinum-resistant ovarian cancer.Org: Blacktown Cancer and Hematology Centre, Albury Wodonga Cancer Care,
Abstract
Open-label, prospective phase 2 study to evaluate the efficacy and safety of camrelizumab combined with etoposide and cisplatin as neoadjuvant therapy in patients with neuroendocrine carcinoma of the cervix.Org: Clinical Oncology School of Fujian Medical University,
Abstract
Study on the efficacy and toxicity of pamiparib combined with tamoxifen in the treatment of patients with epithelial ovarian cancer with biochemical recurrence during first-line PARPi maintenance therapy.Org: Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma,
Abstract
A three-arm randomized phase II study of dostarlimab alone or with bevacizumab versus nonplatinum chemotherapy in recurrent gynecological clear cell carcinoma: DOVE (APGOT-OV7/ENGOT-ov80 study).Org: National University Cancer Institute, Singapore, Cancer Research UK & University College London Cancer Trials Centre,
Abstract
Fruquintinib plus sintilimab in treated advanced endometrial cancer (EMC) patients (pts) with PMMR status: Results from a multicenter, single-arm phase 2 study.Org: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Liaoning Cancer Hospital, Liaoning, China, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China, Department of Gynecologic Oncology, affiliated Cancer Hospital of Chonqing University, Chongqing, China, Beijing Obstetrics and Gynecolgoy Hospital, Capital Medical University, Beijing, China,
Abstract
Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Investigational Cancer Therapeutics, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with abemaciclib, in endometrioid endometrial cancer (EEC): Results from the EMBER phase 1a/1b study.Org: Next Oncology Virginia and Virginia Cancer Specialists, Sir Charles Gairdner Hospital, Calvary Mater Hospital, University of Vermont Cancer Center, Stephenson Cancer Center,
Abstract
A randomized, multicenter, open-label phase III trial of hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer (KOV-HIPEC-02).Org: Inje University Busan Paik Hospital, Seoul St Mary’s Hospital, Pusan Yangsan National University Hospital, Soonchunhyang University Cheonan Hospital, Seoul Metropolitan Government Seoul National University Boramae Medical Center,
Abstract
A phase IV trial to confirm the efficacy of olaparib in combination with bevacizumab as maintenance frontline treatment of HRD-positive ovarian tumours (IOlanTHe).Org: Humanitas University + IRCCS Humanitas Research Hospital, Unit of Gynaecological Oncology Research, University of Milan-Bicocca and Gynecologic Oncology Program, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Obstetrics and Gynecology Unit ASO Ordine Mauriziano,
Abstract
A phase 2 study to evaluate efficacy and safety of PRGN-2009, a novel gorilla adenovirus-based immunotherapy, in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer.Org: Cancer Vaccine Institute, UW Medicine, Precigen, Inc.,
Abstract
Triage of advanced cervical cancer through immunotherapy induction (TRACTION).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX,
Abstract
A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer.Org: Lyon University Hospital, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), EPSILYON, Université Claude Bernard Lyon 1, Gustave Roussy, Département de Médecine Oncologique, Peter MacCallum Cancer Centre, University of Melbourne, Prince of Wales Hospital and University of New South Wales,
Abstract
REJOICE-Ovarian01: A phase 2/3 study of raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer (OVC).Org: Section of Gynecologic Oncology,
Abstract
Phase II clinical trial of PLX038 in patients with platinum resistant ovarian, primary peritoneal and fallopian tube cancer.Org: Mayo Clinic Cancer Center Research Office, Prolynx Inc.,
Abstract
GOG3069: Phase 2 study of alpelisib and fulvestrant for PIK3CA-mutated estrogen receptor (ER)-positive endometrioid endometrial cancers.Org: Kettering Health Cancer Center, St. Vincent Hospital and Health Care Centers, Legacy Good Samaritan Medical Center, University of Wisconsin-Madison School of Medicine and Public Health, The University of Cincinnati Cancer,
Abstract
Open-label, phase 2 study of adebrelimab combined with fuzuloparib in the treatment of patients with HRD-positive, recurrent platinum-resistant ovarian cancer.Org: Clinical Oncology School of Fujian Medical University,
Abstract
Randomized pilot study assessing the safety and tolerability hyperthermic intraperitoneal chemotherapy (HIPEC) at completion of interval cytoreductive surgery or chemotherapy the day prior to interval cytoreductive surgery for patients with stage III/IV ovarian cancer undergoing neoadjuvant chemotherapy.Org: Ohio State University Wexner Medical Center and James Cancer Hospital, Ohio Health,
Abstract
A prospective, randomized, single-blinded study evaluating the effect of frozen-section directed excision on positive surgical margins in high-grade vulvar dysplasia.Org: Atrium Health Levine Cancer Institute, Charlotte, NC, Division of Gynecologic Oncology, University of Pennsylvania, Levine Cancer Institute, Atrium Health Carolinas Medical Center,
Abstract
BMI correlation with outcomes in patients with head and neck cancer undergoing immunotherapy: A comprehensive review and meta-analysis.Org: Hematology and Oncology Department, Texas Tech University Health Sciences Center,
Abstract
Comparative analysis of pembrolizumab and cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma: Real-world data.Org: Massey Comprehensive Cancer Center, Division of Hematology, Oncology, and Palliative Care,
Abstract
Repurposing atovaquone as a STAT3 inhibitor for the treatment of platinum resistant ovarian cancer.Org: Emory Winship Cancer Institue, Emory Winship Cancer Institute,
Abstract
Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026).Org: The GOG Foundation, Inc., Women and Infants Hospital, Brown University, Spectrum Health Cancer Center, LSU Health School of Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences Yale University School of Medicine,
Abstract
Off-label use of checkpoint inhibitor (CPI) monotherapy in PD-L1–negative or unknown recurrent/metastatic head and neck cancer (R/M HNSCC).Org: Hospital of the University of Pennsylvania, University of Pennsylvania, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Epidemiology Laboratory, Clinical Research, and Community Health, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, University of Sidi Mohamed Ben Abdellah, Fez, Morocco, Informatics,
Abstract
The role and mechanism of circadian clock gene BMAL1 in the proliferation and metastasis of nasopharyngeal carcinoma by inhibition TGF-β1/Smads pathway.Org: Guiyang, China, Guizhou, China, Guizhou Medical University, The School of Clinical Medicine,
Abstract
A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer.Org: Winthrop P. Rockefeller Cancer Institute, Women's Cancer Center of Nevada,
Abstract
Impact of immune-related adverse events (irAE) onset on disease response and survival in patients (pts) with head-neck cancer treated with immune check point inhibitors (ICI).Org: University of Virginia, Charlottesville, VA, USA, Penn Medicine Abramson Cancer Center,
Abstract
AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC).Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, University of Chicago Medicine, UCSF Helen Diller Family Comprehensive Cancer Center,
Abstract
GOG 3088: A randomized phase II study of letrozole versus observation in patients with newly diagnosed uterine leiomyosarcoma.Org: Gynecologic Oncology Group Statistical and Data Center, Mount Pleasant, SC, Texas Oncology and Gynecologic Oncology Group (GOG) Foundation, Shenandoah, TX, GOG and Gynecologic Oncology,
Abstract
Identifying patients at high risk of recurrence by rebound of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma.Org: Fudan University Shanghai Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Efficacy of nimotuzumab added to concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma.Org: Fudan University Shanghai Cancer Center (Xiamen Branch), Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Department of Radiation Oncology, The First Affiliated Hospital of Xiamen University,
Abstract
Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage III and IV ovarian cancer after interval cytoreductive surgery (FOCUS).Org: Biomedical Statistics Center, Samsung Medical Center, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Department of Obstetrics and Gynecology, Ajou University School of Medicine, Gynecologic Cancer Center, Kyungpook National University Medical Center, Department of Obstetrics and Gynecology, Korea University College of Medicine,
Abstract
Safety and efficacy of iparomlimab and tuvonralimab in combination with gemcitabine and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase 2 trial (DUBHE-N-302).Org: Qilu Pharmaceutical, Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China, Sun Yat-sen University Cancer Center Gansu Hospital,
Abstract
Correlation between irAEs and treatment efficacy of anti-PD-1 single agent in patients with recurrent/metastatic head and neck squamous cell carcinoma: A monocentric real-world observational study.Org: IOV – IRCCS,
Abstract
Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent, or metastatic head and neck squamous cell carcinoma.Org: International Breast Cancer Study Group Statistical Center, Center for Head & Neck Oncology,
Abstract
Significance of imaging-detected extranodal extension (iENE) in locally advanced head and neck squamous cell carcinoma (LASCCHN) treated with induction chemotherapy followed by chemoradiotherapy.Org: Department of Head and Neck Medical Oncology,
Abstract
Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study.Org: National Clinical Research Centre for Cancer,
Abstract
Clinical, molecular, and immunologic profiling of brain metastases (BM) in head and neck squamous cell carcinoma (HNSCC).Org: Phase Genomics, Inc.,
Abstract
A phase 2 study of trifluridine/tipiracil (FTD/TPI) in recurrent/metastatic nasopharyngeal (r/m NPC) carcinomas with or without prior exposure to fluoropyrimidines.Org: National University Health Systems,
Abstract
Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.Org: The Affiliated Cancer Hospital of Guangxi Medical University, First Affiliated Hospital of Guangxi Medical University, First People’s Hospital of Yulin City,
Abstract
A phase 1 study of fianlimab (anti–LAG-3) in combination with cemiplimab (anti–PD-1) in patients with advanced HNSCC.Org: Zuckerberg Cancer Center, Northwell Health Cancer Institute, Tallaght University Hospital,
Abstract
Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100.Org: H. Lee Moffitt Cancer Center and Research Institute, Banner MD Anderson Cancer Center, Johns Hopkins Medicine, University of Chicago, Nanobiotix,
Abstract
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02).Org: Hadassah Medical Moscow, Srinagarind Hospital, Chris O’Brien Lifehouse,
Abstract
Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).Org: Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, Guangzhou, China, Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China, Department of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, guangzhou, China, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China, Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China,
Abstract
Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy.Org: Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China, The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China, Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China,
Abstract
Characterizing the impact of sarcopenia on treatment response and survival in previously treated recurrent or metastatic nasopharyngeal carcinoma: Insights from a secondary analysis of the KL-A167 randomized trial.Org: Chengdu Institute of Computer Application, Chinese Academy of Sciences; University of Chinese Academy of Sciences, Chengdu, China, Department of Oncology, The General Hospital of Western Theater Command, Chengdu, China, Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, Chongqing University, Chongqing, China, Division of Abdominal Tumor Multimodality Treatment, Department of Radiation Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China,
Abstract
Validation of HLA presented tumor-exclusive peptides in an independent cohort of head and neck squamous cell carcinoma.Org: Department of Otolaryngology and Head & Neck Surgery, Ulm University Medical Center, Quantitative Biology Center (QBiC), Department for Medical Oncology and Pneumology, Ulm University - Institute of Medical Systems Biology,
Abstract
A phase II trial of reirradiation combined with pembrolizumab in patients with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (HNSCC).Org: UPMC Hillman Cancer Center Biostatistics Facility, University of Maryland Department of Medicine,
Abstract
A phase II study of nivolumab in patients with recurrent or metastatic carcinosarcomas.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Seoul National University Hospital, Division of Hematology-Oncology, Department of Medicine, Seoul Medical Center, Seo-Gu, South Korea, Department of Medicine, Icahn School of Medicine at Mount Sinai, Samsung Medical Center,
Abstract
Associations of ctDNA clearance and pathological response after neoadjuvant treatment in patients with locally advanced oral cancer.Org: Oromaxillofacial Head and Neck Surgery, Huashan Hospital, Fudan University,
Abstract
Interrogating the tumor microenvironment (TME) in patients (pts) with head and neck mucosal squamous cell carcinoma (HNmSCC) treated with programmed death-1 (PD-1) inhibitors.Org: Centenary Institute, Sydney University,
Abstract
Real world effectiveness and safety of low dose nivolumab with metronomic chemotherapy in patients with advanced platinum-resistant head and neck cancer: An Indian institutional experience.Org: HCG Manavata Cancer Centre, Curie Manavata Cancer Centre, Cancer Centres of America,
Abstract
The potential prognostic value of the head and neck advanced lung inflammation index (HN-ALI) for patients treated with immunotherapy.Org: IRCCS Azienda Ospedaliero-Universitaria Sant'Orsola Malpighi of Bologna, Department of Medical and Surgical Sciences, University of Bologna, Department of Oncology, Modena University Hospital, University Hospital of Modena and Reggio Emilia, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna,
Abstract
Efficacy from the phase 1 study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with head and neck squamous cell carcinoma.Org: Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business, Fulgent Pharma,
Abstract
Predicting response to immune checkpoint blockade in recurrent/metastatic head and neck squamous cell carcinoma using personalized circulating tumor DNA.Org: Cambridge, United Kingdom,
Abstract
Features of HPV+ OPSCC predictive of recurrence identified by transcriptional profiling of a case-control cohort.Org: University of Pennsylvania, The University of Chicago Medicine Center for Advanced Care at Orland Park,
Abstract
Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy in local advanced nasopharyngeal carcinoma.Org: The Affiliated Hospital of Guangdong Medical University,
Abstract
An open-label, single-center phase II trial of cadonilimab (an anti-PD-1/CTLA-4 bispecific antibody) in combination with platinum-based dual-drug neoadjuvant chemotherapy for locally advanced, resectable head and neck squamous cell carcinoma.Org: The Fifth Affiliated Hospital of Guangzhou Medical University,
Abstract
Personalized circulating tumor (ct)DNA for monitoring disease status in HPV-negative head and neck squamous cell carcinoma.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Dana-Farber Cancer Institute, DFCI/PCC Fellowship Program - Attendings,
Abstract
Saliva-based detection of oral HPV and oral cancer.Org: The University of Chicago Medicine Center for Advanced Care at Orland Park, University of Chicago, Department of Medicine, Icahn School of Medicine at Mount Sinai, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Abstract
The combination of patient-specific tumor and HPV sequencing to enable high-sensitivity detection of ctDNA in patients with HPV-associated oropharyngeal carcinoma.Org: Memorial Sloan Kettering Cancer Center, Invitae, Invitae Corporation, AstraZeneca,
Abstract
Genomic characteristics of exceptional responders to treatment with PD-1 inhibitors in refractory/metastatic head and neck squamous cell carcinoma.Org: Atrium Health Wake Forest Baptist Medical Center, Winston Salem, NC, Winston-Salem, NC, Wake Forest Baptist Medical Center,
Abstract
Effect of CBD on anti-tumor immune response and interaction with GPR55 on MAPK signaling in head and neck squamous cell carcinoma.Org: University of California, San Diego Center for Advanced Laboratory Medicine, Tohoku University Hospital,
Abstract
Molecular analysis of surgical margins with NGS to assess microscopic residual disease in early oral squamous cell carcinomas.Org: Departement of Pathology and Medical Biology,
Abstract
Multi-feature next-generation liquid biopsy for diagnosis and prognosis in HPV-associated head and neck cancer.Org: Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA, Department of Pathology, Massachusetts General Hospital, Boston, MA, Department of Head and Neck Radiation Oncology, Massachusetts General Hospital, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, German Cancer Research Center, Heidelberg, Germany,
Abstract
Neoadjuvant immunotherapy for oropharynx cancer: Correlative studies and long-term outcomes from the CIAO trial.Org: Cleveland Clinic Taussig Cancer Instititute, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, City of Hope National Medical Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
Can TTMV clearance predict recurrence in HPV HNSCC?Org: Hematology and Medical Oncology, Universitätsklinikum Jena, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Medical Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Tisch Cancer Institute,
Abstract
Development and validation of an assay to quantify plasma cell-free human papillomavirus DNA for 13 high-risk types that cause 98% of HPV-positive cancers.Org: MD Anderson Hematology/Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
Perimarginal lymph node metastasis in gingivo-buccal complex carcinoma: Is it time to push the limits of neck dissection?Org: Department of Otorhinolaryngology and Head & Neck Surgery, Department of Otorhinolaryngology & Head and Neck Surgery, Department of Oto-laryngology &Head and Neck Surgery,
Abstract
Association of artificial intelligence–derived collagen disorder architecture (CoDA) features with survival outcome and objective response to immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma.Org: Picture Health, Case Medical Center - Seidman Cancer Center, Advocate Medical Group, Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University,
Abstract
A prospective multicenter trial of dose escalation for weekly gemcitabine concurrent with intensity-modulated radiotherapy following cisplatin and gemcitabine induction chemotherapy in patients with locally advanced nasopharyngeal carcinoma.Org: The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China, Department of Oncology, Jiangmen Central Hospital, Jiangmen, China,
Abstract
TTMV and association with relapse in patients with HPV related SCCHN undergoing CRT.Org: Mount Sinai Hospital-Breast Medical Oncology, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Medical Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Tisch Cancer Institute,
Abstract
Induction-concurrent versus concurrent-adjuvant chemoradiotherapy in patients with high-risk N2–3 nasopharyngeal carcinoma: An open-label, randomised, controlled, phase 3 trial.Org: Clinical Trials Centre,
Abstract
Analysis of PD-L1 expression in locally advanced head and neck squamous cell carcinoma and its correlation with the efficacy of neoadjuvant immunotherapy + chemotherapy: A retrospective real-world study.Org: Head and Neck Surgery Department I, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Translational Medicine Center, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Department of Radiation Oncology, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China,
Abstract
Induction chemotherapy effects on very advanced (T3/T4) human papillomavirus-related oropharyngeal cancer for participation in hypoxia-directed major de-escalation (30 Gy) definitive treatment trial.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Evaluating perceived barriers to optimal care in head and neck cancer: A mixed-methods study.Org: Pittsburgh Veteran's Affairs Medical Center, Sharp Grossmont Hospital, Association of Community Cancer Centers, Association of Cancer Care Centers, Head and Neck Cancer Alliance,
Abstract
Neoadjuvant tislelizumab plus chemotherapy followed by salvage surgery and adjuvant tislelizumab for recurrent head and neck squamous cell carcinoma after radiotherapy: A single-arm, phase II trial.Org: Peking University School and Hospital of Stomatology, Beijing, China, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China,
Abstract
Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): An open-label, single-arm, phase 2 study.Org: Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital,
Abstract
Beyond the initial diagnosis: Epidemiological factors associated with second primary cancers among patients with head and neck squamous cell carcinoma (a SEER-based study).Org: Albert Einstein Medical Center, NJMS Rutgers,
Abstract
Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial.Org: Fujian Province Cancer Hospital, Department of Radiation Oncology, Jiangxi Cancer Hospital, Department of Radiation Oncology, Fudan University Shanghai Cancer Center,
Abstract
Mapping the mental health correlates of head and neck cancer: A systemic review and meta-analysis.Org: Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom, Psychiatry Department, Basurto University Hospital, Bilbao, United Kingdom, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom, Vall d'Hebron Institute of Oncology, Barcelona, Spain, Radiation Oncology Department, Cruces University Hospital, Bilbao, Spain,
Abstract
Survey of long term survivors of oral cancer: Looking beyond cancer biology.Org: Fortis Hospital Mulund, Tata Memorial Centre - ACTREC,
Abstract
Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial.Org: Department of Head and Neck Tumor Radiotherapy, Department of Cardiology, Cardiac Prevention and Assessment Center,
Abstract
MR radiomics and neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma.Org: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
Neoadjuvant and adjuvant toripalimab for high-risk locoregionally advanced nasopharyngeal carcinoma: A randomized, double-blind, placebo-controlled phase 2 trial.Org: Sun Yat-sen University Cancer Centre, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine,
Abstract
Photoimmunotherapy in nasopharyngeal carcinoma recurrence.Org: Graduate School of Biomedical and Health Sciences, Okayama University Graduate School of Medicine, Kanazawa University, International University of Health and Welfare, Mita Hospital,
Abstract
Neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Recent safety and efficacy findings from a phase 1b/2 open-label combination study of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma (HNSCC).Org: Thomas Jefferson University, University of Miami Miller School of Medicine, Miami, FL, University of Kentucky, Lexington, KY, Rakuten Medical, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Relationship between infiltration of tissue-resident memory T cells (TRM) in head and neck squamous cell carcinoma (HNSCC) tissue and localization and age.Org: Ulm University Medical Center, CRUK and NIHR Experimental Cancer Medicine Center, Head & Neck Surgery,
Abstract
Validation of a prognostic nomogram for locally advanced oropharyngeal carcinoma (OPC) treated with intensity modulated radiation therapy (IMRT) ± systemic therapy (ST).Org: UO Oncologia Medica 2, University of Brescia, Radiation Oncology Policlinico San Martino IRCCS, Cruces University Hospital, Radiotherapists Unit,
Abstract
Clinical validation of a mesenchymal gene expression signature for prognosis and treatment decision making in early-stage oral cavity squamous cell carcinoma.Org: GeneCentric Therapeutics, Inc,
Abstract
Clinical and genomic characterization of sporadic medullary thyroid carcinoma in Chinese patients.Org: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan,
Abstract
Association of quality of life (QoL) with mortality in patients with adenoid cystic carcinoma using an internationally validated QoL questionnaire (EQ-5D-5L): A new baseline.Org: The Christie NHS FT, Centre for Reviews and Dissemination, Royal Devon University Healthcare NHS Foundation Trust,
Abstract
Neoadjuvant immunochemotherapy and new radiomic predictor for resectable locally advanced oral squamous cell carcinoma.Org: Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China, State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Department of Head and Neck Oncology Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, China, State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases and Department of Oral Pathology, West China Hospital of Stomatology, Sichuan University, Chengdu, China, State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases and Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, China,
Abstract
Efficacy and safety of luveltamab tazevibulin vs investigator’s choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study.Org: Medical Oncology Service, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, Yonsei Cancer Center and Severance Hospital, Seoul, South Korea, Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, The Royal Hospital for Women, Sydney, Australia, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA,
Abstract
Clinical outcomes of NOTCH pathway-activated adenoid cystic carcinoma with and without co-occurrent TP53 mutation.Org: Macclesfield District General Hospital, Manchester University NHS Foundation Trust, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre,
Abstract
A phase 1 clinical trial of DB-020 intratympanic injections administered prior to high-dose cisplatin chemotherapy to reduce ototoxicity.Org: Lapuerta Consulting LLC, Decibel Therapeutics Inc,
Abstract
Clinical outcomes in salivary adenoid cystic carcinoma.Org: University of Michigan Department of Otolaryngology Head and Neck Surgery,
Abstract
Induction chemotherapy followed by concurrent chemoradiotherapy combined with toripalimab and Endostar in high-risk locally advanced nasopharyngeal carcinoma: A multicenter, randomized, phase 2 trial.Org: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Department of Radiation Oncology, The Second Affiliated Hospital of Guangxi University of Science and Technology, Liuzhou, China,
Abstract
Patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) with BRAF V600E and/or K601E mutation status: A real-world view of effectiveness of lenvatinib monotherapy.Org: Adelphi Real World,
Abstract
Safety of tabelecleucel with pembrolizumab in recurrent/metastatic Epstein–Barr virus-associated nasopharyngeal carcinoma.Org: Stanford Cancer Center, University of Pennsylvania, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, City of Hope Comprehensive Cancer Center Department of Medical Oncology and Therapeutics Research,
Abstract
Dosimetry of lutetium-177-PSMA-I&T radioligand therapy in recurrent/metastatic adenoid cystic carcinoma.Org: Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands, Department of Medical Imaging, Nuclear Medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands,
Abstract
Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC).Org: Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Seoul National University Hospital, Cancer Research Institute and National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Chrestos Concept GmbH & Co. KG,
Abstract
Effect of RGT-61159 on inhibition of oncogene c-MYB synthesis and tumor growth inhibition in a broad range of ACC PDX models, at well tolerated doses in rodents and non-human primates.Org: Rgenta Therapeutics, University of Massachusetts Medical School,
Abstract
Survival outcomes of concurrent radiotherapy and toripalimab versus radiotherapy alone for elderly patients with postoperative head and neck squamous cell carcinoma unfit for cisplatin.Org: Department of Oral and Maxillofacial Head & Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China,
Abstract
A non-invasive cfDNA fragmentomics assay for differentiating malignant and benign thyroid nodules.Org: Division of Thyroid Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China,
Abstract
Efficacy of cytotoxic chemotherapy in recurrent/metastatic adenoid cystic carcinoma (ACC).Org: Division of Pharmacy,
Abstract
The efficacy and safety of ulinastatin in the prevention and treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A multicenter, open-label, randomized controlled clinical trial.Org: Department of Comprehensive (Head and Neck) Oncology and Hospice Ward, The People's Hospital of Zhongshan City, Department of Radiation Oncology, The Third Affiliated Hospital of Sun Yat-sen University, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-sen University, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Center for Precision Medicine, Sun Yat-sen University,
Abstract
Efficacy and safety of anlotinib combined with sintilizumab in locally advanced or metastatic anaplastic thyroid carcinoma.Org: National Cancer Center Hospital East, Kashiwa, Japan, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Axitinib plus avelumab for recurrent/metastatic adenoid cystic carcinoma (R/M ACC): Biomarker analysis of the phase II trial.Org: University of Sao Paulo, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center,
Abstract
Cobimetinib plus atezolizumab for RAS and NF1/2-mutated poorly differentiated thyroid carcinoma.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Safety and efficacy of AIC100 chimeric antigen receptor (CAR) T-cell therapy in patients with advanced thyroid cancers: Results from the phase 1 study.Org: UH Seidman Cancer Center,
Abstract
Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ oropharyngeal cancer.Org: Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Johns Hopkins University Bloomberg School of Public Health,
Abstract
Biomarker-driven radiation therapy dose reduction after transoral robotic surgery for the treatment of HPV-positive oropharyngeal cancer.Org: Emory University Hospital Midtown,
Abstract
Long term results of phase 3 randomized study evaluating the addition of low dose nivolumab to palliative chemotherapy in head and neck cancer.Org: P.D. Hinduja Hospital, Cancer Research and Statistic Foundation,
Abstract
A phase 1b study of tbio-4101 (autologous selected and expanded tumor-infiltrating lymphocytes [TILs]) with pembrolizumab in patients with anti-PD-1–resistant, advanced head and neck squamous cell carcinoma (aHNSCC).Org: Moffitt Cancer Center, Turnstone Biologics, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck.Org: City of Hope Antelope Valley, Lancaster, CA, San Diego, La Jolla, CA,
Abstract
Novel approach of prophylactic radiation to reduce toxicities comparing 2-step 40 Gy with 56 Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck: A phase III trial (JCOG1912, NEW BRIDGE).Org: Department of Medical Oncology and Hematology, Kobe University Hospital, Aichi Medical University, Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University,
Abstract
Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial.Org: University of Michigan Rogel Cancer Center, University of Chicago, Dana-Farber Cancer Institute, University of Wisconsin, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
A phase III randomized, open-label study to establish the superiority of triple oral metronomic therapy (OMCT) used in addition to chemotherapy regimen (paclitaxel + carboplatin) over chemotherapy alone for the treatment of advanced unresectable head and neck cancer squamous cell cancer (HNSCC).Org: Mahamana Pandit Madan Mohan Malviya Cancer Centre & Homi Bhabha Cancer Hospital, Varanasi, India, Varanasi, Uttar Pradesh, India, Mumbai, India,
Abstract
Pyrotinib in HER2-altered advanced salivary gland carcinomas: Analysis of two cohorts from an exploratory study.Org: Department of Oral and Maxillofacial Head & Neck Oncology, Shanghai Ninth People’s Hospital,
Abstract
Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC).Org: Dana-Farber Cancer Institute, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center, Yale Cancer Center, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): MERIDIAN study.Org: NeoGenomics Ltd,
Abstract
EFFECT-neo: A phase 3 study of pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinoma.Org: Beijing TongRen Hospital, Internet Hospital of Tianjin Medical University General Hospital, Tianjin First Central Hospital,
Abstract
PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC).Org: Stathmi, Inc.,
Abstract
Long term results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.Org: P.D. Hinduja Hospital,
Abstract
TTCC-2022-01: Niraparib and dostarlimab in locally-advanced head and neck squamous cell carcinoma treated with (chemo) radiotherapy (RADIAN).Org: Complejo Hospitalario de Navarra, Hospital Clinic Barcelona / IDIBAPS, IOB-Quirón, H. Germans Trias i Pujol, Vall d’Hebron Institut of Oncology (VHIO),
Abstract
HERD: A multi-centre prospective cohort study to facilitate early detection of relapse in radically treated, high risk head and neck squamous cell carcinoma.Org: Kings College London, Cancer Research UK Cambridge Institute, Cancer Research UK Cambridge Centre, Guys and St Thomas' NHS Trust, Saddlepoint Science,
Abstract
STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma.Org: Winship Cancer Institute, Emory University, Atlanta, GA, USA, The Institute of Cancer Research/The Royal Marsden Hospital, Fondazione IRCCS Istituto Nazionale Tumori and University of Milan, Cliniques Universitaires Saint-Luc,
Abstract
CTEP 10492, a phase 1/1b study of the AKT inhibitor ipatasertib with chemoradiation for locally advanced head and neck squamous cell carcinoma.Org: Rutgers School of Public Health, Cancer Institute of New Jersey, San Diego Moores Cancer Center,
Abstract
Xevinapant with radiation and concurrent carboplatin and paclitaxel in patients ineligible for cisplatin with locoregionally advanced squamous cell carcinoma of the head and neck (EXtRaCT study)Org: The University of Chicago Medicine Center for Advanced Care at Orland Park, University of Michigan,
Abstract
eVOLVE-HNSCC: A global phase 3 study of volrustomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) following definitive concurrent chemoradiotherapy (cCRT).Org: Head and Neck Medical Oncology Unit, Department of Oncology and Hemato-Oncology University of Milan,
Abstract
Phase II trial of immunotherapeutic HPV vaccine PRGN-2009 with pembrolizumab before standard treatment in subjects with newly diagnosed HPV-associated oropharyngeal cancer.Org: Translational Tumor Immunology Program, NIDCD, OCD, Center for Clinical Research,
Abstract
A real-world picture of patients with a new diagnosis of acute myeloid leukemia in Italy.Org: Drugs&Health, Fondazione ReS (Ricerca e Salute) - Research and Health Foundation,
Abstract
Sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid carcinoma: The phase 2 SETHY, GETNE-T2318 trial.Org: Instituto Aragonés de Investigación Sanitaria, UMI, Hospital Clinico Universitario San Carlos, Universidad Complutense de Madrid (UCM), IdISSC,
Abstract
Neoadjuvant adebrelimab plus dalpiciclib in HPV-negative locally advanced head and neck squamous cell carcinoma: A phase II clinical trial.Org: National Clinical Research Center for Oral Diseases, Department of Head and Neck Oncology Surgery,
Abstract
Phase I study of functionally enhanced CD33 CAR T cells in patients with relapsed or refractory acute myeloid leukemia.Org: Beijing Boren Hospital, Beijing GoBroad Boren Hospital, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Blood Diseases Hospital,
Abstract
Molecular characterization and biomarker identification in pediatric B-cell acute lymphoblastic leukemia.Org: Nanjing Geneseeq Technology Inc., Geneseeq Research Institute,
Abstract
FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Leukemia,
Abstract
Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL): Post hoc analysis of adverse events of interest from AALL1931.Org: Primary Children's Hospital,
Abstract
A post-hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who received oral azacitidine (Oral-AZA) maintenance therapy in the QUAZAR AML-001 study.Org: Ludwig Boltzmann Institute for Hematology and Oncology,
Abstract
Evaluation of the toxicity and outcomes of the combination of midostaurin and CLAG-M in patients with FLT3-mutated acute myeloid leukemia (AML): A multi-center retrospective analysis.Org: University of Washington/Fred Hutchison Cancer Center,
Abstract
Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML).Org: Macclesfield, United Kingdom, Princess Margaret Hospital, University Health Network,
Abstract
Achievement of therapeutic levels using dose-reduced peg-asparaginase in adult patients with acute lymphoblastic leukemia.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Chicago, Section of Hematology/Oncology,
Abstract
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia (AML) treated on SWOG S1203.Org: University of Washington/Fred Hutchinson Cancer Center, University of Washington/Fred Hutchinson Cancer Center and SWOG Statistics and Data Management Center, Seattle, WA, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Duke Cancer Institute, Duke University Medical Center, Durham, NC,
Abstract
Outcomes of blast-phase MPN and JAK2, MPL, and CALR mutated de novo AML: A propensity score-adjusted cohort study.Org: Cleveland Clinic Foundation, Cleveland Clinic Taussig Cancer Center, University of Minnesota Medical Center,
Abstract
Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.Org: Rigel Pharmaceuticals, Inc.,
Abstract
PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease.Org: City of Hope National Medical Center, PeproMene Bio,
Abstract
Trends in hematopoietic cell transplantation (HCT) in acute myeloid leukemia (AML) from 2004-2019.Org: Grande International Hospital, The Fred & Pamela Buffett Cancer Center,
Abstract
Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.Org: Georgia Cancer Center, Augusta University, Augusta University/University of Georgia Medical Partnership, School of Medicine, Zhejiang University, Hangzhou, China, University of California, Davis Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL,
Abstract
Mutation profiles and outcomes of patients with acute myeloid leukemia with autoimmune disease.Org: Leukemia Program,
Abstract
Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.Org: CHU Rennes, Univ Rennes, Service d'hématologie clinique et thérapie cellulaire Hopital du Haut-Leveque CHU de Bordeaux, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg,
Abstract
Efficacy of GCN2 inhibition by a novel small molecule AP030 in acute leukemia.Org: University Hospital of Lausanne (CHUV),
Abstract
7+3 versus decitabine + venetoclax: A global, propensity-matched study comparing outcomes for both regimens in AML.Org: Alara Medical Group,
Abstract
Outcomes of patients with bone marrow fibrosis in de novo and secondary acute myeloid leukemia.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Hematopathology, Beijing Friendship Hospital, Capital Medical University, Department of Leukemia,
Abstract
Evaluation of treatment outcomes with CPX-351 in adults with AML: A meta-analysis.Org: SUNY Upstate Medical University, Syracuse, NY, SUNY Upstate University Hospital, SUNY Upstate Medical Center,
Abstract
In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.Org: Hospital Universitario Dr. José Eleuterio González, University of Milano-Bicocca, ICO – Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute,
Abstract
Preliminary safety, efficacy and molecular characterization of emavusertib (CA-4948) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation (FLT3m).Org: Marien Hospital Dusseldorf, Münster University Hospital,
Abstract
Improved overall survival in acute myeloid leukemia over the last 15 years.Org: Nobel College, Pokhara University,
Abstract
Domain-based analysis of RUNX1 somatic mutations in myeloid neoplasms.Org: Pontiac, MI, Wayne State University/Karmanos Cancer Institute, Neal Cancer Center/Houston Methodist Hospital, Wayne State University/Detroit Medical Center Sinai Grace Hospital,
Abstract
Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Leukemia,
Abstract
TP53 mutation screening for patients at risk of myeloid malignancy.Org: Cellular and Molecular Therapeutics Branch, NHLBI/NIH,
Abstract
Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia.Org: Ascentage Pharma Group, Inc.,
Abstract
A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia.Org: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Hygeia Suzhou Yongding Hospital, National Regional Medical Center,
Abstract
Impact of protein energy malnutrition on hospitalized patients with acute myeloid and lymphoid leukemia: A United States population-based cohort study.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Jefferson-Einstein Hospital, Internal Medicine Residency, Einstein Medical Center Philadelphia, Jefferson Einstein Medical Center,
Abstract
Impact of body mass index and karyotype on clinical outcomes in adolescents and young adults (AYA) with acute myeloid leukemia.Org: University of Buffalo Department of Social and Preventive Medicine, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Roswell Park Comprehensive Cancer Center,
Abstract
Treatment of acute myeloid leukemia with Orca-T.Org: Sarah Cannon Transplant and Cellular Therapy Program, Hunstman Cancer Institute at the University of Utah, H. Lee Moffitt Cancer Center and Research Institute, Oregon Health & Science University, City of Hope National Comprehensive Cancer Center,
Abstract
Trajectories of patient-reported outcomes after prolonged stays for hematopoietic cell transplant.Org: Department of Psychosocial Oncology and Palliative Care,
Abstract
Outpatient blinatumomab with digital monitoring in patients with measurable residual disease positive (MRD+) B-ALL in a phase 4 study.Org: Comprehensive Cancer Center of Atrium Health Wake Forest Baptist, Adventist Health System/Sunbelt, Inc. d/b/a Advent Health Orlando, Current Health, Saint Francis Hospital, Inc.,
Abstract
Predictive biomarkers of response to the IRAK4/FLT3 inhibitor emavusertib in hematological malignancies.Org: Monoceros Biosystems LLC, Department of Hematology, Cellular Therapy and Hemostaseology, Leipzig University Hospital, Leipzig, Germany, Department of Medical Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY,
Abstract
Improved survival for myeloid malignancy patients receiving thiotepa/cyclophosphamide (TT/Cy) versus total body irradiation/cyclophosphamide (TBI/Cy) conditioning and allogeneic stem cell transplantation.Org: Bone Marrow and Blood Stem Cell Transplantation Program,
Abstract
Symptom burden in adult survivors of allogeneic hematopoietic stem cell transplantation.Org: Fred and Pamela Buffett Cancer Center,
Abstract
Impact of spleen volume on post-allogenic hematopoietic transplant outcomes in myelofibrosis: Utility of 3D volumetrics in splenomegaly.Org: City of Hope National Medical Center, Arcadia, CA,
Abstract
Biomarkers in a phase 1b study of investigational microbiome therapeutic SER-155 in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT).Org: Memorial Sloan Kettering Cancer Center, Seres Therapeutics, University of Chicago, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Mayo Clinic,
Abstract
Effect of pre-transplant functional status on length of hospital stay in patients undergoing allogeneic hematopoietic stem cell transplant in an outpatient transplant program.Org: The Blood and Marrow Transplant Group of GA, Blood and Marrow Transplant Group of Georgia, The Blood and Marrow Transplant Program, Northside Hospital Physical and Occupational Therapy Department, Northside Gwinnett Hospital,
Abstract
Outcomes of older adults undergoing allogeneic stem cell transplant with post-transplant cyclophosphamide.Org: UMass Memorial Medical Center, Banner Health,
Abstract
Frequency of comedication of proton pump inhibitors with crystalline dasatinib in chronic myeloid leukemia and effects on TKI-bioavailability.Org: Solna, von Euler Consulting,
Abstract
Thiotepa/cyclophosphamide (TT/Cy) preparative regimen for patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation.Org: GlaxoSmithKline Pharmaceuticals,
Abstract
Impact of complete cytogenetic response on survival in patients with myelodysplastic syndromes.Org: Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX,
Abstract
Impact of frailty on patients hospitalized with myelodysplastic syndrome: A nationwide analysis.Org: Dutchess Community College, Wyckoff Heights Medical Center, Nuvance Health/Vassar Brothers Medical Center, Lake Erie College of Osteopathic Medicine, State University of New York Upstate Medical University,
Abstract
Time toxicity for patients receiving oral versus parenteral hypomethylating agents for myelodysplastic syndromes/neoplasms (MDS).Org: Epstein Health, LLC, Oracle Life Sciences,
Abstract
Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge.Org: Yale University, Azienda Ospedaliero Universitaria Careggi, University of Florence, University of Florence, AOUC, Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, University Hospital Leipzig,
Abstract
Cardiovascular complications associated with asciminib use: A retrospective analysis.Org: Willis-Knighton Health System, University of Missouri Kansas City,
Abstract
Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.Org: Yale School of Medicine, Yale Cancer Center, Yale University, University Hospital Leipzig, Cancer Center IRCCS Humanitas Research Hospital,
Abstract
Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial.Org: Princess Margaret Cancer Centre, University Health Network, Cleveland Clinic Taussig Cancer Institute, University of Florence, AOUC, Clinical Investigation Center,
Abstract
Association of elevated pulmonary artery systolic pressure with hematologic progression in myeloproliferative neoplasms.Org: New York University Grossman Long Island School of Medicine,
Abstract
Association between hemoglobin (Hb) improvement and patient-reported outcomes (PROs) in patients (pts) with myelofibrosis (MF) and anemia: Post hoc pooled analysis of momelotinib (MMB) phase 3 trials.Org: Modus Outcomes,
Abstract
Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF).Org: Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Leukemia, MD Anderson Cancer Center, Houston, TX,
Abstract
A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Trends in the thrombotic complications of myeloproliferative neoplasms: A nationwide analysis.Org: Medstar Georgetoen Cancer Institute,
Abstract
Efficacy and safety of ruxolitinib in patients with lower risk myelofibrosis: A single-arm, exploratory and prospective study.Org: The First Affiliated Hospital of Zhejiang University, School of Medicine, Zhejiang University, Hangzhou, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine,
Abstract
Predictors of symptom scores in myeloproliferative neoplasms: A real-world retrospective cohort study.Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic, Mayo Clinic Arizona,
Abstract
Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib in the United States.Org: Sobi Inc., IntegraConnect, PrecisionQ, Leukemia Service,
Abstract
Impact of pacritinib on symptoms in with thrombocytopenia and myelofibrosis who require red blood cell transfusion.Org: Washington University School of Medicine in St. Louis, The John Theurer Cancer Center at Hackensack Meridian Health, Wroclaw Medical University, Sobi Inc., Cleveland Clinic Taussig Cancer Institute,
Abstract
Meta-analysis of mutational site-specificity and concordance/discordance characteristics of myeloid sarcoma.Org: Wayne State University/Karmanos Cancer Institute, Saint Joseph Mercy Oakland Hospital, Neal Cancer Center/Houston Methodist Hospital, Wayne State University/Detroit Medical Center Sinai Grace Hospital, Karmanos Cancer Institute/Department of Oncology,
Abstract
Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.Org: Sylvester Cancer Center, AOU Careggi, Division of Hematology and Hematologic Malignancies, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Josep Carreras Leukemia Research Institute,
Abstract
Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.Org: Istituto di Ematologia s. Orsola-Malpighi,
Abstract
Improving the ICAHT grading criteria using time-series clustering.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center,
Abstract
Genomic evolution of patients with myeloid neoplasms and known antecedent clonal hematopoiesis.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Leukemia, H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute,
Abstract
Predictors of severe hematotoxicity after CAR T-cell therapy.Org: University of Washington/Fred Hutchinson Cancer Center, Fred Hutchinson Cancer Center,
Abstract
Pharmacokinetics and safety of asciminib (ASC) in pediatric patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): Interim results from the ASC4KIDS study.Org: Novartis Institute for BioMedical Research, Kanagawa Children's Medical Center,
Abstract
Estimating the health care costs associated with receipt of lisocabtagene maraleucel: Insights from adults with mantle cell lymphoma (TRANSCEND NHL 001).Org: BluePath Solutions,
Abstract
EX103: A newly designed CD20×CD3 molecule in heavily pre-treated patients with B-cell non-Hodgkin lymphoma from a phase I/II trial.Org: GCP ward, Institute of Hematology & Hospital of Blood Diseases, Department of Hematology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Department of Adult Lymphoma, Beijing GoBroad Boren Hospital, Beijing, China, Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China,
Abstract
A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.Org: Texas Oncology - Baylor Sammons Cancer Center, New South Wales Health,
Abstract
Interim results from the ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.Org: Center for Blood Disorders and Cellular Therapy, Virginia Commonwealth University Massey Cancer Center,
Abstract
Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees.Org: University of Washington/Fred Hutchinson Cancer Center, Fred Hutchinson Cancer Center,
Abstract
Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL).Org: The Ohio State University, Division of Hematology, The Ohio State University, Department of Internal Medicine, The Ohio State University, College of Medicine,
Abstract
Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).Org: UPMC Hillman Cancer Center, University of Pittsburgh, University of Miami/Sylvester Comprehensive Cancer Center, Fred Hutchinson Cancer Center, University of Washington, Mississauga, ON, Canada,
Abstract
A phase 1 study of LY007, a novel anti-CD20 CAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.Org: Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Jiangsu Province Hospital,
Abstract
Association between post-CART terminal complement complex (TCC) levels and clinically significant immune effector cell–associated neurotoxicity syndrome (ICANS).Org: The Ohio State University College of Medicine, The Ohio State University - Division of Hematology, Medical College of Wisconsin, Division of Hematology, The Ohio State University,
Abstract
A phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib.Org: Cellenkos Inc, Genève, Switzerland,
Abstract
Factors before leukapheresis that correlate with severe cytopenia and therapy related myeloid neoplasm post CAR-T.Org: Mayo Hospital,
Abstract
Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study.Org: Rigshospitalet and University of Copenhagen,
Abstract
Long term follow-up results of BRL-201 phase I study, a CRISPR-based non-viral PD-1 locus specific integrated anti-CD19 CAR-T cells in treating relapsed or refractory non-Hodgkin's lymphoma.Org: Brl Medicine Inc., Bone Marrow Transplantation Center,
Abstract
Follow-up on phase 1 study of AT101, a novel anti-CD19 chimeric antigen receptor cell therapy (CAR-T) in patients with relapsed or refractory (r/r) b-cell non-Hodgkin lymphoma.Org: AbClon Inc., Ajou University Hospital, Donga University Hospital, Dong-A University Medical Center,
Abstract
Impact of late immune effector cell associated hematotoxicity (ICAHT) and prolonged neutropenia after CAR-T therapy on infection and survival outcomes.Org: Vanderbilt University Medical Center, Memorial Sloan Kettering Cancer Center, Oregon Health & Science University, University of Pennsylvania, University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6.Org: Lehigh Valley Health Network, University of Oklahoma, Stephenson Cancer Center, H. Lee Moffitt Cancer Center at Memorial Healthcare System, Stony Brook University Medical Center,
Abstract
Patients (pts) with R/R large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) nonconforming product (NCP) under the Expanded Access Protocol (EAP).Org: CCF Taussig Cancer Center,
Abstract
Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2.Org: Department of Internal Medicine – Hematology, Assistance Publique – Hôpitaux de Marseille (AP-HM), University Hospitals Plymouth NHS Trust, Clinical Hematology Department, On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC,
Abstract
Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).Org: Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Sir Charles Gairdner Hospital and the University of Western Australia, The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester,
Abstract
Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.Org: Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital, Shijiazhuang, China, Shanghai East Hospital, Tongji University, Shanghai, China, Department of Hematology, Chinese PLA General Hospital, Beijing, China, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, Department of Medical Oncology, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou, China, The Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang, China, The Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, China, Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China, Curon Biopharmaceutical, Shanghai, China,
Abstract
Factors associated with manufacturing failure of commercial CD19 CAR-T cell products for large b cell lymphoma (LBCL).Org: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Department of Biostatistics, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center,
Abstract
Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).Org: Universitair Ziekenhuis Gent, Health Research Institute IIS-FJD, Lymphoma Service, Memorial Sloan Kettering Cancer Center,
Abstract
Evaluating CR as a surrogate endpoint for PFS in R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A meta-analysis of randomized controlled trials (RCT).Org: Bristol Myers Squibb, EVERSANA, Burlington, ON, Canada, Oxford University Hospitals NHS Trust, Dana-Farber Cancer Institute,
Abstract
Carfilzomib plus rituximab, ifosfamide, carboplatin and etoposide (C-RICE) led to higher response, OS, and PFS in patients with transplant-eligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).Org: University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Roswell Park Comprehensive Cancer Center, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Roswell Park Cancer Institute,
Abstract
Combination of pirtobrutinib and lentiviral transduced bispecific anti-CD20/CD19 (LV20.19) CAR T-cell therapy to improve outcomes in patients with relapsed/refractory lymphoma.Org: Medical College of Wisconsin Center for AIDS Intervention Research, Medical College of Wisconsin, Division of Hematology & Oncology,
Abstract
Real world incidence, prevention, and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax in the inpatient and outpatient settings.Org: St. Luke's Roosevelt,
Abstract
Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA).Org: Beigene Netherlands B.V., The Alfred and Monash University,
Abstract
Association between treatment (tx) response and PFS and OS in R/R chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A 12-month landmark (LM) meta-analysis.Org: a Dassault Systèmes Company,
Abstract
A single-cell multiomics analysis of IRF4 in mediating treatment resistance in ibrutinib-treated chronic lymphocytic leukemia (CLL).Org: Department of Molecular Biology and Biochemistry, Simon Fraser University, CancerCare Manitoba Research Institute,
Abstract
Real-world risk of bleeding events in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) treated with BTKi.Org: Wilmington, PINC AI Applied Sciences,
Abstract
Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the phase 3 Pola-R-CHP versus R-CHOP (POLARIX) study.Org: Centre Henri-Becquerel and University of Rouen, University Hospital Münster, M.D. Anderson Cancer Center, Charles University General Hospital, University of Montpellier,
Abstract
Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma.Org: Antoine-Lacassagne Cancer Center, University of Tennessee Graduate School of Medicine, Takeda Pharmaceuticals International AG,
Abstract
Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL).Org: Mayo Clinic, Stanford University Medical Center, Stanford, CA,
Abstract
A novel and selective oral PI3Kα/δ inhibitor, TQ-B3525, in patients with relapsed and/or refractory follicular lymphoma: A phase II, single-arm, open-label study.Org: The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tongji Hospital of Tongji University, The Affiliated Cancer Hospital of Nanjing Medical University, The Affiliated Hospital of Inner Mongolia Medical College,
Abstract
Non-Hodgkin lymphoma mortality disparities across different sexes, races, and geographic locations.Org: Saint Michael's Medical Center, McGovern Medical School,
Abstract
A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis.Org: School of Clinical Sciences at Monash Health, Concord Hospital,
Abstract
Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.Org: Affiliated Cancer Hosiptal of Zhengzhou University, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.,
Abstract
A phase II multicenter study of abexinostat, an oral histone deacetylase inhibitor, in patients with relapsed/refractory follicular lymphoma.Org: Tianjin People's Hospital, The Affiliated Hospital of Nankai University, Tianjin, China, The Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang, China, Fuijian Medical University Union Hospital, Fuzhou, China, Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China, The First Affiliated Hospital of Wannan Medical College, Wuhu, China,
Abstract
A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis.Org: Merck & Co., Inc., City of Hope National Medical Center,
Abstract
A phase 1 study of SHR-A1912, a CD79b targeted antibody-drug conjugate (ADC), in patients (pts) with B-cell non-Hodgkin lymphoma (B-NHL).Org: Department of Lymphoma Oncology, Shandong Cancer Hospital and Institute, Jinan, China, Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China, Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Department of Lymphoma & Hematology, Hunan Cancer Hospital, Changsha, China, Department of Hematology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China,
Abstract
Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY).Org: Universidad de Navarra, Madrid and Pamplona, Spain, Vall d'Hebron University Hospital, Barcelona, Spain, Istituto Nazionale Tumori, Fondazione ‘G. Pascale’, IRCCS, Naples, Italy, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy, Hospital Universitario de Salamanca – Complejo Asistencial Universitario de Salamanca, Salamanca, Spain,
Abstract
Glofitamab combined with poseltinib and lenalidomide for relapsed/refractory diffuse large B cell lymphoma: Interim analysis of GPL study.Org: Wonju Severance Christian Hospital, Chonbuk Natioanl University Medical School and Hospital, Chungnam National University Sejong Hospital,
Abstract
Survival outcomes after autologous stem cell transplantation in T follicular helper type lymphoma.Org: McGovern Medical School,
Abstract
Longitudinal patterns of patient-reported cognitive impairment in patients with non-Hodgkin lymphoma (NHL) treated with chemotherapy: A group-based trajectory analysis of a nationwide community-based cohort.Org: Spartanburg Medical Center, Medical Oncology Hematology Consultants PA, Newark, DE,
Abstract
CODOX-M/IVAC-R versus DA-EPOCH-R in double/triple-hit large B cell lymphoma in patients ≤ 60 years.Org: Mayo Clinic, Mayo Clinic Florida,
Abstract
Impact of bridging therapy (BT) on lisocabtagene maraleucel (liso-cel) treatment in patients (pt) with R/R follicular lymphoma (FL).Org: Universität zu Köln, Karolinska Institutet and University Hospital, Montpellier University Hospital Center, Groupe de Recherche sur les formes Injectables et les Technologies Associées,
Abstract
Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study.Org: Institut Catala d'Oncologia - Hospital Duran i Reynals, Hematology Department, Hospital 12 de Octubre,
Abstract
Clinical and financial burden of mental health (MH) conditions in patients (pts) with low-grade non-Hodgkin lymphoma (LG-NHL).Org: Real Chemistry, Inc.,
Abstract
Selinexor combined with tislelizumab in patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL): Results of dose escalation of cohort C, from a multicenter, single-arm, phase I/II study (TOUCH).Org: Department of Lymphoma, Fudan University Shanghai Cancer Center,
Abstract
First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study.Org: Grampians Health, Austin Health and University of Melbourne, Olivia Newton-John Cancer Research Institute and La Trobe University, Murdoch Children's Research Institute,
Abstract
Combined modality for localized gastric diffuse large B-cell lymphoma: Long-term outcomes of 50 patients.Org: Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
P-GEMOX with sequential or sandwiched radiotherapy for early-stage extranodal natural killer/T-cell lymphoma.Org: The First Affiliated Hospital - Zhejiang University School of Medical, Hangzhou, China, Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China,
Abstract
Incidence of central nervous system relapse in primary mediastinal B-cell lymphoma: Implications for central nervous system prophylaxis.Org: The Second Clinical Medical College, Jinan University, Hematology Oncology Division,
Abstract
Durable complete response and overall survival in patients with heavily pretreated, poor-prognosis non-Hodgkin lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects.Org: AVM Biotechnology, Inc.,
Abstract
Outcomes and prognostic factors of patients diagnosed with relapsed/refractory primary B-cell lymphoma: A retrospective study.Org: University of Michigan Hospital, Rogel Cancer Center, Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, University of Michigan Medical School, University of Michigan,
Abstract
BCMA-directed CART therapy in patients with multiple myeloma and CNS involvement.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, H. Lee Moffitt Cancer Center and Research Institute, University of Pennsylvania, Hospital of the University of Pennsylvania, University of California, San Francisco,
Abstract
Results from the follicular lymphoma (FL) outcomes in patients (pts) with relapsed/refractory (R/R) disease treated with systemic therapy in a real-world assessment (FLORA) study.Org: Regeneron Pharmaceuticals, Inc., IQVIA, Amsterdam, Netherlands,
Abstract
Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).Org: Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Ascentage Pharma Pty Ltd.,
Abstract
Supplement use habits and perceptions in patients with plasma cell disorders.Org: Icahn School of Medicine at Mount Sinai South Nassau, Myeloma service, Department of Medicine, Memorial Sloan Kettering Cancer Center, HealthTree Foundation, Dartmouth College Geisel School of Medicine, Integrative Medicine Service, Memorial Sloan Kettering Cancer Center,
Abstract
Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Results from the TELLOMAK phase 2 trial.Org: Hôpital Saint Louis, Multidisciplinary Cutaneous Lymphoma Program, Rochester Skin Lymphoma Medical Group, CHU de Rouen - Hôpital Charles-Nicolle, Universitair Ziekenhuis Leuven,
Abstract
Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.Org: University of South Florida Morsani College of Medicine, H. Lee Moffitt Cancer Center and Research Institute, Moffitt Cancer Center,
Abstract
Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy.Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic, Mayo Clinic Rochester, Rochester, MN, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9.Org: Japanese Red Cross Medical Center, St. David's South Austin Medical Center,
Abstract
Second primary B-ALL after exposure to lenalidomide for multiple myeloma: A US multicenter study.Org: Division of Hematology, Rochester, MN, The University of North Carolina at Chapel Hill, Chapel Hill, NC, Columbia University Medical Center, New York, NY, Marshfield Clinic, Marshfield, WI, Division of Hematopathology, Mayo Clinic, Rochester, MN,
Abstract
Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).Org: Froedtert & Medical College of Wisconsin Cancer Center, Tulane Cancer Center, Tulane University Schoool of Medicine, Universitätsklinikum Carl Gustav Carus Dresden,
Abstract
Validation of prototype biomarkers to identify risk factors of inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) infusion in patients with relapsed and refractory multiple myeloma (RRMM) in KarMMa-3.Org: Bristol Myers Squibb, Mayo Clinic, Lille University Hospital, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).Org: Froedtert & Medical College of Wisconsin Cancer Center, Tulane Cancer Center, Tulane University Schoool of Medicine, Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus Dresden,
Abstract
Rapid reduction of free light chains and improvement in renal outcomes in patients with newly diagnosed multiple myeloma admitted with acute kidney injury with daratumumab-based therapy and without plasmapheresis.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA,
Abstract
Association of patient (pt) factors and pharmacodynamic biomarkers with progression-free survival (PFS) after idecabtagene vicleucel (ide-cel) in pts from KarMMa-3.Org: Hospital Clinico Universitario de Salamanca,
Abstract
Incidence of acute kidney injury in patients with relapsed and refractory multiple myeloma treated with teclistamab vs chimeric antigen receptor T-cell therapy.Org: Division of Nephrology and Hypertension,
Abstract
Characterization of the BCMA epitope bound by BCMA-CD3 T cell engager elranatamab.Org: Pfizer Inc., San Diego State University Department of Biology, San Diego, CA, CanSino Biologics, Cambridge University Hospitals NHS Foundation Trust, MaaT Pharma,
Abstract
Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma.Org: Horsham, PA,
Abstract
Patterns and predictors of electronically measured oral anticancer medication (OAM) adherence among patients with multiple myeloma (MM).Org: Eshelman School of Pharmacy, University of Pittsburgh Graduate School of Public Health, University of Pittsburgh School of Nursing,
Abstract
Frontline treatment with zanubrutinib plus rituximab (ZR) followed by short course R-DHAOx in patients with mantle cell lymphoma (MCL): Results of the phase II CHESS clinical trial.Org: Department of Hematology, Huizhou Municipal Central Hospital, Department of Medical Oncology, The Second Hospital of Dalian Medical University, Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University,
Abstract
Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Yale School of Medicine, Yale New Haven Hospital, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.Org: University College London Hospitals, NHS Foundation Trust, Hematología Hospital 12 de Octubre,
Abstract
Post-ASCT consolidation with EPD or ERD in patients with high-risk multiple myeloma.Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Abstract
Real world outcomes of high dose melphalan conditioning prior to autologous stem cell transplant in extramedullary multiple myeloma vs. multiple myeloma without extramedullary involvement: A single center experience.Org: Los Angeles General Internal Medicine Residency Program, University of Southern California/Los Angeles General Medical Center Internal Medicine Residency Program, University of Southern California Keck School of Medicine,
Abstract
Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM).Org: NIHR UCLH Clinical Research Facility, Department of Clinical Haematology,
Abstract
Exposure-response analyses for optimal therapeutic dose selection of ABBV-383 in patients with relapsed/refractory multiple myeloma (RRMM).Org: Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Froedtert & Medical College of Wisconsin Cancer Center,
Abstract
Evaluation of a novel method to guide belantamab mafodotin dosing in multiple myeloma based on a patient-reported questionnaire.Org: Health Data Specialists,
Abstract
Population attributable fractions for risk factors for the progression of monoclonal gammopathy of undetermined significance to multiple myeloma in the Veteran population.Org: Saint Louis University School of Medicine, St. Louis, MO, Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, Saint Louis VA Medical Center John Cochran Division, St. Louis, MO,
Abstract
Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup.Org: Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center,
Abstract
OPTec: A phase 2 study to evaluate outpatient (OP) step-up administration of teclistamab (Tec), a BCMA-targeting bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Org: Denver, CO, Colorado Blood Cancer Institute, Eugene, OR, Janssen US Oncology Medical Affairs, Janssen Scientific Affairs LLC,
Abstract
Mortality trends (1999-2022) in patients with multiple myeloma with pneumonia, influenza, and COVID-19.Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Abstract
Effect of daratumumab on light chain reduction in newly diagnosed multiple myeloma with light chain cast nephropathy.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC,
Abstract
Long-term follow-up of ARI0002h (cesnicabtagene autoleucel), an academic point-of-care B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell strategy: Activity and safety after fractionated initial therapy and booster dose in 60 patients with relapsed/refractory multiple myeloma (RRMM).Org: IMIB-Pascual Parrilla, University of Murcia, Complutense University, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Biomedicina de Sevilla (IBIS)/CSIC,
Abstract
Uncontrolled diabetes mellitus and the progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans.Org: Research Service, St Louis Veterans Affairs Medical Center,
Abstract
Apixaban versus warfarin for primary thromboprophylaxis in patients with multiple myeloma undergoing immunomodulatory treatment.Org: Mount Auburn Hospital, Unity Hospital, Rochester Regional Health, National Cheng Kung University College of Medicine, Tainan,
Abstract
From criteria to clinic: How updated SLiM CRAB criteria influence multiple myeloma diagnostic activity.Org: Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, McKelvey School of Engineering, Washington University in St. Louis, St. Louis, MO, Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, Yale School of Public Health, New Haven, CT, Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, Saint Louis University School of Medicine, St. Louis, MO,
Abstract
Outcomes of myeloma cast nephropathy in the era of anti-CD38 monoclonal antibody-based frontline therapy: A retrospective cohort study.Org: Columbia University Medical Center, Columbia University Irving Medical Center, New York, NY, USA,
Abstract
Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).Org: Clinica São Germano, São Paulo, Brazil, Medical University of Lodz, Lodz, Poland, Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland, The First Affiliated Hospital of Soochow University, Suzhou, China, Gorodskaya Klinicheskaya Bol'nitsa Im. Botkina, Moscow, Russian Federation,
Abstract
Effect of dose-adjusted melphalan on MRD-negativity to full dose melphalan in patients with multiple myeloma post-autologous stem cell transplant.Org: Univ Hosps of Cleveland,
Abstract
First relapse in patients with multiple myeloma: Outcomes and predictors.Org: Mayo Clinic, Rochester Regional Health System, MN, Mayo Clinic Rochester, Rochester, MN, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
Effect of maintenance therapy (MT) on real-world outcomes (RWO) of patients (pts) with newly diagnosed multiple myeloma (NDMM) post stem cell transplant (SCT).Org: COTA, Inc.,
Abstract
Access to palliative care in patients with multiple myeloma in the USA: A National Cancer Database (NCDB) analysis of years 2004-2020.Org: Cleveland Clinic Florida,
Abstract
Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Karmanos Cancer Institute, University of Miami Health System,
Abstract
Real-world outcomes (RWO) with tandem transplantation in patients (pts) with newly diagnosed multiple myeloma (NDMM).Org: COTA, Inc.,
Abstract
Automated myeloma cell selection using machine learning and artificial intelligence.Org: Telo Genomics, Jewish Gen Hosp,
Abstract
Genome-wide 5-hydroxymethylation mapping and epigenetic pathways in multiple myeloma.Org: Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, British Columbia Cancer, Vancouver, BC, Canada, Department of Chemistry, The University of Chicago, Chicago, IL, Department of Public Health Sciences, The University of Chicago, Chicago, IL, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicgao, IL,
Abstract
Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.Org: Myeloma Center,
Abstract
Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma.Org: Yale School of Public Health, Yale University Shool of Medicine,
Abstract
Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).Org: Mayo Clinic, University Medical Center Hamburg-Eppendorf, Regeneron Pharmaceuticals, Inc., EVERSANA, Burlington, ON, Canada, Mount Sinai Hospital-Breast Medical Oncology,
Abstract
Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma.Org: Myeloma Service, Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, New York, NY, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
Long-term outcomes after cardiac transplantation in AL amyloidosis.Org: Vanderbilt University Medical Center,
Abstract
1p and 1q: Partners in crime in multiple myeloma.Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, The Ohio State University - James Cancer Hospital,
Abstract
Long term follow up of monoclonal gammopathy of undetermined significance (MGUS) in US Veterans: Racial differences and associations with other malignancies.Org: VA Long Beach Healthcare System,
Abstract
Unveiling consistency: A large-scale analysis of conference proceedings and subsequent publications in oncology clinical trials using large language models.Org: IMO Health, International Society for Pharmacoeconomics and Outcomes Research,
Abstract
Exploring the role of the combination of FDG-PET plus whole body MRI for staging patients with high-risk smoldering myeloma: A prospective trial.Org: Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS, Meldola (FC), Italy, Hematology Unit - Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS, Meldola, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori","Meldola, Italy", IRCSS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori – IRST, Meldola, Italy, Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy,
Abstract
A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, The Bone Marrow and Transplant Group of Georgia, The Colorado Blood Cancer Institute,
Abstract
A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.Org: Hospital Universitari i Politecnic La Fe de Valencia, Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Medical Clinic and Policlinic, Hematology and Cellular Therapy, University Hospital Leipzig, Weatherall Institute of Molecular Medicine, MRC Molecular Hematology Unit, University of Oxford, University Hospital Muenster,
Abstract
Phase 1b trial of IRAK 1/4 inhibition for low-risk myelodysplastic syndrome refractory/resistant to prior therapies.Org: Rigel Pharmaceuticals, Inc.,
Abstract
A phase 1 single-arm, open-label study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in patients (pts) with acute myeloid leukemia (AML) in complete response (CR) with measurable residual disease (MRD).Org: MD Anderson Cancer Center Madrid, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS, Universitätsklinikum Jena, Technische Universität Dresden, Curis Inc,
Abstract
Covalent-103: A phase 1, open-label, dose-escalation and expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia (AL).Org: Division of Hematology/Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, Biomea Fusion, Inc.,
Abstract
VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).Org: Palacky University and University Hospital Olomouc, University Hospital and Masaryk University, IRCCS Azienda Ospedaliero-Universitaria di Bologna - Institute of Hematology “L. and A. Seràgnoli”,
Abstract
A first-in-human, phase 1, dose escalation study of SGR-2921 as monotherapy in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.Org: Sarah Cannon Transplant & Cellular Therapy Network, Kansas University Medical Center,
Abstract
Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naïve myelofibrosis and moderate thrombocytopenia.Org: The Richard T. Silver, MD Myeloproliferative Neoplasms Center, Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center,
Abstract
HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial.Org: Department of Hematology,The First Affiliated Hospital of Chongqing Medical University, Department of Hematology and Oncology, Chongqing University Cancer Hospital, Department of Hematology Oncology, YunNan Provincial Cancer Hospital, Department of Lymphoma Medicine, Hubei Cancer Hospital, Department of Lymphoma and Hematology, Hunan Cancer Hospital,
Abstract
Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.Org: VCU Massey Comprehensive Cancer Center, Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust,
Abstract
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in patients with polycythemia vera (PV).Org: United Lincolnshire Hospital Trust and University of Lincoln, Sunshine Coast Haematology and Oncology Clinic, Montserrat Cancer Care, The University of Sydney and Royal Prince Alfred Hospital, Royal Perth Hospital,
Abstract
Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.Org: Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Colorado Blood Cancer Institute/Sarah Cannon Research Institute,
Abstract
A phase I, first-in-human study of ONO-7018 in patients with relapsed/refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia.Org: ONO PHARMA USA, INC.,
Abstract
Phase 3 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in patients with essential thrombocythemia (ET).Org: Sheba Medical Center–Tel HaShomer, Tel Aviv-Yafo, Royal Adelaide Hospital and SA Pathology,
Abstract
BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).Org: Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele,
Abstract
BELLWAVE-011: Phase 3 randomized trial of nemtabrutinib versus ibrutinib or acalabrutinib in untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom, Haematology Unit, Bnai Zion Medical Center, Haifa, Israel, Department of Hematology & BMT, Chaim Sheba Medical Center, Tel Aviv, Israel, Summit Cancer Center, Spok, WA, Hadassah Medical Center, Jerusalem, Israel,
Abstract
CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL.Org: Lymphoma and Myeloma Research Amsterdam, St. James's Hospital, BeiGene International GmbH, Department of Haematological Medicine,
Abstract
BGB-11417-203: An ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia.Org: Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Hattiesburg Clinic, Genesis Care North Shore, Affiliated Zhongshan Hospital of Fudan University, BeiGene (Beijing) Co, Ltd,
Abstract
Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3).Org: Division of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, Namık Kemal Üniversitesi, Nantes University Hospital, Centre Hospitalier Universitaire (CHU) de Poitiers,
Abstract
A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed/refractory B-cell malignancies.Org: Willamette Valley Cancer Institute and Reserach Center, US Oncology Hematology Research Program, US Oncology Research and Rocky Mountain Cancer Centers,
Abstract
Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).Org: Hematology Oncology of Indiana/American Oncology Network, Azienda Unità Sanitaria Locale-IRCCS, Gazi Universitesi Tip Fakültesi, ProHealth Care,
Abstract
A phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501, a first-in-class NK cell engager, in patients with relapsed and/or refractory CD20-expressing non-Hodgkin lymphoma.Org: Peninsula Health, Peninsula Private Hospital,
Abstract
Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).Org: Turin, Italy, Varese, Italy, Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Waukesha, WI,
Abstract
First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led study.Org: Barwon Health,
Abstract
EPCORE FL-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma.Org: Manchester Cancer Research Centre, Sir Peter MacCallum Cancer Centre Melbourne, University of Modena and Reggio Emilia,
Abstract
An open label, single arm, multicenter phase II study of the efficacy and safety of LP-168 monotherapy for relapsed or refractory mantle cell lymphoma.Org: Hubei Cancer Hosipital, Meizhou People’s Hospital,
Abstract
Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).Org: The Cancer and Hematology Centers, Grand Rapids, MI, Community Cancer Trials of Utah, Ogden, UT, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, Department of Hematology, Sakarya University, Sakarya, Turkey, Gazi Universitesi Tip Fakültesi, Ankara, Turkey,
Abstract
Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL; OLYMPIA-4).Org: School of Public Health & Preventative Medicine, Monash University, Melbourne, Australia, Hospital Universitario Doctor Peset, Valencia, Spain, Hospital Virgen de las Nieves, Granada, Spain, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, Australia, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea,
Abstract
Multicenter, randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T).Org: Huntsman Cancer Institute/University of Utah, Washington University in St. Louis Department of Genetics, Division of Hematology, Mayo Clinic Florida,
Abstract
Real-world data based on PD-L1 expression in early-stage NSCLC in an east-Asian patient population: A 10-year follow-up study.Org: The Catholic University of Korea, The University of Hong Kong, Seoul St. Mary's Hospital,
Abstract
LOTIS-5: An ongoing, phase 3, randomized study of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL.Org: Centrum Medyczne Pratia Poznań, Department of Oncology and Hematology, Humanitas University and IRCCS Humanitas Research Hospital, ADC Therapeutics SA, ADC Therapeutics Ltd., ADC Therapeutics America, Inc.,
Abstract
Efficacy and safety of perioperative, neoadjuvant or adjuvant immunotherapy alone or in combination chemotherapy in early-stage non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.Org: Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China, Department of Respiratory and Critical Care Medicine, Jinling Hospital, Nanjing Medical University, Nanjing, China,
Abstract
Impact of EGFR mutation and types of treatment on the longitudinal recurrence risk in patients with completely resected non-small cell lung cancer: A combined analysis of two phase III studies (JIPANG and IMPACT).Org: National Cancer Center Hospital East, Kashiwa-Shi, Japan, Division of Data Science, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Japan, Department of Respiratory Internal Medicine, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan, Osaka City General Hospital, Osaka, Japan,
Abstract
MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).Org: Pfizer Oncology Division,
Abstract
Investigation of the role of personalized molecular residual disease in the assessment of high-risk non-small cell lung cancer (NSCLC) post-operation.Org: Shenzhen, China,
Abstract
Efficacy and safety of immunotherapy plus chemotherapy for lung cancer neoadjuvant treatment: A network meta-analysis based on randomized controlled trials.Org: Department of Biotherapy, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University,
Abstract
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.Org: Service de Pneumologie et oncologie thoracique, CIC Inserm 1425, Centre Francois Baclesse, Hôpital Gabriel Montpied, Centre Hospitalier Du Mans,
Abstract
Surgical outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and meta-analysis.Org: Chemotherapy Center,
Abstract
A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis.Org: Boston University Section of Hematology and Medical Oncology,
Abstract
Evaluation of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma and prior anti-CD38–directed therapy: MagnetisMM-32.Org: UCHealth Cancer Care and Hematology, Department of Hematology, Yamagata University Hospital,
Abstract
Unlocking therapeutic potential: IL-1β as a target in non-small cell lung cancer with oncogenic mutations—Prognostic and predictive insights.Org: Loma Linda University Department of Radiation Technology, Department of Oncology/Hematology, Loma Linda University Medical Center, Division of Hematology/ Oncology, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC).Org: Department of Thoracic Surgery and Lung Cancer Center, Pathologic Department,
Abstract
Deep-learning model for real-time prediction of recurrence in early-stage non-small cell lung cancer: A multi-modal approach.Org: Spidercore Inc., Department of Thoracic and Cardiovascular Surgery, Sungkyunkwan University School of Medicine, Samsung Medical Center, Department of Internal Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine,
Abstract
Implications of EGFR expression in MAPK dependency and adaptive immunity status of EGFR-mutated lung adenocarcinoma.Org: Juntendo University Faculty of Medicine and Graduate School of Medicine,
Abstract
Cost-effectiveness in perioperative therapy in the era of immune checkpoint inhibitors.Org: Juntendo University Graduate School of Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine,
Abstract
The association between osimertinib and nutritional deficiency among patients with non-small cell lung cancer.Org: Unity Hospital, Rochester Regional Health System, Mount Auburn Hospital, Harvard Medical School, Cambridge University Hospitals NHS Foundation Trust,
Abstract
Retrospective analysis of change in frequency of STK11 mutation in lung adenocarcinomas over a 10-year period.Org: SUNY Upstate Medical University, Foundation Medicine, Inc., Cambridge, MA,
Abstract
Artificial intelligence-based prediction model of malignant lung nodules for preoperative planning.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Hong Kong Institute for Data Science, City University of Hong Kong, Hong Kong SAR, China, Nanfang Hospital, Southern Medical University, Guangzhou, China,
Abstract
Sex and racial disparities in incidence and survival outcomes in adolescents and young adults (AYA) with lung cancer in the United States.Org: One Brooklyn Health System, One Brookdale Hospital, Brookdale University and Hospital,
Abstract
Prospective “common arm” comparison of US SWOG S0424 and Japanese JME studies in early-stage non-small cell lung cancer (NSCLC): Survival differences in the context of race, gender and smoking.Org: National Hospital Organization Kinki-Chuo Chest Medical Center, IASLC, Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Graduate School of Medicine, Osaka City University,
Abstract
Clinicopathologic and molecular landscape of invasive mucinous adenocarcinoma of the lung.Org: Feinberg School of Medicine, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Tempus AI, Tempus Labs, Inc.,
Abstract
Predicting response of patients with NSCLC to immunotherapy using innate immune fitness (IIF) profiling.Org: GMDx Group Ltd,
Abstract
The genomic, transcriptomic, and immunological profile of patients with recurrent/refractory NSCLC.Org: Caris Life Sciences Research and Development, Caris Life Sciences, Irving, TX,
Abstract
Smoking and pathogenic germline variants in patients with lung cancer.Org: Invitae Corporation, Invitae, University of Colorado Cancer Center, University of Colorado Denver Anschutz Medical Center,
Abstract
Signatures of early plasticity in the histological transformation of lung cancer.Org: Columbia University Vagelos College of Physicians and Surgeons, Memorial Sloan Kettering Cancer Center,
Abstract
Differentially expressed microRNAs in prediagnostic serum linked to lung cancer up to eight years before diagnosis in prospective, population-based cohorts: A HUNT study.Org: Norwegian University of Science and Technology (NTNU), University of Crete, UiT The Arctic University of Norway, Institute of Applied and Computational Mathematics, Institute of Chemical Biology,
Abstract
Comprehensive analysis of predictive factors for efficacy in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer, utilizing individual patient data from the Japan lung cancer society integrated clinical trial database: Is there room for further improvement?Org: Hamamatsu Medical Center, Yokohama Municipal Citizen's Hospital, Center for Innovative Clinical Medicine, Okayama University Hospital, Department of Surgery, Tokyo Medical University,
Abstract
Neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer (NSCLC): A systematic review and extracted individual patient data meta-analysis.Org: Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto,
Abstract
Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium.Org: Oncology Associates of Oregon P.C., Maryland Oncology Hematology, Illinois Cancer Specialists, Southern Cancer Center, Woodlands Medical Specialists,
Abstract
Induction therapy with PD-1 antibody combined with platinum-based doublet chemotherapy for locally-advanced non-small cell lung cancer: A randomised controlled, open-label, phase 2 trial.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Shanghai Pulmonary Hospital, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Multi-institution real world analysis of patients with non-small cell lung cancer (NSCLC) treated with standard of care (SOC) neoadjuvant chemo-immunotherapy (chemoIO).Org: Lowe Center for Thoracic Oncology,
Abstract
Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC).Org: Centre Hospitalier Intercommunal de Créteil, Cancer Center of Kansas, University of Colorado Anschutz Medical Center,
Abstract
Cost analysis of targeted and immunotherapies in operable esophageal and non-small cell lung cancers.Org: Division of General Thoracic Surgery, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery,
Abstract
Analysis of outcomes in resected early-stage non-small cell lung cancer (NSCLC) with rare targetable driver mutations.Org: Princess Margaret Cancer Centre, University Health Network, Department of Medical Oncology and Hematology, Division of Thoracic Surgery, Shizuoka Cancer Center, University of Toronto,
Abstract
Prediction of recurrence in stage I EGFR mutation-positive NSCLC: Combination of CT appearance and selected co-occurring gene alterations by machine learning.Org: Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan, Department of Thoracic Oncology , National Cancer Center Hospital, Tokyo, Japan, Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan, Department of Radiation Oncology, National Cancer Center Hospital, Japan, Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan,
Abstract
Operability changes in patients with NSCLC after neoadjuvant chemotherapy and anti-PD-1/PD-L1.Org: Hospital Clinico San Carlos, Hospital Clínico Universitario de Valladolid, University Hospital Fundación Jiménez Díaz, Ramon y Cajal University Hospital, Hospital Severo Ochoa,
Abstract
The youngest population under 50 years old (P50) with lung cancer (LC) in the French nationwide real-life KBP cohorts: Evolution since 2000.Org: Hopitaux Nord-Ouest, Centre Hospitalier Alpes-Léman CHAL, Groupe Hospitalier du Havre, Établissement de Médecine et SMR de Sainte-Feyre, Ch Abbeville,
Abstract
Final survival outcomes and exploratory biomarker analysis from the randomized, phase 2 neoSCORE trial: Two versus three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small cell lung cancer.Org: The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China, Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China,
Abstract
The safety and efficacy of induction chemoimmunotherapy in initially unresectable stage III non-small cell lung cancer.Org: National Center of Gerontology, Institute of Geriatric Medicine,
Abstract
Next-generation sequencing (NGS) completion and timeliness using reflex testing protocol for patients with stage II-III non-squamous non-small cell lung cancer (NS-NSCLC).Org: University of Virginia - Department of Pathology,
Abstract
Pre- and post-operative lung cancer recurrence prediction following curative surgery: A retrospective study using European radiomics and clinical data.Org: North Estonia Medical Center, Tallinn, Estonia, North Estonia Medical Centre, Optellum Ltd., Oxford, United Kingdom,
Abstract
Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus chemotherapy for potentially resectable non-small cell lung cancer: A phase Ib study.Org: Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, China Jinagsu Province Institute of Cancer Research,
Abstract
Treatment outcomes in locally advanced, unresectable NSCLC treated with concurrent chemoradiation and PD-L1 consolidation: Real-world data from a NCI comprehensive cancer center with a racially diverse, high poverty catchment area.Org: University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine,
Abstract
The impact of HIV and CD4 count stratification on all cause mortality for adenocarcinoma and squamous cell lung cancers in the antiretroviral therapy era: Analysis of National Veterans Affairs and Kaiser Permanente Northern cohorts.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, The University of Texas Health Science Center at Houston, MD Anderson Cancer Center, Baylor College of Medicine, Baylor College of Medicine Division of Diabetes Endocrinology and Metabolism,
Abstract
Feasibility of induction chemoimmunotherapy (ID chemo-IO) followed by chemoradiation for locally advanced unresectable non-small cell lung cancer (NSCLC).Org: Mayo Clinic, Mayo Clinic Rochester, Rochester, MN, Mayo Clinic Department of Pediatric and Adolescent Medicine,
Abstract
Lymph node metastasis prediction with non-small cell lung cancer histopathology imaging.Org: Yale School of Medicine, New Haven, CT,
Abstract
Clinical outcomes of maintenance durvalumab after definitive concurrent chemoradiotherapy in unresectable locally advanced stage III non-small cell lung cancer according to epidermal growth factor receptor and anaplastic lymphoma kinase status: Korean Cancer Study Group LU-22-18.Org: Gangneung Asan Hospital, Yeungnam University Medical Center, Ilslan Paik Hospital, Center for Lung Cancer, Soonchunhyang University Seoul Hospital,
Abstract
Anlotinib plus docetaxel in advanced NSCLC progressing on immunotherapy: A pooled analysis of two randomized trials.Org: The Affiliated People’s Hospital of Ningbo University, The First Affiliated Hospital of Hunan College of Traditional Chinese Medicine, First People’s Hospital of Chenzhou, Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, The Affiliated Cancer Hospital of Xiangya Medical School, Central South University,
Abstract
ALK testing patterns in early-stage non-small cell lung cancer: A real-world evidence study.Org: Augusta, MO, South California, CA,
Abstract
An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer.Org: Picture Health Inc., Dignity Health - St. Rose Dominican Hospital, Northwestern Medicine Developmental Therapeutics Institute,
Abstract
A multi-center cohort study Examining risk factors for central nervous system metastases (CNSm) in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiation (ChemoRT) followed by durvalumab (Durva).Org: UVA Hematology/Oncology, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center,
Abstract
A phase II, two-cohort study of neoadjuvant chemotherapy plus tislelizumab ± bevacizumab followed by hypofractionated radiotherapy, concurrent chemotherapy, and consolidative immunotherapy in locally advanced non-small cell lung cancer (GASTO-1086).Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, Guangdong, China,
Abstract
Integration of circulating tumor DNA and metabolic parameters for outcome prediction in unresectable locally advanced non-small cell lung cancer.Org: Shanghai Proton and Heavy Ion Center,
Abstract
Comparative survival after neoadjuvant vs adjuvant systemic therapy in resectable stage II and stage III non-small cell lung cancer: A retrospective study using the National Cancer Database.Org: Department of Public Health & Preventive Medicine,
Abstract
Efficacy and surgical safety of sequential surgical resection after neoadjuvant chemoimmunotherapy for unresectable stage III NSCLC.Org: Department of Internal Medicine Oncology, Shandong First Medical University and Shandong Academy of Medical Science, Shandong Provincial Institute of Cancer Prevention and Treatment,
Abstract
Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799.Org: LungenClinic, N.N. Blokhin Russian Cancer Research Center, N.N. Petrov National Medical Research Center of Oncology, Thoracic Oncology Unit, Mid North Coast Cancer Institute,
Abstract
Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Dana-Farber Cancer Institute, Ronald Reagan UCLA Medical Center, University of Michigan,
Abstract
Assessing quality of care in early stage resected stage non-small cell lung cancer (NSCLC): An evaluation of epidermal growth factor receptor (EGFR) testing and adjuvant (adj) therapy (tx).Org: Genesis Cancer Center,
Abstract
Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC).Org: Foresight Diagnostics,
Abstract
Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting.Org: Translational Lung Research Center Heidelberg (TLRC-H), Airway Research Center North (ARCN), Evang. Kliniken Essen-Mitte, Klinikum der Stadt Köln gGmbH, Clinic for Internal Medicine I, University Hospital Dresden,
Abstract
Five-year survival outcomes from the PIT-1 trial: Pemetrexed-cisplatin plus bevacizumab or concurrent thoracic radiation therapy followed by surgery in stage IIIA (N2) nonsquamous non-small cell lung cancer.Org: Juntendo University School of Medicine, Tokyo Bay Makuhari Clinic for Advanced Imaging, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,
Abstract
Multidimensional analysis of B7 homolog 3 (B7-H3) RNA expression in small-cell lung cancer (SCLC) molecular subtypes.Org: Daiichi Sankyo, Inc., Caris Life Sciences, Irving, TX,
Abstract
Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A propensity score-matched study.Org: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Shandong Cancer, Jinan, China, Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China, Department of Respiratory Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China,
Abstract
Surrogate endpoints and outcomes in modern small cell lung cancer trials.Org: Case Western Reserve University School of Medicine, Department of Population and Quantitative Health Sciences,
Abstract
EGFR-TKI as neoadjuvant treatment in patients with NSCLC with EGFR sensitive mutation: A retrospective real-world analysis.Org: First Affiliated Hospital of Guangzhou Medical University,
Abstract
Combining a WT1 cancer vaccine (galinpepimut-S) with checkpoint inhibition (nivolumab) in patients with WT1-expressing diffuse pleural mesothelioma (DPM): A phase I study.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).Org: JSInnoPharm, JS InnoPharm (Shanghai) Ltd,
Abstract
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial.Org: Zhengzhou, China, Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer, Luoyang, China, Hunan Provincial Tumor Hospital, Changsha, China,
Abstract
Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC).Org: Harpoon Therapeutics, Inc.,
Abstract
Outcome of chemo-immunotherapy for extensive-stage small-cell lung cancer according to potential clinical trial eligibility: 3-year outcomes from prospective cohort study.Org: Kobe Minimally Invasive Cancer Center, Hyogo Prefectural Amagasaki General Medical Center, NHO Kinki-Chuo Chest Medical Center, NHO Osaka Toneyama Medical Center, Itami City Hospital,
Abstract
Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in patients (Pts) with relapsed small cell lung cancer (SCLC): Results from a phase 2 expansion cohort.Org: Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid (UCM), Virgen del Rocío University Hospital, Hospital Universitario Vall d'Hebron, Hospital Universitario Virgen del Rocio,
Abstract
Survival outcomes of patients with extensive-stage small cell lung cancer who received treatment with atezolizumab in combination with carboplatin and etoposide: A propensity score adjusted cohort study.Org: Lerner Research Institute, Center for Immunotherapy & Precision Immuno-Oncology,
Abstract
Tifcemalimab combined with toripalimab and chemotherapy as 1st line treatment for extensive-stage small cell lung cancer (ES-SCLC): A phase Ib/II, open-label study.Org: The Second Affiliated Hospital of Anhui Medical University,
Abstract
Final analysis of the BIMES trial, a phase II single arm study assessing efficacy and safety of bintrafusp alfa in previously treated advanced malignant pleural mesothelioma (GECP 20/09).Org: Hospital Universitario Virgen de la Victoria, Hospital Josep Trueta, Hospital Parc Taulí Sabadell, Lucus Augusti University Hospital,
Abstract
J-TAIL-2: A prospective, observational study of atezolizumab (atezo) combined with carboplatin and etoposide (CE) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) in Japan.Org: Department of Respiratory Medicine, Tohoku University, Sendai, Japan, Department of Respiratory Medicine and Allergy, Okayama University Hospital, Okayama, Japan, Department of Pulmonary and Breast Surgery, Oita University School of Medicine, Oita, Japan, Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan, Department of Respiratory Medicine, Kanazawa University, Kanazawa, Japan,
Abstract
ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC).Org: Hunan Provincial Oncology Hospital, Peking University Shougang hospital, The First Affiliated Hospital of Gannan Medical College, Yuebei People's Hospital,
Abstract
Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.Org: Bio-Medico Campus University Hospital,
Abstract
Safety and efficacy of durvalumab plus carboplatin and etoposide for patients with previously untreated extensive-stage small-cell lung cancer (ES-SCLC) with a poor performance status: The results from phase II single-arm study (NEJ045A study).Org: Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, Department of Respiratory Medicine, Juntendo University Hospital, Tokyo, Japan, Department of Respiratory Medicine, Kasukabe Medical Center, Kasukabe, Japan, Department of Respiratory Medicine, Toho University Omori Medical Center, Ota-Ku, Japan, Respiratory Medicine, Akita Kousei Medical Center, Akita, Japan,
Abstract
Comprehensive analysis of the value of dynamic changes in ctDNA in SCLC.Org: Department of Population and Quantitative Health Sciences, University Hospital Seidman Cancer Center,
Abstract
BIOLUMA: A phase II trial of nivolumab and ipilimumab in lung cancer—Results from the SCLC TMBhigh cohort.Org: University of Bonn, University of Frankfurt, University of Würzburg, MVZ für Hämatologie und Onkologie Köln Am Sachsenring GmbH, Hospital Cologne-Merheim,
Abstract
Cost-effectiveness study of atezolizumab (ATZ) vs. durvalumab (DUR): Real-world data (RWD) on first-line chemotherapy combined with immune-checkpoint inhibitors (Chemo-ICIs) for extensive disease small-cell lung cancer (ED-SCLC).Org: Kobe Minimally Invasive Cancer Center, Hakodate Goryoukaku Hospital, Fujita Health University Hospital, Onomichi General Hospital, Takarazuka City Hospital,
Abstract
A randomized phase II study of toripalimab consolidation or observation after concurrent chemoradiotherapy in limited-stage small cell lung cancer.Org: Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, Sun Yat-Sen University Cancer Center, Guangzhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
A retrospective study of 157 patients comparing platinum-anthracycline to other platinum combination for untreated unresectable thymoma: NEJ023B.Org: Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan, Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan, Clinical Research Center, Chiba University Hospital, Chiba, Japan, Department of Respiratory Medicine, Jichi Medical University, Saitama Medical Center, Saitama, Japan, Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan,
Abstract
Combining SBRT with GM-CSF and Peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors.Org: Fudan University Shanghai Cancer Center,
Abstract
Tumor-derived serum proteotypes to predict response to immune therapy in patients with limited disease small-cell lung cancer.Org: Frontier Science Foundation - Hellas, Hospital Virgen De La Salud, Hôpital Arnaud de Villeneuve, St. James's Hospital and Trinity College Dublin, Cancer Molecular Diagnostics,
Abstract
An open-label, multicenter, phase Ib/II study of the ATR inhibitor SC0245 in combination with irinotecan in patients with relapsed and refractory extensive stage small cell lung cancer (ES-SCLC).Org: Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Department of Thoracic Oncology, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, China, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China, Biocity Biopharmaceutics Co., Ltd., Shanghai, China, Department of Medical Oncology, Shanghai Chest Hospital, Shanghai, China,
Abstract
Results of a phase III clinical trial with anti-PDL1 treatment in combination with chemotherapy for extensive stage small cell lung cancer.Org: Lee's Pharmaceutical Holdings Ltd., Lee's pharmaceutical holding limited.,
Abstract
Comprehensive molecular characterization of thymic epithelial tumors.Org: Caris Life Sciences Inc, Irving, IN,
Abstract
A phase II, open-label, combination therapy of durvalumab and ceralasertib in relapsed and refractory small cell lung cancer (SUKSES-N4).Org: Department of Health Sciences and Technology, SAIHST, Sungkyungkwan University, Seoul, South Korea, Early Oncology Clinical Science, R&D Oncology, AstraZeneca, Cambridge, United Kingdom, External R&D, R&D Oncology, AstraZeneca, Seoul, South Korea, AstraZeneca, R&D Oncology, Royston, United Kingdom, AstraZeneca, R&D Oncology, Cambridge, United Kingdom,
Abstract
Algorithmic precision in immune checkpoint therapy response prediction for lung cancer: Evaluating the Digital Drug Assignment model's clinical performance.Org: Genomate Health Inc,
Abstract
Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study.Org: Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Jiamusi Cancer Hospital, Xinxiang, Budgetary Healthcare Institution Of Omsk Region "Clinical Oncology Dispensary”,
Abstract
Exploring gut microbiome markers in predicting efficacy of immunotherapy against lung cancer.Org: Breast Medicine, Liaoning, China,
Abstract
Cytoreductive surgery followed by hyperthermic intrathoracic chemotherapy for the treatment of thymic epithelial malignancies with pleural spread or recurrence.Org: Fudan University Zhongshan Hospital, Department of Statistics, Zhongshan Hospital Fudan University,
Abstract
A phase II clinical trial of selinexor in patients with advanced thymoma and thymic carcinoma.Org: MedStar Health/Georgetown University Hospital, Copenhagen University Hospital, Rigshospitalet, Institut du Thorax Curie Montsouris, Institut Curie, Paris, and UVSQ, Region Hovedstaden,
Abstract
S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma.Org: Sugar Land, TX, NewYork-Presbyterian Hospital/Weill Cornell Medicine,
Abstract
Association of napsin A-specific T cell clonotypes with durable clinical benefit to immunotherapy in patients with metastatic NSCLC. Org: Fox Chase Cancer Center/Temple Health,
Abstract
Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies.Org: Centrum für Integrierte Onkologie, Cancer Center Yonsei University College of Medicine,
Abstract
IGF-1R, E-cadherin, N-cadherin, and occludin gene expression and resistance to EGFR tyrosine-kinase inhibitors in patients with lung adenocarcinoma in Serbia.Org: Montefiore New Rochelle, Institute for Oncology and Radiology of Serbia, University of Belgrade, Department of Pharmacology and Toxicology, University of Novi Sad, Institute for Pulmonary Diseases of Vojvodina,
Abstract
Unraveling CASTOR1's tumor suppressive role: Genetic ablation of CASTOR1 and KRAS-driven mouse model of non-small cell lung cancer.Org: Rezo Therapeutics, Department of Pharmacology & Chemical Biology,
Abstract
Gene expression correlates of adagrasib response in KRASG12C mutated non-small cell lung cancer (NSCLC).Org: Monoceros Biosystems, LLC,
Abstract
Identifying digital pathology imaging based biomarkers of checkpoint inhibitor response in non-small cell lung cancer.Org: National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Bethesda, VA, Bethesda, MD, SUNY Upstate Medical University,
Abstract
PD-L1 and alternative immune checkpoints (AICs) in non-small cell lung cancer (NSCLC): Insights into the tumor immune microenvironment (TIME) and immunotherapy (IO) outcomes.Org: Montefiore Einstein Comprehensive Cancer Center/Albert Einstein College of Medicine, Caris Life Sciences, Irving, TX, Fox Chase Cancer Center, Lombardi Comprehensive Cancer Center, Georgetown University Medical School,
Abstract
Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC).Org: Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business, Caris Life Sciences, Irving, TX, University of California, Irvine Medical Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Molecular profiling across histologies in lung cancer: Time to change WHO nomenclature?Org: Roche Sequencing Solutions, Foundation Medicine Inc., Center for Thoracic Oncology, Mount Sinai Medical System,
Abstract
Characterization of HER2 alterations in lung adenocarcinoma.Org: Temple University Hospital,
Abstract
Immune infiltrate characterization and differential gene expression by RNA-sequencing analysis in patients with oncogene-addicted NSCLC with early progression under targeted therapy.Org: Genomic Platform and Biobank, AMMICa UAR3655/US23, Gustave Roussy, Cancer Campus,
Abstract
Deep learning–based chest CT model to predict treatment response to immune checkpoint inhibitors in non-small cell lung cancer independently and additively to histopathological biomarkers.Org: Oncology Therapeutic Development, Lunit Inc., Seoul National University Hospital, South Korea, Samsung Medical Center,
Abstract
A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC.Org: Shanghai Sixth People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Xi’an International Medical Center Hospital, The People’s Hospital of Liaoning Province, The First People's Hospital of Changzhou,
Abstract
Timing of immunotherapy in stage IV non-small cell lung cancer.Org: Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Yufu, Japan, Penn State Health Milton S. Hershey Medical Center,
Abstract
MEK inhibitor combined with RTK inhibitor (trametinib plus anlotinib) in non-G12C KRAS-mutant non-small cell lung cancer: A new strategy.Org: Shanghai Chest Hospital, Jiaotong University, Shanghai Jiao Tong University School of Medicine,
Abstract
Germline NQO1c.559C>T as a biomarker of genetic susceptibility to immune checkpoint blockade resistance.Org: Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, Biomedical Research Institute of Málaga (IBIMA BIONAND Platform), Málaga, Spain, IBIMA, Málaga, Spain, IBIMA, Malaga, Spain, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain, UGC Oncología Intercentros, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Malaga, Spain, UGC Oncología Intercentros, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Málaga, Spain, Hospital Universitario Virgen de la Victoria, IBIMA, Malaga, Spain, Institute of Biomedical Research in Malaga (IBIMA), Malaga, Spain,
Abstract
Young adults (YA) with non-small cell lung cancer (NSCLC): Snapshot of the oncogenic drivers and immune landscapes.Org: The James, The Ohio State University Comprehensive Cancer Center,
Abstract
Correlation of immune phenotypes derived from H&E-stained whole slide images with prognosis and response to checkpoint inhibitors in NSCLC.Org: PathAI, Incendia Therapeutics, Explicyte Immuno-Oncology, Institut Bergonié, Early Phase Trials Unit, Institut Bergonié and University of Bordeaux, Bordeaux, France,
Abstract
Phase 2 study of pembrolizumab plus pemetrexed for older patients with non-squamous non-small cell lung cancer with PD-L1 tumor proportion score of less than 50%: CJLSG1901.Org: Osaka City General Hospital, Japanese Red Cross Okayama Hospital, Tosei General Hospital, Toyohashi Municipal Hospital, Matsunami General Hospital,
Abstract
Phase II study of combination of radiotherapy with pembrolizumab plus chemotherapy in patients with previously untreated metastatic non-small cell lung cancer: North Japan Lung Cancer Study Group 1902.Org: Omagari Kosei Medical Center, Daisen, Japan, Sendai, Japan, Hirosaki University Graduate School of Medicine, Hirosaki, Japan,
Abstract
Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.Org: Nantes University Hospital Center, Azienda Ospedaliero-Universitaria San Luigi Gonzaga,
Abstract
Comparison of ICI plus chemotherapy or ipilimumab plus nivolumab based therapy for patients with NSCLC with TPS (1-49%): TOPGAN2023-01.Org: Hirosaki University, Japanese Foundation for Cancer Research, Kanazawa University Hospital, University of Yamanashi, The Jikei University Daisan Hospital,
Abstract
Efficacy and clinicogenomic biomarkers of response to dual versus single agent checkpoint inhibitor therapy in untreated metastatic non-small cell lung cancer.Org: Department of Medicine, Tufts Medical Center, Boston, MA, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, Lowe Center for Thoracic Oncology, Boston, MA, Centre de Recherche Du Centre Hospitalier de L'Université de Montréal, Montreal, QC, Canada, Dana-Farber Cancer Center, Boston, MA,
Abstract
Mefatinib as first-line treatment of EGFR sensitizing mutation-positive non-small-cell lung cancer: A phase III efficacy and biomarker study.Org: Huadong Medicine Co., Ltd, Huadong Global Development Center, HangZhou ZhongMei HuaDong Pharmaceutical Company,
Abstract
Survival outcome of metastatic pulmonary sarcomatoid carcinoma in immunotherapy era: An NCDB analysis.Org: Penn State Health Milton S. Hershey Medical Center,
Abstract
Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry.Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business,
Abstract
A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer (SqCLC).Org: Moffit Cancer Center,
Abstract
Survey of actionable driver mutations KRAS and EGFR in non–small cell lung cancer to evaluate coexisting splicing gene and pathway mutations: A CBioportal database analysis.Org: University of California Irvine Healthcare,
Abstract
Immune-related adverse events after 2 years in patients with advanced non-small-cell lung cancer receiving extended immune checkpoint inhibitor therapy.Org: Penn Medicine Abramson Cancer Center, University of Pennsylvania,
Abstract
Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study.Org: Jiangxi Provincial People's Hospital,
Abstract
A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and EGFR mutation–positive non-small cell lung cancer (OPEN/TORG2040).Org: Kitasato Univeristy Hospital, Sagamihara-Shi, Japan, Toho University Omori Medical Center, Tokyo, Japan, Division of Respirology Neurology and Rheumatology Department of Internal Medicine, Kurume University Hospital, Kurume, Japan, Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan, Tochigi Cancer Center, Utsunomiya, Japan,
Abstract
A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.Org: Harbor-UCLA Medical Center, Department of Medical Oncology, University of Kentucky, Markey Cancer Center, University College London Cancer Institute, University College London Hospital NHS Trust,
Abstract
MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study.Org: Sarah Cannon Research Institute/Tennessee Oncology, Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh, Medical College of Wisconsin, Next Oncology Virginia and Virginia Cancer Specialists, Medical University of South Carolina Hollings Cancer Center,
Abstract
Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.Org: IDIBELL Medical Oncology,
Abstract
Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRAS G12C mutation: A phase 1b study.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, University Hospital Saint-Luc, Brussels, Belgium, Hospital Clinic Barcelona, Barcelona, Spain, CHU de Québec-Université Laval, Québec, QC, Canada, University of Iowa Hospitals and Clinics, Iowa City, IA,
Abstract
Impact of maintenance pemetrexed cessation on clinical outcomes of patients with metastatic non-squamous NSCLC.Org: Vanderbilt University School of Medicine, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Department of Medicine, Icahn School of Medicine at Mount Sinai, Vanderbilt University Medical Center,
Abstract
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.Org: Urumqi, China, Shijiazhuang, China, Changchun, China, Shangsha, China,
Abstract
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP-OLIGO study (WJOG11118L): Feasibility analysis of induction therapy and local ablative therapy.Org: Radiation and Proton Therapy Center, Shizuoka Cancer Center, Division of Thoracic Surgery, Shizuoka Cancer Center, Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Department of Clinical Radiology, Graduate School of Medical Sciences, Department of Radiation Oncology, Juntendo University, Graduate School of Medicine,
Abstract
Socioeconomic disparities in survival outcomes of patients with NSCLC with brain metastases: A real-world analysis.Org: St. John's Medical College, Bangalore, India,
Abstract
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.Org: LungenClinic, Grosshansdorf, Germany, Institutul Oncologic Prof Dr Ion Chiricuţă and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania, L’institut du Thorax, Nantes, France, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain, Hospital Universitario La Fe, Valencia, Spain,
Abstract
Efficacy and safety of vebreltinib in patients with advanced NSCLC harboring MET exon 14-skipping: Results of 2.5-year follow-up in KUNPENG.Org: Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Lung Cancer Center, Pulmonary and Critical Care Medicine, Zhongshan Hospital Affiliated to Fudan University, Shandong First Medical University and Shandong Academy of Medical Sciences,
Abstract
Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations.Org: Department of Medicine, Medical Oncology, Memorial Sloan Kettering Cancer Center,
Abstract
Phase Ib clinical study of first-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous non-small cell lung cancer with EGFR mutation.Org: Tianjin Medical University Cancer Institute and Hospital, Tianjin, China,
Abstract
Real-world outcomes of osimertinib (Osi) vs. afatinib or erlotinib in patients with classical vs. atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).Org: Penn Medicine Abramson Cancer Center, Perelman School of Medicine,
Abstract
Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer.Org: Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Division of Medical Oncology, National Cancer Centre Singapore, Duke-NUS Medical School, START Madrid, Hospital Fundación Jiménez Díaz, Jawaharlal Institute of Postgraduate Medical Education and Research,
Abstract
Machine learning prediction of prognosis in lung cancer with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND).Org: Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Miyagi, Japan, Wakayama Medical University, Wakayama-Shi, Japan, Department of Medical Oncology, Kindai University, Osaka, Japan, Biostatistics Center, Kurume University, Kurume, Japan, Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan,
Abstract
Evaluation of the genomic and immune profiles of patients with lung adenosquamous carcinoma (LUAS) and association of response to treatment.Org: Caris Life Sciences, Irving, TX, The Warren Alpert Medical School of Brown University, Columbia University Irving Medical Center, New York, NY, USA, Yale Cancer Center, Penn State Milton S. Hershey Medical Center, Hershey, PA,
Abstract
Metabolic profile and therapeutic vulnerabilities of multi-omic characterization of KRAS/STK11/KEAP1 co-mutant non–small cell lung cancer (NSCLC).Org: Caris Life Sciences, Irving, TX, Penn State Milton S. Hershey Medical Center, Hershey, PA, Caris Life Sciences Research and Development, Montefiore Einstein Comprehensive Cancer Center/Albert Einstein College of Medicine,
Abstract
A phase I/Ib study of the aurora kinase A inhibitor alisertib in combination with osimertinib in advanced osimertinib-resistant EGFR-mutated lung cancer.Org: University of California, San Francisco, San Francisco, CA,
Abstract
Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal, or bone metastases in the phase II VISION trial.Org: Asklepios Clinics Munich-Gauting, Delta Hat, Merck N.V.-S.A., Thoracic Oncology Service,
Abstract
A randomized phase II trial of 8 months of afatinib switching to osimertinib (A) versus osimertinib alone (B) as first-line treatment in advanced NSCLC patients with common EGFR mutation: YAMATO study (TORG1939/WJOG12919L).Org: Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Japan, Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan, Department of Respiratory Medicine, Japanese Red Cross Ise Hospital, Ise, Japan, Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan,
Abstract
Detection of comprehensive oncogenic driver alteration of non-small cell lung cancer from cytology specimens by multi-gene PCR panel.Org: Department of Thoracic Oncology Division, Kashiwa-Shi,
Abstract
Structure-based classification and nomogram prediction for differential inhibitor sensitivity of EGFR exon 19 deletions.Org: State Key Laboratory of Molecular Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
J-TAIL-2: A prospective observational study of atezolizumab (atezo) combination therapy in patients (pts) with non-small cell lung cancer (NSCLC) in Japan.Org: Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan, Department of Thoracic Oncology, Kansai Medical University, Osaka, Japan, Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, Fukujuji Hospital, Tokyo, Japan, Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan,
Abstract
A phase II trial to evaluate the epithelial-to-mesenchymal (EMT) inhibitor sotevtamab combined with docetaxel in patients with metastatic non-small cell lung cancer following failure of primary chemoimmunotherapy.Org: Hematology-Oncology Division, University of Montreal Health Centre (CHUM), Montréal, QC, Canada, CISSS des Laurentides, St Jerome, QC, Canada, Hopital Maisonneuve-Rosemont, Montreal, QC, Canada, Institut universitaire de cardiologie et de pneumologie de Québec - IUCPQ, Quebec, QC, Canada, Institut de recherche en immunologie et en cancérologie · IRIC, Montreal, QC, Canada,
Abstract
Association of RNA-sequencing signatures with clinical outcomes of pembrolizumab + chemotherapy in patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) enrolled in the phase 2 KEYNOTE-782 trial.Org: Complutense University and CIBERONC, Tel-Aviv University Medical School, Central University Hospital of Asturias, Insular Maternal-Child University Hospital Complex of Gran Canaria, University of Las Palmas de Gran Canaria,
Abstract
Characteristics and clinical outcomes of US veterans with advanced non–small cell lung cancer (NSCLC) by KRAS subtype: A National Veterans Health Administration analysis.Org: Durham VA Health Care System, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, National Oncology Program, Department of Veterans Affairs James Hailey Hospital,
Abstract
Prospective nutritional status and body mass composition assessment in patients with advanced NSCLC treated with immune checkpoint inhibitors.Org: Azienda Ospedaliero Universitaria delle Marche, Department of Information Engineering, Università Politecnica delle Marche (UNIVPM), Dietology and Clinical Nutrition, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona,
Abstract
Eosinophil-neutrophil ratio as a sex-dependent prognostic marker in immune checkpoint therapy for metastatic NSCLC and transcriptomic evaluation of intratumoral eosinophil-T cell interaction.Org: The Pelotonia Institute for Immuno-Oncology,
Abstract
Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-MET exon 14 skipping mutations (METex14).Org: Department of Pulmonology, Department of Early Clinical Trials, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology,
Abstract
Precision medicine in NSCLC: Challenges and practice gaps in community cancer clinics.Org: University of Vermont Medical Center, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, PRIME Education, LLC,
Abstract
A real-world study on biomarker retesting among patients with non-small cell lung cancer and disparity in outcomes.Org: AbbVie Inc., North Chicago, IL, Perelman School of Medicine at the University of Pennsylvania, Abramson Cancer Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05.Org: University Hospital of Nantes, Daiichi Sankyo Europe GmbH, Department of Medical Oncology, Thoracic Group,
Abstract
High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.Org: The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China,
Abstract
Lung cancer MDT quality assessment: A nationwide study.Org: Vestfold Hospital Trust, Nordland Hospital, Nordlandssykehuset, Section of Oncology, Drammen Hospital,
Abstract
A phase II, open-label, single-arm, multicenter, efficacy and safety study of 80 mg osimertinib in patients with leptomeningeal metastases (LM) associated with epidermal growth factor receptor (EGFR) mutation–positive non-small cell lung cancer (NSCLC): BLOSSOM.Org: Section of Hematology-Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, South Korea, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, AstraZeneca, Cambridge, United Kingdom, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea, National Cancer Center, Goyang, South Korea, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea, Keimyung University, Daegu, South Korea,
Abstract
Enfortumab vedotin (EV) in non-squamous and squamous non–small cell lung cancer (NSCLC) cohorts of EV-202.Org: Georgia Cancer Specialists/Northside Hospital Atlanta, NextPoint Therapeutics, VA Medical Center,
Abstract
Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02.Org: Northwestern University Feinberg School of Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Regional and Virgen de la Victoria University Hospitals, IBIMA, Hospital Clínic de Barcelona, IDIBAPS,
Abstract
Genomic profiling of non-small cell lung cancer with rare aberrations in EGFR codon L858 and the survival outcome under real-world first-line EGFR tyrosine kinase inhibitor treatment compared to classic EGFRL858R.Org: Orthopedics Research Institute of Zhejiang University, Department of Thyroid Surgery, The Second Affiliated Hospital, Department of Thoracic Surgery, The First Affiliated Hospital of Fujian Medical University, Department of Oncology, The First Affiliated Hospital of Nanchang University, Geneseeq Research Institution, Nanjing Geneseeq Technology Inc.,
Abstract
Genomic landscape of MTAP deletions and association with EGFR alterations in NSCLC.Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Nykode Therapeutics, Center for Molecular Oncology,
Abstract
Response to targeted and immune therapy in patients with NSCLC and BRAF non-V600E mutations: A retrospective, multicenter analysis within the national Network Genomic Medicine Lung Cancer (nNGM) in Germany.Org: DKFZ-Hector Cancer Institute, Network Genomic Medicine, TU Dresden, Justus-Liebig-University, University Hospital Frankfurt,
Abstract
Association of combination tumor texture and vessel tortuosity with progression free survival across PD-L1 subgroups in durvalumab treated non-small cell lung cancer (NSCLC): Blinded validation results from CP1108.Org: Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, Emory University Hospital, University Hospitals Cleveland Medical Center, New York University School of Medicine, Laura and Isaac Perlmutter Cancer Center,
Abstract
Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study.Org: Yale New Haven Hospital, Yale Cancer Center, Stanford Hospital and Clinics, Campus Bio Medico University of Rome, MedStar Health/Georgetown University Hospital,
Abstract
Survival outcomes and subgroup analyses derived from a phase III randomized trial comparing afatinib to chemotherapy in treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation (ACHILLES/TORG1834).Org: Miyagi Cancer Center, Department of Respiratory Medicine, Saiatama Medical University International Medical Center, Department of Respiratory Medicine, Iwakuni Clinical Center, Department of Medical Oncology, Chiba University, Department of Respiratory Medicine, Fujita Health University School of Medicine,
Abstract
A phase 2, multicenter, open-label, dose-optimization study evaluating telomere-targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Updated results.Org: Medical University in Lublin, Lublin, Szolnok, Hungary, Matrai Gyogyintezet,
Abstract
Characterization of DNA damage repair (DDR) alterations and the tumor immune microenvironment (TIME) in advanced non-small cell lung cancer (NSCLC).Org: University of Illinois, Chicago College of Medicine,
Abstract
Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC).Org: Newton, MA,
Abstract
TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma.Org: Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute,
Abstract
FDA analysis of immune checkpoint inhibitors in combination with vascular endothelial growth factor tyrosine kinase inhibitors in the second-line treatment of patients with advanced non-small cell lung cancer.Org: U.S. Food and Drug Administration, Silver Spring, MD, Office of Oncologic Diseases, Center for Drug Evaluation and Research, Oncology Center of Excellence,
Abstract
Effect of tumor burden on survival in patients with stage IV EGFR-mutant NSCLC receiving osimertinib monotherapy.Org: Cleveland Clinic Taussig Cancer Instititute, Taussig Cancer Institute, Cleveland Clinic Foundation,
Abstract
Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC).Org: Thoracic Medicine Department 2, The Affiliated Cancer Hospital of Xiangya School of Medicine and Hunan Cancer Hospital, Central South University, Changsha, China, First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, China, Tianjin Cancer Institute and Hospital, Tianjin, China, Department of Medical Oncology, The First Hospital of Lanzhou University, Lanzhou, China, Department of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun, China,
Abstract
Prospective validation of in silico clinical trials prediction using an EGFR-mutated NSCLC mechanistic computational disease model.Org: Hospices Civils de Lyon Cancer Institute, Novadiscovery,
Abstract
Efficacy and safety of bronchial arterial chemoembolization (BACE) in combination with tislelizumab for non-small cell lung cancer (NSCLC): A phase II study.Org: The First Affiliated Hospital of Zhengzhou University, Zhengzhou Gensciences, China National Biotec Group,
Abstract
Molecular and clinical characteristics of patients with non-small-cell lung cancer (NSCLC) harboring KRAS G12V mutations.Org: Lung Cancer Group, St. Marien-Hospital, University of Witten/Herdecke, Klinikum Lüdenscheid, Theresienkrankenhaus,
Abstract
Correlation of the combination of CT-derived tumor texture and vessel tortuosity on survival outcomes for immunotherapy but not for chemotherapy in metastatic non-small cell lung cancer (mNSCLC): Results from a CheckMate227 (CM227) subset.Org: Atlanta Veterans Administration Medical Center,
Abstract
Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: Results from a phase Ib/II study.Org: Affiliated Jinling Hospital, Medical School of Nanjing University,
Abstract
Association of human leukocyte antigen (HLA) status with immune checkpoint inhibitor (ICI) pneumonitis in patients with non-small cell lung cancer (NSCLC).Org: Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China, Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong, Department of Cellular and Anatomical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China,
Abstract
Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis.Org: Janssen China Research and Development, Xi'an Janssen Pharmaceutical Ltd,
Abstract
Characterization of TP53 mutations in actionable driver-negative non-small cell lung cancer (NSCLC).Org: Montefiore Medical Center and Albert Einstein College of Medicine, West Cancer Center and Research Institute, Caris Life Sciences, Barbara Ann Karmanos Cancer Institute, Wayne State University,
Abstract
Early FDG PET imaging and circulating T-cell repertoire biomarkers of response to chemotherapy and PD-1 checkpoint inhibitors in patients with stage IV NSCLC.Org: University of Washington Fred Hutchinson Cancer Research Center,
Abstract
Clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in patients (pts) with checkpoint inhibitor (CPI) –pretreated advanced/metastatic non-small cell lung cancer (NSCLC): Preliminary results of a P2 trial.Org: Texas Oncology Odessa, NeoTx Ltd,
Abstract
Amivantamab plus capmatinib in advanced non-small cell lung cancer (NSCLC) harboring MET alterations: Recommended phase 2 combination dose and preliminary dose-escalation results from the phase 1/2 METalmark study.Org: Virginia Health Specialists, Fairfax, VA, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Janssen Research & Development, San Diego, CA, Janssen Research & Development, Bridgewater, NJ, Janssen Research & Development, Beerse, Belgium,
Abstract
Final analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer KRAS G12C mutation.Org: Wakayama Medical University Hospital, Wakayama-Shi, NA, Japan, Department of Respiratory Medicine, Kumamoto University Hospital, Kumamoto, Japan, Kurume University School of Medicine, Fukuoka, Japan, Department of Respiratory and Allergy Medicine, Nagoya City University Hospital, Nagoya, Japan, Kitakyushu Municipal Medical Center, Kitakyushu, Japan,
Abstract
High PD-L1 expression among patients with ALK rearranged non–small cell lung cancer and response to first line ALK tyrosine kinase inhibitors.Org: University of Colorado Cancer Center Biostatistics Core, University of Colorado Department of Pathology, University of Colorado - Department of Pathology,
Abstract
OSIRAM-1/TORG1833: Overall survival results of a randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer.Org: Kurume University Hospital, Teikyo University School of Medicine, National Hospital Organization Yokohama Medical Center,
Abstract
Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02.Org: CNIO-H12O Lung Cancer Unit, Departamento de Investigacion de Cancer de Pulmon, Hospital Universitario 12 de Octubre, CNIO-H12O Lung Cancer Unit, Department of Oncology, National Cheng Kung University Hospital, Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Università degli Studi di Milano-Bicocca,
Abstract
Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd).Org: University Hospital of Nantes Medical Oncology,
Abstract
Efficacy of immunotherapy in first-line treatment for non-small cell lung cancer with HER2 mutation: Results from LC-SCRUM-Asia.Org: Japanese Red Cross Medical Center, Tokyo, Japan, Sendai Kousei Hospital, Sendai, Japan, Yamaguchi-Ube Medical Center, Yamaguchi, Japan, Chiba Cancer Center, Chiba, Japan, Kobe City Medical Center General Hospital, Kobe, Japan,
Abstract
Efficacy of immunotherapy retreatment in patients with non-small cell lung cancer receiving consolidative durvalumab.Org: The University of North Carolina Medical Center,
Abstract
Preliminary results from a FIH, open-label phase 1 study with BMC128, a rationally designed live bacterial consortium, in combination with nivolumab.Org: Rambam Hospital,
Abstract
A phase 1b study of ensartinib in combination with platinum-based chemotherapy and bevacizumab in ALK-positive non-small cell lung cancer (NSCLC).Org: Xcovery Holdings Inc,
Abstract
Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade.Org: Campus Biomedico, Santa Maria della Misericordia Hospital,
Abstract
Real-world treatment patterns and outcomes in US patients (pts) with advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy (PBC) and anti–PD-(L)1 treatment.Org: NYU Perlmutter Cancer Center, GSK plc, GSK,
Abstract
PD-L1 expression in pulmonary sarcomatoid carcinoma and response to immunotherapy.Org: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology,
Abstract
Therapeutic activity of a new KRASG12C inhibitor JMKX001899 in brain metastases: Preclinical models of KRASG12C-mutant non-small cell lung cancer.Org: CAMS Key Laboratory of Translational Research on Lung Cancer,
Abstract
The role of pulmonary metastasectomy for non-primary lung cancer: Umbrella review of meta-analysis.Org: University of Missouri-Kansas City School of Medicine,
Abstract
Loss of heterozygosity (LOH) in KEAP1/STK11-mutated lung adenocarcinoma to characterize a new subgroup of hard-to-treat patients with unmet need in the real-world setting.Org: Department of Medical Oncology and Hematology, University Hospital Zurich, Department of Pathology and Molecular Pathology, University of Zurich / ETH Zurich,
Abstract
CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC).Org: School of Medicine, Kyungpook National University, Daegu, South Korea, Picture Health, Cleveland, OH, Kyungpook National University Hospital, Daegu, South Korea, University of Texas at Austin, Weatherford, TX, Picture Health Inc., Cleveland, OH, Feinberg School of Medicine, Chicago, IL, Feinberg School of Medicine, Northwestern University, Chicago, IL, Richmond University Medical Center, Staten Island, NY, Northwestern University, Chicago, IL, University Hospitals Cleveland Medical Center, Cleveland, OH, Perlmutter Cancer Center, NYU Langone Health, New York, NY,
Abstract
Double lung transplantation in patients with metastatic lung-limited non-small cell lung carcinoma (NSCLC): A case series.Org: Robert H Lurie Comprehensive Cancer Center,
Abstract
Performance of comprehensive genomic profiling (CGP) versus single gene testing (SGT) in guideline-recommended biomarker selection in non-small cell lung cancer (NSCLC).Org: Illumina, San Diego, CA, Illumina Inc., San Diego, CA,
Abstract
Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III clinical trials.Org: Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Northwestern University Feinberg School of Medicine, Northwestern Memorial Hospital, Chicago, IL, John H. Stroger, Jr. Hospital of Cook County,
Abstract
KRAS mutation subtypes responded differently to combination immunotherapy via disturbing myeloid-derived suppressor cells in non-small cell lung cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
The clinical utility of a circulating tumor cell based cerebrospinal fluid assay in the diagnosis and molecular analysis of leptomeningeal disease in patients with metastatic non-small cell lung cancer.Org: Lennar Foundation Cancer Center,
Abstract
Overall survival following heterogeneous FDG-guided dose-escalation for locally advanced NSCLC in the international phase III NARLAL2 trial.Org: Department of Oncology, Odense University Hospital, Odense, Denmark, Vejle Hospital, Vejle, Denmark, Aarhus University Hospital, Aarhus, Denmark, Odense University Hospital, Odense, Denmark, Odense University Hospital, Odense C, Denmark,
Abstract
Immunotherapy outcomes and profile in lung cancer brain metastases.Org: Caris Life Sciences, Irving, TX, Levine Cancer Institute, West Virginia University Camden Clark Medical Center, Penn State Milton S. Hershey Medical Center, Hershey, PA, Rhode Island Hospital,
Abstract
Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.Org: Federal University of Amazonas - UFAM, Federal University of Pará - UFPA, Catholic University of Pelotas, University Hospital HUG,
Abstract
IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).Org: Tongji University Affiliated Shanghai Pulmonary Hospital, Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rend.Int., Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary, MI Zaporizhzhia Regional Clinical Oncological Dispensary Zaporizhzhia SMU Ch of Oncology, LKI Lungenfachklinik Immenhausen,
Abstract
Clinical impact of the rapid genomic screening platform for non-small cell lung cancer in Asia-Pacific (LC-SCRUM-AP).Org: Chang Gung Memorial Hospital Linkou Branch, Kuala Lumpur Hospital, Siriraj Hospital, Precision Medicine Asia, PREMIA Holdings (HK) Limited,
Abstract
LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET+) NSCLC.Org: Chengdu Institute of Respiratory Health, Branch of National Clinical Research Center for Respiratory Disease, The Third People's Hospital of Chengdu, Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf,
Abstract
Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.Org: University of Malaya Medical Centre, Hospital Umum Sarawak, Hospital Tengku Ampuan Afzan, First Affiliated Hospital of Army Medical University, Huizhou Municipal Central Hospital of Guangdong Province,
Abstract
Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): Primary analysis from multicenter single arm phase II study (Evolution trial; WJOG11819L).Org: Department of Respiratory Medicine, NHO Nagoya Medical Center,
Abstract
The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non–small-cell lung cancer (NSCLC).Org: Moderna, Inc., Merck & Co., Inc.,
Abstract
Bevacizumab in combination with chemotherapy for treating patients with advanced RET+ non-small cell lung cancer.Org: CHI De Creteil, Créteil, European Hospital Georges Pompidou, Hospital General Universitario Gregorio Marañon, Azienda Ospedaliera di Perugia,
Abstract
Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study.Org: Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Department I of Thoracic Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Tottori University Hospital, University Hospital KU Leuven,
Abstract
Overall survival after treatment with CAN-2409 plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with an inadequate response to ICI.Org: Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, NYU Langone Medical Center, New York, NY, Division of Hematology, Oncology, and Palliative Care, Massey Comprehensive Cancer Center, Virginia Commonwealth University Health System, Richmond, VA, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, Division of Thoracic Surgery, Division of Pulmonary and Critical Medicine, Mayo Clinic, Rochester, MN,
Abstract
A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153.Org: Universty of Iowa Holden Comprehensive Cancer Center, Jesse Brown VA Medical Center, VA Nebraska Western Iowa Health Care System,
Abstract
VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom)+zimberelimab (zim)+chemotherapy (chemo) or zim+chemo followed by adjuvant dom+zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC).Org: Fort Wayne Medical Oncology and Hematology, Christian Hospital, University Hospitals Birmingham NHS Foundation Trust, Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS), Shaare Zedek Medical Center,
Abstract
Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC).Org: University of Newcastle,
Abstract
Efficacy and safety of aumolertinib combined with or without chemotherapy as an adjuvant treatment for stage II-IIIA non-small cell lung cancer following complete tumour resection: The first third-generation EGFR-TKI versus chemotherapy phase III clinical study (APEX).Org: Sichuan Provincial People's Hospital, Tianjin Chest Hospital, Air Force Military Medical University, The First Affiliated Hospital of Jilin University, The First People's Hospital of Yunnan Province,
Abstract
Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).Org: Mayo Clinic, Duke University Medical Center, University of Chicago, Helen F. Graham Cancer Center and Research Institute, Newark, DE, Dana-Farber Cancer Institute,
Abstract
Clinical-genomic characteristics in patients with EGFR-mutated non-small cell lung cancer harboring MET copy number gains after progression on EGFR-TKI: A report from LC-SCRUM-TRY.Org: Yamaguchi-Ube Medical Center, Iwakuni Clinical Center,
Abstract
JCOG2002: A randomized phase III study of thoracic radiotherapy for extensive stage small cell lung cancer.Org: Department of Radiation Oncology, Iizuka Hospital, Iizuka, Japan, Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Mibu, Japan, Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan, Department of Clinical Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan, Yokohama Municipal Citizen's Hospital, Yokohama, Japan,
Abstract
Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.Org: Mesothelioma Research Programme, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, United Kingdom, University of Oxford, Oxford, United Kingdom, The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom, University of Bristol, Bristol, United Kingdom, The Royal Marsden NHS Foundation Trust, London, United Kingdom, University of Glasgow, Glasgow, United Kingdom, Barts Cancer Centre, London, United Kingdom, Respiratory Department, Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom, Oxford University, Oxford, United Kingdom, The Christie NHS Foundation Trust, Manchester, United Kingdom, University of Vermont, Larner College of Medicine, Burlington, VT, RS Oncology LLC, Cambridge, MA, Bexon Clinical Consulting, LLC, Montclair, NJ, King's College London, London, United Kingdom,
Abstract
A randomized phase II trial of atezolizumab with or without tiragolumab before and after definitive chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC; AFT-57).Org: Rush University Cancer Center, Ideker Laboratory, Alliance Foundation Trials,
Abstract
IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC).Org: University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Jilin Cancer Hospital, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Hospital Universitario 12 de Octubre,
Abstract
Phase II study of induction platinum doublet in combination with nivolumab followed by surgery or concurrent chemotherapy-nivolumab-radiation in unresectable stage IIIA-C non-small cell lung cancer (NSCLC).Org: University of Kentucky College Department of Behavioral Health, The University of Kentucky Department of Human Health Sciences,
Abstract
Neoadjuvant toripalimab plus chemotherapy for resectable stage II-IIIB non-squamous non-small cell lung cancer with EGFR mutations: A multi-center, multi-cohort, exploratory study.Org: Department of Thoracic Surgery, Peking University People's Hospital, Beijing, China, Department of Thoracic Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Department of Thoracic Surgery, China Aerospace Science & Industry Corporation 731 Hospital, Beijing, China, Department of Thoracic Surgery, Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Tianjin Medical University General Hospital, Tianjin, China,
Abstract
SWOG S2302, PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.Org: Fred Hutchison Cancer Center,
Abstract
DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC).Org: Boehringer Ingelheim, France S.A.S., Boehringer Ingelheim (China) Investment Co., Ltd.,
Abstract
A phase II exploratory trial of adebrelimab in combination with chemotherapy and concurrent radiotherapy as a first-line treatment for oligo-metastatic extensive-stage small-cell lung cancer.Org: Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China, Department of Oncology, XiangYang Central Hospital, Hubei University of Arts and Science, Xiangyang, China, Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China,
Abstract
Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC).Org: Genentech, Roche Products Ltd., F. Hoffmann-La Roche Ltd,
Abstract
AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors.Org: Affini-T Therapeutics, Inc.,
Abstract
Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).Org: The Royal Marsden Hospital and The Institute of Cancer Research,
Abstract
Phase I/II trial of healthy donor fecal microbiota transplant (hdFMT) in PD-1 relapsed/refractory (R/R) non-small cell lung cancer (NSCLC).Org: Center for Cancer Research, NCI/NIH,
Abstract
TRITON: Phase 3b study of tremelimumab (T) + durvalumab (D) vs pembrolizumab (P), in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11 and/or KEAP1 and/or KRAS mutations.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Fox Chase Cancer Center, David Geffen School of Medicine at UCLA, Winship Cancer Institute at Emory University, Georgetown University Medical School,
Abstract
Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.Org: Boehringer Ingelheim (Canada) Ltd,
Abstract
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.Org: Hospital del Mar-CIBERONC, Institute Curie,
Abstract
SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.Org: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy, Department of Pulmonology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, Netherlands, Institut du Thorax Curie Montsouris, Institut Curie, Paris, and UVSQ, Paris Saclay University, Versailles, France,
Abstract
A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study.Org: Richard L Roudebush VA Medical Center,
Abstract
Tazemetostat in combination with topotecan and pembrolizumab in patients with recurrent small cell lung cancer.Org: Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA, Philadelphia, PA, National Cancer Center Hospital East, Kashiwa, Japan, Shinjuku-Ku, Japan,
Abstract
Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study.Org: Puma Biotechnology Inc.,
Abstract
A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01).Org: Department of Shanghai Lung Center, Ospedale San Giovanni Addolorata,
Abstract
Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI, in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC).Org: J INTS BIO Inc., Ramathibodi Hospital,
Abstract
Randomized phase III study comparing suspension or continuation of PD-1 pathway blockade for patients with advanced non-small-cell lung cancer (SAVE study: JCOG1701).Org: Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Japan, JCOG Data Center/Operations Office, National Cancer Center, Tokyo, Japan, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan, Miyagi Cancer Center, Natori-Shi, Japan,
Abstract
A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer.Org: High Technology Medical Center, University Clinic Ltd., Tbilisi, Georgia, LTD High Technology Hospital Med Center, Batumi, Georgia, JSC Vian Caraps Medline, European University, Tbilisi, Georgia, University of Tennessee Medical Center, Knoxville, TN, Mid Florida Cancer Centers, Orange City, FL,
Abstract
iNUDGE: Integration of liquid biopsy based next generation gene sequencing in newly diagnosed NSCLC—A stepped wedge cluster randomized clinical trial.Org: Penn Center for Cancer Care Innovation, Center for Clinical Epidemiology and Biostatistics, Ann B. Barshinger Cancer Institute, Department of Family Medicine & Community Health,
Abstract
A phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L1 ≥50%.Org: University of Tennessee Medical Center, Mid Florida Cancer Centers, Clermont Oncology Center, Emad Ibrahim, MD, Inc., Desert Hematology Oncology Medical Group, Inc.,
Abstract
TOP: A phase III, multicentre, randomized controlled study comparing osimertinib in combination with carboplatin and pemetrexed to osimertinib monotherapy for untreated patients with advanced non-squamous (Non-sq) non-small cell lung cancer (NSCLC) with concurrent EGFR and TP53 mutations.Org: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China, The First People's Hospital of Foshan, Foshan, China, Department of Respiratory Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China, Central Hospital of Guangdong Provincial Nongken, Zhanjiang, China, Henan Cancer Hospital, Zhengzhou, China, Taizhou First People's Hospital, Taizhou, China, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China, The First People's Hospital of Changzhou, Changzhou, China, Shengli Oilfield Central Hospital, Dongying, China, Taizhou Central Hospital, Taizhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
A phase 1/2, open label study of amivantamab in combination with tyrosine kinase inhibitors among participants with advanced NSCLC harboring ALK, ROS1, and RET gene fusions.Org: University of Michigan - Rogel Cancer Center,
Abstract
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002).Org: Next Oncology Virginia and Virginia Cancer Specialists, Henry Ford Cancer Institute, Detroit, MI, UC Davis Comprehensive Cancer Center, Department of Medical Oncology, Harbin Medical University Cancer Hospital, Henan Cancer Hospital,
Abstract
LUNAR-2: Pivotal, randomized, open-label study of tumor treating fields (TTFields, 150 kHz) concomitant with pembrolizumab and platinum based chemotherapy for the treatment of metastatic non-small cell lung cancer.Org: Franciscan Health Indianapolis,
Abstract
REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations.Org: Memorial Sloan Kettering Cancer Center, New York, NY, Institut Gustave Roussy, Villejuif, France, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan,
Abstract
A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer.Org: NCIC Clinical Trials Group,
Abstract
FURVENT: Phase 3 trial of furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).Org: Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO), Cancer Research Unit, Princess Margaret Cancer Centre, University of Toronto, Institut Gustave Roussy, Department of Medical Oncology,
Abstract
Utilizing data to drive solutions for healthcare worker wellbeing.Org: RoswellPark Comprehensive Cancer Center,
Abstract
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.Org: Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Jilin Cancer Hospital, Taiho Oncology Inc.,
Abstract
A phase 2 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab and chemotherapy in patients with stage 4 non-small cell lung cancer.Org: White Plains Hospital, Center for Cancer Care, White Plains, NY, Medstar Franklin Square Medical Center,
Abstract
Keeping health care professionals healthy: Systematic strategies for mitigation, wellness, and burnout prevention.Org: City of Hope National Medical Center,
Abstract
Demographic trends and outcome measures found in randomized controlled trials of wellness interventions among medical trainees: A systematic review.Org: St. Francis - Emory Healthcare Internal Medicine Residency Program, Mercer University School of Medicine, Pastoral Institute, Bernard Becker Medical Library Washington University School of Medicine,
Abstract
Factors influencing career choices and post-fellowship perspectives in adult hematology/oncology fellows: A nationwide cross-sectional study.Org: Coastal Cancer Center,
Abstract
Factors influencing career choices and post-fellowship perspectives in adult hematology/oncology physicians: A nationwide cross-sectional study.Org: Coastal Cancer Center,
Abstract
Observing attending physician teaching behaviors during inpatient hematology/oncology consultation.Org: The Regents of the University of California,
Abstract
Understanding fellow hematology curriculums: Characterizing perspectives and defining opportunities for improvement.Org: Mayo Clinic, Rochester, MN,
Abstract
Development and implementation of a geriatric oncology interprofessional case-based educational intervention for cancer care providers.Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, DF, Mexico, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, Universidad Nacional Autónoma de México, Mexico City, DF, Mexico, Universidad Nacional Autónoma de México, Mexico City, Mexico,
Abstract
Decision making in oncology: Unleashing the power of artificial intelligence—Beyond the question of feasibility.Org: Instituto Oncológico Henry Moore, Instituto Oncologico Henry Moore, Universidad del Salvador, Henry Moore Institute, University of Buenos Aires,
Abstract
Educational intervention to facilitate clinician-patient discussions of lung cancer biomarker testing at safety net and non-safety net centers.Org: Center for Business Models in Healthcare, Glencoe, IL, LUNGevity Foundation, Bethesda, MD, University of Illinois Hospital & Health Sciences System, Chicago, IL, Department of Hematology/Oncology, University of Illinois, Chicago College of Medicine, Chicago, IL, Emory University Hospital, Atlanta, GA,
Abstract
Utility of a collaborative hematology oncology (HO) podcast series for post-ASCO updates and teaching critical appraisal.Org: Abington Memorial Hospital, United States Air Force,
Abstract
Formation and evaluation of the ASCO medical education community of practice (Med Ed CoP).Org: University of Manchester/The Christie NHS Foundation Trust,
Abstract
Roll out and influence of an educational program: Talking about risk, uncertainties of testing in genetics (TRUSTING).Org: SHORE-C, Barking, Havering and Redbridge University Hospitals NHS Trust, Ashford & St Peter's NHS Foundation Trust, Guildford,
Abstract
Training of clinical oncologists in Africa: Results of a regional survey.Org: College of Medicine, University of Ibadan, Ibadan, Nigeria, St. Paul's Hospital Mellinnium Medical Collage, Addis Ababa, Ethiopia, El Zaitoun Specialized Hospital, Ministry of Health and Population, Cairo, Egypt, Faculty of Health Sciences, University of Buea, Buea, Cameroon,
Abstract
Two years of teaching close to home: Lessons learned from a near-peer model for an introductory lecture series for hematology-oncology fellows.Org: Beth Israel Deaconess Medical Center, Harvard Medical School,
Abstract
Fortifying the workforce: A national survey of hematology/oncology fellowship program directors and training fellows for community-based careers.Org: Mercy Catholic Medical Center,
Abstract
A multicenter analysis of didactic curricula in a hematology oncology fellowship program.Org: Massachusetts General Cancer Center, UNC Health Care System, Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University,
Abstract
Alignment of patient-clinician perspectives in triple-negative breast cancer (TNBC).Org: PlatformQ Health Education, MBC Alliance, Unity Point Health,
Abstract
Surveying oncologists' awareness and challenges in addressing social determinants of health: A national study.Org: PVI, PeerView Institute for Medical Education,
Abstract
Optimizing hematology/oncology (H/O) curricula for internal medicine (IM) residents: A two-institution Delphi survey.Org: The Regents of the University of California, San Francisco,
Abstract
Implementing a research methods curriculum for first year hematology oncology fellows.Org: Division of Hematology & Oncology, Heersink School of Medicine, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Massachusetts General Cancer Center, Boston, MA,
Abstract
Improving goal concordant care clinician workshops: Do patients benefit?Org: City of Hope National Medical Center, City of Hope Comprehensive Cancer Center, City of Hope National Comprehensive Cancer Center,
Abstract
Educating hematology-oncology fellows about how to communicate with patients about cancer clinical trials: A needs assessment.Org: Durham VA Health Care System and Duke University School of Medicine, The Leukemia and Lymphoma Society,
Abstract
Filling the gap in competency-based training for medical oncology with supervised online patient counseling: A qualitative study.Org: The Institute for Cancer Care at Mercy, Public Health Sciences Department, ITMO University,
Abstract
A national survey of obstetrics and gynecology resident perspectives on their preparedness to provide care for racially and socioeconomically diverse gynecologic oncology populations.Org: University of Connecticut Health Center,
Abstract
Predictive factors for academic oncology career placement.Org: Montefiore Medical Center/Albert Einstein College of Medicine,
Abstract
Knowledge of diagnosis characteristics and treatment received among Mexican breast cancer survivors.Org: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,
Abstract
Practice makes perfect: Using simulation to build and assess competency in bone marrow biopsy for heme/onc fellows.Org: Gundersen Health System, La Crosse, WI,
Abstract
Integration of a focused podcast curriculum (PC) to improve hematology oncology fellow (HOF) knowledge: A multi-center cluster randomized controlled trial.Org: Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Wake Forest Baptist Health, Hematology and Oncology, University of Oklahoma HSC, Olive View-UCLA Medical Center,
Abstract
Precision medicine preceptorship in breast and lung cancer for Latin American oncologists.Org: Emory University Winship Cancer Institute, Winship Cancer Institute at Emory University, Emory University School of Medicine, Emory Winship Cancer Institute, Winship Cancer Institute, Emory University School of Medicine,
Abstract
Analysis of hematology-oncology fellowship match outcomes (2007-2022) and cross-subspecialty comparisons: A retrospective cohort study.Org: Quinnipiac University, Frank H. Netter, MD, School of Medicine, St. Vincent's Medical Center, Bridgeport, CT, Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN,
Abstract
Medical students' views on oncology specialty: A cross-sectional study.Org: Department of Medical Oncology, Tawam Hospital, Abu Dhabi Health Services Co., Alain, United Arab Emirates, Public Health Institute, United Arab Emirates University, Alain, United Arab Emirates, Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Alain, United Arab Emirates, College of Medicine and Health Sciences, United Arab Emirates University, Alain, United Arab Emirates, Department of Radiation Oncology at Dalhousie University, Halifax, Canada,
Abstract
Development of a professional oncology navigation training and credentialing program: ACS Leadership in Oncology Navigation (ACS LION).Org: American Cancer Society, Sanofi, University of Illinois at Chicago,
Abstract
Bioethics of over- and undertreatment in older adults with cancer.Org: SCOREboard Advisory Group,
Abstract
Exploring the digital footprint: Social media use among hematology oncology fellowship programs in the U.S.Org: Jacobi Medical Center/Albert Einstein College of Medicine, Patan Academy of Health Sciences, The Wright Center, Department of Hematology and Oncology, Jacobi Medical Center, Albert Einstein College of Medicine,
Abstract
YouTube as a reliable source of information on antibody drug conjugates: A qualitative analysis.Org: NewYork-Presbyterian Queens, Gian Sagar Medical College, Lokmanya Tilak Municipal Medical College, Government Medical College Patiala, TD Medical College--Alappuzha,
Abstract
Hematology/oncology fellowship programs’ instagram presence.Org: Penn State Health Milton S. Hershey Medical Center, Penn Medicine Abramson Cancer Center, Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan,
Abstract
The role of social media and email in hematology oncology fellowship program recruitment: Insights from national survey of program directors.Org: The Wright Center,
Abstract
Cracking the code: Can bibliometric attributes predict NIH R01 grant funding outcomes in gastrointestinal oncology? Exploring patterns from a five-year analysis.Org: Edward Via College of Osteopathic Medicine,
Abstract
Health insurance plans offered at NCI-designated cancer centers.Org: University of Oklahoma College of Medicine, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, University of Oklahoma Health Sciences Center, UT Southwestern Medical Center, The University of Oklahoma Stephenson Cancer Center,
Abstract
AI in oncology: Resident perspectives by gender and tech literacy.Org: Faculdade De Ciencias Medicas Da Santa Casa De Sao Paulo, UFPR, Univeristy of Toronto, Kingston Health Sciences Center,
Abstract
Development of equity, diversity, and inclusion competencies in residents and faculty in oncology through formal and informal learning.Org: Queen's University Belfast, Maastricht University Medical Center,
Abstract
Outcomes following long-term response to immune checkpoint inhibitors in patients with advanced melanoma.Org: The Crown Princess Mary Cancer Centre, Department of Dermatology, University Hospital Essen, Department of Dermatology, University Hospital of Zurich, Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), APHP Hôpital Saint-Louis,
Abstract
When to stop immunotherapy for advanced melanoma: Emulation of target trials.Org: Université Paris Cité et INSERM, CHRU Lille - Hôpital Claude Huriez, Rhône-Alpes, CHU de Dijon, CHU Albert Michallon,
Abstract
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma.Org: I-Med Radiology,
Abstract
The 31-GEP to identify patients with localized cutaneous melanoma at the highest risk of metastasis to the central nervous system.Org: Castle Biosciences, Northeast Dermatology Associates,
Abstract
A phase 2 clinical trial of regorafenib in patients with advanced pretreated melanoma (RegoMel).Org: Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel,
Abstract
Length of treatment after partial or complete remission in immunotherapy for metastatic melanoma: An EUMelaReg real world study.Org: Beilinson Medical Center, EuMelaReg, Military Medical Academy, National Cancer Center Bulgaria, University of Kiel,
Abstract
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years.Org: Instituto Oncológico Fundación Arturo López Pérez and Department of Oncology, Instituto Nacional del Cáncer, Santiago, Chile, FAICIC Clinical Research, Veracruz, Mexico, Dermatology, Centre Hospitalier Universitaire de Lyon, Lyon, Rhône-Alpes, France,
Abstract
Randomized phase II evaluation of nivolumab (nivo), or relatlimab (rela), or combined nivo-rela lead-in followed by nivo-rela as first line therapy for patients (pts) with advanced melanoma (mel).Org: Department of Immunology, University of Pittsburgh,
Abstract
Continuous intrathecal infusion of nivolumab in advanced melanoma with leptomeningeal disease.Org: UFR Médecine Paris Nord, Neurosurgery Department, Assistance Publique hôpitaux de Paris, Beaujon Hospital, Mutimodal imaging lab (Biomaps) Université Paris Saclay/CEA/CNRS UMR9011/INSERM UMR1281,
Abstract
A phase I/II study of KD6001, a novel fully human anti-CTLA4 IgG1 monoclonal antibody, in combination with toripalimab in patients with advanced melanoma.Org: Shanghai Celgen Bio-pharmaceutical Co., Ltd.,
Abstract
Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).Org: Immunocore Ltd., Immunocore LLC,
Abstract
Efficacy of encorafenib/binimetinib in patients with metastatic melanoma with brain metastases: Results from the nationwide Dutch Melanoma Treatment Registry.Org: University Medical Center of Utrecht, Maastricht University Medical Centre, Zuyderland MC, Medisch Spectrum Twente, Maxima Medical Center,
Abstract
A phase I dose escalation trial of BCD-145 in patients with unresectable or metastatic melanoma.Org: JSC Biocad, St. Petersburg Clinical Scientific and Practical Centre of Specialized Kinds of Medical Care (Oncologic), Modern Medical Technologies Clinic, JCS Biocad,
Abstract
Long-term overall survival after isolated liver perfusion with melphalan in patients with isolated liver metastases of uveal melanoma (SCANDIUM trial).Org: Sahlgrenska Center for Cancer Research, Transplant Institute, Glostrup Hospital, Copenhagen University Hospital Glostrup, Skane University Hospital,
Abstract
First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment.Org: Melanoma Research Alliance,
Abstract
Advanced stage melanoma during pregnancy: Real-world management.Org: Netherlands Cancer Institute (NKI), University of Colorado at Denver - Anschutz Medical Campus,
Abstract
Overall survival after isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (the SCANDIUM II trial).Org: University of Gothenburg, Skane University Hospital Comprehensive Cancer Center, University Hospital of Umeå,
Abstract
Use of baseline and serial ctDNA dynamics to predict outcomes in patients treated with first-line tebentafusp, including those who were and were not treated beyond progression.Org: The Clatterbridge Cancer Centre and University of Liverpool,
Abstract
A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial.Org: Bucks, Nottingham University Hospitals NHS Trust, Churchill Hospital, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Trust,
Abstract
Association between clinical and disease characteristics and detectable or undetectable baseline ctDNA in patients with metastatic uveal melanoma.Org: Mount Vernon Cancer Centre, Immunocore Ltd., Northwell Health Cancer Institute, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, The Clatterbridge Cancer Centre and University of Liverpool,
Abstract
EVICTION study: ICT01, an anti-Butyrophilin 3A monoclonal antibody activating γ9δ2 T cells in combination with pembrolizumab in checkpoint inhibitor refractory melanoma.Org: Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Sutton, United Kingdom, Center for Cancer Immunotherapy, Nice, France, Oullins-Pierre-Bénite, France,
Abstract
Using serial 18F-FDG PET/CT PERCIST response to predict responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma.Org: Faculty of Medicine at University of Queensland,
Abstract
Development of a novel granulocyte scoring system for use as a predictive/prognostic biomarker in patients with advanced melanoma undergoing treatment with combination immunotherapy.Org: The Royal Marsden Hospital, The Royal Marsden Hospital NHS Foundation Trust, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,
Abstract
Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: Lenvamel, a multicenter retrospective study of the French Group of Skin Cancers.Org: Service de dermatologie, CHU de Nice, Nice, France, Service de Dermatologie, Centre Hospitalier Universitaire and Université Franche Comté, Inserm 1098 RIGHT, Besançon, France, Hôpital Avicenne – APHP, Bobigny, France, Service de Dermatologie, Hôpital Avicenne, Université Sorbonne Paris Nord, Bobigny, France, Service de Dermatologie, CHU Bordeaux, Bordeaux, France,
Abstract
Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma.Org: Laura and Isaac Permitter Cancer Center,
Abstract
Circulating tumor DNA analysis in patients with BRAF-mutated metastatic cutaneous melanoma treated with BRAF and MEK inhibitors: Analysis of the OPTIMEL study.Org: Service de Biopathologie, CNRS UMR 7039 CRAN Université de Lorraine, Methodology Biostatistics Unit pour Nassim, CHRU Nancy, Centre Hospitalier Régional Metz-Thionville,
Abstract
Pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): Long-term results of the phase 2 KEYNOTE-629 study.Org: Hospital Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Royal Brisbane and Women's Hospital, Herston, and University of Queensland, Brisbane, Australia, CHRU Lille - Hôpital Claude Huriez, Lille, France, Aix-Marseille University, Hôpital de la Timone, Marseille, France, Johannes Wesling Medical Center, Ruhr University Bochum, Minden, Germany,
Abstract
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.Org: Departments of Cutaneous Oncology and Immunology,
Abstract
Camrelizumab plus apatinib and temozolomide as first-line therapy for advanced acral melanoma: 2-year survival results from CAP 03.Org: Department of Melanoma and Sarcoma Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Melanoma Institute Australia, Department of Genitourinary Oncology,
Abstract
Overall survival and efficacy subgroup analysis of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.Org: The Comprehensive Cancer Center of Drum-Tower Hospital, The Third People's Hospital of Zhengzhou, The First Affiliated Hospital of Dalian Medical University,
Abstract
Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Final results and exploratory biomarker analysis from the phase 2 TRICOTEL study.Org: University of Zürich Hospital, ISS AG, Integrated Scientific Services,
Abstract
Retro TIMing: A multicentric retrospective analysis of immunotherapy timing in metastatic melanoma.Org: Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, Unidade Local de Saúde de Santo António,
Abstract
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC).Org: Analysis Group Ltd.,
Abstract
Analyzing the gut microbiome in adolescent and young adult patients with melanoma receiving immune checkpoint blockade.Org: MD Anderson Hematology/Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study.Org: Fujian Cancer Hospital, First Chest Radiotherapy Department, Hunan Cancer Hospital, Changsha, China, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Department of Melanoma Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China, The Third People's Hospital of Zhengzhou,
Abstract
The efficacy and safety of toripalimab combined with anlotinib in the first-line treatment of Chinese patients with metastatic melanoma.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China,
Abstract
Association between circulating tumor DNA (ctDNA) and recurrence-free survival (RFS) in patients (pts) with resected stage III melanoma: An exploratory analysis of SWOG S1404.Org: Natera Inc., UCLA, Jonsson Comprehensive Cancer Center,
Abstract
Prediction of melanoma metastasis using dermatoscopy deep features: An international multicenter cohort study.Org: Department of Medical Oncology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece, Department of Medical Physics, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece, Department of Dermatology, Medical University of Vienna, Vienna, Austria, Dermatology Unit, University of Campania L. Vanvitelli, Sant'antimo, Italy, Department of Dermatology, Hospital de Clínicas de Porto Alegre - Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil,
Abstract
Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results.Org: Sidney Kimmel Cancer Center, Thomas Jefferson University, Gruppo Multimedica, Charité Hospital Berlin, University Hospital Wuerzburg, University Hospital Giessen and Marburg,
Abstract
Lenvatinib (len) plus pembrolizumab (pembro) in patients with advanced melanoma that progressed on anti–PD-(L)1 therapy: Over 4 years of follow-up from the phase 2 LEAP-004 study.Org: John Wayne Cancer Institute, Centre hospitalier de l’Université de Montréal (CHUM), Centre de recherche du CHUM, Skåne University Hospital Comprehensive Cancer Centrer and Lund University, Hospital General Universitario Gregorio Marañón and CIBERONC,
Abstract
Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD-1 therapy in patients with metastatic melanoma.Org: IEO European Institute of Oncology IRCCS, Merck and Co Inc Kenilworth,
Abstract
Correlation of eTILs with recurrence free survival (RFS) in stage IIB-IIIA melanoma and use as biomarker for stratification for clinical trials.Org: Department of Epidemiology and Population Health, Geisinger Health System Department of Pathology,
Abstract
ADU-1604, a novel CTLA-4 blocking antibody, to modulate pharmacodynamic markers in patients with PD1 relapse/refractory melanoma.Org: Maria Skłodowska-Curie National Institute of Oncology Center, Warsaw, Poland, University of Siena and Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy, Gustave Roussy and Paris-Saclay University, Villejuif, France, Veneto Institute of Oncology, IOV–IRCCS, Veneto, Italy, Hospital General Universitario Gregorio Marañón and CIBERONC, Madrid, Spain,
Abstract
The DIET study: A randomized controlled trial of a high fiber diet intervention (HFDI) in patients (pts) with melanoma receiving immune checkpoint blockade (ICB).Org: Bionutrition Research Core,
Abstract
Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: Clinical outcomes and biomarker analysis.Org: Melanoma Medical Oncology Department, Rheumatology and Clinical Immunology Section,
Abstract
Intracranial outcomes with ipilimumab and nivolumab in melanoma brain metastases following progression on anti-PD-1 therapy.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Immune phenotype profiling based on anatomic origin of melanoma and impact on clinical outcomes of immune checkpoint inhibitor treatment.Org: Lunit Inc., Yonsei University College of Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Stanford University School of Medicine,
Abstract
Clinical validation of a prognostic 7-marker IHC assay (7-IHC) in 382 patients (pts) with stage IB/IIA cutaneous melanoma (CM; MELARISK-001).Org: University Medical Center Gronigen, Groningen University, Dr Balmis General University Hospital, Institute for Health and Biomedical Research (ISABIAL), North Estonia Medical Centre Foundation,
Abstract
Antigen-specific profiling for neoadjuvant anti-PD-1 therapy in melanoma.Org: St. Luke's Hospital,
Abstract
Neoadjuvant pembrolizumab plus lenvatinib in patients with resectable stage III melanoma (NeoPele): Analysis of tumor microenvironment (TME) correlated to pathological response.Org: Melanoma Institute Australia, Faculty of Medicine and Health, The University of Sydney, Charles Perkins Centre, The University of Sydney, The University of Sydney, Blacktown Hospital,
Abstract
Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 451 patients (pts) with stage I/II melanoma who did not undergo sentinel lymph node biopsy.Org: Center for Dermatooncology, SkylineDX B.V., SkylineDx BV,
Abstract
A prognostic model based on selected cell state and cellular community scores in patients with advanced melanoma treated with immune checkpoint inhibitors (Ecotype-ICI score) as a predictor of ICI immunotherapeutic benefits.Org: Huntsman Cancer Institute and Department of Neurosurgery, University of Kentucky Markey Cancer Center, University of Iowa Hospitals and Clinics Holden Comprehensive Cancer Center, Division of Cancer Treatment and Diagnosis National Cancer Institute National Institutes of Health, Melanoma Program UPMC Hillman Cancer Center,
Abstract
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: Propensity score–matched recurrence-free, distant metastasis-free, and overall survival analysis.Org: Leiden University Medical Center, Maastricht University Medical Centre, Zuyderland MC, The Netherlands Cancer Institute, University Medical Center of Utrecht,
Abstract
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).Org: University Hospital Jean Minjoz, Université de Franche-Comté, Inserm RIGHT, Besançon, CHU de Bordeaux,
Abstract
Incidence and risk factors for central nervous system (CNS) metastasis (met) in patients (pts) with stage III melanoma treated with adjuvant (ADJ) anti-PD1 immunotherapy (IMT).Org: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Melanoma Institute Australia, Wollstonecraft, NSW, Australia, Melanoma Institute Australia, Sydney, NSW, Australia, Melanoma Institute Australia, Wollstonecraft, Australia, The University of Sydney and Sydney Cancer Centre, Wollstonecraft, NSW, Australia,
Abstract
Use of early circulating tumour DNA dynamics in patients with stage III melanoma receiving neoadjuvant combination immunotherapy.Org: Macquarie University, Chris O'Brien Lifehouse, Melanoma Institute Australia, Netherlands Cancer Institute (NKI-AVL),
Abstract
Identifying the high risk group in stage pT1bN0 cutaneous melanoma.Org: Department of Soft Tissue/Bone Sarcoma and Melanoma, Medical University of Warsaw,
Abstract
Prognosis of deep margin excisions within or beyond subcutaneous fat for invasive acral melanoma of the sole: A multi-institutional retrospective study.Org: Department Of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan, Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan, Department of Dermatology, Mie University, Mie, Japan, Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan, Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan,
Abstract
Characterization of driver oncogenic mutations of in-transit melanoma metastases.Org: University of Virginia, Charlottesville, VA, USA, Charlottesville, VA,
Abstract
Biomarker analysis and updated clinical outcomes: Neoadjuvant systemic treatment (NST) with nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma.Org: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, UCSF Dermatopathology Service, San Francisco, CA, Melanoma Medical Oncology Department, University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX,
Abstract
Neoadjuvant pembrolizumab and lenvatinib in resectable mucosal melanoma: NeoPlus study update.Org: Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Department of Melanoma and Sarcoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Haidian District, China,
Abstract
Serum multiplex analysis of checkpoint proteins in association with immune-related adverse events in patients with melanoma receiving adjuvant anti-PD-1 therapy.Org: University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center,
Abstract
Neoadjuvant immunotherapy (neoIT) in melanoma: A prediction tool for pathological response and recurrence, and the role of adjuvant (Adj) therapy (Tx) to improve recurrence-free survival (RFS).Org: Sydney Medical School,
Abstract
Metabolic factors affecting response to adjuvant anti-PD1 therapy for melanoma.Org: Melanoma Program, UPMC Hillman Cancer Center,
Abstract
Primary immunotherapy monotherapy (PRIMO) in locally advanced cutaneous squamous cell carcinoma.Org: Cleveland Clinic Taussig Cancer Instititute, OHB Neonatology,
Abstract
Combined EORTC FDG-PET/CT and RECIST 1.1 response criteria and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.Org: A.C. Camargo Cancer Center, Melanoma Institute Australia,
Abstract
The impact of adjuvant radiation therapy on disease-specific survival in stage I and II Merkel cell carcinoma: A SEER database analysis.Org: Washington University School of Medicine in St Louis,
Abstract
Germline pathogenic variants in a large convenience cohort of multiple melanoma subtypes.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Phase 1b trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC).Org: H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute and Harvard Medical School, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cutaneous squamous cell carcinoma (cSCC).Org: UPMC Health System, Predxbio,
Abstract
Durability of immune checkpoint inhibitor (ICI) response following treatment discontinuation in advanced merkel cell carcinoma (MCC).Org: Nova Southeastern Univesity, Ft. Lauderdale, Nova Southeastern University,
Abstract
The 15-gene expression profile test is independent from PRAME and 7-gene next-generation sequencing: Results from 3,267 clinically tested uveal melanomas.Org: Friendswood,
Abstract
Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.Org: AZ Sint-Augustinus,
Abstract
Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.Org: Elekta - Kaiku Health, Antoni van Leeuwenhoek/Netherlands Cancer Institute (NKI), Sydney Medical School, Faculty of Medicine and Health Sciences, The University of Sydney,
Abstract
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.Org: Iovance Biotherapeutics, H. Lee Moffitt Cancer Center and Research Institute, UPMC Hillman Cancer Center, The Royal Marsden Hospital NHS Foundation Trust, Perlmutter Cancer Center, NYU Langone Health,
Abstract
A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec (VO) combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).Org: UPMC Hillman Cancer Center, Pittsburgh, PA, Replimune, Inc., Woburn, MA, Gustave Roussy and Paris-Saclay University,
Abstract
A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301).Org: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Dermatology, University Hospital St. Pölten, Karl Landsteiner University of Health Sciences, Greenville Health System, Abindgon,
Abstract
Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitors by investigation of CD8+ immune infiltrate with [89Zr] crefmirlimab berdoxam PET.Org: Department of Dermatology, Eberhard Karls University of Tübingen, Department of Dermatology, University Hospital Tuebingen, Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tübingen, Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University Hospital Tuebingen,
Abstract
A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases.Org: Stanford University School of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University,
Abstract
A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma.Org: UPMC Hillman Cancer Center, Pittsburgh, PA, UT Health Science Center at San Antonio, Mays Cancer Center, San Antonio, TX,
Abstract
A phase I/IIa of [212Pb]VMT01 targeted a-particle therapy for unresectable or metastatic melanoma.Org: University of Wisconsin SMPH,
Abstract
First-in-human study of 225actinium mti-201 (225Ac-MTI-201) in metastatic uveal melanoma (UM).Org: H. Lee Moffitt Cancer Center and Research Institute, Washington University School of Medicine in St Louis, Modulation Therapeutics,
Abstract
Randomized phase II trial of pembrolizumab/lenvatinib (P+L) +/- responder fecal microbiota transplant (R-FMT) in PD-1 relapsed/refractory (R/R) cutaneous melanoma (MEL).Org: UPMC Hillman Cancer Center, University of Pittsburgh, University of Pittsburgh Medical Center (UPMC), Nihon Medi-Physics,
Abstract
Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with uveal melanoma and advanced cancers.Org: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy, U.O.C. Immunoterapia Oncologica Azienda Ospedaliera Universitaria Senese, Siena, Italy, iOnctura SA, Geneva, Switzerland, iOnctura, Geneva, Switzerland, Covance Clinical and Peri-approval Services LTD, Milano, Italy,
Abstract
A phase III, open-label, multicenter, randomized controlled trial of tunlametinib versus investigator-selected chemotherapy in patients with advanced NRAS-mutant melanoma who had previously received immunotherapy.Org: Drum-Tower Hospital,
Abstract
Novel RNA-nanoparticle vaccine for the treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy.Org: University of Florida Department of Surgery, University of Florida College of Public Health and Health Professions, University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy,
Abstract
Reduced dose fludarabine/cyclophosphamide lymphodepletion for tumor-infiltrating lymphocytes therapy (LN-144, lifileucel) in metastatic melanoma.Org: University of Kansas Cancer Center, Kansas City, KS,
Abstract
Precision genome profiling for pediatric leukemia with a software-controlled enrichment method using nanopore sequencer.Org: Division of Genome Analysis Platform Development,
Abstract
A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.Org: H. Lee Moffitt Cancer Center and Research Institute, Regeneron Pharmaceuticals, Inc., Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Accelerated aging among survivors of childhood leukemia and lymphoma: Estimates of early onset and excess morbidity from the COMPASS model.Org: Harvard T. H. Chan School of Public Health,
Abstract
Racial disparities in pediatric patients with acute myeloid leukemia.Org: Creighton University Medical Center, Creighton Hematology Oncology,
Abstract
A phase 1/2 study of vusolimogene oderparepvec (RP1) in primary melanoma (mel) to reduce the risk of sentinel lymph node (SLN) metastasis.Org: UPMC Hillman Cancer Center,
Abstract
The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma.Org: The Netherlands Cancer Institute, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Cancer Center Amsterdam, University Medical Center Groningen, Leiden University Medical Center,
Abstract
A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors.Org: UofL Health – Brown Cancer Center,
Abstract
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).Org: Melanoma Institute Australia,
Abstract
INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma.Org: Sydney Medical School,
Abstract
Intralesional administration of L19IL2/L19TNF in high-risk locally advanced basal cell carcinoma or cutaneous squamous cell carcinoma.Org: Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tübingen, Tübingen, Germany, Philogen S.p.A., Sovicille, Italy, Universität Tübingen, Tübingen, Germany, Philochem AG, Otelfingen, Switzerland,
Abstract
A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma.Org: Lehigh Valley Topper Cancer Institute,
Abstract
INTASYL PH-762: PD-1 intratumoral immunotherapy for cutaneous carcinoma.Org: Prosoft Clinical,
Abstract
TRICK-MCC: A proof-of-concept, investigator-initiated study of combination therapy with anti–PD-1, anti–LAG-3, and anti–TIM-3 in participants with advanced or metastatic PD-(L)1 refractory Merkel cell carcinoma.Org: University of Washington, Seattle, WA,
Abstract
A phase 2, open-label, 2-cohort study to evaluate patient preference for nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) subcutaneous (SC) vs NIVO + RELA FDC intravenous (IV) and NIVO SC vs NIVO IV in participants with melanoma.Org: Alaska Oncology and Hematology, LLC., Bristol Myers Squibb Research,
Abstract
Testicular germ cell tumor survival among children, adolescents, and young adults: A population-based retrospective cohort study.Org: Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, Cancer Research Program, ICES, Toronto, ON, Canada, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia, Queensland Digital Health Centre and Centre for Health Sciences Research, The University of Queensland, Brisbane, Australia, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel,
Abstract
Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma.Org: Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Queen Mary Hospital and Hong Kong Children's Hospital, IRCCS Istituto Giannina Gaslini, Center for Pediatric and Adolescent Medicine,
Abstract
Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma.Org: Pediatric Cancer Center Barcelona, Queen Mary Hospital and Hong Kong Children's Hospital, IRCCS Istituto Giannina Gaslini, Center for Pediatric and Adolescent Medicine, Riley Hospital for Children,
Abstract
Preclinical efficacy of BRG1/BRM ATPase inhibitor in B lymphoblastic leukemia.Org: Seattle Children's Research Institute, Ben Towne Center for Childhood Cancer Research,
Abstract
Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial.Org: Kids Cancer Centre, Sydney Children's Hospital, University Hospital – Rigshospitalet, Children’s Health Queensland Hospital and Health Service, Department of Paediatric Haematology/Oncology,
Abstract
Phase I trial of chidamide, an oral HDAC inhibitor, in combination with oral etoposide in patients with refractory/recurrent neuroblastoma.Org: Yuexiu District, Guangzhou,
Abstract
Harmonizing cancer care delivery for AYAs with osteosarcoma: Comparison of pediatric and medical oncology approaches in a single center.Org: Department of Sarcoma Medical Oncology, Department of Orthopedic Oncology,
Abstract
MRI compared to 123I-MIBG scan for detection of central nervous system relapse in neuroblastoma.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Demographic factors of prognosis in pediatric neuroblastoma.Org: Creighton University Medical Center, Creighton Hematology Oncology,
Abstract
AI/ML-derived mechanistically interpretable whole-genome biomarkers of patient survival in pre-treatment primary neuroblastoma tumors and whole blood.Org: Children's Hospital of Los Angeles,
Abstract
Revealing and targeting metabolic drivers contributing to treatment escape in diffuse midline glioma.Org: Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences,
Abstract
Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.Org: Hospital Sant Joan de Deu,
Abstract
Institutional review of pediatric oncology patients participating in early phase clinical trials.Org: Children’s Mercy Hospitals and Clinics,
Abstract
Targeted treatment in inflammatory myofibroblastic tumors in children.Org: Pediatric Hematology-Oncology, Istanbul, Turkey,
Abstract
Clinical characteristics, prognosis, and immunotherapy outcome in pediatric melanoma: Analysis from a large Chinese cohort.Org: Sun Yat-sen Univeresity Cancer Center,
Abstract
Efficacy and safety of the use of dinutuximab in newly diagnosed or relapse high risk neuroblastoma: Single arm systematic review and meta-analysis.Org: Pediatric Oncology Institute, GRAACC Hospital, Federal University of São Paulo, Viçosa, Brazil, Federal University of São João Del-rei,
Abstract
Clinical and molecular characteristics and targeted therapy of pediatric non-infantile fibrosarcoma NTRK rearrangement–related tumors.Org: Children's hospital of Chongqing Medical University,
Abstract
Evaluating antitumor activity and response determinants to trastuzumab deruxtecan in pediatric solid tumors.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Pediatric cancer registry in Turkey 2002-2023: 22 years of achievement (TPOG & TPHD).Org: Hacettepe University Faculty of Medicine Department of Pediatric Oncology, Medical Park Hospital,
Abstract
Diffuse midline gliomas in children: Does changing strategies change results?Org: Pediatric Hematology-Oncology,
Abstract
Clinical application of individualized tumor-informed circulating tumor DNA for therapeutic response and relapse prediction in patients with neuroblastoma.Org: Sun Yat-sen University Cancer Center Gansu Hospital, OrigiMed,
Abstract
Phase I dose escalation and pharmacokinetics clinical trial of mitoxantrone hydrochloride liposome in children with relapsed and refractory solid tumors.Org: Wuhan Children's Hospital,
Abstract
Feasibility of tumor-informed circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment in pediatric patients with solid tumors.Org: The University of Texas Dell Medical School,
Abstract
Survival outcomes in patients with high-risk neuroblastoma (HRNB) in remission after relapsed or refractory treatment receiving eflornithine (DFMO) maintenance.Org: Penn State Health Children’s Hospital, US WorldMeds, Louisville,
Abstract
Intravitreal chemotherapy (IVC) in retinoblastoma: A study of clinical variables and ocular preservation outcomes.Org: Hospital Santa Marcelina, Oncoclinicas&CO/MedSir,
Abstract
Central pathological review and molecular classification of medulloblastoma in countries with limited resources: A commitment to equitable access.Org: Hospital Santa Marcelina, Oncoclinicas&CO/MedSir, Sao Paulo, Brazil,
Abstract
Evaluation of kidney function and body composition in adult survivors of unilateral, non-metastatic, non-syndromic Wilms tumor: A report from the St. Jude Lifetime Cohort Study.Org: University of Tennessee Health Sciences Center,
Abstract
Real-world experience of larotrectinib in children, adolescents and young adults with TRK fusion solid tumors in France.Org: Oncology Center SIREDO, Pediatric Immuno-Hemato-Oncology Unit, Department of Pediatric Hematology-Oncology, University Hospital of Montpellier, Oscar Lambret Cancer Center,
Abstract
PP2A activation as a new therapeutic strategy in neuroblastoma: Making sense out of senescence.Org: Atux Iskay LLC,
Abstract
Biomarker development from functional precision medicine datasets via explainable machine learning.Org: First Ascent Biomedical, Florida International University, Nicklaus Children's Hospital, University of Miami Miller School of Medicine, Miami, FL,
Abstract
The role of immune checkpoint blockade in children, adolescents, and young adults: A systematic review and meta-analysis.Org: Federal University of Rio de Janeiro, Universidade Federal do Ceará, Federal Fluminense University,
Abstract
N9: Pilot study of novel shortened induction for high-risk neuroblastoma.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Evaluating scholastic achievement in pediatric brain tumor survivors compared to healthy controls.Org: Department of Radiation Oncology, University of Florida College of Medicine Jacksonville, Jacksonville, FL, Department of Radiation Oncology, University of Florida, Jacksonville, FL, Department of Surgery, University of Florida College of Medicine Jacksonville, Jacksonville, FL, Nemours Children's Health, Jacksonville, FL, Department of Neurosurgery, University of Florida College of Medicine Jacksonville, Jacksonville, FL,
Abstract
Overall survival prediction and risk stratification in patients with neuroblastoma through machine learning in the large multi-institutional PRIMAGE cohort.Org: Quantitative Imaging Biomarkers in Medicine, Quibim, Grupo de Investigación Biomédica en Imagen, Instituto de Investigación Sanitaria La Fe, Área Clínica de Imagen Médica,
Abstract
The dose-response relationship between cumulative alkylating agent exposure and sperm concentration in adult survivors of childhood cancer: A report from the St. Jude Lifetime (SJLIFE) cohort study.Org: Fertility Associates of Memphis,
Abstract
Effect of oncolytic herpes simplex virus on fusion-positive rhabdomyosarcoma to radiotherapy.Org: Univesrity of Alabama at Birmingham, The Children's Hospital of Alabama,
Abstract
Effects of cardiac radiation on sleep and psychological distress in adult survivors of pediatric Hodgkin lymphoma without breathing sleep disorders.Org: St. Jude Children's Research Hospital, St. Jude Children’s Research Hospital, Memphis, TN,
Abstract
AMH levels after initial cycles of chemotherapy in female adolescents with Ewing sarcoma and implications for preservation of fertility.Org: Peking University People’s Hospital, Beijing, China, Peking University People's Hospital,
Abstract
Mapping aging phenotypes in childhood cancer survivors: A report from the St. Jude Lifetime Cohort.Org: St. Jude Children's Research Hospital, Washington University School of Medicine in St Louis,
Abstract
Risk of low bone mineral density in young pediatric cancer survivors with sarcopenia.Org: University of Granada, Granada, Loyola University Andalusia, Virgen de las Nieves University Hospital, University of Cordoba,
Abstract
Social support dynamics within parent-AYA cancer survivor dyads in a rural, socioeconomically disadvantaged, majority Hispanic/Latino region.Org: Department of Psychiatry and Behavioral Sciences, Jacob's Heart Children's Cancer Support Services,
Abstract
Factors associated with fertility status assessment among female survivors of childhood cancer.Org: Children's Colorado,
Abstract
Experiences of underrepresented adolescent and young adult (AYA) cancer survivors engaging in research-related activities.Org: University of Rochester Medical School, University of Michigan,
Abstract
The effects of oral nutritional supplements on functional outcomes and body composition in patients with solid cancer undergoing systemic chemotherapy: A pilot study.Org: Division of Hemato-Oncology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, Chungnam National University Hospital, Daejeon, South Korea, Chungnam National University Hospital, Jung-Gu, South Korea, Department of Medical Science and Internal Medicine, College of Medicine, Chungnam National University, Daejeon, South Korea, Division of Hematology and Oncology, Department of Internal Medicine, Chungnam National University College of Medicine, Chungnam National University Hospital, Daejeon, South Korea,
Abstract
Cost-effectiveness of single-day intravenous fosaprepitant versus three-day oral aprepitant anti-emetic regimen in pediatric patients receiving highly-emetogenic chemotherapy.Org: All India Institute of Medical Science (AIIMS), All India Institute of Medical Sciences (AIIMS), Rishikesh, India,
Abstract
Personal symptom ecosystem predicts progression of chronic health conditions (CHCs) in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort study (SJLIFE).Org: St. Jude Children's Research Hospital, Memphis, TN,
Abstract
Effect of cancer screening with multi-cancer early detection testing and whole body MRI on cancer worry in a high-risk population.Org: City of Hope National Medical Center, Duarte, CA, CanSino Biologics,
Abstract
Trends in human papilloma virus vaccination uptake by sex and race/ethnicity among US adolescents and young adults, 2011-2020.Org: University of Florida Department of Health Outcomes and Biomedical Informatics, Gainesville, FL, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Dallas, TX, Baylor College of Medicine,
Abstract
Incidence trends of advanced breast cancer in an era of its routine screening in the United States: A population-based study.Org: One Brooklyn Health/Brookdale University Hospital and Medical Center,
Abstract
Population attributable fraction of reproductive factors in triple negative breast cancer by race.Org: Cancer in the Know and SWOG Patient Advocate,
Abstract
Impact of colorectal cancer screening on the incidence of advanced stages of the disease in the United States: An analysis of 181,442 patients.Org: One Brooklyn Health/Brookdale University Hospital and Medical Center,
Abstract
Impact of the oral contraceptive pill on the rate of ovarian cancer incidence in different races of women.Org: HCA Florida Brandon Hospital, Comprehensive Hematology-Oncology,
Abstract
Differences in shared decision-making and prostate cancer screening by sexual orientation and race/ethnicity.Org: Department of Health Policy,
Abstract
The utility of HPV16 E6 as a potential biomarker for HPV-related cancers in HIV-infected men who have sex with men.Org: National Center for Global Health and Medicine, German Cancer Research Center,
Abstract
Acceptability of stool-based DNA colorectal cancer (CRC) screening among Black/African American patients served by a Federally Qualified Health Center (FQHC).Org: Department of Medicine, University of Wisconsin, Madison, WI, Center for Urban Population Health, Madison, WI, The University of Texas MD Anderson Cancer Center, Longview, TX, Outreach Community Health Center, Milwaukee, WI, Progressive Community Health Centers, Milwaukee, WI,
Abstract
E-cigarette use and United States Preventive Services Task Force (USPSTF) lung cancer screening (LCS) eligibility.Org: Zilber School of Public Health, University of Wisconsin-Milwaukee, School of Population and Public Health, Quality Operations, Sentara Halifax Regional Hospital,
Abstract
A multicohort platform trial to improve drug access for pediatric cancer patients in Japan: The PARTNER trial (NCCH2220).Org: Department of Pediatric Oncology,
Abstract
Racial differences in background parenchymal enhancement, a novel marker of breast cancer.Org: University of Pennsylvania Health System,
Abstract
Association of polygenic-based breast cancer risk prediction with patient management.Org: Myriad Genetics, Inc., Optum, Stanford University School of Medicine,
Abstract
Improving a polygenic risk score (PRS) for breast cancer (BC) risk assessment in diverse ancestries.Org: Myriad Genetics, Inc., Stanford University School of Medicine, Cleveland Clinic Taussig Cancer Instititute, Nashville Breast Center,
Abstract
TAZNI: A phase I/II combination trial of tazemetostat with nivolumab and ipilimumab for children with INI1-negative or SMARCA4-deficient tumors.Org: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University,
Abstract
Budget impact model of LungFlag, a predictive risk model for lung cancer screening.Org: Medial-EarlySign,
Abstract
Evaluation of cost-effective multiple cancer early detection with extremely low coverage whole genome sequencing from plasma.Org: Berry Oncology Corporation, International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute,
Abstract
AI-based approach to enable proactive identification of early lung cancer: A retrospective population health study and economic model.Org: Clinithink, PA Consulting,
Abstract
Are cancer screening recommendations from top US cancer centers concordant with the USPSTF guidelines?Org: Queen's Cancer Research Institute, Institute for Health Policy Studies,
Abstract
Lung cancer screening among women Veterans within the Veterans’ Health Administration.Org: Birmingham VA Medical Center, Ralph H Johnson VA Medical Center, Atlanta VA Medical Center,
Abstract
Cancer screening in sexual and gender minority populations: A systematic review and meta-analysis.Org: Corewell Health William Beaumont University Hospital, Royal Oak, MI, Roswell Park Comprehensive Cancer Center, Buffalo, NY, University of Vermont Medical Center,
Abstract
Impact of molecular therapy on radioactive iodine uptake in patients with oncogene-driven metastatic differentiated thyroid cancer.Org: Division of Endocrinology and Diabetes, The Thyroid Center,
Abstract
Association of a polygenic risk score with risk of abnormal ultrasound findings and ovarian cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.Org: National Cancer Institute, Vilnius, Lithuania, American Cancer Society, National Institutes of Health All of Us Research Program,
Abstract
An emulated target trial assessing the impact of physical activity on 14-year cancer risk: Insights from the Cancer Prevention Study-II.Org: BrightEdge,
Abstract
Estimating risk for pancreatic cancer among 9.4 million veterans in care.Org: VA Connecticut Healthcare System,
Abstract
Dietary patterns and the risk of hematological malignancy in the California Teachers study cohort.Org: New Orleans, LA,
Abstract
Perceptions of non-disclosure of results in clinical trial designs for multicancer detection tests.Org: Division of Cancer Prevention, ICF,
Abstract
Significant results from a major multi-year, multi-cancer follow-up study with an enrollment of over 19,000 individuals.Org: Anpac Bio-Medical Science (Shanghai) Co., Ltd.,
Abstract
Analytical and clinical validation of a circulating tumor DNA–based assay for multicancer early detection.Org: Medical Genetics Institute, Gene Solutions, Viet Nam,
Abstract
A pilot study on ultra-sensitive circulating tumor DNA detection with a novel methylation amplifier probe in colorectal cancer.Org: Shanghai Weihe Medical Laboratory Co., Ltd., Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology,
Abstract
Cervical cancer screening in 48000 females over two decades: Feasibility and success of community-based screening in Kerala, India.Org: Malabar Cancer Care Society, Breast Cancer Hub, Apollo Proton Cancer Centre,
Abstract
Information and prevention needs among germline TP53 (gTP53m) pathogenic variants carriers.Org: Institute of Pediatric Hematology and Oncology, Department of Oncogenetics,
Abstract
T cell-mediated rejection and cancer risk in 579,905 organ transplant recipients.Org: Division of Cardiology, Lemuel Shattuck Hospital, Massachusetts Department of Public Health, Department of Mathematics Education,
Abstract
Risk of subsequent primary cancers among adult cancer survivors.Org: Department of Cancer Epidemiology and Prevention Research,
Abstract
Utility of colposcopy for the screening and management of cervical cancer in Africa: A cross-sectional analysis of providers’ training and practices.Org: WHO Africa Regional Office, Universite Abomey Calavi, Centre De Recherche En Santé Des Femmes, University of Cape Town, Université Des Sciences De La Santé-chu De Libreville,
Abstract
Health equity in multi-cancer early detection (MCEDs): A literature review and content analysis.Org: Department of General Internal Medicine, The Ohio State University College of Medicine, The Ohio State University - James Cancer Hospital,
Abstract
BRCA functional domains associated with PARP-inhibitors in patients with prostate cancer: The PROGRESS study.Org: Department of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, Palermo, Italy, UOC Oncologia 1, Istituto Oncologico Veneto, IRCCS, Padova, Padova, Italy, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy, Azienda Ospedaliera Universitaria Careggi, Firenze, Florence, Italy, Division of Medical Oncology, AOU Consorziale Policlinico di Bari, Bari, Italy, Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, Italy, Azienda di Rilievo Nazionale ad Alta Specializzazione Civico, Di Cristina, Benfratelli, Palermo, Italy, Universita Studi Roma-Sapienza, Roma, Italy, IRCCS, Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy, Azienda Ospedaliera Antonio Cardarelli, Napoli, Napoli, Italy, Azienda Ospedaliera Cannizzaro, Catania, Catania, Italy, Oncologia Medica, A.O.U. Federico II di Napoli, Napoli, Campania, Italy, Divisione di Oncologia Medica A, Policlinico Umberto I, Roma, Rome, Italy, Ri.MED Foundation, Proteomic's Unit, Department of Research IRCCS ISMETT, Palermo, Italy, Department of Biomedicine, Neurosciences and Advanced Diagnostics-BINRED, University of Palermo, Palermo, Italy,
Abstract
Outcomes of a program to improve breast cancer early detection in Cote d’Ivoire.Org: CHU Treichville, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Université d'Angers, Université Alassane Ouattara Bouaké, Projet Santé Mammaire,
Abstract
Patterns of cancer screening practice and mutational status of cancer-predisposing genes among individuals at high risk for cancer.Org: Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago, Chicago, IL,
Abstract
Participant adherence in a lung cancer screening (LCS) program in a non-smoking population.Org: NYU Perlmutter Cancer Center,
Abstract
Associations of prior lung diseases on risk of lung cancer in populations with no smoking history: A systematic review and meta-analysis.Org: Hospital of the University of Pennsylvania, Philadelphia, PA, Seoul St. Mary's, Seoul, South Korea, Division of Global Health Equity, Brigham and Women’s Hospital, Boston, MA, Massachusetts Eye and Ear Infirmary, Boston, MA, School of Dentistry, University of California, San Francisco, San Francisco, CA,
Abstract
In-utero and newborn factors and thyroid cancer incidence in adult women in the Sister Study cohort.Org: National Institute of Environmental Health Sciences, Research Triangle Park, NC, NIEHS,
Abstract
Blood type as a risk factor for pancreatic ductal adenocarcinoma.Org: Yale University School of Medicine, VA Connecticut Healthcare System, Perelman School of Medicine, University of Pennsylvania,
Abstract
Association of social determinants of health (SDH), allostatic load (AL) and incident cancers in the multi-ethnic study of atherosclerosis (MESA).Org: University of Michigan Comprehensive Cancer Center, University of Michigan, Johns Hopkins University Bloomberg School of Public Health, University of Chicago, Drexel University,
Abstract
The prevalence of sickle cell phenotype and its association with clinical outcomes in patients with solid malignancies.Org: Jackson Memorial Hospital/ University of Miami,
Abstract
Adverse childhood experiences and cancer: A systematic review and meta-analysis.Org: Johannes Gutenberg University, Brock University, St. Catharines,
Abstract
Cancer in Southeast Asia: A comparative analysis of 2022 incidence and mortality data.Org: University of the Philippines College of Medicine, International Agency for Research on Cancer, Center for Cancer Registries, Center for Cancer Control and Information Services, National Cancer Institute of Thailand,
Abstract
Burden of gastrointestinal luminal tract cancer (GLC) from 2000 to 2019 in low SDI countries.Org: Weiss Memorial Hospital, John A. Burns School of Medicine,
Abstract
Associations between violence, distress, and cancer in transgender and non-transgender people.Org: Yale Cancer Center, University of Rochester Medical Center, James P. Wilmot Cancer Center - Pluta, Columbia University - Mailman School of Public Health, Emory University, Atlanta, GA, USA,
Abstract
Sugar-sweetened beverage intake and risk of oral cavity cancer: Results from 3 prospective US cohort studies.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Research Center, Department of Otolaryngology, Head and Neck Surgery, University of Washington,
Abstract
Increasing cancer-related mortality and demographic disparities in young adults in the United States between 1999 and 2020.Org: The University of Toledo College of Medicine and Life Sciences, The Univeristy of Toledo College of Medicine and Life Sciences, Division of Oncologic and Endocrine Surgery,
Abstract
Metabolomics signatures of air pollution mixtures and lung cancer risk: A large-scale metabolome-wide association study in the Cancer Prevention Study cohorts.Org: ISGLOBAL,
Abstract
Association between congenital heart disease and cancer: A meta-analysis of 30 million patients.Org: Larkin Community Hospital, North Bengal Medical College And Hospital, Maulana Azad Medical College, Crozer Chester Medical Center, Florida State University,
Abstract
Joint effects of long-term exposure to multiple air pollutants and breast cancer risk.Org: Prevention Environmental Cancer Department, Centre de Recherche en Epidémiologie et Santé des Populations,
Abstract
Statewide burden of cancer attributable to alcohol use in the United States in the last three decades, projections of deaths to 2040: A benchmarking study.Org: Kent State University, St. George's University School of Medicine,
Abstract
Cancer burden in South Asians in the United States: Epidemiologic report using Surveillance, Epidemiology, and End Results (SEER) program.Org: Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Taussig Cancer Institute, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Leukemia Program,
Abstract
Association of neighborhood-level superfund sites with atmospheric toxic exposures and increasing cancer risk in the United States: A proof-of-concept geospatial study.Org: University of Alabama at Birmingham Department of Hematology, Birmingham, AL,
Abstract
Uptake of risk-reduction, surveillance, and therapeutic interventions among patients with breast cancer with pathogenic germline variants.Org: Stanford University School of Medicine, Invitae Corporation, Invitae, Beth Israel Deaconess Medical Center,
Abstract
Clinical utility of AlphaMissense in predicting pathogenicity of DNA damage repair genes in cancer.Org: Memorial Sloan Kettering Cancer Center, New York, NY, USA, Memorial Sloan Kettering Cancer Center, Middletown, NJ,
Abstract
Evaluating genetic features and clinical characteristics of young women diagnosed with breast cancer by the age of 35.Org: Cooper University Healthcare,
Abstract
Prevalence of pathogenic genetic variants in patients with gastric cancer ascertained through multi-gene panel testing.Org: University of Chicago, Invitae Corporation, The Ohio State University - James Cancer Hospital, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Germline landscape of ovarian cancer across age groups: Spotlight on elderly patients.Org: New York, NY, Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center,
Abstract
Clinical and economic benefit of genomic testing strategies to guide the treatment of patients with HR+/HER2- breast cancer in the US.Org: Putnam Associates,
Abstract
Association between wildfire PM2.5 and genitourinary cancer survival in California.Org: Air Quality Research Center at University of California,
Abstract
Association between CH mutation in TET2 and solid cancer in elderly Asian women.Org: Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Lucence Diagnostics Pte. Ltd., Department of Anatomical Pathology, Division of Pathology, Singapore General Hospital, Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore,
Abstract
Correlation of patient HLA class I genotypes with severe immune-related adverse events: A retrospective study in Chinese population.Org: Center of Evidence-Based Medicine,
Abstract
Evolving burden of lung cancer attributable to occupational carcinogens in 38 OECD countries: Global, national differences, age dynamics and implications for global health.Org: Mamata Medical College, Khammam, India, Government Medical College and Hospital, Chandigarh, India,
Abstract
Impact of pathogenic germline variants in HRR genes on gastroesophageal cancer in a large real-world Chinese population: A comprehensive study.Org: Changzhou No.2 People's Hospital Affiliated to Nanjing Medical University,
Abstract
The global burden of primary liver cancer and underlying etiologies from 1990 to 2021.Org: Institute for Health Metrics and Evaluation, Department of Health Metrics Sciences,
Abstract
Germline and somatic MUTYH mutations: Clinicopathologic and mutational analysis in a pan-cancer cohort.Org: Memorial Sloan Kettering Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Germline variation and risk of immune-related adverse events (irAEs): A real-world BioVU study.Org: UCSF Hem/Onc Fellowship,
Abstract
Germline sequence variation in Rwandan patients with breast and prostate cancer.Org: University of Mauritius,
Abstract
Attitudes and engagement about cascade genetic testing in a population-based cohort of women diagnosed with cancer.Org: University of Michigan, Emory University, Atlanta, GA, USA, University of Southern California Marshall School of Business, Stanford Cancer Institute, Stanford University School of Medicine,
Abstract
A portrait of germline pathogenic variants from a large real-world cohort of Brazilian patients with breast cancer.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Medica Scientia Innovation Research (MEDSIR), Pfizer,
Abstract
The genetic risk architecture of mucosal melanoma.Org: The University of Texas at MD Anderson Cancer Center,
Abstract
Timing of genetic testing referral and genetic testing results in patients with multiple primary cancers.Org: Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, Stanford University Department of Psychiatry and Behavioral Sciences,
Abstract
Universal germline testing for cancer susceptibility and actionable noncancer disorders among 19,842 patients: Initial findings from the City of Hope INSPIRE study.Org: City of Hope National Medical Center Medical Oncology and Therapeutics Research,
Abstract
Risk of secondary leukemias in patients with germline PALB2 pathogenic variants after chemotherapy exposure.Org: Massachussets General Hospital,
Abstract
Barriers to implementing clinical cancer genetics in sub-Saharan Africa: Perspectives of participants of a virtual cancer genetics course.Org: King Faisal Hospital, Kigali University Teaching Hospital, Rwanda Biomedical Center,
Abstract
Association of germline HSD3B1 (c.1100) genotype with tumoral and clinical outcomes in breast and endometrial cancers.Org: University of South Carolina,
Abstract
A targeted panel of actionable high-risk hereditary cancer predisposition genes to identify patients with pathogenic/likely pathogenic variants (PVs) irrespective of meeting established NCCN testing criteria.Org: NYU Langone Medical Center, Natera, Inc., New York University School of Medicine,
Abstract
Implementation of universal germline testing in underserved patients with young onset gastrointestinal cancer.Org: Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center,
Abstract
Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial.Org: Department of Surgery, University of California, San Francisco, San Francisco, CA, Department of Medicine, University of California, San Francisco, San Francisco, CA, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Weill Cornell Medicine Department of Population Health Sciences, New York, NY, University of California, San Francisco Department of Surgery, San Francisco, CA,
Abstract
Familial disclosure of mutational status and cascade testing: Relationships with cancer-predisposing genes and race/ethnicity.Org: Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL, The University of Chicago Medicine Center for Advanced Care at Orland Park, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL,
Abstract
Variant of uncertain significance (VUS) genetic testing results and mastectomy choice in lumpectomy-eligible patients.Org: Department of Human Genetics, Department of Obstetrics, Gynecologic, and Reproductive Sciences,
Abstract
Impact of cancer screening results on patient-reported outcomes (PRO) and behavioral intentions.Org: Evidera, Inc, GRAIL, LLC, a subsidiary of Illumina, Inc., Ontada, Mayo Clinic, Dana-Farber Cancer Institute,
Abstract
The contribution of rare and common genetic variants to risk of prostate cancer and second primary cancer after prostate in the UK Biobank.Org: Barbara Ann Karmanos Cancer Institute, Duke Cancer Institute and Department of Medicine, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Karmanos Cancer Institute, Wayne State University School of Medicine, Northshore University Health System,
Abstract
Glucagon-like peptide-1 (GLP-1) agonist use and weight change among patients with breast cancer.Org: NewYork Presbyterian-Cornell, Drexel University College of Medicine,
Abstract
Interactive assistance via eHealth for small- and medium-sized enterprises’ employer and health care manager teams on tobacco control (eSMART-TC): A cluster randomized hybrid type II trial (N-EQUITY2101/J-SUPPORT2102).Org: National Cancer Center Institute for Cancer Control, Graduate School of Health Innovation, Kanagawa University of Human Services, Research Center for Health Policy and Economics, Hitotsubashi Institute for Advanced Study,
Abstract
Increased risk for thyroid carcinoma in patients with Li-Fraumeni syndrome.Org: Philadelphia College of Osteopathic Medicine, Lewis Katz School of Medicine at Temple University, Center for Clinical Epidemiology and Biostatistics (CCEB), University of Pennsylvania, University of Pennsylvania School of Medicine, Temple University School of Medicine,
Abstract
Hematologic malignancies in Li-Fraumeni syndrome.Org: Scripps Clinic, University of Wisconsin Hospital and Clinics, University of Wisconsin-Madison Department of Medicine,
Abstract
Nutraceutical and dietary supplement use in the cancer population: The impact of evidence-based education.Org: Northwell LIJ/Staten island University Hospital,
Abstract
Implementing DPYD/UGT1A1 testing to prevent treatment related adverse events (TRAE) in patients with gastrointestinal (GI) cancer: Results of a pragmatic implementation trial.Org: Qral Group, Center for Applied Genomics, Letsgetchecked, Penn Medicine at Lancaster General Health,
Abstract
Large cohort analysis of incidental CDH1 PVs among patients undergoing MGPT.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, Txinno Bioscience,
Abstract
Second neoplasms in patients with hereditary retinoblastoma.Org: La Paz University Hospital, Head of Pediatric Oncology Department,
Abstract
Predictive models as a clinical decision support tool for genetic cancer risk assessment among Mexican patients at risk of hereditary colorectal cancer.Org: Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran, Mexico City, Mexico, Centro de Cáncer de Mama, Hospital Zambrano Hellion-Tecnológico de Monterrey, San Pedro Garza García, NL, Mexico, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Escuela de Medicina del Tecnológico de Monterrey, Monterrey, Mexico, Hospital San José, Monterrey, Mexico,
Abstract
Genetic counseling and subsequent cascade genetic testing for women with a family history of pathogenic BRCA1 mutation: A cost-effectiveness model.Org: Bethlehem, PA,
Abstract
Pathogenic germline variant discovery in plasma cell disorders: Insights from genetic counseling referrals and testing.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,
Abstract
Blood-based colorectal cancer (CRC) screening implementation into clinical practice in the outpatient clinical setting in the Appalachian highlands.Org: Johnston Memorial Hospital, Smyth County Community Hospital, Russell County Medical Center, Ballad Health, Abingdon, VA,
Abstract
Feasibility and tolerance of high-dose methotrexate (HDMTX) in older patients with osteosarcoma.Org: Mayo Clinic, Rochester, MN, Division of Medical Oncology, Mayo Clinic, Rochester, MN,
Abstract
Clinically significant variant classification resulting from the addition of RNA sequencing: Experience at high-volume cancer genetics center.Org: Nancy & James Grosfeld Cancer Genetics Center Corewell Health, Beaumont Health,
Abstract
Transcriptomic analysis of novel tumor suppressor gene fusions in bone sarcomas.Org: BostonGene, Corp., The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Sarcoma Oncology Center,
Abstract
Extracorporeal irradiation and reimplantation for bone sarcomas: Medium- and long-term oncologic and functional outcomes.Org: HCG Cancer Centre, Sparsh Orthopedic Oncology Clinic,
Abstract
Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS).Org: Columbia University - Mailman School of Public Health, Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Division of Hematology Oncology, UPMC Hillman Cancer Center/University of Pittsburgh, Division of Medical Oncology, Mayo Clinic,
Abstract
Novel models for the functional characterization of SDHA germline variants to predict cancer risk.Org: Portland VA Health Care System,
Abstract
Improving feasibility and timeliness of hereditary cancer risk assessment with a brief patient-administered digital tool and rapidly available telehealth genetic counseling.Org: Genome Medical,
Abstract
Contribution of mammography to breast cancer detection among pathogenic germline BRCA carriers by age and mutated gene.Org: The Hebrew University, The Suzanne Levy-Gertner Oncogenetics Unit, Sheba Tel-Hashomer Medical Center,
Abstract
Personalized tumor-informed circulating tumor DNA analysis in monitoring recurrence following resection of high-risk stage II-III gastrointestinal stromal tumor.Org: Peking University People's Hospital, Peking University People’s Hospital, Beijing, China, Burning Rock Biotech, Guangzhou, China, Chinese People’s Liberation Army General Hospital, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,
Abstract
Phase 1 results of the WEE1 inhibitor, azenosertib, in combination with gemcitabine (gem) in adult and pediatric patients (pts) with relapsed or refractory (R/R) osteosarcoma.Org: Zentalis Pharmaceuticals,
Abstract
AlphaMissense performance as a classifier of germline and somatic variants of unknown significance in high-grade sarcoma.Org: University of Oxford, Oxford University Hospitals NHS Foundation Trust,
Abstract
HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer.Org: Penn Medicine Abramson Cancer Center, University of Pennsylvania, Abramson Cancer Center, Hospital of the University of Pennsylvania, Memorial Sloan Kettering Cancer Center,
Abstract
Updated results from ALTER-S002: A single-arm multicenter trial of the combination of anlotinib with chemotherapy in patients with stage IIB classic osteosarcoma of the extremity.Org: Guizhou Medical University Affiliated Tumor Hospital, The Affiliated Hospital of Jiangxi University of TCM, Guizhou Cancer Hospital/The Affiliated Cancer Hospital of Guizhou Medical University,
Abstract
Apatinib combined with ifosfamide and etoposide versus ifosfamide and etoposide in relapsed or refractory osteosarcoma (OAIE/PKUPH-sarcoma 11): A multicenter, randomized controlled trial.Org: Jiangsu Hengrui Pharmaceuticals Co, Ltd., Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University,
Abstract
Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS): A multicenter study.Org: Natera, Inc.,
Abstract
Predictive gene signature for trabectedin efficacy in advanced soft‐tissue sarcoma: A Spanish group for research in sarcoma (GEIS) study.Org: Health Research Institute-Fundación Jiménez Díaz University Hospital, Autonomous University of Madrid (IIS-FJD, UAM), Madrid, Spain, Instituto de Biomedicina de Sevilla, Seville, Spain, University Hospital Miguel Servet, Zaragoza, Spain, University Hospital Gregorio Marañon, Madrid, Spain, Complejo Asistencial Universitario de Leon, Leon, Spain,
Abstract
Characterizing patterns of mTORC1 activation across sarcoma subtypes using single-sample gene set enrichment analysis (ssGSEA) and a national biomarker database.Org: University of Minnesota Academic Health Center,
Abstract
New soft tissue sarcoma (STS) transcriptomic clusters to unveil STS subsets with unique biological characteristics and refine the accuracy of overall survival (OS) prediction.Org: Instituto Português de Oncologia de Lisboa Francisco Gentil, Instituto Superior Técnico, Translational Oncobiology Lab, Instituto de Medicina Molecular João Lobo Antunes, F. Hoffmann-La Roche AG,
Abstract
Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).Org: Dana-Farber Cancer Institute, Harvard Medical School, Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Mayo Clinic Florida,
Abstract
Immune infiltrate analysis to reveal distinct immune classes for leiomyosarcomas.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Genomic Medicine,
Abstract
Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.Org: XlifeSc Ltd, Guangzhou, China, Hong Kong Baptist University and The Hong Kong Polytechnic University, Hong Kong, China,
Abstract
Combination targeted therapy of avapritinib and sunitinib for patients with refractory advanced gastrointestinal stromal tumors after failure of standard treatments: Early results from a multi-institutional pilot study.Org: Department of Gastrointestinal Hernia Surgery, Nanfang Hospital Ganzhou Hospital, Ganzhou, Jiangxi, China, First Affiliated Hospital of Jilin University, Jilin, China, Sir Run Run Shaw Hospital, School of Medicine, Hangzhou, China,
Abstract
A potential novel therapeutic target for invasive soft tissue sarcoma detected through tumor immune microenvironment and genetic profile analyses.Org: Department of Orthopaedic Surgery, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, Department of Immunology, Kindai University Faculty of Medicine, Osaka, Japan, Department of Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-Ku, Japan, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, Department of Orthopedic Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan,
Abstract
Efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: A phase 2 trial.Org: Shanghai Sixth People's Hospital, Jiangsu Hengrui Pharmaceuticals Co. Ltd,
Abstract
Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2–p53 antagonist brigimadlin and p53 function: A longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human phase Ia/Ib study.Org: Boehringer Ingelheim Pharma GmbH & Co. KG, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, National Cancer Center Hospital East, Kashiwa, Japan, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland,
Abstract
Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma.Org: Memorial Sloan Kettering Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
Comparison of machine learning algorithms for the radiomic classification of gastric subepithelial tumors.Org: Samsung Medical Center, Seoul National University Hospital, South Korea,
Abstract
Molecular characterization of long-term and short-term survivors of metastatic uterine leiomyosarcoma.Org: Mid Atlantic Gynecologic Oncology and Pelvic Surgery Associates,
Abstract
Anti-angiogenic TKIs in patients with advanced Ewing sarcoma: A systematic review and single-arm meta-analysis.Org: Universidade Estadual do Centro Oeste (UNICENTRO), Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Emily Couric Clinical Cancer Center, University of Virginia,
Abstract
Phase II study to evaluate surufatinib in patients with osteosarcoma and soft tissue sarcoma that has failed standard chemotherapy: Updated analysis.Org: Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, China, Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China,
Abstract
Efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after developing resistance to several TKIs: A multicentered retrospective study.Org: Department of Orthopaedics, Zhejiang University, Hangzhou, China, Musculoskeletal Tumor Center, Peking University People’s Hospital, Beijing, China, Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China, Peking University People’s Hospital, Beijing, China,
Abstract
Proteomic analysis in patients with dedifferentiated liposarcoma (DDLPS) in a phase Ia/Ib study of the MDM2–p53 antagonist brigimadlin.Org: Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, Early Phase Clinical Trials Department, Maria Skłodowska-Curie National Research Institute and Oncology Centre,
Abstract
Efficacy of nirogacestat in participants with poor prognostic factors for desmoid tumors: Analyses from the randomized phase 3 DeFi study.Org: Policlinico Universitario Campus Bio-Medico, Rome, Italy, UCLA David Geffen School of Medicine, Los Angeles, CA, SpringWorks Therapeutics, Inc., Stamford, CT, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany,
Abstract
Phase 2a results of SQ3370, a doxorubicin-based click chemistry therapeutic in patients with advanced STS: Planned interim analysis.Org: Shasqi Inc.,
Abstract
Results of a randomized phase II trial of 2nd-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib: Japan Clinical Oncology Group study JCOG1802 (2ND-STEP).Org: Fukui University School of Medicine,
Abstract
Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study.Org: Chengdu Shang Jin Nan Fu Hospital,
Abstract
A phase 2 trial of the CDK4 inhibitor dalpiciclib in well-differentiated or dedifferentiated liposarcoma.Org: Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Huaiyin District Jinan, China, Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China, Department of Medicine, Qingdao University, Qingdao, China,
Abstract
Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in a phase 2 expansion cohort of patients (Pts) with synovial sarcoma (SS).Org: Massachusetts General Hospital Center,
Abstract
The CT-based multi-omics model for prognostic prediction and tumor microenvironmental alterations in retroperitoneal liposarcoma: A retrospective multicohort analysis.Org: Department of General Surgery, Xuhui Hospital, Fudan University, Shanghai, China, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai, China, Jinshan Hospital, Fudan University, Shanghai, China, Department of Radiology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China, Department of General Surgery, Shanghai Fifth People’s Hospital, Fudan University, Shanghai, China,
Abstract
An open label, phase 1b/2 trial of LVGN6051 (4-1BB agonistic antibody) combined with anlotinib for refractory soft tissue sarcoma (STS).Org: Shanghai Sixth People's Hospital, Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital,
Abstract
Integrated multi-omics analysis reveals immune landscape of tertiary lymphoid structure in retroperitoneal liposarcoma.Org: Shanghai Traditional Chinese Medicine-Integrated Hospital, Jinshan Hospital, Fudan University, Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, Department of General Surgery, Shanghai Fifth People’s Hospital, Fudan University, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China,
Abstract
First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas.Org: Villalba General Hospital, Servicio de Cirugía General y Digestiva, Hospitals Universitario Vall d'Hebron, Pediatric Surgery Department, Universitat Politècnica de Catalunya (UPC),
Abstract
Use of histologic and immunologic factors in sarcoma to predict response rates to immunotherapy.Org: Stanford Cancer Institute, Stanford Cancer Center,
Abstract
Phase II study in pediatric and AYA patients with non-metastatic high-grade extremity osteosarcoma with a risk-adapted strategy based on P-glycoprotein (ISG/OS-2): A correlative study on tumour immune microenvironment.Org: IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Istituto Ortopedico Gaetano Pini, Milan, Italy, University of Pisa, Pisa, Italy,
Abstract
Prognostic significance of plasma circulating tumor DNA fraction in patients with advanced sarcoma: A French Sarcoma Group study.Org: København,
Abstract
Analysis of the time to progression in patients who underwent metastasectomy plus isolated lung chemoperfusion for disease recurrence after metastasectomy alone.Org: N.N. Petrov National Research Medical Center of Oncology,
Abstract
Do patients with myxofibrosarcoma and undifferentiated pleomorphic sarcoma have different clinical outcomes to immune checkpoint blockade-based therapy?Org: Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center - Fellowship (GME Office), Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center,
Abstract
Intimal sarcomas (ISarc) of the cardiac chambers (CC) of the heart and great vessels (GV): A comprehensive genomic profiling (CGP) study.Org: SUNY Upstate Medical University, Foundation Medicine, Inc., Cambridge, MA,
Abstract
Analyzing the effect of treatment modalities on survival in synovial sarcoma.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton Hematology Oncology, Omaha, NE,
Abstract
Active surveillance in patients with extra-abdominal desmoid-type fibromatosis: A combined analysis of three prospective observational studies.Org: Erasmus MC Cancer Istitute, Rotterdam, Netherlands, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Candiolo (TO), Italy,
Abstract
Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I), nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma.Org: Sarcoma Oncology Research Center, Santa Monica, CA, Sarcoma Oncology Center, City of Hope Comprehensive Cancer Center, UCLA David Geffen School of Medicine,
Abstract
Efficacy and safety of IBI110 (anti-LAG-3 antibody) plus sintilimab (anti-PD-1 antibody) in patients with advanced alveolar soft part sarcoma: Results from a phase II study.Org: Department of Bone and Soft Tissue Tumor,
Abstract
Fragility index analysis of systemic therapy clinical trials in soft tissue sarcoma (STS).Org: Princess Margaret Cancer Centre, Queen's Cancer Research Institute, Queen's University Belfast, University Health Network, University of Toronto,
Abstract
Primary localized malignant PEComa treated with surgery: A report of a large series of patients treated in a referral institution.Org: Unit of Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy,
Abstract
Efficacy and safety of nirogacestat in patients with desmoid tumor and adenomatous polyposis coli (APC) mutation: Phase 3 DeFi analyses.Org: Stamford, CT,
Abstract
Patient-reported global health to predict adverse health outcomes in an expanded cohort of patients with advanced sarcoma.Org: The Ohio State University James Comprehensive Cancer Center,
Abstract
Redefining radiologic responses (RR) in solid tumors: Shall we brace ourselves for a post-RECIST era? Results from a randomized clinical trial (RCT) on neoadjuvant chemotherapy in high-risk soft-tissue sarcomas (HR-STS) of the trunk or extremities.Org: Department of Radiology - Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy, Department of Radiology - Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies - IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Surgery – IRCCS Humanitas Research Hospital, Rozzano, Italy, Department of Cancer Medicine - Ospedale Città della Scienza e della Salute, Torino, Italy,
Abstract
A phase II study of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable malignant peripheral nerve sheath tumors.Org: Columbia University - Mailman School of Public Health,
Abstract
Safety and toxicity evaluation of the combination of selinexor with atezolizumab in patients with soft tissue sarcomas.Org: Early Clinical Trials Development Program, Biometric Research Branch, National Cancer Institute at Frederick,
Abstract
Phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma.Org: Department of Biomedical Convergence Science and Technology, Kyungpook National University, Daegu, South Korea, Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, South Korea, Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea, Department of Radiology, Yonsei University College of Medicine, Seoul, South Korea, Division of Hematology-Oncology, Department of Medicine, Seoul Medical Center, Seo-Gu, South Korea,
Abstract
Systemic therapy in NF-1 associated malignant peripheral nerve sheath tumors (MPNST).Org: Texas A&M School of Engineering Medicine, The University of Texas MD Anderson Cancer Center Hematology/Oncology Fellowship,
Abstract
A signal-finding study of nivolumab and relatlimab in patients with advanced chordoma.Org: Division of Hematology and Oncology, UCLA Department of Medicine, Los Angeles, CA, Division of Hematology and Medical Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Departments of Pediatrics and Orthopaedic Surgery, David Geffen School of Medicine, University of California Los Angeles, Cumming School of Medicine, Department of Surgery, Orthopedic Surgery, Calgary, Department of Orthopedic Surgery, UCLA,
Abstract
Maintenance treatment with toripalimab and anlotinib after anthracycline-based chemotherapy in patients with advanced soft tissue sarcoma (TORAN): A single-arm, phase 2 trial.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Hospital, Sichuan University, Chengdu Origen Biotechnology,
Abstract
A phase II study of an oncolytic herpes simplex virus 2 and an anti-PD-1 antibody in patients with advanced sarcoma.Org: Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital, Beijing, China, Xuzhou Central Hospital, Xuzhou, China, Department of Medical Oncology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Department of Oncology, Linyi Cancer Hospital, Linyi, China, Binhui Biopharmaceutical Co., Ltd, Wuhan, China,
Abstract
Anlotinib versus placebo as adjuvant therapy for completely resected high-grade soft tissue sarcomas: Interim results of a phase 2, double-blinded, randomized controlled trial.Org: Centre for Cancer Research & Melbourne Medical School, Dentistry and Health Sciences, Victorian Comprehensive Cancer Centre, Pharmaceutical Sciences,
Abstract
Development and validation of a deep learning–based cardiovascular disease risk prediction model for long-term breast cancer survivors.Org: National Health Insurance Ilsan Hospital,
Abstract
A first-in-human phase 1 trial of T cell membrane-anchored tumor targeted IL12 (ATTIL12) -T cell therapy in advanced/metastatic soft tissue and bone sarcoma.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
DTx-based cardio-oncology rehabilitation for lung cancer survivors: A randomized controlled trial.Org: Recovery Plus USA Inc.,
Abstract
The predictive role of mammographic breast calcifications in cardiovascular disease among women undergoing breast cancer screening: Insights from a retrospective database analysis of breast cancer screening.Org: West Virginia University Camden Clark Medical Center, Parkersburg, Camden Clark Medical Center, West Virginia School of Osteopathic Medicine, Lewisburg,
Abstract
The impact of glucagon-like peptide 1 agonists on anthracycline or human epidermal growth factor receptor 2 inhibitor-associated cardiotoxicity in patients with breast cancer and diabetes mellitus.Org: Danbury, CT, Tainan, Taiwan,
Abstract
Randomized phase III trial of neo-adjuvant and adjuvant chemotherapy vs adjuvant chemotherapy alone for localized soft tissue sarcoma (NACLESS, JCOG2102).Org: Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto-Shi, Japan, Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, Division of Musculoskeletal Oncology and Orthopaedic Surgery, Tochigi Cancer Center, Tochigi, Japan, Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan,
Abstract
Off-label use of fam-trastuzumab deruxtecan-nxki with early activity in a cohort of patients with desmoplastic small round cell tumor.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in preclinical melanoma models.Org: IRCCS Fondazione G. Pascale, IRCCS CROB, IRCCS- S. Raffaele Scientific Institute, Istituto Nazionale Tumori- IRCCS- Fondazione G. Pascale, San Raffaele Institute,
Abstract
Randomized controlled, open-label, phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma.Org: Mannheim University Medical Center (UMM), Istituto Nazionale Tumori Pascale, Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone",
Abstract
Impact of protein-energy malnutrition on patients with breast cancer hospitalized for acute decompensated heart failure: Insight from the NIS database 2020.Org: Jefferson Einstein Hospital, Depatment of Hematology-Oncology,
Abstract
Exploring the prevalence and disparities of heart failure in patients with lung cancer and the associated risk factor analysis.Org: State University of New York Upstate Medical University, Upstate Medical University, Wyckoff Heights Medical Center, Nuvance Health/Vassar Brothers Medical Center, Lake Erie College of Osteopathic Medicine,
Abstract
Predictors of cardiotoxicity in patients with early breast cancer treated with doxorubicin and/or trastuzumab: Implications of race/ethnicity and insurance status.Org: Advocate Aurora Health, Milwaukee, WI,
Abstract
Goals of care discordance in advanced cancer compared to other advanced conditions.Org: Division of General Internal Medicine and Health Services Research, Division of Hematology and Oncology, UCLA Department of Medicine, Department of Medicine, University of California, San Francisco, Departments of Medicine and Family Medicine, University of California, Irvine,
Abstract
Peak study: A phase 3, randomized, open-label multi-center clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).Org: Centro de Oncologia de Precision,
Abstract
End-of-life care preferences in patients with gallbladder cancer: Shifting patterns and disparities over two decades.Org: Roswell Park Comprehensive Cancer Center, Karachi Medical and Dental College, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, William Beaumont University Hospital, Corewell Health William Beaumont University Hospital,
Abstract
Using natural language processing to qualitatively assess goals of care conversations for patients with cancer.Org: Department of Biostatistics & Bioinformatics, CALGB Statistical Center,
Abstract
Trajectories of cancer-related behavioral symptoms (CRBS) burden after breast cancer (BC).Org: IRCCS Istituto Nazionale Tumori “Fondazione Pascale”, labeled Ligue Contre le Cancer,
Abstract
PROSTOX, a signature of late GU toxicity after SBRT radiotherapy in MIRAGE, a prospective trial.Org: University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, Stanford University, Stanford, CA, California Pacific Medical Center Research Institute, San Francisco, CA, Women's Health Integrated Research Center at Inova Health System, Annandale, VA, Women’s Health Integrated Research Center at Inova Health System, Department of Defense Gynecologic Cancer Center of Excellence, Annandale, VA, Stanford University Medical Center, Palo Alto, CA, Pingtung Veterans General Hospital, Pingtung, South Korea, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
Efficacy and safety of immune checkpoint inhibitors in advanced solid tumors with hepatitis B infection.Org: Fuyang Cancer Hospital,
Abstract
Effect of anti CTLA-4 and PD-1 monoclonal antibodies on systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models.Org: University of Messina, Azienda Ospedaliera San Camillo, Azienda USL Toscana Nord-Ovest, Versilia Hospital,
Abstract
DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study.Org: The Cancer & Hematology Centers,
Abstract
The utility of procalcitonin in febrile neutropenia.Org: University of Nebraska Medical Center, Omaha, NE,
Abstract
Cardiac and mortality outcomes in patients with breast cancer undergoing trastuzumab-based therapies.Org: Cleveland Clinic Foundation,
Abstract
In-hospital outcomes and mortality of drug-induced pneumonitis and radiation pneumonitis in patients with thoracic cancer.Org: Dartmouth-Hitchcock Medical Center, Trinity Health Oakland Hospital/Wayne State University, Wayne State University,
Abstract
The impact of body mass index (BMI) on overall survival (OS) among patients receiving immune checkpoint inhibitors (ICIs): A population-based study.Org: Inst for Clinical Evaluative Sci,
Abstract
Impact of chemotherapy-induced peripheral neuropathy permanence on patients' preference to discontinue chemotherapy.Org: University of Michigan College of Pharmacy, University of Michigan School of Public Health, Rogel Cancer Center, University of Michigan, Department of Biostatistics, University of Michigan,
Abstract
Head and neck cancer survivors: Long-term nutrition impact symptoms, eating problems, and barriers to care impact psychosocial health.Org: Cancer Support Community,
Abstract
Late mortality and chronic health conditions in long-term survivors of nasopharyngeal cancers: The 20-year follow-up of territory-wide Hong Kong Nasopharyngeal Cancer Survivor Study (HKNPCSS).Org: Department of Pharmacy and Pharmacology, Clinical Oncology Center, Shenzhen Hospital,
Abstract
Risk and impacts of drug-induced liver injury (DILI) due to immune-checkpoint inhibitors (ICI) on overall survival in patients with newly diagnosed cancer: A retrospective cohort study.Org: Department of Biomedical Informatics, The Ohio State University, Department of Biomedical Informatics, The Ohio State University College of Medicine,
Abstract
Physical activity and dexamethasone for cancer related fatigue: A preliminary placebo controlled randomized control trial.Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Attitudes and beliefs regarding sexual dysfunction among patients with advanced cancer receiving palliative care.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX,
Abstract
Defining musical toxicity after breast cancer treatment: A classification tree analysis.Org: Mayo Clinic Department of Quantitative Health Sciences, Mayo Clinic Department of Physical Medicine and Rehabilitation,
Abstract
Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: A case-control study with translational correlates.Org: Departments of Medicine and Oncology, McGill University, Centre de recherche du CHUM, Institut du Cancer de Montréal, Meakins-Christie Laboratories, Department of Medicine, McGill University Health Centre, Division of Cardiology, McGill University,
Abstract
The effect of sodium glucose cotransporter-2 inhibitors on mortality and cardiovascular outcomes of patients with prostate cancer receiving luteinizing hormone releasing hormone agonists.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Unity Hospital, Rochester Regional Health System, Rochester, NY, Mount Auburn Hospital,
Abstract
A phase I/II trial of neoadjuvant pegylated arginine deiminase (ADI-PEG 20) with ifosfamide and radiotherapy in soft tissue sarcomas (STS) of the trunk or extremity.Org: Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, Washington University School of Medicine in St Louis, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, Washington University in St. Louis, Washington University School of Medicine in St. Louis,
Abstract
Delayed immune-related adverse events in patients with advanced melanoma treated with immune checkpoint inhibitors.Org: BCCA,
Abstract
Systemic inflammation-modified PG-SGA index in the survival prediction of advanced cancers.Org: West China Hospital, Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China,
Abstract
“Let’s talk about sex, fertility and menopause”: The Irish experience for those diagnosed with metastatic breast cancer (MBC)—An all-Ireland patient-led survey (CTRIAL-IE 23-05).Org: St. Luke’s Radiation Oncology Network and Trinity St. James's Cancer Institute, Cancer Care West, University Hospital Galway, Marymount University Hospice,
Abstract
The safety and efficacy of diclofenac sodium suppository as adjunctive opioids in the treatment of cancer pain: A prospective, multi-center, real-world study.Org: Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, The Renmin Hospital of Wuhan University, People's Hospital of Hejiang County, Yanggu People's Hospital, People's Hospital of NingGuo,
Abstract
Self-expressed needs and gaps in our care of metastatic breast cancer (MBC): An all-Ireland patient-led online survey (CTRIAL-IE 23-05).Org: St. Luke’s Radiation Oncology Network, Cancer Care West, University Hospital Galway, Marymount University Hospice, Northern Ireland,
Abstract
Body mass index and the risk of subsequent cancers among older cancer survivors.Org: American Cancer Society, Atlanta Cancer Care, Galderma R&D,
Abstract
Informal caregiving for older adults on systemic treatment for hepatocellular carcinoma.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,
Abstract
Experience of young patients with cancer discussing cannabis with their providers.Org: Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Sylvester Comprehensive Cancer Center, Miami, FL, SUNY Downstate Medical Center, Brooklyn, NY, University of Miami, Coral Gables, FL,
Abstract
Efficacy of treatment with traditional Chinese patent medicine (Fufang E'jiao Syrup) for cancer-related fatigue in patients with advanced cancer: A randomized, double-blinded, placebo-controlled, multicenter trial.Org: School of Beijing University of Chinese Medicine,
Abstract
Accuracy of medical oncology prognosis for patients with metastatic cancer evaluated for enrollment onto an ongoing randomized clinical trial.Org: University Hospitals Seidman Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Case Western Reserve University School of Medicine,
Abstract
Chemotherapy-induced peripheral neuropathy research: A National Institute of Health (NIH) grant portfolio analysis.Org: National Cancer Institute, Vilnius, Lithuania, Division of Cancer Prevention, Georgetown University Lombardi Comprehensive Cancer Center,
Abstract
An anti-EpCAM x anti-CD3 bispecific antibody, M701, for the treatment of malignant ascites due to epithelial cancer: Interim results of a prospective randomized controlled phase II trial.Org: Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Changzhi People's Hospital, Department of Oncology, Jinan Central Hospital, Central Hospital Affiliated to Shandong First Medical University, Wuhan YZY Biopharma Co, Ltd,
Abstract
Factors associated with sexual function and sexual satisfaction in young women with breast cancer.Org: Department of Medicine, Yale University School of Medicine, New Haven, CT, Departamento de Tumores Mamarios, Instituto Nacional de Cancerología, Mexico City, Mexico, Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico, Departamento de Tumores Mamarios, Instituto Nacional de Cancerología/CONAHCYT, Mexico City, Mexico, Médicos e Investigadores en la Lucha contra el Cáncer de Mama (MILC), Mexico City, Mexico,
Abstract
Symptom burden in adolescents and young adults with cancer: A subgroup analysis of the enhanced, EHR-facilitated cancer symptom control (E2C2) trial.Org: Mayo Clinic, Rochester, MN, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indianapolis, IN, Scottsdale, AZ,
Abstract
Trends and racial disparities in palliative care utilization among patients with prostate cancer: A ten-year retrospective study.Org: Internal Medicine Residency, St Elizabeth Youngstown Hospital, University of Ilorin, Ladoke Akintola University of Technology, Christina Care Hospital,
Abstract
Characterizing disparities in receipt of palliative care for Asian Americans, Native Hawaiians, and Pacific Islanders with metastatic cancer in the United States.Org: University of Cambridge,
Abstract
When pain management meets harm reduction: Patients with cancer navigate the opioid crisis—2016 to 2020 National Inpatient Sample analysis.Org: Tribhuvan University Teaching Hospital, Norwalk Hospital,
Abstract
Incidence of osteonecrosis of the jaw (ONJ) in the randomized non-inferiority phase III trial SAKK 96/12 REDUSE comparing denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w).Org: Department of Medical Oncology, Kantonsspital Graubuenden, Chur, Switzerland, Med Onkologie, Winterthur, Switzerland, Kantonsspital Graubünden, Chur, Università della Svizzera Italiana, Lugano, Lugano, Switzerland, Cantonal Hospital St. Gallen, St. Gallen, Switzerland,
Abstract
Prevalence of cannabis related potential medication interactions (PMI) among patients with cancer during treatment.Org: Cleveland, CA,
Abstract
Functional impairments, fatigue, and pain in newly diagnosed solid-tumors: Retrospective path analysis.Org: Department of Supportive Oncology, Department of Cancer Biostatistics,
Abstract
Impact of palliative care on hospital length of stay and charges in hospitalized patients with cancer at end of life.Org: Division of Hematology-Oncology, Department of Medicine, Seoul Medical Center, Seo-Gu, South Korea, UMass Chan Medical School, Johns Hopkins Medicine,
Abstract
Exploring “good days” in advanced cancer: Activities, behaviors, and quality of life.Org: Palliative Research Center (PaRC) and Department of Medicine,
Abstract
Cannabis use for cancer-related symptoms in rural versus urban Minnesota.Org: HealthPartners Cancer Research Center, HealthPartners Institute for Education and Research,
Abstract
Behavioral economic interventions to embed early palliative care in community oncology (BE-EPiC): A pragmatic cluster-randomized trial.Org: Penn Medicine Lancaster General Health,
Abstract
Risk-stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program in women with advanced gynaecological cancers: A prospective study.Org: UHN - Princess Margaret Cancer Centre, Princess Margaret Cancer Centre- University Health Network,
Abstract
Proactive, automated monitoring of uncontrolled symptoms in prostate cancer survivors across the cancer control continuum.Org: Department of Medical Oncology, Mayo Clinic, Rochester, MN, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Mayo Clinic Rochester, Rochester, MN,
Abstract
Real-world quality analysis of palliative care utilization in patients with brain metastases at three academic institutes.Org: University of Vermont College of Medicine, University of Virginia Medical Center,
Abstract
Effect of palliative care on economic burden in lung cancer admissions: Insights from the NIS database.Org: John H. Stroger, Jr. Hospital of Cook County,
Abstract
Impact of steroids indication on the efficacy of immunotherapy in a multi-tumor cohort of patients: Time and dose-dependent evaluation.Org: Instituto Ramón y Cajal de Investigación Sanitaria (IRICYS), Universidad de Alcalá,
Abstract
Abuse potential and analgesic efficacy of different IV opioid infusion rates among patients hospitalized with cancer pain: A randomized crossover trial.Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
An Indian real-world experience of intravenous fosnetupitant-palonosetron (IV NEPA) in preventing delayed and extended delayed CINV.Org: Glenmark Pharmaceuticals Ltd, Delhi State Cancer Institute, Jawaharlal Nehru Cancer Hospital and Research Centre, Hanji Cancer Hospital, Lakshya Cancer Hospital and Research Centre,
Abstract
Prescribers of opioids for head and neck cancer (HNC) survivors.Org: University of California, Berkeley,
Abstract
A meta-analysis GWAS of taxane-induced peripheral neuropathy in patients with breast cancer.Org: National Human Genome Research Institute,
Abstract
Novel screening approach for cancer cachexia using metagenomic gut microbiome profiling in patients with advanced non-small cell lung cancer.Org: Centre De Recherche Du Centre Hospitalier De L'université De Montréal (CRCHUM), Komagome Hospital, Research Institute for Microbial Diseases, Waseda University,
Abstract
Retrospective analysis of peripheral neuropathy in blood cancer survivors evaluated for cellular therapy.Org: Oklahoma State University,
Abstract
Sleep apnea and glymphatic dysfunction as a mediator of executive dysfunction and neurodegenerative risk in cancer related cognitive impairment (CRCI).Org: University of Cincinnati College of Medicine,
Abstract
Trichology to predict efficacy of scalp cooling: New pathologic insights besides encouraging clinical results.Org: Praxis für Hämatologie und Onkologie, Noack Statistik GmbH,
Abstract
Association of lung cancer-associated cachexia with the metastatic spread to pleura.Org: The Medical University of Gdańsk, Clinic of Oncology and Radiotherapy, Department of Pneumonology and Allergology,
Abstract
Cognitive symptoms in patients with cancer receiving PD-1/PD-L1 checkpoint inhibitors: Insights from a cross-sectional pilot study.Org: University of Connecticut Internal Medicine Residency Program, University of Connecticut Health Center,
Abstract
Psychological adjustment and perception of patients’ relatives and healthcare providers regarding continuous deep sedation until death: A mixed-methods study.Org: Paris Cité University, Gustave Roussy Département d'Organisation du Parcours Patient, Interdisciplinary Cancer Pathway Department, Diaconesses Hospital,
Abstract
Mental healthcare utilization and psychosocial outcomes among patients with recently diagnosed cancer: A National Health Interview Survey report.Org: University of Colorado Denver Anschutz Medical Center,
Abstract
Decades old communication training influences seen in patient-centric communication skills of transplant hematologists.Org: University of Wisconsin Hospital and Clinics, University of Wisconsin, University of Wisconsin Carbone Cancer Center,
Abstract
The adherence and response of a combined approach of online self-help cognitive behavioral therapy and phone-based psychological guidance among French patients with cancer with insomnia.Org: Centre for Epidemiology and Population Health, Oncostat team, CESP U1018, Département d'Organisation du Parcours Patient, Psycho-oncology Unit,
Abstract
Exploring lived experiences in oral cavity cancer: An Asia-Pacific perspective on psychosocial challenges and opportunities for enhanced patient-centric care.Org: MSD (Australia) Pty Ltd,
Abstract
Young lung cancer: Psychosocial needs assessment.Org: Dana-Farber Cancer Institute, Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
Novel genome-wide significant germline genetic variants associated with venous thrombo-embolism (VTE) and arterial embolism (ATE) risk in patients with ALK and ROS1 fusion non-small cell lung cancer (NSCLC).Org: Haifa, Israel, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus,
Abstract
Patient-reported symptom interference with activity- and mood-related functioning prior to start of an early-phase oncology combination trial including immune checkpoint blockade.Org: Department of Symptom Research,
Abstract
Electronic capture of cancer patients' health related social needs in a community oncology network.Org: Greenwood,
Abstract
Racial and ethnic differences in patient-reported provider communication among patients with cancer.Org: Hospital of the University of Pennsylvania, University of Pennsylvania, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Memorial Sloan Kettering Cancer Center,
Abstract
The role of personalized therapy in cancer associated depression among 10,673 patients.Org: OneOme, LLC, Englander Institute of Precision Medicine,
Abstract
Association between psychological distress and treatment efficacy in patients with newly diagnosed SCLC.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Second Xiangya Hospital of Central South University, Central South University, Changsha, China,
Abstract
Investigating the mediating role of mental adjustment in the relationship between perceived stress and quality of life in patients with cancer.Org: University of Nigeria Nsukka, Project Pink Blue- Health and Psychological Trust Centre,
Abstract
Coping in caregivers of patients with primary malignant brain tumors: A mediation analysis of a randomized controlled trial.Org: Massachusetts General Hospital, Harvard Medical School, Harvard University,
Abstract
“Things we deal with in exchange for cure”: How hematologists discuss graft versus host disease with patients considering allogeneic stem cell transplant.Org: University of Wisconsin Carbone Cancer Center, James P. Wilmot Cancer Center - Pluta, University of Rochester Medical Center, University of Wisconsin, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Sociodemographic characteristics associated with reading online health education materials among patients with cancer.Org: Navigating Cancer,
Abstract
Disclosure of metastatic breast cancer information: Patients’ understanding and patients’ and oncologists’ experiences.Org: Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Hospital Zambrano Hellion-Tecnológico de Monterrey, Centro Estatal de Cancerología Chihuahua, Hospital General de Querétaro,
Abstract
Exploring the structure of psychological distress and its symptoms: A psychometric network analysis.Org: ASST Valle Olona, Ospedale Civile Di Saronno,
Abstract
Examining patient preferences in the delivery of healthcare education.Org: Orlando Health Cancer Institute, Black Diamond Therapeutics,
Abstract
Impact of prophylactic laser therapy on mucositis in patients with head and neck cancer (HNC) undergoing radiotherapy in Brazil.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Medica Scientia Innovation Research (MEDSIR),
Abstract
A decision support intervention for patients with advanced lung cancer amid growing therapeutic complexity: Results of a randomized controlled trial.Org: Baden- Wuerttemberg Cooperative State University Stuttgart (DHBW),
Abstract
Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial.Org: Royal Brisbane and Women’s Hospital and University of Queensland, Brisbane, Australia, Royal Brisbane And Women's Hospital, Brisbane, Australia, Pathology Queensland, Brisbane, Australia, Royal Brisbane and Women's Hospital, Herston, Australia, Royal Brisbane and Women's Hospital, Herston, QLD, Australia,
Abstract
Organ-specific immune-related adverse events and survival in patients with cancer with immune checkpoint inhibitors.Org: The First Affiliated Hospital with Shandong First Medical University,
Abstract
Aromatase inhibitor musculoskeletal toxicity (AIMT) in patients (pts) with early breast cancer (EBC): Prevalence, management, and association with non-adherence to AI.Org: Cancer Survivorship Program, INSERM 981, Gustave Roussy, Villejuif, France, INSERM 981, Gustave Roussy Département d'Organisation du Parcours Patient, Villejuif, France, France,
Abstract
Association between hyperglycemia and the development of chemotherapy-induced peripheral neuropathy among patients with breast cancer.Org: Columbia University Irving Medical Center, New York, NY, USA, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Columbia University - Mailman School of Public Health,
Abstract
Direct oral anticoagulant versus low molecular weight heparin for venous thromboembolism in patients receiving immune checkpoint inhibitors.Org: Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, Department of Medicine, Icahn School of Medicine at Mount Sinai, Danbury Hospital,
Abstract
Acupuncture as a modality of treatment for chemotherapy-induced peripheral neuropathy in breast cancer: A phase 3 randomized controlled trial (ABC-CIPN).Org: Acushashtra, Advance Centre for Treatment, Research and Education in Cancer,
Abstract
Comparative analysis of efficacy and safety profiles between conventional pegfilgrastim and its biosimilar agents in patients receiving cytotoxic chemotherapy: A systemic review and meta-analysis.Org: Pakistan,
Abstract
Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies.Org: Samsung Medical Centre, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Memorial Sloan Kettering Cancer Center,
Abstract
Patterns of immune-related adverse events (irAEs) in adolescent and young adult (AYA) patients with melanoma receiving immune checkpoint inhibitors (ICIs).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, MD Anderson Hematology/Oncology Fellowship, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial.Org: West China Hospital, Sichuan University,
Abstract
Neurofilament light chains: A biomarker for vincristine-related neuropathy.Org: Ohio State University Comprehensive Canvcer Hospital,
Abstract
Deep mapping of the cytokine release syndrome inflammatory continuum: Comprehensive grade-specific profiling and differentiation from sepsis in patients receiving immune checkpoint therapy.Org: Lausanne University and CHUV,
Abstract
Phase I/II trial of gabapentin plus intranasal ketamine for the prevention and treatment of pain in patients undergoing radiotherapy for head and neck cancer.Org: Vanderbilt University Medical Center, Nashville, TN,
Abstract
The influence of sarcopenia and myosteatosis on severe laboratory toxicity and overall mortality in older adults with cancer receiving chemotherapy.Org: University Health Network, University of Toronto, Toronto General Hospital, Princess Margaret Cancer Centre,
Abstract
Frequency of certain germline polymorphisms among ethnicities and adverse drug reaction risk associated with colorectal cancer therapies.Org: OneOme, LLC, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Englander Institute of Precision Medicine, NewYork-Presbyterian Hospital,
Abstract
Women’s insights on sexual health after breast cancer (WISH-BREAST).Org: Valley Health System, Alloy Health,
Abstract
Early combination with mycophenolate mofetil for immune-related hepatitis in patients with solid tumors treated with immune checkpoint inhibitors.Org: Department of Dermatologic Oncology,
Abstract
AI-based radiomics model for predicting immune checkpoint inhibitor–related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study.Org: School of Medicine, Kyungpook National University, Daegu, South Korea, Picture Health, Cleveland, OH, Kyungpook National University Hospital, Daegu, South Korea, University of Texas at Austin, Weatherford, TX, Picture Health Inc., Cleveland, OH, Feinberg School of Medicine, Chicago, IL, Feinberg School of Medicine, Northwestern University, Chicago, IL, Richmond University Medical Center, Staten Island, NY, Northwestern University, Chicago, IL, NYU Perlmutter Cancer Center, New York, NY,
Abstract
The influence of psychosocial factors on first-time chemotherapy-induced nausea and vomiting: A prospective multicenter cohort study.Org: Department of Oncology, Chengdu Shang Jin Nan Fu Hospital/ Shang Jin Hospital of West China Hospital, Sichuan University, Chengdu, China, Breast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, Department of Oncology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China, Department of Oncology, Panzhihua University Affiliated Hospital, Panzhihua, China, Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China,
Abstract
Comparing the characteristics and outcomes of hospitalizations between cancer and non-cancer survivors.Org: University Health Network, Princess Margaret Cancer Centre, Division of General Internal Medicine and Health Services Research, University of California, Los Angeles, Los Angeles, CA, St Michael's Hospital, University of Toronto,
Abstract
Interventions of the nurse navigator in the identification and management of toxicities after the start of treatment in patients with cancer using antineoplastic therapy.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Medica Scientia Innovation Research (MEDSIR),
Abstract
Quantification of treatment-related time toxicity in patients with advanced stage cancer.Org: University of Texas at Austin,
Abstract
Improving chemotherapy-induced alopecia for women receiving anthracycline plus taxane chemotherapy using the Paxman scalp cooling system at lower temperatures.Org: Memorial Sloan Kettering Cancer Center, New York, NY, Dermatology Service, NYU Langone Health, New York, NY,
Abstract
Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC).Org: Richmond University Medical Center, Northwestern Medicine Devleopmental Therapeutics Institute,
Abstract
A randomized trial to assess the effect of oral cryotherapy in the prevention of mucositis in patients with head and neck cancer receiving chemo-radiotherapy.Org: Jawaharlal Institute of Post-Graduate Medical Education & Research, Tata Memorial Cancer Centre,
Abstract
Association of a germline single nucleotide polymorphism (SNP) in the interleukin-7 (IL7) gene with immune-related adverse events (irAEs) in the CheckMate 025 trial.Org: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Bristol Myers Squibb, The Lank Center for Genitourinary Oncology,
Abstract
Risk assessment of cardiovascular adverse events with BTK inhibitors in hematological malignancies: Insights from FAERS.Org: Cincinnati Children s Hospital Medical Center,
Abstract
The CROWN study: Cardiac outcomes with near-complete estrogen deprivation.Org: Duke Cancer Institute, Wake Forest University School of Medicine, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Virginia Commonwealth University School of Medicine, VCU Health,
Abstract
Telehealth cognitive-behavioral therapy for cancer-related cognitive impairment: 2024 update of a model for remote clinical trial participation.Org: UPMC Health Plan,
Abstract
Enhancing prostate cancer diagnosis communication: A multicenter study evaluating the impact of animated videos, CartDiag Prostate study.Org: HIA Bégin, Military Hospital Begin, GH Pointe a Pitre, Clinique Hartman, Hôpital d’Instruction des Armées de Bégin,
Abstract
Patterns and risk factors of immune-related adverse events in a real-world cohort with lung cancer receiving immunotherapy.Org: Tufts Medical Center/Tufts University School of Medicine,
Abstract
A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy treatment (ACT).Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Predictive factors for cardiac events following concurrent chemotherapy and radiation with durvalumab consolidation for unresectable non-metastatic non-small cell lung cancer.Org: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Biostatistics, Indiana University School of Medicine, Indianapolis, IN, Feinberg School of Medicine,
Abstract
A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment (YCT).Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Pilot evaluation of portable scalp cooling for chemotherapy-associated alopecia in early-stage breast cancer.Org: Providence Cancer Institute,
Abstract
Randomized double-blind placebo-controlled trial evaluating pregabalin for chronic cough in patients with lung cancer.Org: Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, MS Ramaiah Memorial Hospital, Emeritus Professor, Tata Memorial Centre (TMC), Tata Memorial Hospital, Tata Memorial Centre,
Abstract
Preventing chemotherapy-induced peripheral neuropathy with acupuncture, a multinational parallel randomized controlled trials project (PACT).Org: The Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital, Daegu Catholic University, Jiangsu Province Hospital of Chinese Medicine, Daegu Haany University, Daegu Catholic University Medical Center,
Abstract
Risk assessment of myelosuppression with PARP inhibitors in prostate cancer: Insights from FAERS.Org: Cincinnati Children s Hospital Medical Center,
Abstract
Racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer.Org: Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS,
Abstract
Comparison of prophylactic effects for chemotherapy-induced neutropenia between same-day vs next-day administration of pegteograstim in chemotherapy regimen composed of day 1 intensive myelosuppressive agent: A randomized phase III trial (CONCISE, KCSG PC22-11).Org: Hanyang University Seoul Hospital, Yangsan, South Korea, Uijeongbu St. Mary’s Hospital, Uijeongbu, South Korea, Dong-A University College of Medicine,
Abstract
Randomized, placebo-controlled trial of atorvastatin to prevent hearing loss in patients with head and neck squamous cell carcinoma receiving cisplatin based chemoradiation (CRT).Org: NIDCD/NIH, National Center for Rehabilitative Auditory Research, NIH/NHLBI, NIH/NIDCD,
Abstract
LOOP: An observational, prospective, multicenter study of patients with non-small cell lung cancer in the US receiving standard-of-care and initiating an approved therapy with risk of pneumonitis/ILD.Org: Waltham, MA,
Abstract
Comparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+/HER2- aBC: Results of the multicenter, real-world, Italian study PALMARES-2.Org: IRCCS Policlinico S. Matteo, Dip Scienze Medico Chirurgiche Medicina, ICS Maugeri IRCCS, Ospedale di Mirano Dolo, ASST Fatebenefratelli Sacco,
Abstract
Acupuncture for preventing progression of taxane-induced peripheral neuropathy (ATP): A phase II randomized, placebo-controlled trial.Org: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Role of celecoxib in reducing cognitive impairment in patients receiving definitive chemoradiation for head and neck carcinoma: A phase II randomized placebo controlled trial (CELCI-HN study).Org: IRCH, National Cancer Institute-All India Institute of Medical Science (AIIMS), Radiation Oncology, NCI AIIMS,
Abstract
Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline.Org: Comprehensive Breast Care,
Abstract
H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).Org: Sarah Cannon Research Institute/Tennessee Oncology, Saint Luke's Cancer Institute, Florida Cancer Specialists/Sarah Cannon Research Institute, Royal Marsden NHS Foundation Trust, Lineberger Comprehensive Cancer Center,
Abstract
Guard 01: A randomized, multicentre, controlled trail on the prophylactic use of efbemalenograstim alfa for concurrent chemo-radiotherapy induced neutropenia.Org: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center Gansu Hospital, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Oncologic outcome of response-guided axillary treatment in patients with cN1 breast cancer after primary systemic therapy.Org: Borstkanker Onderzoek Groep Study Center,
Abstract
Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.Org: Exact Sciences Corporation, Cancer Research and Biostatistics (CRAB), Seattle, WA, ASCO, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Loyola University Chicago Stritch School of Medicine,
Abstract
Genomic and tumor microenvironment dynamics of brain metastases in breast cancer.Org: Tulane Medical University,
Abstract
Cognitive function in patients with HR+ advanced breast cancer treated with endocrine therapy with or without CDK4/6 inhibitors in the SONIA trial.Org: Psychosocial Research and Epidemiology, Netherlands Cancer Institute (Netherlands ),
Abstract
Non-basal subtype defined by FOXC1 expression as an independent predictor of capecitabine efficacy in the triple negative breast cancer GEICAM/2003-11_CIBOMA/2004-01 trial.Org: Onconostic Technologies, Evanston, IL, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Instituto Nacional de Enfermedades Neoplásicas (INEN), Universidad Ricardo Palma, Instituto Nacional del Cáncer; LACOG (Latin American Cooperative Oncology Group), Hospital Amaral Carvalho; LACOG (Latin American Cooperative Oncology Group),
Abstract
Clinical utility of molecular imaging in newly diagnosed metastatic breast cancer.Org: Department of Nuclear Medicine and Molecular Imaging, Department of Radiology and Nuclear Medicine, Maasstad Ziekenhuis, Department of Clinical Pharmacy and Pharmacology, Amsterdam University Medical Center; Cancer Centre Amsterdam,
Abstract
Associations of predictive biomarkers, MHC-I and MHC-II, with clinical and molecular features in a diverse breast cancer cohort.Org: Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, The University of North Carolina at Chapel Hill,
Abstract
The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer.Org: Mayo Clinic, Mayo Clinic Department of Oncology,
Abstract
TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2.Org: Breast Medicine Service,
Abstract
Ultra-hypofractionated adjuvant radiation therapy for breast cancer (UK FAST-Forward trial): A real life scenario analysis in a developing country.Org: RadioSerra, Petrópolis,
Abstract
ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC).Org: Hospital of Xinjiang Production and Construction Corps,
Abstract
Risk factors of breast cancer among patients from a lower- and middle-income country: A case-control study from Nepal.Org: Patan Academy of Health Scences, Kathmandu, Nepal,
Abstract
Exosome-delivered microRNAs confer adriamycin-resistance through modulating the immune and metabolism-related gene PTEN in HER2-negative breast cancer.Org: The First Affiliated Hospital with Nanjing Medical University, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Dalian Medical University, Bengbu Medical College,
Abstract
Arthralgia and myalgias associated with aromatase inhibitors: Frequency and characterization in real-life patients.Org: Servicio de Oncologia Clinica, University of Uruguay, Hospital de Clinicas,
Abstract
Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial.Org: UCLA Santa Monica Hematology/Oncology Regulatory-2, Novartis Healthcare Private Limited, Novartis Ireland,
Abstract
Exploring factors impacting quality of life in patients with breast cancer undergoing adjuvant hormone therapy: Experience of the Medical Oncology Department-CHU Hassan II-FEZ University Hospital.Org: Department of Medical Oncology, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, University of Sidi Mohamed Ben Abdellah, Fez, Morocco, Epidemiology Laboratory, Clinical Research, and Community Health, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, University of Sidi Mohamed Ben Abdellah, Fez, Morocco, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, University of Sidi Mohamed Ben Abdellah, Fez, Morocco, Department of Radiotherapy. Hassan II University Hospital, Medical School of University of Sidi Mohamed Ben Abdallah, Fez, Morocco, Department of Medical Oncology, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, University of Sidi Mohamed Ben Abdellah, Meknes, Morocco,
Abstract
Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy.Org: Tranquil Clinical Research,
Abstract
Prediction of CCL2 in breast cancer based on enhanced MRI radiomics model with integrated bioinformatics analysis and machine learning.Org: China Medical University, Shenyang, China,
Abstract
Association between PIK3CA mutations and disease-free survival in patients with HR+, HER2- tumors treated with adjuvant hormonal therapy: A real-world study in Croatia.Org: University Hospital Center Split, University of Split, University Hospital Center Zagreb, University of Zagreb, University of Rijeka,
Abstract
HR+/HER2- early breast cancer with a high risk of recurrence: The impact of online education on clinician knowledge, competence, and confidence in utilization of clinical practice guidelines to enhance patient care.Org: Medscape Oncology, Carrollton, TX, Medscape LLC,
Abstract
Real-world safety and discontinuation rates of fam-trastuzumab deruxtecan in advanced HER2-positive and HER2-low cancer.Org: University of Kansas School of Medicine - Wichita,
Abstract
Efficacy of a combined diet and exercise intervention in patients with breast cancer undergoing chemotherapy: A meta-analysis of randomized controlled trials.Org: University of Luxembourg, Centro Universitário Lusíada, Universitat Internacional de Catalunya, Faisalabad Medical University, Cardiff University School of Medicine,
Abstract
The efficacy of primary progesterone on survival in early breast cancer: A real world scenario.Org: Tata Memorial Hospital, Homi Bhabha National Institute,
Abstract
De-escalation neoadjuvant chemotherapy in triple negative breast cancer.Org: Hospital Arnau de Vilanova de Lleida, Hospital Arnau de Vilanova; GEICAM Spanish Breast Cancer Group, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,
Abstract
Adherence to adjuvant hormone therapy in hormone-sensitive breast cancer: Insights from the Medical Oncology Department at Hassan II University Hospital, Morocco.Org: Department of Medical Oncology, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, University of Sidi Mohamed Ben Abdellah, Fez, Morocco, Epidemiology Laboratory, Clinical Research, and Community Health, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, University of Sidi Mohamed Ben Abdellah, Fez, Morocco, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, University of Sidi Mohamed Ben Abdellah, Fez, Morocco, Department of Radiotherapy, Hassan II University Hospital, Medical School of University of Sidi Mohamed Ben Abdallah, Fez, Morocco, Department of Medical Oncology, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, University of Sidi Mohamed Ben Abdellah, Meknes, Morocco,
Abstract
Trends in the management of small HER2-positive breast cancers.Org: Outcomes Research Consortium, Department of Anesthesiology, Integrated Surgical Institute,
Abstract
Factors that impact aromatase inhibitor adherence in early-stage hormone receptor positive breast cancer.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Effects of a pilot 12-week exercise program on breast cancer survivors’ quality of life.Org: Kinesiology and Rehabilitation Science, Rehabilitation Hospital of the Pacific,
Abstract
Examining a genomic test in predicting extended endocrine benefit and recurrence risk in a diverse breast cancer population.Org: John A. Burns School of Medicine, University of Hawaii Cancer Center,
Abstract
A pilot study evaluating exercise intervention and body composition changes in patients with breast cancer and survivors.Org: University of Hawaii at Manoa,
Abstract
Optimal neoadjuvant treatment and prognostic factors in patients with HR-positive/HER2-positive early or locally advanced breast cancer: A national real-world study in China.Org: Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China,
Abstract
Clinical outcomes and prognostic factors in epithelial-myoepithelial carcinoma (EMC) of the breast.Org: H. Lee Moffitt Cancer Center and Research Institute, BronxCare Health System, Mount Sinai Hospital-Breast Medical Oncology, Rochester General Hospital, University of South Florida Morsani College of Medicine,
Abstract
Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancer.Org: Chinese University of Hong Kong Medical Centre, Department of Medicine, The University of Hong Kong, United Christian Hospital, Hong Kong Baptist Hospital, Kwong Wah Hospital,
Abstract
Clinical outcomes in patients with early-stage breast cancer in a racially and ethnically diverse patient population.Org: Glenn Family Breast Center and Breast Medical Oncology,
Abstract
Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US.Org: RTI International,
Abstract
Cost-effectiveness of adjuvant abemaciclib and ribociclib in high-risk, hormone receptor–positive, early breast cancer in India.Org: Department of Medical Oncology, BRA-IRCH,
Abstract
Tolerance and safety of adjuvant metronomic capecitabine in Indian patients with non-metastatic triple negative breast cancer (TNBC): An institutional experience.Org: Consultant, Department of Academics,
Abstract
An overview of psychological analysis of patients with breast cancer undergoing total mastectomy and breast conservation surgery and its impact on objectified body consciousness at a tertiary care cancer centre.Org: Aster International Institute of Oncology,
Abstract
Clinical factors associated with response to neoadjuvant chemotherapy in women of Hispanic origin diagnosed with early-stage TNBC or HER2+ breast cancer in the United States.Org: Maroone Cancer Center, Cleveland Clinic Florida,
Abstract
Risk factors for positive margin in breast conservation surgery for localized breast cancer.Org: Charleston Area Medical Center (CAMC) Health Education and Research Institute,
Abstract
Genomic profile in Mexican women with early-stage breast cancer using Mammaprint+Blueprint assay: A retrospective study.Org: Centro Medico ABC Observatorio, Unidad de Cancerología, Opcion Oncologia, Doctors Hospital AUNA, Ginequito,
Abstract
Factors associated with benefit of adjuvant chemotherapy in patients with T1b/T1c HR-positive/HER2-negative breast cancer and high multigene recurrence score.Org: Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL,
Abstract
Receptor expression testing of the synchronous axillary nodal metastasis in early-stage breast cancer: Comparison of primary tumor and its draining nodes.Org: Marshall University, Edwards Cancer Center, Marshall University School of Medicine,
Abstract
Retrospective study on the profile of patients undergoing intraoperative radiotherapy with INTRABEAM for breast cancer treatment at a Brazilian cancer center.Org: A.C. Camargo Cancer Center,
Abstract
Degradation of estrogen receptor α induced by ionizing radiation contributes to senescence of ER+ breast cancer cells.Org: Institute of Modern Physics,
Abstract
Clinical differences and management trends of localized breast cancer in the advanced geriatric population.Org: Charleston Area Medical Center (CAMC) Health Education and Research Institute,
Abstract
An open-label randomized trial comparing addition of olanzapine 5 mg versus olanzapine 10 mg as anti-emetic to standard anti-emetic regime for doxorubicin or epirubicin and cyclophosphamide in breast cancer.Org: Command Hospital (AF), Central Regional Referral Hospital,
Abstract
Pretreatment neutrophil to lymphocyte ratio as a predictor of pathological complete response to neoadjuvant immunotherapy in early breast cancer.Org: Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
The correlation between Ki 67 and Oncotype Dx on HR+, HER2- early breast cancer management: Insights of molecular testing.Org: University of Miami Hospital/Jackson Memorial Hospital, Ecua-american Laboratories, Hospital de los Valles,
Abstract
Targeted genotyping for recurring variants in cancer susceptibility genes in non-Ashkenazi Jewish patients with breast cancer diagnosed ≥ 50 years.Org: Breast Cancer Institute, The Jusidman Cancer Center, Sheba Tel Hashomer Medical Center, The Susanne Levy Gertner Oncogenetics Unit, The Meirav High Risk Clinic,
Abstract
Predicting locoregional recurrence in triple-negative breast cancer using novel molecular subtyping.Org: Fudan University Shanghai Cancer Centre,
Abstract
Efficacy and safety of concurrent capecitabine and radiotherapy as adjuvant treatment in triple negative breast cancer.Org: Prof. Dr. Al. Trestioreanu Bucharest Institute of Oncology, UMF Carol Davila,
Abstract
LC3AB protein-based gene (PbG) signatures as an indicator of relapse even after achieving pathological complete response.Org: Department of Pathology and Cell Biology,
Abstract
Clinical features of breast cancer in Ashkenazi Jewish carriers of the two founder BRCA1 pathogenic variants.Org: Shaare Zedek Medical Center, Faculty of Medicine, Cairo University, Hebrew University-Hadassah Medical School, Sharett Institute of Oncology, Hadassah Medical Center,
Abstract
The role of obesity in the clinicopathologic variables and treatment of early stage breast cancer.Org: Comprehensive Hematology-Oncology, St. Petersburg, FL,
Abstract
Neoadjuvant pertuzumab, docetaxel, carboplatin, and trastuzumab (PTCH) regimen in patients with HER2 positive early, locally advanced, and oligometastatic breast cancer: Real-world Indian experience.Org: Dr. BRA-IRCH, Institute of Rotary Cancer Hospital (IRCH),
Abstract
Preliminary exploration of Trop2 ADC in combination with immune checkpoint inhibitors in the different molecular subtypes of invasive breast carcinoma.Org: Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, The Fourth Hospital of Hebei Medical University,
Abstract
Deliberate inclusion of multiple co-correlated gene target sets during discovery for improved biomarker translation to a clinical assay in early-stage breast cancer.Org: IV BioHoldings,
Abstract
Characterizing the 70-gene MammaPrint risk stratification in Chinese luminal type breast cancer and its correlation with clinicopathological characteristics, immune and metabolic functions.Org: Genecast Research Institute,
Abstract
Immune subtyping of ER-positive, PR-negative and HER2-negative breast cancers by immunohistochemistry: Molecular basis and clinical relevance.Org: The First Affiliated Hospital of Medical College of Xi'an Jiaotong University,
Abstract
Association of plasma kynurenine (KYN) with plasma osteopontin (OPN) in patients with locally invasive breast cancer.Org: The Dartmouth Institute,
Abstract
A set of molecular biomarkers as an indicator of cancer risk.Org: Department of Pathology and Cell Biology, UND School of Medicine and Health Sciences,
Abstract
Molecular profiling in ABC: Is complementary testing with tissue and plasma necessary and clinically relevant?Org: Fortis Cancer Institute, Metro Hospital, Sahyadri Hospital, Gleneagles BGS Hospital, Apollo Hospitals,
Abstract
Prediction of pathological response to neo-adjuvant chemotherapy using texture parameters of initial 18-FDG PET/CT in estrogen receptor positive/Her2 negative (ER+/HER2-) early breast cancer (eBC).Org: Institut de Cancérologie de l'Ouest, Angers, France, Institut de Cancérologie de l'Ouest, Saint-Herblain, France, Institut de Cancérologie de l'Ouest, France, France, Institut de Cancérologie de l'Ouest-René Gauducheau, Centre de Recherche en Cancérologie, Saint-Herblain, France, Institut de Cancerologie de l'Ouest, Saint-Herblain, France,
Abstract
Mechanism study on fig exosome-like nanoparticles inhibiting the progression of bone metastasis in breast cancer.Org: Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Key Laboratory of Minimally Invasive Surgery and Precision Treatment for Breast Cancer of Chongqing Municipal Health Commission, Department of Pathology, Southwest Hospital, Army Medical University, Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, Pancreatic Injury and Repair Key Laboratory of Sichuan Province, The General Hospital of Western Theater Command,
Abstract
Short-term and long-term survival outcomes in patients with invasive lobular carcinoma vs. invasive ductal carcinoma of the breast.Org: Montefiore Einstein Comprehensive Cancer Center/Albert Einstein College of Medicine, Albert Einstein College of Medicine,
Abstract
Advancements in breast cancer progression monitoring: Analysis of methylated circulating cell- free DNA.Org: Taipei Medical University Hospital,
Abstract
Coping with inter-observer variability when assessing AI for scoring of HER2-stained whole slides.Org: IHP Paris,
Abstract
Pilot evaluation of allostatic load and breast cancer characteristics in a predominantly Han Chinese population.Org: People's Hospital of Sichuan Province,
Abstract
A liquid biopsy-based assay for classifying breast cancer from benign nodule.Org: Breast Center, The Fourth Hospital of Hebei Medical University, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc.,
Abstract
Is there a correlation between estrogen receptor expression level and early breast cancer survival? A retrospective study.Org: Zagazig University Hospitals, Egypt, Medical Oncology-King Saud Medical City, Riyadh, King Abdullah Medical City,
Abstract
Overall survival in patients with HER2-low breast cancer at a reference hospital in Mexico.Org: Instituto Mexicano del Seguro Social, Instituo Mexicano del Seguro Social, Instituto Mexicano del Seguro Social Hospital de Oncologia Centro Medico Nacional Siglo XXI,
Abstract
Uncovering of NRAGE/JNK and PI3K/AKT pathways through serial WGS of patients with breast cancer.Org: Cell and Matrix Research Institute, School of Medicine, Kyungpook National University,
Abstract
Spatial transcriptomic and proteomic insight into Trop-2, HER2, and AR expression: A pathway to tailored therapies in triple-negative breast cancer.Org: University Hospital Center of Liege, Laboratoire d’Anatomie Pathologique,
Abstract
HER2 low hormone positive breast cancer: Unveiling the driver.Org: Medical Research Institute, University of Alexandria,
Abstract
Effect of neratinib on HER2 mRNA stability via hsa-miR-23a-5p and efficacy of CDK4/6 inhibitors in HER2-low breast cancer.Org: The Second Clinical College of Guangzhou University of Chinese Medicine,
Abstract
FKBP10-inhibited β-catenin ubiquitination in the malignant transformation of breast epithelial cells.Org: Changzhou No. 2 People's Hospital,
Abstract
Can patients with biopsy-diagnosed DCIS safely spare sentinel lymph node biopsy (SLNB)?Org: Sun Yat-sen Memorial Hospital of SunYat-sen University,
Abstract
Change in tumor microenvironment and PD-L1 expression with rucaparib treatment in triple-negative breast cancer.Org: George Washington University Hospital,
Abstract
Interpectoral nodal dissection for invasive breast cancer: A retrospective single institution study from India.Org: Sri Ramachandra Institute of Higher Education And Research, Chennai, India,
Abstract
Retrospective observational study of patients with luminal breast cancer in early stages: 10-year follow-up—Which luminal breast cancer relapse?Org: Hospital Universitario Regional Málaga,
Abstract
Ipsilateral recurrence and breast cancer outcomes in carriers of BRCA1/2 pathogenic variants according to locoregional treatments.Org: The Suzanne Levy-Gertner Oncogenetics Unit, Sheba Tel-Hashomer Medical Center, Radiation Oncology Department, The Jusidman Cancer Center, Breast Oncology Institute,
Abstract
Clinicopathological features and prognosis for pregnancy-associated breast cancer: A matched case-control study.Org: Tawam Hospital, Al Ain, United Arab Emirates, Tawam Hospital, Abu Dhabi Health Care Services Co., Alain, United Arab Emirates, Department of Pharmacy, Tawam Hospital, AbuDhabi Health Services Co, Alain, United Arab Emirates,
Abstract
Information and support needs of young Black women with early breast cancer to enable self-management and informed decisions during breast cancer treatment.Org: Center for Business Models in Healthcare, Glencoe, IL, Glencoe, IL, Tigerlily Foundation, Stone Ridge, VA, Genentech Inc.,
Abstract
Demographics and socioeconomic factors of adenocarcinoma with apocrine metaplasia.Org: Arizona State University, Brandeis University,
Abstract
Pathologic examination of specimen after vacuum-assisted biopsy (VAB) in patients with breast cancer after neoadjuvant systemic therapy (NST).Org: Federal State Budget Institution, National Medical Research Center of Oncology named after N.N. Petrov, Ministry of Healthcare of Russian Federation,
Abstract
De-escalation of breast cancer surgery using vacuum-assisted biopsy (VAB): Interim results.Org: Federal State Budget Institution, National Medical Research Center of Oncology named after N.N. Petrov, Ministry of Healthcare of Russian Federation,
Abstract
SE-GAP-ResNet: A machine learning model for abnormal breast detection.Org: Xi'an Jiaotong-Liverpool University, Southeast University,
Abstract
Is a completion axillary dissection in patients with early breast cancer with a positive sentinel node necessary? An NCDB-based trial emulation of ACOSOG Z0011.Org: Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Emory University, Atlanta, GA, USA, Emory University Hospital, Winship Cancer Institute of Emory University, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Evaluation of the immune landscape associated with the efficacy of immunotherapy in patients with triple-negative breast cancer: Starlet study, synergy between research and clinical work.Org: Medical Oncology, Comprehensive Cancer Centre, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy, Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Breast Surgery Unit, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Medical Oncology, Comprehensive Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy,
Abstract
Ductal carcinoma in situ: Molecular and cellular basis of malignancy.Org: KU Indian Creek Breast Surgery Center, University of Kansas Hospital,
Abstract
Inhibition of AR and DNA-PK for radio-sensitization of AR-driven cancers.Org: Cancer Research UK Cambridge Institute, Artios Pharma, National Institutes of Health All of Us Research Program, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, AstraZeneca,
Abstract
Reconstructive plastic surgery in combined treatment of breast cancer: Predictive risk factors of complications and reconstruction failure.Org: Federal State Budget Institution, National Medical Research Center of Oncology named after N.N. Petrov, Ministry of Healthcare of Russian Federation, Saint Petersburg, Russian Federation,
Abstract
KHRONOS Project: Is time to surgery really important in the treatment of early breast cancer?Org: Instituto de Salud Carlos III,
Abstract
A comparative study on quality of life of patients with breast cancer receiving subcutaneous gland resection combined with primary prosthesis implantation: Minimally invasive versus open surgery.Org: Key Laboratory of Minimally Invasive Surgery and Precision Treatment for Breast Cancer of Chongqing Municipal Health Commission, Chongqing, China,
Abstract
Prognosis of locoregional recurrence after early breast cancer with immediate breast reconstruction.Org: Department of Breast Surgery, Kyorin University School of Medicine/Saitama Medical Center, Tokyo, Japan, Department of Breast Surgery, Japanese Red Cross Medical Center/Department of Breast Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan, Department of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kanagawa, Japan, Yokohama City University Medical Center, Yokohama, Japan,
Abstract
3D cell cultures exhibit increased drug resistance, particularly to taxanes.Org: SageMedic Corp.,
Abstract
Breast cancer recurrence rate after mastectomy in young females.Org: Simmons Cancer Institute at Southern Illinois University,
Abstract
Patient reported outcomes for anterior and postpectoral prosthesis implantation in single-port laparoscopic breast.Org: Xijing Hospital Fourth Military University, Xi'an, China,
Abstract
Impact of comorbidity on surgical management of breast cancer in elderly patients.Org: SBIH Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM, Moscow, Russian Federation,
Abstract
Impact of breast-conserving surgery incisions on aesthetics, satisfaction, and complications: A prospective study.Org: Departments of Obstetrics & Gynecology and Pediatrics, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Chinese Evidence-based Medicine Center,
Abstract
Optimization of surgical management of the axilla since MonarchE trial.Org: Georges François Leclerc Comprehensive Cancer Care Centre, Centre Georges François Leclerc, Centre Georges Francois Leclerc,
Abstract
Patient characteristics associated with primary prophylactic granulocyte colony-stimulating factor (G-CSF) use among women treated for early-stage breast cancer.Org: Memorial Sloan Kettering Cancer Center, Kaiser Permanente Washington Health Research Institute, Rogel Cancer Center, University of Michigan, The Permanente Medical Group Consulting Services, Kaiser Permanente Division of Research,
Abstract
Intraoperative ultrasound guided wire (IOUS-wire) localization biopsy with frozen section versus preoperative fine needle aspiration cytology (FNAC) for the evaluation of clinically positive nodes in patients with early breast cancer in China real-world clinical practice.Org: The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,
Abstract
A prospective cohort study on rivaroxaban in the prevention of catheter-related thrombosis in breast cancer.Org: Department of Medical Oncology, Beijing Chaoyang District San Huan Cancer Hospital, Beijing, China, Department of Medical Oncology, Beijing Chao yang District San huan Cancer Hospital, Beijing, China, Beijing Chaoyang District San Huan Cancer Hospital, Beijing, China, Special Medical Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,
Abstract
A nomogram to predict the risk of axillary upstaging in patients with Z0011-eligible breast cancer.Org: Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China,
Abstract
Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
The predictive role of Ki67 in pathological complete response (pCR) and invasive disease-free survival (IDFS) in HER2-positive breast cancer: A retrospective study of 246 cases.Org: University Carl Gustav Carus,
Abstract
Assessment of breast cancer optimal care timeframes in a regional and rural real-world setting: A regional cancer centre experience in Australia.Org: Townsville Cancer Care Centre,
Abstract
Use of an AI-powered visualization platform to support precision clinical decision-making in patients with breast cancer undergoing neoadjuvant chemotherapy.Org: SimBioSys, Inc.,
Abstract
Efficacy and biomarker analysis of carboplatin plus taxanes neoadjuvant chemotherapy in triple-negative breast cancer: A prospective multicenter cohort study.Org: Center for Thyroid and Breast Surgery, Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China, Department of Medical Oncology, Affiliated Hospital of Hebei University;Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Hebei, China, Genecast Biotechnology Co., Ltd., Wuxi, China, Breast center, Department of Thyroid-Breast-Hernia Surgery, Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,
Abstract
A proof-of-concept study of LXP5268 as an add-on neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer.Org: LAUNXP Biomedical Co., Ltd,
Abstract
Retrospective analysis of factors impacting efficacy of patients with later stage breast cancer receiving neoadjuvant therapy.Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Beijing University Cancer Hospital, Beijing University Cancer Hospital & Institute, Department of Breast Oncology, Peking University Cancer Hospital,
Abstract
Evaluation of early response in association with pathological response in patients with breast cancer receiving neoadjuvant chemotherapy.Org: Second Hospital of Shandong University, Jinan, China, The Second Hospital of Shandong University, Jinan, China,
Abstract
Efficacy and safety of neoadjuvant trastuzumab, pyrotinib, and dalpiciclib without chemotherapy in early-stage HR-negative/HER2-positive breast cancer: An open-label, single-arm phase II trial.Org: The First People's Hospital of Xiangtan City, Xiangtan, ShaoYang Central Hospital,
Abstract
Prediction of pathologic complete response to chemoimmunotherapy in triple-negative breast cancer using tumor-infiltrating lymphocytes: Exploiting cutoff values.Org: Hospital 9 de Julho, Hospital Santa Paula, Clínica AMO, Instituto do Câncer do Ceara,
Abstract
A propensity-matched analysis of the efficacy and safety of neoadjuvant inetetamab and pertuzumab with paclitaxel and carboplatin (TCbIP) on locally advanced HER2-positive breast cancer.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Molecular Oncology,
Abstract
Clinical significance of circulating tumor DNA in neoadjuvant-treated HER2-negative luminal B breast cancer.Org: Genecast Biotechnology Co., Ltd, Beijing, China,
Abstract
Pathological complete response rate to anthracycline versus non−anthracycline based chemotherapy regimens in localized and regional HER2 neu positive breast cancer.Org: Johns Hopkins Aramco HealthCare, Dhahran,
Abstract
Impact of peridiagnostic genetic counseling and germline testing on treatment decisions for patients with triple negative breast cancer undergoing pembrolizumab-chemotherapy neoadjuvant approach.Org: CABA, Argentina, Argentine Association of Clinical Oncology, Research Department, Olivos, Argentina,
Abstract
Axillary lymph nodes pCR (apCR) versus breast pCR (bpCR): A meta-analysis involving 10,723 patients.Org: The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China, Xian, China, The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China,
Abstract
Real-world comparison: Neoadjuvant pembrolizumab (pembro-NACT) vs. dose-dense neoadjuvant chemotherapy (ddNACT) in early stage triple-negative breast cancer (TNBC).Org: Zucker School of Medicine,
Abstract
Real life data of KEYNOTE 522: The Cleveland Clinic experience.Org: Cleveland Clinic Akron General, Department of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic Moll Cancer Center at Fairview,
Abstract
The preliminary efficacy and safety results of neoadjuvant phase 2 study of penpulimab combined with taxanes and carboplatin in triple-negative breast cancer (neoTAPPL).Org: Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Key Laboratory of Minimally Invasive Surgery and Precision Treatment for Breast Cancer of Chongqing Municipal Health Commission, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Sounthwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Department of Thoracic Surgery, the Eighth Medical Center of Chinese PLA General Hospital, Chongqing, China, Central Medical Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. L., Nanjing, China,
Abstract
Predicting peripheral neuropathy following neoadjuvant therapy in patients with breast cancer.Org: SimBioSys, Inc.,
Abstract
A prospective phase II study of neoadjuvant therapy guided by personalized drug-testing on patient-derived tumor-like cell clusters for early breast cancer.Org: College of Future Technology Peking University, Peking University People's Hospital Breast Center,
Abstract
Circulating tumor DNA (ctDNA) to predict response to neoadjuvant chemotherapy (NAC) and prognosis in patients (pts) with early breast cancer (BC).Org: Florida Hospital Cancer Institute, Altamonte Springs,
Abstract
Neoadjuvant pyrotinib and inetetamab in combination with chemotherapy for locally advanced HER2-positive breast cancer (NeoPICD study): A prospective, multicenter, open-label, single-arm study.Org: Department of Thyroid and Breast Surgery, Quzhou People's Hospital, Quzhou, China, Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, Department of Breast Surgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, Ruian People's Hospital, Ruian, China, Department Of Thyroid And Breast Surgery, Wenzhou Central Hospital, Wenzhou, Zhejiang, China,
Abstract
Time to surgery after neoadjuvant chemotherapy in breast cancer and its impact on survival in a middle-income country.Org: Sociedad de Lucha Contra El Cáncer, SOLCA - Guayaquil, Guayaquil, Ecuador,
Abstract
Systemic inflammatory markers in neoadjuvant pembrolizumab therapy for triple-negative breast cancer: Prognostic insights and nomogram construction.Org: IRCCS AUSL Reggio Emilia, Azienda Unità Sanitaria Locale di Reggio Emilia IRCCS, Medical Oncology Unit, Clinical Cancer Centre, Arcispedale Santa Maria Nuova-IRCCS,
Abstract
Automated digital oncologic data review for breast cancer research: AI-enabled mCODE and field-of-interest extraction framework.Org: Seoul Medical Informatics Intelligence Lab Inc., Institute of Innovative Digital Healthcare,
Abstract
Neoadjuvant dalpiciclib combined with aromatase inhibitors in stage I-III HER2 negative luminal B breast cancer (DANCER): Preliminary findings from an ongoing phase II study.Org: Genecast Precision Medical Diagnostic Laboratory, Wuxi Co., Ltd, Wuxi, China,
Abstract
Role of NEDD9 expression in non-metastatic HER2-positive breast cancer.Org: Sonic Healthcare USA, WVU Health Sciences Center, West Virginia University Children's Hospital, West Virginia University Department of Medicine,
Abstract
Long-term outcomes of neoadjuvant treatment in older patients with HER2-positive breast cancer: Evidence from a single center in Mexico.Org: Instituto Nacional de Cancerología,
Abstract
Efficacy and safety of recombinant humanized anti-HER2 antibody-MMAE conjugate (RC48) in neoadjuvant for HER2-positive breast cancer: A single-arm phase II study.Org: Air Force Medical University,
Abstract
Genomic analysis of the tumor microenvironment in Asian and Native Hawaiian and Pacific Islander patients with triple negative breast cancer.Org: University of Hawaii Manoa, Kapiolani Medical Center for Women and Children,
Abstract
The relationship between PIK3CA mutations and survival in patients with human epidermal growth factor receptor 2–positive breast cancer receiving pyrotinib combined with trastuzumab for neoadjuvant treatment.Org: the Eighth Medical Center of Chinese PLA General Hospital,
Abstract
Predictive markers of complete pathological response to neoadjuvant chemo-immunotherapy in triple negative breast cancer.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Institute of Oncology Ljubljana,
Abstract
Determinants of pathological complete response and tumor regression in high-risk breast cancer treated with neoadjuvant radiotherapy and chemotherapy.Org: Heinrich Heine University Dusseldorf, Department of Radiation Oncology, University Hospital Düsseldorf, Heinrich Heine Universität Düsseldorf, EVK Dusseldorf, Sana Krankenhaus Gerresheim,
Abstract
Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy.Org: Kyungpook National University Chilgok Hospital, Kyungpook National University, Predicine, Inc., Hayward, CanSino Biologics,
Abstract
Neoadjuvant chemotherapy as an indication to preserve nipple areolar complex in advanced breast cancer.Org: Ulsan University, College of Medicine,
Abstract
Predicting pathological response in early-stage triple-negative breast cancer: Exploring the role of BRCA gene mutations—A retrospective single-institution study.Org: Joan C. Edwards School of Medicine, Edward Comprehensive Care Center,
Abstract
Neoadjuvant aromatase inhibitor therapy for ER+ breast cancer: The NAOMI trial.Org: Dartmouth-Hitchcock Medical Center, Dartmouth College Geisel School of Medicine, Medical College of Wisconsin,
Abstract
Predictors of response and surgical approach after neoadjuvant chemotherapy in receptor-positive/HER2-negative stage II-III breast cancer patients treated in two private cancer care centers in Lima, Peru: Real-world data.Org: Clinica Internacional, Universidad Peruana de Ciencias Aplicadas, ALIADA Centro Oncologico,
Abstract
A retrospective, single-center study comparing two neoadjuvant protocols for patients with HER2-positive breast cancer.Org: Sheba Medical Center, Or-Yeuda, Sheba Medical Center, TEL Hashomer,
Abstract
Results of neoadjuvant therapy for patients with triple negative breast cancer in a public hospital in Brazil (Federal District).Org: Hospital Regional de Taguatinga, Santa Lucia Sul, Hospital Santa Lucia Sul,
Abstract
PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1).Org: The University of Chicago Medicine Center for Advanced Care at Orland Park, Quantum Leap Healthcare Collaborative,
Abstract
Unveiling the relationship between the UGT2B gene family and neoadjuvant treatment response in patients with HER2-positive breast cancer.Org: Instituto Biomedicina Sevilla, Institute of Biomedicine of Seville (IBiS), Andalusian - Roche Network Mixed Alliance in Precision Medical Oncology,
Abstract
Treatment outcomes of the KEYNOTE-522 regimen in an ethnically diverse patient population: A real world experience.Org: Maimonides Cancer Center,
Abstract
Trends and outcomes in patients receiving neoadjuvant chemotherapy for breast cancer in Ontario: A population-based study.Org: ICES Central,
Abstract
A prospective, open-label, single-arm phase II clinical study of inetetamab in combination with pyrotinib and albumin-bound paclitaxel for the neoadjuvant treatment of patients with HER2+ early and locally advanced breast cancer.Org: Department of Thyroid, Breast, and Vascular Surgery at Xijing Hospital, Air Force Medical University,
Abstract
Efficacy and toxicity of trastuzumab emtansine among patients with HER-2-positive metastatic breast cancer in Saudi Arabia.Org: King Faisal Specialist Hospital and Research Center, Alfaisal University College of Medicine, HCA Houston Healthcare Kingwood/University of Houston,
Abstract
Survival and safety analysis of eribulin in Indian patients with metastatic breast cancer: A real world clinical experience.Org: Rajiv Gandi Cancer Institute & Research Centre,
Abstract
Trastuzumab, pertuzumab and nab-paclitaxel plus pyrotinib or not in neoadjuvant treatment of HER2-positive breast cancer: A multi-center, randomized, open-label, phase II study.Org: Shangyu People's Hospital, Shaoxing, China,
Abstract
Real world experience with cyclin dependent kinase inhibitors in metastatic breast cancer from India.Org: Rajiv Gandi Cancer Institute & Research Centre,
Abstract
Real life comparison between doxorubicin and cyclophosphamide (AC) dose-dense (dd) and conventional dose AC in patients with triple negative breast cancer (TNBC) under neoadjuvant treatment.Org: A.C. Camargo Cancer Center, São Paulo, Brazil, Brazil,
Abstract
Comparative analysis of Keynote522 treatment outcomes in Hispanic versus non-Hispanic patients with breast cancer: A single tertiary center experience.Org: Joe R. & Teresa Lozano Long School of Medicine, University of Texas Health and Science Center at San Antonio,
Abstract
Heterogeneity of immune status in patient-derived malignant pleural effusion and ascites: Relationship to the ex-vivo efficacy of a HER2-targeted tri-specific antibody and a novel cytokine fusion protein.Org: Nanjing JSIAMA Biopharmaceuticals Ltd, Nanjing JSIAMA Biopharmaceuticals Ltd., K2 Oncology Co. Ltd.,
Abstract
Pyrotinib plus taxanes or vinorelbine for human epidermal growth factor receptor 2-positive metastatic breast cancer: A prospective study.Org: Imaging Department, Jiangsu Cancer Hospital Medical Oncology, Jiangsu Cancer Hopistal,
Abstract
Efficacy and safety of disitamab vedotin (RC48) in HER2-expressing breast cancer: A multicenter retrospective study.Org: Guizhou University of Traditional Chinese Medicine, Affiliated Hospital of Zunyi Medical University, Department of Oncology, Guizhou Provincial People's Hospital, Zunyi Medical University, Department of Breast Surgery, Guizhou Provincial People's Hospital,
Abstract
Real-world efficacy and safety of inetetamab-based therapy in patients with HER2-positive metastatic breast cancer with prior trastuzumab exposure: A multi-center retrospective study.Org: Department of Breast Internal Medicine, Liaoning Cancer Hospital and Institute, Shenyang, China, Breast Cancer Center, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China, Cancer Center of First Hospital of Jilin University, Changchun, China, Anshan Cancer Hospital, Anshan, China, Institute of Oncology, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China,
Abstract
Efficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer (BC): A single-arm phase II trial.Org: Tianjin Cancer Hospital Airport Hospital,
Abstract
Novel oleanolic acid derivative ZQL-4c as a target for SCD to modulate lipid metabolism reprogramming to overcome trastuzumab resistance in HER2 positive breast cancer.Org: College of Pharmaceutical Science and Technology, Dalian University of Technology, Shenyang, Liaoning, China,
Abstract
Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting.Org: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shangai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
Efficacy and safety of HER2-ADC SHR-A1811 in HER2-positive breast cancer with brain metastases.Org: Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,
Abstract
Comparing the mutation profiles of primary HER2-positive breast cancers in patients with and without brain metastases.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
Evaluating the correlation between expression levels of carboxyl terminal modulator protein (CTMP) and the efficacy of trastuzumab in Syrian patients with HER2+ metastatic breast cancer.Org: Damascus University, Syrian Arab Republic,
Abstract
Innovative fiber optic–based approach of HER2 expression quantitative assessment using inPROBE technology.Org: SDS Optic Inc.,
Abstract
Clinical outcomes of patients with HR-positive advanced breast cancer treated with eribulin: A retrospective multicenter study from China.Org: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China, Cancer Center of First Hospital of Jilin University, Changchun, China, Department of Medical Oncology, Liaoning Provincial People's Hospital, Shenyang, China,
Abstract
Real-world analysis of inetetamab combined with pyrotinib plus chemotherapy for the treatment of HER2-positive advanced breast cancer: A multi-center retrospective study.Org: The First Hospital of Chongqing Medical University Affiliated Hospital, Zhangjiakou First Hospital, Guiyang Maternal and Child Health Hospital, Yancheng First People's Hospital,
Abstract
Clinical efficacy of pyrotinib combined with stereotactic radiosurgery in HER2-positive breast cancer brain metastases.Org: Guanghzou, China,
Abstract
T-DM1 in Chinese patients with Her2-positive metastatic breast cancer: A multi-center, retrospective, real world study.Org: National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Shougang Beijing University Hospital,
Abstract
Use of multimodal circulating tumor cell assay to detect HER2-ultralow and ER co-expression matched with single-cell chromosomal instability in metastatic breast cancer.Org: Epic Sciences, Inc., San Diego State University Department of Biology, San Diego, CA, La Jolla, CA,
Abstract
Effect of HER2-low expression on the efficacy of CDK4/6 inhibitors in breast cancer: A meta-analysis.Org: The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine Breast Center, The Second Clinical College of Guangzhou University of Chinese Medicine,
Abstract
Evaluation of AI-assisted HER2 scoring in breast carcinoma-stained whole-slide images.Org: DiaDeep, IHP Group, Pathology Department, IHP Paris,
Abstract
Unraveling the synergistic mechanisms of pyrotinib in combination with trastuzumab: Insights from the PHILA trial.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Molecular Oncology,
Abstract
Treatment of HER2 positive stage 4 breast cancer: When to stop anti-HER2 agents.Org: Nahanishi Clinic, Naha, Japan, Naha, Japan,
Abstract
The efficacy and safety of trastuzumab biosimilar HLX02 compared with reference trastuzumab plus pertuzumab in combination with chemotherapy as the first-line treatment for HER2 positive metastatic breast cancer: A real-world study in China.Org: Peking University Cancer Hospital & Institute, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China,
Abstract
Enhancing HER2 evaluation: Correlation of APIS Breast Cancer Subtyping Kit and IHC/ISH with accurate HER2 quantification.Org: APIS Assay Technologies Ltd., MVZ Prof. Dr. Med. A. Niendorf Pathologie Hamburg-West GmbH,
Abstract
Evaluating tumor inflammation and PD-L1 expression in sequential biopsies of real-world primary and metastatic breast cancer.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Duke University Medical Center, Duke Cancer Institute, Wake Forest Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC,
Abstract
Trends over time in liquid biopsy testing in patients with metastatic breast cancer (MBC) across the Mayo Clinic enterprise.Org: Mayo Clinic Health System Franciscan Healthcare in Sparta, Mayo Clinic Health System - La Crosse,
Abstract
Is early inclusion of neratinib with HER blockers possible in the treatment of stage 4 HER2 positive cancer?Org: Ilboza medical, Uzbekistan,
Abstract
Safety and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Fudan University Shanghai Cancer Center, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Expanding multiple features of extracranial metastasis to predict survival for patients with breast cancer brain metastasis: A population-based retrospective analysis.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Outcome with pertuzumab, docetaxel, and trastuzumab (PTH) regimen in patients with HER2 positive metastatic breast cancer: Real-world data from a single center in India.Org: Associate Consultant,
Abstract
Is HER2-negative breast cancer really negative? Clinical implication of novel assessment method using inPROBE technology.Org: Institute of Health Sciences Faculty of Medicine, The John Paul II Catholic University of Lublin,
Abstract
Trastuzumab-induced cardiotoxicity in patients with metastatic HER2-positive breast cancer treated at a reference hospital in Mexico.Org: Hospital de Oncologia Centro Medico Nacional Siglo XXI,
Abstract
Linking the companion diagnostic function of cancer genome profiling to therapy: Investigation of TMB-high predictors.Org: Hiroshima Prefectural Hospital, Hiroshima City North Medical Center Asa Citizens Hospital, JA Onomichi General Hospital, JA Hiroshima General Hospital,
Abstract
Interim safety analysis of phase IB trial of HER2 inhibitor tucatinib combined with PI3Kα inhibitor alpelisib in HER2+ PIK3CA-mutated metastatic breast cancer.Org: University of Colorado Health Cancer Care, University of Colorado Cancer Center, Louisiana State University Health Sciences Center Shreveport, University of Wisconsin, Mount Sinai Medical Center,
Abstract
Analysis of risk factors for recurrence within 12 months after surgery in patients with breast cancer receiving neoadjuvant therapy at a Brazilian cancer center.Org: A.C. Camargo Cancer Center, São Paulo, Brazil,
Abstract
Real-world data comparison of time to next treatment for patients with HER2 positive metastatic breast cancer treated in the second line of therapy with fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine.Org: South Carolina Oncology Associates,
Abstract
Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China.Org: National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Internal Medicine-Oncology, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, Shanxi Provincial Cancer Hospital, Taiyuan, China,
Abstract
Profile of breast cancer in patients with Li-Fraumeni syndrome: An institutional experience.Org: All India Institute of Medical Sciences (AIIMS), Rishikesh, India, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Dr. BRA-IRCH, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
The efficacy of PARP inhibitors in the treatment of patients with synchronous breast cancer.Org: Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Tashkent, Uzbekistan, Republican Specialized Scientific and Practical Center of Oncology and Radiology, Tashkent, Uzbekistan, Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Toshkent, Uzbekistan,
Abstract
Prevalence of somatic PIK3CA mutations in hormone receptor-positive metastatic breast cancer: The Indian experience.Org: All India Institute of Medical Sciences (AIIMS), Rishikesh, India, Dr. BRA-IRCH, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,
Abstract
Transcriptomic analysis of the tumor immune microenvironment (TIME) in patients with breast cancer with liver metastasis (BCLM).Org: Cedars-Sinai Cancer Huntington, Pasadena, CA,
Abstract
Mutational landscape of HER-2 low breast cancer.Org: University of California, San Francisco, UC Irvine Health, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, University of California, Irvine Medical Center,
Abstract
Risk predictors as companion diagnostics for ER positive, HER2 negative early staged breast cancers from India.Org: Cancer Institute (WIA), Chennai, India,
Abstract
SORBS1 expression as a biomarker for obesity and breast cancer prognosis: Insights from genomic analysis and survival outcomes.Org: Sidra Medicine, Shri Mata Vaishno Devi University, University of Kashmir, United Arab Emirates University, Translational Research Institute and Dermatology Institute,
Abstract
Patterns of progression in oligometastatic hormone receptor positive breast cancer after first-line systemic treatment at the metastatic stage.Org: Département de Chirurgie Oncologique,
Abstract
Cisplatin monotherapy as a treatment option for patients with HER-2–negative breast cancer facing hepatic visceral crisis or impending visceral crisis: A single-center cohort study.Org: The Maria Skłodowska-Curie National Research Institute of Oncology, Kraków Branch, Department of Oncology, Wrocław Medical University,
Abstract
Results of a retrospective study on the efficacy and safety of alpelisib in patients with HR+/HER2- metastatic breast cancer in real-world clinical practice.Org: Republican Clinical Oncological Dispensary of the Ministry of Health of the Republic of Bashkortostan, Ufa, Russian Federation, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation, Republican Clinical Oncology Dispensary, Ufa, Russian Federation, Republican Clinical Oncology Dispanceri, Ufa, Russian Federation, Federal State Budgetary Educational Institution of Higher Education "Bashkir State Medical University" of the Ministry of Health of the Russian Federation, Ufa, Russian Federation,
Abstract
Natural products to enhance anti-tumor effects of trastuzumab and paclitaxel on the SKBR3, which is human breast cancer cell line.Org: Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, Izmir International Biomedicine and Genome Institute, Department of Medical Pharmacology, Department of Medical Biology and Genetics,
Abstract
PIK3CA testing and treatment patterns among patients with metastatic breast cancer in US community clinical practice.Org: Genentech, Ellison Institute of Technology,
Abstract
The effects of anlotinib combined with chemotherapy following progression on cyclin-dependent kinase 4/6 inhibitor in hormone receptor-positive metastatic breast cancer.Org: Jiangsu Cancer Hospital, Nanjing, Jiangsu, China,
Abstract
Serial analysis of ESR1 and PIK3CA mutations in cell-free DNA from metastatic breast cancer during 1st line endocrine therapy.Org: Genopeaks Co., Ltd.,
Abstract
WITHDRAWN: Age-defined outcomes in patients with breast cancer treated with aromatase inhibitor therapy: Insights from a National Inpatient Sample Database analysis.Org: University of California, Riverside, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Community Hospital of San Bernardino, Trumbull Regional Medical Center, Western Reserve Health Education,
Abstract
Acceptance and usability testing of a visual care-navigation tool for patients, survivors, caregivers, nurses, and oncologists.Org: Manta Cares Inc.,
Abstract
Real-world experience with CDK4/6 inhibitors in the first-line palliative setting for HR+/HER2- advanced breast cancer.Org: Windsor, ON, Canada,
Abstract
Efficacy and safety of dalpiciclib, fulvestrant, and pyrotinib in HR+ HER2-low advanced breast cancer following cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and aromatase inhibitors (AIs): A Bayesian optimal phase II trial.Org: First Hospital of China Medical University,
Abstract
Effect of timing of recurrence on outcomes in patients with metastatic breast cancer treated with CDK4/6 inhibitors.Org: University of Rochester Medical School, James P. Wilmot Cancer Center - Pluta,
Abstract
Defining low-HER2 cancers using RNA quantification by next generation sequencing.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack Medical Center, NJ, Genomic Testing Cooperative, Irvine,
Abstract
Identifying mutations in ctDNA to predict antibody-drug conjugate response in breast cancer.Org: UT Southwestern Medical Center, Dallas, TX,
Abstract
A phase II trial of anlotinib and fulvestrant in patients with HR-positive and HER2-negative, secondary aromatase inhibitor–resistant, metastatic breast cancer.Org: The Third Hospital of Nanchang, Nanchang People's Hospital,
Abstract
Metastatic breast cancer in elderly women: A retrospective cohort study in Morocco.Org: University of Sidi Mohamed Ben Abdellah,
Abstract
Clinical utility of an ultra-sensitive ctDNA NGS assay for the detection and monitoring in HR-positive, HER2-negative breast cancer.Org: Huidu Shanghai Medical Sciences, Ltd.,
Abstract
The association between age, toxicity and outcomes of abemaciclib treatment in HR+/HER2- metastatic breast cancer.Org: Faculty of Medicine, University of Ljubljana,
Abstract
Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) in patients with HR-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) with PIK3CA mutations (m) in routine practice at several Russian centers.Org: Moscow Multidisciplinary Clinical Center "Kommunarka" of the Moscow Department of Health, Moscow, Russian Federation, SBIH Moscow Multidisciplinary Clinical Center "Kommunarka" of the Moscow Department of Health, Moscow, Russian Federation, Moscow City Oncology Hospital 62, Moscow, Russian Federation, Moscow City Oncology Hospital 62, Krasnogorskiy Rayon, Russian Federation, Moscow City Clinical Oncology Hospital No. 1, Moscow, Russian Federation,
Abstract
Dalpiciclib and chidamide in patients with HR+/HER2- advanced breast cancer and resistance to CDK4/6 inhibitors: A phase Ib trial.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China,
Abstract
The association of hormone receptor expression level and clinical efficacy of CDK4/6 inhibitor in hormone receptor-positive, HER2-negative metastatic breast cancer.Org: Department of Clinical Oncology, Queen Elizabeth Hospital, Queen Elizabeth Hospital, Hong Kong Sanatorium & Hospital,
Abstract
Evaluating the impact of GLP-1 receptor agonists on weight management in patients with breast cancer undergoing endocrine therapy: A comparative analysis.Org: University of Texas Health Sciences Center in San Antonio,
Abstract
The impact of vitamin D levels on the progression-free survival of women with hormone receptor-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors.Org: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,
Abstract
Use of Oncotype vs. Breast Cancer Index (BCI) for extended endocrine therapy decisions: A single center analysis in stage IA hormone receptor positive breast cancer.Org: UPMC Harrisburg, UPMC Cancer Center- UPMC Pinnacle,
Abstract
Toxicity differences in CDK 4/6 inhibitors seen in Asian and Pacific Islanders.Org: University of California Irvine, Los Angeles Medical Center, University of Hawaii Cancer Center, Honolulu, HI,
Abstract
Real-world treatment patterns and clinical outcomes among patients with HR+/HER2- advanced/metastatic breast cancer receiving palbociclib in Brazil: IRIS study.Org: Cerner Enviza,
Abstract
How overall survival is conditioned in the progression to treatment with cyclin inhibitors plus endocrine treatment in metastatic breast cancer with luminal phenotype.Org: Hospital Arnau de Vilanova de Lleida, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Arnau de Vilanova; GEICAM Spanish Breast Cancer Group,
Abstract
Real-world comparison of the efficacy of three CDK4/6 inhibitors (CDK4/6i) in the first-line treatment of endocrine-sensitive advanced breast cancer (aBC): Single institution experience.Org: School of Medicine, University of Zagreb, Department of Pathology, University Hospital Center Zagreb, Department of Pathology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Center,
Abstract
Comparative analysis of genomic tests for the prediction for late recurrence risk in hormone receptor–positive invasive breast cancer in a sample of Colombian patients.Org: Centro De Tratamiento e Investigación Sobre Cancer Luis Carlos Sarmiento Angulo,
Abstract
Employing semi-quantitative methods to classify breast cancer markers (ER, PR, HER2, Ki67) expression, using the RT-qPCR based APIS Breast Cancer Subtyping Kit.Org: APIS Assay Technologies Ltd., MVZ Prof. Dr. Med. A. Niendorf Pathologie Hamburg-West GmbH,
Abstract
Early tumor response in first‐line palbociclib plus AI in Chinese women with HR+/HER2- advanced breast cancer: Primary analysis of a multicenter, prospective real-world study.Org: The Affiliated People's Hospital of Ningbo University, Medical School of Zhejiang University,
Abstract
Fulvestrant and elacestrant utilization on prognostic outcome of patients with HR+ve/HER2-ve MBC.Org: Mediclinic City Hospital, TriNetX Europe,
Abstract
ESR1 mutations kit performance with SensID ESR1 reference set 1% AF.Org: APIS Assay Technologies Ltd.,
Abstract
Body composition measures as a determinant of alpelisib-related toxicity.Org: Sourasky Medical Center, Oncology Division,
Abstract
Genomic testing and uptake of alteration-targeted therapies among patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC).Org: Saint Luke's Hospital of Kansas City, University of Missouri-KC School of Medicine, Saint Luke’s Cancer Institute,
Abstract
Single institution retrospective review of patients with metastatic hormone receptor positive breast cancer receiving first line therapy of CDK4/6 inhibitors.Org: James Graham Brown Cancer Center,
Abstract
The analysis of prescribing CDK4/6 inhibitors for patients with breast cancer in real clinical practice.Org: City Clinical Oncology Dispensary, St. Petersburg City Clinical Oncology Dispensary, Saint Petersburg State University, Medical Faculty,
Abstract
Efficacy and safety of sacituzumab govitecan in HR+/HER2– advanced breast cancer: A comprehensive systematic review and meta-analysis.Org: The Frank H. Netter M.D. School of Medicine at Quinnipiac University, Samaritan Medical Centre, BronxCare Health System, Independent Research Associate,
Abstract
Co-occurrence of ESR1 and PIK3CA mutations in HR+/HER2- metastatic breast cancer: Incidence and outcomes with targeted therapy.Org: Plantation, Fort Lauderdale,
Abstract
Switching from nonsteroidal aromatase inhibitors to exemestane and its impact on menopausal symptoms.Org: Mount Sinai St. Lukes,
Abstract
Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University,
Abstract
Ethnic and clinical differences in gBRCA and HRD mutated breast and ovarian cancers and their response to PARP inhibitors.Org: Sheikh Shakbout Medical City, Sheikh Shakhbout Medical City in Partnership With Mayo Clinic,
Abstract
Frequency of dose reductions of abemaciclib in metastatic and early-stage hormone positive, HER2 negative breast cancer.Org: Scripps Clinic/Green Hospital, La Jolla, CA,
Abstract
Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2- advanced or metastatic breast cancer: A systematic review and meta-analysis.Org: Services Institute of Medical Sciences,
Abstract
Real-world data of efficacy and safety of denosumab on patients with breast cancer with bone metastasis: Results from Chinese clinical experience.Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China,
Abstract
Percutaneous cryoablation of breast cancer metastases: Analysis of long-term single center experience, efficacy and outcomes.Org: Biostatistics Core,
Abstract
Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis.Org: Faculdade de Medicina da Universidade de Sao Paulo,
Abstract
(CDK) 4/6 inhibitors: An effective treatment for homologous recombination deficient (HRD) luminal breast cancers (BC)?Org: UNEB,
Abstract
Subclonal mutational signatures in breast cancer brain metastases.Org: Barretos Cancer Hospital, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, Stanford University, Stanford, CA, California Pacific Medical Center Research Institute, San Francisco, CA, Women's Health Integrated Research Center at Inova Health System, Annandale, VA, Women’s Health Integrated Research Center at Inova Health System, Department of Defense Gynecologic Cancer Center of Excellence, Annandale, VA, Stanford University Medical Center, Palo Alto, CA, Pingtung Veterans General Hospital, Pingtung, South Korea,
Abstract
Phase I study of TQB3728 tablets, an oral inhibitor of apoptosis proteins in patients with advanced solid tumor.Org: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Prognostic factors for patients with breast cancer brain metastasis after stereotactic radiotherapy.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital,
Abstract
Clinical significance of supraclavicular lymph node (SCLN) dissection for patients with breast cancer with ipsilateral SCLN metastasis.Org: Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, the Central Hospital of Wuhan,
Abstract
Survival analysis of brain metastases secondary to breast cancer: A single-center experience.Org: Oregon Health & Science University, Portland, OR,
Abstract
Effect of tumorspheres cultured from circulating cancer stem cells on the innate checkpoint CD47 in patients with breast cancer.Org: Medical Laboratory of Dr. Pachmann, Bayreuth, Medical Laboratory Dr. Pachmann,
Abstract
Investigating the outcome of vascular emboli in patients with breast cancer.Org: Cadi Ayad University, Avicenne Military Hospital,
Abstract
4CAST: A phase 1b dose exploration, open-label, single-center study evaluating the safety of INO-464 in combination with chemotherapy in patients with metastatic breast cancer.Org: The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, NSW, Australia, St. Vincent's Hospital, Darlinghurst, NSW, Australia,
Abstract
Predictors of time to brain metastasis and survival in patients diagnosed with breast cancer.Org: Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL,
Abstract
Are we ready to use PSMA as a theranostic biomarker in clinical practice for patients with breast cancer?Org: Azienda Unità Sanitaria Locale (AUSL) Imola,
Abstract
Outcomes of personalized therapy guided by Exacta encyclopedic tumor analysis for women with broadly refractory advanced breast cancer.Org: Avinash Cancer Clinic,
Abstract
Differential efficacy of SV-BR-1-GM in inducing intracranial metastasis regression.Org: Froedtert & Medical College of Wisconsin, Mayo Clinic Florida, BriaCell Therapeutics Corp., Morehouse School of Medicine,
Abstract
A multicenter real-world study on the efficacy and safety of anlotinib-based treatment for metastatic breast cancer.Org: Department of Day Care,
Abstract
DNA methylation-based biological age and time to relapse in triple negative breast cancer.Org: University of Missouri Hospital, University of Missouri at Columbia, University of Missouri Columbia,
Abstract
Multicentric retrospective study on the treatment characteristics, efficacy and safety of eribulin in Slovenian patients with breast cancer.Org: University Medical Centre Maribor,
Abstract
Association between genetic susceptibility and mortality in triple-negative breast cancer.Org: The Pennsylvania State University, Geisinger Northeast, The Wright Center for Graduate Medical Education,
Abstract
Novel organoid platform for drug screening of patients with breast cancer.Org: Cellentia, Acrocyte Therapeutics Inc., New Taipei City, Taiwan,
Abstract
Efficacy and safety of apatinib combined with nab-paclitaxel for second-line treatment of metastatic triple negative breast cancer (TNBC): An open-label phase II trial.Org: Fujian Normal University,
Abstract
A genetically engineered epothilone analog as a novel oral microtubule inhibitor: A clinical study of utidelone capsule for advanced breast cancer.Org: National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Beijing Biostar Pharmaceuticals Co., Ltd., Beijing, China,
Abstract
Safety analysis for BH009 vs docetaxel from a bioavailability study.Org: Zhuhai Beihai Biotech Co, Ltd,
Abstract
Efficacy and safety of eribulin-based chemotherapy in patients with advanced breast cancer: A single-centre retrospective study.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital,
Abstract
ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), for the treatment of first-line metastatic triple negative breast cancer (mTNBC).Org: Weifang People's Hospital & The First Affiliated Hospital of Weifang Medical University, Department of Breast Surgery, Hubei Cancer Hospital Tongji Medical College Huazhong University of Science and Technology; Hubei Provincial Clinical Research Center for Breast Cancer; Wuhan Clinical Research Center for Breast Cancer, The Nanchang Third Hospital, The Second Affiliated Hospital, Zhejiang University School of Medicine, Department of Breast Surgery, Hubei Cancer Hospital Tongji Medical College Huazhong University of Science and Technology; Hubei Provincial Clinical Research Center for Breast Cancer, and Wuhan Clinical Research Center for Breast Cancer,
Abstract
Unveiling the complexity: Liquid biopsy-based proteomic exploration of triple-negative breast cancer in women.Org: FAMERP, CNPEM, UFMT, UNESP,
Abstract
Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: A single-centre retrospective study.Org: Fujian Normal University, Department of Breast Oncology, Fujian Cancer Hospital, Department of Oncology, Fujian Medical University Union Hospital, Department of Breast Medical Oncology, Fujian Cancer Hospital, Fuzhou University,
Abstract
A phase II trial combining SHR-1316, bevacizumab, and cisplatin/carboplatin in patients with TNBC with active brain metastases.Org: Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China,
Abstract
Real-world outcomes of sacituzumab govitecan in breast cancer.Org: Willis-Knighton Health System, Shreveport, LA,
Abstract
CNS efficacy of trastuzumab deruxtecan in metastatic breast cancer: A single-institution, real-world analysis.Org: UC San Diego, UC San Diego Moores Cancer Center,
Abstract
Dose escalation and expansion results from the phase I study of F0024, a trophoblast cell-surface antigen 2 (TROP2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.Org: Department of Medical Oncology/Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Ltd.,
Abstract
NSQIP audit of enhanced recovery after surgery protocols for radical cystectomy.Org: Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School,
Abstract
5-year multicenter analysis of clinical trial participation and total cost of care for older adults with cancer.Org: Sarah Cannon Research Institute (SCRI), SCRI Oncology Partners, The US Oncology Network, Texas Oncology,
Abstract
Evolution of germline BRCA1/2 testing practices: A five-year comparative analysis among oncology providers and patients.Org: North Memorial Health Cancer Center, Johns Hopkins Department of Surgery,
Abstract
Improving delivery of smoking cessation assistance for patients with cancer: Results of the Beyond ASK quality improvement.Org: Department of Surgery, University of Kentucky College of Medicine, Mailman School of Public Health, Columbia University,
Abstract
Early palliative care among patients diagnosed with advanced cancers in the US (2010-2019): Trends and contribution of provider variation.Org: Retired, MD, Department of Surveillance and Health Equity Science, American Cancer Society,
Abstract
Beyond the binary: A transformative implementation science initiative to improve LGBTQ+ cancer care.Org: Dana-Farber Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute, PRIME Education, LLC,
Abstract
Biologic and prognostic significance of HER2-low and ER-low expressions in de novo metastatic breast cancer.Org: Hebei Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Cang Zhou, China,
Abstract
Impact of trial eligibility criteria on enrollment to KRASG12C inhibitor trials in patients with non-small cell lung cancer.Org: NYP/Columbia,
Abstract
Patient-reported fatigue and risk of treatment-related adverse events (AEs) in patients receiving systemic therapy in cancer clinical trials.Org: SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center, Seattle, WA, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Carelon Medical Benefits Management,
Abstract
The toxicity swimmer plot: A novel approach for evaluating patient-level toxicity following immune checkpoint inhibitor (ICI) therapy on the Checkmate 214 trial.Org: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Georgetown-Lombardi Comprehensive Cancer Center, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center,
Abstract
Association of higher baseline stress and pain with clinical outcomes: Secondary analysis from Alliance A011502.Org: Channing Laboratory, Johns Hopkins Kimmel Cancer Center, Sweetwater Regional Cancer Center,
Abstract
Discrimination and disparities experienced among LGBTQ+ young adult cancer survivors (22-39) and adult cancer survivors (40+): A mixed-method study.Org: James P. Wilmot Cancer Center - Pluta, University of Rochester Medical Center, Rochester, NY, Virginia Commonwealth University School of Medicine, Richmond, VA,
Abstract
SNF-CLIMEDIN: A prospective randomized trial of digital intervention in patients with advanced NSCLC—A HeCOG study.Org: Care Across, London, United Kingdom, Molecular Oncology Laboratory, Hellenic Foundation for Cancer Research, Thessaloniki, Greece, Faculty of Social Sciences, University of East Anglia, Norwich, United Kingdom, Laboratory of Health Economics and management (LabHEM) Economics Department, University of Piraeus, Piraeus, Greece, Pulmonary Department, Lung Cancer Oncology Unit, Aristotle University of Thessaloniki, G. Papanicolaou Hospital, Thessaloniki, Greece,
Abstract
Fertility among young breast cancer survivors attempting pregnancy: A prospective, multicentre cohort study.Org: Dana-Farber Cancer Institute, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Mayo Clinic, Massachusetts General Hospital, Stanford Comprehensive Cancer Institute,
Abstract
A United Kingdom prospective, multicentre, observational cohort study investigating tolerance of anti-cancer systemic therapy in the elderly: The TOASTIE study.Org: The Beatson West of Scotland Cancer Centre, Freeman Hospital, NHS, Northern Ireland Cancer Centre, Singleton Hospital, Respiratory Department, Northumbria Healthcare NHS Foundation Trust,
Abstract
A retrospective, descriptive analysis of a single-center experience with patients with metaplastic breast cancer.Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida,
Abstract
Human-AI teams to improve accuracy and timeliness of oncology trial prescreening: Preplanned interim analysis of a randomized trial.Org: Perelman School of Medicine, University of Pennsylvania, Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania Perelman School of Medicine,
Abstract
AI-assisted clinical summary and treatment planning for cancer care: A comparative study of human vs. AI-based approaches.Org: Need Inc., Schulich School of Medicine and Dentistry, London Regional Cancer Center,
Abstract
Disparities uncovered: LGBTQ+ patients report on their cancer care journey.Org: South Weymouth, MA, Prime Education, Inc.,
Abstract
Real-world data comparison of time to next treatment for patients with HER2 low metastatic treated with either chemotherapy or fam-trastuzumab deruxtecan-nxki following chemotherapy in the metastatic setting.Org: University of Pittsburgh Medical Center (UPMC), Integra Connect PrecisionQ, Highlands Oncology Group, South Carolina Oncology Associates, Integra Connect,
Abstract
The transformative role of digital health platforms: Bridging diversity gaps in cancer care in younger patient populations.Org: Leal Health, formerly Trialjectory, Clifton, NJ,
Abstract
Association between patient tumour characteristics and five-year survival in Nigerian patients with breast cancer.Org: Lagos University College of Medicine/Teaching Hospital, University of Nigeria Teaching Hospital,
Abstract
Assessing the environmental and downstream human health impacts of decentralizing cancer care.Org: Dana-Farber Cancer Institute, Massachusetts General Hospital,
Abstract
Utilization of PARP inhibitors in the management of ovarian cancer in Nigeria.Org: Holy Name Medical Center, Windsor University School of Medicine, State Specialist Hospital, New Vision University Hospital, ABUAD Multisystem Hospital,
Abstract
Antibody-drug conjugates (ADC) in patients with advanced/metastatic HER2-low expressing breast cancer: A systematic review and meta-analysis.Org: Catholic University of Pelotas, RS, Brazil, Pelotas, Brazil, Universidade Estadual do Centro Oeste (UNICENTRO), Guarapuava, Brazil, Federal University of Amazonas - UFAM, Manaus, Brazil, University of Brasilia, Brasilia, Brazil,
Abstract
EGFR mutation testing trends for patients with metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) in Queensland, Australia from 2014-2021.Org: Gold Coast University Hospital, Griffith University School of Medicine and Dentistry, Cancer Alliance Queensland, Sunshine Coast Hospital and Health Service,
Abstract
Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.Org: Winship Cancer Institute of Emory University, Atlanta, GA, University of Alabama at Birmingham, Birmingham, AL, University of California, San Francisco, San Francisco, CA, University of California, San Diego, La Jolla, CA, UC Davis Comprehensive Cancer Center, Sacramento, CA,
Abstract
Bridging gaps with navigator support and its influence on breast cancer clinical trial matching and accessibility.Org: Quantum Leap Healthcare Collaborative, University of California Irvine, Helen Diller Family Comprehensive Cancer Center,
Abstract
Optimizing colorectal cancer screening outreach: A probability-based strategy by Temple University Hospital.Org: Temple University Hospital, Philadelphia, PA,
Abstract
Impact of quality of life and geographic distance on radiation adherence in patients with locally advanced cervical cancer residing in rural areas.Org: Petre Shotadze Tbilisi Medical Academy,
Abstract
Barriers to enrollment in clinical trials in gynecologic oncology.Org: NewYork Presbyterian Hospital Columbia/Cornell, Division of Gynecologic Oncology, University of Pennsylvania,
Abstract
Mechanisms of mammalian orthoreovirus-induced cell death and NF-kB activation in ER+ breast cancer.Org: Iowa State University,
Abstract
A cancer center department of supportive oncology: Patient demographic characteristics.Org: Department of Supportive Oncology, Atrium Health Levine Cancer Institute,
Abstract
Access to care for blood cancer: Allogeneic hematopoietic cell transplant caregiver requirements.Org: University of Wisconsin-Madison Carbone Cancer Center, NMDP,
Abstract
Effect of a novel artificial intelligence (AI) –enabled multi-trial matching system on patient matching using real-world data.Org: Massive Bio, Capital Health Medical Center - Hopewell Campus,
Abstract
Barriers to accessing cancer care from patients’ perspective: A single cancer center experience.Org: Jefferson Einstein Medical Center, Philadelphia College of Osteopathic Medicine,
Abstract
A simple and data-driven framework to foster multidisciplinary and timely care in resource-limited settings: A pilot program in Argentina.Org: Hospital Carlos G. Durand, Argentina,
Abstract
Factors associated with delay in breast biopsy in a vulnerable population.Org: Louisiana State University Shreveport, Louisiana State University Health Sciences Center - Shreveport, Louisiana State University Shreveport Program,
Abstract
Understanding barriers to guideline-concordant treatment in foregut cancer: From data to solutions.Org: Kellogg School of Management,
Abstract
Expanding diversity in colorectal cancer studies with a focus on Hispanic and Latino participant enrollment.Org: I.H.S Health, LLC,
Abstract
Effect of mail-in sperm cryopreservation solution on access to cryopreservation: A national demographic analysis.Org: Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, Department of Urology and Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, Fellow Health, San Leandro, CA,
Abstract
Primary health clinicians' attitudes towards liquid biopsy as diagnostic test for advanced lung cancer.Org: University of Otago, Wellington, University of Waikato, Wellington Blood and Cancer Services,
Abstract
Fresh frozen plasma (FFP) for hypogammaglobulinemia (HypoG) in patients (Pts) with recurrent infections (Infxs) after B-cell directed treatment: A single institution experience with economic impact analysis.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, MaineHealth Cancer Care,
Abstract
Tracking the FDA precision oncology drug approval landscape in OncoKB.Org: Memorial Sloan Kettering Cancer Center, Center for Molecular Oncology, Department of Pathology and Laboratory Medicine,
Abstract
Improving access to infusion services: Results of an operational sprint.Org: Miami Cancer Institute - Baptist Health South Florida,
Abstract
FIT as a population-based and financially viable method to screen underserved patients for colorectal cancer.Org: Temple University Hospital, Philadelphia, PA,
Abstract
Disparities in access to antineoplastic immunotherapy and outcomes by insurance status: A nationwide analysis.Org: State University of New York, Upstate Medical University, University of Missouri-Columbia, School of Medicine,
Abstract
Timeframe for lymphedema therapy for head and neck cancer survivors.Org: Vanderbilt University Medical Center,
Abstract
Characterization of cancer clinical trials in the community setting.Org: Flatiron Health, San Francisco, CA, New York Oncology Hematology PC, Nykode Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA,
Abstract
Enrollment strategies to promote inclusion in a colorectal cancer screening study.Org: Moskowitz Practice, Freenome Holdings, Inc,
Abstract
Effect of a comprehensive cancer care pathway and a navigation cancer program on breast cancer care in a middle-income country.Org: Fundacion Centro de Tratamiento e Investigacion Sobre Cancer, Centro de Tratamiento e Investigacion Sobre Cancer CTIC, Fundacion Centro de Tratamiento e Investigacion Sobre Cancer CTIC,
Abstract
Practice patterns in prostate cancer therapy among healthcare professionals: Comparison with expert recommendations from an online tool.Org: Clinical Care Options, LLC, City of Hope Comprehensive Cancer Center, University of California, San Diego Health, Division of Hematology & Oncology, University of Washington & Fred Hutchinson Cancer Center, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine,
Abstract
MET exon 14 skipping in NSCLC: An unMET Indian need.Org: Rajiv Gandhi Cancer Institute and Research Center, Tata Memorial Hospital, Tata Memorial Centre,
Abstract
Incidence of germline genetic testing in Veterans with breast cancer in the Veterans Health Administration.Org: VA Salt Lake City Health Care, VHA National Oncology Program Office,
Abstract
Factors associated with delays in receipt of neoadjuvant chemotherapy in patients with operable breast cancer.Org: Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Columbia University Irving Medical Center, New York, NY, USA, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Gynecologic Oncology, University of Pennsylvania,
Abstract
Impact of a proactive patient assistance program for diverse ambulatory oncology patients: A retrospective cohort study.Org: Health Options LLC,
Abstract
“What you're hearing from all of us is simplify the language”: A focus group study on biomarker testing in oncology.Org: Ovarian Cancer Research Alliance,
Abstract
Improving sleep outcomes in patients with cancer with chronic insomnia using cognitive behavioral therapy: A retrospective study.Org: Miami Cancer Institute - Baptist Health South Florida,
Abstract
Informing optimal treatment (tx) sequences for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma (la/mUC) in the United States: Results of a clinical simulation modeling exercise.Org: Evidera, Inc, EMD Serono Research & Development Institute, The Healthcare Business of Merck KGaA,
Abstract
Exploring the potential of the traditional Indian system of medicine, Ayurveda, for developing an evidence-based integrative model of cancer care in elderly patients with cancer.Org: Rasayu Cancer Clinic, Pune, India,
Abstract
Impact of a care delivery intervention for patients with socioeconomic disadvantages, in their preferred language of English or Spanish.Org: Rosalind Franklin University of Medicine and Science Chicago Medical School,
Abstract
Delays in receipt of neoadjuvant chemotherapy compared to upfront surgery in patients with operable breast cancer.Org: Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Columbia University Irving Medical Center, New York, NY, USA, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Gynecologic Oncology, University of Pennsylvania,
Abstract
Barricades to aiding cascading: Patient-reported barriers to uptake in the context of clinician-facilitated cascade testing for hereditary cancer syndromes.Org: Weill Cornell Medicine, New York, NY,
Abstract
Application of multidisciplinary team model based on full-course management in health promotion of patients with breast cancer.Org: Nanjing Medical University,
Abstract
Objective acuity measures for infusion therapy staffing: A predictive model approach—Phase I.Org: Clinton, Elgin,
Abstract
Contemporary management of patients with advanced melanoma: Utility of an online interactive decision support tool to assess concordance of healthcare professional treatment patterns with expert recommendations.Org: Clinical Care Options, LLC, Stanford Cancer Institute, University of California, San Francisco, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,
Abstract
Screening for social determinants of health among patients with advanced and metastatic cancer undergoing comprehensive genomic profiling in underserved communities.Org: Carolina Blood and Cancer Care Associates, Rock Hill, SC, Laboratory Corporation of America, Burlington, NC,
Abstract
Greening Ireland’s oncology practice: Reducing climate toxicity and improving sustainability in a national chemotherapy formulary.Org: Bon Secours Cork Cancer Centre,
Abstract
Treatment rates and reasons for non-treatment in a real-world cohort of patients with pancreatic cancer.Org: Gastrointestinal Oncology, Northern California, Downey,
Abstract
A retrospective machine learning–based analysis of nationwide cancer comprehensive genomic profiling data to identify features associated with recommendation of mutation-based therapy.Org: Division of Integrative Genomics, Department of Clinical Genomics, The University of Tokyo Hospital,
Abstract
Oncology triage utilization among patients with gynecologic cancers.Org: Northwestern Memorial Hospital, Chicago, IL, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University,
Abstract
Predicting persistent fever in patients with cancer using machine learning.Org: Department of Hematology & Stem Cell Transplantation, West German Cancer Institute, Essen, Germany, Institute for Artificial Intelligence in Medicine, Essen, Germany, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany, University Hospital Essen, Essen, Germany, Department of Hematology & Stem Cell Transplantation, University Hospital Essen, Essen, Germany, Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany,
Abstract
Representativeness of race, ethnicity and social determinants of health in patients with advanced non-small cell lung cancer via linkage of real-world electronic health records, administrative claims, and consumer financial data.Org: North Chicago, IL,
Abstract
The unmet needs of women with metastatic breast cancer in Mexico: A qualitative study.Org: Department of Medicine, Yale University School of Medicine, New Haven, CT, Palliative Care Service, Instituto Nacional de Cancerología, Mexico City, Mexico, Médicos e Investigadores en la Lucha contra el Cáncer de Mama (MILC), Mexico City, Mexico, Instituto Nacional de Cancerología, Mexico City, DF, Mexico, Departamento de Oncología Médica, Instituto Nacional de Cancerología, Mexico City, DF, Mexico, Médicos e Investigadores en la Lucha contra el Cáncer de Mama (MILC), Mexico City, DF, Mexico, Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza Garcia, NL, Mexico,
Abstract
Expanding access to care through physician and medically integrated dispensing: Legal and regulatory considerations.Org: Frier Levitt, Pine Brook,
Abstract
Non-receipt of targeted and immunotherapies in diverse patients with metastatic cancers.Org: Keck School of Medicine of the University of Southern California,
Abstract
Rapid label expansion based on public-private collaboration in IMPRESS-Norway.Org: Oslo University Hospital-Norwegian Radium Hospital, Department of Cancer Immunology, The Arctic University of Norway, Centre for Cancer Biomarkers CCBIO,
Abstract
Clinicians' experiences and perspectives of a web-based lung cancer referral pathway.Org: James Cook University,
Abstract
Retrospective study on the correlation between MASCC score and the evolution of febrile neutropenia for patients with solid cancer.Org: CISSS Monteregie-Centre, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke (CRCHUS),
Abstract
From what works to what matters: Whole person cancer care and the integrative oncology leadership collaborative (IOLC).Org: Dayton VA Medical Center, Healing Works Foundation, Sidney Kimmel Cancer Center at Jefferson university, University of Calgary, Cumming School of Medicine, Anne Arundel Medical Center, Luminis Health,
Abstract
NGS panels' capture of biomarkers associated with targeted therapies in clinical trials.Org: Illumina, Inc.,
Abstract
Assessing the landscape of integrative oncology at US comprehensive cancer centers (CCC).Org: City of Hope National Medical Center, City of Hope National Comprehensive Cancer Center,
Abstract
Optimizing clinical research in a regional cancer center network: A survey-based approach.Org: Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Impact of staffing an inpatient oncology consult service with dedicated hospital-based oncologists.Org: San Francisco, San Francisco, CA, San Francisco Helen Diller Family Comprehensive,
Abstract
The structure of academic cancer service lines: Results of an Association of American Cancer Institutes survey.Org: Virginia Commonwealth University Massey Comprehensive Cancer Center, Association of American Cancer Institutes,
Abstract
Effect of alternative dosing strategies on sustainable healthcare: A carbon footprint analysis of nivolumab and pembrolizumab treatment in the Netherlands.Org: Erasmus University Medical Center, Rotterdam, Netherlands,
Abstract
Similarities and differences of lung cancer (LC) multidisciplinary teams (MDTs) in China compared to Europe and Canada.Org: Vintura, Lung Cancer Center, Xiangya Hospital, Central South University, Lung Cancer Center, West China Hospital,
Abstract
Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): Updated results from a single-center, real-world study.Org: Jiaotong University,
Abstract
Relationship between immune phenotype and treatment selection of Chemo-IO vs. IO-only in TPS-high NSCLC using hypothetical test-and-control group generation based on survival data extracted from phase III trials.Org: Oncology Therapeutic Development, Lunit Inc.,
Abstract
A propensity-matched cohort study of neoadjuvant immunotherapy combined with chemotherapy versus neoadjuvant chemotherapy for early-stage triple-negative breast cancer.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Learning from Black patients with TNBC to implement equitable cancer care.Org: Stone Ridge, Branford,
Abstract
Association between GPRC5A expression and carboplatin efficacy in triple-negative breast cancer patients.Org: Jiangsu Province Hospital, Nanjing, China, Department of General Surgery, the First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China,
Abstract
Identifying and addressing real-world challenges to triple-negative breast cancer (TNBC) care: A quality improvement initiative.Org: Florida Oncology & Hematology,
Abstract
Effect of transcription factor WT1 on triple-negative breast cancer metastasis through PFKFB4-mediated glycolysis.Org: Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Key Laboratory of Minimally Invasive Surgery and Precision Treatment for Breast Cancer of Chongqing Municipal Health Commission, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Sounthwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Department of Thoracic Surgery, the Eighth Medical Center of Chinese PLA General Hospital, Chongqing, China, Central Medical Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. L., Nanjing, China, Key Laboratory of Minimally Invasive Surgery and Precision Treatment for Breast Cancer of Chongqing Municipal Health Commission, Chongqing, China, Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University,
Abstract
The role of stress in modulating AIPB expression and estradiol synthesis in triple-negative breast tumors.Org: Savannah, GA,
Abstract
Treatment patterns of adenoid cystic carcinoma of the breast: A systematic review.Org: Center for Advance Medicine, R.J. Zuckerberg Cancer Center, Brown Cancer Center, Robert Wood Johnson Library of the Health Sciences,
Abstract
Activation of dendritic cells by a synthesized small molecule for breast cancer vaccination.Org: The Hong Kong Polytechnic University,
Abstract
The long noncoding RNA MANCR to promote and stabilize triple negative breast cancer.Org: University of Vermont Larner College of Medicine,
Abstract
Clinical, histopathological, and molecular biomarkers in a multicentric cohort of Mexican women with triple-negative breast cancer.Org: Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, NL, Mexico, Instituto de Investigaciones Biomédicas, Mexico City, DF, Mexico, Centro de Cáncer de Mama, TecSalud,
Abstract
Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multicenter, open-label, single-arm, phase II study.Org: The Cancer Center of the Fifth Affiliated Hospital, The First People's Hospital of Zhaoqing, Jiangmen Central Hospital, Zhuhai Maternity and Child Health Hospital, Zhuhai Hospital of lntegrated Traditional Chinese and Western Medicine,
Abstract
Prevalence of “HER2 ultra-low” among patients with advanced breast cancer with historical IHC0 status.Org: nference Inc., AstraZeneca LLC,
Abstract
Analysis of regulation of cell death pathway genes in CSC-enriched TNBC after treatment with doxorubicin: A potencial biomarker.Org: Nova Lima, MG, Brazil, Fundação Ezequiel Dias, Nova Lima, Brazil,
Abstract
A phase II trial of anlotinib combined chemotherapy as second-line and above therapy in HER2-negative advanced breast cancer.Org: Jiangsu Cancer Hospital, Nanjing Yoko Biomedical, Jiangsu HengRui Medicine, China National Biotec Group, The Affiliated Cancer Hospital of Nanjing Medical University,
Abstract
Mutations and mortality in very young patients with breast cancer.Org: Ochsner Clinic Foundation, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Ochsner Health Center,
Abstract
Impact of aromatase inhibitors on mortality and hospitalization costs in patients with breast cancer: A National Inpatient Sample analysis 2020.Org: Jacobi Medical Center/North Central Bronx, NYC Health and Hospitals, Northwell Health, New Hyde Park, NY,
Abstract
Cryptolepine: A naturally derived alkaloid inhibits breast cancer progression by blocking cell cycle progression and inducing apoptosis.Org: University of Kashmir, Srinagar, India,
Abstract
Frequency of HER2-Low in breast cancer biopsies in Chile.Org: Clínica Santa María, Universidad Finis Terrae,
Abstract
Effect of AURKA targeting on nuclear PD-L1 and the efficacy of immune checkpoint inhibitors in triple-negative breast cancer.Org: Mayo Clinic, Rochester, MN,
Abstract
Clinical features and outcomes of patients with breast cancer with leptomeningeal carcinomatosis.Org: University of California, San Diego Medical Center, UC San Diego Moores Cancer Center, University of California, San Diego Center for Advanced Laboratory Medicine,
Abstract
A phase Ia/b trial of ARX788 combined with toripalimab for HER2-low advanced breast cancer (ABC) and other HER2-expressing solid tumors.Org: Department of Breast Medical Oncology, Fujian Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Center of Hepato-Pancreato-Biliary Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, First Affiliated Hospital of Wannan Medical College, Sun Yat-sen University Cancer Center Gansu Hospital,
Abstract
Study of single live circulating tumor cells capture and their genomic profile and enriched mutations of PIK3CA and HRR pathway in patients with breast cancer.Org: Stanford University School Medicine, Indx Technology, Indx.ai, School of Consciousness, MIT WPU, Yashoda Hospital,
Abstract
The role of epithelial-mesenchymal transition markers in invasive breast cancer among patients of Arab descent.Org: Al Assad University Hospital, Harper Prof Bldg, Ascension St. John Hospital,
Abstract
Evaluation and treatment response in patients with hormone receptor-positive, HER2 low metastatic breast cancer: A single center retrospective analysis.Org: Henry Ford Hospital, Detroit, MI,
Abstract
Novel prognostic staging system for patients with de novo metastatic breast cancer: A real-world experience.Org: University of Missouri KC-School of Medicine,
Abstract
A meta-analysis of the difference in response to trastuzumab-deruxtecan (T-DXd) based on HER2 immunohistochemistry (IHC) in HER2 low metastatic breast cancer (mBC).Org: SUNY Upstate University Hospital, SUNY Upstate Medical University, SUNY Upstate Medical Center,
Abstract
Closing classification gaps in luminal breast cancer with single-cell RNA-seq insights from normal breast lineages.Org: Corp.,
Abstract
Landscape of HER2-low breast cancer: Insights from a six-year study on incidence and clinicopathological characteristics.Org: Saint Joseph University of Beirut, Hotel-Dieu de France,
Abstract
Implementation of a virtual tumor board through VA National TeleOncology service.Org: VA Health Care System, VA Pittsburgh Healthcare System,
Abstract
Everolimus for advanced breast cancer: Is the histological subtype important?Org: Hospital Universitario Reina Sofía, Virgen Macarena University Hospital, Virgen de las Nieves Hospital, Jaen University Hospital,
Abstract
Perspectives on clinical adoption barriers to blood-based multi-cancer early detection tests across stakeholders.Org: Health Advances, LLC, Personalized Medicine Coalition, Health Advances LLC,
Abstract
Workforce evaluation in the field of radiation oncology: National data from a limited-resource setting.Org: National Center of Oncology named after V.A. Fanarjyan, Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center After R.Yeolyan,
Abstract
Impact of preparation and execution of strategy to mitigate the platinum shortage within a network of community oncology practices.Org: Rocky Mountain Cancer Centers/The US Oncology Network, Boulder, CO,
Abstract
Optimizing the oncology ecosystem: Addressing barriers between community and academic oncologists.Org: University of Maryland Medical Center,
Abstract
Engaging student volunteers in non-clinical navigation: ACS community access to resources, education, and support (ACS CARES).Org: American Cancer Society, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, University of Iowa Hospitals and Clinics, Medical University of South Carolina Hollings Cancer Center, University of California Irvine,
Abstract
Use of bispecific antibodies (BsAbs) in community practices: Key attributes to develop logistics and workflow for management of cytokine release syndrome (CRS).Org: Tennessee Oncology, PLLC, Chattanooga, TN, Nashville, West Cancer Center & Research Institute,
Abstract
Utilization and trends of BRAF and MEK inhibitors among Medicare D patients: 2013-2021.Org: West Virginia University School of Medicine, George Washington University School of Medicine and Health Sciences, West Virginia University Department of Medicine,
Abstract
Improving LDCT screening rates within a large multidisciplinary community based practice using integrated ACR accredited imaging centers.Org: New York Imaging Specialists,
Abstract
Large language foundation models encode clinical radiation oncology domain knowledge: Performance on the American College of Radiology Standardized Examination.Org: ArteraAI,
Abstract
Comparing literature-based cell-free miRNA panels to whole genome miRNA screening for cancer detection.Org: Pharus Diagnostics (Pharus, Inc.),
Abstract
Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials.Org: University of Utrecht, Yale Center for Analytical Sciences,
Abstract
Financial impact of fixed-dose versus weight-based dosing approaches for pembrolizumab and nivolumab in the Oncology Care Model for The US Oncology Network (The Network).Org: McKesson, The US Oncology Network, The Woodlands, TX,
Abstract
Natural language processing for automated breast cancer recurrence detection and classification in computed tomography reports.Org: Department of Computer Science, Division of Plastic Surgery,
Abstract
Use of a deep learning model on H&E slides to predict nucleic acid yield for NGS testing.Org: Tempus AI, Chicago, IL, Il-Yang Pharmaceuticals,
Abstract
A transfer learning-based graph neural network model using mIF images to predict neoadjuvant immunochemotherapy response in patients with gastrointestinal cancer.Org: The Second Affiliated Hospital of Harbin Medical University, Tangshan Workers' Hospital,
Abstract
Automated survivorship care plan generation using large language models.Org: University of Illinois Urbana-Champaign,
Abstract
Real-world performance of the digital drug-assignment system for precision oncology in lung cancer.Org: Department of Pulmonology, Matrahaza University and Teaching Hospital, Matrahaza, Hungary, Oncompass Medicine, Budapest, Hungary, Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Budapest, Hungary, MIND Clinic, Budapest, Hungary, Genomate Health Inc, Genomate, MA,
Abstract
Tumor origin identification through machine learning and gene expression profiling.Org: HaploX Biotechnology, Shenzhen, China,
Abstract
An unsupervised H&E-based machine-learning approach for precise prediction of tumor microenvironment subtypes.Org: BostonGene Corporation, Corp.,
Abstract
Improving dynamic prognostication of patients with hepatocellular carcinoma by node fusion algorithm equipped survival path mapping.Org: Department of Minimally Invasive Interventional Therapy,
Abstract
Development and validation of MOSPROC, an easily applicable predictive score of mortality for patients with prostate cancer.Org: Topazium Artificial Intelligence,
Abstract
Identification of genes related to PD-L1 expression in non-small cell lung cancer (NSCLC) tumor samples by GFPrint, a machine learning framework (MLF).Org: Topazium, Topazium Artificial Intelligence, Biomakers SA,
Abstract
Multi-institutional validation survey on Belong.life's conversational artificial intelligence (AI) oncology mentor, "Dave.Org: Shaarei Tzedek Medical Center, Assuta Ashdod University Medical Center, Ichilov Hospital, Belong.Life,
Abstract
Treatment patterns among HCPs and concordance with expert recommendations in HER2-negative early breast cancer: Analysis of an interactive online treatment decision support tool.Org: Cancer Center Stanford,
Abstract
Clinical large language model to predict loss to follow up for oncology patients discharged to skilled nursing facilities.Org: University of Florida Department of Health Outcomes and Biomedical Informatics, University of Florida Department of of Health Outcomes and Biomedical Informatics, Department of Health Outcomes and Biomedical Informatics,
Abstract
Pan-cancer G2C-Pro: A two-stage Gaussian clustering to prognostically stratify patients with advanced tumors treated with immune checkpoint inhibitors.Org: Department of Clinical, Special, and Dental Sciences (DISCO),
Abstract
Artificial intelligence–aided lung cancer screening in routine clinical practice: A pilot of LungFlag at Geisinger.Org: Roche Information Solutions, Roche Molecular Systems Inc.,
Abstract
Impact of Exigent Research Network’s partnership with the Tempus AI TIME Program on the screening and matching of patients for clinical trials.Org: Hematology Oncology Associates of CNY, Cancer Care Associates of York, Utah Cancer Specialists, New Jersey Cancer Care, Cancer Care Northwest,
Abstract
OncoGPT: Enhancing oncological decision-making with ASCO guideline–trained AI.Org: The Ohio State University - James Cancer Hospital, Columbus, OH, Thomas Jefferson University, Philadelphia, PA,
Abstract
Large language models for precision oncology: Clinical decision support through expert-guided learning.Org: Department of Gynecology and Center for Hereditary Breast and Ovarian Cancer, University Hospital rechts der Isar, Technical University of Munich (TUM), Munich, Germany, Department of Medicine III, University Hospital rechts der Isar, Technical University of Munich (TUM), Munich, Germany, Department of Medicine II, University Hospital rechts der Isar, Technical University of Munich (TUM), Munich, Germany, Institute of Pathology, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany, Center for Personalized Medicine (ZPM), University Hospital rechts der Isar, Technical University of Munich (TUM), Munich, Germany,
Abstract
AI-based quantification of TILs using hematoxylin and eosin and immunohistochemistry-stained slides in triple-negative breast cancer.Org: Biomy Inc., National Hospital Organization (NHO) Hokkaido Cancer Center, Hokkaido University Hospital Cancer Center, Center of Development of Advanced Diagnostics, Graduate School of Medicine, The University of Tokyo,
Abstract
Clustering analysis for predicting racial disparities in genitourinary cancer–related financial burden.Org: Baptist Health South Florida, Corewell Health William Beaumont University Hospital, CK-12 Foundation, Miami Cancer Institute - Baptist Health South Florida, Stanford University School of Medicine,
Abstract
Retrieval-augmented large language models for clinical trial screening.Org: Memorial Sloan Kettering Cancer Center, National University of Singapore, National Cancer Centre Singapore, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Exploring AI-generated content and professional guidelines in cancer symptom management: A comparative analysis between ChatGPT and NCCN guidelines.Org: University of Pittsburgh Medical Center (UPMC), Palliative Research Center (PaRC) and Department of Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of General Internal Medicine and Health Services Research, University of California, Los Angeles, Los Angeles, CA, Section of Palliative Care and Medical Ethics,
Abstract
A meta-analysis of models for predicting the incidence of brain metastasis in patients with lung cancer.Org: CK-12 Foundation,
Abstract
Prospective assessment of AI-enabled cost savings, continuous support, and psychosocial enhancement (AI New Era Study).Org: Hangzhou Institute of Medicine Cancer Hospital (Zhejiang Cancer Hospital), Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), OrigiMed Internet Hospital, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University,
Abstract
Feasibility study utilizing a combinatorial functional precision medicine platform, Optim.AI, to help guide treatment for pancreatic cancer.Org: Kyan Technologies Pte Ltd,
Abstract
Utility of liquid biopsy for predicting cancer type and informing treatment of carcinoma with unknown primary.Org: Geneseeq Research Institute, Nanjing Geneseeq Technology Inc.,
Abstract
Development of a video-based deep learning model for differentiation of malignant and benign lesions during staging laparoscopy: Is the machine better than the expert?Org: Department of Human Structure and Repair, Faculty of Medicine, Ghent University, Ghent, Belgium, Center for Biosystems and Biotech Data Science, Ghent University Global Campus, Incheon, South Korea, Department of Human Structure and Repair, Ghent University Faculty of Medicine, Ghent, Belgium, Department of Pathology, Ghent University Hospital, Ghent, Belgium, Department of Gastrointestinal Surgery, Ghent University Hospital, Ghent, Belgium,
Abstract
A digital pathology AI model to predict immune-oncology biomarker status and pembrolizumab response in a real-world cohort of patients with colorectal and breast cancer.Org: Caris Life Sciences, Irving, TX,
Abstract
Evaluating generalizability of landmark randomized controlled trials in common metastatic cancers using machine learning-based emulated trials.Org: Navajo Indian Health Service,
Abstract
Changes in non-small cell lung cancer (NSCLC) next-generation sequencing (NGS) rates after electronic health record (EHR) integration using large-scale, multi-institutional, real-world data.Org: Ochsner Health Center, Tempus AI,
Abstract
Automating the detection of treatment progression in patients with lung cancer using large language models.Org: University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center (UPMC),
Abstract
Prediction of therapeutic response and cancer outcomes in solid tumours via in silico clinical trials.Org: Concr LTD, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow,
Abstract
Quantifying clinical actionability of updated tumor profiling reports through electronic health record (EHR)-enabled, on-demand ordering and resulting.Org: Trihealth Cancer and Blood Institute,
Abstract
A web-based, LLM-powered AI symptom summarization tool (ASST) for monitoring of breast cancer treatment toxicity.Org: Stanford Medicine Cancer Center,
Abstract
Novel approach to implementing natural language processing for clinical staging of non-small-cell lung cancer.Org: Office of Health Informatics and Analytics, UCLA Department of Medicine,
Abstract
Reliability of YouTube content targeting Arabic-speaking patients with breast cancer regarding post-mastectomy reconstruction.Org: Monteal, Taif University,
Abstract
Assessing ChatGPT's potential as a clinical resource for medical oncologists: An evaluation with board-style questions and real-world patient cases.Org: VCU/Massey Comprehensive Cancer Center, Veterans Affairs Medical Center, Virginia Commonwealth University School of Medicine,
Abstract
AI-generated synthetic clinical-genomic data for precision oncology research: Validation using a case study on lung adenocarcinoma.Org: Medisyn Inc., Guardant Health Inc., GuardantHealth,
Abstract
Advancing precision medicine in cutaneous oncology through 3D high-frequency ultrasound imaging.Org: The Emory Clinic,
Abstract
Performance of three commercially available large language models and one locally fine-tuned model at preparing formal letters to appeal medical insurance denials of radiotherapy services.Org: Washington University School of Medicine in St Louis,
Abstract
Comprehensive genomic profiling in solid tumors: Enhancing treatment selection and prognosis.Org: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Division of Hepatology, Liver Disease Center, Organ Transplantation Center,
Abstract
Generative AI enhanced with NCCN clinical practice guidelines for clinical decision support: A case study on bone cancer.Org: UPMC Hillman Cancer Center, University of Pittsburgh,
Abstract
A prospective study comparing AI-based clinical trial eligibility screening with traditional EMR-based screening.Org: Cerritos, Plymouth Meeting,
Abstract
Clinical decision making by ChatGPT vs medical oncologists: A retrospective concordance study.Org: Nairi MC, Yerevan State Medical University After M.Heratsi, Department of Pediatric Oncology and Hematology,
Abstract
Investigating large language model (LLM) performance using in-context learning (ICL) for interpretation of ESMO and NCCN guidelines for lung cancer.Org: Oulu University Hospital, University of Oulu, MRC Oulu, Gosta Labs,
Abstract
Can ChatGPT provide accurate financial toxicity resources to patients with cancer?Org: NYU Lanone,
Abstract
Exploring the literature on artificial intelligence use in oncology.Org: Blue Spark Technologies, Westlake, OH,
Abstract
Implementing a natural language processing pipeline to expedite clinical chart review to assess germline genetic testing in veterans with breast cancer.Org: VA Salt Lake City Health Care, University of Utah, Durham VA Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, VHA National Oncology Program Office,
Abstract
Dynamic machine learning model to forecast patient availability for clinical trials.Org: ConcertAI, Cambridge University Hospitals NHS Foundation Trust, Bengaluru, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA,
Abstract
Detection of contralateral breast cancer in patients with primary breast cancer through AI-assisted mammography.Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea,
Abstract
Results of the COMPARE-GPT study: Comparison of medication package inserts and GPT-4 cancer drug information.Org: Cleveland Clinic Taussig Cancer Instititute, Valley Health System,
Abstract
Integrating electronic health records (EHRs) to facilitate cancer biomarker testing: Real-world implementation barriers and solutions.Org: SOMC Cancer Center, Banner University Medical Center, Sanford USD Medical Center,
Abstract
Auto-machine learning for opportunistic thyroid nodule detection in lung cancer screening chest CT.Org: John Snow Labs, Gesund.ai, Michael G. DeGroote School of Medicine,
Abstract
Decision-making concordance: A comparative analysis between a multidisciplinary tumor board and a large language model (ChatGPT) in breast cancer management.Org: San Pedro Garza García, San Pedro Garza Garcia, Centro de Cancer de Mama,
Abstract
Technology enhanced multidisciplinary cancer conferences in gynecologic oncology.Org: Williamsville, NY,
Abstract
Use of an application that extracts and consolidates adverse events and concomitant medication data from clinical systems to increase clinical trial data entry efficiency, trust, and satisfaction.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Comparative analysis of ChatGPT-4.0’s management of six gastrointestinal cancers according to the NCCN guidelines.Org: Los Robles Regional Medical Center, General Surgical Associates,
Abstract
PENTAGON (Predicting Clinical Trials in Gynecologic Oncology): A retrospective study assessing study design factors that affect enrollment in gynecologic cancer trials.Org: Louisiana Cancer Research Center, Louisiana State University Health Science Center,
Abstract
Patient-centered development and dissemination of MTCEducate.org, an online educational aid for patients with a rare cancer.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of California, San Francisco,
Abstract
AI frontiers in oncology: Bridging the gap between humanity and machine.Org: Staten Island University Hospital, Stony Brook Medicine, Northwell Staten Island University Hospital,
Abstract
Finding errors in the blink of AI: Use of an artificial intelligence tool to identify clinically important corrections to references cited by NCCN Guidelines for gynecologic malignancies.Org: Johns Hopkins University Bloomberg School of Public Health, Johns Hopkins University School of Medicine,
Abstract
Effects of preoperative breast MRI on surgical management in women aged 40 years and younger with breast cancer.Org: George Washington University School of Medicine and Health Sciences, George Washington University Hospital,
Abstract
Evaluation of a web-based, interactive guide to enhance patient-clinician electronic communication.Org: Cleveland Clinic Taussig Cancer Instititute, University of Florida Department of Health Outcomes and Biomedical Informatics,
Abstract
Navigating cancer care through digital dialogue: Analyzing key phrases shared by patients in real-time exchange messages using an electronic patient-reported outcome measure (ePROM).Org: Thummi Global, Universidade Federal de São Paulo (UNIFESP),
Abstract
Impact of digital tools in oncology: A global analysis of the adoption of ONCOassist and NCCN Chemotherapy Order Templates (NCCN Templates) in collaboration with OncoAlert.Org: Genitourinary Tumors, Institute of Oncology Angel H Roffo, Molecular Pathology Laboratory, National Comprehensive Cancer Network, ONCOassist,
Abstract
Usability and feasibility of the open-source GeRI platform for remote assessments in older adults with prostate cancer.Org: The University of Chicago Medicine Center for Advanced Care at Orland Park, Chicago, IL, Il-Yang Pharmaceuticals,
Abstract
MSK Engage: A comprehensive program for collection of patient reported outcomes at scale.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Real-world implementation of an EHR-integrated, SMS text remote patient monitoring platform at an academic cancer center.Org: Memora Health,
Abstract
Enhancing oncology research through data sharing and re-use: A five-year review of Vivli's global data platform.Org: Vivli, Bedford, MA, Welwyn Garden City, United Kingdom,
Abstract
Health information and technology engagement for clinical research and healthcare purposes (HITECH) survey of patients with a history of cancer.Org: VA Greater Los Angeles Healthcare System, UCLA Medical Center,
Abstract
Treatment (Tx) inequities in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) harboring actionable driver oncogenes (ADO) in the first-line (1L) setting.Org: New York Cancer and Blood Specialists, OneOncology, LLC,
Abstract
Engagement of patients with cancer with digital health platforms: An age-based analysis.Org: Care Across, London Regional Cancer Center,
Abstract
Systematic review of rural interventions addressing barriers and facilitators in recruitment and adherence of oncology clinical trials.Org: Baylor College of Medicine,
Abstract
Implementing large language model-based artificial intelligence (AI) technology in proposing effective treatment plans in patients with cancer.Org: Kerala Cancer Care, MOSC Medical College, EMC,
Abstract
On improving clinical trial diversity: Viewpoints from underrepresented breast cancer survivors.Org: Department of Health Outcomes and Behavior,
Abstract
UK Cancer and Transition Service (UCATS): Providing tailored cancer care to the gender-diverse community.Org: OUTpatients, Chelsea Westminster Hospitals NHS Trust, Chelsea and Westminster Hospital,
Abstract
Unraveling the impact of social determinants of health on HER2+ early breast cancer screening and treatment in a county oncology setting in China.Org: The People's Hospital of Liuyang, Changsha, China, Inner Mongolia Forestry General Hospital, Hulunbeier, China, Guiping People's Hospital, Guigang, China, Huixian City People's Hospital, Xinxiang, China, Lixin County People's Hospital, Bozhou, China,
Abstract
Effects of socioeconomic status (SES) and healthcare resource (HCR) availability on survival in Black patients (pts) versus (vs) White pts with multiple myeloma (MM): A SEER Medicare analysis.Org: Genentech, Genesis Research, AbbVie Inc., North Chicago, IL, Translational Genomics Research Institute (TGen North),
Abstract
Improving ethnic and racial diversity within clinical trial populations through community recruitment and inclusion initiatives: Experience from MyTACTIC.Org: US Medical Affairs Oncology, Genentech, Inc.,
Abstract
Availability of cranial prostheses for Black patients at comprehensive cancer centers.Org: The Ohio State University Wexner Medical Center, Michigan State University College of Human Medicine,
Abstract
Assessing barriers to prostate cancer clinical trial participation among Black and African Americans: A multi-perspective qualitative study.Org: David Geffen School of Medicine at UCLA, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Sandra and Edward Meyer Cancer Center, The Pennsylvania Prostate Cancer Coalition, Tisch Cancer Institute,
Abstract
Financial toxicity in the background of free health care: A cross-sectional survey in a tertiary care hospital in India.Org: Army Hospital Research and Referral, INS Asvini,
Abstract
Racial and elderly disparities in receipt of guideline-concordant care in stage I-III breast cancer.Org: Perelman School of Medicine University of Pennsylvania, University of Pennsylvania, Department of Medicine (Hematology - Oncology Division),
Abstract
Breast cancer treatment access disparities: A retrospective cohort study of breast cancer in patients treated at a high-complex cancer center in southern Brazil.Org: Universidade Federal de Ciencias da Saude de Porto Alegre,
Abstract
Disparities in cancer care: Is there a benefit for increased use of inpatient chemotherapy (IPC) in safety-net hospitals?Org: Jacobi Medical Center/North Central Bronx, Bronx, NY, Nykode Therapeutics, Albert Einstein College of Medicine,
Abstract
Improving diversity in phase I oncology clinical trials: A single institution experience at the University of Colorado Cancer Center.Org: School of Medicine, Zhejiang University, Hangzhou, China, University of Colorado Anschutz Medical Campus, Division of Gynecologic Oncology, University of Pennsylvania, Department of Obstetrics & Gynecology, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Racial and ethnic disparities in hospital outcomes following hospitalizations for mastectomy for breast cancer.Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Miami, FL,
Abstract
The heavy implications of racial and socioeconomic factors affecting cachexia incidence at gastrointestinal malignancy diagnosis: A single-institution study.Org: Tufts Medical Center/Tufts University, Boston, MA,
Abstract
Health equity regional symposia: Convening local stakeholders to address health disparities in the US.Org: Ochsner Xavier Institute for Health Equity,
Abstract
Efficacy of a culturally tailored screening campaign to tackle cervical cancer disparities among Hispanic patients.Org: Keck School of Medicine of University of Southern California,
Abstract
Integrating social drivers of health screening into ambulatory cancer care.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Health System,
Abstract
Ethnic disparities in breast cancer: A comprehensive analysis of socio-demographic and clinical characteristics among African American, Hispanic, and Caucasian women.Org: Mount Sinai Hospital-Breast Medical Oncology, Chicago, IL, Il-Yang Pharmaceuticals, Chicgao, Ross University School of Medicine,
Abstract
Association between socioeconomic factors and utilization of next-generation sequencing in metastatic breast cancer.Org: University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center (UPMC), University of Pittsburgh, Pittsburgh, PA,
Abstract
Recruiting Black and White patients to a behavioral oncology clinical trial: Lessons from the DISCO trial.Org: Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI, Wayne State University, Karmanos Cancer Center,
Abstract
Utilization of circulating tumor DNA (ctDNA) testing by race and ethnicity in more than 135,000 patients.Org: Guardant Health Inc., Duke University Medical Center, Perlmutter Cancer Center, NYU Langone Health, NYU Langone Health, New York, NY, Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX,
Abstract
Bridging the gap: Leveraging AI to enhance access to clinical trials for underrepresented and underserved populations with cancer.Org: Leal Health (formerly Trialjectory),
Abstract
Evaluation of a summer program for minority high school students in the clinical cancer center: The Future Gen Cancer Scholars program.Org: Bayview Academy, Providence Public School Department, Papitto Opportunity Connection, Brown Alpert Medical School, Brown Alpert School of Medicine,
Abstract
Characterization of social determinants of health in patients considered for participation in treatment clinical trials at a community cancer center serving the Great Plains.Org: University of South Dakota Sanford School of Medicine,
Abstract
Factors associated with delays in care of suspicious lung nodules at an academic medical center.Org: University of Chicago,
Abstract
Impact of eligibility criteria discordance on clinical trial accrual in diffuse large B-cell lymphoma (DLBCL).Org: Department of Medicine, Duke University School of Medicine, Durham, NC, Department of Statistics, University of Chicago, Chicago, IL, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, Division of Hematologic Malignancies & Cellular Therapy, Duke University School of Medicine, Durham, NC,
Abstract
Overcoming racial and ethnic disparities in clinical trial enrollment real world evidence from an NCI-Designated Cancer Center in a minority majority county.Org: School of Medicine, Zhejiang University, Hangzhou, China, University of California Irvine, Irvine, University of California Medical Center,
Abstract
Influence of patient awareness and health disparities on early identification of neutropenic sepsis risk.Org: 52 North Health, Macmillan Cancer Support,
Abstract
Trends of demographic and clinical traits of young patients with breast cancer from the National Cancer Database: Disproportionate effect on underrepresented underserved populations.Org: Cedars-Sinai Medical Center,
Abstract
Individual and neighborhood-level factors associated with disruptions in patients with gynecologic cancers undergoing radiation treatment.Org: Johns Hopkins University Bloomberg School of Public Health,
Abstract
Rural-urban disparities in colorectal cancer-related mortality changes in the United States.Org: Feist-Weiller Cancer Center at LSUHSC-Shreveport, Vydehi Institute Of Medical Sciences & Research Center,
Abstract
Mindfulness-based group medical visits: Strategies to improve equitable access and inclusion for diverse patients in cancer treatment.Org: University of California, San Francisco, San Francisco, CA,
Abstract
Timeliness of breast cancer care: Real-world experience at a tertiary care and a public safety-net hospital.Org: Olive View-UCLA Medical Center, University of California Irvine, Memorial Sloan Kettering Cancer Center,
Abstract
Racial disparities in the intervention trials in colon cancer.Org: North Alabama Medical Center,
Abstract
Disparities in clinical trial participation: Survey of patients with cancer at an academic medical center.Org: University of Cincinnati College of Medicine, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, University of Cincinnati Cancer Center,
Abstract
Assessing social determinants of health and optimizing resource support for patients with metastatic breast cancer: Results from the LIFT-UP study.Org: Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, NA, Dana-Farber Cancer Institute, Harvard Medical School,
Abstract
Representation of Hispanics with liver cancer in oncology genotype databases.Org: Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program,
Abstract
A bird's-eye view of disparity from public historic cancer mortality data in the US: Advocacy for gastrointestinal cancers and for inter-agency data harmonization.Org: HEAR2CARE.ORG,
Abstract
Racial/ethnic distribution of participants in NRG oncology clinical trials: 2014-2023.Org: UCSF Medical Center-Mount Zion, University of Florida Health Cancer Center Orlando, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
Supporting patient access to pharmaceutical-sponsored assistance programs: Implications for health equity and care delivery at safety-net systems.Org: Parkland Health,
Abstract
Clinical practice guidelines for adolescent and young adult cancer: A literature review.Org: Moses Cone Hospital,
Abstract
Healthcare disparities are associated with eligibility and enrollment in clinical trials in Louisiana.Org: Louisiana State University School of Medicine, Louisiana State University Health Sciences Center Shreveport,
Abstract
Understanding the relationship between palliative care consultation and mental health services in patients with pancreatic cancer: A US cross-sectional analysis.Org: Saint Louis University School of Medicine,
Abstract
Disparities in head and neck cancer (HNC): An insight of the National Inpatient (NIS) database.Org: SBH Health System, St. Barnabas Hospital,
Abstract
Racial disparities in patients with ALL according to a national dataset.Org: Trihealth - Cincinnati,
Abstract
Breast cancer disparities among Hispanics in the US: Insights into healthcare access.Org: Beth Israel Deaconess Medical Center, Harvard Medical School, Tufts Medical Center/Tufts University,
Abstract
A systematic review of racial disparity in pivotal poly (ADP-ribose) polymerase (PARP) inhibitor trials.Org: University of Tennessee Health Science Center, Memphis, TN, University of Tennessee Health Science Center, Piperton, TN,
Abstract
Racial differences in degrees of side effects to taxane based chemotherapy in patients with breast cancer.Org: Ochsner Health System, New Orleans, LA, Ochsner Health Center, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Ochsner Clinic Foundation,
Abstract
Disparities in patients with HER2-positive breast cancer receiving optimal treatment: Analysis of the real-world ASCO CancerLinQ dataset.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Boston, MA, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX,
Abstract
Clinical characteristics and treatment outcomes in Hispanic/Latino patients with advanced renal cell carcinoma at a single institution.Org: University of Miami Miller School of Medicine, Miami, FL, Jackson Memorial Hospital, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Sylvester Comprehensive Cancer Center, Miami, FL,
Abstract
Navigating the intersection: Exploring racial disparities in major cardiovascular and cerebrovascular events among patients with hepatocellular carcinoma.Org: Landmark Medical Center, Woonsocket, River 3 Renal, New York Medical College - Saint Michael's Medical Center, Valhalla,
Abstract
Rectal cancer: Demographics and healthcare outcomes in a minority-rich community hospital.Org: Trinitas Regional Medical Center, RWJBarnabas Health, Elizabeth,
Abstract
Why cancer survivors who are parents are not getting support for their children.Org: Kesem, Covina,
Abstract
Advancing team science and health equity in clinical oncology using the All of Us Research Program dataset.Org: National Institutes of Health All of Us Research Program, Delta Research and Educational Foundation (DREF),
Abstract
Social determinants of health and treatment outcomes among a retrospective cohort of patients receiving immunotherapy for cancer.Org: Atrium-Wake Forest Baptist Health,
Abstract
Ethnicity and health insurance disparities in rectal carcinoma.Org: Trinitas Regional Medical Center, RWJBarnabas Health, Elizabeth, NJ, Union, NJ,
Abstract
Identifying factors underlying increased emergency care needs of Black patients with pancreas cancer.Org: Health Information Exchange at Northwell Health,
Abstract
Impact of racial disparities in adjuvant treatment of triple negative breast cancer (TNBC) among American Indians/Alaskan Natives (AI/AN) and non-Hispanic Whites (NHW) on overall survival (OS).Org: Fargo, ND, Sanford Center for Biobehavioral Research, Grand Forks, ND,
Abstract
The physician oncology referral process and its effect on tumor board outcomes.Org: Christian Brothers University,
Abstract
Access to germline testing and prevalence of somatic mutations in patients with breast cancer from disadvantaged areas: A single-center study.Org: Roswell Park Cancer Institute, Roswell Park Comprehensive Cancer Center, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan,
Abstract
Investigation of racial disparities in hepatocellular carcinoma and rates of liver transplant: A SEER 2000-2020 study.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton University Medical Center,
Abstract
Sarcoma drug approvals in Latin America compared to the FDA and EMA: An analysis by the LACOG Sarcoma Group.Org: Brazilian National Cancer Institute,
Abstract
Patient experience and pain outcomes among Black women with early-stage breast cancer after mastectomy.Org: Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, USA, Rollins School of Public Health, Emory University School of Medicine,
Abstract
Black/African American participation in cancer clinical trials: A qualitative study of community members, patients with cancer, and survivors (Detroit, MI) using CBPR.Org: MED-IQ, Caribbean Community Service Center, Eastside Community Network, Detroit Medical Center, Friends of Parkside,
Abstract
Expansion of outreach to native Hawaii and Pacific Islander communities to increase breast cancer screening and clinical trial awareness in underserved and rural Oahu.Org: John A. Burns School of Medicine, University of Hawaii at Manoa, University of Hawaii Cancer Center,
Abstract
Barriers to receipt of oncological care at the community level.Org: Mercy Catholic Medical Center, Lansdowne, PA, Mercy Catholic Medical Center, Darby, PA,
Abstract
Increased NGS testing and real-world clinical usage of targeted therapy: All dressed up, nowhere to go.Org: Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India, Indiana University – Purdue University Indianapolis, Delhi State Cancer Institute,
Abstract
Racial disparities in breast cancer care among reproductive-aged women continued after COVID-19 pandemic.Org: Komodo Health, San Francisco, CA, Komodo Health, New York, NY,
Abstract
Feasibility of universal breast cancer risk assessment in a diverse, publicly insured obstetrician gynecology clinic.Org: Weill Cornell Medical College University, New York, NY, New York Medical College - Saint Michael's Medical Center, Valhalla, NY, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,
Abstract
A comprehensive analysis of patient demographics and disparities in contemporary oncology clinical trials (2022-2023).Org: TriStar Centennial Medical Center,
Abstract
Overall survival in older patients with urologic cancer using G8 and G8m in a Brazilian cancer center.Org: A.C. Camargo Cancer Center, São Paulo, Brazil,
Abstract
Investigating perioperative interventions to enhance surgical outcomes for older adults with cancer: A systematic review.Org: University of Oklahoma Health Science Center, Department of Hematology & Oncology, College of Medicine, University of Oklahoma Health Sciences Center,
Abstract
Predicting fitness for chemotherapy in older adults with metastatic bladder cancer.Org: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Memorial Sloan Kettering Cancer Center,
Abstract
Effect of age on delivering chemotherapy to older adults with advanced pancreatic adenocarcinoma.Org: University of Miami Miller SOM Department of Medicine, Miami VAHS Geriatric Research Education and Clinical Center (GRECC),
Abstract
Implementing a mutidisciplinary approach for older adults with cancer: Challenges and achievements in a geriatric oncology program in Sao Paulo, Brazil.Org: Hcor,
Abstract
Paramedical staffs' perception of their role during the continuum of care from detection to treatment in nursing homes: Results of the ONCOPAD-Pre survey.Org: Université Lyon 2/Laboratoire PôPs - Unité U1296 - Radiations: Défense, Santé, Environnement, Médipôle Hôpital Mutualiste Lyon-Villeurbanne,
Abstract
Evaluation of a self-reported G8 screening tool on Epic MyChart for older patients with cancer.Org: Physiology, Cell Biology at Thomas Jefferson University,
Abstract
Value of a multidisciplinary geriatric oncology committee on patient care in a community-based, academic cancer center.Org: University of Maryland Baltimore Washington Medical Center,
Abstract
Updated safety and efficacy analysis comparing elderly vs nonelderly patients treated with consolidation nivolumab or nivolumab plus ipilimumab after chemoradiation for unresectable stage III NSCLC from the BTCRC LUN 16-081 clinical trial.Org: Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University Simon Comprehensive Cancer Center, Indiana University Melvin and Simon Comprehensive Cancer Center, Indiana University – Purdue University Indianapolis,
Abstract
Treatment outcomes and survival of patients with breast cancer aged 75 and older: A comparative study using propensity score-adjusted analysis.Org: National Hospital Organization Nagasaki Medical Center, Omura, Nagasaki Medical Center, Omura-Shi,
Abstract
Inflammatory biomarkers and frailty transitions in older adults with cancer: Findings from a national cohort study.Org: Chungnam National University College of Nursing,
Abstract
Geriatric enrollment patterns in clinical trials at a National Cancer Institute.Org: Mount Sinai Beth Israel,
Abstract
Patient’s perception of cancer treatment outcomes in geriatric age groups: A retrospective analysis from a tertiary care centre in India.Org: Tata Memorial Hospital, Tata Memorial Centre,
Abstract
Breast cancer outcomes and treatment toxicity in geriatric patients compared to other patients at the Cancer Disease Hospital in Zambia.Org: Cancer Diseases Hospital,
Abstract
Incidence of mortality in vulnerable and non-vulnerable older patients with cancer.Org: Centro Universitario Contra el Cancer U.A.N.L., Monte Verde-Juarez, NL, Mexico, Bayer de Mexico, Ciudad De Mexico, Mexico, Servicio de Geriatría, Hospital Universitario, José Eleuterio González, Monterrey, NL, Mexico,
Abstract
Advancing inclusive research (AIR) in Africa: Strengthening healthcare systems to enhance access on the continent through the Africa AIR site alliance model.Org: Roche Kenya Ltd., Roche SA,
Abstract
Visualizing veterans’ care: Understanding the breadth of older veterans’ paid and family support network and implications for cancer care in the older adult population.Org: JJ Peters VA Medical Center, Ichan School of Medicine at Mount Sinai,
Abstract
U.S. FDA analysis of enrollment of Asian patients from India in cancer clinical trials leading to approval from 2010 to 2022.Org: U.S. Food and Drug Administration, Oncology Center of Excellence, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research,
Abstract
Plasma microRNA signature as a potential early detection biomarker in breast cancer.Org: Oncoliq, Laboratorio de Oncologıa Molecular y Nuevos Blancos Terapeuticos, Instituto de Biologıa y Medicina Experimental (IBYME), CONICET, IBYME, Instituto Quirúrgico del Callao, Hospital Maria Curie,
Abstract
Global perspective of barriers in research among oncologists from low-middle income countries.Org: Cancer Institute of the State of São Paulo, São Paulo, Brazil, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh, Tata Medical Center, Kolkata, India, Tata Memorial Hospital, Mumbai, India, Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan,
Abstract
Achieving World Health Organization Global Breast Cancer Initiative targets: A situational analysis and action plan in Nigeria.Org: Obafemi Awolowo University, Federal Medical Centre, University of Ilorin Teaching Hospital, University of Maiduguri Teaching Hospital, Aminu Kano Teaching Hospital,
Abstract
Efficacy and safety of DOACs versus LMWH for elderly patients with active cancer: A meta-analysis.Org: Brasilia, Brazil, Tubarao, Brazil, Rio Branco, Brazil, Brasilia University Hospital, Oncologia D´Or,
Abstract
PENTA as a model for advanced integrated cancer management in low-resource settings.Org: OxLER, Bogota, Please Select, Bogota, Colombia,
Abstract
Genetic testing in cancer care: An assessment of current practice in Africa.Org: NSIA-LUTH Cancer Center, Lagos, Nigeria, BIO Ventures for Global Health (BVGH), Seattle, WA, Inkosi Albert Luthuli Central Hospital, Durban-South Africa, Adeniyi Jones Primary Healthcare Centre, Lagos, Nigeria, Johns Hopkins Medicine, Bethesda, MD,
Abstract
Health resource utilization expenditures in oncology within a virtual primary cancer survivor care clinic.Org: Survivor Healthcare, QualityMetric,
Abstract
Influence of multidisciplinary teams (MDT) on breast satisfaction and sexual well-being in the immediate postoperative phase following breast-conserving surgery (BCS).Org: Dartmouth-Hitchcock Medical Center, Trinity Health Oakland Hospital/Wayne State University, Ross University School of Medicine, Trinity Health Oakland Hospital/Wayne State University School of Medicine,
Abstract
A prospective phase II study of an exercise-nutrition-psychology integrated rehabilitation model based on mobile health and virtual reality for patients with cancer.Org: The Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University,
Abstract
Evidence to support ePRO-based patient care in survivorship for outpatient with advanced upper gastrointestinal cancer.Org: Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX,
Abstract
Survivorship care plans and fear of recurrence in patients with breast cancer (BC).Org: Ardmore, PA,
Abstract
KANSURVIVE: Testing a telementoring model for improving cancer survivorship care in rural practice.Org: University of Kansas Medical Center, Department of Biostatistics & Data Science, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, University of Kansas Cancer Center, Kansas City, KS,
Abstract
Mapping models of care for children, adolescent and young adult cancer survivors: A scoping review.Org: Department of Medicine, Brigham and Women’s Hospital, Boston, MA, Queensland University of Technology, South Brisbane, QLD, Australia, Flinders University, Adelaide, SA, Australia, Queensland University of Technology, Kelvin Grove, QLD, Australia, Flinders University, Bedford Park, SA, Australia,
Abstract
Personalised app-based information for patients with breast cancer: A pilot study to assess the efficacy and usability of the Answers 4 Cancers app.Org: Mater Misericordiae University Hospital,
Abstract
Time to treatment and follicular thyroid cancer survival: A SEER database analysis.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton Hematology Oncology, Omaha, NE,
Abstract
Demographic disparities influencing survival of patients with glioblastoma.Org: Grant Medical College,
Abstract
Addressing cancer survivorship needs in geriatric survivors: Feasibility of a primary care–based survivorship clinic.Org: Stanford Health Care, Stanford Comprehensive Cancer Institute,
Abstract
Personalized risk assessment of new onset depression in long-term cancer survivors.Org: Public Policy and Effectiveness Research Center, Department of Chronic Disease Epidemiology, Yale School of Public Health, Department of Surgery, Yale University School of Medicine,
Abstract
Characterizing vaginal stenosis in female cancer survivors.Org: University of Miami Miller School of Medicine, Miami, FL, Department of Obstetrics, Gynecologic, and Reproductive Sciences, Sylvester Comprehensive Cancer Center, University of Miami Health System,
Abstract
Understanding and comparing the views of specialty care providers and PCPs on addressing cancer survivorship needs via survivorship care plan portal.Org: Center for Health Services Research,
Abstract
Adoption of decentralized trial elements in cancer clinical trials supporting FDA approvals during COVID-19.Org: Duke Clinical Research Institute, Decentrialized Trials and Research Alliance, Clinical Trials Transformation Initiative,
Abstract
Feasibility of using simple diet self-assessment tool (SDSAT) to establish trajectory of dietary intake for patients undergoing chemotherapy.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Rural palliative care in cancer: Using telemedicine to bridge the gap.Org: VCUHealth/Massey Cancer Center,
Abstract
A paradox of size: Case-volume, financial outcomes, and risk in the enhancing oncology model baseline period.Org: The US Oncology Network, The Woodlands, TX, McKesson, Greenwood, IN,
Abstract
Enhancing thoracic oncology in Armenia: Impact of the implementation of an expert-guided virtual multidisciplinary tumor board.Org: Yeolyan Hematology and Oncology Center, Department of Pediatric Oncology and Hematology, Immune Oncology Research Institute, Yerevan State Medical University after M. Heratsi, Memorial Sloan Kettering Cancer Center,
Abstract
Remote patient monitoring for early detection of immune checkpoint inhibitor therapy-related pneumonitis in high-risk patients: A pilot-feasibility study.Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic School of Graduate Medical Education,
Abstract
Standardizing radiologic reporting of response to improve the patient experience: Comparing response categories of RECIST 1.1 and a novel, real-world, standardized, oncologic response lexicon derived from clinical radiology reports.Org: Instituto do Cancer do Estado de São Paulo-ICESP,
Abstract
MRI-Linac radiation therapy outcomes in patients with prostate, breast and other advanced malignancies.Org: Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Radiation Oncology Division,
Abstract
Travel-associated carbon emissions of patients receiving cancer treatment from an urban safety net hospital.Org: Jacobi Medical Center/North Central Bronx, Albert Einstein Medical Center, Bronx, NY, Department of Medicine, Icahn School of Medicine at Mount Sinai, Albert Einstein College of Medicine,
Abstract
Testicular cancer survivorship program at National Cancer Institute in Slovakia.Org: Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia, Translation Research Unit, Comenius University and National Cancer Institute, Bratislava, Slovakia, Comenius University, Bratislava, Slovakia, Comenius University and National Cancer Institute, Bratislava, Slovakia, National Cancer Institute, Bratislava, Slovakia,
Abstract
The value of blinded independent central review (BICR) in recent trials in non-small cell lung cancer (NSCLC).Org: Fox Chase Cancer Center, Temple University Health System,
Abstract
Heterogeneity in methods for estimating renal function in anticancer drug development.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY, Roswell Park Comprehensive Cancer Center, Buffalo, NY, Mount Sinai Beth Israel, New York, NY, Icahn School of Medicine at Mount Sinai, New York, NY, Department of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY,
Abstract
Impact of the integration of remote clinical oncology pharmacists into routine precision medicine workflows on biomarker testing rates within The US Oncology Network community-based practices.Org: McKesson Corporation,
Abstract
Enhancing diverse representation in clinical studies: Recommendations from external subject matter experts (SMEs) and patients to optimize protocols, informed consent and study designs.Org: Charles Retina Institute, Wagner Kapoor Institute, Norfolk, VA,
Abstract
The impact of end-of-life quality metrics on date of death and hospice documentation over time.Org: The US Oncology Network, The Woodlands, TX, McKesson Specialty Health, Spring, TX, McKesson,
Abstract
Double reading performance and the impact of adjudication on progression-free survival estimations: Findings from a lung clinical trial.Org: Median Technologies,
Abstract
Utility of automated data transfer for cancer clinical trials.Org: Flatiron Health, San Francisco, CA, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Washington University School of Medicine in St Louis,
Abstract
A prospective double-blind clinical study: Effect of probiotics and thalidomide on radiation enteritis in patients with pelvic cancer undergoing concurrent chemoradiotherapy.Org: Jiangxi Provincial Tumor Hospital,
Abstract
Statistical fragility of findings from randomized phase 3 trials in pediatric oncology.Org: Boston Children's Hospital, Boston Children’s Hospital, Dana-Farber Cancer Institute, Dana-Farber/Boston Children's Cancer and Blood Disorders Center,
Abstract
The feasibility and preliminary efficacy of a locally developed digital health intervention in improving breast cancer survivor’s quality of life (QOL): Qualitative and quantitative analysis result.Org: University Malaya Medical Centre,
Abstract
Cancer screening and first-time visits to oncology services during and after COVID-19 pandemic in Uruguay.Org: Honorary Commission for the Fight Against Cancer (CHLCC),
Abstract
Pilot study to evaluate automated laboratory data transfer into Medidata Rave for NCI-supported pediatric cooperative group trials in the Pediatric Early Phase Clinical Trials Network (PEP-CTN) and Pediatric Brain Tumor Consortium (PBTC).Org: Emory University/Children's Healthcare of Atlanta, Texas Children's Cancer and Hematology Centers,
Abstract
MetaAnalysisOnline.com: A new easy-to-use bioinformatic tool for the meta-analysis of clinical trials.Org: Semmelweis University,
Abstract
Patients with a history of more than one cancer diagnosis: An opportunity to expand eligibility criteria?Org: Oncology Consultants, PA - Medical Center, Houston, TX, Oncology Consultants, Houston, TX, Npowermedicine Inc, Redwood City, CA, N-power Medicine, Redwood City, CA, New Mexico Cancer Center, Albuquerque, NM,
Abstract
Examining global and gender disparities in high-impact evidence synthesis on lung cancer: A 2000-2024 analysis of Cochrane Library.Org: King George's Medical University, Bangalore Medical College & Research Institute, Miami Cardiac & Vascular Institute,
Abstract
Influence of family caregivers on clinical trial decisions: Results from a qualitative study.Org: Case Western Reserve University School of Medicine, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, University Hospitals Seidman Cancer Center, School of Nursing, University of Alabama at Birmingham, Birmingham, AL,
Abstract
Fostering diversity and inclusion in the preempt CRC study through strategic site selection and innovative recruitment tools.Org: New York University School of Medicine, Freenome Holdings Inc., Kaiser Permanente Oakland Medical Center,
Abstract
Progress Tracker Breast Cancer Registry: A Breast Cancer Canada initiative.Org: Breast Cancer Canada, POET Oncology,
Abstract
Patterns of breast cancer trial enrollment in a prospective patient database at a comprehensive cancer center.Org: Baylor College of Medicine, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, O'Neal Comprehensive Cancer Center at UAB,
Abstract
Reduced time to efficacy signals in advanced cancer trials using Chauhan weighted trajectory analysis.Org: Byte36 Technologies,
Abstract
The prevalence of RCTs in PARP and immune-checkpoint blockade combination trials: An appraisal of clinical evidence generation in oncology.Org: Beth Israel Deaconess Medical Center, Boston, MA, Cancer Research Institute, New York City, NY, New York, NY,
Abstract
Compliance with Centers for Medicare & Medicaid Services (CMS) 2021 price transparency requirements among proton therapy centers.Org: UPMC Hillman Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Pittsburgh, PA,
Abstract
Enrollment of older adults in clinical trials for oncology indications, 2010-2020: An evaluation by the FDA.Org: Brillient Corporation, Reston, VA, Office of Clinical Pharmacology, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology,
Abstract
Cost effectiveness of colorectal cancer screening in the Dominican Republic.Org: Hospital General de la Plaza de la Salud,
Abstract
Precision oncology clinical trials: A systematic review of phase II clinical trials with biomarker-driven, adaptive design.Org: Catholic University of Korea, Seoul St Mary's Hospital,
Abstract
Assessing the relevance and requirement of a prostate cancer passport: A patient-centric survey.Org: St. James Hospital, Dublin, Ireland,
Abstract
A community hospital cancer services approach to the reduction of OP-35 rule hospitalizations.Org: Inova Health System,
Abstract
Associations between prognosis and primary endpoint selection in phase III oncology trials in the United States.Org: The University of Tokyo, Tokyo, Japan, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Japan Association for Development of Community Medicine,
Abstract
Latin America and cancer clinical trials: Underrepresented region with significant growth potential.Org: Fortrea Inc., Durham, NC,
Abstract
Single point of entry to the European precision cancer medicine trial network PRIME-ROSE.Org: Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital and University of Oslo, Oslo, Norway, National Cancer Institute, Vilnius, Lithuania, The Swedish Institute for Health Economics, Lund, Sweden, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland,
Abstract
Cancer care during a time of crisis: Israel’s experience during wartime.Org: Braun School of Public Health and Community Medicine, Hadassah Medical Organization, Hebrew University-Hadassah Medical School, The Department of Oncology,
Abstract
The single center experience with the war-related Ukrainian patients with various cancer diagnoses treated in clinical trials between 2022-2024.Org: Clinic of Oncology and Radiotherapy at University Gdansk, University Gdansk,
Abstract
Modeling any potential change in size, cost or patient benefit, resulting from incorporation of ctDNA, or other “optimizing diagnostic,” as part of a novel “SMARTer” oncology registration trial design.Org: aiGENE, Inc., Harpers Ferry, WV, University of Colorado, Aurora, CO,
Abstract
Predictors of mood-related psychiatric disorders after cancer diagnosis.Org: Hospital of the University of Pennsylvania, Perelman School of Medicine, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Epidemiology Laboratory, Clinical Research, and Community Health, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, University of Sidi Mohamed Ben Abdellah, Fez, Morocco, Informatics,
Abstract
An analysis of the trends and distribution of political contributions from hematologists and oncologists in the United States.Org: University of Southern California Marshall School of Business,
Abstract
Discrepancies in therapeutic indications for the same oncology drugs among FDA, EMA, and Brazilian agency.Org: Centro de Pesquisas Oncológicas de Santa Catarina (CEPON), Centro de Pesquisas Oncológicas - CEPON,
Abstract
Budget impact analysis of participating in sponsored clinical trials in cancer within the Colombian healthcare system: A real-world evidence approach.Org: Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo,
Abstract
Disparities by sex in Hispanic patients with cutaneous melanoma: A national database analysis.Org: Creighton University School of Medicine Phoenix Regional Campus, University of Nebraska Medical Center, Department of Dermatology,
Abstract
Influence of health insurance type on time to breast cancer diagnosis and treatment among members of a large national payor.Org: CVS Health, Lincoln, RI,
Abstract
Influence of sociodemographic factors on time to diagnosis and treatment among members of a large national payor diagnosed with lung cancer.Org: CVS Health, Lincoln, RI,
Abstract
COVID vs. non-COVID oncology patient cohorts: Demographics and cancer variables.Org: Texas Woman’s University, Texas Woman's University,
Abstract
CAR T-cell therapies: Measuring the growing need for increasing long-term safety protocols.Org: St. Luke's Cancer Care Associates,
Abstract
Hematologic parameters as predictors of overall survival in metastatic solid tumor and aggressive lymphoma.Org: University of Miami/Jackson Memorial Hospital, Jackson Memorial Hospital/ University of Miami, University of Miami Miller School of Medicine, Miami, FL, University of Miami Hospital/Jackson Memorial Hospital, University of Miami Health System,
Abstract
Impact of frailty on hospitalized patients with prostate cancer: A retrospective analysis.Org: SSM St Mary's hospital,
Abstract
Inpatient outcomes of patients with new solid tumors admitted to a comprehensive cancer center.Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
The predictive value of the MASCC score in patients with febrile neutropenia.Org: NCH Downtown Naples Hospital,
Abstract
Adherence for members taking oral oncolytic agents undergoing dose modification strategies.Org: Lincoln, RI,
Abstract
Economic analysis of combined multi-cancer detection blood test and usual care.Org: Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group, Burning Rock Biotech, Guangzhou, China,
Abstract
Is essential thrombocytosis associated with worse outcomes in patients with stroke? Results from 2016-2020 National Inpatient Sample study.Org: Rochester General Hospital, Tribhuvan University Teaching Hospital, Norwalk Hospital,
Abstract
Comparison of standard charges for complex proton therapy among Medicare Prospective Payment System (PPS) –exempt and –non-exempt cancer centers.Org: UPMC Hillman Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Factors linked to patient rehabilitation disposition following surgical treatment of bone-related complications.Org: Sidney Kimmel Medical College of Thomas Jefferson University, Thomas Jefferson University, Thomas Jefferson University Hospital,
Abstract
Correlation of cost in teaching hospital with outcomes in patients with cardiac myxoma: A retrospective study using the national in-patient data sample (NIS).Org: St. Barnabas Health System,
Abstract
Discharge outcomes in COVID and non-COVID cohorts of hospitalized patients with cancer: A comparative analysis in the first year of the COVID-19 pandemic.Org: Texas Woman’s University,
Abstract
Comparative effectiveness of the bivalent COVID-19 mRNA vaccines, mRNA1273-222 and BNT162b2, in immunocompromised adults in the US.Org: VHN Consulting Inc, Veradigm,
Abstract
Assessing the impact of unmeasured confounding in external control arms via tipping point analyses.Org: Medidata Solutions, Medidata AI, a Dassault Systèmes Company,
Abstract
Daily diary engagement among caregivers of patients undergoing hematopoietic stem cell transplant.Org: H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine,
Abstract
The real-world impact of next-generation sequencing in advanced stages of solid tumor malignancies.Org: Orlando Health Cancer Institute, University of South Florida Morsani College of Medicine, Comprehensive Hematology-Oncology,
Abstract
In-hospital mortality patterns and risk factors in patients with cancer with COVID-19.Org: The University of Toledo Department of Medicine,
Abstract
Epidemiological analysis and overall survival of adrenal malignancies in a developing Middle Eastern country over 18 years.Org: Edinburgh Medical School, Royal Papworth Hospital NHS Foundation Trust, Geisinger Medical Center, Abdali Hospital, King Hussein Cancer Center,
Abstract
Exploring outcomes in hospitalized patients with COVID-19 based on nutritional status: Comparing those with and without a cancer diagnosis.Org: Charleston Area Medical Center (CAMC)/Outcomes Research,
Abstract
Epidemiology of rare endocrine tumors in a developing Middle Eastern country over 18 years.Org: Edinburgh Medical School, Edinburgh, United Kingdom, Royal Papworth Hospital NHS Foundation Trust, Faculty of Medicine, Jordan University, Amman, Jordan,
Abstract
Adapting a prescreening program from VHIO to match molecular alterations in over 10,000 patients' tumors with targeted agents and immunotherapies in early clinical trials.Org: Oncology Data Science Group,
Abstract
Origin associated with heterogeneity amongst Hispanic patients with breast cancer in the United States.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Hospital-Breast Medical Oncology,
Abstract
Recent trends in incidence, survival and mortality of female breast in the US: A Surveillance, Epidemiology, and End Results (SEER) database study 2010-2020.Org: University of Nebraska Medical Center, Omaha, NE,
Abstract
Atrial flutter in a patient population with cancer: Comparison of incidence, mortality, and readmission rates.Org: LSU-Shreveport, Louisiana State University in Shreveport,
Abstract
Uptake of recommendations for broadening clinical trial eligibility criteria for patients with brain metastasis and leptomeningeal disease in lung cancer clinical trials: A systematic review.Org: Geisel School of Medicine at Dartmouth,
Abstract
Thromboembolic incidents in prostate cancer patients: A nationwide propensity-matched study.Org: Louisiana State University in Shreveport,
Abstract
Association of social determinant of health (SDOH) with clinical outcomes in patients with cancer: Opioid use, emergency admission, anxiety, depression, and length of hospital stays.Org: University at Buffalo Jacobs School of Medicine and Biomedical Sciences, City of Hope National Comprehensive Cancer Center, Boston Medical Center,
Abstract
Exploring sexual and reproductive health among adolescent and young adult patients with cancer: A patient-oriented qualitative study using novel, serial focus groups.Org: Patient Research Partner, Division of Pediatric Hematology/Oncology/BMT, B.C. Children's Hospital, Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Department of Medicine, University of Ottawa,
Abstract
Impact of cancer treatment in patients with inflammatory bowel disease: A systematic review and meta analysis.Org: Saint Vincent Cancer and Wellness Center,
Abstract
The integration of big data analytics in examining the effects of mental illness screening on mortality and burden of illness among patients with cancer.Org: Boston Medical Center, City of Hope National Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences,
Abstract
The outcome of COVID-19 infection among Saudi oncology patients.Org: Women College Ain Shams University,
Abstract
Employing machine learning (ML) and explainable artificial intelligence (XAI) to predict and explain suicidal ideation among patients with prostate cancer.Org: University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Boston Medical Center, City of Hope National Comprehensive Cancer Center,
Abstract
Innovative performance-based remuneration model for oncologists: Balancing productivity with quality of care in a Brazilian healthcare setting.Org: Grupo SOnHe, Campinas,
Abstract
Outcomes of pericardial complications among patients with solid and liquid cancer: Analysis of National Inpatient Sample database.Org: Elmhurst, Queens, NY, Elmhurst Hospital Center,
Abstract
Immune response to SARS-CoV-2 vaccine administered to patients with solid cancers under systemic treatment: A prospective, monocentric study (Immunocovid-19).Org: Clinical Microbiology Laboratory, IRCCS-ASMN, Reggio Emilia, Italy, Clinical Chemistry Laboratory, IRCCS-ASMN, Reggio Emilia, Italy, Unit of Research and Statistic Infrastructure, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy,
Abstract
Integration of patient navigation into clinical operations of an outpatient cancer center.Org: Dana-Farber Cancer Institute, Boston, MA, USA,
Abstract
Outcomes of patients with metastatic solid cancers treated on early phase clinical trials in western Australia.Org: School of Medicine, University of Western Australia,
Abstract
National Comprehensive Cancer Network guideline compliance in an oncology value-based care program serving Medicare members.Org: CVS Health, Lincoln, RI,
Abstract
Oral oncolytics medically integrated dispensing: Impact on medical spending compared to non-integrated dispensing.Org: Prime Therapeutics, Prime Therapeutics, LLC,
Abstract
Influence of aging, comorbidities, and chemotherapy on dementia in patients with metastatic cancer.Org: Cancer Care & Research Center, Marshfield Clinic Research Institute, Marshfield Clinic Health System, Center for Clinical Epidemiology and Public Health, Center for Precision Medicine Research,
Abstract
Childhood Cancer in Cameroon and Kenya: Preliminary findings of an implementation effectiveness study for early detection of childhood cancer.Org: Hospital for Sick Children, University of Nairobi, Mother and Child Center of Chantal Biya Foundation, CBCHS, EWSS,
Abstract
Assessing patient eligibility at breast imaging for receipt of additional health screenings.Org: Rush Medical College,
Abstract
Hospitalization risk in multiple myeloma episodes of care.Org: McKesson, The US Oncology Network, The Woodlands,
Abstract
Factors influencing the clinical added value (CAV) in France over more than a decade.Org: Haute Autorité de Santé, Saint Denis,
Abstract
Investigating disparities in enrollment of patients in lung cancer clinical trials that led to FDA approval for immunotherapies between 2015 and 2023: A comparison with the US population.Org: Drexel University College of Medicine, University of Illinois College of Medicine Peoria (UICOMP),
Abstract
Mapping disparities in head and neck cancer care: Geospatial analysis of social vulnerability and healthcare access in the US.Org: Guidehouse Inc.,
Abstract
Comparing emergency department and oncology urgent care for non-emergent acute care.Org: UTSW Harold C Simmons Comprehensive Cancer Center,
Abstract
Patient (pt) interview–based content validation of the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0).Org: GSK plc, GSK, Evidera, Inc,
Abstract
Access to and equity in cancer clinical trials in Oregon.Org: Portland State University, Oregon Health Authority Health Promotion and Chronic Disease Prevention Section,
Abstract
Patient (pt) experience with and perceptions of transfusion-dependent (TD) and transfusion-independent (TI) myelofibrosis (MF): A qualitative interview study.Org: GSK plc, Evidera, Inc, GSK,
Abstract
Educating a diverse group of women in Los Angeles County on ovarian and uterine cancers and clinical trials.Org: MiOra, Encino,
Abstract
Geographic variations in corporate sponsorship for cancer center charity events.Org: University of New Mexico Comprehensive Cancer Center,
Abstract
Impact of COVID-19 on post-treatment breast cancer surveillance and outcomes.Org: Department of Research & Evaluation, Santa Barbara Cottage Hospital, Santa Barbara, CA, Department of Research and Evaluation,
Abstract
Assessing the missions and visions of NCI-designated cancer centers and their affiliated hospitals.Org: University of Oklahoma College of Medicine, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, University of Oklahoma Health Sciences Center, UT Southwestern Medical Center, National Cancer Institute, Vilnius, Lithuania,
Abstract
The journey of patients with lung cancer: The gap between symptom onset and treatment.Org: University Hospital of Larissa, University General Hospital of Larissa, University of Thessaly,
Abstract
Site research infrastructure and institutional performance: A report from the Voting Body of the Children’s Oncology Group (COG).Org: University of Oklahoma Health Sciences Center, Georgetown University Lombardi Comprehensive Cancer Center, St. Luke's Cancer Institute, Children's Hospital Colorado, Aurora, CO, University of California Davis, Sacramento, CA,
Abstract
Real-world evaluation of oncolytic biosimilar adoption on medication adherence and out-of-pocket costs among members of a national payor.Org: CVS Health, Lincoln, RI,
Abstract
Overestimation of survival in individuals with cancer treated in the real world with new cancer drugs: A population-based cohort study.Org: BC Cancer-Vancouver Centre, University of British Columbia,
Abstract
Predictors of time to diagnosis and treatment: A retrospective cohort study of patients with clinically localized prostate cancer in Nigeria.Org: Ahmadu Bello University, Ahmadu Bello University Teaching Hospital, Benue State University Teaching hospital (BSUTH), University of Lagos, Lagos University Teaching Hospital,
Abstract
A variety of inflammatory shadows caused by COVID-19 on chest CT that closely resembled lung cancer in annual lung cancer screening.Org: Department of Premier Preventive Medicine, Osaka Metropolitan University,
Abstract
Investigations of the quality of fertility preservation education provided to patients with cancer at a large community hospital.Org: Schulich School of Medicine and Dentistry, University of Western Ontario,
Abstract
CGP-based IO biomarker assessment and treatment utilization across a major US health system.Org: Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Health Research Accelerator, Microsoft Research,
Abstract
Improving the multiple myeloma and clinical trial awareness among Los Angeles County adults.Org: Encino,
Abstract
Utilization of TAS-102 (TAS) or regorefenib (Rego) among commercially insured refractory metastatic colorectal cancer (R-mCRC) patients.Org: University of Southern California Marshall School of Business, Medical Oncology and Therapeutics, City of Hope/AccessHope,
Abstract
A comparative analysis of needs and role of patient navigation among early-phase cancer clinical trial participants and non-participants at a single cancer center.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Health System, Mount Sinai Hospital-Breast Medical Oncology,
Abstract
Evaluation of clinical adherence measures for oral oncolytics: A systematic review.Org: The University of North Carolina at Chapel Hill, The University of North Carolina Medical Center, Northwestern Memorial Hospital, Chicago, IL, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill,
Abstract
Access to cancer center information for patients with limited English proficiency from NCI Cancer Center websites.Org: Northwestern/McGaw Medical Center, McGaw Medical Center of Northwestern University, Biostatistics, Feinberg School of Medicine, Northwestern University, Department of Medicine, Northwestern University Feinberg School of Medicine,
Abstract
Costs and access barriers to ondansetron: A national analysis of Medicare part D and Medicare Advantage plans.Org: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Dallas, TX, UT Southwestern Medical Center,
Abstract
Financial toxicity screening preferences in patients with breast cancer.Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Johns Hopkins Kimmel Cancer Center, Emory University School of Medicine, University of Michigan,
Abstract
Evaluating the impact of depression on self-reported quality of life measurements for patients with a history of cancer: A 2022 behavioral risk factor surveillance system questionnaire study.Org: University of Utah, Oregon Health & Science University,
Abstract
Disparities in gynecologic oncology clinical trial availability in the United States: A state-level analysis.Org: Rice University, Saint Vincent College,
Abstract
Substance use among individuals with cancer: A US population-based cohort study.Org: Massachussetts General Hospital, Brigham & Women's Hospital,
Abstract
Evaluation of online patient education materials for acute myeloid leukemia.Org: Westchester Medical Center, Hawthorne,
Abstract
Time-to-first treatment for new cancer diagnoses before and during the COVID-19 pandemic in Manitoba, Canada.Org: CancerCare Manitoba, Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy, University of Manitoba,
Abstract
Precision oncology and AI: The ACMA system for personalized treatment matching using real-world data.Org: OrigiMed, Shanghai Henlius Biotech, China National Biotec Group,
Abstract
Molecular and genomic testing in Native American patients with metastatic lung and colorectal cancers: A retrospective chart review.Org: Oklahoma University Health Sciences Center,
Abstract
Racial differences in therapies received by patients with cutaneous T cell lymphoma (CTCL): A single center retrospective cohort analysis.Org: Emory University School of Medicine, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Emory University, Atlanta, GA, USA, Rollins School of Public Health, Winship Cancer Institute of Emory University,
Abstract
Oncofertility: The unmet need.Org: Sri Ramachandra Institute of Higher Education And Research, Chennai, India,
Abstract
Adherence and persistence of encorafenib in combination with cetuximab among patients with BRAF metastatic CRC in the United States (US) based on two claims databases.Org: Genesis Research Group, Hoboken, NJ,
Abstract
Disparities in cancer care utilization in patients with brain tumors: A nationwide analysis.Org: Shalamar Hospital, King Edward Medical University Lahore,
Abstract
Impact of the COVID-19 pandemic on timely treatment among patients with breast, lung, and colorectal cancer.Org: Harvard University T.H. Chan School of Public Health,
Abstract
Claims and cost responsibility trends for high-deductible insurance plan participants with breast and prostate cancer in the New Hampshire Limited Use Commercial Health Care Claims data.Org: University of Wisconsin-Milwaukee, Milwaukee, Wigen Biomedicine Technology (Shanghai),
Abstract
Patient reported colonoscopy barriers: A cross sectional survey.Org: Ohio University Heritage College of Osteopathic Medicine,
Abstract
Safety and acceptance of nirmatrelvir/ritonavir in early SARS-CoV-2 treatment in Greek patients with solid cancer.Org: HeSMO,
Abstract
Comparing ventricular tachycardia across the nation: Stratification by different malignancies.Org: Louisiana State University in Shreveport, Shreveport, LA, Lantheus Medical Imaging, Houston Methodist Hospital, Houston, TX,
Abstract
Financial toxicity (FT), quality of life (QoL), and medication adherence patient-reported outcomes (PROs) in CLL on first-line (1L) oral oncolytics.Org: Adult and Child Center for Outcomes Research & Delivery Science (ACCORDS),
Abstract
Impact of wildfires on radiotherapy adherence in patients with cancer: A multi-clinic study.Org: University of California Irvine, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Racial disparities in incidence and survival in renal cell carcinoma in adolescents and young adults (AYA).Org: Fundacion Santa Fe de Bogotá,
Abstract
Time to treatment initiation for breast, prostate, non-small cell lung, and colon cancers from 2018 to 2022.Org: UMass Memorial Healthcare, UMass Memorial Health Care,
Abstract
A real-world longitudinal assessment of the treatment-related symptoms and associated burden among patients receiving chemotherapy.Org: Genentech Inc., Carevive Systems Inc., Parexel, Medidata Solutions,
Abstract
A real-world assessment of the treatment-related symptoms and associated burden among patients with lung cancer receiving chemotherapy.Org: Brookline,
Abstract
Evolution of quality of life (QoL) and symptom burden (SB) in patients receiving inpatient palliative care (PC) following one week of care in a specialized palliative care unit (PCU): A comparison of two groups, with one receiving specialized outpatient palliative care prior to admission.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Sarcoma Center Berlin-Brandenburg, Helios Hospital Bad Saarow, Bad Saarow, Germany, Helios Klinikum Bad Saarow-Sarcoma Center Berlin-Brandenburg and University Medicine Greifswald, Bad Saarow, Germany,
Abstract
Effects of nursing intervention based on gratitude extension-construction theory on gratitude level, recurrence fear and post-traumatic growth of patients with breast cancer after surgery.Org: The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Nanjing Yoko Biomedical, China National Biotec Group,
Abstract
Evaluating the impact of socioeconomic status on patient satisfaction in radiation oncology.Org: Corewell Health System - Beaumont University Hospital, Royal Oak, MI,
Abstract
EHR documentation of cost discussions and financial interventions for a cohort of patients with advanced cancer: Findings from a retrospective chart review-based study.Org: Case Western Reserve School of Medicine, Cleveland, OH, Division of Hematology and Oncology, UCLA Department of Medicine, Los Angeles, CA, Division of General Internal Medicine and Health Services Research, University of California, Los Angeles, Los Angeles, CA,
Abstract
Patients’ voices matter: Translating pretreatment patient-reported outcomes into high and low health-related quality of life provides a new clinical aspect on prognosis and survival in patients with previously untreated diffuse large B‐cell lymphoma.Org: F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada, Genentech Inc., South San Francisco, CA, Genentech,
Abstract
The Progress Tracker Breast Cancer Registry: Feasibility of a longitudinal patient-led, patient-reported outcomes (PROM) registry.Org: Caldwell, NJ, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, Breast Cancer Canada, Sarnia, ON, Canada, Breast Cancer Canada; POET Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, Breast Cancer Canada; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada,
Abstract
Immunotherapy related patient-reported outcomes from five randomized controlled trials in patients with triple negative breast cancer: A systematic review.Org: NewYork-Presbyterian Brooklyn Methodist Hospital,
Abstract
Correlation of stress, depression, sleep, and pain with race and body mass index (BMI): Secondary analysis from Alliance A011502.Org: Roswell Park Comprehensive Cancer Center, Mayo Clinic, Channing Laboratory, Johns Hopkins Kimmel Cancer Center, Sweetwater Regional Cancer Center,
Abstract
Exploring sexual health in premenopausal patients with hormone positive early breast cancer: Comparison between LHRH and oophorectomy.Org: Radiation Medicine Center, Mardaleishvili Medical Centre,
Abstract
A prospective study to evaluate the prevelance of chemobrain (CB) in patients (pts) receiving adjuvant treatment.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, University Hospital of Larissa, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,
Abstract
Development and validation of a novel web application for patient-reported outcome measures monitoring.Org: Kolenchery, Ernakulam, Meeval Care,
Abstract
Unveiling impacts: A quality of life survey for individuals with a history or diagnosis of cancer.Org: Advocates for Collaborative Education, METAvivor, Inflammatory Breast Cancer Research Foundation, International Cancer Advocacy Network (ICAN), Lobular Breast Cancer Alliance,
Abstract
Radiation dose esclation with contact X-ray brachytherapy (Papillon) and quality of life in patients with rectal cancer: Results from the phase 3 randomised trial OPERA.Org: University of Liverpool, Centre Antoine Lacassagne, Clatterbridge Cancer Centre NHS FT, Imperial College,
Abstract
A real-world, patient-reported outcomes study in patients with platinum-sensitive recurrent ovarian cancer receiving long-term maintenance therapy with niraparib.Org: Henan Provincial People's Hospital, Guangzhou Women and Children's Medical Center affliated to Guangzhou Medical University, The Affiliated Cancer Hospital, School of Medicine, University of Electronic Science and Technology of China,
Abstract
Preliminary validation of a novel patient-reported outcomes (PRO) questionnaire for patients with cutaneous T-cell lymphoma: The CTCL-PRO-18.Org: Saint Louis University College for Public Health and Social Justice,
Abstract
Patient-centered perspectives: Examining quality-of-life integration in phase III lung cancer trials (2019-2023).Org: Sinai Hospital of Baltimore, Osmania Medical College, University of Illinois College of Medicine Peoria,
Abstract
Can systematic dental examinations or treatments in addition to routine multidisciplinary treatment in a palliative care unit (PCU) improve the quality of life (QoL) and symptom burden (SB) of patients (Pt) receiving palliative care (PC)?Org: Sarcoma Center Berlin Brandenburg Helios Clinc Bad Saarow, Sarcoma Center Berlin-Brandenburg, Helios Hospital Bad Saarow,
Abstract
An application (ePRO) -based patient reported outcomes of quality of life from an innovative cancer care delivery model.Org: Sarvodaya Cancer Institute, Faridabad, District Hospital, Ujjain, Civil Hospital Junagadh Gujrat,
Abstract
With eyes on the future: Prospective evaluation of immune-related adverse events in patients with lung cancer.Org: Hospital das Clinicas UFMG,
Abstract
Social isolation and psychosocial functioning among cancer survivors in the Cancer Prevention Study-3.Org: American Cancer Society, Rollins School of Public Health, Emory University, Atlanta, GA, USA,
Abstract
Association between perceived quality of care and social isolation among cancer survivors in the US.Org: Trinity Health Ann Arbor,
Abstract
Understanding breast cancer (BC) from the patient (pt) perspective: A qualitative study of symptoms, impacts and health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative (HR+, HER2–) BC.Org: Roche Global Breast Cancer Council, Europa Donna Slovenia,
Abstract
Longitudinal race/ethnicity (R/E) specific trends in patient-reported outcomes (PRO) in elderly women with breast cancer (BC) in the SEER-MHOS database.Org: Wisconsin Department of Health Services,
Abstract
PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform.Org: Treatment Technologies and Insights, Inc.,
Abstract
Cross-cultural differences in diet and quality of life between Taiwanese and American women during breast cancer treatment.Org: Georgetown University Medical School, National Taiwan University Hospital and National Taiwan University College of Medicine,
Abstract
Acupuncture for cancer symptoms: Clinical application and longitudinal impact.Org: Atrium Health Carolinas Medical Center, Charlotte, NC, NC Medical Research, Levine Cancer Institute, Department of Supportive Oncology,
Abstract
Trends and landscape of clinical outcome assessment use to support oncology product approvals.Org: Clario, Philadelphia, PA, PainReform,
Abstract
Patient Reported Outcome Measurement Information System (PROMIS) in routine oncological care: A literature review and survey of users.Org: KPMG,
Abstract
Impact of early phase study enrollment for pediatric oncology patients on symptom burden and quality of life (QOL): Early report of trial-in-progress results.Org: British Columbia Children's Hospital, Cancer Care Manitoba, Hopital Ste-Justine, Montreal Children's Hospital, Children's Hospital of Ontario,
Abstract
Screening oncology articles in a qualitative literature review using large language models: A comparison of GPT4 versus fine-tuned open source models using expert-annotated data.Org: BioSpark AI Technologies, Clinical Outcomes Solutions, BioSpark AI Technologies Inc.,
Abstract
Characterization of remote symptom alerts generated from patient-reported outcome (PRO) symptom monitoring in a real-world breast cancer population.Org: Dell Medical School at The University of Texas at Austin,
Abstract
Coping strategies and patient-reported outcomes (PROs) in early-phase cancer clinical trial (EP-CT) participants.Org: Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, MA, USA, Massachusetts General Hospital, University of Oklahoma Health Sciences Center, Brigham and Women's Hospital/Massachusetts General Hospital, University of Oklahoma Stephenson Cancer Center,
Abstract
Utilizing large language models (LLMs) to pre-label candidate concepts from in conceptual development landscape reviews in oncology.Org: BioSpark AI Technologies, BioSpark AI Technologies Inc.,
Abstract
Longitudinal changes in patient-reported outcomes (PROs) among early phase cancer clinical trial (EP-CT) participants.Org: Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, MA, USA, Massachusetts General Hospital, Brigham and Women's Hospital/Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, University of Oklahoma Health Sciences Center,
Abstract
Patient-reported and clinical outcomes among patients with pancreatic cancer.Org: Henry Ford Hospital, Henry Ford Health System, Henry Ford Cancer Institute, Detroit, MI,
Abstract
Evaluation of a technology enhanced breast multidisciplinary cancer conference (MCC).Org: Magee Womens Hospital of UPMC,
Abstract
EROS: Engendering reproductive health within oncologic survivorship—ECOG-ACRIN E1Q11 assessing discrepancy in clinician-patient importance of sexuality over 2 years post-cancer diagnosis.Org: John H. Stroger, Jr. Hospital of Cook County, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, University of Illinois Urbana-Champaign, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP,
Abstract
Maximizing efficiency and patient outcomes to meet the demands of a rapidly growing cancer institute.Org: New Hanover Regional Medical Center, Zimmer Cancer Institute,
Abstract
Reducing the time to chemotherapy start for planned admissions.Org: MedStar Georgetown Cancer Institute, MedStar Washington Hospital Center,
Abstract
Preferences of financial discussion among cancer care physicians and patients with cancer at a government cancer center in Nepal.Org: Bhaktapur Cancer Hospital,
Abstract
Evaluating the impact of translational research enrollment on the patient care experience of Veterans with prostate cancer who receive care through the Veterans Affairs (VA) healthcare system.Org: William S. Middleton Memorial Veterans Hospital,
Abstract
Implementation of patient navigation services to improve colorectal cancer health literacy in a vulnerable community health center population.Org: Jefferson Einstein Montgomery,
Abstract
Assessment of health-related quality of life (HRQoL) in triple-class–exposed patients with relapsed or refractory multiple myeloma (RRMM) treated with linvoseltamab in the LINKER-MM1 trial.Org: Indiana University Simon Cancer Center and Roudebush VAMC, Louisville, KY,
Abstract
Perspectives of facilitators and barriers to cancer clinical trial participation: A mixed-methods study.Org: University of Kentucky Markey Comprehensive Cancer Center,
Abstract
Can a medically integrated oncology pharmacy decrease waste and avoidance?Org: American Oncology Network Pharmacy,
Abstract
Targeted interventions to address local challenges in HR+/HER2- and HER2+ breast cancer treatment in community-based settings.Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Sarah Cannon Research Institute/Tennessee Oncology, PRIME Education, LLC,
Abstract
Oncologic outpatient specialty palliative care referral utilization: A single institution quality improvement project.Org: University of Kansas Medical Center, Department of Biostatistics & Data Science, Division of Gynecologic Oncology, University of Pennsylvania, University of Kansas School of Medicine - Wichita, University of Kansas Cancer Center, Kansas City, KS, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
Trainee-led quality improvement (QI) project examining PCP prophylaxis in patients on chronic, high-dose corticosteroids.Org: Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Johns Hopkins University Bloomberg School of Public Health,
Abstract
Climate therapy: Developing a climate change charter for Cancer Trials Ireland (CTI).Org: Cancer Trials Ireland, Cork University Hospital Group, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Creating a national model to build anti-cancer stewardship and quality improvement initiatives.Org: Pharmacy Benefits Management, Dept of Veterans Affairs, Pharmacy Benefits Management Services, VA Great Lakes Health Care System - VISN 12, VISN 8 Pharmacy Benefits Management,
Abstract
Educating and empowering health care teams who present to the hospital to recognize and intervene on cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients on bispecific t-cell engager therapy (BiTEs): A quality improvement study.Org: Stony Brook University Hospital, Stony Brook, NY,
Abstract
Association of Fried’s frailty phenotype, but not the clinical frailty scale, with overall survival in older adults with acute myeloid leukemia.Org: Division of Geriatrics, University of Pennsylvania, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Pennsylvania Health System,
Abstract
Developing a manual clinical trials screening process in a diverse southern gynecologic oncology practice in the Deep South.Org: Louisiana State University, Department of Gynecologic Oncology,
Abstract
Impact of multidisciplinary tumor boards on clinical decision making in a genitourinary oncology clinic in Mexico city.Org: Insurgentes Mixcoac, Salvador Zubirán National Institute of Health Sciences and Nutrition,
Abstract
Unveiling a low-hanging fruit: Single-center study on secondary immunodeficiency in newly diagnosed chronic lymphocytic leukemia and multiple myeloma.Org: Rochester General Hospital, Rochester, NY,
Abstract
Insight into quality of life: Understanding the experience of patients with cancer in southern Brazil's public healthcare system.Org: Hospital Evangelico HECI - Centro de Pesquisas Clinicas em Oncologia (CPCO), Hospital Evangelico de Cachoeiro de Itapemirim, Faculdade Multivix,
Abstract
Creating and establishing a sustainable culture of clinical and translational research at an academic cancer center.Org: University of Missouri School of Medicine,
Abstract
Clinical pathways utilization and concordance with standard of care.Org: Thomas Jefferson University Hospital, Philadelphia, PA,
Abstract
A novel 3D-printed scaffold for patient-specific partial breast reconstruction: A prospective, single-arm clinical trial.Org: Xijing Hospital Fourth Military University, Xi'an, shaanxi, China, Xijing Houspital, Xi'an Jiaotong University, Fourth Military Medical University,
Abstract
Treatment outcomes and prognostic factors of bowel function recovery after hyperthermic intraperitoneal chemotherapy and cytoreductive surgery for metastatic cancers of the abdomen and pelvis.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Baylor College of Medicine,
Abstract
Improving adequacy rates of bone marrow aspirate and core biopsies through training and a bedside X-ray device.Org: Westchester Medical Center, Valhalla, NY, Nykode Therapeutics,
Abstract
Development and preliminary validation of a platform for systematic, unbiased pre-screening of non-small cell lung cancer (NSCLC) across three community oncology practices.Org: New Mexico Oncology Hematology, Albuquerque, NM, New Mexico Cancer Center, Pacific Cancer Care, Monterey, CA, N-power Medicine, Redwood City, CA, Npowermedicine Inc, Redwood City, CA,
Abstract
The effect of distance reiki on patient reported quality of life, correlated with changes in immune repertoires among patients with multiple myeloma: A pilot study.Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN,
Abstract
An international expert consensus on improving the quality of care in patients with cancer by optimal central vascular access device selection.Org: Florida Atlantic University-Creative Precision Oncology, Affiliated Qingdao Central Hospital of Qingdao University, Catholic University Hospital 'A. Gemelli',
Abstract
Lessons learned in migrating from one commercial genetics decision-support tool to another: Assessment of data integrity and utilization readiness.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutch Cancer Center,
Abstract
LDCT lung cancer screening implementation in a Veterans Affairs hospital: A quality initiative.Org: Captain James A Lowell Federal Healthcare Center, RFUMS, FHCC,
Abstract
Electronic clinical quality measure (eCQM) concordance and quality care disparities among patients with breast cancer (BC).Org: CancerLinQ,
Abstract
Clinical outcomes of patients receiving venetoclax and hypomethylating agents for AML in academic and academic-community partnerships.Org: UVA Health System, University of Virginia Medical School, University of Virginia Cancer Center,
Abstract
Improving the understanding of integrative oncology approaches among hospitalized patients with cancer.Org: Sidney Kimmel Medical College of Thomas Jefferson University, Sidney Kimmel Cancer Center at Thomas Jefferson University, Thomas Jefferson University Hospital, Thomas Jefferson University,
Abstract
Pathways for provider initiated genetic testing to bridge the gap in germline genetic testing for metastatic breast cancer.Org: The University of Texas Health Science Center at Houston, McGovern Medical School, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Irradiate the knowledge gap: Empowering residents for blood product selection at Albany Medical Center.Org: Albany Medical Center, New York Oncology Hematology PC,
Abstract
Paclitaxel hypersensitivity reaction (HSR) rate: Titrated versus non-titrated infusions among gynecologic oncology patients.Org: University of Virginia Medical Center, University of Virginia, Charlottesville, VA, USA,
Abstract
Implementation of a hepatitis B screening program in patients receiving systemic anti-cancer therapy: A Canadian single center retrospective review.Org: University of Ottawa, Ottawa Hospital Research Institute, Ottawa Hospital Cancer Centre, The Ottawa Hospital Research Institute, The Ottawa Hospital Cancer Centre,
Abstract
Mobilizing exercise recommendations for people with bone metastases: An experience-based co-design approach.Org: Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada, University of British Columbia, Vancouver, BC, Canada, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada, University of Victoria, Victoria, BC, Canada, Canadian Cancer Society, Toronto, ON, Canada, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Patient Partner, Toronto, ON, Canada, University of Alberta, Edmonton, AB, Canada, BC Cancer/ University of British Columbia, Vancouver, BC, Canada, BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada, British Columbia Cancer Agency, Vancouver, BC, Canada,
Abstract
Patterns of vancomycin use in high-risk febrile neutropenia.Org: Henry Ford Health System, Henry Ford Hospital,
Abstract
Assessing the understanding and utilization of integrative oncology among patients with a history of cancer.Org: Sidney Kimmel Medical College of Thomas Jefferson University, Sidney Kimmel Cancer Center at Thomas Jefferson University,
Abstract
Quality improvement initiative leveraging tumor sequencing results to increase genetics referrals.Org: University of Michigan, Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, University of Michigan Medical School,
Abstract
An analysis of factors contributing to low colonoscopy rates at Kline Health Center in comparison to the national average in the USA (according to the internal quality measures of the medical group fiscal year 2023) and a follow-up initiative to improve colon cancer screening participation.Org: Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
Improving symptom screening rates for patients with head and neck cancer.Org: Temerty Faculty of Medicine, Centre for Quality Improvement and Patient Safety, Oncology Administration, Department of Radiation Therapy, Evaluative Clinical Sciences,
Abstract
Results of a quality improvement program to increase complete lung cancer biomarker testing rates by focusing on system, physician, and other factors associated with adverse health outcomes.Org: Youngstown, OH, Bon Secours St. Francis Cancer Center, Greenville, SC, Atlanta Cancer Care, OncoLens,
Abstract
Sleep disturbance and fatigue in patients with ovarian cancer during chemotherapy and surgery compared to PARPi maintenance therapy.Org: Cancer Support Community, Merck & Co., Inc.,
Abstract
Independent validation of 30-day emergency department visit after initial chemotherapy A-PROACCT model.Org: Orlando Health Cancer Institute,
Abstract
Addressing misinformation about cancer care in the clinical setting: A pilot study of a conversation guide and training for cancer care providers.Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Breaking the bad news of cancer: Exploring patient-doctor communication among clinical oncologists in Nigeria.Org: Department of Radiation Medicine, University of Nigeria Teaching Hospital, Enugu Nigeria., Federal University of Health Sciences, Otukpo, Makurdi, Benue, Nigeria, University of Nigeria Nsukka, Nsukka, Enugu, Nigeria, Cormode Cancer Foundation, Lagos, Nigeria, University of Nigeria Teaching Hospital, Enugu, Nigeria,
Abstract
Esophageal cancer in the United States: A 21-year mortality analysis (1999-2020).Org: H. Lee Moffitt Cancer Center and Research Institute, Services Institute of Medical Sciences, Dow University of Health Sciences, MCC Physicians,
Abstract
Outcomes of rituximab as treatment for immune thrombocytopenic purpura in patients who have failed steroids or IVIG: A retrospective study in a community practice.Org: Wichita, Kansas University School of Medicine - Wichita, KU School of Medicine-Wichita, Cancer Ctr of Kansas,
Abstract
Analyzing influential factors in suboptimal cervical cancer screening rates at Kline Health Center and implementing a subsequent initiative for improvement.Org: Brigham and Women's Hospital/Massachusetts General Hospital, New York Medical College - Saint Michael's Medical Center,
Abstract
Questionnaire survey and analysis of drug clinical research implementation capabilities of breast cancer treatment departments in Chinese hospitals.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Real-world (RW) antiemetic use and its association with duration of oral azacitidine (Oral-AZA) maintenance in patients (pts) with acute myeloid leukemia (AML) in the United States (US).Org: STATinMED Research,
Abstract
Guideline concordance of recurrence risk assessment for early breast cancer in a county-level setting in China.Org: The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China, The People's Hospital of Liuyang, Changsha, China, Changsha, China, Inner Mongolia Forestry General Hospital, Hulunbeier, China,
Abstract
Refining the 30-day emergency department visit after initial chemotherapy administration A-PROACCT model.Org: Orlando Health Cancer Institute,
Abstract
Retrospective study of BRAF inhibitor-based therapy in patients with BRAF mutated advanced solid tumors (RBAST study).Org: Department of Medical Oncology, Shaanxi Provincial People's Hospital, Xi'an Medical University, Medical oncology, Shaanxi Provincial People's Hospital, Shaanxi Provincial Peaple's Hospital, Shaxi Provincial People's Hospital,
Abstract
Aesthetics treatment with injectable fillers in patients with cancer: Safety and quality of life during active antineoplastic therapy.Org: Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Tel Aviv Sourasky Medical center, Tel Aviv, Israel,
Abstract
Real-world safety and efficacy of concurrent immunotherapy and thoracic chemoradiotherapy: A multi-institutional analysis.Org: Department of Radiation Oncology, Tongji Medical College, Hubei Cancer Hospital, Huazhong University of Science and Technology, Wuhan, China, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Efficacy and toxicity of KIT targeted therapy in elderly patients with melanoma.Org: Mayo Clinic, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Mayo Clinic Florida,
Abstract
Real world outcomes of 2,339 patients with early-stage triple-negative breast cancer (TNBC) treated in British Columbia.Org: BC Breast Cancer Outcomes Unit,
Abstract
Efficacy and toxicity of BRAF targeted therapy in elderly patients with melanoma.Org: Mayo Clinic, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Mayo Clinic Florida, Mayo Clinic Arizona,
Abstract
Cancer statistics: The United States vs. worldwide.Org: Mercy Catholic Medical Center, Lansdowne, PA, Virginia Commonwealth University School of Medicine, Maimonides Medical Center, Brooklyn, NY, Allegheny Health Network Cancer Institute,
Abstract
Cross-sectional and longitudinal associations between PG-SGA criteria with survival of cancer patients.Org: West China Hospital, Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, State Key Laboratory of Biotherapy, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China,
Abstract
Real-world treatment patterns and overall survival (OS) in locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC) in the U.S.Org: Analysis Group, Inc., Merck & Co., Inc., Department of Medical Oncology, Dana-Farber Cancer Institute,
Abstract
Real-world clinical effectiveness and treatment patterns in the early-stage esophageal/gastroesophageal junction cancer (EC/GEJC) population treated in the community oncology setting in the United States.Org: Merck & Co., Inc., Ontada, Rocky Mountain Cancer Centers,
Abstract
Clinicopathological characteristics and outcomes of patients with HER2-low breast cancer: 6-year ambispective cohort study from India.Org: Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Kasturba Medical College, Udupi, Manipal University Kasturba Medical College Manipal,
Abstract
Surgical decision-making after neoadjuvant chemotherapy for breast cancer.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York Oncology Hematology PC, Nykode Therapeutics,
Abstract
Analyzing megestrol prescribing patterns in the Medicare cancer population in a community oncology network.Org: The US Oncology Network, The Woodlands, Txinno Bioscience, Dallas,
Abstract
Different dosing strategies of pembrolizumab in the treatment of NSCLC: A real-world retrospective observational study.Org: University Clinic Golnik, University of Ljubljana, Faculty of Pharmacy,
Abstract
Tolerability, dose intensity, and prescribing patterns of capecitabine by race.Org: Tufts Medical Center Hematology-Oncology Fellowship,
Abstract
Nutritional assessment for 891 patients with common cancer in a cancer hospital of southwest China.Org: Chongqing University Cancer Hospital, Chongqing Cancer Hospital,
Abstract
Disparities in incidence and mortality of hematologic cancers in Southeast Asia: A 2020 analysis.Org: Franklin Regional High School, Murrysville, PA, Manila, Philippines, Corazon Locsin Montelibano Memorial Regional Hospital, Bacolod City, Philippines,
Abstract
Infections as a “cause of death” in patients with cancer: Need improved focus to improve outcomes?Org: Sarvodaya Hospital,
Abstract
Adherence to fertility preservation guidelines in young patients with breast cancer: A retrospective analysis.Org: Centro Estatal de Cancerología - Chihuahua, Centro Estatal de Cancerologia - Chihuahua,
Abstract
Gender disparities in incidence of psychological disorder among patients with breast cancer: A national cohort study.Org: Department of Psychiatry, Gangnam Severance Hospital, Yonsei University College of Medicine, Biostatistics Collaboration Unit, Yonsei University College of Medicine, St. Mary's Hospital, The Catholic University Medical College,
Abstract
Cancer burden across South Asia in 2020: A global cancer observatory analysis.Org: Georgetown School of Medicine, Jigme Dorji Wangchuk National Referral Hospital, Balco Medical Centre, Highmark Health, BINOR,
Abstract
First-line pembrolizumab for lung cancer in a Spanish real-world study.Org: Hospital Universitario Dr. Balmis de Alicante ISABIAL, Hospital Universitario La Coruña, Oncology Pharmacy Department, Catalan Institute of Oncology-Hospitalet, Hospital Universitario de Asturias,
Abstract
Mental health prevalence in Brazil: Understanding anxiety and depression in southern Capixaba region.Org: Hospital Evangelico HECI - Centro de Pesquisas Clinicas em Oncologia (CPCO), Cachoeiro De Itapemirim, Brazil, Hospital Evangelico HECI - Centro de Pesquisas Clincias em Oncologia (CPCO), Cachoeiro De Itapemirim, Brazil, Hospital Evangelico HECI - Centro de Pesquisas Clinicas em Oncologia (CPCO/HECI), Cachoeiro De Itapemirim, Brazil, Hospital Evangelico de Cachoeiro de Itapemirim, Cachoeiro De Itapemirim, Brazil, Faculdade Multivix, Cachoeiro De Itapemirim, Brazil,
Abstract
Real-world safety and healthcare resource utilization (HCRU) of lurbinectedin (lurbi) in patients (pts) with small cell lung cancer (SCLC): Jazz EMERGE 402 updated analysis.Org: Baptist Cancer Center, Memphis, TN, Rochester Regional Health, Rochester, NY, Carrie J. Babb Cancer Center, Bolivar, MO, Eastern Connecticut Hematology and Oncology Associates, Norwich, CT, Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec – Université Laval, Québec, QC, Canada,
Abstract
CancerX Data Sprint: Advancing national oncology data standards through a unique public-private partnership.Org: U.S. Department of Health and Human Services (HHS),
Abstract
Treatment patterns and outcomes in patients with early onset cholangiocarcinoma: A large database analysis.Org: Carver College of Medicine - University of Iowa,
Abstract
Real-world efficacy and adverse events of neoadjuvant immunotherapy in patients with early-stage triple-negative breast cancer: A multi-center experience.Org: Rochester Regional Health System, Pioneer Valley Oncology & Hematology,
Abstract
Real-world outcomes and molecular correlates of incorporating immunotherapy (IO) and bevacizumab (Bev) in treating patients with peritoneal mesothelioma (PeM): A comparative analysis with pleural mesothelioma (PM).Org: Lombardi Comprehensive Cancer Center of Georgetown University,
Abstract
Real-world data of cancer-associated venous thromboembolism in a tertiary-care hospital in India.Org: All India Institute of Medical Sciences (AIIMS), Rishikesh, India,
Abstract
Evaluation of recurrence rate in Canadian patients with stage II/III HR+/HER2- early breast cancer in the real-world setting.Org: Centre Hospitalier de l’Universite de Montreal, Hopital St-Sacrement, Center of Oncology Léon Richard, Novartis Pharmaceuticals Canada Inc., Novartis Canada,
Abstract
Trastuzumab biosimilars interchangeability: Preliminary real-world data in neoadjuvant breast cancer setting.Org: Hospital Erasto Gaertner,
Abstract
Trends in survival in solid malignancies with synchronous brain metastases: A population-based study.Org: Mahatma Gandhi Medical College & Hospital,
Abstract
Preferences among patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) in the era of B-cell maturation antigen (BCMA)-directed T-cell–engaging therapies.Org: Mayo Clinic Florida, Regeneron Pharmaceuticals, Inc., RTI Health Solutions,
Abstract
Melanoma immunotherapy longitudinal database: A comprehensive approach to capture oncological and toxicity data.Org: University of Texas MD Anderson Cancer Center, Quantitative Research Computing Department, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Rheumatology and Clinical Immunology Section,
Abstract
Evidence into practice: Changes in haploidentical versus double umbilical cord blood graft utilization for hematopoietic cell transplantation in the U.S. in relation to a pivotal randomized clinical trial.Org: University of Virginia Medical Center, University of Virginia, Charlottesville, VA, USA, CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, University of Virginia Health System,
Abstract
Asian and Pacific Islander cancer mortality trends in the United States between 1999-2020.Org: The University of Toledo College of Medicine and Life Sciences, The Univeristy of Toledo College of Medicine and Life Sciences, The University of Toledo Department of Medicine,
Abstract
Disparities and outcomes of immune checkpoint inhibitor therapies in LMICs: Retrospective study on current state, efficacy, and challenges in Armenia.Org: National Center of Oncology Armenia, Mikayelyan University Hospital, Armenian National Oncological Center, Erebouni Medical Center, Erebuni Medical Center,
Abstract
Clinical nSights: A software platform to accelerate real world oncology analyses.Org: nference, nference Labs,
Abstract
Use of CAR T cell vs non-CAR T cell therapy in the treatment of patients (pts) with multiple myeloma (MM) in the Medicare population.Org: Humbi AI,
Abstract
Unveiling the impact: Exploring thrombotic outcomes in hospitalized patients with COVID-19—Comparing those with and without a cancer diagnosis.Org: Charleston Area Medical Center (CAMC) Health Education and Research Institute, Charleston Area Medical Center (CAMC)/Outcomes Research,
Abstract
Prevalence of polypharmacy, drug-drug interactions, and inappropriate prescription in elderly patients with urological cancers.Org: Hospital Universitario Marques Valdecilla, HUMV,
Abstract
Clinical and outcome patterns in epithelial ovarian cancer (EOC) within a Latin American cohort.Org: Ninth of July University (UNINOVE), Sao Paulo, Brazil, Instituto Nacional de Enfermedades Neoplasicas, Lima, 51, Peru, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru, AUNA Ideas, Lima, Peru, Instituto De Enfermedades Neoplasicas, Lima, NY, Peru,
Abstract
Clinicopathologic features of patients with breast cancer in a single tertiary hospital in the Philippines.Org: St. Luke's Medical Center,
Abstract
A single institution review of immunotherapy use, adverse events, and outcomes in early-onset cancer.Org: University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, University Hospitals Center for Clinical Research, Case Western Reserve University School of Medicine, University Hospitals Sussex NHS Foundation Trust,
Abstract
Long-term survival of patients with lung cancer with kinase fusions (KF) treated at a tertiary community-based cancer program.Org: City of Hope - Atlanta,
Abstract
In-hospital outcomes of patients with lung cancer with and without superior vena cava thrombosis: A nationwide analysis.Org: Brooklyn Hospital Program, The Brooklyn Hospital Center, Brooklyn Hospital Center, Sound Physicians, Parkview Regional Medical Center,
Abstract
Real-world first-line treatment patterns and outcomes in patients with locally advanced or metastatic urothelial carcinoma in the United States.Org: University of Kansas Medical Center, Department of Biostatistics & Data Science, Astellas Pharma Inc., Astellas Pharma, Inc., Analysis Group, Inc., Pfizer Inc.,
Abstract
Real-world experience with fostamatinib in patients with immune thrombocytopenia: Results of an observational study (FORTE).Org: Southern Illinois University School of Medicine, Springfield, IL, Rigel Pharmaceuticals, Inc., Boston Medical Center,
Abstract
Incidence and outcomes of atrial fibrillation in different cancer subtypes: A propensity-matched analysis of Nationwide Readmissions Database.Org: Louisiana State University in Shreveport, John H. Stroger Jr. Hospital of Cook County, LSU Health Shreveport, LSU-Shreveport, Louisiana State University Health Sciences Center Shreveport,
Abstract
Retroperitoneal leiomyosarcoma; Demographics, clinicopathological, survival analysis, role of adjuvant radiation and genomic analysis.Org: Bolan Medical College, Dow International Medical College,
Abstract
Bevacizumab combination therapy versus standard chemotherapy for ovarian cancer in shorter and longer followup duration: A systematic review and meta-analysis of randomized controlled trials.Org: Allama Iqbal Medical College, King Edward Medical College, Fayoum University,
Abstract
Chalazion associated with proteasome inhibitors approved for multiple myeloma: Analysis of FAERS database.Org: Dayanand Medical College,
Abstract
Nationwide real-world usage of blood-based (liquid) biomarker testing in Japan.Org: Medical Affairs, MSD K.K., Tokyo, Japan, Oncology Medical Affairs, MSD K.K., Tokyo, Japan,
Abstract
Physician justification for anti-cancer treatment decisions in the evolving oncology market.Org: Ipsos Insight,
Abstract
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.Org: University of Chicago Medicine, University of Chicago, University of Chicago Medical Center, Chicago, IL,
Abstract
Usage pattern of anticoagulants in oncology patients receiving active anticancer therapies in Europe and Asia.Org: IQVIA, Amsterdam, Netherlands, London Regional Cancer Center, Madrid, Spain, Spain, Chicago, IL,
Abstract
Stereotactic radiosurgery in patients with small cell lung cancer and 1-10 brain metastases: A multi-institutional, phase II, prospective clinical trial.Org: DFCI/BWH Cancer Center, Milford Regional Medical Center, South Shore Health, Brigham and Women's Hospital/Dana-Farber Cancer Institute/Milford Regional Medical Center/South Shore Health, Brigham and Women's Hospital/Dana-Farber Cancer Institute/South Shore Health/Sturdy Health,
Abstract
Re-irradiation in recurrent glioblastoma: PET- or MRI-based? Results of a prospective randomized clinical trial.Org: Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany, Department of Nuclear Medicine, School of Medicine, Technical University Munich, Munich, Germany, Institute of Medical Biometry and Statistics, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany, Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany, Department of Radiation Oncology, University Hospital, Ludwig Maximilians University of Munich, Munich, Germany,
Abstract
Efficacy of next-generation genomic sequencing (NGS) applied to cerebrospinal fluid (CSF) in the identification of actionable mutations in Mexican patients.Org: Hospital Ángeles Puebla,
Abstract
Breaking barriers: Real-world data on immunotherapy in non-small cell lung cancer with large brain metastases.Org: MedStar Georgetown Cancer Institute, Washington, DC,
Abstract
Impact of gadopiclenol on decision making in patients with brain metastases: A post-hoc study.Org: UKHD,
Abstract
Evaluating hemoglobin thresholds for blood transfusions in oncology patients admitted in the intensive care unit.Org: Northeast Georgia Medical Center,
Abstract
Current trends in lung cancer brain metastases trials.Org: Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China, Northwestern Memorial Hospital, Chicago, IL, Feinberg School of Medicine, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Prediction of brain metastases of breast cancer using next generation sequencing genomics.Org: Wake Forest Baptist Medical Center, Wake Forest School of Medicine, Winston-Salem, NC, Atrium-Wake Forest Baptist Health,
Abstract
Effect of the timing of recurrence on survival among patients with breast cancer with brain metastasis.Org: Xavier University of Louisiana,
Abstract
Stereotactic radiosurgery (SRS) for non-small cell lung cancer (NSCLC) in the oncogene-addicted era: A real-world UK tertiary center experience.Org: Royal Marsden NHS Trust, Lung Unit,
Abstract
Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM).Org: Department of Neurology, Brigham and Woman’s Hospital, Harvard Medical School, Boston, MA, Cleveland Clinic Lerner Research Institute, Cleveland, OH, MediciNova, La Jolla, CA,
Abstract
A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).Org: Boehringer Ingelheim España S.A., Venn Life Sciences,
Abstract
A phase Ib, window-of-opportunity study of neoadjuvant avelumab and hypofractionated proton beam therapy for recurrent radiation-relapsed meningioma.Org: Washington University School of Medicine in St. Louis, Mayo Clinic, Washington University in St. Louis, BostonGene, Corp., BostonGene Corporation,
Abstract
Diagnosis and genetic characterization of CNS metastases in lung cancer via shallow whole-genome sequencing of CSF cell-free DNA.Org: Genetron Health (Beijing) Co. Ltd.,
Abstract
HLA class-I antigen presentation machinery (APM) alterations mediate immune evasion in lung cancer brain metastases.Org: Yale University, Catalan Institute of Oncology-Hospitalet, Hospital Duran i Reynals, IDIBELL Medical Oncology,
Abstract
A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas.Org: London Regional Cancer Program,
Abstract
Primary malignant brain tumours (PMBT) in phase I studies: Barriers to treatment and patient outcomes.Org: Departments of Neuro Oncology/Drug Development, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, London, United Kingdom, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Department of NeuroOncology, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Drug Development Unit at The Institute of Cancer Research and The Royal Marsden Foundation Trust, London, United Kingdom, The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom, Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom,
Abstract
Tyrosine kinase inhibitors with and without upfront CNS radiation for brain metastases in oncogene-driven non-small cell lung cancer (TURBO-NSCLC).Org: The James Cancer Hospital, Ohio State University Wexner Medical Center, University of Colorado Denver, Anschutz Medical Campus,
Abstract
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.Org: Berry Consultants, LLC, Seagen, Cleveland Clinic Taussig Cancer Instititute, Yale School of Medicine, University of California Irvine,
Abstract
Alterations of the tumor microenvironment (TME) in recurrent glioblastoma following apatinib in combination with temozolomide.Org: The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd.,
Abstract
Prognostic factors of grade 4 IDH-mutant astrocytoma.Org: Mayo Clinic, Rochester Regional Health System, MN,
Abstract
Socioeconomic disparities impact on the outcome of patients with diffuse and anaplastic astrocytoma: A SEER analysis of pediatric and adult populations.Org: Ascension Macomb Oakland Hospital, Faculty of Medicine, Ain Shams University, Ascension St John Hospital and Medical Center,
Abstract
Single institution analysis of glioblastoma multiforme (GBM) outcomes based on year of diagnosis: A 17 year review.Org: University College Cork, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Cork University Hospital Group,
Abstract
Descriptive analysis of brain metastases (BM) of solid neoplasms in an academic hospital from a low- and middle-income country (LMIC) with a Hispanic population.Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,
Abstract
A meta-analysis analyzing the efficacy of trastuzumab-deruxtecan (T-DXd) on central nervous system (CNS) disease in patients with metastatic breast cancer (mBC).Org: SUNY Upstate University Hospital, SUNY Upstate Medical University, SUNY Upstate Medical Center,
Abstract
NXL-004: A novel trans-differentiation therapy for glioblastoma treatment.Org: NeuExcell Therapeutics Suzhou, Dushuhu Hospital, NeuExcell Therapeutics Inc,
Abstract
Prospective validation from a retrospective trial that validated an AI/ML-derived whole-genome biomarker as the most accurate and precise predictor of survival and response to treatment in glioblastoma.Org: HudsonAlpha Clinical Services Lab LLC, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, Beijing Genomics Institute (BGI) -Shenzhen, Piedmont Healthcare and Case Western Reserve University School of Medicine,
Abstract
Transcriptional mechanisms of phenotypic plasticity in glioblastoma.Org: Institute For Systems Biology, Duke Medical Center,
Abstract
Analysis of transition metals in glioblastoma tumor and plasma samples.Org: Pennsylvania State University,
Abstract
Onco-functional outcome after resection for eloquent glioblastoma (GLIOFO): A propensity-score matched analysis of an international, multicentre, cohort study.Org: Harvard T.H. School of Public Health, Haaglanden Medical Center,
Abstract
Impact of next generation sequencing in high grade glioma management.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Cork University Hospital Group, University College Cork, Department of Neuropathology,
Abstract
The role of the ubiquitin ligase UBE4B in neural tumors in adults and children.Org: UCSD, San Diego, CA, Caris Life Sciences, Irving, TX, Caris Life Sciences, Phoenix, AZ, West Virginia University, Morgantown, WV, University of Minnesota Masonic Cancer Center, Minneapolis, MN,
Abstract
Targeting androgen receptor signaling in glioblastoma: A novel biomarker and therapeutic approach.Org: UNSW Sydney, St Vincent's Clinical School/Garvan Institute of Medical Research, QIMR Bergdorfer Medical Research Institute,
Abstract
The role of neoadjuvant clinical trials in patients with newly diagnosed glioblastoma.Org: Johns Hopkins University Bloomberg School of Public Health, John Hopkins University,
Abstract
Assessment of CDKN2A homozygous and hemizygous deletion status in gliomas.Org: Nanjing Simcere Diagnostics Co., Ltd,
Abstract
Deep learning for 4D modeling of glioblastoma multiforme with tumor treating fields (TTFields) therapy.Org: University of California Irvine, UCI Health,
Abstract
Survival implications and radiographic predictors of prognosis in patients with IDH-mutant astrocytoma with CDKN2A/b homozygous deletion: An international, multi-centered study.Org: University of Erlangen-Nuremberg,
Abstract
Personalized neoantigen-pulsed autologous dendritic cells vaccine as an adjuvant treatment for patients with newly-diagnosed glioblastoma multiforme: A phase I trial.Org: ZSky BioTech Co. LTD, Beijing, China,
Abstract
Exploring the diagnostic potential of cerebrospinal fluid (CSF) IL-10:IL-6 ratio in patients with primary central nervous system lymphoma (PCNSL).Org: Post Graduate Institute of Medical Education and Research, Chandigarh, Department of Clinical Hematology and Medical Oncology, Post Graduate Institute Of Medical Education & Research,
Abstract
Convolutional neural network and glioma genotyping: A systematic review.Org: Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran (Islamic Republic of), Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran (Islamic Republic of), Deakin University, Waurn Ponds, Australia, Deakin University, Geelong, Australia, University of Granada, Granada, Spain,
Abstract
Health state utility assessment for low-grade glioma.Org: Doctor of Osteopathic Medicine Program, OpenNotes and Beth Israel Deaconess Medical Center, Department of Health Research Methods, Evidence, and Impact,
Abstract
Combined NF2/PTEN mutations as predictors of meningioma aggressiveness.Org: University of Pennsylvania,
Abstract
Pineal gland: Sleep, malignancy and statistics.Org: Mercy Catholic Medical Center, Lansdowne, PA, Darby, PA,
Abstract
Incidence of venous thromboembolism in newly diagnosed glioblastoma multiforme and associated risk factors: A retrospective chart review.Org: International Medical Center,
Abstract
Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609).Org: SWOG Cancer Research Network Group Chair's Office, Oregon Health and Science University Knight Cancer Institute,
Abstract
Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant IO trials (PATHdata): Final analysis of a multi-institutional reproducibility study.Org: Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tuebingen, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Pathology, The University of Texas MD Anderson Cancer Center,
Abstract
Schwannomas: Experience from a single center reference in Peru.Org: National Institute of Neoplastic Diseases,
Abstract
Effect of fecal transplantation on patient reported outcomes after immune checkpoint inhibitor colitis.Org: The University of Texas School of Public Health,
Abstract
Single center experience of IDH inhibitors in high-grade gliomas.Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Immunological profiling of glioblastoma cellular composition to predict response to dendritic cell vaccination.Org: University of Sao Paulo (USP), Faculdade de Medicina Universiadade de S. Paulo,
Abstract
Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma: Preliminary efficacy and mechanism as a monotherapy.Org: Huashan Hospital Fudan University, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group, Zhejiang University, Hangzhou, China,
Abstract
Characteristics of hospital admission during checkpoint-inhibition therapy.Org: Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Claudia-von Schelling Comprehensive Cancer Center, Hannover Medical School, Hannover, Germany, Hannover Medical School, Hannover, Germany, Department of Neurology, Hannover Medical School, Claudia-von Schelling Comprehensive Cancer Center, Hannover Medical School, Hannover, Germany, Department of Neurology, Hannover Medical School, Hannover, Germany, Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany, Department of Gastroenterology, Claudia von Schilling Comprehensive Cancer Center, Hannover Medical School, Hannover, Germany, Department of Pneumology, Claudia von Schilling Comprehensive Cancer Center, Hannover Medical School, Hannover, Germany, Department of Dermatology, Allergology and Venerology, Claudia von Schilling Comprehensive Cancer Center, Hannover Medical School, Hannover, Germany, Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Claudia von Shilling Comprehensive Cancer Center, Hannover Medical School, Hannover, Germany, Department of Neurology, Claudia von Shilling Comprehensive Cancer Center, Hannover Medical School, Hannover, Germany, Department of Dermatology, Medical Center Minden, Minden, Germany, Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Claudia-von Shilling Comprehensive Cancer Center, Hannover Medical School, Hannover, Germany,
Abstract
Addition of IL-6 and phosphate to the m-EASIX score and detection of ICANS and CRS progression.Org: University of Arizona Cancer Center,
Abstract
Example of a simple and scalable manufacturing process for immunomodulatory alpha neutrophils, a specifically designed immuno-cell therapy with direct and indirect anti-cancer activity for solid tumour indications.Org: LIfT Biosciences Ltd., Foghorn Therapeutics,
Abstract
Effects of neutralization of tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial, and hepatocellular cancer.Org: University of Navarra Clinic, Pamplona, Spain, START-CIOCC Hospital Universitario HM Sanchinarro, Madrid, Spain, Medical Oncology Department, Catalan Institute of Oncology (ICO), L'hospitalet De Llobregat, Spain, Department of Oncology/Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland, Department of Hematology/Oncology, University of Wuerzburg, Wuerzburg, Germany,
Abstract
Preclinical analysis of the efficacy of near-infrared photoimmunotherapy and anti-PD-1 antibody combination therapy for treating CD73-positive lung cancer.Org: Laboratory of Bioanalysis and Molecular Imaging,
Abstract
Low-dose radiation as a preconditioning regimen for dendritic cell vaccines.Org: Washington University School of Medicine, St. Louis, MO,
Abstract
Single-cell transcriptome sequencing to explore the infiltration and disappearance of NK cells in liver cancer.Org: Inner Mongolia Autonomous Region People Hospital, Hohhot First Hospital,
Abstract
Immunomodulatory alpha neutrophils: The first-in-class neutrophil progenitor-based allogeneic immuno-cell therapy with cytotoxic and immunomodulatory functionality for the treatment of solid tumours.Org: LIfT Biosciences Ltd., Foghorn Therapeutics,
Abstract
Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab.Org: Gent University Hospital,
Abstract
A first-in-human, phase I, dose-escalation study to evaluate pharmacokinetics, safety, and tolerability of KD6001, a novel anti-CTLA-4 monoclonal antibody (mAb) in patients with advanced solid tumors.Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing),
Abstract
A novel B7-H3 x CD3 bispecific T-cell engager for the treatment of B7-H3+ tumors.Org: Excelmab Inc., Guangzhou, China,
Abstract
Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors.Org: New Experimental Therapeutics (NEXT), START San Antonio, Sarah Cannon Research Institute/Tennessee Oncology, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Merck & Co., Inc.,
Abstract
Influence of gender on acute kidney injury among patients undergoing chimeric antigen receptor T-cell (CAR-T cell) therapy: Insights from National Inpatient Sample.Org: Kansas University School of Medicine - Wichita, University of Kansas School of Medicine - Wichita, Cancer Center of Kansas,
Abstract
Novel specific TCRs targeting KRASG12V-related cancers.Org: Beijing CorreGene Biotechnology Co., Ltd.,
Abstract
Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer.Org: Beijing Imunopharm Technology Co., Ltd.,
Abstract
A phase Ia, dose-escalation study of IMB071703 injection in patients (pts) with recurrent or metastatic, advanced solid tumors.Org: Shanghai East Hospital, Tongji University, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Intracellular retention of TCRαβ/CD3 and CD7 to generate novel allogeneic CAR-T cells targeting CD7 for treating T-cell malignancies.Org: Fundamenta Therapeutics Co., Ltd.,
Abstract
Co-treatment of human GBM cell lines with imipridone ONC206 and tumor treating fields: Effect on on cell death and p-AKT.Org: Brown University, Providence, RI,
Abstract
A phase Ib/II study of an anti-CD137 agonist antibody ADG106 in combination with weekly paclitaxel and dose-dense doxorubicin/cyclophosphamide.Org: National University Cancer Institute, National University Health Systems, National Cancer Institute, Vilnius, Lithuania,
Abstract
IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: A phase I dose-escalation study.Org: Fudan University Shanghai Cancer Center, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Shandong Provincial Institute of Cancer Prevention and Treatment, The First Affiliated Hospital of Henan University of Science and Technology, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, China,
Abstract
Intracellular retention of TCRαβ/CD3 to generate novel allogeneic CAR-T cells targeting CLL1 for treating acute myelocytic leukemia.Org: Fundamenta Therapeutics Co., Ltd.,
Abstract
Dose escalation of KY-0118, PD-1, and IL-2v due-target fusion protein in patients with advanced renal clear cell carcinoma, urothelial carcinoma, and malignant melanoma.Org: Novatim Immune Therapeutics (Zhejiang), Shanghai, China, Gracell Biotechnologies, Ltd., Fudan University, Shanghai, China,
Abstract
Non-clinical evaluation of NT-112, an autologous T cell product engineered to express an HLA-C*08:02-restricted TCR targeting KRAS G12D and resistant to TGF-b inhibition.Org: Neogene Therapeutics, Santa Monica, CanSino Biologics, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Netherlands Cancer Institute,
Abstract
Risk stratification for immune effector cell-associated neurotoxicity syndrome in patients receiving chimeric antigen receptor T cell therapy.Org: Piedmont Athens Regional Hospital,
Abstract
Effect of cancer immunotherapy with CD39/PD-L1 bispecific antibody OriA631-b.Org: Shanghai Key Laboratory of Maternal Fetal Medicine Shanghai, Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University,
Abstract
Interim analysis of a phase I study using cryopreserved non-genetically modified allogeneic natural killer cells with enhanced cytotoxicity (SNK02) in patients with advanced solid tumors without lymphodepletion.Org: Medical Imaging Center of Southern California, NKGen Biotech Inc.,
Abstract
Effect of tobacco use on response to immunotherapy in patients with cancer.Org: Charleston Area Medical Center (CAMC) Health Education and Research Institute, Charleston Area Medical Center (CAMC)/Outcomes Research,
Abstract
Retrospective analysis on association of body mass index and immune checkpoint inhibitor response.Org: University of Vermont Medical Center, North Alabama Medical Center, William Beaumont University Hospital, University of California Irvine, Roswell Park Comprehensive Cancer Center,
Abstract
Next generation CD44v6-specific CAR-NK cells for the treatment of solid tumors.Org: Charité University Medicine Berlin, Charité - Universitätsmedizin Berlin, Berlin, Germany,
Abstract
Open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-175 in human leukocyte antigen-a*02:01-positive adult subjects with unresectable, advanced and/or metastatic solid tumors that are positive for the TP53 R175H mutation.Org: Baylor Charles A. Sammons Cancer Center, Neogene Therapeutics, Inc. – An AstraZeneca Group company,
Abstract
A phase 1/2 study to evaluate the efficacy and safety of HB0025 monotherapy for patients (pts) with advanced renal cell carcinoma (RCC).Org: Shanghai Cancer Center, Hunan Center hospital,
Abstract
Analysis of long-lasting tumor-specific antibodies from murine tumors treated with Aliya pulsed electric fields.Org: Galvanize Therapeutics,
Abstract
Analytical and clinical validation of a personalized, tumor-informed circulating tumor DNA assay for minimal residual disease detection.Org: HaploX Biotechnology, Shenzhen, China,
Abstract
Impact of circulating tumor DNA genomic mutations and circulating tumor cells biomarker duo on clinical concordance in localized, progressive, and metastatic disease.Org: Actorius Innovation and Research, Artemis Hospital,
Abstract
Development of a novel cell-free DNA fragmentomics assay for monitoring disease progression in real-time for stage IV cancer patients.Org: Cadex Genomics Inc., InnoGenomics Technologies, Highland Hospital/Alameda Health Systems, Cadex Genomics, Inc., BioRanking,
Abstract
The promising feeder-free allogenic NK cell therapy: Clinical outcomes of GIC-102 monotherapy (GIC-102101) and synergistic potential with GI-101 (CD80-IgG4 Fc-IL2v) in advanced solid tumors and hematologic malignancies.Org: GI Cell, GI Innovation,
Abstract
Analysis of proteomics based on LC-MS detection on the efficacy of immunocombined therapy for hepatocellular carcinoma.Org: Phase I Clinical Trial Unit,
Abstract
Predicting immunotherapy toxicity through single-cell sequencing of peripheral immune cells: A pilot study.Org: The Garvan Institute of Medical Research,
Abstract
First-line immunochemotherapy modulates peripheral immune landscape in advanced gastric cancer and gastroesophageal junction cancer (GC/GEJC): Prediction of response to combination therapy.Org: The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, Simcere Medical Laboratory Science Co., Ltd.,, State Key Laboratory of Neurology and Oncology Drug Development,
Abstract
Measure of minimal residual burden on circulating tumor cells with over-expression of programmed death-ligand 1 as a dynamic biomarker in patients with colorectal cancer.Org: Admatius, Actorius and School of Consciousness, MIT-WPU, Bhaktivedanta Hospital and Research Centre and School of Consciousness, MIT WPU,
Abstract
A first-in-human study to evaluate a personalized neoantigen-based mRNA-loaded dendritic cell vaccine, in combination with ablation, in patients with hepatocellular carcinoma.Org: Department of Interventional Ultrasound, Fifth Medical Center of Chinese PLA General Hospital,
Abstract
Comparative genomic profiling of circulating tumor DNA and paired formalin-fixed paraffin-embedded (FFPE) DNA from Indian patients with breast cancer.Org: OneCell Dx, Indx Technology, OneCell Dx Inc., Apollo Speciality Hospital,
Abstract
Metformin and cytokine release syndrome after immune effector cell therapy.Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic Rochester, Rochester, MN,
Abstract
Cytotoxic function of human natural killer cells is transiently inhibited by transforming growth factor beta (TGFβ).Org: Southern Illinois University School of Medicine, Springfield, IL,
Abstract
Pan-tumor circulating tumor DNA testing in the community oncology setting.Org: Ontada, Boston, MA,
Abstract
Potential of near real-time detection of cancer and immuno-oncology failure, within weeks of initiating therapy.Org: Colorado State University,
Abstract
The effect of resting dendritic cells on overall survival in the hepatocellular carcinoma tumor microenvironment.Org: Corewell Health System - Beaumont University Hospital, William Beaumont University Hospital, Royal Oak, MI, NYU Langone Health, New York, NY, New York, NY,
Abstract
Correlation of distinct circulating cytokine/chemokine profiles with clinical benefits of Pexa-Vec (thymidine kinase-deactivated vaccinia virus plus GM-CSF) and cemiplimab (REGN2810; anti-PD-1) in metastatic or unresectable renal cell carcinoma (mRCC).Org: Chonnam National University Medical School and Hwasun Hospital, Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonesi University College of Medicine, Department of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center,
Abstract
Platelet-mediated circulating tumor cell evasion from natural killer cell killing via immune checkpoint CD155-TIGIT.Org: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, China, Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China, Shanghai Dunwill Medical Technology Company, Shanghai, China, Shanghai Geriatric Institute of Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China,
Abstract
Pharmacokinetics, pharmacodynamics, and toxicity of a PD-1-targeted IL-15 in cynomolgus monkeys.Org: Pfizer Inc.,
Abstract
Effect of RIPK3 on non-canonical PANoptosis to suppress anti-tumor immunity in lung cancer.Org: Shanghai Chest Hospital, Jiaotong University,
Abstract
Cardiotoxicity of immune checkpoint inhibitors: A retrospective cohort study of 93,362 patients.Org: Baylor University Medical Center, Dallas, TX,
Abstract
Relationship between immune-inflammatory markers and clinical features and deepness of tumor response and prognosis of patients with PD-L1 ≥50% metastatic NSCLC receiving first-line immunotherapy.Org: Fengtai District,
Abstract
Effect of SLAMF8 on the phagocytosis of tumor-associated macrophages in colorectal cancer.Org: Naning Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College of Xuzhou Medical University, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University,
Abstract
A novel co-receptor with mutated TIGIT to enhance PSCA CAR-T therapy for bladder cancer.Org: Chongqing Institute of Precision Medicine and Biotechnology Co, Ltd, Chongqing Precision Biotech Co., Ltd.,
Abstract
Long cell-free DNA fragments predict early-progression in patients with advanced or metastatic cancer treated with immune-checkpoint inhibition.Org: Computational Pharmacology and Clinical Oncology, Adelis Technologies, CHU de La Timone APHM, Timone University Hospital Centre, ID.solutions,
Abstract
The clinical application of circulating tumor cells (CTCs) for immunotherapy in advanced pancreatic cancer.Org: Cancer Research Center, Beijing Chest Hospital, Capital Medical University/ Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijin, China, Department of Oncology, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China, Department of of Pathology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Cytelligen, San Diego, CA,
Abstract
Impact of urolithin A supplementation, a mitophagy activator on mitochondrial health of immune cells (MitoIMMUNE): A randomized, double-blind, placebo-controlled trial in healthy adults.Org: Amazentis SA, Lausanne, Switzerland, Buck Institute for Research on Aging, Novato, CA, Georg-Speyer-Haus Chemotherapeutisches Institut,
Abstract
The prognostic impact of transforming growth factor beta 2 (TGFB2) mRNA levels, in conjunction with interferon-gamma receptor activation of interferon regulatory factor 5 (IRF5) and expression of CD276/B7-H3 in low-grade gliomas.Org: Sapu Bioscience LLC, Oncotelic Therapeutics,
Abstract
YF550-C1, an E3 ligase inhibitor of CBL-B, to demonstrate T cell and NK cell activation and anti-tumor activities in syngeneic and PDX tumor model.Org: Zhuhai Yufan Biotechnologies Co, Ltd, Guangzhou, China, Tsinghua University, Beijing, China,
Abstract
Novel engineered regulatory macrophages combined with ICIs for post-transplant recurrence after liver transplantation for HCC.Org: The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Department of Liver Surgery and Liver Transplantation Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China,
Abstract
An exhaustive pre-clinical study of a circRNA drug candidate (cmRNA1210) encoding IL-12sc for anti-tumor therapeutics.Org: Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Suzhou CureMed Biopharma Technology Co., Ltd., Suzhou, China,
Abstract
CRPA1A2: A novel TCR-based T-cell engager targeting MAGEA1-positive solid tumors.Org: Beijing CorreGene Biotechnology Co., Ltd.,
Abstract
Pre-clinical safety and efficacy evaluation of sodium chloride nanoparticles for treating non-muscle invasive bladder cancer.Org: The University of Georgia,
Abstract
A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors.Org: NEXT Oncology, San Antonio, TX, Horizon Oncology Research LLC, Lafayette, IN, Summit Cancer Centers, Spokane Valley, WA, Huaota Biopharma Co., Ltd., Shanghai, China, Huaota Biopharm Co., Ltd., Shanghai, China,
Abstract
Effect of UNO101 on tumor microenvironment in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies..Org: Soroka - Clalit and Ben Gurion University Medical Center, Stanford University Medical Center, Stanford, CA, Beyond Cancer,
Abstract
Novel TROP2-targeted CAR T cells with high specificity and sustained efficacy for solid tumors in animal models.Org: OBI Pharma, Inc.,
Abstract
Expression of alternatively spliced PD-L1 RNA with skipping of transmembrane domain.Org: Genomic Testing Cooperative, Irvine, CA,
Abstract
Intravenous infusion (IV) or intracavitary perfusion (IP) of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody: Analyses of two phase 1 studies.Org: Immvira Co., Ltd., ImmVira Co., Limited,
Abstract
Hyaluronic acid hydrogel to modulate tumor cell clustering and programmed death ligand 1 signaling in cancer stem cells.Org: Department of Mechanical Engineering,
Abstract
Therapeutic potential of immune-cold solid tumors through homologous recombination deficiency.Org: OneCell Dx Inc., OneCell Dx, Indx Technology, OneCell Diagnostics,
Abstract
Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC).Org: Thomas Jefferson University Hospital, Philadelphia, PA, Florida Cancer Specialists and Research Institute, Sarasota, FL, Amgen, Thousand Oaks, CA, Amgen Europe B.V., Breda, Netherlands,
Abstract
Antitumor mechanisms of OncoTherad (MRB-CFI-1) nanoimmunotherapy involving monoamine oxidases: Clinical implications in BCG-unresponsive non-muscle invasive bladder cancer.Org: Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIM), Department of Structural and Functional Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil, Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIM) – Departament of Structural and Functional Biology, Institute of Biology - University of Cam, Campinas, Brazil, Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIM) - School of Medicine, University of Campinas (UNICAMP), Campinas, Brazil, Laboratory of urogenital carcinogenesis and immunotherapy (LCURGIM), Campinas, Brazil, Laboratory of Urogenital Carcinogenesis and Immunotherapy, School of Medicine, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil,
Abstract
Treatment-related adverse events of PD-1 versus PD-L1 inhibitors commonly used in lung cancer therapy: Analysis of real-world FAERS data.Org: Louisiana State University Program,
Abstract
TROCEPT: An oncolytic virus platform engineered for αvß6 integrin targeted tumor-localised expression of an immune checkpoint inhibitor following intravenous delivery.Org: Accession Therapeutics Ltd.,
Abstract
Immune checkpoint inhibitors and immune mediated diabetes mellitus: Meta-review of case reports.Org: Central Michigan University College of Medicine, Central Michigan University Educational Partners, Detroit Medical Center-Sinai Grace Hospital,
Abstract
Strong single-agent and PD-1/PD-L1 combination antitumor activity of antisense oligonucleotides suppressing Neuropilin 1 expression.Org: Secarna Pharmaceuticals, Planegg-Martinsried, Department of Biomedicine, University of Basel, Department of Biomedicine, University of Basel, Switzerland,
Abstract
Association between antibiotic use and mortality among older persons receiving first-line immune checkpoint inhibitors for non-small cell lung cancer (NSCLC).Org: Department of Medicine, Rutgers-Robert Wood Johnson Medical School, Rutgers University,
Abstract
Pembrolizumab-induced myocarditis: A systematic review of case reports.Org: Newton Medical Center,
Abstract
Risk factors for thrombotic events among patients taking immune checkpoint inhibitors: A systematic review and meta-analysis.Org: D. Samuel Gottesman Library,
Abstract
Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse events (irAE) requiring hospitalization: A single-center 10-year experience.Org: Far Eastern Memorial Hospital, Salem,
Abstract
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with other solid tumors: Safety and efficacy results from a phase I study.Org: Innovent Biologics (Suzhou) Co., Ltd., Beijing, China, Innovent Biologics (Suzhou) Co., Ltd., Shanghai, China,
Abstract
Effect of TT-816, a novel immune response modifier targeting cannabinoid CB2 receptor, on antitumor immunity and cancer growth.Org: Teon Therapeutics,
Abstract
Phase I summary of the HB0025 efficacy and safety to the heavily pretreated non-small cell lung cancer (NSCLC) population.Org: Fudan University Shanghai Cancer Center, Phase I Cinical Trial Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, China, Jinan Central Hospital, Shandong University, Shandong University of Traditional Chinese Medicine Affiliated Hospital,
Abstract
A phase 1 study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD), and to determine the recommended phase 2 dose (RP2D) of subcutaneous (SC) cetrelimab (CET) in patients (pts) with advanced solid malignancies.Org: Medical Oncology, START Madrid-FJD, University Hospital Fundación Jiménez Diaz, Madrid, Spain, Gregorio Marañón University General Hospital, Madrid, Spain, Newcastle University, Newcastle upon Tyne, United Kingdom, Janssen Research & Development LLC, Titusville, NJ, Janssen (A Pharmaceutical Company of Johnson & Johnson), Montclair, NJ,
Abstract
Anti-TNFR2 monoclonal antibody LBL-019 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose escalation Study.Org: Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China, Department of Oncology, Fujian Cancer Hospital, Fuzhou, China, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Lung & Gastrointestinal Oncology Department, Hunan Cancer Hospital, Changsha, China, Department of Internal Medicine-Oncology, Hubei Cancer Hospital, Wuhan, China,
Abstract
Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study.Org: Celebration, FL,
Abstract
Updated estimates of eligibility and response: Immune checkpoint inhibitors.Org: HUG, Geneva, Switzerland,
Abstract
Effect of aberrant N-glycosylation of PD-L1 on the potency of anti-PD-1 treatments.Org: Ben Gurion University of the Negev, Ben-Gurion University of the Negev,
Abstract
Combination treatment effect of an immunotherapeutic agent with microtubule inhibitors.Org: Marshall B. Ketchum University, Molecular Pharmacology Branch,
Abstract
Utility of the NLR and the ratio of NLR after and before adverse events for identifying irAEs and bacterial infections in patients with cancer during PD-(L)1 inhibitors treatment.Org: Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital,
Abstract
Relationship of angiotensin II receptor blocker (ARB) to the effectiveness of immune checkpoint blockade (ICB) in non-small-cell lung cancer (NSCLC) and inhibition of angiotensin II/AGTR1 signaling in fibroblasts to reduce collagen deposition in the tumor microenvironment (TME).Org: The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Nanjing, China, Jiangsu Province Hospital,
Abstract
Impact of the tumor proportion score (TPS) and the combined positive score (CPS) on the use of immunotherapy in patients with metastatic non-small cell lung cancer.Org: University of Illinois College of Medicine Peoria (UICOMP), Department of Medical Oncology, Yeditepe University Hospital, Istanbul, Turkey, Department of Pathology, Yeditepe University Hospital, Istanbul, Turkey,
Abstract
Pelareorep driven blood TIL expansion in patients with pancreatic, breast and colon cancer.Org: Oncolytics Biotech,
Abstract
PD-1 checkpoint inhibitors related immune-mediated hepatitis in colon cancer: A systematic review and meta-analysis.Org: New York Medical College - Saint Michael's Medical Center, Landmark Medical Center,
Abstract
STRIvE-02 Arm C: Phase 1 study of concurrent PD-1 inhibition with B7-H3 CAR T cell immunotherapy for recurrent/refractory pediatric solid tumors.Org: Seattle Children’s Research Institute, Seattle Childrens Research Institute,
Abstract
Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis.Org: Niterói, Acre Federal University, Federal University of Santa Catarina, Florianopolis, Viçosa Federal University,
Abstract
Arthralgia in patients with cancer receiving immune checkpoint inhibitor: A systematic review and meta-analysis.Org: University of Hawaii Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, John A. Burns School of Medicine, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Beth Israel,
Abstract
Integrated analysis of two phase 2 trials of nivolumab in metastatic rare solid cancer with dMMR or pMMR (MASTER KEY sub-studies: ROCK and ROLL trial).Org: Department of Medical Oncology, Kyoto University Hospital, Kyoto, Japan, Department of Hematology, Oncology & Cardiovascular medicine, Kyushu University Hospital, Fukuoka, Japan, Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan,
Abstract
Toxicity of weight-based vs. flat dosing for immune checkpoint inhibitors in patients with low weight: Retrospective analysis from a tertiary care center.Org: Chardon, OH, Cancer Informatics,
Abstract
Long-term pooled safety analysis of tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.Org: Royal Free Hospital NHS Trust and University College London, BeiGene (New Jersey) Co., Ltd.,
Abstract
Interplay of cachexia progression on the efficacy and toxicity of immune checkpoint inhibitors in patients with esophageal squamous cell cancer (ESCC): A longitudinal perspective.Org: Shandong Academy of Medical Science,
Abstract
Safety and preliminary efficacy of different doses of fecal microbiota capsule transplantation combined with anti-PD-1 inhibitor for patients with advanced malignant solid tumors.Org: State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease,
Abstract
Phase Ib study of a high potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced solid tumors.Org: Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, China, The First Hospital of Jilin University, Changchun, Jilin Province, China, Shanghai Jiatan Pharmatech CO., LTD., Shanghai, Shanghai, China, Shanghai Jiatan Pharmatech CO., LTD., Shanghai, China,
Abstract
Benchmarking the transcriptomic predictive biomarkers for immunotherapy plus chemotherapy: Results from phase III RATIONALE-309 and ORIENT-11 randomized trials.Org: Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China, Shantou University Medical College, Shantou, China,
Abstract
Synergistic antitumor activity of METTL3 peptide degrader and immune checkpoint inhibitor in advanced urothelial cancer.Org: School of Biomedical Sciences, Hunan University, First Affiliated Hospital of Air Force Military Medical University,
Abstract
Effect of GSDMD-mediated pyroptosis on the myocardial injury induced by PD-1 inhibitor combined with x-ray radiation.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Affiliated Hospital of Guizhou Medical University/Affiliated Cancer Hospital of Guizhou Medical University,
Abstract
Alleviating lung injury and pulmonary fibrosis in radiotherapy-immunotherapy combination: The role of low-dose radiation therapy.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Affiliated Hospital of Guizhou Medical University/Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China,
Abstract
Preliminary safety, antitumor activity, and pharmacodynamics of intratumoral ABO2011 (IL-12 mRNA) in patients with advanced solid tumors.Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, Department of Good Clinical Practice (GCP) center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Oncology, Shanxi Cancer Hospital, Taiyuan, China, Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,
Abstract
Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study.Org: The Fourth Ward of Medical Oncology, Shandong First Medical University Affiliated Cancer Hospital/Shandong Cancer Hospital/Shandong Cancer Prevention and Treatment Research Institute, Digestive Internal Medicine Second Ward, Pancreatic Oncology Department, Wuxi People's Hospital,
Abstract
The pan-cancer landscape of SMARCA4 and SMARCB1 alterations in a large cohort of Chinese patients.Org: General Hospital of Central Theater Command, Suzhou, China,
Abstract
A precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumors: An open-label, prospective, multicenter clinical study (PRaG 5.0 study).Org: The Second Affiliated Hospital of Soochow University, Department of Radiotherapy & Oncology,
Abstract
Possibilities of long-term atezolizumab immunotherapy in patients with metastatic urothelial cancer.Org: Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Tashkent, Uzbekistan,
Abstract
Effect of IL-15 on anti-tumor immune response to radio-immunotherapy through systemic immune activation.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China,
Abstract
Robust pancreatic tumor suppression by a novel combination treatment with anti-PD-1 immune checkpoint antibody and stroma modifying RNA oligonucleotide STNM01 in mice.Org: Molecular Oncologic Pathology, Department of Pathology and Host-Defense, Faculty of Medicine, Kagawa University, Takamatsu, Kagawa, Japan, Pharmacology, Department of Morphological and Functional Medicine, Faculty of Medicine, Kagawa University, Takamatsu, Kagawa, Japan, TME Therapeutics Inc., Minato-Ku, Japan, Tokyo Medical University, Shinjuku-Ku, Tokyo, Japan, Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Shinjuku-Ku, Tokyo, Japan,
Abstract
Impact of time-of-day infusion of camrelizumab combined with chemotherapy on efficacy in advanced malignant tumors.Org: Department of General Practice, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China, Guangdong Second Provincial General Hospital, Guangzhou, China, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China, Beijing Friendship Hospital, Beijing, China,
Abstract
Effect of targeting DDR pathway on the late-phase autophagy and the killing effect of CD8+ T cells.Org: Department of Biochemistry and Molecular Biology, Tianjin Key Laboratory of Medical Epigenetics,
Abstract
The rationale of reprogramming TREM2+ macrophages for overcoming the resistance to immune checkpoint inhibitors in pancreatic adenocarcinoma.Org: Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine,
Abstract
Prediction accuracy of biomarkers for response to immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis.Org: State Key Laboratory of Molecular Oncology, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences,
Abstract
Envafolimab plus chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Tangdu Hospital, Air Force Military Medical University, Xi'an, China,
Abstract
Immune-related adverse event prediction and influential factor identification.Org: Georgetown University Medical Center, Washington, DC, Georgetown Lombardi Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
PD-1 inhibitor combined with ablation in liver metastasis: A retrospective, multicenter study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, The First Affiliated Hospital of Zhengzhou University, Cancer Hospital Affiliated to Xinjiang Medical University,
Abstract
Predictive cytokine biomarkers for immune-related adverse events associated with immune checkpoint inhibitor therapy in Hodgkin lymphoma.Org: NYU Langone Medical Center, NYU Langone Health, New York, NY, Perlmutter Cancer Center, New York University Langone Health,
Abstract
Tumor-derived ILT3 inhibition to reshape the immunosuppressive microenvironment and potentiate the PD-L1 blockade immunotherapy in lung adenocarcinoma.Org: Department of Thoracic Radiation Oncology,
Abstract
Tumor purity as confounder for the determination of tumor mutational burden (TMB).Org: Heidelberg University Hospital, Heidelberg, Germany,
Abstract
A universal pipeline to combine spatial transcriptomics, proteomics, and diagnostic H&E assays on a single tissue section to study tissue microenvironment.Org: Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), National Cancer Centre Singapore, Department of Anatomical Pathology, Division of Pathology, Singapore General Hospital,
Abstract
Pervasive loss of antigen presentation in solid tumors driven by loss of HLA class I expression.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Buffalo, NY, Durham, NC, Burlington, NC,
Abstract
Comparison of pembrolizumab plus chemotherapy versus concurrent or sequential radiochemotherapy in patients with driver mutation-lacking lung adenocarcinoma presenting with recurrent laryngeal nerve invasion leading to hoarseness.Org: Jiangmen, China,
Abstract
Correlation of allele-specific HLA loss of heterozygosity in patients with cancer with driver mutations.Org: Affini-T Therapeutics, Inc., Foundation Medicine, Inc., Cambridge, MA, Memorial Sloan Kettering Cancer Center,
Abstract
Altering the gut microbiome and TME in advanced liver cancers: A phase II study of nivolumab, tadalafil, and oral vancomycin in refractory HCC or liver-dominant metastatic CRC or PDAC.Org: Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program,
Abstract
Efficacy and safety analysis of first-line tirelizumab combined with paclitaxel-containing chemotherapy regimen in 30 cases of real-world advanced gastric cancer in China.Org: China-Japan Friendship Hospital, Beijing University of Chinese Medicine,
Abstract
Pathological evaluation of tumor immune microenvironment before first-line anti-PD1 plus anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma (HCC): Towards a prediction for treatment efficacy.Org: Virtue Diagnostics (Suzhou) Co., Ltd., Panovue Biotechnology (Beijing) Co., Ltd.,
Abstract
Characterization of enhancer of zeste homolog 2 (EZH2) expression, activity, and association with the tumor immune microenvironment in olfactory neuroblastoma (ONB).Org: Caris Life Sciences, Irving, TX, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Huntsman Cancer Institute, Lombardi Comprehensive Cancer Center, Hunstman Cancer Hospital, University of Utah Health,
Abstract
Baseline heterogeneity of myeloid and stroma cells to predict pCR, baseline lymph node (LN) metastasis, and 1-year EFS in locally advanced ESCC with neoadjuvant immunotherapy: Final results from a single-arm, phase II clinical trial (SEEK-01).Org: Fudan University (Xiamen Branch), Xiamen, China,
Abstract
Advancing drug development by leveraging microdissection for proteogenomic analysis of histological sections.Org: University of Arkansas for Medical Sciences (UAMS), Loyola University Maryland, Avoneaux Medical Institute,
Abstract
Integrative multimodality spatial biomarker analysis for tailoring checkpoint inhibitor therapies in non-small cell lung cancer.Org: Aliri,
Abstract
Melanoma tumor microbiome as a predictor of anti-PD-1 and anti-CTLA-4 immunotherapy response.Org: University of California Irvine, San Diego State University Department of Biology, San Diego, CA, La Jolla, CA,
Abstract
Biological subgroups in melanoma: A correlation of tumor genomic and transcriptomic analysis with spatial immunophenotyping.Org: School of Medicine, Zhejiang University, Hangzhou, China, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, Huntsman Cancer Institute at the University of Utah,
Abstract
Fusobacterium nucleatum to promote esophageal squamous cell carcinoma progression via CCL20/CCR6-mediated migration of macrophages to the tumour micro environment.Org: Hospital of Hebei Medical University, Shijiazhuang, China,
Abstract
TERT-associated DNA polymerases genes link CAF and CD8+ T Cells to improve immunotherapy response rate across multiple cancers.Org: Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan, China, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
A rapid strategy to develop personalized cancer nanovaccines for different immunogenic tumors.Org: National Institute for Materials Science (NIMS),
Abstract
Positive associations of active immune therapy OBI-833/OBI-821 induced immune responses with clinical outcomes in patients with non-small cell lung cancer.Org: Tri-Service General Hospital,
Abstract
Development of an arenavirus-based immunotherapy for treatment of KRAS mutant cancer.Org: HOOKIPA Pharma Inc.,
Abstract
In vitro cell killing proficiency of autologous immune cells educated with allogenic multi-cancer tumor cell lysate.Org: Datar Cancer Genetics, Worcester Polytechnic Institute, Datar Cancer Genetics Inc,
Abstract
Unveiling a novel NKG2A inhibitor based on monoclonal antibody to HLAE-peptide complex.Org: Ben-Gurion University of the Negev,
Abstract
Effect of blocking CD96 on CD8+ T cell–mediated elimination of tumor dormancy.Org: Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,
Abstract
Unraveling the role of CTLA-4 variants in acute kidney injury after ICI treatments.Org: University of Florida Department of Health Outcomes and Biomedical Informatics, Department of Biostatistics and Health Data Science, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN,
Abstract
Combining the potency of a neoantigen-expressing DNA vector, an anti-CTLA-4 antibody, and an attenuated poxvirus in a personalized immunization platform: Preclinical studies of ODI-2001.Org: Odimma Therapeutics, myNEO,
Abstract
Bronchoalveolar lavage fluid analysis in patients with checkpoint inhibitor pneumonitis.Org: Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Department of Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China, Chinese Academy of Medical Sciences & Peking Union Medical College,
Abstract
Seasonal patterns in immunotherapy outcomes.Org: The University of Manchester and The Christie NHS Foundation Trust, The Christie NHS Foundation Trust, University of Manchester and The Christie NHS Foundation Trust, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Division of Cancer Sciences,
Abstract
First-in-human study of ZGGS15, a dual specific antibody targeting LAG-3 and TIGIT, as monotherapy in patients with advanced solid tumors.Org: Department of Medical Oncology, Linyi Cancer Hospital,
Abstract
ITHindex: An integrated tool for quantifying intra-tumor heterogeneity using omics data in cancers.Org: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Burning Rock Biotech, Guangzhou, China, Burning Rock Biotech, Shanghai, China,
Abstract
Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity.Org: Michigan Institute of Urology,
Abstract
Immune checkpoint inhibitors in advanced malignant peritoneal mesothelioma: Clinical insights, immunopathologic profiling, and prognostic implications from a single-center study.Org: Department of General and Oncological Surgery,
Abstract
Incidence of brain metastases within the VA Healthcare System.Org: Duke Cancer Institute, Durham VA Health Care System, Radiation Oncology Service,
Abstract
Feasibility study of a personalized tumor membrane vesicle vaccine immunotherapy for head and neck squamous cell carcinoma (HNSCC).Org: Metaclipse Therapeutics Corporation,
Abstract
Reporting of immune-related adverse events (irAEs) in US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.Org: Washington University in St. Louis, Medical College of Georgia at Augusta University, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
ADPORT-601: First-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in patients with select advanced solid tumors.Org: NEXT Oncology, Fairfax, VA, Norton Cancer Institute, Louisville, KY, Portage Biotech, Westport, CT,
Abstract
Effect of a novel anti-PD-1-proIL-2 bifunctional fusion protein on potent anti-tumor activity via PD-1 checkpoint inhibition and conditional IL-2R agonism.Org: Proviva Therapeutics, Bedford, MA, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Phase I/II safety and preliminary efficacy of PM1022, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors.Org: Shanghai East Hospital, Tongji University, Shanghai, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Science, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, Department of Medical Oncology, Shanghai East Hospital, School of Medicine, Tongji University,
Abstract
Using exponential decay to model survival curves in immunotherapy trials.Org: Western University, The Ottawa Hospital Cancer Centre,
Abstract
COPD comorbidity and checkpoint inhibitor pneumonitis in a case-control study of patients with lung cancer.Org: Atrium Health Wake Forest Baptist Medical Center, Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Wake Forest School of Medicine, Winston-Salem, NC,
Abstract
Phase I safety and preliminary efficacy of PM1009, a bispecific antibody targeting TIGIT and PVRIG, in patients with advanced solid tumors.Org: Shanghai East Hospital, Tongji University, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai Henlius Biotech, China National Biotec Group,
Abstract
Routine documentation of pre-treatment functional variables to predict survival in patients on immunotherapy.Org: Department of Hematology & Oncology, College of Medicine, University of Oklahoma Health Sciences Center, Wake Forest Baptist Medical Center, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Atrium Health Wake Forest Baptist Medical Center, Wake Forest University School of Medicine,
Abstract
Update on the prognostic value of a novel immune-related toxicity grading system (OST score) in patients with advanced solid tumours treated with immune checkpoint inhibitors (ICI).Org: Guy's and St. Thomas' NHS Foundation Trust, Guy's and St. Thomas' Hospital,
Abstract
Comparative efficacy of six programmed cell death protein-1 inhibitors in first-line treatment for advanced non-small cell lung cancer: A retrospective cohort study.Org: Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital,
Abstract
Immune related adverse events: Timing, identification patterns, and impact on survival.Org: Gundersen Clinic Ltd,
Abstract
Prediction of immune-related adverse events in urological cancer during checkpoint inhibitor immunotherapy through immunohistochemical analysis of tumorous LCP1/ADPGK.Org: Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, National Urological Cancer Center,
Abstract
The timing of checkpoint inhibition in relation to stem cell transplantation increases the risk of inflammatory adverse events.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, The University of Texas Health Science Center at Houston, Baylor College of Medicine, The University of Texas Health Sciences Center, Texas A&M Unniversity,
Abstract
Immune checkpoint inhibitor-related reproductive adverse effects: A pharmacovigilance analysis based on the FAERS database.Org: Koc University Medical School,
Abstract
Effect of common medications on immune checkpoint inhibitor efficacy.Org: Department of Hematology/Oncology, University of Michigan, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Veterans Affairs Ann Arbor Healthcare System,
Abstract
NCI MATCH (EAY131) arm Z1D: Retrospective evaluation of attributions of adverse events experienced on nivolumab in patients with MSI-high tumors.Org: University of Maryland, Germantown, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, Cancer Diagnosis Program, National Cancer Institute, Rockville, MD, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD,
Abstract
Immune-related adverse events in patients treated with immunotherapy according to corticosteroid exposure.Org: Hospital General Regional No. 1. “Dr. Carlos Mac Gregor Sánchez Navarro”,
Abstract
Diverging acquired resistance evolutionary pathways in fusion-positive patients treated with tyrosine kinase inhibitors.Org: Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College,
Abstract
Predictors of endocrine immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICI) in routine clinical practice.Org: FSBEI He Rosunimed of MOH of Russia,
Abstract
9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study.Org: Gynecologic Oncology Department, Fudan University Cancer Hospital, Medical Oncology Department, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Urology Department, Affiliated Cancer Hospital of Chongqing University, Urologic Oncology Department, Tianjin Medical University Cancer Hospital, Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute & Hospital,
Abstract
Comparison of efficacy of antibody drug conjugate (ADCs) between younger and older patients: A meta-analysis of phase 3 studies.Org: Hôpitaux-Universitaires-Paris-Seine-St-Denis, Sevran, UCOG, Hôpital René Muret, HUPSSD,
Abstract
Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors.Org: Minghui Pharmaceutical (Hangzhou) Ltd.,
Abstract
Immune checkpoint inhibitor-associated gastrointestinal adverse events in patients with colorectal cancer.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, The University of Texas Health Science Center at Houston,
Abstract
ReNeu: A pivotal phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN).Org: University of Florida Clinical Research Center, The University of Arkansas for Medical Sciences/Arkansas Children’s Hospital, AdventHealth for Children,
Abstract
Preclinical studies of an innovative 5T4-ADC ACR246 with the potential to better treat 5T4-positive solid tumors.Org: Hangzhou Adcoris Biopharma Co., Ltd,
Abstract
Association between stromal tumor-infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in patients with early breast cancer (BC) treated with neoadjuvant chemotherapy and HER2-directed therapies in NSABP B-41.Org: NSABP/NRG Oncology and the UPMC Hillman Cancer Center,
Abstract
Impact of commonly prescribed medications on immune-related adverse events.Org: Veterans Affairs Ann Arbor Healthcare System,
Abstract
A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Newcastle University, Northern Centre for Cancer Care (NCCC), New Experimental Therapeutics (NEXT), Merck Serono Ltd.,
Abstract
Results of a phase 1/2 study of MHB036C: A potential best-in-class TROP2 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in locally advanced or metastatic solid tumors.Org: Zheijang Cancer Hospital, Department of Oncology, the Second People's Hospital of Yibin, Nanyang First People's Hospital,
Abstract
Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study.Org: Department of Abdominal and Pelvic Medical Oncology, The First People's Hospital of Tianmen City, Affiliated Hospital of Hubei Technology College, Tianmen, China,
Abstract
Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.Org: Royal Marsden/Institute of Cancer Research, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Sir Bobby Robson Cancer Trial Research Centre,
Abstract
Enrichment of somatic mosaic states involving DNA damage response and repair genes in patients treated with 177Lutetium.Org: Mayo Clinic Arizona, Phoenix, AZ, Mayo Clinic Florida, Jacksonville, FL, Mayo Clinic, Rochester, MN, Division of Medical Oncology, Mayo Clinic, Rochester, MN, Department of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL, Mayo Clinic Comprehensive Cancer Center, Phoenix, AZ,
Abstract
Reproducible and high sample throughput isomiR next-generation sequencing for cancer diagnosis.Org: Jiansheng Medical Technology Co., Ltd, Guang'anmen Hospital,
Abstract
Phase 1 study of ZV0203, a first in class pertuzumab ADC, in patients with HER2 positive advanced solid tumors.Org: Hangzhou Adcoris Biopharma Co., Ltd,
Abstract
Discovery of HDM2010, a highly potent PTPN2 inhibitor for immunotherapy.Org: Global Drug R&D Center,
Abstract
Adverse events of patients treated with antibody-drug conjugates in phase 1 clinical trials at the Royal Marsden Drug Development Unit from 2014 to 2024.Org: The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,
Abstract
FS-1502 in patients with HER2 high expression, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: An open-label, multicenter, phase II study.Org: Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Shanxi Provincial People's Hospital,
Abstract
Hemay181: A novel SDC (sugar linked drug conjugate) for solid tumors targeting tumor microenvironment.Org: Hemay, Ganzhou Hemay Pharmaceuticals Co., Ltd.,
Abstract
Increased risk of hyperglycemia in patients with advanced urothelial cancer treated with enfortumab vedotin: A systematic review and meta-analysis.Org: Renaissance School of Medicine at Stony Brook University,
Abstract
First-in-human phase I clinical trial of RSO-021, a first-in class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE).Org: Bexon Clinical Consulting, LLC,
Abstract
BC3195, a novel ADC targeting CDH3: Preliminary results of a first-in-human phase I study in patients with advanced solid malignancies.Org: Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Biocity Biopharmaceutics, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Supersulfide metabolome of exhaled breath condensate for diagnostic biomarkers of esophageal cancer.Org: Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan, Department of Environmental Medicine and Molecular Toxicology, Tohoku University Graduate School of Medicine, Sendai, Japan, Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine, Sendai, Japan,
Abstract
The role of folate receptor-positive circulating tumor cells in the prognosis analysis of esophageal squamous cell carcinomas.Org: School of Medicine, University of Electronic Science and Technology of China,
Abstract
A phase I clinical study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and preliminary efficacy of SCB-219M in patients with chemotherapy-induced thrombocytopenia (CIT): An interim analysis.Org: Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Sixth People's Hospital of Chengdu,
Abstract
Development of novel MUC1-C targeting antibody-drug conjugate for pancreatic cancer treatment.Org: XYone Therapeutics,
Abstract
Blood metabolites–based MCTarg for multi-cancer screening and clinical diagnosis.Org: Metanotitia Inc., Jiangxi Institute of Respiratory Disease,
Abstract
Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors.Org: Southern Oncology Clinical Research Unit Pty Ltd., Macquarie University, Cabrini Research, Alfred Health, Carolina BioOncology Institute,
Abstract
SCR-A002, a novel FGFR2b-targeting antibody-drug-conjugate for solid tumors.Org: State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China, Jiangsu Simcere Pharmaceutical,
Abstract
Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from the randomized phase II trial CHIVA (GINECO).Org: CHU Saint-Etienne, EMR3738 Therapeutic Targeting Laboratory in Oncology, Lyon-Sud Hospital, Hôpital Privé du Confluent, Centre Hospitalier Lyon Sud, Oncologie Médicale,
Abstract
A novel oral microtubule inhibitor utidelone capsule (UTD2): A phase 1 clinical study to assess the tolerability, safety, and efficacy in advanced solid tumors.Org: Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Washington University in St. Louis, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Beijing Biostar Pharmaceuticals, Biostar Pharma,
Abstract
Circulating tumor cells enumeration and characterization in patients with lung cancer treated with immunotherapy.Org: Division of Medical Oncology, Department of Oncology, London Regional Cancer Program, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, London Regional Cancer Program, London, ON, Canada, Department of Oncology, Division of Medical Oncology, Schulich School of Medicine & Dentistry, Western University and London Regional Cancer Program, London, ON, Canada, University of Western Ontario, London, ON, Canada, Department of Oncology, Division of Medical Oncology, London Regional Cancer Program, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, Epic Sciences, San Diego, CA, London Health Sciences Centre, London, ON, Canada,
Abstract
HER2 expression-independent antitumor effect of trastuzumab deruxtecan (T-DXd) on pediatric solid tumors.Org: Division of Cancer Immunodiagnostics, Children's Cancer Center, National Center for Child Health and Development,
Abstract
Role of serum α-Klotho level in patients with breast carcinoma.Org: Kasturba Medical College, Karnataka,
Abstract
Plasma circulating tumor DNA in patients with cutaneous squamous cell carcinoma: Initial experience.Org: Cleveland Clinic Taussig Cancer Instititute,
Abstract
Assessment of plasma cell-free DNA fragmentation for multi-cancer early detection: An independent clinical validation study.Org: HaploX Biotechnology, Shenzhen, China, Department of Clinical Laboratory, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Peking University Shenzhen Hospital,
Abstract
YB-800, a monoclonal antibody targeting the human neuronal pentraxin receptor (NPTXR), as a potential candidate for the design of a first in class antibody drug conjugate (ADC) as novel therapeutic intervention in gastro-intestinal cancers.Org: Ymmunobio, University Clinic Essen,
Abstract
Novel protein drug conjugate ANXV-chemo and cytotoxic and anti-proliferative effects against human triple-negative breast cancer in vitro.Org: Annexin Pharmaceuticals AB (publ), Truly Labs AB, ALMIR Conseil,
Abstract
Effect of circulating tumor cells in clinically stable patients on the conundrum of recurrence with cellular residual disease.Org: Max Healthcare, Kokilaben Dhirubhai Ambani Hospital, MIT WPU,
Abstract
Concordance between tissue (tumor DNA) and liquid (ctDNA) biopsy next-generation sequencing (NGS) data in detection of PIK3CA, AKT1, and PTEN alterations in breast cancer: A retrospective analysis.Org: Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, AstraZeneca, Gaithersburg, MD,
Abstract
Enhancing liquid biopsy potential: The impact of the R3CE 3D culture platform.Org: Institute of Molecular and Cellular Biology, National Taiwan University, Taipei, Taiwan, Stanford Cancer Institute, Palo Alto, CA, Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan, Department of General Surgery, Chang Gung Memorial Hospital at Tao-Yuan, Tao-Yuan, Taiwan, AcroCyte Therapeutics Inc., New Taipei City, Taiwan,
Abstract
Advancing cancer MRD monitoring through tumor whole-genome informed, duplex ctDNA sequencing.Org: Genome Insight Inc., San Diego, CA, Genome Insight, Inc., Genome Insight, San Diego, CA,
Abstract
The NAVigate-HPV Registry: A comprehensive biomarker evidence base for HPV-driven cancers.Org: Naveris, Inc., The Ohio State University - James Cancer Hospital, CARTI, Hollings Cancer Center, Medical University of South Carolina,
Abstract
Disease monitoring using plasma-based circulating tumor DNA (ctDNA) assays in rare malignancies.Org: Mayo Clinic Florida, Jacksonville, FL,
Abstract
Multi-cancer early detection (MCED) in circulating tumor DNA (ctDNA) using an ultrasensitive mutation-based amplicon next-generation sequencing (NGS) assay.Org: Lucence Diagnostics Pte Ltd,
Abstract
Flushing fluid of post-bronchoscopic biopsy as a novel liquid biopsy specimen for genome profiling in advanced lung cancer.Org: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, Guangzhou Institute of Respiratory Health, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University,
Abstract
Examination of genomic profile of true single circulating tumor cells (sCTC) from hepatocellular carcinoma and its effect on mutational features.Org: Fortis Healthcare,
Abstract
Thioredoxin 1 in blood as a monitoring biomarker for patients with breast cancer post-treatment.Org: E&S Healthcare,
Abstract
Type III collagen pro-peptides (PRO-C3) as a proposed prognostic biomarker of risk of survival outcomes in clinical trials of patients with solid tumors.Org: Nordic Bioscience,
Abstract
Cancer associated macrophages in blood correlates with poor outcomes in patients with clinically resectable disease in gastrointestinal cancers.Org: Rutgers School of Engineering,
Abstract
Simultaneous detection of tumor-derived mutations in DNA and RNA extracted from a single circulating tumor cell based on droplet digital polymerase chain reaction.Org: CytoGen,
Abstract
Pre- and post-radical surgery comparative quantification of circulating tumor cells and circulating tumor-associated cells.Org: Datar Cancer Genetics, Datar Cancer Genetics Inc, Datar Cancer Genetics Limited, Datar Cancer Genetics Pvt Ltd,
Abstract
Molecular profiling using next generation sequencing with high-purity enrichment of circulating tumor cells.Org: CytoGen, Inc.,
Abstract
Development of custom amplicon-based test systems for detecting KRAS, NRAS, and BRAF gene mutations in colorectal cancer using next-generation sequencing (NGS).Org: Genomed,
Abstract
Evaluation of concordance between blood-based and matched tissue molecular testing in a regional cancer center.Org: Hoag Family Cancer Institute and University of Southern California, Newport Beach, CA,
Abstract
Correlating survival outcomes in patients with advanced prostate cancer with novel hyperpolarized 13C MRI metabolic imaging biomarkers.Org: Radiology and Biomedical Imaging, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Helen Diller Family Comprehensive Cancer Center,
Abstract
MSK-ACCESS powered with SOPHiA DDM: Performance analysis of a decentralized MSK-ACCESS solution.Org: SOPHiA GENETICS,
Abstract
Reporting an Indian multicentric community oncology practice’s observation on patterns of homologous recombinant deficiency across various solid cancers evaluated through tumor-DNA-based NGS.Org: MOC Cancer Care & Research Centre, Mumbai, Maharashtra, India, MOC Cancer Care and Research Centre, Mumbai, Maharashtra, India, MOC Cancer Care & Research Centre, Mumbai, India, MOC Cancer Care and Research Centre, Mumbai, India, Mumbai Oncocare Centre, Mumbai, India,
Abstract
Dual analysis of IL-8 in non-small cell lung cancer: A clinical perspective on protein and RNA evaluation via imaging mass cytometry.Org: Aliri, Loos, France, France,
Abstract
Role of artificial intelligence in ocular tumors: A systematic review.Org: Faculty of Mathematics, Statistics, and Computer Sciences, University of Tabriz, Tabriz, Iran,
Abstract
Next-generation sequencing in patients with lung cancer undergoing immunotherapy: Retrospective analysis.Org: University of Vermont Medical Center, Corewell Health System - Beaumont University Hospital, William Beaumont University Hospital, University of Vermont Cancer Center, University of California, Riverside,
Abstract
Dual targeting of αv and α5β1 integrins in triple-negative breast cancer (TNBC).Org: Tufts Medical Center/Tufts University, Boston Pharmaceuticals, MaaT Pharma, Tufts University School of Medicine,
Abstract
Characterizing clinical trials for CAR T targeting solid tumors from 2018 to 2023: A systematic review.Org: Division of Hematologic Malignancies & Cellular Therapies, US Myeloma Research Innovations Research Collaborative,
Abstract
CancerHallmarks.com: A tool for the enrichment analysis of the cancer hallmarks.Org: Semmelweis University, Budapest, Hungary, Semmelweis Egyetem Pulmonologiai Klinika, Seagen, Inc.,
Abstract
Multidimensional tumor profiling and its meaningful impact on personalized therapy outcomes: Insights from a real-world study.Org: Datar Cancer Genetics Europe GmbH,
Abstract
Pharmacodynamics of venetoclax plus cirtuvivint a first-in-class splice variant regulator.Org: Biological Testing Branch, Pharmacodynamics Biomarker Program, Clinical Pharmacodynamic Biomarker Program, Frederick National Laboratories for Cancer Research,
Abstract
A blood-based screening test for colorectal cancer (CRC) using methylation sequencing.Org: Strand Life Sciences, Strand Life Sciences Scientific Advisory Board,
Abstract
Evaluating the significance of next-generation sequencing (NGS) testing in Indian patients with advanced malignancies: An observational study on clinical outcomes and treatment costs.Org: Apollo Healthcare,
Abstract
A phase 1 study of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated (TAA) CD8+T cells in patients with advanced solid tumors.Org: Shanghai Cancer Center Fudan University,
Abstract
Study on the mechanism of ginsenoside Rg5 attenuating radiation myocarditis through GDF11-SIRT1 pathway.Org: Sichuan Cancer Hospital & Institute, Sichuan, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Chengdu, China, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Initial clinical experience with the first-in-class anti-metastasis therapeutic TTX-MC138.Org: TransCode Therapeutics, Inc.,
Abstract
Pharmacogenomic diversity of clinically significant cancer treatment biomarkers in ancestrally diverse US population.Org: Medical College of Wisconsin, Milwaukee, WI,
Abstract
Evaluation of a novel Pan-RAS/β-Catenin inhibitor, ADT-030, for treatment of pancreatic cancer.Org: ADT Pharmaceuticals, LLC.,
Abstract
Molecular imaging research on 18F-FDG PET/CT and biomarker analysis to predict the efficacy of neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIB NSCLC.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Shandong Cancer Hospital Affiliated to Shandong University,
Abstract
Effect of sodium thiosulfate anhydrous on cisplatin-induced ototoxicity in pediatric cancers: Turkish compassionate use treatment protocol—Updated results.Org: Ankara University Department of Pediatrics, Acibadem MAA University, Ege University Faculty of Medicine, Uludag University Faculty of Medicine, Inonu University Faculty of Medicine,
Abstract
A potent and selective pan-RAS inhibitor, ADT-1004, targeting complex KRAS mutations for pancreatic cancer.Org: ADT Pharmaceuticals, LLC.,
Abstract
Effect of DeltaRex-G ± DeltaRex-G Plus (an FDA-approved drug) on advanced chemoresistant pancreatic cancer, sarcoma, and breast cancer.Org: William H. Isacoff, MD, Inc,
Abstract
A phase II study of liposomal irinotecan-based chemotherapy with or without PD-1 inhibitor in patients with unresectable locally advanced or metastatic biliary tract cancer.Org: Zhejiang Chinese Medical University,
Abstract
Use of integrated multi-omics analysis to determine antitumor efficacy of donafenib in combination with FADS2 inhibition in hepatocellular carcinoma.Org: Beijing Cancer Hospital & Institute, Department of Interventional Therapy, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China,
Abstract
Repurposing hemostatic drug desmopressin in AVPR2-expressing triple-negative breast cancer: Target expression analysis and preclinical antineoplastic effects on tumor growth and metastatic progression.Org: Center of Translational Medicine, El Cruce “Néstor Kirchner” Hospital, Montefiore Einstein Comprehensive Cancer Center/Albert Einstein College of Medicine, Center for Molecular and Translational Oncology (COMTra), Science and Technology Department, National University of Quilmes, Provincial Institute for Cancer Prevention and Treatment (IPC),
Abstract
First-in-human study of ZG0895, a TLR8 selective agonist, as monotherapy in patients with advanced solid tumors.Org: Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,
Abstract
Preclinical characterization of pretargeted radioimmunotherapy (PRIT) with GD2-SADA, a self-assembling and disassembling bispecific fusion protein.Org: Y-mAbs Therapeutics, Inc, Y-mAbs A/S, City of Hope National Medical Center, University of Maryland School of Medicine,
Abstract
An open-label phase I study to evaluate the safety, tolerability and preliminary efficacy of YY001 in patients with advanced solid tumors.Org: Shanghai East Hospital, Tongji University, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai Henlius Biotech, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
A phase I clinical trial investigating the safety, tolerability, and pharmacokinetics of HX301 (narazaciclib), a novel multi-kinase inhibitor targeting CSF1R, CDK 4/6, and ARK5, in patients with advanced solid tumors.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Unraveling the role of ubiquitin C-terminal hydrolase L1 in high grade serous ovarian cancer pathogenesis.Org: Women’s Oncology, Women and Infants Hospital, Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Department of Pathobiology, Brown University, Reproductive Endocrinology and Infertility, Women and Infants Hospital,
Abstract
Antitumor activity of nab-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts.Org: Aadi Bioscience,
Abstract
Effect of targeting FAK by ifebemtinib and immunogenic cell death of Kras G12C/G12D inhibition on the efficacy of PD1 blockade.Org: InxMed (Shanghai) Co., Ltd, Shanghai, China,
Abstract
Performance of surufatinib in treating advanced neuroendocrine neoplasms: Insights from a real-world study.Org: Department of Pharmacy, Fudan University Shanghai Cancer Center,
Abstract
A double-blind, randomized, two-arm, single-dose, parallel-group study in healthy participants to compare the pharmacokinetics, pharmacodynamics, and immunogenicity of FKS518 proposed biosimilar to denosumab with the originator (LUMIADE-1 study).Org: Lake Zurich, IL, MTZ Clinical Research Center, Eysins, Switzerland,
Abstract
Phase I clinical study of FC084CSA, a high selective AXL kinase inhibitor that ameliorates tumor microenvironment and augments the effectivity of immunotherapy.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Shanghai Pulmonary Hospital, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai Henlius Biotech,
Abstract
Single-cell and bulk sequencing analysis to evaluate the oncogenic role of PDE3A in pan-cancer and validation in breast cancer.Org: The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China, The First Affiliated Hospital of Xian Jiaotong University, Xi'an, China, The First Affiliated Hospital of Xi’an Jiaotong University,
Abstract
First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Hospital, Sichuan University, Chengdu Origen Biotechnology, China National Biotec Group,
Abstract
Surufatinib plus PD-1/L1 inhibitors as maintenance therapy following first line (1L) platinum-based chemotherapy combined with PD-1/L1 inhibitors in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC).Org: Department of Respiratory Medicine,Taizhou Hosipital of Zhejiang Province, The Fifth Medical Center of the Chinese People's Liberation Army General Hospital, The Southwest Hospital of AMU,
Abstract
In silico design of novel multitarget small molecule inhibitors to treat PTEN-mutant endometrial carcinoma.Org: Molecular Targeted Therapeutics Laboratory,
Abstract
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the illudofulvene drug CAP-0121.Org: Skaggs School of Pharmacy and Pharmaceutical Sciences, Califia Pharma, Inc., University of California, San Diego Center for Advanced Laboratory Medicine,
Abstract
An open-label, single-arm, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the ATR inhibitor SC0245 in advanced solid malignancies.Org: Shandong Cancer Hospital, Shandong First Medical University, Jinan, China,
Abstract
Effect of screening with a pan-TRK immunohistochemistry-based algorithm on NTRK fusion detection rates.Org: IMTIB, Istituto oncologico di ricerca (IOR), Hospital Italiano de Buenos Aires, Ciudad Autónoma De Buenos Aires, Hospital Univ Austral,
Abstract
Multi-omics study on the molecular mechanism of anlotinib in regulating tumor metabolism.Org: Nanjing University of Chinese Medicine,
Abstract
Patient-derived 3D bioprinting pan-cancer drug screening platform for personalized medicine.Org: Department of Liver Surgery, Peking Union Medical College Hospital, Beijing, China, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Department of Physiology, Institute of Basic Medical Sciences, CAMS, Beijing, China, Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China, Department of Head and Neck Surgical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China,
Abstract
Characterization of novel compounds that directly bind to and inactivate the HPV E6 protein for treatment of HPV-associated cervical and oropharyngeal cancers.Org: Kovina Therapeutics Inc.,
Abstract
Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors.Org: Randwick, NSW, Australia, Central Clinical School, Califon, NJ, Scientia Clinical Research Ltd,
Abstract
A multicenter, open‑label, phase 1a study of HC‑5404 in patients with advanced solid tumors.Org: Regions Hospital Cancer Care Center,
Abstract
EXPRESS study: A trial exploring the association of low level of genomic alteration with exceptional and unexpected response to targeted therapies in patients with advanced solid tumors.Org: Institut Curie Paris, Paris Saclay University & Gustave Roussy, Digestive Surgery Department, Centre d'Oncologie de Gentilly, Hopital Privé de la Loire,
Abstract
Prevalence of NTRK gene fusions in solid tumors in northeastern Mexico.Org: Centro Universitario contra el Cáncer,
Abstract
Integrated genomic and transcriptomic characterization of neuroendocrine carcinomas for improved treatment decision-making.Org: Advanced Cancer Treatment Centers,
Abstract
First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics of BY101298: Initial report from dose escalation cohort.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan, China National Biotec Group, Shandong Suncadia Medicine,
Abstract
Adjuvant donafenib for patients with hepatocellular carcinoma at high risk of recurrence following radical resection: A multi-center, retrospective study in China.Org: No.2 People’s Hospital of Fuyang City, Division of Life Sciences and Medicine, University of Science and Technology of China,
Abstract
First-in-human study of HMPL-295, an ERK1/2 inhibitor, in patients with advanced solid tumors: Dose-escalation results of monotherapy.Org: Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Shanghai, China, Shandong Cancer Hospital, Jinan, China, Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, SYSU, Guangzhou, China, The Sixth Affiliated hospital, Sun Yat-sen University, Guangzhou, China, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Third Affiliated Hospital of Kunming Medical University, Kunming, China, Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Department of Medical Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China,
Abstract
Efficacy and safety of surufatinib combined with EP regimen and serplulimab in first-line treatment of NEC.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital,
Abstract
Efficacy and safety of second-line treatment with surufatinib for anlotinib-resistant radioiodine-refractory differentiated thyroid cancer: An exploratory multicenter study.Org: Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
Abstract
Serabelisib, sapanisertib (PIKTOR) and paclitaxel: A combinatorial approach to improve PI3K/mTOR/AKT pathway inhibition and treatment response in solid tumors.Org: Avera Cancer Institute, Sioux Falls, SD, Faeth Therapeutics,
Abstract
KEYNOTE-158: Final analysis of pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors.Org: MSD (China) Co., Ltd., Shanghai, China, MSD (China) Co., Ltd., Beijing, China,
Abstract
A phase I/II study of C019199 in combination with sintilimab in advanced malignancy.Org: The First Affiliated Hospital of Xiamen University, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,
Abstract
Phase 1 study of ERK inhibitor JSI-1187 for patients with advanced solid tumors with MAPK pathway mutations.Org: Strategia Pharmaceuticals, LLC,
Abstract
Peony exploratory analyses of biomarker changes: From baseline to surgical samples in patients with HER2+ breast cancer.Org: Roche (China) Holding, Ltd., Product Development Oncology (PDO) at Roche Product Development,
Abstract
Overcoming chemoresistance in triple-negative breast cancer (TNBC): Targeting PD-L1 stability and ferroptosis through integrated lipid metabolism and immune modulation.Org: Department of General Surgery, Chang Gung Memorial Hospital at Tao-Yuan, Tao-Yuan, Taiwan, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China,
Abstract
Multicenter study evaluating the utility of AI-aided HER2 scoring in the clinically relevant categories.Org: Pathgroup Labs, Alverno Laboratories, Ibex Medical Analytics,
Abstract
Clinical efficacy of a next-generation sequencing (NGS) and immunohistochemistry (IHC) panel in patients with advanced cancer in Argentina.Org: UADE, Centro Oncológico San Peregrino, Centro Oncológico Integral COI Neuquen, Cemener, Sanatorio Parque,
Abstract
Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).Org: Digestive Molecular Clinical Oncology Research Unit, AOUI Verona, Scuola di Specializzazione in Oncologia Medica, iOnctura BV,
Abstract
Characterization of Von Hippel Lindau gene variants by race.Org: Abha, Saudi Arabia, Monument Health-John T. Vucurevich Cancer Care Institute, Rapid City, SD,
Abstract
Establishing optimized staining protocol and cutoff values of pan-TRK immunohistochemistry for detecting NTRK fusions in solid tumors: A Chinese multicenter cross-sectional study.Org: School of Medicine, Shanghai Jiaotong University, Department of Pathology,Jiangsu Province Hospital, Department of Pathology, Fujian Medical University Cancer Hospital, Tianjin Medical University Cancer Hospital and Institute, Department of Pathology, Sichuan Clinical Research Center for Cancer,
Abstract
Prognostication of ß-catenin (CTNNB1) in patients with HCC treated with first line immunotherapy.Org: Mayo Clinic, Mayo Clinic Cancer Center, Alliance Statistics and Data Management Center,
Abstract
A multi-modal artificial intelligence model trained on H&E tissue images and clinical patient data for prediction of BRAF mutations in colorectal cancer.Org: Mindpeak GmbH,
Abstract
Examination of in vitro and in vivo antitumor activity of PARP1 selective inhibitor D0112-005.Org: Chengdu Easton Biopharmaceuticals Co., Ltd.,
Abstract
NTRK positivity and conversion to appropriate personalized treatment.Org: Diaceutics, Parsippany, NJ, Utah Tech University, St. George Hospital,
Abstract
CK2 expression in cancer and associated clinical characteristics.Org: Chobanian and Avedisian School of Medicine, Boston University Chobanian & Avedisian School of Medicine, Universidad San Sebastian, Santiago, Chile,
Abstract
Multi-specimen comprehensive genomic profiling for diagnostic disambiguation in advanced and metastatic solid tumors.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC,
Abstract
A method for assessing the predictivity of drug-specific biomarkers before interventional clinical data is available.Org: Pangea Biomed,
Abstract
Experience of personalizing cancer treatment in economically-constrained and resource-restricted community oncology practice in India through cost-effective broad spectrum NGS and survival outcomes: An observational study of 3 years.Org: MOC Cancer Care & Research Centre, Nashik, Maharashtra, India,
Abstract
The clinical utility of the 90-gene expression assay on diagnosis and management in patients with cancer of unknown or unclear primary.Org: Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Canhelp Genomics Co., Ltd.,
Abstract
Utilizing comprehensive next-generation sequencing to determine the clinical significance of copy number variation in advanced/metastatic non-small cell lung cancer.Org: Department of Clinical Oncology, LKS Faculty of Medicine, University of Hong Kong, Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Department of Clinical Oncology, The University of Hong Kong, School of Biomedical Science, Li Ka Shing Faculty of Medicine, The University of Hong Kong,
Abstract
Reasons for biomarker testing in NSCLC: An analysis of reasoning between 2021-2023 in early- vs. late-stage patients.Org: Ipsos, New York Oncology Hematology PC, Nykode Therapeutics, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center,
Abstract
INSIHGT: A scalable and homogeneous 3D multiplexed molecular mapping platform for spatial biology and precision medicine.Org: Chinese University of Hong Kong Medical Centre, The Chinese University of Hong Kong,
Abstract
Pharmacokinetic analysis of OMO-103 in patient tissues with advanced solid tumors.Org: Peptomyc SL, Biognosys AG,
Abstract
Feasibility of implementing whole genome sequencing into routine oncology care.Org: Caryl and Israel Englander Institute for Precision Medicine,
Abstract
Using sample reinterrogation to guide high-parameter, spatially resolved tissue biomarker discovery.Org: Canopy Biosciences, St. Louis, MO, Canopy Biosciences, Hannover, Germany, Canopy Biosciences, Leipzig, Germany,
Abstract
Gene fusions: A retrospective analysis of therapies and treatments of MTB patients over 7 years.Org: Inova Schar Cancer Institute, Fairfax, VA, Vanda Pharmaceuticals, Georgetown University Medical School, Washington University School of Medicine in St Louis,
Abstract
The Gundersen Precision Oncology Cohort: A biospecimen resource for mutation characterization and target discovery.Org: Gundersen Medical Foundation, La Crosse,
Abstract
Relevance of immune tumor microenvironment and its interaction with HABP4 and SERBP1 proteins in bladder cancer.Org: Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIM), Department of Structural and Functional Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil, Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIM) – Departament of Structural and Functional Biology, Institute of Biology - University of Cam, Campinas, Brazil, Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIM) - School of Medicine, University of Campinas (UNICAMP), Campinas, Brazil, Laboratory of urogenital carcinogenesis and immunotherapy (LCURGIM), Campinas, Brazil, Centro de Oncologia Integrativa e Prevenção - COIP, São Paulo, Brazil, Department of Pathology, School of Medicine, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil, Campinas, Brazil, University of Campinas (UNICAMP), Campinas, Brazil, Laboratory of Urogenital Carcinogenesis and Immunotherapy, School of Medicine, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil, Campinas, Brazil,
Abstract
Enabling accessibility to the CellScape spatial biology workflow for researchers using standard histology protocols and pre-slided specimens.Org: Canopy Biosciences,
Abstract
Navigating the clinical trial maze: Identifying barriers to enrollment among patients with advanced cancer in a community-academic partnership.Org: Infirmary Cancer Care / Affiliate of UAB O'Neal Comprehensive Cancer Center, Infirmary Health System Inc, University of Alabama-Birmingham, Department of Medicine - Division of Hematology/Oncology,
Abstract
Evaluation of biomarkers of response in patients with breast cancer with BRCA 1/2 pathogenic variants treated with PARP inhibitors.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Characterization of BTX-10908, a first-in-class, orally bioavailable SOS1 bifunctional degrader for the treatment of KRAS- and RTK-driven cancers.Org: BioTheryX, Incyte, San Diego State University Department of Biology, San Diego, CA, CanSino Biologics,
Abstract
A study of the gaps and opportunities with fusion detection beyond NTRKs on 422 patients from the community.Org: UC San Diego Moores Cancer Center, NeoGenomics Laboratories, Inc.,
Abstract
A phase Ib study of JMT103, a receptor activator of NF-kB ligand (RANKL) antibody, in patients (pts) with bone metastases from solid tumors.Org: Xuancheng People's Hospital, Beijing Shijitan Hospital, Handan First Hospital, Huizhou Central People’s Hospital,
Abstract
Exploring CK2 transcriptional regulation and signaling pathways in cancer.Org: Universidad San Sebastian,
Abstract
Evaluation of lipopolymer as therapeutic siRNA delivery agents in non-malignant and malignant primary cells.Org: University of Alberta, British Columbia Cancer Agency,
Abstract
Time dependency for HPV ctDNA detection as a prognostic biomarker for anal cancer.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Gastrointestinal Radiation Oncology, University of Texas MD Anderson Cancer Center, Hematology/Oncology Fellowship Program, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Effect of indole 3-propionic acid from microbiota on the immunity of CD8+ T cell to improve chemotherapy of colorectal cancer.Org: The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Development of HLB3-002 (recombinant human PH20 stand-alone) and its applicability as an anticancer diffusion agent.Org: Huonslab,
Abstract
Three-year disease-free survival after transanal vs. laparoscopic total mesorectal excision for rectal cancer (TaLaR): A randomized clinical trial.Org: Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China, The Sixth Affiliated Hospital of Sun Yat-Sen, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital,
Abstract
Synergistic inhibition of CXCL8 following MRTX1133 treatment with ONC212 or 5-FU in KRAS G12D and G12V mutant CRC and PDAC cell lines.Org: Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Providence, RI,
Abstract
Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).Org: Keck Medical Center of University of Southern California,
Abstract
Preliminary results of atezolizumab and pirfenidone in non-small cell lung cancer.Org: University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
Impact of APC mutations on prognosis and tumor microenvironment in colorectal signet ring cell carcinoma.Org: Department of Pathology, Shanxi Cancer Hospital, Taiyuan, China, Shanxi Province Cancer Hospital, Taiyuan, Shanxi, China, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, Jiangsu, China, The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion.Org: Chongqing Precision Biotech Co., Ltd.,
Abstract
Efficacy and safety of nivolumab in pretreated patients with metastatic squamous cell carcinoma of anus: A real-world experience.Org: Radiation Oncology Center, Surgery of the Alimentary Tract, General Surgery and Transplantation Unit, Division of Pancreatic Surgery,
Abstract
Trend of anal cancer prevalence, risk factors, treatment, and mortality in different age groups based on National Inpatient Sample Data from 2016 to 2020.Org: John H. Stroger, Jr. Hospital of Cook County, John H. Stroger Jr. Hospital of Cook County, John H Stroger, Jr. Hospital of Cook County,
Abstract
Survival and prognosis of anus, anal canal and anorectal carcinoma: Analysis of National Surveillance, Epidemiology, and End Results database from 2000-2020.Org: Saint Clare's Health System, Government Medical College Omandurar, Lumbini Medical College and Teaching Hospital, Maroules Hematology Onc, LLC,
Abstract
AURKA blockage as a strategy to overcome resistance to olaparib and platinum in high-grade ovarian cancer (HGOC).Org: Translational Oncology and Pathology Group, La Paz University Hospital-IdiPAZ, Instituto de Investigación Sanitaria (INCLIVA), Hospital La Paz, Center for Biomedical Research in the Cancer Network (Centro de Investigación Biomédica en Red de Cáncer, CIBERONC),
Abstract
A study on classifying tumor neoantigens to enhance the accuracy of liquid biopsy in CRC cancer.Org: HaploX Biotechnology, Shenzhen, China,
Abstract
Paradoxical association of B7H3 with clinical outcomes in patients with colorectal cancer.Org: Montefiore Wakefield Campus,
Abstract
Effect of tocotrienol and tocopherol regulation by the microbiome on colitis-associated cancer.Org: BioCorteX Inc.,
Abstract
First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer.Org: Rambam Medical Center and Technion-Israel Institute of Technology, Insitut de Cancérologie de l’Óuest – Centre René Gauducheau, Pan-American Center for Oncology Trials, Community Health Cancer Center North,
Abstract
Association of overexpression of TNF receptor superfamily members (CD40, BAFFR, LTβR and RANK) with favorable prognosis in patients with colorectal adenocarcinoma.Org: University of Patras,
Abstract
Association of gut microbe and stress-related cancer metastasis and oleic acid degradation.Org: The Sixth Affiliated Hospital of Sun Yat-Sen, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group, Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China,
Abstract
Molecular insights into oxaliplatin-induced peripheral neuropathy in colorectal cancer: Unraveling a potential signature.Org: Indiana University – Purdue University Indianapolis,
Abstract
Evaluating peripheral myeloid-derived suppressor cells as factor for the diagnosis and treatment efficiency of patients with colorectal cancer.Org: Laboratory Medicine Department,
Abstract
Synergistic cytotoxicity of histone deacetylase, poly-ADP ribose polymerase inhibitors and decitabine in breast and ovarian cancer cells: Therapeutic implications.Org: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Quality indicators in the care of patients with rectal cancer in social security in Guatemala: Results of a retrospective population study.Org: Instituto Guatemalteco de Seguridad Social, Integra Cáncer Institute,
Abstract
Disparities in diagnosis and access to care in patients with young-onset rectal cancers in northeast Ohio.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Department of Surgery, Brigham and Women's Hospital, Boston, MA, University Hospitals Cleveland Medical Center,
Abstract
Association of baseline hypertension and hyperlipidemia with the clinical characteristics and outcomes in patients with colorectal cancer: A single institution experience.Org: Univerisity of Texas Southwestern Medical Center,
Abstract
Trophoblast cell-surface antigen 2 is a biomarker and potential therapeutic target in human colon cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Rising trend of early-onset colorectal cancer in the US: Incidence and projections to 2030.Org: University of the East Ramon Magsaysay Medical Center,
Abstract
Impact of delirium on outcomes among hospitalized patients with colorectal cancer: A United States population-based cohort study.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Jefferson-Einstein Hospital, Jefferson Einstein Medical Center,
Abstract
Cost-effectiveness of targeted vs. multi-cancer blood tests for colorectal cancer.Org: Freenome Inc, Freenome, Inc.,
Abstract
Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study.Org: Johns Hopkins University Hospital,
Abstract
Exploring young-onset colorectal cancer sex difference incidence rates by race and ethnicity: A SEER database analysis (2000-2020).Org: Atlantic Hematology Oncology Associates - Hackensack Meridian Health,
Abstract
Genetic landscape of colorectal cancer (CRC) across genetic ancestries: Implications for early cancer detection (ECD).Org: Department of Biomedical Data Science, Stanford Medical School and Institute for Computational and Mathematical Engineering, Stanford University, Stanford, CA, Natera, Inc., Austin, TX, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Galatea Bio, Hialeah, FL, Albert Einstein Cancer Center, New York, NY,
Abstract
Investigating racial, gender, and socioeconomic disparities in early-onset versus late-onset colorectal cancer: An analysis using the NIH All of Us database.Org: Harlem Hospital Center, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Cisplatin and capecitabine as definitive chemoradiation for squamous cell carcinoma of the anal canal (SCCAC): A prospective cohort.Org: Institudo do Câncer do Estado de São Paulo,
Abstract
Types of thromboembolic events and their outcomes among patients with active colorectal cancer: A nationwide propensity matched analysis.Org: Louisiana State University in Shreveport, Houston Methodist Hospital, LSU-Shreveport, LSU Health Shreveport, Louisiana State University Health Sciences Center Shreveport,
Abstract
The association of protein-energy malnutrition and in-hospital clinical outcomes among patients with colorectal cancer hospitalized for gastrointestinal bleeding: A nationwide analysis.Org: University of Missouri School of Medicine, Johns Hopkins University Bloomberg School of Public Health, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Jefferson-Einstein Hospital,
Abstract
Mutational landscape and evolutionary pattern of peritoneal metastases in colorectal cancer.Org: Department of Medical Informatics, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, China, Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China, Nanjing Drum Tower Hospital Clinical College of Nanjing Universty of Chinese Medicine, Nanjing, China, Colorectal Surgery, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China, Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China,
Abstract
Use of epigenetic inhibitor screen to identify HDAC1/2 inhibitor as a pro-differentiation therapy in colorectal cancer.Org: Hungarian Academy of Sciences Research Centre for Natural Sciences,
Abstract
Benefits for adjuvant chemotherapy of resected colon carcinoma examined by Artificial Intelligence Laboratory (NCI-Br) through synthetic data and machine learning: A tribute to Prof. Charles George Moertel.Org: Faculdade de Ciências Médicas, National Cancer Institute - Brazil, Instituto Nacional de Câncer - Brasil,
Abstract
Application and evaluation of fecal SDC2 gene methylation in the diagnosis and treatment of colorectal cancer.Org: Shanghai Tenth People's Hospital, Shanghai Tenth People’s Hospital, Tongji University School of Medicine,
Abstract
The effect of HER2-targeted inhibitors as second-line or later-line regimens in the treatment of HER2-positive advanced colorectal cancer: A systematic review and meta-analysis.Org: Fujian Medical University Union Hospital, Fuzhou, China,
Abstract
Changes in US colorectal cancer mortality trends over the past 20 years.Org: New York Medical College - Saint Michael's Medical Center, Saint Michael's Medical Center, Corewell Health System - Beaumont University Hospital, Royal Oak, MI, UPMC Harrisburg,
Abstract
Phase IB/II first line panitumumab, irinotecan, trifluridine/tipiracil in RAS wild-type patients with metastatic colorectal cancer: PIT study.Org: Lyell McEwin Hospital, The Queen Elizabeth Hospital and University of Adelaide,
Abstract
Prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data.Org: George Mason University, Manassas, VA, Fairfax, VA, Vanda Pharmaceuticals,
Abstract
Survival benefit with regorafenib and/or trifluridine/tipiracil sequencing to rechallenge with anti-EGFR-based third-line regimens in metastatic colorectal cancer: A multicenter retrospective real-world subgroups comparison.Org: ASL Viterbo, “Vito Fazzi” Hospital, ASL Frosinone, Sora (FR), Isola Tiberina Hospital-Gemelli Isola,
Abstract
Single-center retrospective analysis of second-line treatment with regorafenib in patients with advanced colorectal cancer among the COVID-19 pandemic.Org: Cancer Chemotherapy and Radiation Department,
Abstract
Survival analysis and associated factors in metastatic early-onset colorectal cancer vs. metastatic average-onset colorectal cancer.Org: Universidad Peruana Cayetano Heredia,
Abstract
Incidence and potential prognostic implications of fibroblast growth factor receptor gene alterations and coexisting mutations in colorectal cancer.Org: Liverpool Hospital Anatomical Pathology, Macarthur Cancer Therapy Centre, Ingham Institute for Applied Medical Research, Western Sydney University, Liverpool Cancer Therapy Centre,
Abstract
Modified FOLFOXIRI plus bevacizumab as a salvage regimen for patients with refractory metastatic colorectal cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The Sixth Affiliated Hospital of Sun Yat-Sen, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China, SYSU,
Abstract
Predictors of survival outcome of TAS102 combined with bevacizumab compared to TAS102 alone in Saudi patients with metastatic colorectal cancer beyond second line of systemic therapy.Org: Makkah Saudi Arabia, King Abdulla Medical City/Makkah, Mekkah, Umm AlQura University, King Abdulaziz Medical City (NGHA),
Abstract
The treatment outcomes of patients with BRAFV600E–mutated metastatic colorectal cancer (mCRC): The Polish retrospective cohort study.Org: Institute of Medical Science, University of Opole, Military Clinical Hospital with Polyclinic, Department of Clinical Biochemistry and Laboratory Diagnostics,
Abstract
Real-world impact of KRAS mutations on clinical outcomes in metastatic colorectal cancer treated with trifluridine-tipiracil in the USA.Org: Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY, Caris Life Sciences, Irving, TX, Irving, TX, San Diego, CA,
Abstract
Dermatology-related quality of life outcomes in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: A prespecified secondary analysis of the phase 2 randomized PanaMa (AIO KRK 0212) trial.Org: Gesundheitszentrum St Marien, Amberg, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, Charité-University madicine Berlin, Department of Hematology, Oncology and Tumorimmunology, Berlin, Germany, Practice of Hematology and Oncology (HOPE), Hamburg, Germany, Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany,
Abstract
A rapid assessment tool for systemic treatment outcomes in colorectal cancer with deep bidirectional transformers.Org: Office of Data Services at Division of Digital Health,
Abstract
Correlation between metastatic site and immunotherapy efficacy in patients with advanced dMMR/MSI colorectal cancer: Real-World Italian multicentric retrospective study (Colon-MSI).Org: Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Medical Oncology Department, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Updated efficacy and safety results from the phase Ib/II study of surufatinib combined with camrelizumab and chemotherapy in patients with advanced colorectal cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Jiangsu Cancer Hospital, Nanjing, China,
Abstract
Regorafenib Plus for third-line treatment in metastatic colorectal cancer: A real-world study.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Beijing Chaoyang Hospital, Capital Medical University,
Abstract
Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial.Org: Veneto Institute of Oncology IOV-IRCCS Padua, Asklepios Tumorzentrum Hamburg, Takeda Pharma Vertrieb GmbH & Co. KG, HUTCHMED International Inc., University Hospitals Gasthuisberg / Leuven & KULeuven,
Abstract
Concurrent hyperthermic intraperitoneal chemotherapy and intraoperative radiotherapy with cytoreductive surgery in patients with rectal cancer with peritoneal carcinomatosis.Org: King Faisal Specialist Hospital and Research Centre,
Abstract
Chemotherapy plus EGFR antibody as conversion treatment in RAS wild type, right-sided metastatic colon cancer: A systematic review and meta-analysis.Org: Department of General Surgery, Qilu Hospital of Shandong University, Jinan, China, Department of General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China, Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan, China,
Abstract
Treatment of colon cancer using a novel approach comprising cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy and intraoperative radiation therapy.Org: King Faisal Specialist Hospital and Research Centre,
Abstract
A new prognostic tool for metastatic colorectal cancer patients receiving anti-angiogenic treatment, the PALM score: A single-center experience.Org: Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, University Hospital 12 de Octubre, University of Cagliari, Medical Oncolgy Unit,
Abstract
The impact of metformin on clinical outcomes of metastatic colorectal cancer with known molecular profile treated with cytotoxic chemotherapy or immune checkpoint inhibitor.Org: Caris Life Sciences, Irving, TX, West Cancer Center and Research Institute,
Abstract
FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated (mut) metastatic colorectal cancer (mCRC): An individual patient data-based pooled analysis of randomized trials.Org: Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Charité Universitätsmedizin Berlin, Berlin, Germany, Oncology Unit 1, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, Department of Medical Oncology, University Campus Biomedico, Roma, Italy, Division of Clinical Pharmacology and Oncology, Department of Health Sciences, School of Psychology, University of Florence, Florence, Italy, University of Pisa, Pisa, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS Padua, Padua, Italy, U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy, Hämatologisch Onkologische Praxis Eppendorf (HOPE) and Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy, CdC Poliambulanza, Brescia, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS, Padua, Italy, IRCSS-CRO Aviano, Department of Clinical Oncology, Aviano, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Martin Luther University, Halle, Germany,
Abstract
Outcomes of patients with peritoneal carcinomatosis treated with HIPEC and chemotherapy or HIPEC alone: A single center community experience.Org: 22101 Moross Rd,
Abstract
Racial differences in genomic profiles and clinical outcomes of patients with colorectal carcinoma: A single institution retrospective study.Org: University of South Alabama College of Medicine,
Abstract
Impact of DNA damage repair alterations on real-world response to therapy in metastatic colorectal cancer.Org: Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
The impact of socioeconomic status on gastrointestinal cancer care delivery in southeast Texas.Org: Baptist Hospitals of Southeast Texas, Lamar University,
Abstract
A propensity score–matched comparison of fruquintinib (FRU) versus FRU combined with PD-1 inhibitors for microsatellite stability (MSS) metastatic colorectal cancer: Real-world data.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Simultaneous operations in patients with colorectal cancer with liver metastases.Org: Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Tashkent, Uzbekistan, Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Toshkent, Uzbekistan,
Abstract
Radiomic survival prediction with liver metastases in colorectal cancer.Org: Montefiore Medical Center/Albert Einstein College of Medicine, The Catholic University of Korea, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Association of CDX2 expression with clinical, pathologic, and molecular features in MSI-H colorectal cancer.Org: University of Pittsburgh Medical Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, University of Pittsburgh, Pittsburgh, PA,
Abstract
Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE).Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Fudan University Shanghai Cancer Center,
Abstract
A single-sample gene-expression classifier for the intrinsic consensus molecular subtypes in colorectal cancer.Org: University of Geneva, University Hospital Geneva,
Abstract
A phase 1 dose escalation study of a novel coupled CAR T cell therapy, GCC19CART, for patients with metastatic colorectal cancer.Org: ICT, Innovative Cellular Therapeutics Co.,
Abstract
PIPAC in patients with peritoneal metastases from gastrointestinal tract (PIPOX): An open label, non-comparative phase 1/2 dose escalation and expansion trial.Org: Institut Cancérologique de l'Ouest, EMR 3738 Université Claude Bernard Lyon 1, Hopital d'instruction des armées de Begin, Lariboisiere Hospital - APHP, Insitut de Cancerologie de L'ouest,
Abstract
Efficacy of trifluridine/tipiracil in 3rd or 4th line of treatment in patients with advanced or metastatic colorectal cancer: A real-world data analysis with subgroups exploration.Org: Pulmonology and Hematology Center, Department of Enviromental Health And Occupational Medicine, Wroclaw University of Science and Technology,
Abstract
Does sidedness predict risk of perforation with chemotherapy in colon cancer? Results from the National Inpatient Samples Database (NISD).Org: Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA, Philadelphia, PA, University of Massachusetts Chan Medical School, Worcester, MA,
Abstract
Genomic analysis of recurrent early stage and de novo metastatic colorectal cancer among veterans.Org: VA Salt Lake City Healthcare System, VA Informatics and Computing Infrastructure,
Abstract
Real world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer.Org: Ballarat Health Services, Royal Hobart Hospital, South West Regional Cancer Centre, Cairns and Hinterland Health,
Abstract
Predictors of receiving targeted treatment among eligible patients with metastatic colorectal cancer.Org: Optum Life Sciences, Optum Global Solutions,
Abstract
Distinctive clinical and molecular aberrations of colorectal cancer patients with ovarian metastases.Org: Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center,
Abstract
Upregulation of GREB1 in colorectal cancer ovarian metastases may be a potential therapeutic target.Org: The Ohio State University - James Cancer Hospital, The Ohio State University Wexner Medical Center, UC Irvine, The Ohio State University James Cancer Center,
Abstract
Long term outcome of patients with rectal cancer with complete clinical response or near complete clinical response after neoadjuvant therapy: A multicenter registry study by Chinese Watch and Wait Database.Org: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastric and Colorectal Surgery, General Surgery Center, Yunnan Province Tumor Hospital,
Abstract
Development of a highly efficacious, first-in-class antibody-drug conjugate against a novel MUC1-C oncoprotein for metastatic colorectal cancer.Org: XYone Therapeutics, BWH, Harvard Medical School,
Abstract
Liquid biopsy multiomics enable clinical triage for early colorectal cancer diagnosis.Org: DiaCarta, Inc., DiaCarta Inc, Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Navy Medical University (The Second Military Medical University), Shanghai, China, DiaCarta Inc., University of Naples "Federico II", Napoli, Italy,
Abstract
Triplet chemotherapy combined with anti-EGFR treatment in RAS wild-type colon cancer: A network meta-analysis.Org: IRCSS-CRO Aviano, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Unit of Medical Oncology, San Giovanni di Dio Hospital, Department of Medical Area, University of Udine, Department of Medicine, University of Udine,
Abstract
Preliminary efficacy and safety of total neoadjuvant therapy combined with PD-L1 blockade in pMMR/MSS locally advanced rectal cancer (ESTIMATE): A prospective, single-arm, phase II trial.Org: Yunnan Cancer Hospital, Kunming, Yunnan, China,
Abstract
Delineating histomorphological signatures of iCMS subtypes in colorectal cancer using multiplexed fluorescence-in-situ hybridization.Org: Genome Institute of Singapore, National Cancer Center Singapore, National Cancer Centre of Singapore,
Abstract
A phase ib-II study of dabrafenib, trametinib, cetuximab plus irinotecan in patients with BRAF mutant metastatic colorectal cancer: Subgroup analysis and biomarker identification.Org: Sichuan Cancer Hospital and Institute, Chengdu, China, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, University of Electronic Science and Technology of China,
Abstract
Prognostic implications of distal resection margin length in rectal cancer proctectomy: A retrospective analysis.Org: Peking University Shougang hospital, Peking University Cancer Hospital & Institute,
Abstract
The impact of COVID-19 and missed diagnosis of colorectal cancer.Org: Palo Alto Medical Foundation Research Institute, Palo Alto, CA, Pingtung Veterans General Hospital, Pingtung, Taiwan, California Pacific Medical Center Research Institute, San Francisco, CA,
Abstract
Mortality and equitability of radiation treatment in locally advanced rectal cancer: A review from a national cohort.Org: Department of Radiation Oncology East Carolina University,
Abstract
FOLFOX-based hepatic arterial infusion chemotherapy combined with regorafenib for unresectable colorectal liver metastases.Org: Hubei Province Key Laboratory of Molecular Imaging,
Abstract
Short course versus long course neoadjuvant radiation for patients with locally advanced rectal cancer (LARC): National Cancer Database (NCDB) analysis of the years 2004-2020.Org: University of South Alabama College of Medicine, Van Elslander Cancer Center,
Abstract
Efficacy and safety of fruquintinib across different subgroups of patients with previously treated metastatic colorectal cancer: A meta-analysis.Org: Universidade Federal da Bahia,
Abstract
Efficacy and safety of neoadjuvant chemoradiotherapy combined with tislelizumab and thymalfasin in the treatment of locally advanced lower rectal cancer.Org: National Clinical Research Center for Digestive Diseases,
Abstract
Patient factors related to the real-world adoption of 3 months of adjuvant chemotherapy (ACT) in patients with stage III colorectal cancer (CRC).Org: BC Cancer - Vancouver Centre, University of British Columbia,
Abstract
Systemic assessment of manual circular stapler versus powered circular stapler for anastomosis in rectal cancer: A multicenter prospective cohort study.Org: 270 Dong'an Road,
Abstract
Bowel bag sparing in palliative radiotherapy (pRT) of rectal cancer (rCa): Tradeoff between organs at risk (OARs) and use of AI to reduce radiation oncologist (RO) workload.Org: Södersjukhuset,
Abstract
The utility of multiple clinical variables in predicting survival outcome for patients with rectal cancer: An integrated regression and retrospective cohort analysis.Org: HaploX Biotechnology, Shenzhen, China, Peking University Shougang hospital, Peking University Cancer Hospital & Institute,
Abstract
Transanal endoscopic microsurgery vs. radical surgery for mid-low rectal cancer in patients with clinical complete or near-complete response after neoadjuvant chemoradiotherapy.Org: Peking University Peoples Hospital, Academy of Medical Sciences,
Abstract
Adenocarcinoma in multiple adenomatous polyps: An analysis of demographic and socioeconomic factors.Org: Creighton University School of Medicine (Phoenix Regional Campus),
Abstract
Metabolic disorders in patients diagnosed with colorectal cancer.Org: Department of Internal Medicine, Oregon Health & Science University, Portland, OR, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, Department of General, Visceral and Transplantation Surgery, University Hospital of Heidelberg, Heidelberg, Germany, Fred Hutchinson Cancer Research Center, Seattle, WA, Department of Surgery, The University of Tennessee, Memphis, TN,
Abstract
Rethinking rectal cancer management through COVID: Real word evidence in a public hospital in the south of Brazil.Org: Hospital de Clinicas de Porto Alegre,
Abstract
Three-year survival data from a phase 2 trial of neoadjuvant short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China,
Abstract
An economic analysis of low-energy contact x-ray brachytherapy for treatment of rectal cancer.Org: Health Technology Wales, North Cumbria Integrated Care NHS Foundation Trust,
Abstract
Prediction models of locally advanced rectal cancer prognosis incorporating perioperative longitudinal clinical data: A retrospective longitudinal cohort study.Org: Graduate Institute of Biomedical Informatics, College of Medical Science and Technology,
Abstract
Circulating tumor DNA as a predictor of treatment response to neoadjuvant chemotherapy in stage 2/3 rectal cancer without high risks: Subset analysis from the COPEC trial.Org: Colorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University; Department of General Surgery Depart.2 (Colorectal Gastrointestinal Surgery), West China Tianfu Hospital, Sichuan University, Chengdu, China, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China, Department of Radiology, West China Hospital, Sichuan University, Chengdu, China, Genecast Biotechnology Co., Ltd, Wuxi, Jiangsu, China, Genecast Biotechnology Co., Ltd., Wuxi, China,
Abstract
Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay.Org: BC Cancer-Vancouver Centre, University of British Columbia, Genome Sciences Centre, BCCA, Personalis, Inc., Pancreas Centre BC,
Abstract
The safety and efficacy of immune checkpoint inhibitor in combination with FOLFOX as neoadjuvant/adjuvant therapy in patients with locally advanced colon cancer.Org: Xiangya Hospital of Central South University, Changsha, China, Changsha, China National Biotec Group, Central South University, Hunan Center hospital,
Abstract
Digital droplet PCR-based detection of KRAS, NRAS, and BRAF mutation in plasma samples from patients with colorectal cancer.Org: Seoul National University Boramae Medical Center, Gencurix Inc.,
Abstract
The relationship between mismatch repair (MMR) proteins status and the response to conventional neoadjuvant therapy in colorectal cancer (CRC).Org: Fudan University Shanghai Cancer Center, Shanghai General Hospital, Shanghai Jiaotong University Medical School,
Abstract
Contact x-ray brachytherapy for the treatment of rectal cancer: A systematic review and meta-analysis.Org: Royal Surrey County Hospital, Castle Hill Hospital, CentreAntoineLacassagne, Professor, Wirral,
Abstract
Neoadjuvant chemotherapy versus surgery plus adjuvant chemotherapy for locally advanced colon cancer: A meta-analysis of randomized controlled trials.Org: Municipal University of São Caetano do Sul, Hospital Heliópolis, Universidade Federal de Minas Gerais, IAMSPE - SP,
Abstract
Real-world multi-target stool DNA longitudinal adherence for colorectal cancer re-screening in a large, national population.Org: Division of Gastroenterology and Hepatology, Mayo Clinic, School of Public Health, University of Michigan,
Abstract
Efficacy of chemotherapy followed by chemoradiation versus initial chemoradiation as part of the total neoadjuvant therapy for patients with locally advanced rectal cancer: An NCDB analysis.Org: Markey Medical Center,
Abstract
Real-world multi-target stool DNA adherence in an underserved and vulnerable prison patient population.Org: Lifecare Family Medicine of Bellevue,
Abstract
The impact of treatment approach on survival among patients with clinical stage T2N0 and T3N0 rectal cancer.Org: Memorial Healthcare System, Hollywood, FL,
Abstract
AI-assisted colonoscopy in gastroenterology fellowship training: An interim analysis of a randomized controlled trial.Org: University of Southern California Marshall School of Business,
Abstract
Laparoscopic-assisted vs open surgery for low rectal cancer: 5-year outcomes of the LASRE randomized clinical trial.Org: Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China, Zhangzhou Affiliated Hospital, Fujian Medical University, Zhangzhou, China, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China,
Abstract
Disease response of neoadjuvant chemoradiation guiding local excision approach in localized rectal cancer: A systematic review and meta-analysis of prospective data.Org: Universidade Tiradentes, Faculdade de medicina UFC, Vitta Centro De Oncologia, Markey Cancer Center, University of Kentucky,
Abstract
A GWAS in Swedish colorectal cancer families with gastric and prostate cancer.Org: Intervention and Technology,
Abstract
The epidemiology and demographic statistics of serrated adenocarcinoma.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton University School of Medicine - Phoenix Regional Campus, University of California Riverside,
Abstract
Charting heterogeneity and spatial landscape of consensus molecular subtypes in colorectal cancer.Org: The Jackson Laboratory for Genomic Medicine, Hartford hospital,
Abstract
The microbiome landscape of early-onset colorectal cancer: A systematic review.Org: Washington University School of Medicine in St Louis, Washington University in St. Louis, Washington University School of Medicine in St. Louis,
Abstract
Hospitalization outcomes of patients with colorectal cancer (CRC) admitted with Clostridioides difficile colitis.Org: Rochester General Hospital, Tribhuvan University Teaching Hospital, UC Davis Comprehensive Cancer Center, Sacramento, CA,
Abstract
Analysis of patch-based GCN risk score distribution corresponding to gene mutations in colorectal cancer using whole slide images.Org: Department of Pathology, Nanfang Hospital and Basic Medical College, Southern Medical University, Guangzhou, Guangdong, Guangdong, China, Department of pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China,
Abstract
Mortality outcomes in early versus late onset colorectal cancer: A US National Inpatient Sample (NIS) analysis (2020).Org: Montefiore St.Luke's Cornwall, Khyber Medical University,
Abstract
Antibiotic exposure and colon carcinogenesis: In-depth profiling of a 492-patient cohort, with a focus on antibiotic classifications and subtypes.Org: Maimonides Medical Center, Brooklyn, NY, SUNY Downstate University Hospital,
Abstract
Broad-spectrum antibiotic use and risk of early-onset colorectal cancer.Org: MedHealth, Inc, Department of Research and Evaluation, Kaiser Permanente Southern California,
Abstract
COVID-19 breakthrough infections in patients with colorectal cancer: A propensity-matched score analysis.Org: University of Missouri Kansas-city, University of Missouri–Kansas City,
Abstract
Socioeconomic status and fertility counseling in patients with early onset colorectal cancer.Org: NYU Grossman School of Medicine, Department of Population Health, NYU Grossman School of Medicine, Department of Urology,
Abstract
Unveiling the influence of hyponatremia on morbidity, mortality, and resource utilization in colorectal carcinoma: Insights from a 5-year nationwide study.Org: Fort Wayne, IN,
Abstract
Impact of breakthrough SARS-CoV-2 infections on vaccinated patients with colorectal cancer: A retrospective cohort study.Org: University of Missouri–Kansas City,
Abstract
Outcomes of colorectal cancer hospitalization with and without coexisting nutritional anemia: A National Inpatient Sample (NIS) 2016 to 2019 database study.Org: One Brooklyn Health System/Interfaith Medical Center, One Brooklyn Health System/Brookdale University Hospital and Medical Center, NYP Brooklyn Methodist Hospital,
Abstract
Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial.Org: Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Department of General Surgery, Dazhou Central Hospital, Dazhou, China, Department of Gastrointestinal Surgery, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong, China, Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing, China, The First Department of General Surgery, Shaanxi Provincial People's Hospital, Xian, China,
Abstract
Acute cardiac complications in colorectal cancer compared to other gastrointestinal malignancies: A 10-year retrospective study.Org: Southern Illinois University Edwardsville, Cook County Health,
Abstract
Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma.Org: Taussig Cancer Center, Digestive Diseases and Surgery Institute Cleveland Clinic,
Abstract
Clinical validation of Northstar response: A novel methylated ctDNA therapy response monitoring assay in patients with advanced gastrointestinal cancers.Org: UF Health Cancer Center,
Abstract
Whole exome sequencing analysis of intratumoral heterogeneity, tumor neoantigen burden and human leukocyte antigen loss of heterozygosity in HCC.Org: HaploX Biotechnology, Shenzhen, China,
Abstract
Use of artificial intelligence–based digital pathology to predict outcomes for immune checkpoint inhibitor therapy in advanced gastro-esophageal cancer.Org: Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, Stanford Cancer Institute, Stanford University, Stanford, CA, Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China,
Abstract
Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer.Org: Midstate Med Onc and Hem,
Abstract
SLC7A11 as a prognostic biomarker for hepatocellular carcinoma.Org: The First Affiliated Hospital of Jinzhou Medical University, Jinzhou Medical University,
Abstract
Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial.Org: Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Liaoning Cancer Hospital and Institute, Shenyang, China,
Abstract
Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study.Org: Excel Diagnostics Nuclear Oncology Center, RadioMedix Inc., Orano Med SAS,
Abstract
Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment.Org: Division of Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, CHA University - Bundang CHA General Hospital (CHA Bundang Medical Center), Seoul St. Mary's Hospital, The Catholic University of Korea,
Abstract
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with resectable pancreatic ductal adenocarcinoma.Org: Cancer Research Center of Marseille (CRCM), Digestive and Medical Oncology Department, Paul Brousse Hospital, Cancer Centre of Southeastern Ontario/Queen's University, Paoli-Calmettes Institute,
Abstract
Effect of PLCE1-driven aerobic glycolysis through ENO1 modulation on immune evasion in esophageal squamous cell carcinoma (ESCC).Org: The Comprehensive Cancer Centre of Drum Tower Hospital, Department of Pathology, Nanjing Drum Tower Hospital, Shiyan, China, Cancer Center, Department of Pathology, Affiliated People’s Hospital,
Abstract
A cross-sectional study of synchronous liver metastasis in patients with gastric cancer.Org: Zhongda Hospital, Southeast University, Medical School of University, Southeast University, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Effect of two enteral immunonutrition formulas on immune function in Chinese patients with gastrointestinal cancers undergoing surgery: A secondary analysis of a randomized clinical trial.Org: Department of Clinical Nutrition, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of General Surgery, Institute of Geriatric, Medicine, Beijing Hospital, National Center of Gerontology, Chinese Academy of Medical Sciences, Beijing, China, Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China, Department of Gastrointestinal Surgery, Peking University People’s Hospital, Beijing, China, Department of Gastric Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Cancer for Cancer, Tianjin, China,
Abstract
Survival outcomes in patients with stage IV gastric cancer with Krukenberg tumors: A systematic review and meta-analysis.Org: Fatima Jinnah Medical University,
Abstract
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.Org: Emory University School of Medicine and Winship Cancer Institute, Investigational Drug Branch, Winship Cancer Institute of Emory Univeristy,
Abstract
Safety and efficacy of radiotherapy in combination with immunochemotherapy for advanced esophageal cancer: A retrospective analysis.Org: Jiangsu Cancer Hospital, Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Department of Clinical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University,
Abstract
Digital versus manual pathology scoring of PD-L1 in patients with esophageal squamous cell carcinoma (ESCC).Org: National Taiwan University Biomedical Park Hospital,
Abstract
Impact of positive tumor-informed margin and TP53 mutations on surgical outcomes in esophageal squamous cell carcinoma.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China,
Abstract
Retrospective study of continued immunotherapy in patients with advanced esophageal squamous cell carcinoma after progression on first-line immunotherapy combination chemotherapy.Org: Huai 'an First People's Hospital,
Abstract
Association of a clinical model based on skeletal muscle radiation attenuation with efficacy for patients with gastric cancer treated with chemotherapy plus PD-1 antibodies: A single-center retrospective study.Org: Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China,
Abstract
Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC).Org: AbelZeta Pharma, Inc., Shanghai, China, AstraZeneca, Cambridge, United Kingdom,
Abstract
A single-arm exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma.Org: Jiangsu Simcere Diagnostics Co., Ltd., Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Graduate School of Dalian Medical University,
Abstract
Outstanding safety and efficacy data of IMC002, an autologous CLDN18.2-targeting CAR-T, in CLDN18.2+ advanced solid tumors.Org: Shanghai Changhai Hospital,
Abstract
Immune checkpoint inhibitor retreatment in second-line treatment of esophageal cancer: A real-world study.Org: The First Affiliated Hospital of Henan University of Science and Technology, Luoyang Central Hospital affiliated to Zhengzhou University, China National Biotec Group, Department of Gastroenterology Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China,
Abstract
Intratumoral and fecal microbiota to reveal microbial markers associated with gastric carcinogenesis.Org: Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China, Liaoning Cancer Hospital and Institute, Shenyang, China, Shenyang, China, Breast Medicine Service, Liaoning, China,
Abstract
Population based assessment of HER-2 and PD-L1 positivity in gastric and gastroesophageal junction adenocarcinomas in a Canadian population.Org: QEII Health Sciences Center, Research Methods Unit, Nova Scotia Health Authority, Queen Elizabeth II Health Sciences Centre/Capital Health,
Abstract
A single-arm, open-label phase II clinical trial of SHR-1210 (camrelizumab) in combination with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma.Org: Department of Medical Oncology, The First Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China, Anyang Tumor Hospital, Anyang, Henan, China, Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China, Nanyang Medical College First Affiliated Hospital, Nanyang, China, Department of Oncology, Anyang Tumor Hospital, Anyang, Henan, China, Xinyang Tumor Hospital, Xinyang, China,
Abstract
Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China,
Abstract
Effect of AFPGC immune-microenvironment and resistance to immunotherapy.Org: Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China,
Abstract
Phase II randomized clinical trial comparing albumin-bound docetaxel vs. docetaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.Org: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Tianjin Medical University Cancer Institiute and Hospital, Tianjin, China, Department of VIP Medical Services, Shanxi Province Cancer Hospital, Shanxi, China, Fujian Cancer Hospital, Fuzhou, China, Jilin Cancer Hospital, Changchun, China, Affiliated Cancer Hospital of Harbin Medical University, Harbin, China, Meizhou People's Hospital, Meizhou, China, Hunan Cancer hospital, Changsha, China, Linfen City People's Hospital, Linfen, China, Sichuan Provincial People's Hospital, Chengdu, China, Yunnan Cancer Hospital, Kunming, China, Henan Cancer Hospital, Zhengzhou, China, The First Affiliated Hospital of Xiamen University, Xiamen, China, Gansu Provincial Cancer Hospital, Lanzhou, China, Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China, Changzhi People's Hospital, Changzhi, China, CSPC ZhongQi Pharmaceutical Technology Co., Ltd, Shijiazhuang, China, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China,
Abstract
Polymeric micellar paclitaxel plus cisplatin combined with tislelizumab as the first-line treatment of advanced unresectable esophageal squamous cell carcinoma: A phase II study.Org: Department of Clinical Oncology, Queen Elizabeth Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China,
Abstract
Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).Org: Global Biostatistical Science, Global Development,
Abstract
First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multicenter phase II trial.Org: Department of Medical Oncology, Anyang Cancer Hospital, Anyang, China,
Abstract
Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1st-RT): A single-arm, open-label, phase 2 trial.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong University of Traditional Chinese Medicine Affiliated Hospital, Shandong First Medical University and Shandong Academy of Medical Sciences,
Abstract
Efficacy and safety of immunotherapy in patients with liver metastases in patients with esophageal cancer: A retrospective, real-world study.Org: Luoyang Central Hospital affiliated to Zhengzhou University, Xinxiang Medical University,
Abstract
Efficacy and safety of SOX regimen combined with inetetamab as first-line treatment for HER2-positive advanced gastric cancer.Org: The Second Affiliated Hospital of Shandong First Medical University, Tai’an, China,
Abstract
Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.Org: Zhumadian Central Hospital,
Abstract
Understanding the relationship between obesity and in-hospital outcomes in gastric cancer patients : A nationwide analysis.Org: State University of New York Upstate Medical University, Upstate Medical University, Wyckoff Heights Medical Center, Nuvance Health/Vassar Brothers Medical Center, Lake Erie College of Osteopathic Medicine,
Abstract
Revolutionizing outcome prediction for immunotherapy with vision transformer-based pathomics signature in esophageal squamous cell cancer.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China,
Abstract
Envafolimab in combination with lenvatinib and albumin paclitaxel for previously treated advanced gastric/gastroesophageal junction adenocarcinoma: Preliminary analysis of a phase II, two-cohort study.Org: Department of Oncology, Shanghai Medical College, Fudan University, Shangai, China, Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shangai, China,
Abstract
Effect of simvastatin on PD-L1 via ILF3 to enhance CD8+ T cell-mediated ferroptosis in gastric cancer cells.Org: Qilu Hospital of Shandong University, Shandong University of Traditional Chinese Medicine Affiliated Hospital,
Abstract
Early evidence of pancreatic enzyme insufficiency in patients with gastric neoplasia.Org: KUMC, KUSoM-W,
Abstract
Optimization of sinoporphyrin sodium (DVDMS)-mediated photodynamic therapy (PDT) in patients (pts) with advanced esophageal cancer (EC): A multicentre phase II single-arm clinical trial.Org: Yichun People’s Hospital, Yichun, China, The First Affiliated Hospital of Henan Science and Technology University,
Abstract
Interaction between histology and staging on survival outcomes of patients diagnosed with esophageal cancer over the past decade.Org: Palisades Medical Center, UTHealth School of Public Health,
Abstract
Enhancing the efficacy of anti-PD-L1 therapy by cabozantinib in the treatment of advanced esophageal squamous cell carcinoma (ESCC): Rationales from a preclinical study.Org: National Taiwan University Cancer Center/Hospital, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, National Taiwan University Hospital Yunlin Branch,
Abstract
Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial.Org: 3rd Affiliated Hospital of ZhengZhou University,
Abstract
Efficacy and safety of surufatinib, toripalimab, nab-paclitaxel in combination with radiotherapy or surgery in the first-line treatment of esophageal squamous cell cancer: A single-centered prospective clinical trial.Org: Chinese PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
Effectiveness and safety of first-line serplulimab in patients with metastatic/locally advanced esophageal carcinoma (EC): A real-world study.Org: Subei People's Hospital of Jiangsu Province, Taizhou People's Hospital,
Abstract
Immune checkpoint inhibitor plus chemotherapy versus chemotherapy alone in HER2-negative advanced gastric or gastroesophageal junction cancer: A systematic review and meta-analysis of randomized controlled trials.Org: Federal Univerity of Rio de Janeiro, DASA Oncologia, Federal University of Ceará, Clion Clínica de Oncologia, Hospital São Domingos,
Abstract
Analysis of factors affecting complete pathological remission after neoadjuvant immunocombination chemotherapy treatment for locally advanced esophageal squamous carcinoma.Org: Department of Oncology, the Affiliated Hospital of North Sichuan Medical College, Nanchong, China,
Abstract
Analysis of the value of chromosomal instability test for evaluating early efficacy assessment in advanced gastric cancer.Org: Shanghai Tenth People's Hospital, Shanghai Tenth People’s Hospital, Tongji University School of Medicine,
Abstract
Radiotherapy improved the efficacy of immunotherapy for advanced esophageal cancer.Org: Sichuan University.,
Abstract
The role of determining HER2neu status in patients with gastric cancer.Org: CENTEast, Kazakh National Medical University, Kazakhstan Cancer Society, Kazakh Scientific Research Institute of Oncology and Radiology, Kazakh Research Institute of Oncology and Radiology,
Abstract
Immune checkpoint inhibitor treatment in PD-L1-negative gastroesophageal cancer tumors.Org: Khon Kaen University,
Abstract
Effectiveness and safety analysis of serplulimab-based regimens in patients with HER2-negative advanced gastric cancer from a real-world retrospective study.Org: the Fourth Affiliated Hospital of Soochow University,
Abstract
Concordance of PD-L1 combined positive score (CPS) analysis between primary gastric cancer and matched peritoneal metastasis.Org: Department of Translational Medicine Research and New Technologies in Medicine and Surgery, Department of Surgical, Medical, Molecular Pathology and Critical Area,
Abstract
Advanced signet ring cell type gastroesophageal cancers in Latin American patients age 40 and below: A summary of one tertiary care center's experience and a review of the literature.Org: Inova Schar Cancer Institute, Inova Fairfax Hospital,
Abstract
The clinical significance of PRMT8 expression in esophageal squamous cell carcinoma and the influence on prognosis.Org: The Fourth Hospital of Hebei Medical University, Shijiazhuang, China,
Abstract
Efficacy, safety and DNA methylation analysis of cadonilimab combined with taxane and cisplatin as the first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC): An open-label, multicenter phase II trial– Updated results from AK104-IIT-014.Org: Department of VIP Medical Services,
Abstract
A single-arm, multicenter, phase II study of utidelone in advanced solid tumors: Efficacy data from screening and the expansion cohort assessing utidelone plus sintilimab and oxaliplatin for advanced gastric cancer.Org: Peking University Shenzhen Hospital, Beijing Obstetrics and Gynecolgoy Hospital, Capital Medical University, Beijing, China, Beijing Biostar Pharmaceuticals,
Abstract
The clinical significance and expression of MAGE-A3 in patients with esophageal squamous cell carcinoma.Org: The 4th Hospital of Hebei Medical University, Shijiazhuang, China, Department of Medical Oncology, Hebei Medical University Fourth Affiliated Hospital, Shijiazhuang, China, Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China,
Abstract
Association between homologous recombination deficiency (HRD) gene mutations and the efficacy of venadaparib in combination with irinotecan as third- or fourth-line treatment in patients with metastatic gastric cancer (mGC).Org: Idience Inc.,
Abstract
Survival outcomes with curative intent hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal metastasis.Org: Loma Linda Universty Health System, UCSF Fresno, Fresno, Loma Linda University Health System, Riverside,
Abstract
Gastric juice piR-015551: A promising prognostic biomarker for gastric cancer.Org: Huai 'an Cancer Hospital, Huai 'an, Jiangsu, China,
Abstract
Exploration of different immunogenomic TMEs in gastric cancer based on HER2 and PD-L1 expression.Org: Samsung Advanced Institute for Health Sciences and Technology,
Abstract
Survival outcomes post radical gastrectomy and D2 lymphadenectomy: Real-world evidence from a tertiary care cancer center.Org: Basavatarakam Indo-American Cancer Hospital and Research Institute,
Abstract
Phase 2 study of concurrent cisplatin, capecitabine and celecoxib with radiotherapy in patients with carcinoma of the oesophagus.Org: King George Medical University, Lucknow, India,
Abstract
Triple combination treatment of trastuzumab, chemotherapy and immune checkpoint inhibitor in HER2 positive unresectable, locally advanced, metastatic gastric and esophageal adenocarcinoma: A systematic review and meta-analysis.Org: Quezon City, Philippines,
Abstract
Life expectancy of patients with early gastric cancer who underwent curative gastrectomy: Comparison with the general population using the Korean Statistical Information Service database.Org: Asan Medical Center, Seoul National University Hospital, South Korea,
Abstract
Induction immunotherapy-based regimens followed by palliative CCRT may lead to conversion surgery in selected patients and boost survival for stage IV ESCC.Org: National Taiwan University Hospital Yunlin Branch, Yunlin, Yun-lin Branch, Yunlin County,
Abstract
Homologous recombination deficiency score served as an independent prognosis factor in esophageal squamous cell carcinoma.Org: Department of Pathology, Shanghai Chest Hospital, Shanghai Jiaotong University,
Abstract
Impact of regulatory t cells in peripheral blood on pathological complete response in patients with locally advanced gastric or gastroesophageal junction cancer undergoing neoadjuvant chemoimmunotherapy.Org: Surgical Oncology, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Cancer Hospital Affiliated to Zhengzhou University and Henan Cancer Hospital,
Abstract
Evaluating the efficacy of chemoradiotherapy combined with immunotherapy for local-regional recurrent esophageal cancer patients after esophagectomy: A retrospective analysis.Org: Cancer Institute of Jiangsu Province,
Abstract
AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC): A single-arm, open-label, multicenter, phase Ib study.Org: Department of Gastroenterology and Urology,
Abstract
Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Updated data from a prospective, phase II trial.Org: Department of Biotherapy, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University,
Abstract
Tislelizumab combined with chemotherapy or radiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (TINES): A randomized, open, phase II study.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Immunotherapy plus chemotherapy versus chemotherapy alone in perioperative treatment for locally advanced gastric cancer: A systematic review and meta-analysis.Org: Federal University of São João Del-rei, Divinópolis, Brazil, Federal Univerity of Rio de Janeiro, Rio De Janeiro, Brazil, Federal University of Ceará, Fortaleza, Brazil, DASA Oncologia, São Paulo, Brazil, Clion Clínica de Oncologia, Salvador, Brazil,
Abstract
Combining nimotuzumab with PD-L1 inhibitors and chemotherapy to treat esophageal cancer: A retrospective study.Org: First Affiliated Hospital of Guangdong Pharmaceutical University,
Abstract
Correlation of plasma GDF15 with aging, organ disfunction, sarcopenia, and postoperative infectious complication in patients with esophageal cancer. Org: Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan, Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine, Sendai, Japan,
Abstract
Influence of neoadjuvant regimen on the prognosis of locally advanced gastric and gastroesophageal junction cancer with HER2 overexpression.Org: Cancer Hospital Affiliated to Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hosptal,
Abstract
Social factors in the receipt of treatment for locally advanced esophageal cancer.Org: Atrium Health Carolinas Medical Center, Atrium Health Carolinas Medical Center Levine Cancer Institute,
Abstract
Age and body composition of patients receiving treatment for locally advanced esophageal cancer.Org: Atrium Health Carolinas Medical Center, Atrium Health Carolinas Medical Center Levine Cancer Institute,
Abstract
Multidisciplinary care for patients with gastroesophageal cancers (GEC): A quality improvement initiative in community cancer clinics.Org: PRIME Education, LLC, Johns Hopkins Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Patterns of recurrence after esophagectomy following neoadjuvant Immunochemotherapy for esophageal squamous cell carcinoma.Org: The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China, The 4th Hospital of Hebei Medical University, Hebei, Shijiazhuang, China, Hospital of Hebei Medical University, Shijiazhuang, Hebei, China,
Abstract
Camrelizumab combined with apatinib as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A phase 2 trial.Org: The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, First Affiliated Hospital of Zhengzhou University,
Abstract
Interim results from a prospective multicenter phase II trial of stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC trial).Org: Shanghai Chest Hospital, Jiaotong University, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,
Abstract
Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC): A single-center, single-arm, exploratory clinical trial.Org: The Affifiliated Hospital of Qingdao University,
Abstract
Exploration of neoadjuvant chemotherapy and post-tumor microenvironment for advanced gastric cancer (GC) or gastroesophageal junction cancer (EGJ).Org: Chinese People's Liberation Army General Hospital, The 5th Medical Center of the PLA General Hospital,
Abstract
Trends and disparities in the incidence and mortality of stomach cancer in the United States.Org: Multicare Auburn Medical Center, Auburn,
Abstract
Immuno-based conversion therapy for survival in initially unresectable locally advanced or oligometastatic gastric cancer: A retrospective real-world study with multi-omics analysis.Org: Shandong University of Traditional Chinese Medicine Affiliated Hospital,
Abstract
Effect of fluorescent imaging using indocyanine green on surgical morbidity during minimally invasive surgery for esophageal cancer (IndoCinMIE).Org: All India Institute of Medical Sciences (AIIMS), Jodhpur, India, All India of Institute of Medical Sciences, Jodhpur, India,
Abstract
Neoadjuvant sintilimab, albumin-bound paclitaxel, and carboplatin for locally advanced resectable esophageal squamous cell carcinoma: A prospective phase 2 study.Org: Innovent Biologics Co., Ltd.,
Abstract
Short term outcomes of robotic assisted minimally invasive oesophagectomy: A single institutional experience.Org: BLK-Max Super Speciality Hospital, BLK-Max Hospital,
Abstract
Safety and efficacy of intensified preoperative management of locally advanced gastrorsophageal junction cancer (INPROVE).Org: Centro di Riferimento Oncologico (CRO), Aviano, University of Udine, CRO-IRCCS, IRCSS CRO AVIANO,
Abstract
Impact of immunotherapy combined with neoadjuvant chemotherapy or chemoradiotherapy on perioperative safety in locally advanced esophageal squamous cell carcinoma (LA-ESCC): A retrospective propensity score-matched analysis.Org: Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University,
Abstract
A comparative study of double track anastomosis and tubular esophagogastric anastomosis in laparoscopic radical proximal gastrectomy for upper gastric carcinoma.Org: Qilu Hospital of Shandong University,
Abstract
Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study.Org: Department of Gastroenterological Surgery II, Hokkaido University, Faculty of Medicine, Sapporo, Japan, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China,
Abstract
Modifying the gastric tumor microenvironment with tadalafil: A transcriptomic analysis of immune signatures from underserved patients of southern Arizona.Org: The University of Arizona Cancer Center, University of Arizona Cancer Center, University of Arizona College of Medicine, Phoenix, AZ,
Abstract
The efficacy and safety of neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced lymph node-positive esophageal squamous cell carcinoma: A real world study.Org: Lishui City People's Hospital, The First Affiliated Hospital of Huzhou Teachers College,
Abstract
Neoadjuvant serplulimab in combination with concurrent chemoradiotherapy for locally advanced, resectable esophagogastric junction adenocarcinoma.Org: Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Department of General Surgery, Chang Gung Memorial Hospital at Tao-Yuan, Tao-Yuan, Taiwan, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
An analysis of post-operative thromboembolic events in patients diagnosed with gastro-esophageal cancer.Org: Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL, Flare Therapeutics,
Abstract
Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction cancer (GC/GEJC): A prospective, multi-center, phase II study.Org: The Oncological Surgery Department, The First Hospital of Lanzhou University, the Oncology Department, Sun Yat-sen University Cancer Center Gansu Hospital, Gastrointestinal Surgery Department,
Abstract
Analysis of ctDNA assay as a strategy for watchful waiting in locally advanced esophageal cancer.Org: Renown Regional Medical Center, William N. Pennington Cancer Institute - Renown Health,
Abstract
Predictive value of positive lymph node ratio in patients with locally advanced gastric remnant cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Renji Hospital Shanghai Jiaotong University School of Medicine, School of Medicine, Zhejiang University, Hangzhou, China, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Prevalence and outcomes of acute kidney injury among hospitalized patients with gastric cancer: Insights from a National Inpatient Sample study (2018-2020).Org: Brooklyn Hospital Center, Brooklyn, NY, Brooklyn Hospital Program, The Brooklyn Hospital Center, New York, NY,
Abstract
Immunotherapy-based therapy versus chemotherapy for the neoadjuvant treatment of locally advanced dMMR/MSI-H gastric cancer.Org: Laboratory of Gastric Cancer,
Abstract
Hydrogenated oxide material-based hyperthermia and radiotherapy: A new treatment option for esophageal squamous carcinoma.Org: Cancer Hospital & Shenzhen Hospital, University of Science and Technology of China,
Abstract
Neoadjuvant chemoradiotherapy (nCRT) combined with sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Preliminary results of a single-arm, open-label phase Ib trial (CRIS).Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou Yirui Pharmaceutical Technology, China National Biotec Group, Zhejing Cancer Hospital,
Abstract
High versus standard radiation dose of definitive chemoradiotherapy combined with immunotherapy for inoperable esophageal squamous cell carcinoma: A multicenter propensity score matching analysis.Org: Guangdong Esophageal Cancer Research Institute,
Abstract
Neoadjuvant nivolumab plus paclitaxel/cisplatin- chemo-radiotherapy (neo-NTP-CRT) followed by esophagectomy for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II study.Org: Taiwan University Hospital,
Abstract
Analysis of effectiveness of FLOT perioperative chemotherapy in resectable locally advanced gastric or esophago-gastric junction cancer in a Kazakhstani population.Org: National Research Oncology Center,
Abstract
A randomized controlled study on perioperative treatment of esophageal squamous cell carcinoma with camrelizumab combined with nab-paclitaxel and cisplatin.Org: Zhengzhou University First Affiliated Hospital, Jiangsu Hengrui Pharmaceuticals Co.,Ltd,
Abstract
LncRNA EGOT and tumorigenesis via Hedgehog pathway in gastric cancer.Org: Department of Medical Oncology, Huai 'an Cancer Hospital, Huai 'an, Jiangsu, China, Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China, Department of Radiotherapy, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China,
Abstract
Beyond scalpels: A meta-analysis of robotic and laparoscopic gastrectomy in long-term oncological outcomes in gastric cancer.Org: Federal University of Rio Grande do Norte, Universidade Federal de Campina Grande,
Abstract
Sintilimab combined with definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: A single-arm, multicenter, phase 2 trial.Org: Meishan Hospital of Chinese medicine, Meishan, China, Nanbu Hospital of County Chinese medicine, Nanbu, China,
Abstract
Updated results of perioperative PD-1 antibody toripalimab plus FLOT chemotherapy for locally advanced resectable gastric or gastro-esophageal junction adenocarcinoma: A one-arm open-table phase II trial.Org: Tianjin Medical University Institute & Hospital, Department of GI Medical Oncology, Department of Cancer Center,
Abstract
Effect of triplet regimen (single-agent chemotherapy plus anti-PD-1 antibody and tyrosine kinase inhibitors) on survival compared to chemotherapy in the second-line treatment of advanced biliary tract cancer: A retrospective analysis.Org: the Naval Medical University,
Abstract
Efficacy and safety analysis of donafenib combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: A prospective, single-arm, single center, phase II clinical study.Org: Intervention Ward One,
Abstract
Second-line systematic strategy options for the progression of lenvatinib plus tislelizumab treating unresectable hepatocellular carcinoma: A retrospective study.Org: National Cancer Center Hospital East, Kashiwa, Japan, Cancer Hospital of Chinese Academy of Medical Sciences, Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Patients with metastatic cholangiocarcinoma in Italy and their healthcare resource consumptions and related costs.Org: Drugs&Health, Fondazione ReS (Ricerca e Salute) - Research and Health Foundation,
Abstract
Hepatocellular carcinoma etiology drives survival outcomes: A population-based analysis.Org: University of Miami Miller School of Medicine, Miami, FL, Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Health System,
Abstract
Transarterial chemoembolization combined with donafenib or lenvatinib as first-line treatment for unresectable hepatocellular carcinoma: A single-center real-world retrospective study.Org: The Third Affiliated Hospital of Sun Yat-sen University,
Abstract
Efficacy and safety of transarterial therapy combined with donafenib plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A multicenter retrospective study.Org: Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China, Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Department of Minimally Invasive Interventional Radiology, Hexian Hospital of Panyu District, Guangzhou, China, Department of Hepatobiliary Surgery, The First People’s Hospital of Foshan, Guangdong, China, Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China,
Abstract
Preclinical antitumor efficacy of ETN101, a novel oral anticancer agent with Wnt/ß-catenin signaling inhibition, TME modulation, and VEGFR2 targeting for advanced hepatocellular carcinoma treatment.Org: Daegu-Gyeongbuk Medical Innovation Foundation,
Abstract
Efficacy and safety of regorafenib plus ICIs as second-line treatment in advanced HCC post-frontline treatment failure: A real-world study from a single center.Org: PLA General Hospital,
Abstract
Update results of anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.Org: Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, China, The First Affiliated Hospital of Zhengzhou University, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Plasma growth hormone as a prognostic biomarker to durvalumab and tremelimumab in patients with advanced hepatocellular carcinoma.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Massachusetts General Hospital, The University of Texas Health Science Center at Houston, McGovern Medical School,
Abstract
Efficacy and safety in advanced hepatocellular carcinoma between patients with negative and positive APF treated with targeted and immunotherapy.Org: Comprehensive HCC Center, The Fifth Medical Center of the PLA General Hospital, Chinese PLA Medical School, Peking University 302 Clinical Medical School, Treatment and Research Center for Infectious Diseases,
Abstract
Transcatheter arterial chemoembolization combined with immune checkpoint inhibitors plus bevacizumab or lenvatinib in hepatocellular carcinoma: Results from a retrospective dual-center cohort study.Org: Department of Interventional Therapy, Zhejiang Cancer Hospital, Hangzhou, China, Center of Interventional Medicine, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China, Department of Interventional Radiology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China,
Abstract
A multi-center retrospective study on the efficacy and safety of regorafenib plus immune checkpoint inhibitors with or without TACE as a second-line treatment for advanced hepatocellular carcinoma.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Suncadia Medicine, China National Biotec Group,
Abstract
Lenvatinib, gemcitabine, and oxaliplatin for 67 patients with fibrolamellar carcinoma.Org: FibroFighters Foundation, NY Presbyterian, St. George Hospital, Helen DeVos Children’s Hospital,
Abstract
Real-world study of anlotinib monotherapy and combination therapy for unresectable hepatocellular carcinoma.Org: Department of Infectious Diseases, Guangdong Institute of Hepatology, Guangzhou Medical University,
Abstract
Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Two stage, multi-center trial of cadonilimab and LM-302 for patients with CLDN18.2+ biliary tract cancer (BTC) that failed chemotherapy and PD-(L)1 antibody (ZSAB-Calm).Org: Institute of Fudan-Minhang Academic Health System,
Abstract
A single-arm, prospective study on the efficacy and safety of TACE-HAIC combined with lenvatinib and tislelizumab in the treatment of unresectable hepatocellular carcinoma.Org: The Second People's Hospital of Yibin, Yibin, China,
Abstract
CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.Org: Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Division of Hepato-Gastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan,
Abstract
Comparison of checkpoint inhibitor–based regimens as first-line therapy in advanced hepatocellular carcinoma: A Frequentist Network meta-analysis of randomized clinical trials.Org: Saint Mary's and Saint Clare's Hospital, Howard University Hospital, Reg Cancer Center at St Michael's Medical Center, St. Michael's Medical Ctr,
Abstract
Comparing the efficacy and safety of TACE combined with donafenib or lenvatinib in the treatment of unresectable hepatocellular carcinoma.Org: University of Science and Technology of China,
Abstract
Safety and efficacy of camrelizumab and apatinib in combination with IMRT in unresectable hepatocellular carcinoma: A non-randomised phase 2 study.Org: Department of Hepatopancreatobiliary Surgery Unit I,
Abstract
Efficacy and safety of donafenib combined with anti-PD-1 antibodies for initially unresectable hepatocellular carcinoma (HCC): A retrospective real-world study.Org: People's Hospital of Hunan Province,
Abstract
Efficacy and safety of TACE combined with ablation and regorafenib for unresectable hepatocellular carcinoma: A real-world study.Org: Beijing Youan Hospital,
Abstract
Tislelizumab in combination with GEMOX and lenvatinib for conversion therapy of unresectable extrahepatic biliary tract carcinoma (eBTC): A prospective, single-arm, phase 2 study.Org: Department of Organ transplantation, the Third Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Faculty of Hepatopancreatobiliary Surgery, the First Medical Center of Chinese People’s Liberation Army (PLA) General Hospital,
Abstract
The safety of atezolizumab plus bevacizumab (atezo/bev) treatment in Chinese patients (pts) with hepatocellular carcinoma (HCC) with active hepatitis B virus (HBV) infection: Results from the TALENTop study.Org: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Department of Hepatobiliary Pancreatic Surgery, Henan Provincial People's Hospital, Zhengzhou, China, Department of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China,
Abstract
Cadonilimab in combined with gemcitabine and cisplatin in advanced biliary tract cancer (BicureX): A phase II, single-arm clinical trial.Org: West China Hospital, Sichuan University,
Abstract
Lenvatinib (Lenv) plus tislelizumab (Tis) combined with or without transarterial chemoembolization (TACE) in first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, non-randomized, open-label, phase II cohort study.Org: State Key Laboratory of Complex Severe and Rare Diseases, Division of Pulmonary and Critical Care Medicine, State Key Laboratory of Severe and Rare Diseases,
Abstract
A real-world experience of hepatic arterial infusion chemotherapy combined with tislelizumab and lenvatinib for unresectable hepatocellular carcinoma with type IV portal vein tumor thrombus.Org: Department II of Interventional Radiology,
Abstract
Des-gamma-carboxy prothrombin (DCP) as a prognostic biomarker in patients with advanced hepatocellular carcinoma treated with atezolizumab/bevacizumab.Org: University of California, San Diego, San Diego, CA, UC San Diego Moores Cancer Center, San Diego, CA,
Abstract
Combining immune checkpoint inhibitors and molecular-targeted agents with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium tumor thrombus.Org: Department of Minimally Invasive Intervention, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Efficacy and safety of regorafenib combined with PD-1 inhibitors in patients with advanced hepatocellular beyond atezolizumab plus bevacizumab: A retrospective analysis of real-world evidence.Org: The PLA 307 Clinical College of Anhui Medical University, The Fifth Clinical Medical College of Anhui Medical University, Institute of Molecular Medicine (IMM),
Abstract
A retrospective study on the efficacy and safety of donafenib combined with transarterial chemoembolization (TACE) and with/without immunotherapy in intermediate-advanced hepatocellular carcinoma (HCC).Org: Affiliated Hospital of Nantong University, Nantong Third People's Hospital, Nantong University,
Abstract
Liquid biopsy-based prediction of clinical benefit from immune checkpoint inhibitors in advanced biliary tract cancer.Org: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Geneplus-Beijing, Beijing, China, Division of Pulmonary and Critical Care Medicine, State Key Laboratory of Severe and Rare Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China,
Abstract
Efficacy and safety of regorafenib and/or immune checkpoint inhibitors as a second-line therapy for advanced hepatocellular carcinoma: A real-world study from a single center.Org: Beijing YouAn Hospital Affiliated to Capital Medical University,
Abstract
Effect of BCL9/BCL9L inhibition–derived Th1 cells on dendritic cells–mediated antigen presentation in hepatocellular carcinoma and on the efficacy of CAR-T immunotherapy.Org: Key Laboratory of Smart Drug Delivery and Shanghai Engineering Research Center of Immune Therapy, School of Pharmacy, Fudan University, Shanghai, China, Department of Pharmacology, School of Basic Medical Science, Fudan University, Shanghai, China, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Jiahui International Cancer Center, Shanghai, China, SPH Biotherapeutics (Shanghai) Limited, Shanghai, China,
Abstract
Changing treatment patterns for hepatocellular carcinoma: A SEER-Medicare study.Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Dana Farber Cancer Institute, Boston, MA, Dana-Farber Cancer Institute, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
The efficacy and safety of donafenib combined with transcatheter arterial chemoembolization and anti-PD-1 antibodies as first-line therapy for hepatocellular carcinoma: A retrospective study.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Department of Interventional Radiology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
TACE-HAIC combined with donafenib and immunotherapy for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A retrospective analysis.Org: Harbin Medical University Cancer Hospital, Harbin, China,
Abstract
Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Sun Yat Sen University Cancer Center, Laboratory of Oncology in South China,
Abstract
A retrospective analysis of efficacy and safety of lenvatinib combined with PD-1 inhibitor and chemotherapy in advanced biliary tract cancer (BTC).Org: The Fifth Medical Center of PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
The activity and safety of icaritin for patients with unresectable HCC: A real world, retrospective study.Org: Department of Interventional Radiology, Zhejiang Cancer Hospital, Hangzhou, China, Tianjin First Center Hospital, Tianjin, China, First affiliated hospital of Xi'an Jiaotong University, Xian, China, Tianjin Third Center Hospital, Tianjin, China, Department of Interventional medicine,The Affiliated Hospital of Qingdao University, Qingdao, China,
Abstract
The treatment outcomes of patients who failed to be randomly assigned after atezo/bev induction therapy in the Chinese TALENTop study.Org: Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department Of Hepatic Surgery, Shanghai Eastern Hepatobiliary Surgery Hospital, SYSUCC, Guangzhou, Tongji Hospital, Huazhong University of Science and Technology, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin’s Clinical Research Center for Cancer,
Abstract
Hepatic artery infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced hepatocellular carcinoma with portal vein tumor thrombus: A single center retrospective study.Org: Department II of Interventional Radiology,
Abstract
The safety and efficacy of adebelimumab combined apatinib and hepatic artery infusion chemotherapy in the treatment of unresectable hepatocellular carcinoma: A retrospective study.Org: Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China,
Abstract
Effect of immune checkpoint inhibitor administration timing on survival outcomes in advanced biliary tract cancers: A single-center propensity score matching analysis.Org: West China Hospital, Sichuan University, Chengdu Origen Biotechnology, Sichuan Baili Pharmaceutical, China National Biotec Group,
Abstract
Hepatic artery infusion chemotherapy (HAIC) plus sintilimab and bevacizumab biosimilar (IBI305) in initial unresectable hepatocellular carcinoma (HCC): A retrospective study.Org: Department of Hepatobiliary and Pancreatic Oncology, Tianjin Cancer Hospital Airport Hospital,
Abstract
A prospective cohort study on the improvement of disease-free progression survival in patients with hepatocellular carcinoma by combining Sophora japonica granules with targeted and immune checkpoint inhibitors.Org: Fourth Clinical Medical College, Xinjiang Medical University, Urumqi, China, Traditional Chinese Medicine Hospital of Xinjiang Uyghur Autonomous Region, Second Department of Oncology, Xinjiang, China, Traditional Chinese Medicine Hospital of Xinjiang Uyghur Autonomous Region, Second Department of Oncology, Urumchi, China,
Abstract
Efficacy and safety of arterial FOLFOX chemotherapy plus anti-PD-(L)1 immunotherapy as first-line treatment for unresectable intrahepatic cholangiocarcinoma: A propensity score matched analysis.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
Comparative efficacy of systemic sequential regorafenib after TACE combined with first-line targeted drugs (donafenib, sorafenib, or lenvatinib) after treatment failure for advanced hepatocellular carcinoma: A retrospective, single-center, real-world study.Org: University of Science and Technology of China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Hefei, China,
Abstract
Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A single-arm, open-label, phase II study (ENLIGHTEN study).Org: First People’s Hospital of Foshan, Foshan First People's Hospital,
Abstract
A retrospective study of PD-1/PD-L1 combination therapy versus TKI monotherapy in elderly patients with uHCC.Org: Phase I Clinical Trial Unit, Department of Clinical Research & Development, First Hospital of Jilin University, The First Hospital of Jilin University, Changchun, Jilin Province, China,
Abstract
Body mass index (BMI) as a prelude to hepatocellular carcinoma (HCC) and metabolic dysfunction–associated steatohepatitis (MASH) risk factors in patients with no identified risk factor for developing hepatocellular carcinoma (HCC).Org: Memorial Sloan Kettering Cancer Center, New York, NY, Department of Epidemiology & Biostatistics, Weill Cornell Medical College University, Weill Medical College at Cornell University,
Abstract
Pyroptosis-related pattern depicting tumor microenvironment and association with prognosis and efficacy in patients with hepatocellular carcinoma receiving combined molecular targeted therapy and immune checkpoint inhibitors: A multi-omics study.Org: CAMS (Cancer Institute and Hospital, Chinese Academy of Medical Sciences),
Abstract
Use of a nationwide, patient-powered observational platform to define the landscape of treatment, molecular profiling, and outcomes for fibrolamellar carcinoma.Org: xCures, Inc,
Abstract
Association between somatic mutation pathways and treatment response in patients with biliary tract cancers (BTCs).Org: Beth Israel Deaconess Medical Center, Mount Sinai Beth Israel, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Impact of cholangiocarcinoma on the severity of acute cholangitis: A nationwide sample analysis.Org: University of Kansas Medical Center, Department of Biostatistics & Data Science, Division of Hematologic Malignancies and Cellular Therapeutics, University of Nebraska Medical Center, Khyber Medical University,
Abstract
Outcomes of patients with intrahepatic cholangiocarcinoma with a focus on the interaction between tumor stage and age on mortality over the past decade.Org: Palisades Medical Center, North Bergen, NJ, Rutgers New Jersey Medical School, Newark, NJ, UTHealth School of Public Health,
Abstract
Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC).Org: Croix-Rousse Hospital, Service d’Hépato-Gastroentérologie, Hôpital Purpan, FFCD - INSERM U1231, Hopital Duchenne,
Abstract
Role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) in unresectable hepatocellular carcinoma (uHCC): Subgroup analysis of patients treated with camrelizumab (cam) + rivoceranib (rivo) in the CARES-310 trial.Org: Hong Kong Cancer Institute,
Abstract
Factors associated with the receipt of palliative care in Native American patients with hepatocellular carcinoma: A retrospective analysis.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton University Medical Center, Creighton Hematology Oncology, Omaha, NE,
Abstract
A machine learning–based radiomics approach to predict MUC4 mutation and response to immunotherapy in cholangiocarcinoma.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China, First Affiliated Hospital of Zhejiang University School of Medicine,
Abstract
Hepatic artery infusion of FOLFOX chemotherapy and camrelizumab combined with sorafenib for advanced stage hepatocellular carcinoma (Double-IA-001): A phase II trial.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma.Org: The First Department of Hepatic Surgery, Department of Special Treatment I and Liver Transplantation,
Abstract
Utility of an amplicon-based ctDNA platform for advanced cholangiocarcinomas (CCA) in asia.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, The University of Hong Kong, Queen Mary Hospital, Lucence Diagnostics Pte Ltd,
Abstract
Patients with hepatocellular carcinoma (HCC) who require multiple transarterial chemoembolization (TACE) treatments in quick succession and prediction of outcome.Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical School, MedStar Georgetown University Hospital, Indiana University – Purdue University Indianapolis, Lehigh Valley Health Network,
Abstract
Magnesium microspheres to enhance lipiodol-mediated transarterial chemo-embolization (TACE) of hepatocellular carcinoma: From bench to a pilot clinical study.Org: The Fifth Affiliated Hospital of Wenzhou Medical University,
Abstract
Survival of primary gallbladder cancer in the United States: SEER database analysis from 2000-2020.Org: Saint Clare's Health System, Denville, NJ, Government Medical College Omandurar, Lumbini Medical College and Teaching Hospital, Maimonides Medical Center, Brooklyn, NY, Patan Academy of Health Sciences, Kathmandu, Nepal,
Abstract
Survival outcomes in patients with advanced intrahepatic cholangiocarcinoma in United States: A nationwide analysis.Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Wyckoff Heights Medical Center, Mayo Hospital, King Edward Medical University,
Abstract
Stereotactic body radiation therapy combined with atezolizumab and bevacizumab for hepatocellular carcinoma with extrahepatic metastasis: Preliminary result of a single-arm study.Org: Fudan University Shanghai Cancer Center, Shanghai Henlius Biotech, China National Biotec Group,
Abstract
Targeting USP7 to induce ubiquitination degradation of oncogenic ATAD2 and effects on cholangiocarcinoma growth.Org: Jiangxi Medical College, Nanchang University,
Abstract
Fibrolamellar hepatocellular carcinoma (FL-HCC) epidemiology, survival characteristics, and outcomes: Surveillance, epidemiology, and end results database (SEER) study.Org: Faculty of Medicine, Cairo University,
Abstract
Predictors of poor response to immune-checkpoint inhibitor (ICI) treatment among patient with hepatocellular carcinoma (HCC).Org: The Ohio State University Wexner Medical Center, Columbus, OH, The Ohio State University College of Medicine, The Ohio State University Wexner Medical Center and Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,
Abstract
Clinicopathologic and treatment characteristics of mixed hepatocellular carcinoma-intrahepatic cholangiocarcinoma (HCC-ICC).Org: West Suburban Medical Center,
Abstract
The efficacy of atezolizumab plus bevacizumab in the treatment of unresectable hepatocellular carcinoma in cirrhotic and non-cirrhotic patients.Org: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico,
Abstract
Epidemiology, survival and new treatment modalities for intrahepatic cholangiocarcinoma (IHCC).Org: Ascension Providence Hospital, Ascension Providence/MSUCHM Program, Newland Medical Associates, P.C.,
Abstract
Nivolumab monotherapy and associations in the treatment of advanced unresectable biliary tract cancer (BTC): A systematic review and meta-analysis.Org: Canoas Health Office, Canoas, Brazil, Federal University of Pelotas, Belo Horizonte, Brazil,
Abstract
Clinical and molecular mechanisms for predicting the efficacy of immunotherapy for hepatocellular carcinoma based on gut microbiome.Org: Liver Cancer Center,
Abstract
Immunotherapy responses in viral hepatitis-induced hepatocellular carcinoma: A meta-analysis.Org: Mercy Hospital Fort Smith, Arkansas College of Osteopathic Medicine,
Abstract
Epigenetic silencing of LDHB to promote hepatocellular carcinoma by remodeling the tumor microenvironment.Org: Jiangxi Medical College, Nanchang University, Nanchang, China,
Abstract
Differential IDH1 and IDH2 mutation-related landscape in intrahepatic cholangiocarcinoma.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, First Affiliated Hospital of Zhejiang University School of Medicine,
Abstract
Predictors of good outcomes in patients with hepatocellular carcinoma (HCC) treated with transarterial radioembolization (TARE).Org: The Ohio State University Wexner Medical Center, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,
Abstract
Preliminary data of a phase Ib/II trial evaluating the efficacy and safety of adebrelimab, camrelizumab plus apatinib as first-line therapy in patients with advanced hepatocellular carcinoma.Org: Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China,
Abstract
The efficacy and safety study of thymosin α1 combined with PD-1 antibodies as adjuvant therapy in patients with hepatocellular carcinoma with high-risk recurrence factors after radical resection.Org: Hepatic Surgery Center,
Abstract
Postoperative adjuvant hepatic arterial infusion chemotherapy combined with donafenib in hepatocellular carcinoma with solitary large tumor and microvascular invasion: A multicenter, prospective, single-arm, phase II trial.Org: Department of Hepatobiliary Surgery, Guangzhou Medical University Cancer Hospital and Institute, Guangzhou, China, Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China,
Abstract
Incidence and demographics of bile duct cystadenocarcinoma from the National Cancer Database.Org: Kansas City University, University of Arizona College of Medicine Phoenix,
Abstract
Comparing clinical outcomes between PD-1 and PD-L1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresectable hepatocellular carcinoma: A single-center real-world study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China,
Abstract
Discovering urinary protein biomarkers for hepatocellular carcinoma in the population of patients with chronic hepatitis b: A single-center case-control study.Org: Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Liver Transplantation Center, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China, Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China, Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of medical oncology, Peking Union Medical College Hospital, Beijing, China,
Abstract
Potential impact of malnutrition on patients with hepatocellular carcinoma undergoing liver transplantation: A nationwide analysis.Org: Presbyterian Health System, Albuquerque, NM, Wageningen University and Research, Wageningen, Netherlands,
Abstract
Intervention to improve care delivery and patient self-management for people with primary liver cancer who have socioeconomic disadvantages.Org: Glencoe, Department of Gastroenterology and Multiorgan Transplant Institute, Oschner Health Center,
Abstract
Effects of Attractive Pickering emulsion gels loaded with oxaliplatin and lactate dehydrogenase inhibitors in hepatocellular carcinoma.Org: Zhejiang University School of Medicine First Affiliated Hospital,
Abstract
Temporal dynamics and prognostic significance of cancer free status in patients with intermediate stage hepatocellular carcinoma: A multicenter cohort study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
Efficacy and safety of donafenib as adjuvant therapy for patients with hepatocellular carcinoma undergoing curative resection: A retrospective, multicenter cohort study.Org: Li Huili Hospital,
Abstract
Prognostic significance of real-world (RW) recurrence patterns after resection or ablation of early-stage hepatocellular carcinoma (HCC): Insights from the US Medicare population.Org: Genentech, Genesis Research Group,
Abstract
Adjuvant therapy with donafenib plus anti–PD-1 antibody for patients (pts) with hepatocellular carcinoma (HCC) at high risk of recurrence after resection (PATH study).Org: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China,
Abstract
Short-term and long-term outcomes of transduodenal ampullectomy for patients with early ampullary cancer.Org: Ibaraki Medical Center,
Abstract
Utilization of personalized tumor-specific methylation haplotypes of circulating DNA to monitor minimal residual disease in patients with hepatocellular carcinoma undergoing curative resection.Org: Singlera Genomics Ltd.,
Abstract
Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study.Org: The First Affiliated Hospital of USTC, Hefei, China, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China,
Abstract
Impact of the COVID-19 pandemic on disease progression in patients with hepatobiliary and pancreatic cancer.Org: Medical College of Georgia at Augusta University, Georgia Cancer Center, Augusta University,
Abstract
The safety and short-term efficacy of selective internal radiation therapy combined with systemic treatment for unresectable malignant hepatic tumors in Chinese patients.Org: Department of Hepatobiliary, The First Affiliated Hospital of Army Military Medical University, Chongqing, China, Weifang People's Hospital, Weifang, ShangDong/WeiFang, China, Department of Hepatobiliary Surgery, First Affiliated Hospital of Third Military Medical University (Army Medical University),, Chongqing, China, Department of Hepatobiliary Surgery, First Affiliated Hospital of Third Military Medical University (Army Medical University), Chong, China, Department of Orthopedics/Dermatology of Jiangbei Campus,The First Affiliated Hospital of Army Medical University, Chongqing, China,
Abstract
Neoadjuvant tislelizumab combined with lenvatinib plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase II trial.Org: The First Affiliated Hospital of Army Military Medical University,
Abstract
A prospective study of radiofrequency ablation combined with systematic neoadjuvant therapy in the treatment of recurrent hepatocellular carcinoma (RANT study).Org: The First Affiliated Hospital of Army Military Medical University,
Abstract
Effect of malnutrition on cirrhotic patients with hepatocellular carcinoma: A nationwide study.Org: Wageningen University and Research,
Abstract
Associations between radiomic phenotypes and genomic mechanisms in HBV-associated cholangiocarcinoma.Org: First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China,
Abstract
The efficacy and safety of donafenib-containing regimens as first-line therapy for hepatocellular carcinoma (HCC): A multicenter retrospective study.Org: Hepatological Surgery Department, Interventional Radiology Department of Lianyungang First People's Hospital, Nanjing Gulouhospital Group Suqian Hospital, Nanjing Gulou Hospital Group Suqian Hospital, Suqianfirst People's Hospital,
Abstract
Association of chr11q13 amplification with survival and recurrence in patients with surgically treated hepatocellular carcinoma.Org: Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao Sino-Cell Biomedicine, OrigiMed, Shanghai Henlius Biotech,
Abstract
Peritumoral HLJ1-STAT3 pathway investigation in carcinogen-induced hepatocellular carcinoma.Org: National Taiwan University Cancer Center/Hospital, Taipei City, Taiwan, Zhong Zheng Qu, National Taiwan University College of Medicine, Taipei Medical University Hospital,
Abstract
Impact of preoperative frailty on outcomes of hepatic resection among elderly patients with hepatocellular carcinoma: A comprehensive multicenter cohort study.Org: Phase I Clinical Trial Unit, Department of Clinical Research, First Hospital of Jilin University, Changchun, China, The First Department of General Surgery, The Fourth Hospital of Harbin, Harbin, China, Department of General Surgery, Ziyang First People’s Hospital, Ziyang, Sichuan, China, Department of Hepatobiliary Surgery, Fuyang People’s Hospital, Fuyang, China, Department of General Surgery, Liuyang People’s Hospital, Liuyang, China,
Abstract
Adjuvant tislelizumab combined with capecitabine for patients with biliary tract cancer with high risk of postoperative relapse (ACTIVE): Primary analysis from a prospective cohort study.Org: Department of Genral Surgery, Fundan University,
Abstract
Inpatient mortality outcomes of patients with hepatocellular carcinoma with congestive heart failure: A nationwide retrospective cohort study.Org: Mount Sinai Morningside/West,
Abstract
Surgical resection versus thermal ablation: Comparison of sequential options after successful TACE downstaging therapy for unresectable hepatocellular carcinoma—A long-term multi-institutional study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Minimally Invasive Interventional Therapy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,
Abstract
Effect of regulatory B cell expansion on tissue-resident TPH cells immune evasion in hepatocellular carcinoma.Org: Department of Clinical Laboratory, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China,
Abstract
Tislelizumab plus tyrosine kinase inhibitor versus active surveillance in patients with ablated high-risk hepatocellular carcinoma: An open-label, parallel controlled, prospective cohort study.Org: Hefei, China,
Abstract
Machine learning identification of hypoxia-related genes and prognostic risk-scoring model for effective survival stratification in hepatocellular carcinoma.Org: Department of Health Technology and Informatics, Hong Kong Polytechnic University,
Abstract
Long-term survival outcomes with regular recurrence surveillance following surgical resection in early-stage hepatocellular carcinoma: Insights from a multicenter prospective study.Org: Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China, Department of Hepatobiliary Surgery, First Affiliated Hospital of Nantong University, Nantong, China, Department of Hepatobiliary Surgery, First Affiliated Hospital of Harbin Medical University, Harbin, China,
Abstract
Preoperative BMI and long-term survival in NAFLD-associated hepatocellular carcinoma: A multicenter study revealing a paradox.Org: First Affiliated Hospital of Shandong First Medical University, Second People’s Hospital of Changzhi, Huzhou Central Hospital, Liuyang People’s Hospital, The Fourth Hospital of Harbin,
Abstract
Integrating pathomics and radiomics for predicting survival among patients with intrahepatic cholangiocarcinoma undergoing surgical resection.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine, Hangzhou Yirui Pharmaceutical Technology, China National Biotec Group,
Abstract
Treatment duration of adjuvant immune checkpoint inhibitor in hepatocellular carcinoma after curative resection: A prospective cohort study.Org: Guangxi Medical University Cancer Hospital, Guangxi Medical University Affiliated Tumor Hospital,
Abstract
Laparoscopic versus open hepatectomy for exophytic hepatocellular carcinoma: A multicenter propensity-matched comparative study.Org: Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital, Fujian Medical University, Fujian, China, Fuzhou, China, Department of Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Fuzhou, China,
Abstract
A pilot trial of personalized neoantigen pulsed autologous dendritic cell vaccine as adjuvant treatment in hepatocellular carcinoma.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Hospital, Sichuan University, Chengdu, China,
Abstract
The relationship of preoperative frailty with short- and long-term surgical outcomes among octogenarians with hepatocellular carcinoma: A multicenter comprehensive analysis.Org: Department of Hepatobiliary Surgery, Tongling Municipal Hospital, Tongling, China, Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China, The 2nd Department of General Surgery, The Second People’s Hospital of Changzhi, Changzhi, China, Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China, Department of Hepatobiliary Surgery, Huzhou Central Hospital, Zhejiang University Huzhou Hospital, Huzhou, China,
Abstract
Nodular number as a prognostic indicator in hepatic resection for intermediate-stage hepatocellular carcinoma: An international multicenter observational study.Org: IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Recanati/Miller Transplantation Institute, Pu’er People’s Hospital, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Ziyang First People’s Hospital,
Abstract
Durvalumab plus gemcitabine/cisplatin/nab-paclitaxel in resectable biliary tract cancer: A phase II, single-arm, open-label study (DurGAP).Org: Department of Hepatobiliary and Pancreatic Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China,
Abstract
Neoadjuvant immune-checkpoint blockade therapy combined with TACE for resectable hepatocellular carcinoma with high recurrence risk: A phase II, single-arm clinical trial (MORNING).Org: Center of Hepato-Pancreato-Biliary Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Department of Interventional Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Department of Interventional Radiology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Clinical Trials Unit, Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Laparoscopic versus open hepatectomy for hepatocellular carcinoma following conversion therapy: A systematic review and meta-analysis.Org: Pontifical Catholic University of Rio Grande do Sul, University of Extreme South of Santa Catarina, Federal University of Piaui, Departament of Urology, Federal University of Juiz de Fora,
Abstract
Impact of adjuvant chemotherapy on outcomes after curative-intent surgery for biliary tract cancer: A 10-year retrospective single-center study.Org: Montefiore Albert Einstein College of Medicine,
Abstract
TACE combined with tislelizumab and lenvatinib in the treatment of advanced liver cancer: A real world study.Org: Department of General Surgery (Hepatopancreatobiliary Surgery), Affiliated Hospital of Southwest Medical University, Luzhou, The Affiliated Hospital of Southwest Medical University, Luzhou,
Abstract
Survival outcomes in patients with non-metastatic intrahepatic cholangiocarcinoma in United States: A nationwide analysis.Org: Lifespan Cancer Institute/Brown University School of Medicine-Rhode Island Hospital,
Abstract
Efficacy of oncolytic virus combined with HAIC of mFOLFOX for IMCC: A single-center, single-arm, prospective study.Org: Hepatobiliary Pancreatic Center Department,
Abstract
Risk factors associated with liver cancer in all US participants.Org: Department of Biostatistics and Health Data Science,
Abstract
An analysis of the evidence underpinning the surgical treatment of hepatocellular carcinoma.Org: Medical College of Georgia, Augusta, GA,
Abstract
Factors associated with surgical intervention in Native American patients with hepatocellular carcinoma.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton University Medical Center, Creighton Hematology Oncology, Omaha, NE,
Abstract
Longitudinal survival and complete tumor resection rates in Native American patients with hepatocellular carcinoma treated at academic institutions.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton University Medical Center, Creighton Hematology Oncology, Omaha, NE,
Abstract
WDR4 as a potential indicator of clinical prognosis and immunotherapy in hepatocellular carcinoma.Org: Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province,
Abstract
Influence on surgical approach in hepatocholangiocarcinoma: A demographic and socioeconomic analysis.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton Hematology Oncology, Omaha, NE,
Abstract
Bi-institutional spline curve analysis of lymph node mapping in gallbladder cancer operated over 12 years: Impact of location and number of lymph nodal stations.Org: Tata Memorial Hospital (HBNI), Tata Memorial Centre, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Tata Memorial Center (HBNI),
Abstract
Claims-based analysis of treatment practices of patients with metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NET) in the USA.Org: University of Arizona of Pharmacy, Center for Health Outcomes and PharmacoEconomic Research, Merative, ITM Pharma Solutions GmbH,
Abstract
Demographic and socioeconomic factors of enterochromaffin cell carcinoid.Org: Creighton University School of Medicine-Phoenix, Hunter College, Grand Canyon University,
Abstract
Predictors of malignancy and survival in patients with pheochromocytoma and paraganglioma.Org: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,
Abstract
Diagnostic performance of Cu64-dotatate-PET/CT or Ga68-dotatate-PET/CT with 18F-fluorodeoxyglucose (FDG)-PET/CT for neuroendocrine tumor evaluation.Org: MultiFunctional Imaging LLC, South Ogden, UT,
Abstract
Extra-adrenal paraganglioma demographic data: A NCDB study.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton University School of Medicine - Phoenix Regional Campus, Arizona State University, University of Arizona College of Medicine, Phoenix, AZ, Creighton University School of Medicine (Phoenix Regional Campus), Phoenix, AZ,
Abstract
Prognostic indicators of recurrence after surgical resection in non-pancreatic gastrointestinal neuroendocrine tumors.Org: Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Sinai Hospital of Baltimore, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University,
Abstract
A reassessment of the clinical utility of 68Ga-DOTATATE PET/CT in patients with gastroenteropancreatic neuroendocrine tumors.Org: University of Rochester Medical School, James P. Wilmot Cancer Center - Pluta, University of Rochester Medical Center,
Abstract
Survival outcomes associated with treatment modalities in stage 4 gallbladder neuroendocrine tumors: A nationwide analysis.Org: Wyckoff Heights Medical Center, Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, King Edward Medical University, Shalamar Hospital,
Abstract
Impact of EOB-MRI on the outcome of patients with pancreatic cancer in real-world settings.Org: Bayer Yakuhin Ltd., Tokyo, Japan, Bayer Yakuhin Ltd., Osaka, Japan, Bayer Consumer Care AG, Basel, Swaziland, IQVIA Solutions Japan G.K., Tokyo, Japan, Hamamatsu University School of Medicine, Shizuoka, Japan,
Abstract
Quality of life (QoL) benefits following 177Lu-DOTATATE therapy in patients (pts) with 68Ga-DOTATATE PET positive primary site agnostic neuroendocrine tumors (NET).Org: St. Joseph's Health Care, Division of Endocrinology and Metabolism,
Abstract
The factors associated with all-cause in-hospital mortality in patients with malignant well-differentiated gastroenteropancreatic neuroendocrine tumors: A retrospective analysis of National Inpatient Survey (NIS) 2020 dataset.Org: Internal Medicine Residency, Jefferson-Einstein Hospital, Philadelphia, PA, PainReform, Johns Hopkins University Bloomberg School of Public Health,
Abstract
Effectiveness and safety of irreversible electroporation when used for the ablation of stage 3 pancreatic adenocarcinoma: A registry study (DIRECT).Org: University of Louisville School of Medicine, Northwest Community Healthcare, Carolinas HealthCare System, University of Texas Rio Grande Valley, Miami Cancer Institute at Baptist Health,
Abstract
PBP1510, a novel monoclonal antibody targeting pancreatic adenocarcinoma upregulated factor (PAUF): Phase 1/2a monotherapy and combination with gemcitabine in patients with advanced/metastatic pancreatic cancer.Org: Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain, Department of Medical Oncology Hospital Universitario La Paz, Madrid, Spain, Prestige BioPharma IDC Co., Ltd., Busan, South Korea, Prestige Biopharma Limited, Singapore, Singapore,
Abstract
A single-center retrospective analysis of allergies and survival outcomes in pancreatic adenocarcinoma.Org: National Capital Consortium (Bethesda, MD),
Abstract
Surufatinib combined with TAS-102 in third- or later-line therapy of patients with metastatic pancreatic cancer (mPDAC): An open-label, single-arm, phase II study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,
Abstract
Liquid biopsy in patients with metastatic pancreatic cancer using an optimized targeted sequencing approach: Data from the pancreatic cancer registry PanDaDETECT.Org: St. Josef Hospital, Ruhr University, Ludwig Maximilian University of Munich, Germanium, Georgius Agricola Stiftung Ruhr,
Abstract
Identification of markers associated with toxicity of FOLFIRINOX in patients over 70 years with digestive cancers.Org: Assistance Publique des Hopitaux de Marseille,
Abstract
Longitudinal changes in triceps skinfold thickness and serum albumin during chemotherapy in patients with pancreatic cancer: Gender-based prognostic insights—A prospective cohort study.Org: Samsung Medical Center, Seoul National University Hospital, South Korea,
Abstract
Mutational analysis of cfDNA to identify predictive biomarkers in previously untreated patients with metastatic pancreatic cancer receiving the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.Org: Actuate Therapeutics, Inc.,
Abstract
Exploring the association of smoking status with clinical outcomes in patients with mPDAC treated on a clinical trial of maintenance niraparib plus immune checkpoint blockade.Org: Penn Medicine Abramson Cancer Center,
Abstract
Exploring racial disparities and tumor characteristics of CA19-9 producer and non-producer among patients with advanced pancreatic ductal adenocarcinoma (PDAC): Implications for survival and personalized treatment strategies.Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Morningside-West, Columbia University Herbert Irving Comprehensive Cancer Center,
Abstract
Predictive value of baseline 68Ga‑FAPI PET/CT in the first-line therapy of pancreatic ductal adenocarcinoma (PDAC).Org: Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital, Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Longitudinal tissue-based evaluation of TIGIT expression in patients with pancreatic cancer: Effect of expression with advancing clinical stages and across racial groups.Org: College of Osteopathic Medicine, Institute of Global Health,
Abstract
Efficacy of platinum chemotherapy agents in adenosquamous carcinoma of the pancreas.Org: 2nd Department of Surgery, Areteion Hospital National and Kapodistrian University of Athens, Aretaieion Hospital, Oncology 2nd Department of Surgery Areteion Hospital National and Kapodistrian University of Athens,
Abstract
Meta-analysis comparing the incidence of serious adverse events, overall survival, and progression-free survival in patients with pancreatic adenocarcinoma harboring unresectable tumors treated with modified FOLFIRINOX or FOLFIRINOX regimen.Org: Sapu Bioscience LLC.,
Abstract
Demographic and socioeconomic analysis of patients with glucagonoma: Insights from the National Cancer Database.Org: Creighton SOM,
Abstract
Adverse events in real-world patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX (FFX) or gemcitabine with nab-paclitaxel (GnP) in the first line (1L).Org: Ipsen Biopharmaceuticals, Inc.,
Abstract
Second-line (2L) treatment patterns and clinical outcomes among real-world (RW) patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with FOLFIRINOX (FFX) or gemcitabine + nab-paclitaxel (GnP) in the first-line (1L).Org: Ipsen Biopharmaceuticals, Inc.,
Abstract
Unveiling the nexus: Use of e-frailty index in predicting chemotherapy tolerance in older patients with pancreatic cancer.Org: Senior Adult Oncology Program,
Abstract
Interaction of BRCA1 vs BRCA2 pathogenic variants with primary tumor location in pancreatic cancer.Org: University of Miami Miller School of Medicine, Miami, FL, University of Pennsylvania - Perelman School of Medicine, Penn Medicine Abramson Cancer Center,
Abstract
Tislelizumab with anlotinib and chemotherapy for second-line treatment of pancreatic ductal adenocarcinoma: A pilot study early result.Org: First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Xi'an, China, First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Xian, China,
Abstract
Treatment modalities for advanced solid pseudopapillary tumor of the pancreas.Org: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Pancreatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Oncology, Shenzhen People’s Hospital, Shenzhen, China,
Abstract
Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C.Org: Department of Oncology, Jiading Central Hospital, Shanghai, China, Department of Medical Oncology, Zhejiang Provincal People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China, Department of Oncology, Yancheng Third People's Hospital, Yancheng, China, Department of Oncology, Wuxi Branch of Ruijin Hospital, Wuxi, China, The Affiliated People’s Hospital of Ningbo University, Ningbo, China,
Abstract
Impact of treatment setting on survival outcomes in undifferentiated pancreatic carcinoma: An analysis of the National Cancer Database.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton University Medical Center, Creighton Hematology Oncology, Omaha, NE,
Abstract
ITGB6 as an inhibitor of T-cell killing via modulation of paracrine TGFβ signaling in pancreatic ductal adenocarcinoma.Org: Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Providence, RI,
Abstract
An open-label, placebo-controlled, randomized phase II trial of camrelizumab combined with or without apatinib or capecitabine in the treatment of previously treated advanced pancreatic cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Fudan University Shanghai Cancer Center, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine,
Abstract
Molecular and clinical features of pancreatic acinar cell carcinoma: A single institutional experience.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
Phase II trial of biologically optimized schedule of gemcitabine and nab-paclitaxel in metastatic pancreatic cancer.Org: The Ohio State University Comprehensive Cancer Center and Department of Internal Medicine, Center for Biostatistics, Department of Biomedical Informatics,
Abstract
Correlation of therapy-induced neutropenia with survival in patients with metastatic pancreatic cancer treated with GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.Org: Actuate Therapeutics, Inc., Courante Oncology,
Abstract
First-line treatment patterns among patients with metastatic pancreatic ductal adenocarcinoma in the real-world setting.Org: Ipsen Biopharmaceuticals,
Abstract
Efficacy and safety of sitagliptin, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).Org: Tiianjin,
Abstract
The impact of neighborhood socioeconomic deprivation on overall survival for patients with metastatic pancreatic cancer: An incidence-based retrospective cohort study.Org: USF Morsani School of Medicine,
Abstract
Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.Org: Mayo Clinic, Actuate Therapeutics, Inc., Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Legorreta Cancer Center at Brown University,
Abstract
PD-1 blockade plus chemotherapy followed by concurrent SBRT with SIB as preoperative therapy for patients with potentially resectable pancreatic cancer: A single-arm phase 2 study.Org: Affiliated Hospital of Medical School, Nanjing University, The Comprehensive Cancer Center of Drum Tower Hospital, Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Department of Hepatopancreatobiliary Surgery, Drum Tower Hospital, Medical School of Nanjing University, Digestive department of Drum Tower Hospital, Medical School of Nanjing University,
Abstract
Phase I study of ProAgio, an αvβ3 integrin cytotoxin, in patients with previously treated advanced pancreatic cancer and other solid tumors.Org: Department of Biology,
Abstract
Systematic therapy for metastatic solid pseudopapillary neoplasm of the pancreas: A single-center experience.Org: Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College,Beijing,China, Cancer Hospital Chinese Academy of Medical Sciences,Beijing,China, National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China,
Abstract
Counting coins and cardiovascular catastrophes: The income–pancreas connection.Org: Landmark Medical Center, New York Medical College - Saint Michael's Medical Center, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Mayo Clinic, Sheikh Shakhbout Medical City in Partnership With Mayo Clinic,
Abstract
Nab-paclitaxel and gemcitabine (modified) in combination with oral cobimetinib and encorafenib following FOLFIRINOX in patients with metastatic G12D and G12V pancreatic cancer.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL, Sylvester Cancer Center,
Abstract
Exploration of microRNA biomarker panel as a predictor of evolution of pancreatitis to pancreatic ductal adenocarcinoma.Org: Carmel School, Carmel, IN,
Abstract
Differentiating pancreatic cancer via cfDNA levels in liquid biopsies.Org: Lithuanian University of Health Sciences, Medical Academy, Department of Physics, Mathematics and Biophysics, Institute for Digestive Research, Laboratory of Surgical Gastroenterology,
Abstract
Resectability rate of pancreatic cancer after neoadjuvant therapy.Org: Prince Mohamed Bin Naser Hospital, Ain Shams University, Transplant Center of Excellence, Prince Sultan Bin Abdulaziz Medical City, Menoufia University,
Abstract
Effect of biocompatible snowman-like tumor-targeting dimer nanoparticles on delivery efficiency and anti-tumor therapy.Org: The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China,
Abstract
Impact of personalized peptide neoantigen vaccines on immunologic responses in patients with pancreatic cancer.Org: ANDA Biology Medicine Development (Shenzhen) Co., Shenzhen, China, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China,
Abstract
Pancreatoblastoma: A study of demographic and socioeconomic factors.Org: Phoenix AZ, Omaha NE, Sierra College, Rocklin CA, UC Riverside,
Abstract
Early treatment ctDNA dynamics to predict response to chemotherapy in patients with metastatic pancreatic cancer: A prospective, observational pilot study.Org: Hempstead,
Abstract
Chemotherapy with or without surgery for locally advanced or borderline resectable pancreatic ductal adenocarcinoma: A retrospective multicenter international study.Org: Universitätsklinikum Magdeburg, University Hospital Munich - Grosshadern, Klinik für Innere Medizin I, Universitätsklinikum Ulm, University Hospital, Johann Wolfgang Goethe-University Frankfurt, Universitätsklinikum Bonn,
Abstract
Early prediction of pancreatic cancer through detection of methylated circulating DNA in blood.Org: Taipei Medical University Hospital,
Abstract
ctDNA for clinical decision support in pancreatic cancer.Org: Division of Medical Oncology/Hematology, North Shore University Hospital,
Abstract
TisCRT-LAPC: A phase II study of tislelizumab combined with nab-paclitaxel and gemcitabine (AG) followed by consolidative radiotherapy in locally advanced pancreatic cancer (LAPC).Org: Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China, Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China, Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China, Department of General Surgery, Zhongshan Hospital Fudan University, Shanghai, China,
Abstract
Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis.Org: Dept of Oncology, Research Institute and Hospital, National Cancer Center, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Nucleus Network,
Abstract
An NCDB analysis of the predictive factors associated with the receival of tumor resection in mucinous cystadenoma of the pancreas.Org: Creighton University Medical Center, Creighton University School of Medicine Phoenix Regional Campus,
Abstract
Correlation of significant delays and ethnic disparities in the receipt of treatment, palliative care, and supportive care interventions in pancreatic adenocarcinoma.Org: Penn Medicine Princeton Medical Center, Loma Linda University Department of Radiation Technology,
Abstract
Experience of seven Spanish centres with echoendoscopically implanted 32P microparticles associated with chemotherapy in locally advanced pancreatic adenocarcinoma.Org: Hospital Universitario Ramón y Cajal, Madrid, Spain, Hospital Universitario de Fuenlabrada, Madrid, Spain, Department of Medical Oncology, Gastrointestinal Oncology Unit, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain, Hospital Clinico Universitario de Valladolid, Valladolid, Spain, Hospital Universitario Insular de Gran Canaria, Las Palmas De Gran Canaria, Spain,
Abstract
Unfolding the role of cell state on stress granule heterogeneity and function in pancreatic cancer.Org: Thomas Jefferson University,
Abstract
Development of a multi-analyte blood test for the early detection of pancreatic ductal adenocarcinoma (PDAC) and performance compared to CA19-9.Org: Proteomedix, Immunovia, Marlborough,
Abstract
Analyzing imbalance of short tandem repeats for pancreatic cancer detection.Org: Interpace Diagnostics,
Abstract
Recurrence patterns and surveillance strategies in long-term survivors of resected pancreatic cancer.Org: Columbia University Vagelos College of Physicians & Surgeons,
Abstract
Circulating tumor DNA for recurrence monitoring following resection for pancreas adenocarcinoma.Org: Northwell Health Cancer Institute, Northwell Health, New Hyde Park, NY,
Abstract
Effect of heart failure on mortality and clinical outcomes in patients hospitalized with pancreatic cancer.Org: Wyckoff Heights Medical Center, Brooklyn, NY, Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Miami, FL,
Abstract
Improved germline screening for patients with pancreatic cancer through provider driven testing.Org: University of Virginia, Charlottesville, VA, USA, University of Virginia Cancer Center, Division of Hematology/Oncology, University of Virginia,
Abstract
Association of human interpretable features derived from pancreatic ductal adenocarcinoma pathology slides with disease-free survival.Org: Mayo Clinic, Rochester, MN,
Abstract
Impact of delirium on in-patient outcomes in patients with pancreatic cancer: A nationwide study.Org: Wyckoff Heights Medical Center, Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida,
Abstract
Laparoscopic versus open pancreatoduodenectomy for periampullary tumors: An updated systematic review and meta-analysis.Org: University Centre of Associated Colleges for Education, São João Da Boa Vista, Brazil, Federal University of Rio de Janeiro, Rio De Janeiro, Brazil, Metropolitan University of Santos, Santos, Brazil, A.C. Camargo Cancer Center, São Paulo, Brazil,
Abstract
Yolk sac tumor of the liver: Presentation, diagnosis, and treatment review.Org: Long Island Jewish Medical Center, Zucker School of Medicine at Hofstra/Northwell, Northwell Health System, Northwell Health North Shore/LIJ Medical Center, Manhasset, NY,
Abstract
Impact of acute ischemic stroke on mortality in gastrointestinal malignancies: A nationwide analysis.Org: Immunology Unit, Department of Microbiology, Chiang Mai University, Bassett Medical Center, Cooperstown, NY,
Abstract
Impact of bowel ischemia on mortality in gastrointestinal malignancies: A nationwide analysis.Org: Lubbock, TX, University of Miami/Jackson Memorial Hospital, Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand,
Abstract
Epidemiological investigation of neuroendocrine differentiation in carcinomas: Focus on pancreatic and cholangiocarcinoma cohorts.Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China,
Abstract
Enhancing appendiceal cancer care: Towards evidence-based practice and continuous education for healthcare providers.Org: Department of Medicine, Section of Hematology and Oncology, University of Chicago, University of Chicago, Department of Surgery, Section of Surgical Oncology, Yale Univesity Medical Center, Department of Surgery, University of Chicago Hospitals, Department of Surgery, University of California, Irvine,
Abstract
Improving outcomes in high-grade goblet cell adenocarcinomas: The interplay of complete cytoreduction, HIPEC and fibrosis.Org: BI Lahey Health,
Abstract
FOLFOX as a therapeutic option in patients with hepatic failure due to liver metastasis of gastrointestinal (GI) system malignancies: A case series.Org: Ankara Etlik City Hospital, Etlik City Hospital Ankara,
Abstract
A preliminary enrichment analysis of tumor genes in patients suffering from rectal cancer with and without CNS metastasis.Org: Trinitas Regional Medical Center, RWJBarnabas Health,
Abstract
Unveiling inequalities: An analysis of treatment disparities of primary gallbladder neuroendocrine tumors by race, ethnicity, and socioeconomic status from the National Cancer Database.Org: Lifespan Cancer Institute/Brown University School of Medicine-Rhode Island Hospital, Providence, RI, Miami Cancer Institute, Baptist Health South Florida, Miami, FL,
Abstract
Unfavourable carcinoma of unknown primary (CUP) with gastrointestinal profile: A retrospective study.Org: Istituto Europeo di Oncologia IRCCS, Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, European Institute of Oncology IRCCS, University of Milano, European Institute of Oncology, Division of Early Drug Development, European Institute of Oncology (IEO),
Abstract
Portal vein thrombosis in gastrointestinal cancers: Insights into prevalence and prognosis—A nationwide inpatient analysis 2018-2020.Org: The Brooklyn Hospital Center, New York, NY, Parkview Regional Medical Center, Brooklyn Hospital Center, Brooklyn, NY, St. Vincent Hospital and Health Care Centers, Brooklyn Hospital Program,
Abstract
Small bowel adenocarcinoma: A SEER database analysis.Org: Department of Hospital Medicine, East Carolina University Health Beaufort Hospital,
Abstract
Genomic and biomarker analysis of immunotherapy combined with chemotherapy treated for patients with metastatic BTC cancer: A real world study.Org: Chinese People's Liberation Army General Hospital, Chinese People’s Liberation Army General Hospital, Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital,
Abstract
Investigation of T cell phenotypes associated with response or resistance to immune checkpoint inhibitors (ICI) through single-cell analysis of renal cell carcinoma (RCC).Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine, Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, The Lank Center for Genitourinary Oncology,
Abstract
A multicenter phase II study of modified FOLFIRINOX for first-line treatment for advanced urachal cancer (ULTMA; KCSG GU20-03).Org: Yonesi University College of Medicine, Yangsan Si, South Korea, Daejeon, South Korea,
Abstract
Fibrolamellar carcinoma registry: Opportunities and challenges.Org: Fibrolamellar Cancer Foundation, Creative Lab at Google,
Abstract
Annotations-free survival prediction with WSIs using graph convolutional neural networks.Org: North China University Of Technology, Department of Renal Cancer and Melanoma,
Abstract
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.Org: Novartis Pharmaceutical Corporation,
Abstract
Prediction of immune checkpoint inhibitor (ICI) response in patients with urothelial cancer (UC) by a novel RNA-based ICI response signature (ICI-PRS).Org: GeneCentric Diagnostics, Inc, GeneCentric Therapeutics Inc.,
Abstract
Neoadjuvant versus adjuvant chemotherapy in muscle-invasive bladder cancer: The RealBLADDER study—Results on behalf of the GOIRC.Org: UO Oncologia Medica 2 Universitaria, University Hospital and University of Cagliari, Cardarelli Hospital, Università degli Studi Di firenze, Comprehensive Cancer Centre Azienda USL-IRCCS di Reggio Emilia,
Abstract
Perceptions and expectations: A study on prognostic perception and quality of life in patients with metastatic renal and bladder cancer.Org: Izmir Economy University Medical Point Hospital, Istanbul University School of Medicine, Trakya University School of Medicine, Cerrahpasa School of Medicine, Bakirköy Dr. Sadi Konuk Training and Research Hospital,
Abstract
Randomized phase II/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study.Org: The University of Tokyo, Tokyo, Japan, National Cancer Center Hospital Japan East, Kashiwa, Japan, Sapporo Medical University Hospital, Sapporo-Shi, Japan, Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, Shizuoka Cancer Center, Nagaizumi, Japan,
Abstract
Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial.Org: Department of Biotherapy, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Hospital, Sichuan University, Chengdu Origen Biotechnology,
Abstract
Genomic alterations and clinical outcomes in patients with non-clear cell RCC: Indiana University experience.Org: IU Simon Cancer Center, Trustees of Indiana University,
Abstract
Exploring genetic ancestry and tumor mutation profiles in renal clear cell carcinoma: A comprehensive analysis using The Cancer Genetic Ancestry Atlas.Org: Emory School of Medicine, Augusta University/University of Georgia Medical Partnership,
Abstract
Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial.Org: Yamaguchi University Hospital, Fundación Arturo López Pérez, Fred Hutchinson Cancer Center and University of Washington, Life Groenkloof Hospital, Istinye University Liv Hospital,
Abstract
Avelumab (A) as neoadjuvant therapy in patients (pts) with muscle-invasive urothelial carcinoma (MIUC): Survival data of AURA trial, Oncodistinct 004.Org: Centre Hospitalier Universitaire de Ambrois Paré, Hôpital Paris Saint-Joseph, University Hospital of Liège, CHU Sart-Tilman, Institut Roi Albert II,
Abstract
A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cleveland Clinic Taussig Cancer Instititute, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,
Abstract
Real-world survival outcomes associated with immunotherapy followed with anti-vascular targeted therapy for metastatic clear cell renal cell carcinoma.Org: Jinan, Shandong, China,
Abstract
Phase II clinical study of the safety and efficacy of sintilimab in combination with axitinib and stereotactic radiotherapy in the treatment of local-regional recurrent renal cell cancer.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
Site of metastasis and clinical outcomes in patients with advanced renal cell carcinoma treated with TKI monotherapy or combination therapy: A real-world analysis.Org: SCIAS Hospital de Barcelona, Macerata General Hospital, Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital,
Abstract
The efficacy and safety of presurgical therapy with tislelizumab and axitinib for renal cell carcinoma with inferior vena cava tumor thrombus.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, The First Affiliated Hospital of Xiamen University, Xiamen, China,
Abstract
Treatment patterns of metastatic urothelial cancer in the United States.Org: Johns Hopkins Greenberg Bladder Cancer Institute,
Abstract
Single cell RNA sequencing to reveal genetic biomarkers and immune microenvironment of patients with aggressive small renal cell carcinoma.Org: Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, South Korea, Department of Biomedical Sciences, Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul, South Korea, Department of Urology, Yonsei Cancer Center, Yonesi University College of Medicine, Seoul, South Korea,
Abstract
Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).Org: Alberta, Canada, Sunnybrook Odette Cancer Centre,
Abstract
Prognostic utility of YBX1-mediated genes in clear cell renal cell carcinoma outcomes.Org: Albert Einstein Medical Center, University of Illinois Chicago,
Abstract
Clinical characteristics of renal cell carcinoma in the transplanted kidney in renal transplant recipients: A systematic scoping review.Org: Honolulu, HI, Rayong Hospital, Rayong, Thailand,
Abstract
The impact of smoking status on genomic profile in patients with renal cell carcinoma.Org: Indiana University Internal Medicine,
Abstract
The prognostic significance of venous tumor thrombus grading for patients with renal cell carcinoma.Org: Jinling School of Clinical Medicine, Nanjing China, Clinical School of Medical College, Shanghai China,
Abstract
A study on the value of ctDNA-based molecular residual disease (MRD) in dynamic monitoring in the clinical treatment of advanced/metastatic renal cell carcinoma.Org: Department of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China,
Abstract
HALP index in patients with metastatic clear-cell RCC treated with nivolumab.Org: Biomedical Research Center, Slovak Academy of Sciences, East Slovak Cancer Institute, F. D. Roosevelt University General Hospital, Banska Bystrica,
Abstract
The prognostic value of Meet-URO score in patients with metastatic clear cell renal cell carcinoma receiving second or third-line tyrosine kinase inhibitors/immune checkpoint inhibitors combination therapy: A real-world study.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, West China Hospital, Sichuan University, Institute of Urology,
Abstract
Clinical and pathological outcomes of nephrectomy/metastasectomy in patients with metastatic renal cell carcinoma after prior immune checkpoint inhibitor exposure.Org: Vandebilt University Medical Center, Department of Medicine, Vanderbilt University Medical Center,
Abstract
Real-world clinical and toxicity outcomes in older Veterans with metastatic renal cell carcinoma (mRCC) treated with front-line systemic therapy.Org: RLR VAMC,
Abstract
Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKls) monotherapy or TKI-IO combination therapy.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China,
Abstract
Association of CD8 T cell infiltration in the tumor microenvironment with survival outcomes in patients with metastatic renal cell carcinoma (mRCC).Org: Winship Cancer Institute of Emory University, Dana-Farber Cancer Institute,
Abstract
A new four-tiered grading scheme for postoperative prognostication in renal cell carcinoma with local recurrence.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China,
Abstract
Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study.Org: Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Department of Urology, Xiangya Hospital Central South Universiity, Department of Urology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University,
Abstract
Impact of β-adrenergic blockade on efficacy of immunotherapy in patients with metastatic clear cell renal cell carcinoma.Org: Dana-Farber Cancer Institute, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Beth Israel Deaconess Medical Center, Yale University School of Medicine, The Lank Center for Genitourinary Oncology,
Abstract
Understanding patient and provider preferences in management of metastatic renal cell carcinoma (mRCC).Org: Division of Hematology/Oncology, University of California, Irvine, Orange, CA, Hoag Family Cancer Institute, Newport Beach, CA, Stern Center for Cancer Clinical Trials and Research, Chao Comprehensive Cancer Center, Orange, CA,
Abstract
Cabozantinib (CABO) after prior immune checkpoint inhibitor (ICI) and tyrosine-kinase inhibitors (TKI) therapy in metastatic renal cell carcinoma (mRCC): Real-world evidence (RWE) from a Moscow observational program.Org: SBIH Moscow Clinical Scientific and Practical Center Named After A.S. Loginov, Moscow, Russian Federation,
Abstract
Association of body mass index (BMI) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC).Org: Emory Winship Cancer Institute, Winship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Emory University School of Medicine, Emory University, Atlanta, GA, USA,
Abstract
Impact of time-of-day administration of immunotherapy on overall survival among patients with metastatic renal cell carcinoma.Org: Hospital Medica Sur, Medica Sur SAB de CV, Fundacion Clinica Medica Sur,
Abstract
Renal cell carcinoma post-kidney transplant: An analysis of OPTN/UNOS database.Org: Department of Transplant Nephrology,
Abstract
Safety and efficacy profile of belzutifan, a hypoxia-inducible factor-2α inhibitor, in patients with renal cell carcinoma: Meta-analysis and systematic review.Org: Nishtar Medical University Multan, Nishtar Medical College and Hospital, Bagahi Primary Healthcare Center, CMH Institute of Medical Sciences,
Abstract
Patient reported outcomes on treatment related side effects with combination therapy in metastatic renal cell carcinoma (RCC).Org: KCCure,
Abstract
Association of race with clinical outcomes in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs).Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA,
Abstract
Efficacy and safety of axitinib in combination with sintilimab as neoadjuvant therapy for patients with locally advanced renal cell carcinoma: A phase II clinical study.Org: Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Clinical outcome differences based on gender in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs).Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA,
Abstract
Impact of cytoreductive nephrectomy (CN) and treatment (trt) sequence on overall survival (OS) in metastatic non-clear cell renal cell cancer (nccRCC).Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, The Medical College of Wisconsin, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, Froedtert and the Medical College of Wisconsin Workforce Health, Milwaukee, WI,
Abstract
Incidence and outcomes of thromboembolic events in renal cancer related hospitalization in the United States: A propensity matched national study.Org: LSU Health Shreveport, John H. Stroger Jr. Hospital of Cook County, Louisiana State University in Shreveport, LSU-Shreveport, Louisiana State University Health Sciences Center Shreveport,
Abstract
Anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma: A single-center, single-arm, phase II trial.Org: Department of Urology Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
Cabozantinib outcomes for metastatic renal cell carcinoma at a tertiary NHS hospital in the United Kingdom (UK).Org: Norfolk and Norwich University Hospitals NHS Trust, Norwich, United Kingdom, Norfolk and Norwich University Hospitals NHS Foundation Trust,
Abstract
Dietary interventions selectively target dysregulated metabolism and reveal metabolic vulnerabilities in preclinical models of advanced renal cell carcinoma.Org: University of Campania L. Vanvitelli,
Abstract
Improved overall survival with immune checkpoint inhibitors in the treatment of metastatic urothelial carcinoma: A national retrospective comparative study.Org: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation,
Abstract
Clinical features, genomic alterations, and survival outcomes for variant histology urothelial carcinoma.Org: Indiana University – Purdue University Indianapolis, Indiana University Simon Comprehensive Cancer Center, IU Simon Cancer Center, Indiana University Simon Cancer Center and Roudebush VAMC,
Abstract
Cabozantinib tolerability in metastatic renal cell carcinoma: A meta-analysis.Org: Shaikh Khalifa bin Zayed Al-Nahyan Medical and Dental College,
Abstract
Single-center retrospective analysis of safety and efficacy of dose-reduced enfortumab vedotin (EV) in frail patients with metastatic urothelial carcinoma (mUC).Org: Washington University School of Medicine in St Louis, St. Louis, MO,
Abstract
Tislelizumab combined with gemcitabine and cisplatin (GC) as adjuvant therapy in patients with high-risk upper urothelial carcinoma (UTUC) after surgery: A 2-year follow-up, real-world study.Org: Xi’an, China,
Abstract
Estimated impact of novel immune checkpoint inhibitors on reducing cancer mortality in patients with locally advanced or metastatic urothelial carcinoma in Russia.Org: National Medical Research Radiological Center, Pharmaceutical Analytics Middle East, A.S. Loginov Moscow Clinical Scientific and Practical Center,
Abstract
Systematic literature review and network meta-analysis of first-line therapies for locally advanced/metastatic urothelial carcinoma.Org: Curta Inc.,
Abstract
SOGUG-AVELUMAB_RWD: Comprehensive analysis of real-word data to evaluate the effectiveness and safety of avelumab maintenance therapy in patients with stage IV urothelial carcinoma conducted in Spain.Org: Hospital Universitario y Politecnico La Fe, Servicio Murciano de Salud, Hospital de Sagunto, Hospital Marina Baixa, Complejo Hospitalario U. de Albacete,
Abstract
Integrative genomic analysis examines molecular and clinical disparities between bladder urothelial carcinoma and upper tract urothelial carcinoma.Org: Konyang University Hospital,
Abstract
Immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis of randomized controlled trials.Org: Federal University of Sao Paulo - UNIFESP,
Abstract
Real-world evidence for enfortumab vedotin (EV) in metastatic urothelial carcinoma (mUC): a multi-centred observational study in a publicly funded Canadian system.Org: Department of Medical Oncology, Tom Baker Cancer Center,
Abstract
Characterizing genomic alterations in patients with metastatic urothelial carcinoma (mUC) treated with enfortumab-vedotin (EV) with a focus on 1q23.3.Org: CFCE - Dana-Farber Cancer Institute, Mass General Brigham,
Abstract
Real-world data (RWD) with avelumab in patients (pts) with locally advanced or metastatic urothelial cancer (la-mUC): The AVEBLADDER study.Org: Universidad Europea del Atlántico, Hospital Universitario de Navarra, Valladolid University Clinical Hospital, Hospital Universitario de Araba-Txagorritxu, Hospital Universitario Galdakao-Usansolo,
Abstract
Costs associated with novel first-line (1L) treatments in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) from a United States (US) Medicare and commercial payer perspective.Org: EMD Serono Research & Development Institute, Evidera, Inc, The Healthcare Business of Merck KGaA, Darmstadt, Germany,
Abstract
Efficacy of erdafitinib in FGFR2/3-altered metastatic urothelial cancer including patients with CDK2NA/B or MTAP loss: Analysis of UNITE study.Org: The University of Texas MD Anderson Hematology/Oncology Fellowship,
Abstract
Treatment and outcomes of bladder cancer in Armenia.Org: Immune Oncology Research Institute, Yeolyan Hematology and Oncology Center, Mikaelyan Institute of Surgery, National Center of Oncology named after V.A. Fanarjyan, City University of Hong Kong,
Abstract
Subgroup analysis of real-world efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial carcinoma from a European database.Org: Charité University Medicine Berlin, Rotkreuzklinikum Munich, Heinrich-Heine-University, Diakonie-Klinikum Stuttgart, Ruhr University Bochum,
Abstract
Preliminary results of bladder sparing by short-course radiotherapy combined with toripalimab in high-risk/extremely high-risk non-muscle invasive bladder cancer (HOPE-04).Org: West China Hospital, Sichuan University, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Institute of Urology,
Abstract
Comparison of clinical outcomes of bladder preservation and surgery in a real-world study of patients with muscle invasive urothelial carcinoma using urine and plasma based MRD (minimal residual disease) assays.Org: Rush University Medical Center, Vanderbilt-Ingram Cancer Center,
Abstract
In-hospital outcomes of acute pulmonary embolism admissions in individuals with genitourinary cancers: Insights from a national population study in the United States.Org: Hoag Family Cancer Institute and University of Southern California, University of California Irvine, Wayne State University School of Medicine,
Abstract
Maintenance therapy with avelumab as the first-line treatment in patients with metastatic urothelial carcinoma: A real-world, ambispective RAVE-Bladder study.Org: Moscow City Oncological Hospital No.1, Krasnoyarsk Regional Clinical Oncological Dispensary Named After A.I. Kryzhanovsky, Clinical hospital #1, Medsi Otradnoe, SBHI Leningrad Regional Clinical Hospital,
Abstract
Livmoniplimab with or without budigalimab in patients with advanced solid tumors: Results from the combination therapy in the urothelial carcinoma dose expansion cohort.Org: Hospital Clínico Universitario-INCLIVIA, Valencia, Spain, Universite Catholique De Louvain, Bruxelles, Belgium, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, VA New York Harbor Healthcare System, Manhattan Campus, New York, NY, Yonsei University Health System and Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Prognostic analysis of disitamab vedotin combined with PD-1 inhibitor first-line treatment in advanced urothelial carcinoma: A propensity score analysis.Org: Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, The Xiangya Hospital of Central South University,
Abstract
TECIC bladder-sparing strategy for high-risk bladder cancer: Exploration and interim analysis of a multicenter, prospective, parallel controlled study (HSCRYO-104).Org: Huashan Hospital Fudan University, School of Public Health, Fudan University,
Abstract
Treatment patterns with intravesical bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer (NMIBC): A real-world data analysis.Org: J&J Innovative Medicine, Johnson & Johnson Innovative Medicine, Raritan, Clinical Oncology Center, Research & Development, Immutep, Saint-Aubin, France,
Abstract
Disitamab vedotin (DV, RC48-ADC) combined with cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): An open-label, single-arm, phase II study.Org: Cancer Hospital Affiliated to Shanxi Medical University, General Internal Medicine,
Abstract
Noninvasive early detection and recurrence monitoring for non-muscle-invasive bladder cancer via urine tumor DNA.Org: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China, AcornMed Biotechnology Co., Ltd., Beijing, China,
Abstract
Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of the bladder: Post hoc analysis of two prospective studies.Org: Soonchunhyang University Bucheon Hospital, Soonchunhyang University Bucheon Hospital, South Korea, Dankook University Hospital, Cheonan, South Korea,
Abstract
A phase 1 study of BAT8007, an anti-nectin-4 monoclonal antibody-exatecan conjugate, in patients with advanced solid tumors.Org: Bio-thera Solution.Ltd,
Abstract
Tumor immune microenvironment analysis and MRI results of a phase II trial investigating tislelizumab (T) in the neoadjuvant treatment of high-risk upper tract urothelial carcinoma (UTUC).Org: Ren Ji Hospital, Renji Hospital Shanghai Jiaotong University School of Medicine,
Abstract
Baseline geriatric 8 (G8) screening tool to predict overall survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors.Org: Augusta University/University of Georgia Medical Partnership, Department of Biostatistics and Bioinformatics, Emory University School of Medicine,
Abstract
Gemcitabine/paclitaxel/adriamycin (GTA) as a nephron-sparing regimen in urothelial carcinoma: The MD Anderson Cancer Center (MDACC) experience.Org: UT Health Sciences Center at Houston,
Abstract
Retrospective analysis of outcomes of patients with bladder cancer when neoadjuvant chemotherapy is delayed.Org: Saskatchewan Health Authority, Allan Blair Cancer Centre,
Abstract
Practice patterns of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world Canadian practice.Org: Tom Baker Cancer Center,
Abstract
Bacillus Calmette-Guerin (BCG) utilization and treatment (Tx) patterns in Chinese patients (pts) with non-muscle invasive bladder cancer (NMIBC): Results from a national urologist survey.Org: MRL Global Medical Affairs, MSD China,
Abstract
Real-world treatment practices in patients with muscle invasive bladder cancer (MIBC) treated in Alberta, Canada.Org: University of Calgary, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Princess Margaret Cancer Center, University Health Network, University of British Columbia,
Abstract
Efficacy and safety of neoadjuvant therapy with disitamab vedotin plus toripalimab in treating muscle invasive urothelial bladder cancer followed by selective bladder-preserving or radical cystectomy.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Xiangya Hospital of Central South University, Changsha, China, Central South University, Changsha, China,
Abstract
Neoadjuvant immunotherapy-driven bladder preservation for muscle-invasive bladder cancer: A multicenter, propensity score-matched cohort study.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Xiangya Hospital of Central South University, Changsha, China, Central South University, Changsha, China,
Abstract
Preliminary results from a multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).Org: West China Hospital, Sichuan University, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Institute of Urology,
Abstract
Effectiveness of adjuvant immunotherapy in muscle-invasive urothelial cancer: A systematic review and meta-analysis of randomized controlled trials.Org: Federal University of São João Del-rei, Divinópolis, Brazil, Divinópolis, Brazil, Brazil, Federal University of Rio Grande do Norte, Natal,
Abstract
Preliminary results from a phase II study to evaluate the efficacy and safety of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104, PD-1/CTLA-4 bispecific antibody) for HER2-expressing muscle-invasive bladder cancer (MIBC).Org: Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of Urology, National Cancer Center & National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, General Internal Medicine, Beijing, China, Cancer Hospital of HuanXing ChaoYang District Beijing, Beijing, China, Urinary Surgery Center, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China,
Abstract
Interim results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Guangdong Provincial Clinical Research Center for Cancer,
Abstract
Nimotuzumab, a novel anti-EGFR with concurrent chemoradiotherapy in muscle invasive bladder cancer: A real-world experience from India.Org: NSCB Medical College,
Abstract
Real-world study of urine-based NGS liquid biopsy in organ preservation therapy of muscle-invasive bladder cancer (MIBC).Org: Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
Abstract
Chemoradiation versus cystectomy for locally advanced bladder cancer: A global, propensity-matched retrospective cohort study.Org: Alara Medical Group, Baylor University Medical Center,
Abstract
Response to neoadjuvant chemotherapy according to molecular subtypes in muscle-invasive bladder carcinoma.Org: University Hospital La Paz - IdiPAZ, Madrid, Spain, Jiménez Díaz Foundation University Hospital, University of Zurich / ETH Zurich, Zurich, Switzerland, IdiPAZ Biobank,
Abstract
Bladder preservation in muscle invasive bladder cancer (MIBC): A population based analysis.Org: BC Cancer-Vancouver Centre, BC Cancer-Victoria Centre,
Abstract
Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in patients with muscle-invasive bladder cancer (MIBC) undergoing trimodality therapy (TMT).Org: Dana-Farber Cancer Institute, Brigham and Women's Hospital/Massachusetts General Hospital, South Shore Health, Sturdy Health,
Abstract
Burden of non-muscle–invasive bladder cancer (NMIBC) leveraging a novel American Urological Association Quality Registry Qdata module: A real-world data analysis based on manual data abstraction.Org: Verana Health,
Abstract
The prognosis for patients with bladder cancer with recurrence after pathologic complete response or pathologic downstaging after radical cystectomy: EUMC RC cohort study.Org: Ewha Womans University Medical Center,
Abstract
Clinical characteristics, oncologic outcome, and survival in patients with urothelial cancer with pure and partial squamous cell differentiation.Org: Urologie Mainz, Department of Urology and Pediatric Urology,
Abstract
Comparative outcomes of radical nephroureterectomy and kidney-sparing surgery in the treatment of high-grade upper tract urothelial carcinoma.Org: Rutgers-RWJ Medical School,
Abstract
Artificial intelligence and identifying prognostic patterns in upper tract urothelical carcinoma (UTUC).Org: University of Munich, Munich, Germany, Germany,
Abstract
Development and validation of a novel prognostic model for overall survival in patients with micropapillary urothelial carcinoma.Org: University of the Aegean, Democritus University of Thrace,
Abstract
Non-invasive detection of urothelial carcinoma through ensembled methylation profiles and fragmentomic patterns in urinary cell-free DNA.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Huidu Shanghai Medical Sciences, Ltd., The First Affiliated Hospital of Zhengzhou University,
Abstract
Stratified absolute benefit with adjuvant immunotherapy (aIO) in muscle-invasive bladder cancer (MIBC): A meta-analysis.Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
First-line (1L) systemic therapy in locally advanced/metastatic urothelial cancer (Ia/mUC): A living interactive systematic review and network meta-analysis.Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Division of Hematology and Medical Oncology, Mayo Clinic, Phoeniz, AZ,
Abstract
Utilization of neoadjuvant chemotherapy (NAC) and pathologic outcomes in upper tract urothelial carcinoma (UTUC).Org: George Washington University School of Medicine and Health Sciences, Drexel University College of Medicine, Johns Hopkins University School of Medicine,
Abstract
Racial and gender disparities in the incidence of bladder cancer: A nationwide analysis.Org: Lake Erie College of Osteopathic Medicine, Wyckoff Heights Medical Center, Nuvance Health/Vassar Brothers Medical Center, State University of New York, Upstate Medical University, University of Missouri-Columbia, School of Medicine,
Abstract
How febrile neutropenia affects hospitalization in patients with bladder cancer: Nationwide insights.Org: University of Missouri-Columbia, School of Medicine, Zhejiang University, Hangzhou, China, Columbia University - Mailman School of Public Health, ModernaTX, Wyckoff Heights Medical Center,
Abstract
Kidney outcomes in patients with bladder cancer: Insights from real-world data—A National Inpatient Sample (NIS) study, 2020.Org: Dept of Medicine, Phaya Thai, Thailand,
Abstract
The tumor immune profile of bladder cancer (BC) with HER2 over-expression and the investigation into RC48-ADC versus BCG in high-risk non-muscle invasive BC with HER2 over-expression.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Institute of Urology, West China Hospital, Sichuan University, Chengdu Origen Biotechnology,
Abstract
Clinical and pathological characteristics of cancer of unknown primary with renal profile using gene expression profiling (GEP)–based cancer classification.Org: Biotheranostics, A Hologic Company,
Abstract
Effect of patient-derived tumor-like cell clusters on personalized medicine of patients with non-muscle invasive bladder cancer.Org: College of Future Technology Peking University, Peking University People’s Hospital, Beijing, China,
Abstract
Meta-analysis of perioperative immune checkpoint inhibitors in urothelial and renal cell carcinoma: Data from the latest available evidence.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario 12 de Octubre, Madrid, Spain, Medical Oncology Service, 12 de Octubre University Hospital,
Abstract
Feasability of single-port gasless retroperitoneal laparoscopic adrenalectomy for patients with adrenal tumor: A prospective control study.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,
Abstract
Hospital related outcomes of acute kidney injury in patients with bladder cancer: A nationwide inpatient study.Org: State University of New York Upstate Medical University, Upstate Medical University, Syracuse, NY, Wyckoff Heights Medical Center, Brooklyn, NY,
Abstract
PD-1 inhibitor plus paclitaxel, pingyangmycin and platinum-based chemotherapy as bladder-sparing therapy for high-risk non-muscle-invasive bladder cancer/muscle-invasive bladder cancer: A retrospective study.Org: Yunnan Cancer Hospital, Kunming, Yunnan, China, Kunming, China,
Abstract
Germline genetic variants in cancers of the bladder, renal pelvis, ureter, or urethra.Org: Division of Human Genetics,
Abstract
Prognostic PSMA-PET PROMISE nomograms for patients with prostate cancer.Org: Cancer Registry North-Rhine Westphalia gGmbH, Cancer Registry North Rhine-Westphalia, NCT University Hospital Essen, Department of Diagnostic and Interventional Radiology and Neuroradiology, Universitätsklinikum Aör Essen,
Abstract
Clinical utility of transcriptomic signatures to identify androgen receptor and neuroendocrine signaling in prostate cancer.Org: Caris MPI,
Abstract
Real-world (rw) treatment (tx) patterns, sequencing, and outcomes in US patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with avelumab first-line maintenance (1LM).Org: EMD Serono Research & Development Institute, The Healthcare Business of Merck KGaA, Tempus AI,
Abstract
Real world data of leuprorelin castration efficacy in patients with prostate cancer: A comprehensive assessment of 1,744 tests.Org: Hospital DF Star,
Abstract
Oncogenic alteration rates, race, and prostate cancer specific mortality in Veterans with metastatic prostate cancer undergoing somatic tumor next generation sequencing.Org: Department of Biostatistics and Epidemiology, University of Pennsylvania, Greater Los Angeles VA, Department of Medical Oncology, University of California, Los Angeles,
Abstract
Predicting PAM50 subtypes from whole slide images of prostate cancer biopsies.Org: Northwestern University Feinberg School of Medicine, Department of Urology, Chicago, IL, Northwestern University Feinberg School of Medicine, Department of Pathology, Chicago, IL, Veracyte, Inc, San Francisco, CA,
Abstract
Clinicopathological features and genomic profiles of prostate cancer with elevated carbohydrate antigen 19-9.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma,
Abstract
ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.Org: United Urology Group,
Abstract
Somatic tissue testing in prostate cancer using the Oncomine V3 panel: A single-institution retrospective analysis.Org: Department of Laboratory Medicine and Molecular Diagnostics, Department of Molecular Genetics, Cancer Genetics and High Risk Program,
Abstract
A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial.Org: Hospital Universitário de Brasília, Fundação Amaral Carvalho, Instituto Nacional do Câncer (INCA), Oncológica do Brasil, BP - Beneficência Portuguesa de São Paulo,
Abstract
Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).Org: Gent University Hospital, Gustave Roussy Cancer Campus, Hospital Clinic i Provincial de Barcelona, Keio University School of Medicine, Peter MacCallum Cancer Center and the University of Melbourne,
Abstract
A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC).Org: Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, XCancer Omaha, Omaha, NE, Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL,
Abstract
Positive psychology interventions in patients with prostate cancer: A systematic review.Org: Columbia University - Mailman School of Public Health, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Columbia University Irving Medical Center, New York, NY, USA, Columbia University Medical Center,
Abstract
Decade-long insights into transperineal prostate biopsy in a west China population: Temporal trend, targeted and repeat biopsies, and pathological characterization.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, West China Hospital, Sichuan University, Institute of Urology, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.Org: Guys' and St. Thomas' NHS Foundation Trust, Southampton Experimental Cancer Medicine Centre, University of Southampton, Velindre Cancer Centre, Velindre University NHS Trust, Cancer Research UK & UCL Cancer Trials Centre, University College London, Department of Laboratory Medicine and Pathology, University of Washington,
Abstract
Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01/02 interim results.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, IRCCS San Raffaele Hospital, Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele,
Abstract
Real-world PET PSMA imaging patterns in a Chicago safety-net hospital.Org: University of Illinois Chicago, Chicago, IL,
Abstract
Treatment analysis of patients diagnosed with intraductal carcinoma of the prostate (IDC-P) in the US from 2000 to 2018.Org: East Carolina University Department of Radiation Oncology, Department of Pathology & Laboratory Medicine, East Carolina University, Division of Hematology/Oncology, East Carolina University,
Abstract
Prognostic nomogram, demographics and comparative analysis of prostate small cell and large cell neuroendocrine carcinoma.Org: San Joaquin General Hospital, Seth GS Medical College and KEM Hospital, University of New Mexico Hospital,
Abstract
Decade of insights: Bleomycin-induced pneumonitis and use of G-CSF in chemotherapy-treated germ cell testicular tumors and Hodgkin lymphoma—Real-world outcomes from an academic cancer center.Org: The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The James Cancer Hospital @ OSU Wexner Medical Center, Tha James Cancer Hospital and Solove Research Institute,
Abstract
Long term sequelae of testicular cancer and treatment: A point prevalence observational study.Org: Tallaght Hospital,
Abstract
Metastatic testicular cancer (TC) presentations and outcomes: A contemporary analysis based on the National Cancer Database (NCDB).Org: Inova Schar Cancer Institute, Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University, Georgetown University, Washington, DC,
Abstract
The demographics of Sertoli cell carcinoma: A National Cancer Database analysis.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton Hematology Oncology, Omaha, NE, University of Arizona College of Medicine, Phoenix, AZ, Creighton University School of Medicine (Phoenix Regional Campus), Phoenix, AZ,
Abstract
Prognostic factors and survival in men with testicular germ cell tumors (GCT).Org: N.N. Petrov National Research Oncology Institute, N.N. Petrov National Medicine Research Center of Oncology,
Abstract
Emergency treatment for primary intracranial germ cell tumours (PICGCTs).Org: Imperial College Healthcare NHS Trust, London Regional Cancer Center,
Abstract
Brain metastases in testicular cancer: A single-institution experience in Guatemala.Org: Liga Nacional Contra El Cancer e Instituto de Cancerologia-INCAN, Guatemala, Guatemala, Liga Nacional Contra El Cancer e Instituto de Cancerologia-INCAN, Guatemala City, Guatemala,
Abstract
Impact of hospital volume on outcomes of autologous stem cell transplant (ASCT) in patients with testicular cancer.Org: Christiana Care Helen F. Graham Cancer Center and Research Institute, Baptist Health System,
Abstract
Clinical characteristics and treatment outcomes of advanced penile squamous cell carcinoma: Real-world evidence from a tertiary cancer center in Brazil.Org: Instituto do Câncer do Estado de São Paulo (ICESP), Universidade de São Paulo,
Abstract
Impact of treatment approaches in patients with advance penile cancer: An analysis from a nationwide study.Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, William Beaumont University Hospital, Royal Oak, MI,
Abstract
Pluvicto in the real world setting and timing to PSA50 as a predictive marker of treatment response.Org: Scripps Clinic/Green Hospital,
Abstract
Molecular characterization of growing teratoma syndrome in patients with testicular germ cell tumor.Org: Bratislava, Medirex group, Biomedical Center,
Abstract
A phase I/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC).Org: UC Davis Department of Internal Medicine, UC Davis Medical Center, Department of Medicine, Brigham and Women’s Hospital,
Abstract
The role of TROP-2 in the progression and target therapy in penile squamous cell carcinoma.Org: Department of Urology Oncological Surgery, Chongqing University Cancer Hospital, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment,
Abstract
Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with advanced germ cell tumors.Org: Rush University Medical Center, Vanderbilt-Ingram Cancer Center,
Abstract
Xerostomia and ocular dryness as predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer.Org: Indiana University Simon Comprehensive Cancer Center,
Abstract
Relugolix prescribing practices and clinical experiences at an urban academic center.Org: Beth Israel Deaconess Medical Center, Boston, MA,
Abstract
Association of baseline characteristics with adverse events (AEs) in the PROpel trial of olaparib (ola) plus abiraterone (abi) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC).Org: Centre Hospitalier de l’Université de Montréal/CRCHUM, Centro Integrado de Oncologia de Curitiba, Radboud Universitair Medisch Centrum, Southampton General Hospital, Centre Hospitalier de Quimper,
Abstract
Utilization of genetic and genomic data and correlation to outcomes of treatment with PARP inhibitors in advanced or metastatic castrate-resistant prostate cancer.Org: University of South Dakota Sanford School of Medicine, Avera Cancer Institute, Sioux Falls, SD,
Abstract
Outcome of prostate cancer with CNS metastasis: An analysis of SEER database (2010-2020).Org: Hospital of the University of Pennsylvania - Abramson Cancer Center, VCU Massey Cancer Center,
Abstract
Comparing patient profiles and treatment outcomes with radium-223 (223Ra) in real-world settings: Academic vs. community practice in the US—Insights from the REASSURE study.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Greater Baltimore Medical Center, Molecular Imaging Center, Keck School of Medicine of USC, Urology of Virginia, Eastern Virginia Medical School, GenesisCare, Fort Myers, FL,
Abstract
A systematic literature review and indirect treatment comparison of PARP inhibitors in combination with next-generation hormonal agents in BRCA-mutated metastatic castration‑resistant prostate cancer.Org: Mtech Access,
Abstract
Real-world treatment landscape in advanced metastatic castration resistant prostate cancer.Org: Johnson & Johnson Consumer, Janssen Research and Development, Janssen Pharmaceuticals, Research & Development, Immutep, Saint-Aubin, France, Johnson and Johnson Innovative Medicine, Spring House, PA,
Abstract
Dosimetry of lutetium-177 PSMA-targeted radiopharmaceutical therapies for prostate cancer patients: A comparative systematic review and meta-analysis.Org: David Geffen School of Medicine at UCLA, Department of Medicine Statistics Core (DOMStat), Department of Medicine's Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine,
Abstract
Genomic profile of Japanese patients with rare ductal adenocarcinoma of the prostate has high grade and poor prognostic aspects.Org: National Defence Medical College, Genomics Unit,
Abstract
Real world outcomes with cabazitaxel (cab) plus carboplatin (car) in metastatic castration-resistant prostate cancer (mCRPC).Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Emory School of Medicine, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Emory University School of Medicine, Winship Cancer Institute of Emory University,
Abstract
Lutetium-177–PSMA-617 experience in Appalachian patients with advanced prostate cancer at West Virginia University Health Science Center.Org: West Virginia University Health Sciences Center Department of Epidemiology and Biostatistics, Department of Medicine, Division of Hematology/Oncology, West Virginia University,
Abstract
Docetaxel plus cis-platinum chemotherapy for the posterior line treatment of metastatic castrate-resistant prostate cancer with elevated neuron specific enolase.Org: Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China,
Abstract
Quality metrics analysis in patients who received Lutetium-177 PSMA-617 (177Lu–PSMA) therapy in a real-world practice setting.Org: Division of Hematology/Oncology, Department of Medicine, University Of Toledo, University of California, Irvine, Irvine, CA, Hoag Family Cancer Institute and University of Southern California, Department of Radiological Sciences,
Abstract
Real-world clinical outcomes and economic burden of early discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer.Org: Asclepius Analytics, IQVIA, Inc.,
Abstract
Prostate-specific membrane antigen PET/CT-guided, metastasis-directed radiotherapy for oligometastatic castration-resistant prostate cancer.Org: Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, UCLA, Los Angeles, CA, Division of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, University of California, Los Angeles, Los Angeles, CA, David Geffen School of Medicine at UCLA, Los Angeles, CA,
Abstract
Efficacy of first line (1L) poly ADP-ribose polymerase inhibitors (PARPi) in combination with androgen pathway inhibitors (API) by homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A living meta-analysis.Org: Mayo Clinic Florida, Jacksonville, FL, DFCI/PCC Fellowship Program - Attendings, Boston, MA,
Abstract
Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) use by US urologists and oncologists.Org: IQVIA, Inc., Carolina Urologic Research Center/GenesisCare,
Abstract
Real world data of 177 Lutetium-PSMA-617 for metastatic castration resistant prostate cancer (mCRPC): Analysis of patients treated from 2 large reference centers.Org: Oncologia D'OR/Instituto D'OR de Ensino e Pesquisa, Instituto D`Or de Ensino e Pesquisa IDOR,
Abstract
Examining laboratory-based VISION eligibility and 177Lu-PSMA-617 outcomes in patients with metastatic castration-resistant prostate cancer.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center, Division of Hematology & Oncology,
Abstract
Exploring the prognostic value of the TRAQinform Profile applied to end-of-treatment PSMA PET/CT in patients with mCRPC and treated with 177Lu-PSMA radioligand therapy: A retrospective, single-center analysis.Org: AIQ Solutions,
Abstract
Genetic analysis of metastatic castration resistant prostate cancer patients treated with Lu-177 PSMA radioligand therapy.Org: Oregon Health & Science University, Portland, OR, Department of Hematology Oncology, Kaiser Permanente, Oregon Health & Sciences University, OHSU Knight Cancer Institute, Portland, OR,
Abstract
Utidelone for heavily pretreated metastatic castration-resistant prostate cancer after failing docetaxel treatment: An open-label, single-arm, phase II trial.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Beijing Biostar Pharmaceuticals,
Abstract
Genetic investigation of prostate cancer: Evaluation of markers and relationship with Gleason score and metastasis.Org: Hospital do Cancer de Muriae, Faculdade Santa Casa de BH,
Abstract
Baseline PSMA PET/CT as a predictive biomarker for toxicity and patient-reported outcomes in mCRPC patients undergoing 177Lu-PSMA radioligand therapy.Org: UCLA Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, AIQ Solutions, Madison, WI,
Abstract
KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study.Org: University of Virginia Comprehensive Cancer Center, New York Cancer and Blood Specialists, Comprehensive Cancer Centers of Nevada, Kangpu Biopharmaceuticals,
Abstract
Efficacy and toxicity of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer in a real-world setting: Results from the U.S. Expanded Access Program and comparisons with phase 3 VISION data.Org: Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Tulane University School of Medicine,
Abstract
Evaluation of tumor gene expression profile and Gleason score in patients with metastatic prostate cancer.Org: Hospital do Cancer de Muriae, Faculdade Santa Casa de BH,
Abstract
Efficacy and safety of PARP inhibitors (PARPi) with immune checkpoint inhibitors (ICI) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and single-arm meta-analysis.Org: Hospital do Servidor Público do Estado de São Paulo, Faculdade de Medicina de Barbacena FAME - FUNJOB, Centro de Oncologia do Paraná,
Abstract
Real-world treatment patterns with lutetium-177-PSMA-617 (177-Lu-PSMA) in patients with metastatic castrate-resistant prostate cancer (mCRPC).Org: Division of Hematology/Oncology, Department of Medicine, University Of Toledo, University of California, Irvine, Irvine, CA, Department of Hematology/Oncology, University of California Irvine Medical Center, Hoag Family Cancer Institute and University of Southern California,
Abstract
Analysis of the efficacy and tolerance or darolutamide in combination with chemotherapy and ADT in patients with metastatic castration-sensitive prostate cancer (mCSPC) in the Spanish population in a daily clinic.Org: Hospital Guadalajara, Hospital General De Segovia, Hospital de Segovia, Hospital de Guadalajara,
Abstract
Characteristics and treatment (Tx) patterns (TxP) of high-risk biochemically recurrent (HR-BCR) non-metastatic castration-sensitive prostate cancer in the real-world by race, age, and prostate-specific antigen (PSA) doubling time (PSADT).Org: Cardinal Health,
Abstract
Can PSMA-PET be a better way to select patients for an intermittent treatment? Results from a prospective cohort.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Medica Scientia Innovation Research (MEDSIR), Hospital DF Star,
Abstract
Real-world (RW) comparison of prostate-specific antigen (PSA) response in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) versus enzalutamide (ENZ).Org: Johnson and Johnson Innovative Medicine, LLC,
Abstract
A qualitative exploration of perceptions of the value of wearable activity monitors among prostate cancer survivors undergoing androgen deprivation therapy.Org: Cedars-Sinai Medical Center, Durham VA Medical Center,
Abstract
Real-world intensification beyond androgen deprivation therapy (ADT) in metastatic hormone sensitive prostate cancer (mHSPC) in the United States 2017-2023: An administrative claims database study.Org: Bayer HealthCare Pharmaceuticals Inc., Bayer AG, Bayer Ltd, Bayer Consumer Care AG, Duke Cancer Institute Center for Prostate and Urologic Cancers,
Abstract
Interim analysis of clinical data and reasons for initiating relugolix on a cohort of US patients: The OPTYX study.Org: University Hospitals Seidman Cancer Center and Case Western Reserve University, University of California, San Diego Health, Northwestern University Feinberg School of Medicine, Department of Urology, Chicago, IL, Chesapeake Urology, Sumitomo Pharma America,
Abstract
Preliminary results of sexual quality of life (QOL) outcome for intermediate-high risk prostate cancers treated by stereotactic radiotherapy (SBRT) and androgen deprivation therapy (ADT): Clinical and dosimetric factors.Org: HCG Cancer Centre Mumbai, HCG Cancer Center Mumbai,
Abstract
Clinical characteristics and outcomes of veterans with metastatic hormone-sensitive prostate cancer (mHSPC) based on volume of disease and site of metastases.Org: Saint Louis University School of Medicine,
Abstract
Association of very deep prostate-specific antigen (PSA) decline with longer radiologic-progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer.Org: Bakirköy Research and Education Hospital, Kanuni Research and Education Hospital,
Abstract
Unveiling the pathologic predictor in patients with metastatic hormone-sensitive prostate cancer treated with abiraterone: Intraductal carcinoma of the prostate and its subtypes.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Institute of Urology, West China Hospital, Sichuan University, Chengdu Origen Biotechnology,
Abstract
Clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer: A final report.Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Dana-Farber Cancer Institute, Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI,
Abstract
Survival outcomes for metastatic castration sensitive prostate cancer: Real world data from a Danish cohort 2016-2022.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark,
Abstract
Prevalence of mutations associated with NCCN criteria for hereditary prostate cancer testing in an Indian population.Org: Princess Margaret Cancer Center, Toronto, ON, Canada, Dr. BRA-IRCH, All India Institute of Medical Sciences (AIIMS), Rishikesh, India, New Delhi, India,
Abstract
Comparison of prostate-specific antigen (PSA) response in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) vs abiraterone acetate (ABI): A real-world (RW) causal analysis.Org: New Jersey Urology, A Summit Health Company, Rowan University School of Osteopathic Medicine, Towson, MD,
Abstract
Comparing overall survival in patients with metastatic prostate cancer using PSA levels: A multivariate analysis using a national database.Org: Brown Cancer Center, James Graham Brown Cancer Center, University of Louisville,
Abstract
Triplet therapy in metastatic hormone-sensitive prostate cancer: A real-world Indian multicentre study.Org: Saroj Gupta Cancer Centre and Research Institute, Apollo Multispecialty Hospital,
Abstract
Avoiding unnecessary biopsy: Development of a predictive calculator to identify non-prostate cancer in patients with Prostate Imaging Reporting and Data System category ≥ 4 lesions.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Institute of Urology, West China Hospital, Sichuan University, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Descriptive analysis of patients on active surveillance escalating to treatment for localized prostate cancer.Org: Jefferson New Jersey, Alabama College of Osteopathic Medicine, Dothan, AL, Stratford, PA, Stratford, NJ,
Abstract
Performance characteristics of ExoDx urinary biomarker: A single-institution analysis.Org: George Washington School of Medicine, The George Washington University School of Medicine and Health Sciences,
Abstract
Experience with de-intensification of intensified treatment in metastatic castration-sensitive prostate cancer in Venezuela: A pilot study.Org: Centro Medico Docente la Trinidad,
Abstract
Stratification of patients with prostate cancer using a comprehensive multiomic approach: Integrating extracellular vesicle transcriptomics profiling with cfDNA methylation in urine-based liquid biopsy.Org: Exosome Diagnostics, Inc.,
Abstract
Management outcomes of localized low-risk prostate cancer: A population-based study.Org: Allegheny-Singer Research Institute,
Abstract
Sequential ADT and abiraterone acetate plus prednisone versus combined ADT with abiraterone acetate plus prednisone for metastatic castration-sensitive prostate cancer: A propensity score-matched study.Org: Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Urology, Sun Yat-sen University Cancer Center, Guanzhou, China,
Abstract
An NCDB demographic and socioeconomic analysis of mixed acinar ductal carcinoma.Org: Creighton University School of Medicine (Phoenix Regional Campus), Phoenix, AZ, University of California, Davis Comprehensive Cancer Center, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, Stanford University, Stanford, CA, California Pacific Medical Center Research Institute, San Francisco, CA, Women's Health Integrated Research Center at Inova Health System, Annandale, VA, Women’s Health Integrated Research Center at Inova Health System, Department of Defense Gynecologic Cancer Center of Excellence, Annandale, VA, Stanford University Medical Center, Palo Alto, CA, Pingtung Veterans General Hospital, Pingtung, South Korea, Creighton Hematology Oncology, Omaha, NE, University of Arizona College of Medicine, Phoenix, AZ,
Abstract
Radical prostatectomy versus XRT for early-stage prostate cancer: A retrospective, propensity-matched cohort study of 29,970 patients.Org: Baylor University Medical Center, Alara Medical Group,
Abstract
Impact of surgical margins on mortality after robotic radical prostatectomy.Org: University of California, Irvine, Irvine, CA, University of Nebraska Medical Center,
Abstract
Rectal spacer in radiotherapy for prostate cancer: Correlation of spacer symmetry to rectal dosimetry.Org: Rambam Medical Center, Haifa, Israel, Israeli Medical Research Center, Technion Israel Institue of Technology, Rambam Health Care Campus,
Abstract
Prognostic impact of BRCA mutation on metastasis-free survival in a localized/locoregional high-risk real-world prostate cancer population.Org: Tempus AI, Chicago, IL, AstraZeneca, Waltham, MA, AstraZeneca R&D Boston,
Abstract
Disparity in education and disease stage in patients with testicular germ cell tumors.Org: Klenová 1, Bratislava, Slovakia,
Abstract
The silent burden: A SEER-based analysis of potential years of life lost due to genitourinary cancers in the United States (1975-2017).Org: Jacobi Medical Center/North Central Bronx, Albert Einstein Medical Center, Bronx, NY, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,
Abstract
Clinician documentation of shared decision making for prostate cancer screening.Org: Medical University of South Carolina Hollings Cancer Center,
Abstract
Addition of MRI or DRE to clinical data and risk prediction for clinically significant prostate cancer.Org: Nanostics Inc., Thomayer University Hospital,
Abstract
Apa-RP: Multicenter phase 2 study of apalutamide (Apa) and androgen deprivation therapy (ADT) for the treatment of high-risk localized prostate cancer (HR LPC) following radical prostatectomy (RP)—Results in Black and non-Black patients (pts).Org: MidLantic Urology LLC, Janssen Medical Affairs, Janssen Biotech Inc,
Abstract
An open label, single arm phase II, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16- or 18-positive cervical cancer and failure of first-line platinum-based chemotherapy (DURBAC).Org: Cellid, Inc, Laboratory of Immunology, College of Pharmacy, Seoul National University and Cellid, Inc.,
Abstract
Maximal androgen blockade therapy (MAB) for prostate cancer (PC) and risk of bone fractures: A systematic literature review and meta-analysis.Org: Department of Oncology, University of Torino at S. Luigi Hospital, Clinic of Nuclear Medicine and PET/CT Center, Cardinal Massaia Hospital,
Abstract
Development and validation of a prognostic nomogram for survival in testicular and non-testicular primary choriocarcinoma (CC).Org: Irbid, Aydoun-Irbid, Farwaniya Hospital, Kuwait,
Abstract
Blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial.Org: Johns Hopkins University School of Medicine, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Abstract
Clinical and analytical validation for HRD status using targeted panel sequencing.Org: Geneseeq Technology Inc.,
Abstract
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial.Org: Institute for Ovarian Cancer,
Abstract
White blood cell kinetics in patients with gynecologic cancer receiving mecapegfilgrastim prophylaxis: A multicenter real-world study.Org: Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Ovarian Tumor Area, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Department of Medical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Medical Oncology, The People's Hospital of Bozhou, Bozhou, China, Department of Medical Oncology, Kunshan First People's Hospital, Kunshan, China,
Abstract
Relationship of cancer stem cell functional assay and objective response rate of patients with recurrent platinum-resistant ovarian cancer in a randomized trial.Org: Kaiser Permanente Los Angeles Medical Center, Charleston Area Medical Center Hospital, LSU School of Medcn, Marshall University School of Medcine, Mercy Clinic Gynecologic Oncology - Coletta,
Abstract
Prevalence of HER-2 expression and correlation with clinicopathological features in gynecological cancer: A single-center retrospective study in China.Org: Chongqing University Cancer Hospital, Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, Affiliated Cancer Hospital of Chonqing University,
Abstract
Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 CC3 study.Org: the Air Force Medical University, Baotou Cancer Hospital, Shanghaijiaotong University School of Medicine, Shanxi Province Tumor Hospital, The Second Norman Bethune Hospital of Jilin University,
Abstract
CRS-HIPEC following neo-adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC) with systemic chemotherapy in primarily advanced inoperable epithelial ovarian cancer: An ISPSM collaborative study.Org: Aster International Institute of Oncology, Bangalore, India,
Abstract
Evaluation of persistence and adherence for oral and injectable androgen deprivation therapies (ADT) in United States (US) patients with prostate cancer (PC).Org: Michigan Institute of Urology, Pfizer Inc., Sumitomo Pharma Switzerland, Analysis Group, Inc., Sumitomo Pharma America,
Abstract
Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial.Org: Sun Yet Sen University Cancer Center,
Abstract
Clinical–epidemiological characterization of cervical cancer in a middle-income country.Org: Sociedad de Lucha Contra El Cáncer, SOLCA - Guayaquil, Guayaquil, Ecuador, Sociedad de Lucha Contra El Cancer, Guayaquil, Guayas, Ecuador,
Abstract
Immunotherapy-based neoadjuvant therapy followed by concurrent chemoradiotherapy in locally advanced and advanced cervical cancer: A real-world study.Org: Department Of Gynecologic Oncology, Shengjing Hospital Of China Medical University, Shenyang, China,
Abstract
Clinical efficacy and safety analysis of immune checkpoint inhibitors combined with concurrent chemoradiotherapy for stage IIIC1-IVA cervical cancer: A prospective cohort study.Org: Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Henan Cancer Hospital,
Abstract
A study of risk factors and clinico-pathological profile of patients with cervical cancer at BPKIHS: A descriptive cross-sectional study.Org: B.P.Koirala Institute of Health Sciences, Dharan, Nepal,
Abstract
Evaluation of malignant potential based on infection with high-risk human papillomaviruses 16, 52, and 58 in the uterine cervix.Org: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Kyungpook National University Hospital, Daegu, South Korea,
Abstract
Effect of ionizing radiation on JAK/STAT pathway and immune microenvironment in cervical cancer.Org: Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China,
Abstract
Survival in cervical cancer IIb-IVA subjected to postchemo-radiotherapy surgery in Ecuador.Org: Sociedad de Lucha Contra El Cancer, SOLCA - Guayaquil,
Abstract
Transcriptomic and epigenetic characterization of mucinous adenocarcinoma of the cervix.Org: Medical College of Wisconsin, Rutgers New Jersey Medical School,
Abstract
Paclitaxel and cisplatin/carboplatin plus tislelizumab in young patients with cervical cancer preserve fertility: Phase II prospective, single arm clinical study.Org: Beigene (Beijing) Biotechnology Co., Ltd, Beijing, China,
Abstract
Improved detection of homologous recombination deficiency using WES sequencing: Insights into a Chinese pan-cancer cohort.Org: HaploX Biotechnology, Shenzhen, China,
Abstract
Cadonilimab safety and efficacy in recurrent or metastatic cervical cancer: First real-world experience from a Chinese multicenter study.Org: Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China, Department of Oncology, Fujian Medical University Affiliated Nanping First Hospital, Nanping, China, Department of Radiology, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University, Fuzhou, Fujian, China, Department of Obstetrics and Gynecology,Fujian Provincial Hospital, Fuzhou, Fujian, China, Department of Obstetrics and Gynecology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China, Gynecology department, People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, China, Department of Obstetrics and Gynecology, Gutian Hospital, Fuzhou, Fujian, China, Beijing GenePlus Technology Co., Ltd., China, Beijing, China,
Abstract
Optimization of intra-peritoneal chemotherapy: Randomized phase II GERCOR CHIMOVIP study.Org: CHR la Miletrie, de la Mileterie Hospital, Centre Hospitalier Intercommunal de Poissy-Saint-Germain, Poissy Saint-Germain Hospital, Multidisciplinary Group in Oncology (GERCOR),
Abstract
Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer.Org: University of Texas Medical Branch at Galveston, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Anlotinib combined with penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Preliminary results from ALTER-GO-020, a single-arm, open-label, multi-cohort, multi-center phase II clinical study.Org: Shanxi Provincial People’s Hospital, Xi'an, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Sichuan Cancer Hospital & Institute, Sichuan, Cancer Center, Chengdu, China,
Abstract
Single-cell sequencing to elucidate the disparities in the immune microenvironment between PIK3CA mutants and wild types.Org: Department of Gynecologic Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China, Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China, Department of Gynecologic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China, Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China,
Abstract
Predictive value of C reactive protein (CRP) and D-dimer in patients with advanced cervical cancer treated with sintilimab and anlotinib.Org: Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Clinical Oncology School of Fujian Medical University, Fuzhou University,
Abstract
Real-world data of a regimen containing zimberelimab in the treatment of recurrent and metastatic cervical cancer.Org: Medical Affairs Department, Guangzhou Gloria Biosciences Co. Ltd.,
Abstract
Survival in patients with cervical cancer undergoing chemo-radiotherapy in a middle-income country.Org: Sociedad de Lucha Contra El Cancer, SOLCA - Guayaquil,
Abstract
Clinical phosphoproteomics reveals aberrant signalling pathways and kinases in treatment-resistant cervical cancer.Org: Karkinos Healthcare Private Limited, Mahavir Cancer Sansthan, Manipal Academy of Higher Education (MAHE), Institute of Bioinformatics, Mahavir Cancer Sansthan and Research Centre,
Abstract
Landscape of genomic alterations in patients with chemoradiation resistant cervical cancer using whole-genome sequencing.Org: Karkinos Healthcare Private Limited, Mahavir Cancer Sansthan, Vedantaa Hospital & Research Centre, Institute of Bioinformatics,
Abstract
Prognostic analysis of PD-1/CTLA-4 bispecific antibody combined with chemotherapy first-line treatment for recurrent or metastatic cervical cancer: A multicenter real-world study.Org: Xiangya School of Medicine,
Abstract
Zimberelimab combined with concurrent chemoradiotherapy for patients with locally advanced cervical cancer: Early results of efficacy and safety.Org: Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Fudan University Zhongshan Hospital,
Abstract
Clinical efficacy and safety of cadonilimab immunotherapy in patients with advanced cervical cancer: A retrospective study.Org: Huazhong University of Science and Technology Union Shenzhen Hospital,
Abstract
Safety and clinical activity of cadonilimab, an anti PD-1/CTLA-4 bispecific antibody, for patients with persistent, recurrent, or metastatic cervical cancer (R/M CC): A retrospective, real-world study.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China,
Abstract
Sintilimab and anlotinib combination therapy in PD-L1-positive recurrent/metastatic cervical carcinoma: A 3-year follow-up of ALTER-C201 study.Org: Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital,
Abstract
Molecular characteristics of non-human papillomavirus driven cervical adenocarcinoma and adenosquamous carcinoma.Org: Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan, Gynecologic Cancer Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University Medical College, Taoyuan, Taiwan, Gynecologic Cancer Research Center, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan,
Abstract
Phase II study of tislelizumab combined with concurrent chemoradiotherapy for locally advanced cervical cancer.Org: Nanning, China,
Abstract
Measuring COVID-19's impact on diagnosis of cervical cancer by race/ethnicity, age, and region of the United States.Org: University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, Stanford University, Stanford, CA, California Pacific Medical Center Research Institute, San Francisco, CA, Women's Health Integrated Research Center at Inova Health System, Annandale, VA, Women’s Health Integrated Research Center at Inova Health System, Department of Defense Gynecologic Cancer Center of Excellence, Annandale, VA, Stanford University Medical Center, Palo Alto, CA, Pingtung Veterans General Hospital, Pingtung, South Korea,
Abstract
Multi-dimensional measurements of long-term quality of life and recovery patterns of patients with cervical cancer after treatment.Org: Khoury College of Computer Science, Northeastern University, Wenzhou University of Technology, School of Humanities and Social Sciences, Shanxi Medical University,
Abstract
The efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: A multicenter study by the Turkish Oncology Group (TOG).Org: Hacettepe University Cancer Institute, Cerrahpasa Medical Faculty, Istanbul University Dep of Oncology, UHS Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Fırat University Department Of Medical Oncology,
Abstract
Liquid biopsy detection of structural variant breakpoints to monitor ovarian cancer clonal evolution.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Genomic Medicine,
Abstract
Deciphering the correlation between Chr3q26.2 amplification through homologous recombination deficiency and improved survival in ovarian cancer under platinum-based adjuvant therapy.Org: Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China,
Abstract
Use of Gynecologic Cancer Intergroup (GCIG) CA125 criteria to evaluate cell cycle checkpoint kinase 1 inhibitor (CHK1i) prexasertib response and disease progression (PD) in recurrent high-grade serous ovarian cancer (HGSOC).Org: Statistical Consulting and Scientific Programming Group, Computer and Statistical Services, Data Management Services, Inc. (a BRMI company),
Abstract
Patterns of pembrolizumab use for recurrent cervical cancer.Org: Columbia University Medical Center, Merck & Co., Inc., Herbert Irving Comprehensive Cancer Center,
Abstract
Homologous recombination deficiency score for predicting efficacy of platinum-based chemotherapy and PARPi maintenance therapy in ovarian cancer.Org: Huai'an Second People's Hospital, Jiangsu simcere diagnostics Co,.Ltd,
Abstract
Leveraging genomic instability scores (GIS) to investigate BRCA variants of unknown significance (VUS) in ovarian cancer: An analysis of 14,513 patients in the Myriad Collaborative Research Registry (MCRR).Org: Myriad Genetics Inc,
Abstract
Multiomic analysis in ovarian clear cell carcinoma to gain insight into biology and therapeutic opportunities.Org: Portland,OR,
Abstract
Reflections on the changes in ascites and serum VEGF1 levels before and after intraperitoneal infusion of bevacizumab.Org: Shengjing Hospital Affiliated to China Medical University, Shengjing Hospital of China Medical University,
Abstract
Identification of tumor-marker gangliosides for early cancer detection: A multi-platform approach.Org: AOA Dx,
Abstract
Weekly BH009 in patients with squamous cell carcinoma of the head and neck (SCCHN) and ovarian cancer: Interim phase I results.Org: Affiliated Zhongshan Hospital of Dalian University,
Abstract
A phase I/II study of maplirpacept in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (OC): Phase 1 results.Org: Pfizer Ltd.,
Abstract
Overall survival in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance: Real-world data of the C-PATROL study.Org: Med. Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany, Oncologic Medical Center at the Jerusalem Hospital Hamburg, Hamburg, Germany, Hospital Aschaffenburg GmbH, Aschaffenburg, Germany, North-Eastern German Society of Gynaecological Oncology (NOGGO) and Department of Gynecology with Center for Oncological Surgery, Charité-University Medicine of Berlin, Campus Virchow Klinikum, Berlin, Germany, National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany,
Abstract
Overall survival and patterns of care for women with rare ovarian cancers: A prospective study from the Australian National Gynae-Oncology Registry (NGOR).Org: Monash University School of Public Health and Preventive Medicine, Mercy Hospital for Women, Monash University School of Public Health and Preventive Medicine and Department of Medical Oncology, Alfred Health,
Abstract
Clinical features and prognostic analysis of 247 patients with ovarian clear cell carcinoma (OCCC) and an exploration of the treatment of recurrent OCCC: A single-center study in China.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,
Abstract
First results of the NOGGO PERCEPTION: Phase II investigational study of pembrolizumab in combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer.Org: North-Eastern German Society of Gynaecological Oncology (NOGGO), Department of Gynecology with Center for Oncological Surgery, Charité-University Medicine of Berlin, Campus Virchow Klinikum, Berlin, Germany, North-Eastern-German Society of Gynaecological Oncology, Berlin, Germany, Kliniken Essen-Mitte, Department of Gynecology and Gynecological Oncology, Essen, Germany, Charité Universitätsmedizin Berlin and North Eastern German Society for Gynecologic Oncology (NOGGO), Berlin, Germany,
Abstract
Enhanced anti-ovarian cancer efficacy with MSLN-chimeric antigen receptor T cells secreting anti-CD39 antibody.Org: OriCell Therapeutics, Shanghai Key Laboratory of Maternal Fetal Medicine Shanghai, Institute of Maternal-Fetal Medicine and Gynecologic Oncology,
Abstract
Charlson’s comorbidity and remission outcomes in women diagnosed with epithelial ovarian cancer.Org: Department of Research and Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, MedHealth, Inc, Merck & Co., Inc.,
Abstract
Development and validation of an efficacy assessment platform utilizing patient-derived xenograft (PDX) models in ovarian cancer research.Org: Sungkyunkwan University of Medicine,
Abstract
Effect of circulating tumor cells (CTC) and CTC clusters with PD-L1 dynamic biomarker on cellular burden in patients with ovarian cancer.Org: MIT-WPU, Pune, India,
Abstract
Disparities in the prevalence of acute pulmonary embolism in patients with ovarian cancer: A nationwide analysis.Org: University of Missouri-Columbia, School of Medicine, Zhejiang University, Hangzhou, China, Columbia, MO, Wyckoff Heights Medical Center, Brooklyn, NY,
Abstract
Analysis of glycemia during olaparib therapy in patients with ovarian cancer.Org: University of Medical Sciences Poznan,
Abstract
Association of homologous recombination repair mutation defined with a 15-gene panel with the prognosis of epithelial ovarian cancer: A Chinese multicenter retrospective study.Org: The Affiliated Zhongda Hospital, Southeast University, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Department of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Department of Obstetrics and Gynaecology, Zhongda Hospital, School of Medicine, Southeast University,
Abstract
Novel liquid biopsy assay to distinguish benign from malignant pelvic masses.Org: GC Genome Yongin-Si,
Abstract
Urinary-based detection of MSL, HE4, and CA125 as an additional dimension for predictive and prognostic modelling in ovarian cancer.Org: Department of Gynecology and Obstetrics, TU Dresden,
Abstract
Neoadjuvant pamiparib in patients with newly diagnosed advanced ovarian cancer: A single-arm, prospective phase II trial.Org: Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China, Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China,
Abstract
An open, prospective, single arm, phase II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) with neoadjuvant chemotherapy in patients with advanced ovarian cancer: Interim analysis from the AK104-IIT-003 study.Org: Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, The Affiliated Cancer Hospital of Xiangya School of Medicine, Yunnan Cancer Hospital, Kunming, Yunnan, China, Guangxi Medical University Cancer Hospital,
Abstract
Unveiling primary platinum resistant ovarian cancer: Demographic and clinical perspectives from multicenter cancer registry in India.Org: Christian Medical College & Hospital, Institute Of Medical Sciences And Sum Hospital, Amala Institute of Medical Sciences, MMHRC, Meenakshi Mission Medical Hospital and Research Centre,
Abstract
Ovarian-Adnexal Reporting & Data System (O-RADS) versus modified benign descriptors and IOTA ADNEX (two-step strategy) in classification of ovarian masses.Org: Fundación Santa Fé de Bogotá, Fundacion Santa Fe de Bogota, Universidad de los Andes, ICCAL Hospital Universitario Fundación Santa Fe de Bogotá,
Abstract
In-hospital outcomes of patients with ovarian cancer and venous thromboembolism: A Nationwide Inpatient Sample analysis.Org: Brookly Hospital Center, Emanuel Cancer Center, Turlock,
Abstract
Demographic factors influencing hysterectomy approaches (with vs. without removal of tubes and/or ovaries): An NCDB review.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton Hematology Oncology, Omaha, NE,
Abstract
Identification of potential biomarkers with alternative splicing landscape of HIPEC-treated ovarian cancer: An RNAseq sub-analysis of a HIPEC clinical trial.Org: Tgen, TGen/City of Hope Comprehensive Cancer Center,
Abstract
Differences in clinical features between CA-125 and RECIST progression in patients with ovarian cancer treated with PARP inhibitors.Org: Qilu Hospital of Shandong University, Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China, Qilu Hospital of Shandong University, Shandong, China, Qilu Hospital of Shandong University, Jinan, China,
Abstract
Chemoresistance in high grade serous ovarian cancer molecular subtypes and the role of NRF2.Org: Cooper Medical School of Rowan University, Baghdad Teaching Hospital, Cooper University Health Care, Department of Pharmacology, Physiology, and Cancer Biology, College of Science and Mathematics,
Abstract
Evaluation of body weight and race on pembrolizumab response in patients with endometrial cancer: A case control study.Org: University of Virginia Health System, University of Virginia School of Medicine, Charlottesville, VA, University of Virginia, Charlottesville, VA, USA,
Abstract
Magnetic resonance texture analysis for predicting histologic tumor type in endometrial cancer.Org: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Kyungpook National University Hospital, Daegu, South Korea,
Abstract
Efficacy and safety of envafolimab plus lenvatinib combined with etoposide in recurrent ovarian, peritoneal, and fallopian tube cancer: An open-label, single-arm study—The ENLEN-OC-001 study.Org: The Affiliated Zhongda Hospital,
Abstract
Overcoming barriers in equitable care delivery for women with gynecologic cancers: Outcomes and analysis from an educational program on health equity.Org: Clinical Care Options, LLC, Vanderbilt University Medical Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of California Irvine, Yale University,
Abstract
Early detection, clinicopathological subtyping and prognosis prediction for patients with endometrial cancer using fragmentoimcs-based liquid-biopsy assay.Org: Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Investigating L1CAM and β-catenin as prognostic indicators in fertility-sparing endometrial cancer treatment.Org: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, University of Ulsan College of Medicine, Asan Medical Center, Seoul National University Hospital, South Korea,
Abstract
Rate of p53 and MMR IHC assessment accordance between matched D&C and hysterectomy samples in uterine cancer.Org: REA Gynaecology and Maternity Hospital,
Abstract
Outcomes in patients with anemia hospitalized for endometrial cancer resection: A nationwide analysis.Org: Nuvance Health/Vassar Brothers Medical Center, Wyckoff Heights Medical Center, Lake Erie College of Osteopathic Medicine, State University of New York, Upstate Medical University, University of Missouri-Columbia, School of Medicine,
Abstract
Clinical significance of the risk model based on exosome-derived miRNA and miR-486-5p for endometrial cancer.Org: Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital,
Abstract
Identification of prognostic indicators and markers of endometrial carcinoma based on shared metabolism-related genes in gynecological tumors.Org: Hangzhou Repugene Technology Co., Hangzhou, China, Hangzhou Repugene Technology Co., Ltd, Hangzhou, China,
Abstract
Chemical hair relaxer use and its potential effect on incidence of endometrial cancer in Black women.Org: Brandon,
Abstract
Demographic factors of malignant endometrioid adenofibroma: An NCDB study.Org: Creighton University School of Medicine - Phoenix Regional Campus, Creighton University School of Medicine Phoenix Regional Campus, Sierra College, UC Riverside, University of Arizona College of Medicine, Phoenix, AZ,
Abstract
Vaginal lacerations during laparoscopic hysterectomy for endometrial cancer and local recurrence risk.Org: Gyn Onc Inst,
Abstract
Development and validation of a prediction model for lymph node metastasis based on molecular classification in endometrial carcinoma.Org: Shandong University of Traditional Chinese Medicine Affiliated Hospital, Qilu Hospital of Shandong University, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China,
Abstract
Assessment of sociodemographic factors in timely endometrial cancer diagnosis following an abnormal transvaginal ultrasound performed for postmenopausal bleeding.Org: Duke School of Medicine,
Abstract
Pole mutated endometrial carcinoma: Clinical and genomic characteristics from a real-world UK cohort.Org: The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research,
Abstract
Perivascular epithelioid cell tumors: A study of demographic and socioeconomic factors.Org: Creighton University School of Medicine Phoenix Regional Campus, Phoenix, AZ, Omaha, NE, Arizona State University, Tempe, AZ,
Abstract
Recurrent vulvar squamous cell carcinoma: Outcomes across the treatment spectrum—Are we making progress?Org: The Ottawa Hospital Research Institute,
Abstract
Demographics, pathologic characteristics, and pattern of recurrence of vulvar cancer at an academic hospital in South Africa: A 10-year retrospective review.Org: University of Pretoria, Pretoria, South Africa Health Product Regulatory Authority, Durban, South Africa,
Abstract
Gynecologic malignancies in women younger than 40 years of age: A SEER database review.Org: Trinity Health of New England,
Abstract
Genomic profiling of Chinese patients with endometrial adenocarcinoma (EA).Org: The First Affiliated Hospital of Kunming Medical University, Medical Affairs Department, 3D Medicines (Beijing),
Abstract
Chemotherapy plus PD-1/PD-L1 inhibitor versus chemotherapy alone in first-line treatment for recurrent or advanced endometrial cancer: A systematic review and meta-analysis of randomized controlled trials.Org: DASA Oncologia, São Paulo, Brazil, Federal University of Ceará, Fortaleza, Brazil, Hospital São Domingos, São Luís, Brazil, Federal University of São João Del-rei, Divinópolis, Brazil, Federal Univerity of Rio de Janeiro, Rio De Janeiro, Brazil,
Abstract
Developing machine learning–based prognostic models for gestational choriocarcinoma: Insights into treatment efficacy and patient survival.Org: Jordan University of Science & Technology,
Abstract
Predictive analysis of placental site trophoblastic tumors (PSTT) and epithelioid trophoblastic tumors (ETT) using machine learning.Org: Jordan University of Science and Technology, Irbid, Jordan, Jordan University of Science and Technology, Aydoun-Irbid, Jordan, Jordan University of Science and Technology, Jordan, Irbid, Jordan,
Abstract
Vulvo-vaginal cancer trends during the pandemic.Org: University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, Stanford University, Stanford, CA, California Pacific Medical Center Research Institute, San Francisco, CA, Women's Health Integrated Research Center at Inova Health System, Annandale, VA, Women’s Health Integrated Research Center at Inova Health System, Department of Defense Gynecologic Cancer Center of Excellence, Annandale, VA, Stanford University Medical Center, Palo Alto, CA, Pingtung Veterans General Hospital, Pingtung, South Korea,
Abstract
Participation of patients with gynecological cancer in phase 1 clinical trials: Experience from 2 NCI-Designated Comprehensive Cancer Centers.Org: Rutgers Robert Wood Johnson Medical School Department of Obstetrics and Gynecology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Montefiore Medical Center/Albert Einstein College of Medicine, Rutgers University,
Abstract
AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer.Org: Caucasus Medical Centre, Big Horn Basin Cancer Center, HINSDALE HOSPITAL, Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, SPSK Nr 2, Pomeranian Medical University, and PGOG, Institut de Cancérologie de Strasbourg Europe, Strasbourg and GINECO,
Abstract
Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV.Org: Hookipa Pharma, Inc.,
Abstract
Outcomes of combined immunotherapy and palliative radiotherapy in patients with recurrent/metastatic head and neck cancers.Org: Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Zhongnan Hospital of Wuhan University, Wuhan, China,
Abstract
High pre-treatment NLR and PLR predict poor prognosis of patients with recurrent/metastatic head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.Org: Veneto Institute of Oncology- IOV -IRCCS, Department of Neurosciences,
Abstract
Prospective monitoring for immunotherapy by liquid biopsy and signal pathway alterations in head and neck cancers.Org: Department of Oral and Maxillofacial Surgery,
Abstract
Genomic and immune profiling of rare non-squamous sinonasal tumors.Org: Winship Cancer Institute, Emory University School of Medicine, Emory University, Atlanta, GA, USA, Caris Life Sciences, Irving, TX, Department of Otolaryngology Head and Neck Surgery, Emory University Hospital Midtown,
Abstract
Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors.Org: Hunan Cancer Hospital & the Affiliated Cancer Hospital of Xiangya School of Medicine, Department II of Head and Neck Radiotherapy,
Abstract
A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES).Org: State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China, Shanghai Xianxiang Medical Technology Co., Ltd, Shanghai, China,
Abstract
Differential gene expression analysis of a phase II randomized clinical trial of patients with endometrial cancer (EC) treated with megestrol acetate ± pterostilbene.Org: City of Hope Comprehensive Medical Center,
Abstract
Long-term survival, toxicities, and the role of chrono-chemotherapy with different infusion rates in patients with locally advanced nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: A retrospective study with a 5-year follow-up.Org: Afiliated Hospital of Guizhou Medical University, Affiliated Hospital of Guizhou Medical University/Affiliated Cancer Hospital of Guizhou Medical University,
Abstract
Screening failure in clinical trials for patients with head and neck squamous cell carcinoma: A retrospective analysis.Org: Institute of Cancer Research/The Royal Marsden Hospital,
Abstract
A phase II trial of neoadjuvant docetaxel/5-FU/cisplatin in combination with prophylactic pegteograstim in unresectable, locally advanced nasal cavity/paranasal squamous cell carcinoma: KCSG HN18-07.Org: Yeungnam Univ University Hospital,
Abstract
Clinical prognostic factors to guide treatment strategy for HPV-positive oropharyngeal cancer from treatment outcomes of induction chemotherapy: A real-world experience.Org: Chonnam National University Hwasun Hospital, Chonnam National University Medical School and Hwasun Hospital,
Abstract
Prevalence and risk factors associated with chronic pain among survivors of head and neck cancer.Org: Duke Global Health Institute,
Abstract
Nuclear receptor subfamily 4A2: Novel role and a potential therapeutic lead in cancers.Org: Islamic University Of Science And Technology, Awantipora, Jammu and Kashmir, India, Sidra Medicine, Doha, Qatar, University of Nebraska Medical Centre, Omaha, NE, Islamic University Of Science And Technology, Awantipora, India,
Abstract
Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C.Org: CEPCM AP-HM,
Abstract
Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).Org: Medical Oncology Society of Turkey, Health Science University Antalya Education and Research Hospital, Prof. Dr. Cemil Tascıoglu Hospital, Marmara University Pendik Research and Training Hospital, Necip Fazil City Hospital Department of Medical Oncology,
Abstract
Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer: An update on recurrence-free survival and correlative biomarkers.Org: University Medical Centre Groningen, University Hospital Zurich, Department of Pathology and Molecular Pathology, Department of Pathology, University Medical Center Groningen,
Abstract
METTL3 as a potential predictive biomarker for immunotherapy response in metastatic head and neck cancer.Org: Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University,
Abstract
Impact of tertiary lymphoid structures in response to immune checkpoint blockade in patients with head and neck squamous cell carcinoma.Org: Massachusetts General Hospital, Harvard Medical School, Center for Head and Neck Cancers, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA,
Abstract
Clinicians' perspectives of barriers and facilitators of suicide screening in head and neck cancer care.Org: Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University School of Medicine, Durham, NC, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC,
Abstract
Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.Org: Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quirón, UVic-UCC, Barcelona, Spain, Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, FL, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain, Sarah Cannon Research Institute UK, London, United Kingdom, Florida Cancer Specialists and Research Institute, Lakewood Ranch, FL,
Abstract
Role of induction chemotherapy in locally advanced oropharyngeal carcinoma in Indian population.Org: Healthcare Global Enterprises Ltd.,
Abstract
A multicenter, retrospective study analysis: Evaluating the efficacy and safety of pembrolizumab in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, Department of Radiation Oncology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China, Department of Oncology, Xiangya Hospital, Central South University, Changsha, China, Department of Radiation Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China,
Abstract
Survival outcomes of patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with platinum-based chemotherapy plus paclitaxel after anti-PD-1 monotherapy.Org: Case Western Reserve School of Medicine, Cleveland, OH, Case Western Reserve University School of Medicine,
Abstract
Preliminary efficacy and safety of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial.Org: Department of Head & Neck Tumors and Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center; Shanghai Medical College, Fudan University, Shanghai, China, Minimally Invasive Therapy Center, Shanghai Cancer Center, Fudan University, Shanghai, China, Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
Immune system evaluation in a cohort of Brazilian patients with head and neck squamous cell carcinoma who are non-smokers and alcoholic beverages abstainers.Org: Instituto de Ciências Biomédicas, CTO/ICESP, Centro de Investigação Translacional em Oncologia, Departamento de Radiologia e Oncologia, Faculdade de Medicina FMU,
Abstract
Differential gene expression and methylation of upper aerodigestive tract and lung squamous cell carcinoma between European ancestry (EA) and African ancestry (AA) patients.Org: University of Maryland Institute of Genome Sciences,
Abstract
Real-world effectiveness and safety of PD-1 inhibitors combined with recombinant human endostatin and chemotherapy in refractory, recurrent/metastatic nasopharyngeal carcinoma.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou Yirui Pharmaceutical Technology,
Abstract
Clinical utility of circulating tumor tissue-modified viral HPV DNA testing in HPV-driven oropharyngeal cancer arising in women.Org: Christiana Care Health System,
Abstract
Prognostic impact of caspase-8 mutation in oral cavity squamous cell carcinoma: A real-world cohort study.Org: Chung Shan Medical University Hospital, Department of Medical Research,
Abstract
Intralesional nivolumab in oral potentially malignant disorders: A phase 1 pilot study on safety, tolerability, and preliminary efficacy.Org: Department of Otorhinolaryngology-Head and Neck Surgery,
Abstract
Impact of comorbidity on outcome and treatment choice in patients with head and neck squamous cell carcinoma (HNSCC).Org: IRCCS-Biostatistical Unit, Otorinolaringoyathry Department, UniCamillus International Medical University,
Abstract
Immunotherapy for local/regional control of locally advanced orbital and periocular squamous cell carcinoma.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, MD Anderson Cancer Center, M.D. Anderson Cancer Center,
Abstract
Economic evaluation of the novel PD-1 inhibitor toripalimab in recurrent or metastatic nasopharyngeal carcinoma: Cost-efficiency and expanded access modeling versus pembrolizumab.Org: Matrix45 LLC,
Abstract
Time restricted eating (TRE) and immunotherapy outcomes in head and neck squamous cell carcinoma (HNSCC) via modulation of microbial butyrate and tryptophan metabolic pathways.Org: Duke Cancer Institute, Duke Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Weekly paclitaxel (P), carboplatin (CP) plus pembrolizumab (PMB) as first-line treatment of recurrent or metastatic (R/M) or locally very advanced (LVA) head and neck squamous cell carcinoma (HNSCC): A retrospective study in 39 patients (pts).Org: Institut de Cancérologie Strasbourg Europe,
Abstract
Beyond margins: TIME-infused insights into recurrence in surgically treated oral squamous cell carcinoma (OSCC).Org: HCG Hospital- Healthcare Global Enterprises Ltd, VPS Lakeshore Hospital, Global Cancer Hospital Bangalore,
Abstract
Differential sensitivities of primary tumor and lymph nodes to induction chemotherapy and definitive radiotherapy in nasopharyngeal carcinoma.Org: Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Zhongnan Hospital of Wuhan University, Wuhan, China,
Abstract
A random forest model to predict the efficacy of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma based on the data from the KL167-II-05-CTP study.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay.Org: Owkin France, Centre Leon Berad,
Abstract
Can elective neck dissection for oral cancers be planned based on depth of invasion?Org: PSG Hospitals, Prathima Institute of Medical Sciences, Mediciti Institute of Medical Sciences,
Abstract
Association between heavy metal concentrations and chemotherapy-related acute adverse events in the patients with nasopharyngeal carcinoma: A prospective, longitudinal, observational study.Org: Guangzhou Concord Cancer Center,
Abstract
Phase 2 study of xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A post hoc activity analysis by blinded independent review committee evaluation.Org: Merck Serono Ltd., Merck, The Healthcare Business of Merck KGaA, Debiopharm, Institut Gustave Roussy,
Abstract
Gemcitabine and cisplatin chemotherapy plus penpulimab combined with or without anlotinib as neoadjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A prospective, phase II clinical trial.Org: Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center,
Abstract
Multi-dimensional cell-free DNA-based liquid biopsy for sensitive detection of head and neck squamous cell carcinomas.Org: Geneseeq Research Institute, Nanjing Geneseeq Technology Inc.,
Abstract
Neoadjuvant docetaxel-cisplatin followed by concurrent chemoradiotherapy and adjuvant tislelizumab for locally advanced nasopharyngeal carcinoma: A multicenter, single-arm, phase II trial.Org: Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China, Guangzhou Medical University Cancer Center, Guangzhou, China, Department of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China, Department of Radiation Oncology, The Central Hospital of Shaoyang, Shaoyang, Hunan, China,
Abstract
Association of absolute neutrophil count with outcomes in patients with head and neck cancer treated with chemoradiation.Org: The Arthur G. James Cancer Hospital, Richard J. Solove Research Institute,
Abstract
Second primary squamous cell cancers in the HPV de-escalation Quarterback Trials.Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Otolaryngology, Head and Neck Surgery, University of Washington, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Laryngeal squamous cell carcinoma (LSCC) prognosis and machine learning insights.Org: Jordan University of Science and Technology, Irbid, Aydoun-Irbid,
Abstract
Neoadjuvant pembrolizumab/nab-paclitaxel/cisplatin in patients with locally advanced head and neck squamous cell carcinoma: A single-arm phase II study.Org: Guangdong Provincial People‘s Hospital,
Abstract
Response-adaptive resection following neoadjuvant penpulimab combined with chemotherapy in HPV-negative operable locally advanced head and neck squamous cell: A phase II clinical trial.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan YZY Biopharma,
Abstract
Impact of joint peer review with a specialist radiologist in head and neck cancer radiotherapy planning.Org: The Clatterbridge Cancer Centre NHS Foundation Trust,
Abstract
Effect of perioperative medical therapy on prognosis in recurrent nasopharyngeal carcinoma: A comparative effectiveness research.Org: Eye & ENT Hospital, EENT Hospital,
Abstract
Primary tracheal cancer: Demographics, histology, and treatment outcomes in the United States from 2000-2018.Org: Department of Cardiovascular Sciences, East Carolina University,
Abstract
Treatment of iodine refractory well differentiated thyroid carcinoma: Real world data from a tertiary center in Mexico.Org: Centro Medico Nacional 20 Noviembre ISSSTE, Ciudad De México, Ciudad De Mexico,
Abstract
Racial and gender disparities in the incidence of thyroid cancer using Nationwide Inpatient Database.Org: Nuvance Health/Vassar Brothers Medical Center, Wyckoff Heights Medical Center, Lake Erie College of Osteopathic Medicine, State University of New York, Upstate Medical University, University of Missouri-Columbia, School of Medicine,
Abstract
Association of low adherence to weekly cisplatin with outcomes in patients with head and neck cancer treated with chemoradiation.Org: The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute,
Abstract
Robotic versus open surgery for thyroidectomy and modified radical neck dissection in patients with papillary thyroid carcinoma with clinical lateral neck node metastasis (cN1b): Effectiveness and safety, oncological outcomes and long-term quality of life.Org: Southwest Hospital Army Medical University, Army Medical University, Key Laboratory of Minimally Invasive Surgery and Precision Treatment for Breast Cancer of Chongqing Municipal Health Commission, Chongqing, China,
Abstract
Induction chemotherapy with nab-paclitaxel plus nedaplatin plus concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A retrospective real-world study.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou Yirui Pharmaceutical Technology, Zhejiang ACEA Pharmaceutical, China National Biotec Group,
Abstract
Epidemiological analysis and overall survival of thyroid cancer in a developing Middle Eastern Country over 18 years.Org: Royal Papworth Hospital NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Edinburgh Medical School, The University of Edinburgh, Faculty of Medicine, Cairo University,
Abstract
Is the gemcitabin cisplatin doublet the optimal induction chemotherapy for non-Asian patients with NPC? Insights from a northeastern Moroccan cohort.Org: Pharmacy and Dental Medicine of Fez, Chu Hassan II Fez, Laboratory of Epidemiology and Clinical Research Faculty, Medical School of University, Hassan II University Hospital,
Abstract
Precision medicine for papillary thyroid carcinoma (PTC) variants: A machine learning approach to prognosis and treatment guidance.Org: Jordan University of Science and Technology, King Hussein Cancer Center, Jordan University of Science & Technology,
Abstract
A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine,
Abstract
Imaging and clinical characteristics of incidental abnormal thyroid uptake on PSMA PET/CT.Org: Oregon Health & Sciences University,
Abstract
Nasopharyngeal cancer mortality in disaggregated Asian and non-Asian Americans.Org: Stanford Medicine Center for Asian Health Research and Education (CARE),
Abstract
De-escalation treatment of patients with HPV-positive oropharyngeal squamous cell carcinoma.Org: State Medical Institution "City Clinical Oncological Hospital № 1"," Moscow, Russian Federation, P. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, City Clinical Cancer Hospital No. 1, Moscow, Russian Federation, Moscow City Clinical Oncology Hospital No. 1, Moscow, Russian Federation, State Medical Institution "S. Yudina Сity Clinical Hospital", Moscow, Russian Federation,
Abstract
Neoadjuvant chemotherapy combined with PD-1 inhibitor for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma: A single-arm, phase II clinical trial.Org: Peking University Cancer Hospital & Institute, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China,
Abstract
Efficacy and safety of selpercatinib in advanced RET-altered thyroid cancers: A meta-analysis and systematic review.Org: Nishtar Hospital,
Abstract
Utilizing stereotactic body radiation therapy in combination with tyrosine kinase inhibitors for therapeutic benefit in thyroid cancer.Org: Northwell Health Department of Radiation Medicine,
Abstract
Atezolizumab plus taxane chemotherapy for the treatment of non-BRAF, non-RAS mutated anaplastic thyroid carcinoma: Final analysis.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Dual immune checkpoint inhibition with nivolumab and ipilimumab (N+I) in patients with advanced anaplastic thyroid carcinoma (ATC).Org: Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Brigham and Women's Hospital/Massachusetts General Hospital, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Phase 3 randomized study for evaluation of physician choice Rx versus best supportive care as second-line or beyond therapy in head and neck cancer with poor performance status.Org: Sunrise Oncology Center,
Abstract
Long-term efficacy of high-dose imatinib in Hispanic patients without access to second-generation tyrosine kinase inhibitors treated in LATAM centers.Org: Universidad Autonoma de Nuevo Leon,
Abstract
PTPN11 variants in chronic myelomonocytic leukemia: Phenotypic and prognostic correlates.Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).Org: Fred Hutchinson Cancer Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Division of Hematopathology, Mayo Clinic, Rochester, MN, Virginia Commonwealth University School of Medicine,
Abstract
PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients.Org: National Cancer Institute, Vilnius, Lithuania, Center for Immune-Oncology, Center for Cancer Research, National Cancer Institute, Precigen, Inc., National Institutes of Health All of Us Research Program,
Abstract
Impact of JAK2 allele burden on MF outcome in the era of ruxolitinib.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Leukemia, Department of Hematopathology, Beijing Friendship Hospital, Capital Medical University,
Abstract
Covalent FAPI PET enables accurate management of medullary thyroid carcinoma: A prospective single-arm comparative clinical trial.Org: Changping Laboratory, Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Key Laboratory of Bioorganic Chemistry and Molecular,
Abstract
Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia (AML) study.Org: NYU Langone Health, New York, NY, Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Augusta University, Augusta, GA, Bio-Path Holdings, Inc., Bellaire, TX,
Abstract
A phase II umbrella clinical trial of advanced salivary gland cancer based on molecular typing.Org: Minimally Invasive Therapy Center,
Abstract
Hematopoietic stem cell transplant for adults with mixed phenotypic acute leukemia.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center,
Abstract
Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.Org: Marien Hospital Düsseldorf, Cancer Center IRCCS Humanitas Research Hospital, IRCSS Azienda Ospedaliera Universitaria di Bologna, MDS Unit, Service d'Hématologie Séniors,
Abstract
Safety and efficacy of CD7-CAR-T cell in patients with relapsed/refractory T-lymphoblastic leukemia/lymphoma: Phase I dose-escalation/dose-expansion study.Org: Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Lymphoma Diagnosis and Treatment Center of Henan Province, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, PersonGen-Anke Cellular Therapeutics Co., Ltd.,
Abstract
Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS).Org: Shengjing Hospital Affiliated to China Medical University, Shenyang, China, Department of Hematology, The First Hospital of China Medical University, Shenyang, China, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China, Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China, Shanghai Sixth People's Hospital, Shanghai, China,
Abstract
Safety outcomes in patients with acute myeloid leukemia receiving gemtuzumab ozogamicin and proceeding to allogeneic hematopoietic stem cell transplantation.Org: Pfizer Inc., Pfizer Inc., London, United Kingdom, Pfizer Inc., Ontario, ON, Canada, Pfizer Inc., Cambridge, MA,
Abstract
Examining two hematologic precursors and their impact on incident lymphoid malignancies.Org: Division of Clinical Trials and Biostatistics, Department of Health Sciences Research,
Abstract
Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study.Org: ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, Ministry of Health, Kogarah, NSW, Australia, AbbVie, North Chicago, IL, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy,
Abstract
Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL‑2 arms 6 and 7.Org: University Hospital and Faculty of Medicine,
Abstract
Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR).Org: University of Kentucky College of Medicine, Celgene, a Bristol Myers Squibb Company, Center for International Blood & Marrow Transplant Research, Medical College of Wisconsin,
Abstract
EPCORE NHL‑1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL.Org: Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland,
Abstract
Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study.Org: University of Oklahoma Stephenson Cancer Center,
Abstract
Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Atrium Health, Levine Cancer Institute, Syneos Health,
Abstract
Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis.Org: Alexandra Hospital - University of Athens, Medical School, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Würzburg University Hospital, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center, Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center,
Abstract
Exploring the role of the combination of FDG PET plus whole body MRI for staging newly diagnosed and relapsed/refractory multiple myeloma: A prospective trial.Org: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS,
Abstract
Final results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (Pts) with multiple myeloma (MM).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, GlaxoSmithKline,
Abstract
Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701.Org: Massachusetts General Hospital, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, Mayo Clinic, National Cancer Institute, Vilnius, Lithuania,
Abstract
Assessing the prognostic value of transcriptomic data in multiple myeloma through machine learning methodologies.Org: Kansas State University–Olathe, 1DATA Consortium, Computational Comparative Medicine,
Abstract
OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS).Org: Zhejiang University Medical School Attached First Hospital, Department of Hematology, The First Affiliated Hospital, Zhejiang University, Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine,
Abstract
Expression of alternatively spliced BCMA RNA with skipping of transmembrane domain.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack, NJ, Genomic Testing Cooperative, Irvine, CA, Irvine, CA, Hackensack University Medical Center,
Abstract
Real-world analysis of HyperCVAD + TKI for untreated Ph+ ALL.Org: Sidney Kimmel Medical College at Thomas Jefferson University,
Abstract
Outcomes of patients who received CAR T cell therapy and developed IEC-HS treated with cytokine directed therapy.Org: Mayo Clinic Division of Nephrology and Hypertension,
Abstract
RNA expression-based risk stratification of de novo acute myeloid leukemia.Org: Independent Researcher,
Abstract
Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity.Org: Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China, Department of Hematology, Henan Cancer Hospital, Zhengzhou, China, Department of Lymphoma Oncology, Shanxi Bethune Hospital, Taiyuan, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China,
Abstract
Class comparison of BCMA-directed therapies in relapsed multiple myeloma.Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic, Rochester, MN, Mayo Clinic Florida, Jacksonville, FL,
Abstract
Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).Org: Hopital Bretonneau,
Abstract
Trends on treatment patterns in patients with newly diagnosed AML: Preliminary findings from a real-world analysis.Org: Quinten Health,
Abstract
A propensity score–matched comparison of cytoreductive strategies in patients with acute myeloid leukemia presenting with hyperleukocytosis.Org: Virginia Commonwealth University School of Medicine, VCU Massey Comprehensive Cancer Center, VCU/Massey Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Predictors of mortality among adults with acute lymphocytic leukemia in relapse with tumor lysis syndrome during chemotherapy.Org: Centinela Hospital Medical Center, GITAM Institute Of Medical Sciences And Research, Liaquat University of Medical and Health Science Jamshoro,
Abstract
Safety outcomes in adult patients with AML who achieved their first complete remission with GO prior to HSCT.Org: H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Center for International Blood and Marrow Transplant Research,
Abstract
Pilot study on the utilization of a non-invasive µCor device for monitoring fluid status and cardiac biomarkers during treatment for patients with hematologic malignancies.Org: Cardiology Department,
Abstract
Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1 mutated de novo acute myeloid leukemia.Org: The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China,
Abstract
Correlation between number of molecular mutations and outcomes in de novo acute myeloid leukemia.Org: University of Kentucky, Lexington, KY,
Abstract
Venetoclax combined with hypomethylating agents for favorable risk acute myeloid leukemia: A single center experience.Org: AdventHealth Stem Cell Transplant and Cellular Therapy,
Abstract
Predictors of disseminated intravascular coagulation in patients with acute myeloid leukemia with severe sepsis and septic shock.Org: Centinela Hospital Medical Center, SSRN Hospital, Liaquat University of Medical and Health Science,
Abstract
Health disparities in acute myeloid leukemia: A decade-long analysis of Afro-Caribbean patients in a safety net New York City hospital.Org: State University of New York (SUNY) Downstate Health Sciences University, State University of New York Downstate and Kings City Hospital Center,
Abstract
Synergistic effects of RPT1G, a first-in-class small molecule NAMPT inhibitor, with venetoclax and olaparib in hematological malignancies.Org: Remedy Plan Therapeutics, UCSF Helen Diller Family Comp Cancer Ctr,
Abstract
Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.Org: Institut Gustave Roussy, University of Miami Miller School of Medicine, Miami, FL, Sylvester Comprehensive Cancer Center, Miami, FL, University of California Irvine, Rigel Pharmaceuticals, Inc.,
Abstract
Timing of allogeneic hematopoietic cell transplantation for myelofibrosis and other myeloproliferative neoplasms.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke Cancer Institute, Duke University Trent Center for Bioethics Humanities and History of Medicine, Durham, NC, Duke University Medical Center,
Abstract
Quantifying the financial impact of treatment intolerance in chronic myeloid leukemia on oncology clinical practices: A mixed methods study.Org: FTI Consulting, Sprouts Consulting,
Abstract
Dasatinib versus high-dose imatinib for chronic-phase chronic myeloid leukemia: A meta-analysis of randomized control trials.Org: Dow Medical College, Karachi, Pakistan, Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, India, Terna Medical College, Navi Mumbai, India, Nishtar Medical University, Multan, Pakistan, University of Bristol - Bristol Medical School, Bristol, United Kingdom,
Abstract
The effects of substituting cladribine for fludarabine on outcomes of a reduced intensity conditioning regimen.Org: Atilim University, Medicana International Ankara Hospital, Medicana Bursa Hospital,
Abstract
ASC4REAL: Efficacy and tolerability comparison between ASCEMBL study, a phase 3 randomized clinical trial (RCT), and consolidated real-world (RW) experience with asciminib (ASC) in patients with CML beyond two TKIs.Org: Novartis Australia,
Abstract
The treatment of patients with chronic myeloid leukemia chronic phase combined with myelofibrosis with tyrosine kinase inhibitors: A Chinese population-based study.Org: Yiwu, Ningbo First Hospital, Shaoxing People's Hospital, Zhuji Affiliated Hospital of Shaoxing University, Lishui Hospital,
Abstract
In-hospital outcomes of patients with myelodysplastic syndromes and rheumatic heart disease: A National Inpatient Sample study (2018-2020).Org: Brooklyn Hospital Center, Brooklyn, NY, The Brooklyn Hospital Center, New York, NY, The Brooklyn Hospital Center, Brooklyn, NY,
Abstract
A nationwide analysis of inpatient mortality for patients with leukemia with iron deficiency anemia.Org: Mount Sinai Morningside/West, New York, NY, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Relationship of body mass index and plasma imatinib levels in CML patients and mitigation of clinical impact using PK-guided dosing strategy.Org: PRISM Biogénopôle APHM, Hematology, APHM,
Abstract
Analyzing the characteristics and prognostic outcomes for patients with myelodysplastic syndrome with Q-gene deletion.Org: University of Arkansas for Medical Sciences (UAMS), Highlands Oncology Group, Christina Care Hospital,
Abstract
Patient reported outcomes among U.S. Veterans living with myeloproliferative neoplasms.Org: MPN Advocacy & Education International, Institute for Clinical Research,
Abstract
Cytogenetic and molecular features of mixed-phenotype acute leukemia in US veterans and its potential impact on therapy.Org: George Washington University Hospital Division of Hematology and Oncology,
Abstract
The role of MDSCs in the development of bone marrow fibrosis.Org: Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China,
Abstract
Real-world retrospective study of oral versus intravenous HMA-induced toxicity in MDS and AML treatment.Org: Thomas Jefferson University Hospital, Sidney Kimmel Medical College of Thomas Jefferson University, Thomas Jefferson University, Sidney Kimmel Cancer Center at Thomas Jefferson University,
Abstract
Myelofibrosis prognostic models validated in an underserved minority population: A retrospective analysis.Org: Montefiore Medical Center/Albert Einstein College of Medicine, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Albert Einstein College of Medicine, Montefiore Einstein Center for Cancer Care,
Abstract
Association between ferritin, hemoglobin, and anemia response in jaktinib-treated patients with myelofibrosis: A post-hoc analysis of the ZGJAK006 study.Org: The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Jiangsu Provincial People’s Hospital, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalize, Shanghai Jiaotong University Medical School,
Abstract
A call for improved anemia treatments in myelofibrosis: A single-center retrospective study.Org: Montefiore Medical Center/Albert Einstein College of Medicine, Montefiore Einstein Center for Cancer Care, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Albert Einstein College of Medicine,
Abstract
Concurrent enhancer of Zeste homolog 2 (EZH2) over-expression with BRAFV600E mutation predicts a poor outcome in patients with Langerhans cell histiocytosis (LCH): A pilot study.Org: Tampa General Hospital,
Abstract
Burden of illness in polycythemia vera: A retrospective medical chart audit study.Org: PharmaEssentia USA Corporation, Mass General Brigham Specialty Pharmacy, Trinity Life Sciences,
Abstract
Real world (RW) study of patients (pts) with relapsed or refractory (RR) blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG).Org: Aixial Group, University Hospital Besancon,
Abstract
Real-world barriers to CAR-T access: A Canadian referral center perspective.Org: Institut Universitaire d'Hémato-Oncologie et de Thérapie Cellulaire, CIUSSS de l’Est de l’Île de Montréal,
Abstract
Long-term survival outcomes in patients with relapsed/refractory large B-cell lymphoma after treatment of relma-cel: 4-year follow-up in RELIANCE study.Org: Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Department of Lymphoma, Guangdong Provincial People's Hospital, Southern Medical University, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences,
Abstract
Flat dose intravenous immunoglobulin (IVIG) for primary infection prophylaxis after CAR-T for B-cell non-Hodgkin lymphoma (B-NHL).Org: Vanderbilt University Medical Center, Nashville, TN,
Abstract
Neurocognitive testing to predict ICANS post-CAR T.Org: University of Kansas Cancer Center UKH, US Myeloma Research Innovations Research Collaborative (USMIRC), Department of Psychiatry and Behavioral Sicences,
Abstract
Epidemiology of mast cell leukemia: A must!Org: Mercy Catholic Medical Center, Lansdowne, PA, Darby, PA,
Abstract
Safety and feasibility of outpatient CAR-T therapy: A single center analysis.Org: University of Oklahoma Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma University Health Sciences Center, University of Oklahoma Health Sciences Center, University of Oklahoma, Stephenson Cancer Center,
Abstract
Cardiovascular adverse events in patients with cancer treated with chimeric antigen receptor (CAR) T-cell therapy: A meta-analysis of both controlled and single-arm clinical trials.Org: University of Missouri–Kansas City, University of Missouri-Columbia, University of Missouri Hospital,
Abstract
Preliminary results of a first-in-human study on ESG206, a novel anti-BAFF-R monoclonal antibody, in relapsed or refractory B-cell malignancies.Org: Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China, Department of Lymphatic Oncology, Beijing Cancer Hospital, Beijing, China, Department of Hematology, Beijing Hospital, Beijing, China, Shanghai Escugen Biotechnology Co., Ltd., Shanghai, China, Shanghai Escugen Biotechnology Co., Ltd., Beijing, China,
Abstract
Bridging therapies used in trials testing CAR-T therapies.Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Drexel University College of Medicine, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
A study of a new mechanism: Intracellular retention allo-CART safety and efficacy for extranodal bulky B-NHL.Org: Fundamenta Therapeutics Co., Ltd., The First Affiliated Hospital of University of Science and Technology of China,
Abstract
Evolving patterns of transplant strategies for mantle cell lymphoma in the era of BTK inhibitors and CAR-T therapy.Org: Penn State Milton. S. Hershey Medical Center,
Abstract
Real-world outcomes following adverse events and dose reduction of first-line ibrutinib in Medicare beneficiaries with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).Org: Inovalon,
Abstract
A retrospective observational study of rapid titration of venetoclax (VEN) in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).Org: University of Virginia Health System, Charlottesville, VA, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Virginia, Charlottesville, VA, USA,
Abstract
The interim analysis of a first-in-human phase 1 trial of ET-901, a CRISPR edited allogeneic immune-cloaked anti-CD19 CAR-T cell therapy in patients with r/r B-NHL.Org: Department of Bio-therapeutic, The First Medical Center, Chinese PLA General Hospital, Beijing, China, EdiGene,
Abstract
Prevalence of adverse events following bispecific antibody therapy in non-Hodgkin lymphoma: A meta-analysis.Org: Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Mayo Clinic, Mayo Clinic Arizona, Phoenix, AZ, Mayo Clinic Scottsdale,
Abstract
Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL.Org: H. Lee Moffitt Cancer Center and Research Institute, BeiGene USA, Inc., San Mateo, CA, Real Chemistry, Inc.,
Abstract
Risk of new-onset hypertension in patients (pts) with newly diagnosed chronic lymphocytic leukemia (CLL) treated with Bruton tyrosine kinase inhibitors (BTKi): A real-world data study using the Symphony Health Solution database.Org: Cardiology Center, Canton, CT,
Abstract
Gender disparity in enrollment in clinical trials for hairy cell leukemia (HCL) in the last 40 years.Org: UNM Comprehensive Cancer Center,
Abstract
Long-term follow-up of patients with hairy cell leukemia treated with different modalities at a single institution: Real-life experience over 25 years.Org: Guthrie Cancer Center, Sayre, PA,
Abstract
Revealing heterogeneity in chronic lymphocytic leukemia: AI-driven insights into aggressive and indolent disease subtypes.Org: Netramark,
Abstract
Effect of rituximab on remissions without minimal residual disease and immunogenicity in patients with relapsed/refractory hairy cell leukemia receiving moxetumomab pasudotox.Org: Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, Laboratory of Pathology, NCI, NIH, Bethesda, MD, Office of Research Nursing, NCI, NIH, Bethesda, MD, Hematology Service, DLM, NIH, Bethesda, MD,
Abstract
Relapse Hodgkin lymphoma autologous stem cell transplant long term follow up.Org: Advocate Lutheran General Hospital,
Abstract
Risk of hypertension in patients with CLL/SLL who participated in ALPINE: A post hoc analysis.Org: BeiGene, Ltd, Cardiology Center, University of Connecticut Health Center,
Abstract
Effects and outcomes of tumor lysis syndrome in patients admitted with Hodgkin and non-Hodgkin lymphoma: A National Inpatient Sample study (2019-2020).Org: Brooklyn Hospital Center, Brooklyn, NY, The Brooklyn Hospital Center, New York, NY, St. Vincent Hospital and Health Care Centers, Parkview Regional Medical Center, Brooklyn Hospital Program,
Abstract
Efficacy outcomes of treatments for double exposed chronic lymphocytic leukemia/small lymphocytic lymphoma: A systematic literature review.Org: Clinical and Administrative Pharmacy, Health Economics and Health Services Research,
Abstract
Hodgkin’s lymphoma, lymphocyte-depleted, reticular: An NCDB analysis of demographic and socioeconomic factors of diagnosed patients.Org: Mackay Memorial Hospital,
Abstract
Efficacy and safety of mosunetuzumab-based regimens as first-line therapy in non-Hodgkin lymphomas: A systematic review of clinical trials.Org: New York Medical College at St.Michael's, New York Medical College at St. Michael’s Medical Center,
Abstract
Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices.Org: University of Pittsburgh Medical Center (UPMC), Integra Connect PrecisionQ, BeiGene,
Abstract
Cardiovascular and hematologic complications of Hodgkin vs non-Hodgkin lymphoma and readmission trends: A National Readmission Database analysis from years 2016-2020.Org: Interfaith Medical Center,
Abstract
Risk of stroke in patients with atrial fibrillation and chronic lymphocytic leukemia.Org: Northwell Staten Island University Hospital, New York Oncology Hematology PC, Nykode Therapeutics, Staten Island University Hospital, Northwell Health, New Hyde Park, NY,
Abstract
Real world outcomes in patients with follicular lymphoma treated with RCHOP vs BR.Org: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, Huntsman Cancer Institute/University of Utah, Hunstman Cancer Institute at the University of Utah,
Abstract
Characteristics, treatment, and outcomes of cutaneous mantle cell lymphoma: A decade-long study at MD Anderson Cancer Center.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Real-world comparison of time to next treatment for patients with high-risk CLL/SLL in first line of treatment.Org: University of Pittsburgh Medical Center (UPMC), Integra Connect PrecisionQ,
Abstract
Therapeutic utilization in chronic lymphocytic leukemia: A cross-sectional analysis of the Lymphoma Coalition’s 2022 Global Patient Survey.Org: Lymphoma Coalition,
Abstract
Survival benefit of autologous transplant (ASCT) for mantle cell lymphoma (MCL) in the California Cancer Registry (CCR).Org: Los Angeles Medical Center,
Abstract
Real-world understanding of the unmet need for treatment of non-covalent BTKi in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).Org: University of Pittsburgh Medical Center (UPMC), Integra Connect PrecisionQ,
Abstract
Outcomes of R-MPV followed by ara-c in primary central nervous system lymphoma: A single-center retrospective analysis.Org: New York Medical College/Westchester Medical Center, Westchester Onc Hem,
Abstract
Real-world cost of disease progression (PD) after frontline (1L) R-CHOP in diffuse large B-cell lymphoma (DLBCL): An analysis of a large US claims database.Org: Rocky Mountain Cancer Centers, The US Oncology Network, Aurora, CO, Genentech, South San Francisco, CA,
Abstract
Long term results of a new treatment strategy for follicular low grade lymphoma (FLGL).Org: University of Puerto Rico Medical School, Auxilio Centro de Cancer,
Abstract
Impact of rituximab maintenance on survival of patients with mantle cell lymphoma: A north Indian tertiary care center experience.Org: Department of Laboratory Oncology,
Abstract
A phase IIA clinical trial to evaluate a reversible Bruton’s tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).Org: Chengdu Hyperway Pharmaceuticals, Chengdu, China,
Abstract
Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma.Org: H. Lee Moffitt Cancer Center and Research Institute, Real Chemistry, Inc., BeiGene USA, Inc., San Mateo, CA,
Abstract
Immunohistochemical markers in the prognostic model for survival of patients with diffuse large B-cell lymphoma.Org: Tashkent Medical Academy,
Abstract
Clinical observation study of recombinant human thrombopoietin in the prevention of chemotherapy-induced thrombocytopenia in patients with aggressive lymphoma.Org: Beijing Tong-Ren Hospital, Beijing Luhe Hospital Capital Medical University, Langfang Traditional Chinese Medicine Hospital, Fuxing Hospital Capital Medical University, Beijing Jishuitan Hospital,
Abstract
Real-world evaluation of treatment pattern, time to next treatment (TTNT), healthcare resource utilization (HCRU), and cost of care in follicular lymphoma (FL).Org: H. Lee Moffitt Cancer Center and Research Institute, BeiGene USA, Inc., San Mateo, CA, Real Chemistry, Inc.,
Abstract
Orelabrutinib, rituximab, temozolomide and high-dose methotrexate (RMOT) in newly diagnosed primary central nervous system lymphoma (PCNSL): A retrospective analysis on efficacy and safety.Org: State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
Sex disparities in short-term outcomes among patients with diffuse large B cell lymphoma undergoing chimeric antigen receptor T-cell therapy in the United States.Org: St. Luke's University Health Network Anderson Campus, Centinela Hospital Medical Center, One Brooklyn Health System/Interfaith Medical Center, Government Medical College Patiala, Independent Researcher,
Abstract
Incidence of any infections and SARS-CoV-2 infections in patients receiving treatment for follicular lymphoma and diffuse large B-cell lymphoma: Real-world evidence from a large US national claims database.Org: Regeneron Pharmaceuticals, Inc.,
Abstract
Comparison of zanubrutinib (zanu) and acalabrutinib (acala) in B-cell malignancies: An adverse event (AE) -based analysis.Org: Leeds Teaching Hospital NHS Trust, ConnectHEOR, Hôpital Avicenne, AP-HP et Université Sorbonne, Division of Biostatistics and Bioinformatics, Penn State College of Medicine,
Abstract
Gender disparities in Waldenstrom macroglobulinemia: Insights from a comprehensive analysis.Org: University of South Florida Morsani College of Medicine, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
CD19/BCMA dual-targeting FasTCAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin lymphoma: An update.Org: Gracell Biotechnologies Ltd., Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Clinical characteristics and independent prognostic factors of patients with mantle cell lymphoma over last two decades with a focus on the interaction between tumor stage and age.Org: Palisades Medical Center, UTHealth School of Public Health, Rutgers New Jersey Medical School,
Abstract
Phase I safety and preliminary efficacy of IMM0306 in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.Org: Lymphatic Comprehensive Internal Medicine Ward, Henan Cancer Hospital, Henan Cancer Hospital, Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, China,
Abstract
Outcome of patients with primary CNS lymphoma treated with methotrexate based regimens: A retrospective study.Org: USC Norris Comprehensive Cancer Center, University of Southern California/Los Angeles General Internal Medicine Residency Program,
Abstract
Health-related quality of life (HRQoL), functioning, and symptoms with odronextamab monotherapy in patients (pts) with relapsed or refractory follicular lymphoma (R/R FL) by POD24 status in the ELM-2 study.Org: IQVIA, Amsterdam, Netherlands,
Abstract
CD19 expression in diffuse large b-cell lymphoma (DLBCL) patient biopsies after treatment with tafasitamab.Org: Incyte Research Institute,
Abstract
Rituximab, chidamide, and zanubrutinib (ZCR) ± CHOP as a regimen for treatment naive (TN) double-expressor DLBCL (DE-DLBCL).Org: Affiliated Dongguan People’s Hospital, Dongguan People’s Hospital,
Abstract
Demographic and survival data of patients with primary diffuse large B-cell lymphoma of the head and neck: A single center experience.Org: Cukurova University Faculty of Medicine Department of Medical Oncology, Adana Acıbadem Hospital,
Abstract
Quantitative systems pharmacology (QSP) model to predict combination activity of CD19-targeted antibody drug conjugate (loncastuximab tesirine) co-dosed with a CD20/CD3 T-cell bispecific (epcoritamab) in patients with diffuse large B-cell lymphoma (DLBCL).Org: Murray Hll, Metrum Research Group, Tariffville,
Abstract
Clinical features and outcomes of patients with follicular lymphoma grade 3A: A real-world study in single center.Org: Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China,
Abstract
Impact of military deployment on non-Hodgkin lymphoma subtype.Org: Wright Patterson Air Force Base, Brooke Army Medical Center, Fort Sam Houston, TX,
Abstract
An institutional experience of a rare diagnosis of subcutaneous panniculitis-like T-cell lymphoma.Org: BSW Health, Texas A&M Health Sciences,
Abstract
External validation of the lactate dehydrogenase/albumin ratio as a clinical predictor of overall survival in Peruvians with diffuse large B cell lymphoma.Org: Instituto de Investigaciones en Ciencias Biomédicas (INICIB), Universidad Ricardo Palma, Departamento de Oncología y Radioterapia, Hospital Nacional Edgardo Rebagliati Martins, Centro de Investigación de Medicina de Precisión,
Abstract
Second line immune targeted therapies in relapsed or refractory diffuse large B-cell lymphoma: A network meta-analysis.Org: MCPHS University, University of South Carolina College of Pharmacy,
Abstract
Effect of AVM0703 treatment on the limitations of R-CHOP and survival in a model applicable to ABC subtype DLBCL.Org: AVM Biotechnology,
Abstract
Effect of 1-L-MT on immunotherapy of diffuse large B-cell lymphoma via downregulation of PD-L1.Org: Shandong Provincial Qianfoshan Hospital,
Abstract
Survival outcomes in primary orbital diffuse large B-cell lymphoma.Org: Hematology Oncology Division, Mayo Clinic-Florida, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Demographic insights in systemic EBV-positive T-cell lymphoproliferative disease of childhood: A comprehensive NCDB analysis.Org: University of Arizona College of Medicine - Phoenix,
Abstract
Incidence, characteristics and outcomes in relapsed and refractory CD20+ PTLD: An institutional retrospective cohort study.Org: Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, University of Michigan, City of Hope National Medical Center,
Abstract
Characteristics and outcomes of plasmablastic lymphoma in a predominantly Hispanic population.Org: Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business,
Abstract
Development of a novel methodology to assess response to lymphoma treatment in real-world data.Org: Cardinal Health, Office of Oncologic Diseases, Oncology Center of Excellence, Office of Biostatistics and Epidemiology,
Abstract
Racial disparities in major adverse cardiovascular and cerebrovascular events in patients with non-Hodgkin lymphoma.Org: Woonsocket, Abu Dhabi,
Abstract
CSF proteomics for predicting response to treatment in patients with primary and secondary central nervous system lymphoma.Org: Penn State College of Medicine, University Park, PA, PainReform, University of Toronto, Toronto Allergy and Asthma Centre,
Abstract
Outcomes in patients (pts) with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with systemic therapy from real world experience (ORCHID) study.Org: Hematology Institute, Clinical Department of Hematology,
Abstract
Concordance between physician response assessment and a novel method per Lugano criteria in patients with lymphoma using real-world data.Org: Cardinal Health, Office of Oncologic Diseases, U.S. Food and Drug Administration, Oncology Center of Excellence, Office of Biostatistics and Epidemiology,
Abstract
Time to antibiotic administration in patients undergoing HSCT with neutropenic fever.Org: MetroHealth Medical Center, Case Western Reserve University School of Medicine, University Hospitals Sussex NHS Foundation Trust, Case Medical Center - Seidman Cancer Center,
Abstract
Survival outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.Org: Hematology Oncology Division, Mayo Clinic-Florida, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Epidemiological insights and survival patterns of HHV8-positive diffuse large B-cell lymphoma (HDN) associated with multicentric Castleman disease (CD): A comprehensive analysis using SEER database.Org: Saint Peter's University Hospital,
Abstract
Can teclistamab be safely administered in the community? A single-center experience.Org: Allegheny Health Network Cancer Institute,
Abstract
Efficacy and safety of GPRC5D-based monotherapies for relapsed/refractory multiple myeloma: A systematic review and meta-analysis.Org: Nepal Army Institute of Health Sciences, Vassar Brothers Medical Center, Nuvance Health,
Abstract
Real-world outcomes of teclistamab for the treatment of relapsed/refractory multiple myeloma at UC San Diego Health: A single-institution experience.Org: Hematology/Oncology Fellowship Program, University of California Health,
Abstract
Risk of gastrointestinal adverse events associated with chimeric antigen receptor T-cell therapy (CAR-T): A nationwide analysis.Org: University of Kansas Medical Center, Department of Biostatistics & Data Science, University of Nebraska Medical Center, Khyber Medical University, Division of Hematologic Malignancies and Cellular Therapeutics,
Abstract
Survival shifts in multiple myeloma: Evaluating the impact of therapeutic advances and racial disparities after a decade of change.Org: Greenville, NC,
Abstract
In-hospital outcomes of autologous stem cell transplantation in patients with multiple myeloma with versus without heart failure.Org: Florida State University, University of Miami Miller School of Medicine, Miami, FL, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL,
Abstract
Analyzing the impact of type 1 and type 2 diabetes on patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM): A retrospective study at a tertiary care center.Org: SUNY Downstate Health Science University,
Abstract
Outcomes of ide-cel in patients with relapsed/refractory multiple myeloma: A single-institution experience.Org: University of California San Diego, Internal Medicine Residency, University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences,
Abstract
Real-world analysis of belantamab mafodotin (belamaf): Care patterns in relapsed/refractory multiple myeloma.Org: GlaxoSmithKline plc, GSK ONCOLOGY,
Abstract
Talquetamab (Tal) therapy in relapsed/refractory (R/R) multiple myeloma (MM): Assessing weight loss and dysgeusia.Org: University of Jordan,
Abstract
Incidence of infections in clinical trials of treatments for relapsed/refractory multiple myeloma: Systematic review and meta-analysis.Org: Pennsylvania State University, College of Medicine,
Abstract
Incidence of thromboses and secondary cancers in patients with multiple myeloma after lenalidomide-based induction followed by maintenance as first-line therapy: A systematic review and meta-analysis.Org: UMKC School of Medicine,
Abstract
Novel method for the detection of circulating tumor plasma cells in multiple myeloma.Org: CytoGen Inc.,
Abstract
Analysis of real-world (RW) pomalidomide (pom) dosing patterns in patients (pts) with multiple myeloma (MM) from the Flatiron database.Org: Myeloma, Waldenstrom’s and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy,
Abstract
Patient-reported treatment-related symptoms and use of the PRO-CTCAE for multiple myeloma clinical trials: A qualitative interview study.Org: Vector Psychometric Group, LLC, Janssen Global Services, LLC,
Abstract
Age-related differences in information-seeking behaviors of patients with multiple myeloma.Org: HealthTree Foundation, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, GlaxoSmithKline plc, Sanofi, Regeneron Pharmaceuticals,
Abstract
Exploring gender-based decision-making differences among patients with relapsed/refractory multiple myeloma.Org: GlaxoSmithKline plc,
Abstract
Comprehensive assessment of adverse event profiles associated with bispecific T cell engagers in multiple myeloma.Org: 1DATA Consortium, Kansas State University–Olathe, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Association of posterior reversible encephalopathy syndrome with proteasome inhibitors approved for multiple myeloma: Analysis of FAERS database.Org: Rochester General Hospital, Dayanand Medical College, University of Arkansas for Medical Sciences (UAMS),
Abstract
Hospitalizations for multiple myeloma in the United States from 2011 to 2019: An analysis of trends and disparities.Org: Steward Carney Hospital,
Abstract
The effect of care team-patient relationship on decision-making in relapsed/refractory multiple myeloma.Org: GlaxoSmithKline plc,
Abstract
Multiple myeloma in the African American population: A 2010-2020 NCDB analysis.Org: Chitwan Medical College,
Abstract
Cost effective utilization of apheresis for stem cell transplantation in multiple myeloma.Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Columbus, OH, The Ohio State University - James Cancer Hospital,
Abstract
Characterization of atypical IGH rearrangement patterns in plasma cell neoplasms.Org: Baylor College of Medicine,
Abstract
Quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma (TENDMM): A systematic review and meta-analysis.Org: Mayo Clinic, Phoenix Tissue Repair, Azidus Brasil, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic, Phoenix, AZ,
Abstract
Real-world comparison of adherence to branded 20 mg dexamethasone tablets and generic 4 mg dexamethasone tablets among patients with multiple myeloma.Org: Edenbridge Pharmaceuticals, Parsippany-Troy, NJ, Parsippany-Troy Hills, NJ, Magnolia Market Access, Bridgewater Township, NJ,
Abstract
The role of patient-driven education in decision-making for relapsed/refractory multiple myeloma.Org: GlaxoSmithKline plc,
Abstract
Prognostic factors for progression of MGUS including immune phenotype.Org: Department of Cancer Prevention and Control,
Abstract
Survival outcomes in patients with primary plasma cell leukemia treated with novel therapies at University of California San Diego Health: A single institution experience.Org: University of California San Diego, Internal Medicine Residency, University of California Irvine, San Diego State University Department of Biology, San Diego, CA, School of Medicine, Zhejiang University, Hangzhou, China,
Abstract
Diagnosis disclosure patterns among patients with plasma cell disorders.Org: Geisel School of Medicine at Dartmouth, University of Illinois Chicago, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center, HealthTree Foundation,
Abstract
Clinical outcomes and resource utilization in patients with multiple myeloma admitted with gastrointestinal bleeding.Org: TriHealth Cancer Institute, Trihealth - Cincinnati,
Abstract
Improving clinical outcomes in multiple myeloma: Weight maintenance strategies to reduce complications during autologous hematopoietic transplantation.Org: Augusta University/University of Georgia Medical Partnership, Georgia Cancer Center, Augusta University, Medical College of Georgia, Augusta, GA, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
Impact of hyponatremia on multiple myeloma hospitalizations: A nationwide analysis.Org: Brooklyn Hospital Center, Brooklyn, NY, Brooklyn ImmunoTherapeutics, Nykode Therapeutics, The Brooklyn Hospital Center, New York, NY, New York Oncology Hematology PC,
Abstract
Efficacy of low-dose direct oral anticoagulants (DOACs) for venous thromboembolism prophylaxis in newly diagnosed multiple myeloma.Org: Cleveland Clinic Taussig Cancer Instititute,
Abstract
Smoking history requirement and lung cancer (LC) screening (LCS) eligibility disparities.Org: Baptist Memorial Healthcare Corp, Thoracic Oncology Research Group,
Abstract
Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN.Org: Lung Clinic Grosshansdorf, The Bloomberg–Kimmel Institute for Cancer Immunotherapy,
Abstract
Efficacy of carfilzomib-based regimens as induction/consolidation therapy in newly diagnosed multiple myeloma: A meta-analysis.Org: Albany Medical Center Hospital, JT Mather/Northwell Health,
Abstract
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).Org: Yale New Haven Hospital, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Princess Margaret Cancer Centre, University Health Network, Massachusetts General Hospital,
Abstract
Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).Org: Knapp Center for Biomedical Discovery, Centre Hospitalier de Universite de Montréal, Zentralklinik Bad Berka GmbH, HIA Sainte-Anne, École de Val de Grace,
Abstract
Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer.Org: Affiliated Hospital of Shandong First Medical University,
Abstract
DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC)—Efficacy and safety analyzed by presence of brain metastasis.Org: Translational Oncology/Early Clinical Trial Unit (ECTU), Hospital Universitario 12 de Octubre, CNIO-H12O Lung Cancer Unit,
Abstract
Niraparib and dostarlimab efficacy in patients with platinum-sensitive relapsed mesothelioma: MIST5, a phase IIa clinical trial.Org: Wythenshawe Hospital, Leicester Clinical Trials Unit - University of Leicester,
Abstract
Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): Results from a multi-center phase II trial.Org: UT Southwestern Medical Center, Dallas, City of Hope National Comprehensive Cancer Center, Duarte, CA, Memorial Sloan Kettering Cancer Center,
Abstract
Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study.Org: Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Medical Oncology of Respiratory, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China, West China Hospital Sichuan University, Chengdu, China, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China, The First Affiliated Hospital of Xiamen University, Xiamen, China,
Abstract
Noncanonical RET fusions in Chinese patients with non-small cell lung cancer from DNA-based next-generation sequencing.Org: Affiliated Huashan Hospital,
Abstract
ctDNA-Lung-DETECT: ctDNA outcomes for resected early stage non-small cell lung cancers at 12 months.Org: Michael Garron Hospital, St Joseph’s Health Centre,
Abstract
Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data.Org: Mary Crowley Cancer Research Center, Guangdong Lung Cancer Institute, Valkyrie Clinical Trials, Inc, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.,
Abstract
A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study.Org: Azienda Ospedaliero-Universitaria di Parma, Azienda Ospedaliero Universitaria Policlinico G. Rodolico - San Marco,
Abstract
Neoadjuvant chemoimmunotherapy in patients with limited-stage small cell lung cancer: A retrospective study.Org: Department of Thoracic Surgery and Lung Cancer Center, West China Hospital, Sichuan University, Chengdu Origen Biotechnology, China National Biotec Group,
Abstract
Anticoagulation and lung cancer mortality: A National Inpatient Sample analysis 2020.Org: Jacobi Medical Center/North Central Bronx, NYC Health and Hospitals, Bronx, NY, Nykode Therapeutics, Northwell Health, New Hyde Park, NY,
Abstract
A prospective phase II randomized clinical study of folic acid in the intervention of radiation esophagitis induced by concurrent chemoradiotherapy in lung cancer.Org: The Affiliated Hospital of Guizhou Medical University, The Affiliated Hospital of Guizhou Medical University & The Affiliated Cancer Hospital of Guizhou Medical University,
Abstract
Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial.Org: Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Hospital Privado de la Comunidad de Mar del Plata, Buenos Aires, Argentina, Department of Cancer Medicine, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Sex-based disparities in patients with lung cancer undergoing lobectomy via robotic-assisted thoracoscopic surgery.Org: St. Luke's University Health Network Anderson Campus, Centinela Hospital Medical Center, One Brooklyn Health System/Interfaith Medical Center, Government Medical College Patiala, Independent Researcher,
Abstract
Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2.Org: Virginia Health Specialists, Fairfax, VA, University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Janssen-Cilag Pharmaceutical, Pefki, Greece, Janssen Research & Development, Shanghai, China,
Abstract
Biomarker testing and adjuvant osimertinib use in patients with resectable EGFR-mutated stage IB–IIIA NSCLC: Physician practices, therapy choice, and barriers among US oncologists.Org: Cardinal Health, Baylor University Medical Center,
Abstract
PM 2.5 and risk of lung cancer and associated mortality: An umbrella meta-analysis.Org: Dr Panjabrao Alias Bhausaheb Deshmukh Memorial Medical College, Amravati, India, Saint Vincent Hospital, Worcester, MA, Ege University Faculty of Medicine, Bornova, Izmir, Turkey, Department of Internal Medicine, Kharkiv National Medical University, Kharkivs'ks Oblast, Ukraine, Smt. NHL Municipal Medical College, Ahmedabad, Gujrat, India,
Abstract
A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease.Org: Stanford University Department of Radiation Oncology,
Abstract
Reducing the risk of grade 3 or greater radiation pneumonitis after radical radiotherapy to the lung.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shanghai Pulmonary Hospital, Shanghai, China, Tongji University School of Medicine,
Abstract
Impact of pneumocystis pneumonia on clinical outcomes in patients with lung malignancy compared to other malignancies.Org: John H. Stroger, Jr. Hospital of Cook County, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, St Elizabeth Youngstown Hospital, University of Ilorin Teaching Hospital, Ladoke Akintola University of Technology,
Abstract
Assessment of carcinoembryonic antigen-related cell adhesion molecule 5 expression by immunohistochemistry in real-world clinical samples of non-small cell lung cancer.Org: Princess Margaret Cancer Centre,
Abstract
Comparison of the efficacy of immunotherapy at different time points during the perioperative period for stage II-III NSCLC.Org: The Second Affiliated Hospital of Air Force Military Medical University, Shaanxi Provincial Cancer Hospital,
Abstract
CASTOR1 phosphorylation as a predictor of survival in male patients with KRAS-mutated lung adenocarcinoma.Org: University of Pittsburgh, Pittsburgh, PA, UPMC Hillman Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Department of Pharmacology & Chemical Biology,
Abstract
Lorlatinib in TKI naïve, advanced ROS1-positive non-small-cell lung cancer: A multicenter, open-label, single-arm, phase 2 trial.Org: Center for Lung Cancer, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Research Institute and Hospital, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Constructing a machine learning-based non-invasive liquid biopsy model for lung cancer detection via miRNA sequencing.Org: New Taipei, Taiwan, Zhubei, Taiwan,
Abstract
Comparative genomic landscape of patients with lung cancer with high-load versus low-load Epstein-Barr virus infection.Org: HaploX Biotechnology, Shenzhen, China,
Abstract
Comprehensive germline and somatic DDR genomic profiles of Chinese patients with multiple primary lung cancer.Org: Beijing Haidian Hospital,
Abstract
Osimertinib related cardiotoxicity in patients with non-small cell lung cancer.Org: West Virginia University Camden Clark Medical Center, Morgantown, WVU Camden Clark Medical Center,
Abstract
The results of adding immunotherapy to chemotherapy in patients with small cell lung cancer: Registurk-Lung study—Real-world data.Org: Adana City Hospital, Sakarya University, School of Medicine, Health Science University, Ankara City Hospital, Department of Medical Oncology, Faculty of Medicine, Dicle University, Dr. A.Y. Oncology Education and Training Hospital,
Abstract
Comparative genomic analysis of circulating tumor cells and primary tissues in early-stage lung cancer: Unveiling signatures of metastatic potential.Org: Beyonddx, Inc,
Abstract
Early-stage lung adenocarcinoma with a micropapillary pattern showing a distinct immunogenic tumor microenvironment.Org: Shengjing Hospital of China Medical University, The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China,
Abstract
Association of N-adhesin and focal adhesion kinase with frequency of tumor spread through the airspace (STAS) in stage I lung carcinoma and correlation with recurrence.Org: Department of Respiratory Medicine, Jinling Hospital, Nanjing University School, Nanjing, China,
Abstract
Comparison and performance of three plasma next-generation sequencing assays versus tissue testing for the detection of actionable driver mutations in advanced non-squamous non-small cell lung carcinoma.Org: Laboratory of Clinical and Experimental Pathology, Biobank Côte d'Azur, Pasteur Hospital, FHU OncoAge, Université Côte d’Azur,
Abstract
Comprehensive genomic and transcriptomic profiling of pulmonary nodules in synchronous multiple primary lung cancer.Org: Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University Lung Cancer Center, Beijing, China, Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China, Kanghui Biotech lnc., Shenyang, China,
Abstract
In silico tumor immune microenvironment (TiME) analysis of non-small cell lung cancer (NSCLC) to inform clinical development of CDR404: A first-of-its-kind MAGE-A4 targeted T-cell engager.Org: CDR Life Inc., Genevia Technologies Oy,
Abstract
Genomic characteristics of tumour necrosis in lung squamous cell carcinoma.Org: Fujian Cancer Hospital, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Department I of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China,
Abstract
A novel strategy for detecting mutations from circulating tumor DNA with blood tissue only.Org: HaploX Biotechnology, Shenzhen, China, Shenzhen, China,
Abstract
Application of ctDNA sequencing in patients with metastasized lung cancer.Org: HaploX Biotechnology, Shenzhen, China,
Abstract
Multi-omics profiling the genomic origin and adeno-squamous transdifferentiation mechanism in adenosquamous carcinoma.Org: Fujian Province Tumor Hospital,
Abstract
ViTR-SP: A CT-based vision transformer model for prediction of pneumonitis in patients with non-small cell lung cancer who received thoracic radiotherapy and immunotherapy.Org: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China, Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University, Jinan, China,
Abstract
Depletion of histone H3K27 demethylase exerts anti-tumor activity as a monotherapy and in combination therapy with ceralasertib in non-small cell lung carcinoma.Org: Pharmacology Discovery Services Taiwan, Ltd., partner lab of Eurofins, Pharmacology Discovery Services Ltd., Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taiwan International Graduate Program in Molecular Medicine, Institute of Biomedical Sciences, Academia Sinica and National Yang Ming Chiao Tung University,
Abstract
Single-cell landscape of the immune microenvironment of leptomeningeal metastases in non-small cell lung cancer treated with pemetrexed sheath injection.Org: Fujian Cancer Hospital, Fuzhou University, Fujian Shengdi Pharmaceutical, China National Biotec Group,
Abstract
Integrating deep learning network and liquid biopsy for the evaluation and prediction of response in patients with advanced non-small cell lung cancer: Initial results from the RATIONALE prospective study.Org: Department of Precision Medicine in Medical, Surgical and Critical Care, Palermo, Italy, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties-PROMISE, University of Palermo, Palermo, Italy., Palermo, Italy, Department of Biomedicine, Neurosciences and Advanced Diagnostics-BINRED, University of Palermo, Palermo, Italy, Department of Biomedicine, Neurosciences and Advanced Diagnostics-Bi.N.D., University of Palermo, Palermo, Italy,
Abstract
Accurate identification of lung cancer in the early phase by serum exosomal miR-1271-5p.Org: Xuyi People's Hospital, Huaian,
Abstract
Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).Org: Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, The Royal Marsden Hospital (Surrey), London, United Kingdom, Beth Israel Deaconess Medical Center, Boston, MA, Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona, Orlando, FL, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR,
Abstract
Multiple sclerosis and lung cancer: A single cancer center experience in Philadelphia.Org: Department of Pharmacology, Physiology, & Cell Biology at Thomas Jefferson University,
Abstract
Optimization of fusion detection in non-small cell lung cancer by amplicon-based RNA sequencing.Org: Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Medical Department, 3D Medicines Inc., Shanghai, China, The Medical Department, 3D Medicines, Inc., Shanghai, China, The Medical Department, 3D Medicines Inc., Shanghai, China, 3D Medicines Inc., Shanghai, Shanghai, China, 3D Medicines Inc., Shanghai, China,
Abstract
Predicting spread through air space and immune status in lung adenocarcinoma by CT-based deep learning model.Org: The People's Hospital of Guangdong Province, Guangzhou, China, Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangdong, Guangzhou, China,
Abstract
Non-invasive diagnosis of nature of pulmonary nodules using the whole genome methylation sequencing of circulating cell-free DNA.Org: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma,
Abstract
Landscape of gene fusions and METex14 skipping in non-small cell lung carcinoma among the Chinese population: Insights from targeted RNA sequencing.Org: Huashan Hospital Fudan University, GeneCast Biotechnology,
Abstract
Histopathological features of SMARCA4-deficient thoracic malignancies: Data from resource-limited setting.Org: Wigmore Clinic, Astghik Medical Center, IRA Medical Group Radiotherapy Center, Histogen Practical Scientific Center of Pathology,
Abstract
Clinical and genomic characteristics of multiple primary lung cancers with germline mutations.Org: Beijing Haidian Hospital, AcornMed Biotechnology Co., Ltd., Beijing, China,
Abstract
Induction immune checkpoint inhibitors and chemotherapy for patients with stage III non-small cell lung cancer: A real-world experience.Org: Yiyang Center Hospital,
Abstract
Shannon index analysis in TCR sequencing for patients with lung adenocarcinoma: The clinical implications.Org: The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China,
Abstract
Potential role and prognostic value of Globo-H in lung cancer.Org: OBI Pharma, Inc., Department of Pathology, China Medical University Hospital, Institute of Medicine, Chung Shan Medical University, School of Medicine, Chung Shan Medical University,
Abstract
Treating lung cancer in resource limited setting: Retrospective study from Armenia.Org: Hematology center after prof. Yeolyan, Hematology center after prof Yeolyan, Muracan University Hospital Chemotherapy Clinic,
Abstract
Lung and bronchus cancer in young females: Exploring sex disparities across diverse racial and ethnic groups in the U.S. (2000-2020).Org: Hackensack Meridian Ocean University Medical Center, Atlantic Hematology Oncology Associates - Hackensack Meridian Health,
Abstract
Association of tissue microbiota with cancer stages in lung adenocarcinoma.Org: Beijing Chaoyang District San Huan Cancer Hospital, Beijing, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Characterization of DNA damage repair mutations in lung cancer in an underserved urban patient population.Org: Department of Hematology Oncology University of Illinois of Chicago College of Medicine,
Abstract
Effect of intrinsic STING of CD8+T cells on self-metabolic reprogramming and anti-tumor effects.Org: Nanjing University of Traditional Chinese Medicine, University of Nottingham,
Abstract
Understanding the safety and toxicity profile of durvalumab for Black patients with lung cancer.Org: Morehouse School of Medicine, Atlanta Cancer Care, Galderma R&D,
Abstract
Cutaneous adverse event profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer: A meta-analysis of phase 3 randomized controlled trials.Org: Mount Sinai Beth Israel, Mount Sinai Hospital-Breast Medical Oncology, Kyoto University Hospital, Center for Thoracic Oncology, Tisch Cancer Institute,
Abstract
Dynamic network biomarker of treg cells differentiation critical state with neoadjuvant treatment in LUSC.Org: Hangzhou Repugene Technology Co., Ltd, Hangzhou, China, Hangzhou Repugene Technology Co., Hangzhou, China,
Abstract
Effect of novel polygenetic variant of HUNT lung cancer model on lung cancer risk assessment over clinical model among light smokers (average <9 pack-years).Org: Institute of Applied and Computational Mathematics, FORTH, Institute of Chemical Biology, Ilia State University,
Abstract
Exploring the role of UMP as a molecular marker in the tumor microenvironment of lung adenocarcinoma.Org: Hangzhou Repugene Technology Co., Ltd, Hangzhou, China, Hangzhou Repugene Technology Co., Hangzhou, China,
Abstract
The treatment modalities and radiotherapy pattern in patients with primary lung cancer in Japan.Org: Global Epidemiology, Office of Chief Medical Officer,
Abstract
Cardiac substructure radiation dose study of conventional radiotherapy for stage N2-3 non-small cell lung cancer.Org: The Affiliated Hospital of Guizhou Medical University & The Affiliated Cancer Hospital of Guizhou Medical University,
Abstract
Predicting pathological response to neoadjuvant immunotherapy plus chemotherapy in resectable non-small cell lung cancer through liquid biopsy.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Temporal trends in clinical and pathologic stage discordance in resectable non-small cell lung cancer.Org: Divisions of Hematology and Oncology, Washington University Medical School,
Abstract
Fetal adenocarcinoma: An NCDB analysis of socioeconomic and demographic factors.Org: Creighton University School of Medicine (Phoenix Regional Campus), Phoenix, AZ, Grand Canyon University, Arizona State University, Hunter College, Creighton Hematology Oncology, Omaha, NE,
Abstract
Multimodal risk stratification of non-metastatic lung adenocarcinoma using AI on histology and immunohistochemistry slides.Org: RI-MUHC,
Abstract
A preliminary study on the timing of radiotherapy for chemoimmunotherapy in oligometastatic non-small-cell lung cancer with negative driver genes.Org: Affiliated Hospital of North Sichuan Medical College, NanChong,
Abstract
Enhancing non-small cell lung cancer treatment utilizing natural killer cell-derived extracellular vesicles (NKEVs) as a novel adoptive cellular therapeutic.Org: Tgen, Baylor University Medical Center,
Abstract
Durvalumab and consolidation SBRT following chemoradiation for stage III non-small cell lung cancer: A single institution pilot study.Org: Brown University - Lifespan Cancer Institute, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Warren Alpert Medical School of Brown University, Rhode Island Hospital,
Abstract
The population-based effects of the FDA’s approval of durvalumab as consolidative therapy in patients with locally-advanced non-small cell lung cancer.Org: Huntington, WV, Presbyterian University Hospital, Saint Mary's Medical Center, Marshall University Joan C. Edwards School of Medicine,
Abstract
Neoadjuvant immuno-chemotherapy in resectable non-small cell lung cancer: A retrospective cohort study.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, London Regional Cancer Program, Schulich School of Medicine and Dentistry, Western University, London Health Sciences Centre,
Abstract
Long-term survival of single and multifocal stage 1 lung carcinoma using image-guided thermal ablation.Org: UCLA Center for Computer Vision and Imaging Biomarkers,
Abstract
Young lung adenocarcinoma: Molecular analysis pointing to early acquisition of aggressive mutations.Org: University of Kentucky College of Public Health, Kentucky Cancer Registry, Cancer Research Informatics Shared Resource Facility, Department of Medical Oncology University of Kentucky Markey Cancer Center,
Abstract
Use of cell-free tumor DNA in early detection of lung cancer.Org: Kaiser Permanente Colorado Institute for Health Research,
Abstract
Pulmonary blastoma: An NCDB analysis of demographic and socioeconomic factors.Org: Creighton University School of Medicine - Phoenix Regional Campus, Creighton University School of Medicine Phoenix Regional Campus, UC Riverside, University of Arizona College of Medicine, Phoenix, AZ, Creighton University School of Medicine (Phoenix Regional Campus), Phoenix, AZ,
Abstract
Neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIb non-small cell lung cancer: Single arm phase II study.Org: Shandong Academy of Medical Sciences,
Abstract
Incidence trends and factors affecting survival in mucinous adenocarcinoma of the lung: Insights from SEER data.Org: Marshfield Clinic Research Institute, University of Nebraska Medical Center, The Wright Center for Graduate Medical Education,
Abstract
Factors associated with early-stage lung cancer diagnosis (ESLCD) in Brazil, 2013-2019: A multivariable analysis.Org: Fundação Oswaldo Cruz (Fiocruz), Escola Nacional de Saúde Pública (Ensp), Departamento de Ciências Sociais, National School of Public Health Sergio Arouca, Instituto Nacional de Câncer (INCA),
Abstract
Tracheal cancer epidemiology and survival trends: A SEER database analysis.Org: Springfield,
Abstract
Trends in malignant pleural mesothelioma prevalence in the United States from 2000 to 2020.Org: Thomas Jefferson University, Sidney Kimmel Cancer Center at Thomas Jefferson University,
Abstract
Helical tomotherapy was superior to intensity-modulated radiation therapy in hippocampal avoidance prophylactic cranial irradiation in patients with limited-stage small-cell lung cancer.Org: Department of Radiation Physics,
Abstract
Prognostic impact of clinical stage on non-surgical patients with pleural mesothelioma.Org: Washington University School of Medicine in St. Louis, Washington University in St. Louis,
Abstract
NeoRad(Low): A phase 2 trial of neoadjuvant (NA) ipilimumab + nivolumab (ipi+nivo) with low dose stereotactic body radiation therapy (SBRT) as an immune stimulant in patients with resectable stage IB-III non-small cell lung cancer (NSCLC).Org: Lifespan Health System, Brown University - Lifespan Cancer Institute, Cancer Center at Brown University, Brown University Department of Family Medicine,
Abstract
Effect of continued immunotherapy on survival of extensive-stage small cell lung cancer: A retrospective analysis.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Science, Shandong First Medical University and Shandong Academy of Medical Sciences,
Abstract
Brain metastases in patients with pleural mesothelioma receiving dual checkpoint blockade compared to single-agent checkpoint blockade or chemotherapy.Org: Hospital of the University of Pennsylvania, Perelman School of Medicine, Penn Medicine at Lancaster General Health, University of Pennsylvania, Abramson Cancer Center,
Abstract
Exploring the role of pembrolizumab in mesothelioma: A single-arm analysis of available data.Org: Nishtar Medical University Multan Pakistan, Lahore General Hospital Pakistan,
Abstract
Real world outcomes in extensive stage small cell lung cancer (ES-SCLC) treated with consolidative thoracic radiation (cTRT) and chemoimmunotherapy (CIT): A population level study.Org: Glans-Look Lung Cancer Research,
Abstract
Lurbinectedin versus platinum rechallenge in relapsed extensive stage small cell lung cancer: A retrospective cohort study.Org: Vanderbilt University School of Medicine, Vanderbilt University Medical Center,
Abstract
Cisplatin versus carboplatin in small cell lung cancer (SCLC): Single-center experience.Org: Bahçelievler,
Abstract
Second-line treatment outcomes following first-line chemotherapy plus immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC): A multicenter study.Org: UVSQ, APHP-Hôpital Ambroise Paré, Department of Respiratory Diseases and Thoracic Oncology, Pôle Hospitalo-Universitaire 11 : Santé Publique, Clinique des données,
Abstract
CDK7 as a biomarker to predict response to etoposide and carboplatin treatment in limited-stage small cell lung cancer with surgical resection.Org: Department Cardiothoracic Surgery,
Abstract
Neuroendocrine features in small cell lung cancer (SCLC) and associations with platinum-sensitivity, metastatic tropism, and overall survival.Org: IU Health,
Abstract
Treatment of relapsed small cell lung cancer in the real-world: A comparison of platinum-etoposide rechallenge and cyclophosphamide-doxorubicin-vincristine (CAV) chemotherapy.Org: The University of Ottawa,
Abstract
Effect of CDC7 inhibition and MYC degradation on neuroendocrine transformation in the lung and prostate cancer. Org: Memorial Sloan Kettering Cancer Center, New York City, Nykode Therapeutics, New York Oncology Hematology PC, Columbia University Vagelos College of Physicians and Surgeons,
Abstract
Efficacy and safety of anti-angiogenic therapy plus immunotherapy as later-line treatment for small cell lung cancer: A real-world study.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
A retrospective study of first line atezolizumab-carboplatin-etoposide in extensive-stage small cell lung cancer: Real world data from a Spanish tertiary center.Org: Department of Medical Oncology, Cruces University Hospital, Barakaldo, Spain, Department of Medical Oncology. Hospital universitario de Cruces, Barakaldo, Spain, Department of Medical Oncology. Hospital Universitario Cruces, Barakaldo, Spain, Deparment of Medical Oncology. Cruces University Hospital, Barakaldo, Spain, Department of Medical Oncology of Cruces University Hospital, Barakaldo, Spain,
Abstract
Correlation between multiorgan immune-related adverse events and clinical outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC) treated with chemo-immunotherapy.Org: Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, The Christie NHS Foundation Trust, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Real-world burden and treatments of chemotherapy-induced myelosuppression among patients with extensive-stage small-cell lung cancer: A retrospective real-world study in China.Org: State Key Laboratory of Molecular Oncology, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Therapeutic stratification for small cell lung cancer with multiplexed proteomic analysis.Org: Yeouido St. Mary’s Hospital,
Abstract
Real-world first-line serplulimab-based immunochemotherapy for extensive-stage small cell lung cancer: The multicenter ASTRUM-005R study.Org: Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Department of Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China, Shanxi Cancer Hospital (Shanxi Cancer Institute), Cancer Hospital of Chinese Academy of Medical Sciences Shanxi Hospital, Shanxi Medical University Affiliated Hospital, Taiyuan, China, Department of Chest Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China, Cancer Center, the 10th Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Southern Medical University, Dongguan, China,
Abstract
Real world outcomes of patients with small cell lung cancer (SCLC) presenting with brain metastasis at diagnosis in a single institution health system.Org: Yale New Haven Hospital, Yale University, Department of Therapeutic Radiology, Yale School of Medicine, Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China,
Abstract
Socioeconomic disparities in survival outcomes of patients with SCLC with brain metastases: A nationwide analysis.Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Flare Therapeutics, St. John's Medical College, Bangalore, India, Bangalore Medical College And Research Institute,
Abstract
Unveiling the challenges of small cell lung cancer in resource-limited settings: A multicenter collaboration analysis of demographics, treatment modalities, and prognosis.Org: All India Institute of Medical Science, Rishikesh, Rishikesh, India, Christian Medical College & Hospital, Ludhiana, India, Institute of Medical Sciences and Sum Hospital, Odisha, India, Amala Institute of Medical Sciences, Kerala, India, MMHRC, Madurai, India,
Abstract
A phase II, open-label, efficacy and safety of olaparib with bevacizumab (SUKSES-B2) in biomarker matched relapsed or refractory small cell lung cancer.Org: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Department of Health Sciences and Technology, SAIHST, Sungkyungkwan University, Seoul, South Korea, Early Oncology Clinical Science, R&D Oncology, AstraZeneca, Cambridge, United Kingdom, External R&D, R&D Oncology, AstraZeneca, Seoul, South Korea, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Samsung Genome Institute, Samsung Medical Center, Seoul, South Korea, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea,
Abstract
Clinical outcomes, demographics and associative analysis of lung cancer patients with Lambert-Eaton myasthenic syndrome: Insights from the National Inpatient Sample (NIS) database.Org: Western Reserve Health Education,
Abstract
Camrelizumab combined with chemotherapy followed by maintenance camrelizumab and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory study.Org: Harbin Medical University Cancer Hospital, Harbin, China,
Abstract
PD-(L)1 inhibitors plus anlotinib: A superior option for second-line treatment of extensive-stage small cell lung cancer.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University,
Abstract
First-line immunotherapy plus chemotherapy for ES-SCLC: Comparison between PD-1 and PD-L1 inhibitors in a real-world setting.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China, Shandong Cancer Hospital, Shandong First Medical University, Jinan, China,
Abstract
Meta-analysis of the efficacy and safety of anlotinib combined with chemotherapy in the treatment of small cell lung cancer.Org: Xianyang Central Hospital,
Abstract
Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization combined with intravenous chemotherapy for extensive-stage small cell lung cancer.Org: The Fifth Hospital Affiliated to Wenzhou Medical University, Fifth Affiliated Hospital of Wenzhou Medical College,
Abstract
Evaluating progression-free survival of EGFR exon 20ins in patients with advanced non-small lung cancer receiving EGFR inhibitors: A real-world data study.Org: BioSpark AI Technologies,
Abstract
First-line sintilimab combined with platinum-based chemotherapy in extensive stage small cell lung cancer: A phase II study and post-hoc biomarker analysis.Org: Shanghai Chest Hospital, Jiaotong University,
Abstract
The outcomes of atezolizumab therapy in combination with carboplatin and etoposide for small-cell lung cancer.Org: Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Tashkent, Uzbekistan,
Abstract
Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Respiratory Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China,
Abstract
PLWH and lung cancer: A single cancer center experience in Philadelphia, PA.Org: Thomas Jefferson University Hospital, Sidney Kimmel Medical College of Thomas Jefferson University, Thomas Jefferson University, Sidney Kimmel Cancer Center at Thomas Jefferson University,
Abstract
Elucidating the role of RBM10 in brain metastasis of EGFR19del lung adenocarcinoma.Org: Harbin Medical University Cancer Hospital,
Abstract
Genetic characteristics of cerebrospinal fluid-derived circulating tumor DNA in brain metastases of lung adenocarcinoma.Org: Rare Oncology Department, Affiliated Cancer Hospital of Shandong First Medical University, Department of Respiratory and Critical Care Medicine, The Second Hospital, Cheeloo College of Medicine, Department of Respiratory and Critical Care Medicine, Qilu Hospital of Shandong University, Department of Respiratory Medicine, Shandong Cancer Hospital and Institute,
Abstract
Outcomes in STK11-, KEAP1-, and KRAS-mutant lung squamous cell carcinoma (LSCC) with use of immune checkpoint inhibitors (ICIs).Org: Indiana University Melvin and Simon Comprehensive Cancer Center, Indianapolis, IN, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University – Purdue University Indianapolis, IU Simon Cancer Center,
Abstract
Effect of NIR-II on cancer nanocomposite vaccines for lymph node targeted delivery and enhanced immunotherapy.Org: School of Biomedical Sciences and Engineering,
Abstract
Tislelizumab combined with chemotherapy in advanced thymic tumors.Org: Nanjing Medical University,
Abstract
A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer.Org: First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology Co. Ltd,
Abstract
Preliminary results of a randomized controlled, open-label, multi-center phase II study of camrelizumab combined with chemotherapy followed by concurrent chemoradiotherapy and camrelizumab consolidation therapy versus standard chemoradiotherapy as first-line treatment for limited-disease small cell lung cancer.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shanghai Pulmonary Hospital, Shanghai, China, Tongji University School of Medicine, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Department of Pulmonary and Critical Care Medicine,
Abstract
Somatostatin analogues in the management of thymic epithelial tumors: A retrospective, single-center study.Org: Rare Tumors Coordinating Center of Campania Region (CRCTR),
Abstract
Heme-oxygenase-1: A potential biomarker for ICIs in patients with advanced lung cancer.Org: Department of Pharmacologican Sciences,
Abstract
Effect of P. gingivalis on osimertinib resistance in EGFR-mutant lung cancer.Org: City of Hope National Medical Center, Duarte, CA, Weizmann Institute of Science, Rehovot, Israel, City of Hope Comprehensive Cancer Center Department of Medical Oncology and Therapeutics Research,
Abstract
Effect of plasma-based molecular testing in patients with newly diagnosed advanced NSCLC on initiation of targeted agents in patients with targetable genomic alterations: A real world experience from the Middle East.Org: Sultan Qaboos Comprehensive Cancer Care and Research Centre,
Abstract
Are the results of clinical trials in patients with NSCLC reflected in real life? The Registurk-Lung study.Org: Necmettin Erbakan University, Kartal Dr Lutfi kirdar Education and Research Hospital, Medicalpark Adana Hospital, Sureyyapasa Chest Disease Hospital, University of Health Sciences Gülhane Education and Research Hospital,
Abstract
Safety in the use of granulocyte-colony stimulating factor during concurrent chemotherapy and thoracic radiotherapy in patients with small-cell lung cancer: A meta-analysis.Org: UNICAMP - State University of Campinas, Santa Marcelina College, Afya, Unipam, Evangélica University of Goiás,
Abstract
Tislelizumab combined with nab-paclitaxel single-agent chemotherapy plus bevacizumab for patients with EGFR-TKIs-resistant advanced NSCLC with ECOG PS 0-2.Org: National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital, Guangzhou Medical University, Department of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health,
Abstract
Ultra-short circulating tumor DNA (usctDNA): A new paradigm for ctDNA liquid biopsy.Org: National Chen Kung University Hospital, Tainan City, AIOnco Inc., National Institute of Standards and Technology,
Abstract
Effect of longitudinal ctDNA monitoring with resistance genomic signatures on prognostication in patients with EGFR-mutated advanced NSCLC.Org: Pune, Advanced Centre for Treatment Research and Education in Cancer, Navi Mumbai, Cupertino, CA,
Abstract
Effect of strong programmed cell death ligand-1 (PD-L1) expressions on clinical outcomes in advanced non-small cell lung cancer treated with third-generation epidermal growth factor receptor-tyrosine kinase inhibitors.Org: Ji Nan, Jin...,
Abstract
Correlation of gut dysbiosis biomarkers and peripheral thyroid hormones conversion in patients with (pts) advanced lung cancer.Org: ClinicObiome, 3Trees,
Abstract
Cardiotoxicity in tumor-bearing mice receving thoracic radiation plus tumor radiation and PD-1 inhibitor therapy.Org: Teaching and Research Department of Oncology, Clinical Medical College of Guizhou Medical University,
Abstract
The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) in advanced non-small cell lung cancer: A multicenter retrospective observational study in China.Org: School of Pharmaceutical Sciences, Shandong Provincial Third Hospital,
Abstract
Using machine learning approach based on gene expression profiling to predict the risk of bone metastasis in lung cancer.Org: Chengdu First People's Hospital,
Abstract
Ubiquitin ligase subunit FBXO9 inhibits V-ATPase assembly and lung cancer metastasis.Org: Nanjing First Hospital, Xiang’an Hospital of Xiamen University, Xiamen University,
Abstract
Malignant effusion aspirate for use in constructing organoids model to assist individualized treatment of advanced non-small cell lung cancer.Org: Hangzhou, Zhejiang, China, Hangzhou Jifu Technology Co., Ltd., Communication University of China No.1, Chaoyang District, Beijing, China,
Abstract
Implementing personalized lung cancer care with spatial profiling, patient derived organoids, and rationally designed drug testing.Org: University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, University of Colorado School of Medicine, Veterans Affairs Medical Center, University of Colorado Denver Anschutz Medical Center,
Abstract
Disparities in the prevalence of EGFR mutations and ALK rearrangements by racial-ethnic group in South Florida with a focus on Hispanic patients, 2011-2019.Org: Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami School of Medicine, Miami, FL, University of Miami Miller School of Medicine, Miami, FL,
Abstract
Impact of intratumor heterogeneity (ITH) on survival outcomes in patients with non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB-H).Org: Northwestern University Feinberg School of Medicine,
Abstract
What is a bad ALK? A scoping review of molecular markers of poor prognosis.Org: McMaster University and Juravinski Cancer Centre, Princess Margaret Cancer Centre, Department of Medical Oncology and Hematology, University Health Network, Hospital Sacré-Coeur de Montréal,
Abstract
Impact of concomitant H1 antihistamine administered during initiation of immune checkpoint inhibitor therapy on survival outcome and safety in patients with advanced primary lung cancer.Org: Tianjin Medical University Cancer Institute and Hospital, Tianjin, China,
Abstract
Are the clinical trials in lung cancer an advantage for patients in developing countries?Org: Ankara Yıldırım Beyazıt University Faculty of Medicine Department of Medical Oncology, Ankara City Hospital,
Abstract
Survival differences in advanced non-small cell lung cancer after developments in regimens with immune check point inhibitors: Population based retrospective study from United States SEER database.Org: Montgomery Regional Medical Campus,
Abstract
The efficacy and safety of furmonertinib in patients with advanced EGFR-mutated NSCLC and leptomeningeal metastases.Org: The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China,
Abstract
Health outcomes of pembrolizumab plus chemotherapy in non-small cell lung cancer.Org: Jaén, Spain, Jaen, Spain,
Abstract
Real-world effectiveness and safety of amivantamab for exon 20 EGFR-mutant non-small cell lung cancer (NSCLC) in French early access program: Amexon 20 GFPC.Org: Hospices Civils of Lyon, Hospital Morvan, Hospital Albert Calmette, CHU Saint-Denis La Réunion, Saint-Denis,
Abstract
Prospective observational study of nutritional and immunological indices as predictive biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer (ICI-PREDICT study).Org: Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Respiratory Medicine, NHO Iwakuni Clinical Center, Iwakuni, Japan, Department of Respiratory Medicine, NHO Nagoya Medical Center, Nagoya, Japan, Department of Respiratory Internal Medicine, NHO Higashihiroshima Medical Center, Higashihiroshima, Japan,
Abstract
Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in large population of non-small cell lung cancer.Org: School of Informatics, The University of Edinburgh,
Abstract
Single-cell transcriptome in the examination of the molecular characteristics of macrophages in lung cancer brain metastasis.Org: Department of Thoracic surgery, Huizhou Central People's Hospital, Huizhou, China,
Abstract
RBM10 mutation as a potential negative prognostic/predictive biomarker to therapy in non-small-cell lung cancer.Org: Department of Medical Oncology and Therapeutics Research, City of Hope National Cancer Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center,
Abstract
Efficacy and safety of time-of-day infusion of pemetrexed plus platinum and paclitaxel plus platinum for patients with advanced non-small cell lung cancer: A retrospective study.Org: Department of General Practice, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China, Guangdong Second Provincial General Hospital, Guangzhou, China, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China, Beijing Friendship Hospital, Beijing, China,
Abstract
Associations of early adverse events with clinical outcomes in patients with NSCLC treated with EGFR tyrosine kinase inhibitors.Org: National Taiwan University Cancer Center/Hospital, National Taiwan University Hospital Yunlin Branch,
Abstract
Current status of PD-(L)1 inhibitor usage in advanced or metastatic non-small cell lung cancer: A national survey of oncologists in China.Org: No. 960 Hospital, The People’s Liberation Army, Cancer Hospital of Chinese Academy of Medical Sciences, The Affiliated Tumor Hospital of Xinjiang Medical University, Henna Cancer Hosptal,
Abstract
A random forest model to predict the efficacy of anti-PD-1/PD-L1 monoclonal antibody in lung adenocarcinoma.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Autologous, oncolytic virus-activated killer (VAK) cell therapy to treat malignant pleural and peritoneal effusions.Org: Wuhan Binhui Biopharmaceutical Co, Ltd, National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering, Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology,
Abstract
Real-world clinical outcomes in Chinese patients with EGFR-mutated NSCLC progressed from first-line EGFR-TKI: A prospective multicenter study.Org: Department of Pulmonary and Critical Care Medicine, Precision Medicine Key Laboratory of Sichuan Province, Suzhou Municipal Hospital, Shenyang Chest Hospital, Medicine and Frontier Science Center of Disease Molecular Network,
Abstract
Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC).Org: Syndax Pharmaceutials, Inc., Tariffville, CT,
Abstract
Efficacy of compound pholcodine syrup and compound codeine phosphate oral solution on lung cancer cough.Org: Chongqing University Cancer Hospital, University Medical Center Groningen, Chongqing Cancer Hospital,
Abstract
Validation of article analysis by ChatGPT: Using a cohort of patients with EGFR mutation-positive non-small cell lung cancer treated with first-line osimertinib.Org: Sunto-Gun, Sunto-Gun Nagaizumi-Cho, 411-8777,
Abstract
Impact of timing of immunotherapy in survival among patients with advanced lung adenocarcinoma treated with first-line immunochemotherapy: A propensity score matching.Org: Shandong Second Medical University,
Abstract
Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, National Cancer Centre Singapore, Department of Clinical Oncology, Queen Elizabeth Hospital, The Chinese University of Hong Kong, Prince of Wales Hospital,
Abstract
First-line treatment of EGFR mutation adenosquamous carcinoma of the lung with aumolertinib: A multicenter, single-arm, prospective study (ARISE Study).Org: The Second Afiliated Hospital of Nanchang University, Tongji Medical College Huazhong University of Science and Technology, Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Jiaotong Uni,
Abstract
Impact of race and gender on outcomes from patients with stage IV non-small cell lung cancer receiving immunotherapy: A retrospective study performed at Mitchell Cancer Institute, Mobile, AL.Org: University of South Alabama Mitchell Cancer Institute,
Abstract
Exposure-response (ER) analyses of efficacy and safety of trastuzumab deruxtecan (T-DXd) to inform dosing recommendation in HER2-mutant non-small cell lung cancer (NSCLC).Org: Syndax Pharmaceuticals Inc.,
Abstract
Surufatinib monotherapy or combined with vinorelbine as a late-line therapy in patients with refractory advanced non–small cell lung cancer (NSCLC).Org: Affiliated Cancer Hospital & Institute of Guangzhou Medical University,
Abstract
5-hydroxymethylcytosine in cell-free DNA as liquid biomarker for immune checkpoint inhibitor therapy in non–small cell lung cancer.Org: Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston Methodist Hospital, Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Department of Medical Oncology, Center for Data Intensive Science at the University of Chicago,
Abstract
High-dose furmonertinib in combination with intraventricular chemotherapy for EGFR exon 20 insertion mutated lung adenocarcinoma with leptomeningeal metastasis.Org: Nanjing Chest Hospital, Nanjing Gaochun People's Hospital,
Abstract
Mapping incidence and survival of non-small-cell lung cancers stratified by mutation type in southern Appalachia: A single center retrospective study.Org: East Tennessee State University, East Tennessee State University Quillen College of Medicine, Department of Medical Education,
Abstract
Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the US.Org: Shaanxi Provincial People’s Hospital, Shaanxi Provincial People's Hospital,
Abstract
Interchangeability of anti-PD1 antibodies in patients (pts) with metastatic NSCLC.Org: Moskovskii Mnogoprofilnyi Klinicheskii Tcentr Kommunarka Departamenta Zdravoohraneniia Goroda Moskvy, N.N. Blokhin National Medical Cancer Research Center of the Ministry of Healthcare of the Russian Federation, Federal State Budgetary Institution N.N. Blokhin National Medical Research Center of Oncology, Clinical and Scientific Research Practical Oncological Center, Saint Petersburg Scientific Practical Center of Specialized Kinds of Medical Care,
Abstract
Effect of first-line bevacizumab on prognosis of second or later-line immunotherapy in patients with advanced non-squamous non-small cell lung cancer: A retrospective analysis.Org: Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan YZY Biopharma, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Qilu Hospital of Shandong University, Jinan,
Abstract
First- and second-line biomarker utilization in non-small cell lung cancer.Org: Cedars-Sinai Medical Center, Los Angeles Medical Center, CanSino Biologics,
Abstract
Efficacy and safety of PD-1 inhibitors plus metronomic oral vinorelbine in elderly pre-treated patients with metastatic non-small-cell lung cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Characteristics, treatment patterns, and prognostic factors in small cell lung cancer transformation of advanced non-small cell lung cancer with epidermal growth factor receptor mutation after tyrosine kinase inhibitor therapy.Org: Taipei Veterans General Hospital, Taipei Medical University Hospital,
Abstract
Response to first-line therapies in metastatic lung adenocarcinoma with low PD-L1 expression: A multi-center retrospective study.Org: Shandong University Cancer Center,
Abstract
A single-arm phase II study of platinum doublet induction chemotherapy combined with toripalimab for driver gene-negative advanced NSCLC.Org: Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Clinical Oncology School of Fujian Medical University,
Abstract
Dermatologic adverse events in EGFR-TKIs: A real-world analysis.Org: Oregon Health & Science University,
Abstract
Efficacy and safety of second-line immunotherapy in patients with advanced non-small cell lung cancer.Org: Hospital Juan Ramón Jiménez, Hospital Juan Ramon Jimenez, Aodo Asociación Onubense Para,
Abstract
Analysis of thromboembolic events in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: A single-center real-world study.Org: Ajou University School of Medicine, Department of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL,
Abstract
Stage IV non-small cell lung cancer in Veterans undergoing lung cancer screening who were not prescribed statins despite U.S. Preventative Services Task Force recommendations.Org: Jesse Brown VAMC, Jesse Brown Va Med Ctr, Division of Research Services,
Abstract
Blood based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer: The IOpener study.Org: Radbound University Medical Center, Elisabeth Tweesteden Hospital, Diakonessenhuis, PamGene International B.V., Amsterdam Medical Center,
Abstract
Effects of lack of access to cancer medication on survival of patients with lung cancer.Org: Naef K. Basile Cancer Institute, American University of Beirut Medical Center,
Abstract
Sugemalimab in locally advanced and advanced Chinese NSCLC: A real-world retrospective study.Org: Department of Medical Oncology, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, Department of Medical Oncology, Beijing Chaoyang Sanhuan Cancer Hospital, Beijing, Beijing, China, Department of Medical Oncology, Cancer Hospital of HuanXing, ChaoYang District, Beijing, Beijing, China, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Pek, Beijing, China,
Abstract
Anti-cancer activity of NTAX-44 (bioprocessed arsenic trioxide) on lung cancer.Org: National Centre for Cell Science, Tata Chemicals, Rasayani Biologics Pvt. Ltd.,
Abstract
PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1 negative metastatic lung adenocarcinoma: A real-world data.Org: Shandong University Cancer Center, Shandong Second Medical University,
Abstract
Prognostic factors for survival in NSCLC treated with immunotherapy: An institutional analysis.Org: Stony Brook University Hospital - Cancer Center, Tufts Medical Center/Tufts University,
Abstract
Real-world KRAS testing and treatment utilization among patients with metastatic non-small cell lung cancer.Org: Integra Connect PrecisionQ, Integra Connect,
Abstract
Physical activity (PA) impact on metabolome and immunity of oncogene addicted non-small cell lung cancer (NSCLC): The EXcellenT trial.Org: Santa Maria delle Croci hospital Ravenna, AUSL della Romagna, Ravenna, UniSR, Servizio di Medicina dello Sport,
Abstract
Prognostic factors and long-term survivors in EGFR-mutated lung cancer: A multi-institutional retrospective analysis.Org: Chang-Gung Memorial Hospital, Chiayi, Chiayi Chang Gung Memorial Hospital, Puzi City, Chang Gung Memorial Hospital Chiayi Branch,
Abstract
Comparing the efficacy of two generations of EGFR-TKIs: An integrated drug-disease mechanistic model approach in EGFR-mutant lung adenocarcinoma.Org: Novadiscovery, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, France; Cancer Research Center of Lyon (INSERM 1052, CNRS 5286), Lyon, France; Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France, Hospices Civils de Lyon Cancer Institute,
Abstract
Cost-efficiency and expanded access modeling of toripalimab versus pembrolizumab in locally advanced or metastatic nonsquamous non-small cell lung cancer.Org: Matrix45 LLC, Coherus Biosciences, University of Arizona of Pharmacy, Center for Health Outcomes and PharmacoEconomic Research, University of Arizona Cancer Center,
Abstract
Real-world data analysis of first-line targeted therapy for patients with non-small cell lung cancer with different EGFR mutation status in a tertiary care hospital.Org: Affiliated Hospital of North Sichuan Medical College, Nanchong, China, NanChong, Sichuan, Nanchong, China,
Abstract
Overall survival (OS) in a u.s. Asian population with stage IV NSCLC with EGFR mutations treated with first-line (1L) osimertinib (Osi) compared to earlier generation (Gen) of TKIs or sequential treatment (Tx).Org: NYU Langone Health, New York, NY, NYU Grossman School of Medicine, Department of Population Health, New York Oncology Hematology PC, NYU Perlmutter Cancer Center, Perlmutter Cancer Center, New York University Langone Health,
Abstract
Real-world outcomes comparison between the MET inhibitors (METi) capmatinib and tepotinib in patients with stage IV non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation.Org: Mayo Clinic Florida, Mayo Clinic,
Abstract
Real-world costs and outcomes associated with biomarker testing by comprehensive genomic profiling (CGP) and non-CGP approaches among patients with metastatic non-small cell lung cancer (mNSCLC).Org: Optum, Eden Prairie, MN, Illumina, Inc., San Diego, CA, Cambridge University Hospitals NHS Foundation Trust,
Abstract
Prevention of pemetrexed-induced rash with low-dose dexamethasone in patients with NSCLC receiving immunotherapy: A prospective, single-arm clinical trial.Org: Department of Oncology, the Second People's Hospital of Yibin, Yibin, China, Department of Oncology, the Second People's Hospital of Yibin, Yibin, SIchuan, China, Department of Oncology,the Second People's Hospital of Yibin City, Yibin, China,
Abstract
Genomic profiling of lung adenocarcinoma and squamous carcinoma in Indian patients: Implications for precision oncology.Org: Kidwai Memorial Institute of Oncology, Manipal Hospital,
Abstract
Spectrum of HER2 alterations in NSCLC: Comparative analysis of tissue and liquid biopsies in lung cancer.Org: Care Hospital,
Abstract
First-line immunotherapy in patients with mNSCLC with rare molecular alterations.Org: Policlinico Agostino Gemelli- Università Cattolica Sacro Cuore,
Abstract
Prediction of oncogene mutation status in non-small cell lung cancer leveraging radiomics from CT scans: A systematic review and meta-analysis with a special focus on artificial-intelligence-based methods.Org: Quantitative Imaging Biomarkers in Medicine, Quibim, Madrid, Spain, Quantitative Imaging Biomarkers in Medicine, Quibim, Valencia, Spain, Quantitative Imaging Biomarkers in Medicine, Quibim, Boston, MA, Área Clínica de Imagen Médica, Hospital Universitari i Politècnic La Fe, Valencia, Spain, Department of Medical Oncology, Hospital Universitario Santa Lucía, Cartagena, Murcia, Spain,
Abstract
Impact of radiation dose to the immune cells in stage IV non-small cell lung cancer in the era of immunotherapy.Org: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University , Jinan, China, Jinan, No, China, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University , Jinan, China, China, China, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China, Jinan, Shandong, China,
Abstract
Exploring the significance of MET overexpression by gene expression profiling versus immunohistochemistry in an EGFR-mutant lung cancer cohort.Org: Medanta Medicity, Gleneagles BGS Hospital, Sahyadri Hospital, HCA Healthcare UK, Metro Hospital,
Abstract
Prognostic nomogram for overall survival in patients with stage IV non-small cell lung cancer treated with chemotherapy combined with high-dose thoracic radiotherapy.Org: The Affiliated Cancer Hospital of Guizhou Medical University,
Abstract
Efficacy of systemic treatments in patients with metastatic lung invasive mucinous adenocarcinoma.Org: Meram Faculty of Medicine, Marmara University Hospital, Ankara Atatürk Sanatoryum Education and Training Hospital,
Abstract
Unleashing deep features and radiomics to enhance best overall response prediction to immunotherapy in advanced non-small cell lung cancer.Org: Quantitative Imaging Biomarkers in Medicine, Quibim, Madrid, Spain, Quibim,
Abstract
Analysis of the LIPI score as a prognostic factor in advanced non-small cell lung cancer.Org: Ionc Instituto Oncologico De Cordoba, Instituto Oncologico de Cordoba, Oncology Institute of Cordoba,
Abstract
Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria.Org: The University of Texas at Austin,
Abstract
Double lung transplantation in patients with recent history of malignancy.Org: Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL, Feinberg School of Medicine,
Abstract
Ethnic disparities in biomarker testing of patients with metastatic NSCLC in the United States: A real-world analysis.Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Miami, FL, John Hopkins University, Baltimore, MD,
Abstract
Lung cancer in females from nonsmoker families in India: Observations and inferences in 5 years.Org: Nanjappa Life Care Hospital, Shimoga, India,
Abstract
Unveiling disparities: Metastatic lung cancer incidence across income strata in metropolitan residencies.Org: McLaren Flint, McLaren Lansing, Authority Health,
Abstract
The patient outcomes with EGFR-mutated advanced non-small-cell lung cancer receiving aumolertinib as first-line treatment.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University of Traditional Chinese Medicine Affiliated Hospital, School of Pharmaceutical Sciences,
Abstract
Sex influence on cancer immunotherapy efficacy and safety in advanced non-small cell lung cancer (NSCLC): A Canadian institution real-world experience.Org: Peter Brojde Lung Cancer Centre,
Abstract
Safety and efficacy of osimertinib plus bevacizumab as first-line treatment in EGFR-mutant NSCLC with brain metastases: A dynamic ctDNA-guided study.Org: Beijing Fengtai District,
Abstract
Time-to-treatment for metastatic non-small cell lung cancer in the era of biomarker testing.Org: McLaren Cancer Institute, Flint, MI, Dept of Med. Michigan State University, Lansing, MI, Karmanos of Lansing (Lansing, MI),
Abstract
Immunotherapy in stage IV non-small cell lung cancer according to racial characteristics and community of residence.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Tisch Cancer Institute,
Abstract
A comparison of real-world incidence of EGFR exon 20 insertion mutations among patients with NSCLC in five Asian markets, stratified by testing methodology.Org: Malaysia,
Abstract
Mutation pattern of EGFR gene in Peruvian patients with non-small cell lung cancer.Org: Oncogenomics,
Abstract
Real-world outcomes of osimertinib in Peruvian patients with advanced NSCLC with EGFR T790M-positive: A multi-institutional experience.Org: Hospital Centro Médico Naval, Hospital Nacional PNP, Hospital Central FAP, Clinica Good Hope,
Abstract
Hematology/oncology clinical investigator training: Is current model of education adequate?Org: University of Chicago, Loyola University Maryland, University of Colorado School of Medicine, University of Chicago Medical Center, Chicago, IL,
Abstract
Evaluating speaker gender in scientific sessions at ASCO and ASCO GI (2019-2023).Org: University of Arizona Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Yale School of Medicine,
Abstract
Are we bridging the gap? A ten-year probe into NIH grants for early-career and independent investigators in oncology.Org: USF Morsani College of Medicine GME, Bayonet Point Hospital, Hudson, FL, Auburn, AL, New Port Richey, FL,
Abstract
Knowledge and confidence gaps in differentiating PARP inhibitors among community oncology providers.Org: Vindico Medical Education,
Abstract
Assessing gender disparities in oncology: Less talk, more action.Org: University of Miami Sylvester Comprehensive Cancer Center, Capital Health, University of California Irvine, Mayo Clinic, Dana-Farber Cancer Institute,
Abstract
Implementation of hematology oncology lecture series for nursing staff.Org: New York Medical College - Saint Michael's Medical Center, Valhalla, NY, Westchester Medical Center,
Abstract
A multicenter analysis evaluating educational resources utilized by hematology/oncology fellows (HOF).Org: Division of Hematology and Oncology, Indiana University Simon Cancer Center,
Abstract
A longitudinal, palliative care educational pilot in hematology-oncology fellowship training.Org: Princeton Health,
Abstract
Unveiling oncologists' geographical journey: Analyzing hematology/oncology fellowship graduates' relocation patterns and their impact on regional disparities in cancer care.Org: Kiran C Patel College of Osteopathic Medicine, Wellstar Spalding Medical Center,
Abstract
Artful oncology: A comprehensive psychosocial oncology curriculum for hematology/oncology fellows.Org: Inova Schar Cancer Institute, Fairfax, VA, Yale School of Medicine, Bridgeport, CT,
Abstract
Revolutionizing global hematology-oncology education: Assessing the two-year impact of a digital platform on socioeconomic equity and inclusivity against gender disparities.Org: Dickinson College, Parker University, Tbilisi State Medical University, Baroda Medical College, Kalamazoo Valley Community College,
Abstract
The effect of an online micro CE/CME on the multidisciplinary care of patients with nonmelanoma skin cancer.Org: Medscape LLC, George Washington University Hospital,
Abstract
Behavioral analysis of social media and email usage among hematology-oncology fellowship applicants: A national survey.Org: Manipal College of Medical Sciences,
Abstract
The impact of online CME on clinicians’ ability to utilize immunotherapy in unique populations of patients with NSCLC.Org: Medscape LLC, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill,
Abstract
Enhancing oncologist knowledge and skills through patient-centric medical education: A collaborative approach with LUNGevity.Org: PVI, PeerView Institute for Medical Education, LUNGevity Foundation, Bethesda, MD, Lombardi Comprehensive Cancer Center, Georgetown University,
Abstract
Longitudinal curriculum to address wellness and professional development in a hematology/oncology fellowship program.Org: Yale New Haven Health,
Abstract
Effect on patient empowerment through the EPEP program.Org: Patient Empowerment Network, Bothell, WA,
Abstract
Fostering collaborative care in multiple myeloma: The impact of holistic education on decision-making with antibody and CAR-T platforms.Org: PVI, PeerView Institute for Medical Education, HealthTree Foundation, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Community oncology preparedness and perceptions of challenges in care with HER2/HER3 therapy for NSCLC.Org: Needham, MA,
Abstract
Impact of a 1-day disease overview session on knowledge and preparedness for incoming hematology/oncology fellows.Org: University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,
Abstract
A retrospective study of tislelizumab combined with bevacizumab, pemetrexed, and carboplatin in driver-gene mutated advanced non-squamous non-small cell lung cancer after tyrosine kinase inhibitors failure.Org: The Second Affiliated Hospital of Zunyi Medical University,
Abstract
Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.Org: Tianjin Lung Cancer Center, Charleston Oncology, Centre Hospitalier de l'Universite de Montreal, Institutul Oncologic Bucureşti Prof. Dr. Alexandru Trestioreanu, Azienda Unita Sanitaria Locale della Romagna,
Abstract
Tracking the information-seeking patterns and preferences of US-based medical oncologists (MOs): A 2-year longitudinal assessment.Org: Research To Practice, Key Biscayne, CE Outcomes,
Abstract
Assessing clinician familiarity with integrative oncology and uptake of an electronic medical record–based education resource.Org: UCLA Department of Medicine, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan,
Abstract
Empowering tomorrow's oncologists: Establishing an oncology student interest group to propel careers in cancer care.Org: University of Minnesota Medical School, MetroWest Medical Center,
Abstract
A medical school curriculum to foster the physician-patient relationship through narrative medicine.Org: Yale School of Medicine, Yale University,
Abstract
Effectiveness of online activities to reinforce multidisciplinary management of advanced soft tissue sarcoma and extend education globally.Org: i3 Health, Oncology Data Advisor,
Abstract
Hidden advertisements included in cancer information posts: Insights from social listening.Org: Dongguk University Ilsan Medical Center, Inha University School of Medicine and Hospital, Division of Communication and Media, Ewha Womans University, Department of Media and Communication Studies, Jeonbuk National University, Department of Oncology and Hematology, Soonchunhyang University Hospital Cheonan,
Abstract
Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma.Org: University Hospitals Sussex NHS Foundation Trust, Churchill Hospital and the University of Oxford, Churchill Hospital and University of Oxford,
Abstract
The impact of an inclusion council in an independent community oncology practice.Org: Lake Wright Cancer Center, Chesapeake, VA, Williamsburg, VA,
Abstract
Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma (HCRN MEL17-309).Org: University of Miami Bascom Palmer Eye Institute,
Abstract
Descriptive and content analysis of breast cancer vlogs on YouTube.Org: St. Mary's Research Centre,
Abstract
Melanoma brain metastasis treated with stereotactic radiosurgery (SRS) and systemic agents (SACT): A single centre perspective from Northeast England.Org: National Health Service, Northern Centre for Cancer Care (NCCC), Northern Center for Cancer Care,
Abstract
A phase 2 safety and efficacy study of neoadjuvant/adjuvant darovasertib for localized ocular melanoma.Org: Queensland Institute of Medical Research Berghofer, Royal Victorian Eye and Ear Hospital, St. Vincent's Pathology, Terrace Eye Centre, The Alfred/Monash University,
Abstract
Clinical outcomes after adjuvant anti-PD1 therapy for high-risk resectable melanoma and predictors of response.Org: Univeristy of Utah, Intermountain Medical Center,
Abstract
Real world experience of bispecific fusion protein in patients with metastatic uveal melanoma: Can we deliver?Org: Bristol Cancer Institute,
Abstract
A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-Squamate.Org: Princess Alexandra Hospital and Faculty of Medicine at University of Queensland, Royal Brisbane & Womens Hospital,
Abstract
Real-world treatment patterns and outcomes of patients with advanced melanoma treated with nivolumab plus relatimab.Org: Georgetown University School of Medicine,
Abstract
OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma.Org: Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, Obsidian Therapeutics, Cambridge, MA,
Abstract
First-line of penpulimab and chemotherapy for advanced non-melanoma cutaneous carcinoma: A single center, single arm, exploratory study.Org: Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Huaiyin District Jinan, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China, Department of Radiation Oncology and Radiology,
Abstract
Target trial emulation with real-world data to determine the population-level cost-effectiveness of multi-gene panel sequencing in advanced melanoma.Org: BC Cancer Research Institute,
Abstract
Survival in de novo metastatic merkel cell carcinoma according to sites of metastases.Org: Dana-Farber Cancer Institute, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA, Harvard Medical School,
Abstract
Spatially mapping the single-cell immune landscapes of melanoma brain metastases using imaging mass cytometry.Org: Mcgill University/MUHC, Montreal neurological hospital, Royal Victoria Hospital/Glen Site/Cedar Cancer Centre,
Abstract
First-line therapy for metastatic uveal melanoma: Experience from a single reference center.Org: FSBI “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, Pirogov Russian National Research Medical University, Moscow, Russian Federation, Kostroma regional Cancer Centre, Kostroma, Russian Federation, Center for Innovative Medical Technologies, Moscow, Russian Federation, S.N. Fedorov NMRC MNTK Eye Microsurgery, Moscow, Russian Federation, N.N. Blokhin National Cancer Research Center, Moscow, Russian Federation,
Abstract
Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.Org: Université Paris Cité, AP-HP Dermato-Oncology and CIC, Cancer Institute APHP, Aix-Marseille University, CEPCM, and CHU de La Timone APHM, Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron Hospital Medical Oncology Department, Leeds Institute of Medical Research at St. James’s, University of Leeds, Jonsson Comprehensive Cancer Center, University of California Los Angeles,
Abstract
Long term outcomes of patients with advanced/unresectable melanoma treated with immune checkpoint inhibitors.Org: BC Cancer-Vancouver Centre, BC Cancer, Vancouver, BC Cancer, Abbotsford, BC Cancer Agency Vancouver Island Centre, BCCA,
Abstract
Characterizing the tumor and immune landscape of patients with melanoma treated with combined checkpoint blockade and MAPK-targeted therapy.Org: Division of Oncology, Rambam health care, Haifa, Israel, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel,
Abstract
Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era.Org: Yale School of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale-New Haven Hospital,
Abstract
Treatment-free survival after immunotherapy discontinuation in advanced melanoma: A systematic review and meta-analysis of real-world studies.Org: Dartmouth Health,
Abstract
Enhanced dacarbazine efficacy in advanced melanoma patients previously treated with immune checkpoint inhibitors in Korea.Org: Ulsan, South Korea,
Abstract
Real world tebentafusp-tebn experience at a tertiary care referral center.Org: Sidney Kimmel Cancer Center at Thomas Jefferson University, Thomas Jefferson University, Philadelphia, PA,
Abstract
Characteristics of patients with metastatic malignant melanoma in Colombia: Results of the Epidemiologic Registry of Malignant Melanoma REMMEC ACHO.Org: ICCAL Hospital Universitario Fundacion Santa Fe de Bogota, Asociacion Colombiana de Hematologia y Oncologia ACHO, Fundación valle del Lili, Universidad El Bosque, Fundación Cardioinfantil,
Abstract
Prospective real-world evidence for the use of immune-checkpoint inhibitors and BRAF-targeted therapy in advanced melanoma from a large Canadian cohort.Org: Pulse Infoframe, Niagara Health System Walker Family Cancer Centre, Credit Valley Hospital,
Abstract
Efficacy and safety of combined anti-angiogenic chemoradiotherapy with PD-1 monoclonal antibody in advanced melanoma: A retrospective study.Org: Department of the Comprehensive Cancer Center, Drum Tower Hospital, the Afffliated Hospital of Nanjing University Medical School,
Abstract
Nivolumab combined with high dose multisite radiotherapy in previously untreated advanced melanoma (NIRVANA): A non-randomised, open-label, multicenter, phase 2 trial.Org: Dermatology Department, Université Côte d'Azur, CHU de Nice, Nice, France,
Abstract
Correlation of previous local vaccination site “flares” during immunotherapy for metastatic melanoma with complete responses to therapy.Org: NewYork-Presbyterian/Weill Cornell Medicine, NewYork-Presbyterian Hospital/Weill Cornell Medicine, Weill Cornell Medical Center/NewYork-Presbyterian,
Abstract
Longitudinal circulating tumor DNA kinetics and correlation with patient outcomes in metastatic melanoma.Org: Rush University Medical Center, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center,
Abstract
A phase II study of tunlametinib in combination with vemurafenib in patients with BRAF V600-mutant advanced melanoma.Org: Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated hospital of Medical School, Nanjing University., Nanjing, China, Department of Melanoma Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China, Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, Department of Head and Neck and Rare Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China, Shanghai Kechow Pharma, Shanghai, China,
Abstract
Examining the risk of immune checkpoint inhibitor-related toxicity among patients with melanoma and their history of cannabis use.Org: Fairfield Medical Center, West Virginia University School of Medicine, Suny Downstate Health Sciences University, George Washington University School of Medicine and Health Sciences, Charleston Area Medical Center (CAMC) Health Education and Research Institute,
Abstract
Clinical and epidemiological profile of patients with atypical melanomas treated with immunotherapy.Org: A.C. Camargo Cancer Center, São Paulo, Brazil,
Abstract
A multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable/metastatic mucosal melanoma.Org: Fujian Cancer Hospital, Sun Yat-sen University Cancer Center Gansu Hospital, West China Hospital, Union Hospital, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,
Abstract
Exploring the correlation between high HRD status and immunotherapy response in melanoma.Org: Lombardi Comprehensive Cancer Center, Washington, DC, Division of Medical Oncology, Department of Medicine, Washington University in St. Louis, St. Louis, MO,
Abstract
CD44 and CD271 expression and chemoresistance in BRAF V600E/K mutation–positive melanoma.Org: A.T. Still University, Kirksville, MO,
Abstract
Temozolomide and nivolumab in patients with refractory metastatic melanoma (MM).Org: Vanderbilt University Medical Center,
Abstract
Real-world effectiveness and safety of dabrafenib-trametinib as first-line of treatment for BRAF mutated metastatic melanoma: Results of the study GEM1801.Org: Unidad Intercentros de Oncología, Hospitales Universitarios Regional y Virgen de la Victoria (HURyVV), Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Instituto Murciano de Investigación Sanitaria (IMIB), Hospital Universitario Clínico San Carlos,
Abstract
Peripheral blood biomarkers in immune checkpoint inhibition therapy in metastatic melanoma.Org: SUNY Upstate Medical University, SUNY Upstate University Hospital,
Abstract
Case series: Outcomes of immunotherapy in locally advanced and metastatic cutaneous squamous cell carcinoma in Lakes and Waikato region.Org: Waikato Hospital, Te Whatu Ora Lakes,
Abstract
NRAS mutation in melanoma: Association of codon-specific changes on patient outcomes.Org: Huntsman Cancer Institute at the University of Utah, Caris Life Sciences, Irving, TX, Irving, TX, Phoenix, AZ, UC San Diego Moores Cancer Center,
Abstract
Impact of sex on immune-related adverse events in patients with melanoma.Org: Universitiy of Campania "Luigi Vanvitelli", AOU Università degli Studi della Campania L. Vanvitelli,
Abstract
Mathematical modeling of routine biological parameters kinetics in order to predict durable benefit for first-line immunotherapy in metastatic or unresectable melanoma.Org: CRCM Inserm U1068,
Abstract
Axitinib in combination with anti–PD-1 ab (pucotenlimab) plus intra-hepatic injection of oncolytic virus (OH2), in patients with mucosal melanoma and liver metastasis: An open-label phase I trial.Org: Department of Melanoma and Sarcoma Oncology,
Abstract
Responses to immune checkpoint inhibitor therapy in NF1 mutated cutaneous melanoma.Org: Holden Comprehensive Cancer Center, University of Iowa Hospitals & Clinics, University of Iowa Hospitals and Clinics,
Abstract
Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study.Org: Department of Melanoma and Sarcoma Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Department of Genitourinary Oncology, Melanoma Institute Australia, Sydney, Australia,
Abstract
RNA expression-based risk stratification of stage III cutaneous melanoma.Org: University of Iowa Hospitals and Clinics, Independent Researcher,
Abstract
Multicenter clinical trial of DNA markers for non-invasive differential diagnosis of benign and malignant melanocytic lesions.Org: N.N.Blokhin NMRC of Oncology MoH of Russia, Department of Molecular Technologies Research Institute of Translational Medicine Federal State Autonomous Educational Institution of Higher Education N. I. Pir, Department of Molecular Technologies Research Institute of Translational Medicine N. I. Pirogov Russian National Research Medical University, Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation, State Budgetary Healthcare Organisation “Clinical Oncology Dispensary No.1” under the Ministry of Healthcare of Krasnodar region (SBHI COD №1),
Abstract
Ulcer-related cutaneous squamous cell carcinoma: New kid on the block.Org: Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel, Department of Radiation Oncology, Tel Aviv Medical Center, Tel Aviv, Israel, Department of Radiation Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Tel Aviv-Yafo, Israel,
Abstract
Sex as a predictor of progression-free survival in sentinel node-negative stage II melanoma.Org: University of Oxford, Oxford University Hospitals NHS Foundation Trust,
Abstract
Neoadjuvant immunotherapy in clinical stage III melanoma: Real life experience in the community setting.Org: The T.W. Lewis Melanoma Center of Excellence, Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Internal Medicine Residency at BUMC,
Abstract
Cutaneous melanoma during pregnancy: Management and real-world outcomes.Org: Mayo Clinic - Department of Maternal Fetal Medicine,
Abstract
Dendritic cell vaccine as a strategy to prevent melanoma recurrence after local resection: A systematic review and meta-analysis.Org: Federal University of Piaui, University of São Paulo/ICESP, Departament of Urology, Catholic University of Pernambuco, Federal University of Juiz de Fora,
Abstract
Gene signature to predict hypophysitis in patients with melanoma treated with anti-PD-1 in adjuvant setting.Org: Istituto Nazionale Tumori IRCCS G. Pascale, IRCCS Fondazione Pascale Napoli, Instituto Nazionale Tumori – IRCCS – Fondazione G. Pascale, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale,
Abstract
Comprehensive genomic and immune profiling of non-V600 BRAF-mutated melanomas: Implications for therapeutic strategies beyond BRAF/MEK inhibitors.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Durham, NC, Labcorp, Burlington, NC, Fortrea Inc., Durham, NC,
Abstract
Options for enhancing specific antitumor immunity in patients with melanoma.Org: State Autonomous Budgetary Healthcare Institution, Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan, Bashkir State Medical University, NRC Institute of Immunology FMBA of Russia, Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of Sciences,
Abstract
Detection of molecular residual disease in stage II and III melanoma utilizing circulating tumor DNA.Org: Rush Medical College of Rush University,
Abstract
Cisplatin-vinblastine-temozolomide regimen for patients with relapsed-refractory melanoma who are ineligible for clinical trials: A tertiary care center experience.Org: University Hospitals Seidman Cancer Center, University Hospitals Case Medical Center Rehabilitation Services, University Hospitals Cleveland Medical Center, University Hospitals Sussex NHS Foundation Trust,
Abstract
Malignant blue nevus: Epidemiology, socioeconomic factors, and disease presentation.Org: Creighton University School of Medicine Phoenix Regional Campus, Grand Canyon University, Arizona State University, Brandeis University, University of Arizona College of Medicine, Phoenix, AZ,
Abstract
Geospatial analysis of the distribution of uveal melanoma patients at a referral center in the United States.Org: Biostatistics Scientific Collaboration Center, Ocular Oncology Service, Wills Eye Hospital,
Abstract
Toripalimab (anti-PD-1) plus recombinant human endostatin as adjuvant therapy in patients with resected stage III melanoma: Interim analysis of an open-label phase II trial.Org: Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine,
Abstract
Comparison of adjuvant targeted and anti-PD1 immunotherapy in BRAF-mutated stage III cutaneous melanoma: Retrospective, single center cohort study.Org: N.N.Blokhin NMRC of Oncology MoH of Russia,
Abstract
PD-1 inhibitors versus conventional therapies for adjuvant treatment of resected acral melanoma: A systematic review and meta-analysis.Org: Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Fudan University (Xiamen Branch), Department of Musculoskeletal Oncology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Epidemiology and clinical management of primary penile melanoma: A review of the National Cancer Database.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton Hematology Oncology, Omaha, NE,
Abstract
Mucosal melanoma treatment patterns and outcomes in real clinical practice: Single institution experience.Org: Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine" of the Ministry of Health of Russia,
Abstract
Immunotherapy toxicity prediction in patients with melanoma using machine learning algorithms.Org: GKT School of Medicine, Curenetics Ltd, School of Physics, Engineering and Computer Science, CurenX, Precision Health, St. George’s Hospital,
Abstract
Analysis of neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma using the SWOG S1801 event-free survival definition.Org: A.C. Camargo Cancer Center, São Paulo, Brazil,
Abstract
Median Breslow thickness during, post and pre-COVID-19 lockdown and correlation with socioeconomic factors.Org: WSU/DMC,
Abstract
Endoscopic surgery combined chemoradiotherapy and PD-1 blockade in patients with sinonasal mucosal melanoma.Org: Eye & ENT Hospital, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd., Shanghai, China; EENT Hospital,
Abstract
Risk score stratification of cutaneous melanomas based on whole slide images using deep learning.Org: Oncodermatology Department,
Abstract
Immunosuppressant drug-associated skin cancer: A real-world pharmacovigilance database analysis.Org: Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, Department of Cardiovascular Medicine, Section of Vascular Medicine, Vascular and Thoracic Institute,
Abstract
Clinical significance of HER2 expression between primary tumors and metastatic lymph nodes in patients with extramammary Paget's disease.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, Guangdong Provincial Clinical Research Center for Cancer, Department of Urology Oncological Surgery, Chongqing University Cancer Hospital,
Abstract
Socioeconomic and demographic factors in multifocal superficial basal cell carcinoma: An NCDB analysis.Org: University of Notre Dame,
Abstract
Phase III randomized trial evaluating tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE 301).Org: Université Lille, Vseobecna fakultni nemocnice v Praze, Biomedicine Institute of Seville (IBIS)/CSIC, University Hospital Virgen Macarena and School of Medicine, lstituto Tumori Giovanni Paolo II,
Abstract
A multi-assay liquid biopsy approach to improve detection of bone and soft tissue sarcomas.Org: Albert Einstein College of Medicine, University of Chicago, University of Colorado at Denver - Anschutz Medical Campus, Montefiore Einstein Center for Cancer Care,
Abstract
Real world experience of molecular landscape of uveal melanomas: Implications for personalized medicine strategies.Org: Leaders in Oncology Care, HCA Healthcare UK,
Abstract
Comparing the impact of insufficient physical activity on cardiovascular disease in survivors of childhood Hodgkin lymphoma and sibling controls: A report from the Childhood Cancer Survivor Study (CCSS).Org: Shiga University,
Abstract
iCatalog: An open-source, collaborative platform for precision oncology studies.Org: Primary Children’s Hospital,
Abstract
Interpretable artificial intelligence-based analysis for morphologic classification of neuroblastic tumors.Org: University of Chicago Pritzker School of Medicine, Children's Hospital of Philadelphia, University of Chicago, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, Stanford University Medical Center, Stanford, CA,
Abstract
Impact of breaks in therapy on survival for pediatric patients with relapsed or refractory solid tumors: A single-center study.Org: UCSF Benioff Children’s Hospitals, Northern Illinois University,
Abstract
Tamoxifen for breast cancer prevention among survivors of pediatric lymphoma previously treated with chest radiation: Clinical benefits, harms and tradeoffs.Org: Harvard Kenneth C. Griffin Graduate School of Arts and Sciences, Department of Family & Social Medicine,
Abstract
Treatment modifications and mortality among female patients with subsequent breast cancer: A report from the Childhood Cancer Survivor Study (CCSS).Org: Northwestern Medicine Lake Forest Hospital,
Abstract
Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.Org: Saint John of God Subiaco Hospital,
Abstract
Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.Org: Deparment of Medical Oncology, IRCCS Ospedale Policlinico San Martino, Immunotherapy and Cell Therapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, IRCCS Istituto Oncologico di Bari Giovanni Paolo II, Oncology Department, Institute of Dermatology, Catholic University Fondazione Policlinico Universitario, Medical Oncology Unit, Department of Oncology, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro,
Abstract
Multidisciplinary PAIN management features of pediatric oncology patients in a pediatric cancer center in Turkiye: A developing country experience.Org: Ankara University, School of Medicine Department of Pedaitric Oncology, Ankara University Faculty of Medicine, Ankara University, School of Medicine, Dept of Pediatric Oncology, Ankara University, School of Medicine, Dept of Pediatrics, Ankara University, School of Medicine, Dept of Anesteshiology and Algology,
Abstract
Association of elevated ctDNA burden following one cycle of chemotherapy with inferior outcomes for patients with metastatic Ewing sarcoma: A report from the Children’s Oncology Group (COG).Org: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Children's Oncology Group Statistics and Data Center, University of Florida, Broad Institute of MIT and Harvard, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Memorial Sloan Kettering Cancer Center,
Abstract
Saturation genome editing-based functional evaluation and clinical classification of BRCA2 single nucleotide variants.Org: Department of Laboratory Medicine and Pathology, University of Washington, Mayo Clinic, Rochester Regional Health System, MN, Ambry Genetics,
Abstract
Tracking uncertainty in germline genetic testing for hereditary cancer syndromes: Sources, attributes, and resolution of variants of uncertain significance in over 1 million individuals.Org: UT Southwestern Medical Center, Dallas, Txinno Bioscience, Invitae, Fort Lauderdale,
Abstract
Accurate parent-of-origin variant assignment for multiple hereditary cancer syndromes using proband-only blood sample analysis.Org: Hereditary Cancer Program, Canada's Michael Smith Genome Sciences Centre, Terry Fox Laboratory, Department of Medical Genetics, BC Children's Hospital,
Abstract
Real-world cancer care utilization among patients with breast cancer with germline variants of uncertain significance.Org: Charleston, SC,
Abstract
Gene-environment interactions between clonal hematopoiesis of indeterminate potential and air pollution in non-small cell lung cancer among non-smokers.Org: Queen's University Belfast, Vanderbilt University Medical Center, McMaster University and Juravinski Cancer Centre,
Abstract
Effect of low-dose tamoxifen on IGF-I/IGFBP-3 and estradiol/SHBG ratio and their prognostic/predictive effect in DCIS/LCIS/ADH.Org: E.O. Ospedali Galliera, Azienda Ospedaliera-Universitaria Città della Salute e della Scienza, ASL AL Piemonte, Oncologia Medica - Ospedale San Bortolo Azienda ULSS8 Berica, Romagna Local Health Authority,
Abstract
Associations between metabolic syndrome-related diseases and colorectal cancer risk: A propensity score-matched analysis using the NIH All of Us research program.Org: Harlem Hospital Center, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Role of military physicians in cancer screening practices: The DEPISTmed study.Org: HIA Begin,
Abstract
Precise health perspectives: Unraveling the interplay of reproductive factors in hormone receptor–positive and triple-negative breast cancer among Bangladeshi women.Org: Unity Through Population Service, Mymensingh Medical College & Hospital, National Institute of Cancer and Research Hospital,
Abstract
Sensitivity and specificity of 61 commercial disease detection products: A systematic review and meta-analysis of 80 cohorts with approximately 445,000 enrolled samples.Org: Department of Pathology, Henan Provincial People's Hospital, Zhengzhou, China, HaploX Biotechnology, Shenzhen, China,
Abstract
Lung cancer among patients with secondhand smoke exposure: A systematic review.Org: University of Missouri–Kansas City School of Medicine,
Abstract
A fragment-based algorithm for identifying pan-cancer differential methylation markers from cfDNA.Org: Institute of Gastrointestinal Oncology,
Abstract
Analysis of diagnosis patterns and implications on cancer stage in patients with lung cancer: A single-institution experience.Org: Fort Smith, Mercy Hospital Clinic 7001 Rogers ave,
Abstract
Patient navigation as an effective way to increase breast, cervical, and colorectal cancer screening among immigrants in the US: A systematic review.Org: George Washington School of Medicine and Health Sciences,
Abstract
Efficacy and safety of dinutuximab in the management of high-risk neuroblastoma: A systematic review and meta-analysis.Org: Life Care Hospital and Research Institute,
Abstract
The frequency of HER2-low breast cancer among BRCA1, BRCA2, and PALB2 mutation carriers.Org: Hospital of University of Pennsylvania,
Abstract
Safety and efficacy of selpercatinib in pediatric patients with RET-altered solid tumors: Updated results from LIBRETTO-121.Org: Children’s Cancer Institute, Children's Cancer Centre, Royal Children's Hospital, Seoul National University Children’s Hospital,
Abstract
A novel multi-cancer screening approach based on screening objectives, cancer occurrence mechanism, and cost modeling.Org: Anpac Bio-Medical Science (Shanghai) Co., Ltd., Shanghai, China,
Abstract
The effect of advances in management of uterine-serous-carcinoma on population mortality.Org: Affiliated Wuxi No. 2 Hospital,
Abstract
Recruitment strategies in a lung cancer screening program for Asian women with no smoking history.Org: NYU Perlmutter Cancer Center,
Abstract
Efficacy of mammography screening in women aged 40–49 years: An updated systematic review and meta-analysis.Org: Shri Sathya Sai Medical College and Research Institute,
Abstract
Patterns and trends in incidence, survival, and treatment among patients with early-onset lung cancer in the U.S.: A population-based study.Org: Department of Thoracic Oncology and Surgery, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou, China, Department of Thoracic Oncology and Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China,
Abstract
Prevalence of obesity and its impact on outcome in children diagnosed with cancer in Canada: A population-based study.Org: Division of Pediatric Hematology-Oncology, Department of Pediatrics, Charles-Bruneau Cancer Center, CHU Sainte-Justine, Montreal, QC, Canada, Division of Pediatric Hematology-Oncology, McMaster Children’s Hospital, Hamilton, ON, Canada, Division of Pediatric Hematology-Oncology, Janeway Child Health Center, St. John’s, NF, Canada, Division of Pediatric Hematology-Oncology, CHU Sherbrooke, Sherbrooke, QC, Canada, Department of Pediatric Hematology/Oncology, CancerCare Manitoba, Winnipeg, MB, Canada,
Abstract
Effects of common nutraceutical supplements marketed for cancer prevention on tumor cell growth.Org: New York Botanical Garden,
Abstract
Impact of obesity on breast cancer clinicopathological characteristics in underserved community dweller women of Chicagoland: An experience from a US safety-net hospital.Org: Mount Sinai Hospital-Breast Medical Oncology, UPMC Harrisburg, Ross University School of Medicine, Sinai Health System,
Abstract
Epidemiological profile of Ophir Loyola Cancer Hospital: A snapshot of the incidence of solid neoplasms in the eastern Amazon.Org: Hospital Ophir Loyola,
Abstract
Radon exposure in Colombian never smoker patients with non-small cell lung cancer: A pilot study.Org: Fundacion Cardioinfantil - Instuto de Cardiologia, University of Santiago de Compostela, Fundación Neumológica Colombiana, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center - CTIC,
Abstract
Psilocybin, peyote, mescaline, and lysergic acid diethylamide (LSD) use in a nationally representative population by cancer history.Org: Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, University of Miami School of Medicine,
Abstract
Examining the epidemiology of AIDS-defining and HPV-associated cancers in HIV endemic areas of south Florida for development of targeted intervention.Org: University of Miami, Miami, FL,
Abstract
An analysis of likely germline events by tumor tissue testing on large somatic panels.Org: Triesta Sciences, HCG Cancer Center Hospital,
Abstract
A geospatial analysis of neighborhood hot spots and socioeconomic disparities associated with high lung cancer incidence for targeted intervention in south Florida.Org: University of Miami Miller School of Medicine, Miami, FL, Miami Cancer Institute - Baptist Health South Florida, Flare Therapeutics,
Abstract
Prevalence of HTLV-1 and 2 infection in the blood donor population of Colombia during 2012 to 2022.Org: Universidad del Bosque, Hospital Universitario Fundación Santa Fe de Bogota,
Abstract
Enhancing early detection of lung cancer: A strategic initiative to boost screening rates among patients.Org: Infirmary Cancer Care/Affiliate of UAB O'Neal Comprehensive Cancer Center, Maryland Oncology Hematology PA,
Abstract
Implementation of video assisted point-of-care germline genetic education and testing for patients with peri-diagnostic pancreatic cancer.Org: Northwell Health/Center for Advanced Medicine, Northwell Cancer Institute,
Abstract
Trends of pancreatic cancer-related mortality among patients with type 2 diabetes mellitus in the United States, 1999-2020.Org: Sindh Institute of Urology and Transplantation (SIUT), Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Division of Hematology/Oncology, Department of Medicine, University Of Toledo,
Abstract
Clinical and histological profiling of triple-negative breast cancer at Chihuahua´s state cancer center: An observational study.Org: CECAN,
Abstract
Effects of telehealth on uptake and timeliness of genetic counseling and genetic testing among patients with endometrial cancer.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Gynecologic Oncology & Reproductive Medicine,
Abstract
Unintentional weight loss, body composition, and all-cause mortality among United States adults with cancer.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Rutgers University,
Abstract
Co-occurrence of germline pathogenic variants in a Brazilian cohort of patients with breast cancer.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Medica Scientia Innovation Research (MEDSIR),
Abstract
Observed germline BRCA1/2 and TP53 tumor genomic profiling allele frequencies.Org: Quest Diagnostics Inc.,
Abstract
Spectrum and characteristics of germline PALB2 pathogenic variants among patients with early-onset breast cancer in China.Org: Fuzhou, Fujian, China,
Abstract
Effect of demographic and clinician factors on patients' likelihood of pursuing hereditary cancer genetic testing.Org: University of Michigan, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, University of Michigan School of Public Health, Rogel Cancer Center,
Abstract
Episodic future thinking: A behavioral intervention to promote weight loss in breast cancer survivors.Org: Fralin Biomedical Research Institute, Virginia Tech University,
Abstract
Does the most common gynecological cancer have an awareness blind spot? An Israeli preliminary study.Org: Assaf Harofeh Medical Center,
Abstract
Impact of American Society of Breast Surgeons (ASBS) guidelines on genetic testing (GT) rates among patients with breast cancer (BC).Org: Washington University in St. Louis, St. Louis, ModernaTX, Washington University School of Medicine in St Louis, Saint Luke's Cancer Institute,
Abstract
A randomized trial of dietary modification with exercise in women who are class 2 obese with non-metastatic breast cancer.Org: Piedmont Fayette Hospital, Piedmont Hospital,
Abstract
Knowledge, attitudes, and practices of university students towards risk factors, screening, and perceived barriers of screening regarding colorectal cancer: A multi-country study from the eastern Mediterranean region.Org: University of Limoges, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance, Limoges University Hospital, Inserm U1094- IRD UMR270- University of Limoges- University Hospital center of Limoges- EpiMaCT - Epidemiology of chronic diseases in tropical zone - Omega Health,
Abstract
Pathogenic germline variants among Thai patients with colorectal cancer: A study in Genomics Thailand Project.Org: Faculty of Medicine Siriraj Hospital, Division of Medical Genetics,
Abstract
Staging of psychiatric disorders in patients with limited and advanced/metastatic solid cancer: A pilot study.Org: Luigi Sacco Hospital, Luigi Sacco University Hospital, Fatebenefratelli and Luigi Sacco Hospital,
Abstract
Disparities in the prevalence of anxiety and major depressive disorder in patients with lung cancer and the associated risk factors: A retrospective analysis.Org: Lake Erie College of Osteopathic Medicine, Wyckoff Heights Medical Center, Nuvance Health/Vassar Brothers Medical Center, State University of New York, Upstate Medical University, University of Missouri-Columbia, School of Medicine,
Abstract
Perceptions of multi-cancer early detection (MCED) screening tests among underrepresented populations.Org: GRAIL LLC, LLC, Evidera, Inc,
Abstract
Clinical, demographic, and contextual determinants of older breast cancer survivors' reports of discussions about exercise with healthcare providers.Org: National Institute on Minority Health and Health Disparities,
Abstract
Defeating cancer through education, prevention, and youth athletics.Org: University of Cincinnati Medical Center, University of Cincinnati College of Medicine, Department of Radiation Oncology, University of Cincinnati,
Abstract
Public awareness of the association between the risk of breast cancer (BC) development and alcohol consumption (AC) among women aged 18–75 years.Org: Clearview Cancer Institute,
Abstract
Leveraging real-world data from multiple institutions to assess the rate of bilateral mastectomy after cancer genetics evaluations with genetic counselors.Org: Genome Medical, South San Francisco, CanSino Biologics, xCures, Inc, Oakland, CA,
Abstract
Mexican physicians' knowledge and attitudes towards hereditary colorectal cancer risk management.Org: Mexican Society of Oncology, Hospital Regional De Río Blanco, Servicios de Salud de Veracruz,
Abstract
Baseline surveillance in Li Fraumeni syndrome using whole-body MRI: A systematic review and meta-analysis.Org: Universidade Estadual do Centro Oeste - UNICENTRO, Guarapuava, Brazil, Federal University of Viçosa, Viçosa, Brazil, Federal University of Sao Paulo - UNIFESP, São Paulo, Brazil, Stanford University, California, CA, Queen’s University and Kingston Health Science Center, Kingston, ON, Canada,
Abstract
Examining knowledge of cancer-related family history in an urban underserved patient population.Org: University of Illinois Chicago College of Medicine, University of Illinois Health,
Abstract
Cemiplimab in locally advanced and/or metastatic secondary angiosarcomas (CEMangio): A phase II clinical trial.Org: Nijmegen, Gelderland, Radboud University Medical Centre, Leiden University Medical Center, Department of Medical Oncology, Radboud University Nijmegen Medical Center,
Abstract
Adherence to cancer screening for patients with Li-Fraumeni syndrome: A report on our experience at Fred Hutchinson Cancer Center.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutch Cancer Center,
Abstract
Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS).Org: Duke Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Durham, NC, Mayo Clinic, Rochester, MN,
Abstract
Phase II trial, multicenter, first line paclitaxel-avelumab treatment for inoperable angiosarcoma.Org: Department of Hemato-oncology,
Abstract
Malignant chondroblastoma: NCDB analysis of demographic and socioeconomic factors.Org: University of Arizona College of Medicine - Phoenix, Creighton University School of Medicine Phoenix Regional Campus, University of California, Davis Comprehensive Cancer Center, Arizona State University, University of Arizona College of Medicine, Tucson,
Abstract
Pagetic osteosarcoma: An analysis of the National Cancer Database.Org: Creighton University School of Medicine - Phoenix Regional Campus, Phoenix, AZ, Creighton University School of Medicine Phoenix Regional Campus, Omaha, NE, Arizona State University,
Abstract
Small cell osteosarcoma: An NCDB analysis of demographic and socioeconomic factors of diagnosed patients.Org: California State University, Sacramento,
Abstract
Dedifferentiated chordoma: Socioeconomic factors and treatment outcomes.Org: Brandeis University, Waltham, MA, MaaT Pharma, Creighton University School of Medicine Phoenix Regional Campus, Omaha NE,
Abstract
Analysis of demographic and socioeconomic factors in adamantinoma using data from the National Cancer Database (NCDB).Org: Creighton University, School of Medicine, University of Arizona College of Medicine, Tucson,
Abstract
Periosteal osteosarcoma: A study of demographic and socioeconomic factors.Org: Creighton University School of Medicine Phoenix Regional Campus, Arizona State University, Brandeis University, Creighton Hematology Oncology, Omaha, NE, University of Arizona College of Medicine, Phoenix, AZ,
Abstract
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-VEGFR targeted therapy: A Phase 2 Trial of Regorafenib combined with avelumab.Org: ImmuSmol,
Abstract
A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in advanced chordoma.Org: Leiden, Netherlands, 250 Euston Road, Chordoma Foundation,
Abstract
Monitoring ovarian function in oncology studies: Results and insights from the DeFi phase 3 study of nirogacestat in desmoid tumor.Org: Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, University of Michigan, Rogel Comprehensive Cancer Center,
Abstract
Bony reconstruction after internal hemipelvectomy: A retrospective analysis of 44 patients undergoing femoro-pelvic pseudoarthrosis.Org: HCG Cancer Centre Mumbai, Sparsh Orthopedic Oncology Clinic,
Abstract
A phase II study of anlotinib and an anti-PDL1 antibody in patients with alveolar soft part sarcoma: Results of expansion cohorts.Org: Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China,
Abstract
Place of Rank ligand inhibitor in giant cell tumour of bone.Org: Pierre and Marie Curie Center, Algiers, Algeria,
Abstract
Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).Org: Laboratory of Carcinogenesis and Translational Research of the Ministry of Education, Beijing Cancer Hospital & Institute, Ningbo Newbay Technology Development Co., Ltd.,
Abstract
Eribulin and irinotecan for refractory or recurrent Ewing sarcoma: A retrospective study.Org: Peking University People’s Hospital, Beijing, China,
Abstract
High-grade surface osteosarcoma: A National Cancer Database study of demographic characteristics.Org: Creighton University School of Medicine - Phoenix Regional Campus, Creighton University School of Medicine Phoenix Regional Campus, Arizona State University, Creighton Hematology Oncology, Omaha, NE, University of Arizona College of Medicine, Phoenix, AZ,
Abstract
Localized GIST in Hispanic population in North and South America.Org: Fundacion GIST Mexico, The Life Raft Group, Department of Surgery, Division of Surgical Oncology, Moores Cancer Center, UC San Diego School of Medicine,
Abstract
Evaluation of tumor immune microenvironment for PD-L1 score and tumor infiltrating lymphocytes in high grade osteosarcomas and their correlation with disease progression.Org: All India Institute of Medical Sciences (AIIMS), Rishikesh, India,
Abstract
Identifying intra-abdominal desmoid type fibromatosis mimicking recurrence/metastasis of GISTs using FAPI PET/CT.Org: University Medical Center Groningen, University of Groningen, Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, The First Affiliated Hospital of Sun Yat-sen University, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Characterizing TP53 mutations in bone and soft tissue sarcoma.Org: Memorial Sloan Kettering Cancer Center, Fellowship (GME Office), Sarcoma Medical Oncology Service,
Abstract
Implementation of a comprehensive genomic profiling (CGP) panel for precision oncology at a cancer center in Brazil.Org: A.C. Camargo Cancer Center, Illumina, Inc.,
Abstract
Understanding clonal heterogeneity and mechanisms of methotrexate resistance in two osteosarcoma PDX models.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Rutgers Cancer Institue of New Jersey,
Abstract
Analysis of demographic and socioeconomic factors in biphasic synovial sarcoma using data from the National Cancer Database.Org: Creighton University School of Medicine Phoenix Regional Campus, School of Medicine, Zhejiang University, Hangzhou, China, Phoenix, AZ, Arizona State University, Tempe, AZ,
Abstract
Epithelioid hemangioendothelioma: Real-world data about a rare entity in a Portuguese tertiary cancer center.Org: Hospital Fernando da Fonseca, Hospital do Espírito Santo de Évora,
Abstract
Correlation between imatinib trough concentration and efficacy in patients with advanced GIST with different genotypes.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Sun Yat-sen University Cancer Center Gansu Hospital, Center of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Juxtacortical chondrosarcoma: An NCDB analysis of demographics and socioeconomic factors.Org: Creighton University School of Medicine, Phoenix, AZ, Creighton University School of Medicine, Omaha, NE, Creighton University School of Medicine-Phoenix, Phoenix, AZ, Sierra College, Rocklin, CA, Creighton Hematology Oncology, Omaha, NE,
Abstract
Survival trends of soft tissue sarcomas and gastrointestinal stromal tumors from 1995 to 2019: A SEER database analysis.Org: University of Connecticut Health Center, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine, Yale New Haven Hospital,
Abstract
Mixed liposarcoma: A study of socioeconomic and demographic factors.Org: Creighton University School of Medicine Phoenix Regional Campus, School of Medicine, Zhejiang University, Hangzhou, China, Grand Canyon University, Sierra College, Creighton Hematology Oncology, Omaha, NE,
Abstract
Pathologic complete response in patients with localized soft tissue sarcoma treated with neoadjuvant therapy and its correlation with clinical outcomes: A systematic review.Org: ATTIKON University Hospital, Section of Medical Oncology, Department of Internal Medicine, Attikon University Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Faculty of Medicine, Cairo University, National and Kapodistrian University of Athens,
Abstract
The role of next-generation sequencing in achieving diagnostic precision for dermatofibrosarcoma protuberans and its fibrosarcomatous variant.Org: Washington Medstar Medical Center,
Abstract
Molecular characteristics of dedifferentiated liposarcoma with broad rhabdomyosarcomatous differentiation.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China,
Abstract
Overall survival in soft tissue sarcomas (STS) in Hispanic vs non-Hispanic White patients: Single center experience.Org: Dignity Health Cancer Institute, Dignity Health Cancer Center, Beth Israel Lahey Health,
Abstract
Comparative analysis of targetable mutations and genomic-directed therapy by tumor genomic profile in soft tissue sarcoma: A single-center retrospective study.Org: Dignity Health Cancer Institute, Dignity Health Cancer Center, Division of Surgical Oncology, Department of Surgery, The Ohio State University,
Abstract
Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma: Patient-reported outcomes (PROs) of the randomized phase II MEDISARC study (AIO-STS-0415).Org: Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, Clinic for Urology, Essen University Hospital, Medizinische Klinik Abteilung II, Uniklinik Tubingen,
Abstract
Differences in baseline ctDNA value between Hispanic and non-Hispanic White patients with soft tissue sarcoma (STS): A single-center retrospective analysis.Org: Dignity Health Cancer Institute, Dignity Health Cancer Center,
Abstract
Clinical profile and response to adjuvant treatments in patients with follicular dendritic cell sarcoma in the United States: Insights from SEER analysis.Org: Mayo Clinic Health Care, Trinity Health Oakland/Wayne State University School of Medicine,
Abstract
The prevalence of fibroadenoma-like areas in malignant phyllodes tumors of the breast: A retrospective analysis from a referral center.Org: Medical Oncology Division, Cliniche Humanitas Gavazzeni, Department of Statistics and Quantitative Methods University of Milan-Bicocca, Division of Melanoma, Soft Tissue Sarcomas and Rare Tumors,
Abstract
Monocyte/lymphocyte ratio to predict immunoradiotherapy response in patients with advanced pretreated sarcoma.Org: Gustave Roussy Cancer Campus, Gustave Roussy Département d'Organisation du Parcours Patient, University of Navarra Clinic, Pamplona, Spain, F. Hoffmann-La Roche Ltd,
Abstract
Correlation of ctDNA and LDH levels in patients with soft tissue sarcoma: A single-center experience.Org: Dignity Health Cancer Institute, Dignity Health Cancer Center,
Abstract
Procollagen C-protein enhancer 1 (PCPE-1) as a potential serum biomarker for osteosarcoma.Org: Ramat Gan, Israel,
Abstract
Analysis of demographic and socioeconomic factors in mixed type rhabdomyosarcoma using NCDB.Org: Creighton University School of Medicine - Phoenix Regional Campus, Grand Canyon University, Arizona State University, Creighton University School of Medicine Phoenix Regional Campus, University of Arizona College of Medicine, Phoenix, AZ,
Abstract
Spindle cell rhabdomyosarcoma: A study of demographics and socioeconomic factors using NCDB.Org: Creighton University School of Medicine - Phoenix Regional Campus, Creighton University School of Medicine Phoenix Regional Campus, Sierra College, University of California, Riverside, University of Arizona College of Medicine, Phoenix, AZ,
Abstract
Factors predicting surgical receipt in extracranial rhabdoid tumors.Org: Creighton University School of Medicine, Omaha, NE,
Abstract
Adult genitourinary sarcomas: A single-centre experience over 25 years.Org: Department of Urology, University of Iowa,
Abstract
Clinicopathological analysis and management of primary cardiac sarcomas: A retrospective study from two cancer centers in China.Org: Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Department of Bone and Soft Tissue Tumor, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute,
Abstract
Correlation of ctDNA with hematologic ratios (NLR, MLR, PLR, ELR) in predicting disease progression in soft tissue sarcomas among non-Hispanic Whites and Hispanics: Single-center experience.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton University Medical Center, Mayo Clinic, Dignity Health Cancer Institute, Dignity Health Cancer Center,
Abstract
Effect of molecular cartography on recurrence-specific drivers through analysis of matched primary and recurrent rhabdomyosarcoma tumors.Org: Yuexiu District, Guangzhou, Sun Yat-sen University Cancer Center Gansu Hospital, OrigiMed, Shanghai OrigiMed Co., Ltd., Shanghai, China,
Abstract
Real world effectiveness of immunotherapy combined with anti-angiogenic therapy in patients with anthracycline-resistant soft tissue sarcomas.Org: First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China,
Abstract
An analysis of treatment trends in sclerosing epithelioid fibrosarcoma.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton Hematology Oncology, Omaha, NE,
Abstract
Revealing the crucial roles of myxoma cells and CD206+ macrophages in cardiac myxoma progression based on single-cell sequencing.Org: State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China, Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China, West China Hospital, Chengdu, Sichuan, China,
Abstract
The effectiveness of adjuvant therapy in adult patients with spindle cell/sclerosing rhabdomyosarcoma: A single-center retrospective study.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Hospital, Sichuan University,
Abstract
Association of mutational status with metastatic pattern, race, ethnicity, and overall survival (OS) in leiomyosarcoma (LMS).Org: University of Miami Miller School of Medicine, Miami, FL, University of Miami Sylvester Comprehensive Cancer Center, University of Miami Hospital/Jackson Memorial Hospital, UVA Health, University of Miami – Sylvester Comprehensive Cancer Center, Miami, FL,
Abstract
Clinical features, molecular findings, and clinical outcomes of follicular dendritic cell sarcoma.Org: Department of Ophthalmology,
Abstract
Neoadjuvant pazopanib with radiation therapy in patients with localized sarcoma: Experience from a sarcoma center.Org: University Hospitals Case Medical Center Rehabilitation Services,
Abstract
Malignant mesenchymoma: A demographic analysis of the National Cancer Database.Org: Creighton University School of Medicine (Phoenix Regional Campus), Phoenix, AZ, Grand Canyon University, Arizona State University, Brandeis University, Creighton University School of Medicine Phoenix Regional Campus,
Abstract
Assessing response and adherence to neoadjuvant treatment in soft tissue sarcomas of the extremities.Org: National Cancer Institute (INCan MEXICO),
Abstract
Soft tissue sarcomas: Disease burden and health system response in Peru.Org: National Institute of Neoplastic Diseases (INEN), Lima, Peru, National Institute of Neoplastic Diseases (INEN), Lima, Lima, Peru, National Institute of Neoplastic Diseases (INEN), Surquillo, Lima, Peru, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Lima, Peru, Instituto Nacional de Enfermedades Neoplásicas INEN, Lima, Lima, Peru,
Abstract
Neoadjuvant treatment with camrelizumab in combination with doxorubicin and ifosfamide: A phase II clinical study of high-risk soft tissue sarcoma.Org: Sun Yat-sen University Cancer Center Gansu Hospital,
Abstract
Characterizing the transformation and diagnosis of atypical lipomatous tumors to dedifferentiated liposarcoma: Single-institutional outcomes.Org: Rush University Medical Center, Chicago, IL,
Abstract
Clinical efficacy and safety of mTOR inhibitor in patients with advanced unresectable epithelioid hemangioendothelioma (EHE).Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
A phase 2 study of regorafenib in metastatic/unresectable, refractory synovial sarcomas.Org: All India Institute of Medical Sciences (AIIMS), Rishikesh, India, Dr. Brairch,
Abstract
Quality of life outcomes in patients with resectable dedifferentiated liposarcoma treated with neoadjuvant immunotherapy.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,
Abstract
Epidemiology, symptomatology, diagnosis and clinical implications of cystic tumors of atrioventricular node (CTAVN): A systematic review.Org: JCCR, M Abdur Rahim Medical College,
Abstract
Epidemiological trends and socioeconomic factors in malignant peripheral nerve sheath tumors with rhabdomyoblastic differentiation: A National Cancer Database study.Org: Creighton University School of Medicine-Phoenix, Phoenix Tissue Repair, Azidus Brasil, Creighton SOM, Brandeis University,
Abstract
Preoperative and postoperative platelet-lymphocyte ratio as a prognostic marker for patients with soft tissue sarcoma treated with curative resection.Org: Kyungpook National University Hospital, Daegu-Gyeongbuk Medical Innovation Foundation, South Korea,
Abstract
An NCDB analysis of patient treatment trends in soft tissue angiosarcoma.Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton Hematology Oncology, Omaha, NE,
Abstract
The efficacy of immune checkpoint inhibitors as a part of multimodality treatment in soft tissue and bone sarcoma in an academic community setting.Org: Endeavor Health (formerly NorthShore University Healthsystem),
Abstract
Epidemiology of undifferentiated sarcomas: A rare entity.Org: Mercy Catholic Medical Center, Lansdowne, PA, Darby, PA,
Abstract
Detection and surveillance of circulating tumor cells in sarcoma for predicting therapy response and prognosis.Org: Beijing Ji Shui Tan Hospital, Beijing Chaoyang Integrative Medicine Rescue And First Aid Hospital, Xiangpeng Youkang (Beijing) Technology Co., Ltd,
Abstract
Efficacy and safety of anthracycline combined with alkylating agent for treatment of advanced leiomyosarcoma.Org: Beijing Sanhuan Cancer Hospital, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College,
Abstract
The influence of yoga and cognitive behavioral therapy on mediational relationships between insomnia and cancer-related fatigue: A URCC NCORP RCT in 550 cancer survivors.Org: Cancer Research of Wisconsin and Northern Michigan Consortium (CROWN), Green Bay, WI, Southeast Clinical Oncology Research Consortium (SCOR),
Abstract
Prospective and external validation of an objective performance status (OPS) in patients with metastatic solid malignancies using wearable accelerometry.Org: START Madrid Fundacion Jimenez Diaz, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital,
Abstract
Technology-enhanced palliative care for patients with advanced cancer undergoing phase I therapies: A pilot randomized clinical trial (RCT).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Effect of nurse-led multi-disciplinary treatment on patients with head and neck tumors: A randomized controlled trial.Org: Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, Chongqing University, Chongqing, Chongqing, China, West China School of Nursing, Sichuan University/Department of Nursing, West China Hospital, Sichuan University, Chengdu, China, Department of Rehabilitation, West China Hospital, Sichuan University, Chengdu, China,
Abstract
Identifying optimized assessment of nerve damage during chemotherapy.Org: Northern Hematology and Oncology Group, Royal Brisbane & Women's Hospital,
Abstract
Examining the risk factors for trastuzumab-related cardiotoxicity in a predominantly Hispanic South Texas population: A descriptive study.Org: Division of General Medical Sciences, Albany Medical College,
Abstract
Use of immunotherapy with check point inhibitors in soft tissue sarcoma: Analysis from single institution.Org: University of Louisville, James Graham Brown Cancer Center,
Abstract
Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among patients with cancer treated with anthracycline: A systematic review and meta-analysis.Org: Department of Internal Medicine, University of Missouri–Kansas City School of Medicine, Division of Cardiology, Department of Medicine, Loma Linda University Health,
Abstract
Patient reported symptoms after cancer diagnosis and the risk of short- and long-term severe mental health events among adolescents and young adults (AYA): A population-based study.Org: Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada, ICES, Toronto, ON, Canada, Institute for Clinical Evaluative Science, Toronto, ON, Canada, Sunnybrook Health Sciences Centre, Toronto, ON, Canada,
Abstract
Update on GALLANT: A phase 2 study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab in previously treated sarcoma (NCT04535713).Org: Sarcoma Oncology Research Center, Santa Monica, CA, Sarcoma Oncology Center,
Abstract
Association of chronic or acute systolic and diastolic heart failure with incidence rates of pneumonia, sepsis, and septic shock in patients with lung cancer.Org: Kansas City, MO,
Abstract
The metabolic profiles of patients with autologous hematopoietic stem cell transplantation with graft versus host disease.Org: Cardiovascular Sciences,
Abstract
Cardiovascular events in patients receiving immuno-oncology agents, in phase I clinical trials: CAVIO study.Org: Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, European Institute of Oncology IRCCS, University of Milano, European Institute of Oncology, Division of Early Drug Development, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy,
Abstract
The relationship between cardiometabolic abnormalities and mortality among women with and without cancer in the Women’s Health Initiative (WHI).Org: Stanford Prevention Research Center, University of Washington School of Nursing, Inova Schar Heart and Vascular,
Abstract
Arterial stiffness and aortic hemodynamics as predictors for new or worsening cardiovascular events in childhood cancer survivors: A report from the St. Jude lifetime cohort.Org: St. Jude Children's Research Hospital, University of Minnesota Masonic Cancer Center, Minneapolis, MN,
Abstract
Factors influencing the mortality risk of heart failure in patients receiving antineoplastic immunotherapy: A national inpatient database study 2016-2020.Org: Apollo Cancer Specialty Hospital,
Abstract
Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis.Org: St. Luke's Medical Center, Quezon City, Manila, Philippines, St. Luke's Medical Center, Taguig, Manila, Philippines, Philippine Society of Medical Oncology, Quezon City, Manila, Philippines, Philippine General Hospital, Manila, Manila, Philippines,
Abstract
Soluble guanylate cyclase activator vericiguat prevents anthracycline-mediated cardiotoxicity and sarcopenia through cGMP-NLRP3-cytokine pathway: Potential application in patients with cancer.Org: IRCCS Ospedale Sacro Cuore Don Calabria,
Abstract
Targeting exercise and sedentary behavior for the prevention of allogeneic stem cell transplant-related cardiovascular dysfunction: The ALLO-Active trial.Org: Baker Heart and Diabetes Institute, Baker Heart & Diabetes Institute, Katholieke Universiteit Leuven, Cancer Council Victoria, CSL Ltd,
Abstract
Impact of cardiac arrhythmias on in-hospital mortality in patients with cytokine release syndrome: Insights from National Inpatient Sample.Org: University of Kansas School of Medicine - Wichita, Kansas University School of Medicine - Wichita, Cancer Ctr of Kansas,
Abstract
The impact of glucagon-like peptide-1 receptor agonists on proteasome inhibitor-associated cardiotoxicity in patients with multiple myeloma.Org: Praxair Cancer Center Danbury Hospital,
Abstract
Prevalence and predictors of coronary artery stent re-stenosis in patients with cancer with prior history of percutaneous coronary intervention: A nationwide analysis.Org: John H. Stroger, Jr. Hospital of Cook County, John H Stroger, Jr. Hospital of Cook County,
Abstract
A randomized, double-blind controlled trial of medicinal cannabis vs placebo for symptom management in patients with advanced cancer receiving palliative care.Org: Mater Research - University of Queensland, Torus Research, Mater Research Institute - University of Queensland, Mater Misericordiae Ltd, St. Vincent's Private Hospital,
Abstract
Outcomes among hospitalized patients with colorectal cancer and comorbid congestive heart failure: A United States population-based cohort study.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Jefferson-Einstein Hospital, Jefferson Einstein Medical Center,
Abstract
Investigation of cardiotoxicity with concomitant use of anthracyclines and checkpoint inhibitors.Org: The University of South Alabama,
Abstract
Trends of stroke-related mortality among patients with cancer in the United States, 1999-2020.Org: Karachi, Pakistan, Toledo, OH, Dr. Ruth KM Pfau Hospital, Rocky Mount, NC, Neurodiagnostic Center of Central Florida,
Abstract
An update on SOC-1882: A phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma.Org: 2811 Wilshire Blvd., Suite 414,
Abstract
Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity.Org: Division of Cardiology, Naples, Italy, Division of Cardiology, Azienda USL Toscana Nord-Ovest, Versilia Hospital, Lido Di Camaiore, Italy, Servizi Cardiologici Integrati, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, Sperimentazione Animale, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy, Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy,
Abstract
Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on ejection fraction reduction, myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.Org: Servizi Cardiologici Integrati, Azienda Ospedaliera San Camillo-Forlanini, IRCCS Ospedale Sacro Cuore Don Calabria, Sperimentazione Animale, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale,
Abstract
Immuno-related cardiac toxicity in patients with cancer: A prospective study applying multiparametric cardiac MRI.Org: Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy, Cardiology Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milano), Italy, Biostatistic Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy, Adaptive Immunity Laboratory, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy,
Abstract
Unveiling the influence of SGLT2 inhibitors on clinical outcomes in patients with cancer with therapy-related cardiac dysfunction: A meta-analysis and systemic review.Org: Shaukat Khanum Memorial Cancer Hospital and Research Center, Camden Clark Medica Center, Mercy Hospital Southeast, Mayo Clinic Alix School of Medicine,
Abstract
Predictors of long-term survival in immune checkpoint inhibitor (ICI)-associated myocarditis.Org: Cardiovascular Imaging Research Center,
Abstract
Prevalence and clinical outcomes of acute heart failure among patients with mediastinal radiation exposure: A propensity score matched analysis.Org: College of Medical Sciences, Bharatpur, Nepal, Bharatpur, Nepal, Maimonides Medical Center (Brooklyn, NY), Patan Academy of Health Sciences, Kathmandu, Nepal, Saint Clare's Health System, Denville, NJ,
Abstract
Impact of multiple myeloma on outcomes of acute myocardial infarction: A propensity score matched analysis.Org: College of Medical Sciences, Bharatpur, Nepal, Patan Academy of Health Sciences, Kathmandu, Nepal, Saint Clare's Health System, Denville, NJ, Maimonides Medical Center, Brooklyn, NY,
Abstract
Cardiovascular toxicity of fluoropyrimidines: Experience from a quaternary referral center.Org: Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Foundation,
Abstract
Beyond the pain: Decoding opioid use in advanced cancer ED visits.Org: Kaiser Permanente Oakland Medical Center,
Abstract
Effect of fructose on anthracycline and HER-2 blocking agent mediated cardiotoxicity through NLRP3 and MyD88 mediated pathways: New roles of sweeteners in cardio-oncology.Org: Fondazione G. Pascale, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar Di Valpolicella,
Abstract
Decision making factors regarding hospice care: A qualitative exploration in patients with recurrent ovarian cancer.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
End of life treatment in gynecological cancers in an integrated care model: A single institution experience from Oman.Org: Sultan Qaboos Comprehensive Cancer Centre, Muscat, Oman,
Abstract
Chemotherapy in the last 30 days of life, correlation with age and palliative care referral: A 1-year retrospective gastrointestinal program experience at SQCCCRC.Org: SQCCCRC, Muscat, Oman,
Abstract
Cardio-Oncology Awareness: A multidisciplinary survey amongst health care trainees and practicing professionals at academic institutions.Org: Sanjay Gandhi Postgraduate Institute of Medical Sciences,
Abstract
Trends in hospice utilization and place of death preferences in multiple myeloma-related deaths from 2003 to 2020: Analysis of CDC Wonder database.Org: University of Exeter Medical school,
Abstract
Resident physicians’ knowledge, attitudes, and practices on advance care planning for patients with advanced cancer in a national university hospital in the Philippines.Org: University of the Philippines - Philippine General Hospital, Philippine General Hospital,
Abstract
Correlation between Palliative Performance Scale results and observed survival among Mexican patients with advanced cancer.Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,
Abstract
Adoption of the International Cognition and Cancer Task Force recommendations for harmonizing studies of cancer-related cognitive impairment: A systematic review of published literature.Org: University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA,
Abstract
Analysis of the fecal metagenome in pelvic radiation survivors with or without chronic gastrointestinal toxicity.Org: University of Cincinnati Cancer Center, Department of Infectious Diseases, University of Cincinnati College of Medicine,
Abstract
A comprehensive analysis of portal vein thrombosis in malignancy.Org: Parkview Cancer Institute,
Abstract
Sweet syndrome in the setting of breast cancer: A literature review.Org: North Shore University Hospital/LIJ Medical Center, Saint Louis School of Medicine,
Abstract
Tachyarrhythmias burden in hospitalized patients with cancer: A nationwide propensity matched analysis.Org: John H. Stroger Jr. Hospital of Cook County, Louisiana State University in Shreveport, Louisiana State University Health Sciences Center Shreveport, LSU Health Shreveport, LSU-Shreveport,
Abstract
Non-bacterial thrombotic endocarditis and pancreatic cancer: A literature review.Org: University Tennessee Health Science Center, Hempstead, NY,
Abstract
Head and neck cancer survivors’ perception of lymphedema care.Org: Vanderbilt University Medical Center,
Abstract
Influence of intensity-modulated radiation therapy on long-term survival and late injury in patients with nasopharyngeal carcinoma after induction chemotherapy.Org: Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China,
Abstract
Effect of combinatorial immune checkpoint blockade on myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β, and interleukin-6: Biochemical implications in cardio-immuno-oncology.Org: Division of Cardiology, Istituto Nazionale Tumori –IRCCS- Fondazione G. Pascale, Naples, Italy, IRCCS Fondazione G. Pascale, Napoli, Italy, Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, Naples, Italy, Servizi Cardiologici Integrati, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, Oncologia Medica, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar Di Valpolicella, Italy,
Abstract
Testosterone replacement therapy (TRT) in patients with locoregional prostate cancer (LPC) treated with prior androgen deprivation therapy (ADT): A single center review.Org: Lahey Hospital and Medical Center, Burlington, MA, Burlington, MA,
Abstract
HRQoL in patients with GBM: The impact of tumor treating fields.Org: UF College of Medicine,
Abstract
Curcumin add-on improves quality of life in patients with locally or advanced head and neck cancer receiving nutritional intervention.Org: Phramongkutklao Hospital,
Abstract
Racial disparities in acute myocardial infarction outcomes in patients with cancer: A nationwide analysis.Org: Maimonides Medical Center, Brooklyn, NY, Maimonides Medical Center (Brooklyn, NY), Patan Academy of Health Sciences, Kathmandu, Nepal, Saint Clare's Health System, Denville, NJ,
Abstract
The effect of epidural steroid injections for the management of spinal malignancy-related pain.Org: Department of Anesthesiology and pain medicine, Seoul National University Bundang Hospital, Seongnam-Si, South Korea, Department of Anesthesiology and pain medicine, Seoul National University Bundang Hospital, Seong-Nam Si, South Korea, Department of Anesthesiology and pain medicine, Seoul National University Bundang Hospital, Seong-Nam Si, Gyeonggi-Do, South Korea,
Abstract
Comparison of infective endocarditis in patients with and without malignancy: A propensity score matched analysis.Org: Maimonides Medical Center (Brooklyn, NY),
Abstract
Angiogenesis inhibitors and cardiovascular outcomes in cancer: Real-world, population-based, matched cohort study.Org: Levine Cancer Institute, Atrium Health Carolinas Medical Center, King Faisal Specialist Hospital & Research Center, Apex Institute of Medical Science,
Abstract
Safety and efficacy of low dose versus high dose corticosteroid for graft versus host disease (GVHD): A systematic review.Org: St. Mary Mercy Medical Group, Institute of Medicine,
Abstract
Psychoneurological symptoms, inflammatory biomarkers and gut microbiome richness and diversity in individuals receiving hematopoietic cell transplantation (HCT).Org: University of Florida College of Nursing,
Abstract
Network pharmacology-based strategy for screening active compounds and significant pathways of huachansu capsule on cancerous pain.Org: Guang 'anmen Hospital, China Academy of Chinese Medical Sciences,
Abstract
Relationship between hope and quality of life in patients with advanced cancer in Uruguay: An observational analysis.Org: Service of Clinical Oncology, Montevideo, Uruguay,
Abstract
Implementation of a palliative care service in a tertiary hospital in a developing country: Methods, strategies and results.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil,
Abstract
Cardiomyopathy among recipients of immune checkpoint inhibitor therapy: A prospective study.Org: Division of Cardiovascular Imaging, St. Francis Hospital & Heart Center, DeMatteis Cardiovascular Institute of St. Francis Hospital, Cardio-Oncology Service, Cardiology Division,
Abstract
Pancreatic-enzyme replacement therapy with pancrelipase plus chemotherapy for patients with pancreatic adenocarcinoma with cachexia and exocrine pancreatic insufficiency (PANCAX-3).Org: Cedars-Sinai Medical Center, Cedars Sinai Medical Center, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA,
Abstract
Opioid use in impending versus pathologic proximal femur fractures.Org: Midwest Orthopedics at Rush University Medical Center,
Abstract
Advance care planning and predictive factors among Brazilian patients with cancer from an outpatient palliative care program.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Medica Scientia Innovation Research (MEDSIR),
Abstract
Patterns of referral to supportive oncology (SO) practice embedded in a cancer center and impact of timing of referrals on end-of-life outcomes.Org: Mount Sinai Hospital-Breast Medical Oncology, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Morningside-West,
Abstract
Comparison of concurrent care and traditional hospice at a regional VA.Org: University of Iowa Hospitals & Clinics, Iowa City VA Medical Center,
Abstract
Inhaled fentanyl aerosol through a drug-device combination for breakthrough cancer pain: A multicenter, randomized, double-blind, placebo-controlled trial.Org: Lee's Pharmaceutical Holdings Limited,
Abstract
Examining emerging trends in palliative care utilization for malignant neoplasms with the highest mortality rates.Org: Arkansas Children's Hospital,
Abstract
The role of integrating palliative care with systemic anticancer treatment at end-of-life: A single center experience.Org: Thailand, Ramathibodi Comprehensive Cancer Center, Ramathibodi Palliative Care Center, Ratchathewi,
Abstract
The efficacy of ketamine for pain management in patients with cancer: A systematic review.Org: University of South Florida Morsani College of Medicine, University of Maryland Capital Region, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, MPH Department of Clinical Science and Nutrition, University of Chester, College of Pharmacy, Tehran University of Medical Sciences,
Abstract
The use of complementary and alternative medicine (CAM) among patients with cancer in Hawaii.Org: John A. Burns School of Medicine, University of Hawaii Cancer Center,
Abstract
Impact of COVID-19 on referrals to outpatient palliative care for patients with advanced cancer in a safety-net health system.Org: UT Southwestern Medical Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX,
Abstract
Pain, palliation, and opioid use patterns: A nationwide analysis of neoplasm-related pain admissions and trends (2016-2020).Org: Jacobi Medical Center/North Central Bronx, Albert Einstein Medical Center, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Henry Ford Hospital, Rutgers NJMS,
Abstract
Prospective assessment of targeted symptom management on supportive care in cancer: An observational cohort study.Org: Sapienza - Università di Roma, Azienda Ospedaliera S. Maria S.C. Oncologia, Hospice Care Unit, USL1 Umbria, Associazione Tumori Toscana, Servizio di Cure Domiciliari Oncologiche,
Abstract
The impact of cannabidiol (CBD) on aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS).Org: University of Michigan Health Management Research Center,
Abstract
Patient-reported experiences with cannabidiol (CBD) after cancer diagnosis.Org: Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
The effect of energy from reiki treatments on sleep quality for patients with breast and prostate cancer on hormone therapy.Org: University of Rochester Medical School, University of Rochester Medical Center, James P. Wilmot Cancer Center - Pluta,
Abstract
The role of shared decision-making in cancer pain management: Insights from a systematic review.Org: Samaritan Medical Center, Department of Pharmacy Practice,
Abstract
Body and mind and self-consciousness awareness workshops: Improving quality of life in patients with cancer.Org: Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Tel Aviv-Yafo, Israel, Sourasky Medical Center, Tel Aviv, Israel, Division of Oncology, Rambam health care, Haifa, Israel,
Abstract
Feasibility of hydromorphone PCA 10-day simple mode home management of patients in severe pain: A prospective multicenter study.Org: The Sixth People's Hospital of Luoyang, Xinxiang First People's Hospital, Henan Honliv Hospital, Anyang District Hospital, Puyang People's Hospital,
Abstract
Pilot study of early integration of interventional pain management for patients with chronic cancer pain.Org: Dana-Farber Cancer Institute, Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
Improving access to palliative care to mitigate multi-dimensional breast cancer suffering.Org: Harvard University Division of Medical Sciences, Purdue University, Tec de Monterrey,
Abstract
Trends in palliative care utilization among patients with ovarian cancer in the United States.Org: Rutgers Robert Wood Johnson Medical School Department of Obstetrics and Gynecology, Rutgers School of Public Health, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Rutgers University,
Abstract
Utilization of palliative care for geriatric veterans with newly diagnosed stage 3 and 4 pancreatic cancer.Org: University of Miami Miller SOM Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, Miami VAHS Geriatric Research Education and Clinical Center (GRECC),
Abstract
Quality of life in patients with malignant wounds treated at a wound care clinic.Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC,
Abstract
Investigating the prevalence and correlates of anxiety and depression among patients with COVID-19 with and without concomitant tumor conditions.Org: Fujian Medical University Union Hospital, Fuzhou, China,
Abstract
A qualitative analysis on the awareness of surrogacy as an alternative parenting option for people diagnosed with cancer.Org: Warren Alpert Medical School of Brown University, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Rhode Island Hospital,
Abstract
Orthorexia nervosa in breast cancer survivors: The role of disease characteristics and psychological aspects (GOIRC 02-2019).Org: Modena University Hospital, Department of Biomedical, Metabolic and Neural Sciences, School of Specialization in Psychiatry,
Abstract
Can narrative medicine methods improve well-being in patients with gastrointestinal malignancy?Org: Keck-USC,
Abstract
A qualitative analysis of religious coping and participation in patients with head and neck cancer.Org: Durham Veteran Affairs Medical Center, Duke Office of Durham and Community Affairs, Stanford Otolaryngology,
Abstract
Prescription drug, healthcare utilization, and lost earnings cost of behavioral interventions for fear of cancer recurrence in breast cancer survivors.Org: The University of Texas Health Science Center at Houston School of Public Health,
Abstract
Assessment of chemotherapy-induced nausea and vomiting in adult patients with hematopoietic stem-cell transplant at a tertiary care hospital.Org: Clinical Pharmacy Department, King Fahad Medical City, Riyadh, Saudi Arabia, Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, Madinah, Saudi Arabia, Research Center, King Fahad Medical City, Riyadh, Saudi Arabia,
Abstract
Association of childhood trauma with choice of bilateral mastectomy for the treatment of unilateral breast cancer.Org: PGSP-Stanford PsyD Consortium, Palo Alto University, Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Department of Psychiatry & Behavioral Sciences,
Abstract
Phase I study of copaiba aqueous mouthwash in patients with head and neck cancer undergoing radiotherapy.Org: Instituto Nacional de Câncer, Rio De Janeiro, Brazil, Instituto Nacional de Cancer, Rio De Janeiro, Brazil,
Abstract
Natural supplementation to effectively combat cancer-related fatigue: Evidence from a meta-analysis on the use of guarana.Org: Centro Universitário FMABC, FMABC,
Abstract
A single-center retrospective review of the impact of cryotherapy on peripheral neuropathy scores in patients with breast cancer who received chemotherapy with a taxane-based treatment regimen.Org: LSU Health Sciences Center,
Abstract
Innovative infusion center assessments of chemotherapy-induced neurotoxicities: A pilot study supporting early and routine screenings as part of survivorship programs.Org: University of South Florida Morsani College of Medicine, USF Health Morsani College of Medicine, Tampa General Hospital,
Abstract
Establishing palliative care in tribal and rural Indian setting: A participatory action research approach.Org: All India Insititute of Medical Sciences, Department of Onco-Anaesthesia and Palliative Medicine, BRA-IRCH, All India Institute of Medical Sciences,
Abstract
Impact of immune checkpoint inhibitor-based combination therapy on palliative care utilization for patients with metastatic renal cell carcinoma.Org: Institute of Urologic Oncology,
Abstract
Acute pancreatitis secondary to tamoxifen-induced hypertriglyceridemia: A systematic review.Org: Brody School of Medicine at East Carolina University, East Carolina University Brody School of Medicine,
Abstract
Hyperammonemic encephalopathy: An unaccounted side effect of 5FU and capecitabine.Org: University of Toledo College of Medicine,
Abstract
Predictors of immediate and delayed cutaneous hypersensitivity reactions to paclitaxel.Org: Columbia University Department of Dermatology,
Abstract
Effect of lactobacillus rhamnosus DY801 on methionine metabolism and Th17 cells in the treatment of acute radiochemotherapy induced bowel injury.Org: Nanfang Hospital Southern Medical University,
Abstract
Real world data of safety of immune-checkpoint inhibitors in patient with cancer at tertiary care hospital in Saudi Arabia.Org: Clinical Pharmacy Department, King Fahad Medical City,
Abstract
Integrated analysis of single-cell data on role of NKG7high CD8+ Teff cells in driving immune-related adverse events.Org: Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, Liaoning, China,
Abstract
Retrospective evaluation of drug to drug interactions with paclitaxel use in military health.Org: Walter Reed National Medical Canter,
Abstract
Understanding discordance in systematic reviews for treating chemotherapy-induced peripheral neuropathy: A focused umbrella review.Org: The University of Texas Medical Branch at Galveston,
Abstract
Cardiotoxicity in patients with breast cancer after modern therapy.Org: Larner College of Medicine,
Abstract
DEFENDOR: Real-world evidence of primary prolonged G-CSF prophylaxis by empegfilgrastim for relative dose intensity compliance in patients with solid tumors—The final analysis.Org: Research Institute of Urology and Interventional Radiology named after N.A. Lopatkin - branch of the National Medical Research Center for Radiology Ministry of Health of Russia, Moscow, Russian Federation, BIHOR "Clinical Oncology Dispensary", Omsk, Russian Federation, Republic Clinical Oncology Dispensary of Chuvash Republic, Cheboksary, Russian Federation, BIH VR "Voronezh Regional Clinical Oncology Center", Voronezh, Russian Federation, State Autonomous Budgetary Healthcare Institution, Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan, Ufa, Russian Federation,
Abstract
Identifying objective risk factors of financial toxicity in patients with cancer.Org: University of Connecticut Internal Medicine Residency Program, University of Connecticut Internal Medicine Residency Programm,
Abstract
Positive baseline thyroid autoantibodies as a predictive biomarker for thyroid immune-related adverse events: A systematic review and meta-analysis.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, University of Missouri–Kansas City School of Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, John A. Burns School of Medicine, University of Hawaii Cancer Center,
Abstract
External validation of a bleeding risk assessment model developed with natural language processing and machine learning (PREDICT-AI study) in patients with anticoagulated cancer with venous thromboembolism in the TESEO international prospective registry.Org: Hospital Central de Asturias, Morales Meseguer University Hospital, Hospital Alvaro Cunqueiro, Hospital Universitario de A Coruña, Elche General Hospital,
Abstract
Screening for ocular toxicities of immunotherapy in a real-world population.Org: School of Medicine, Zhejiang University, Hangzhou, China, Department of Ophthalmology, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Cold prevention of alopecia during chemotherapy: Real clinical practice.Org: Novokuznetsk State Institute of Postgraduate Medical Education – branch of Russian Medical Academy of Continuous Professional Education,
Abstract
Increase in blood pressure in patients with metastatic kidney cancer treated with combination checkpoint inhibitor and vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.Org: University of Florida Department of Health Outcomes and Biomedical Informatics, University of Florida/UF Health Cancer Center,
Abstract
A randomized trial of topical cannabis balms for the treatment of aromatase inhibitor–associated musculoskeletal syndrome (AIMSS).Org: Vireo Health,
Abstract
Continuous glucose monitoring and rates of hyperglycemia during chemotherapy for early-stage breast cancer.Org: Division of Endocrinology, Diabetes, and Metabolism,
Abstract
A retrospective review of recurrent venous thromboembolism in patients with cancer with direct factor Xa inhibitors.Org: Subiaco,
Abstract
Immune-related gastritis: An orphan immune-related adverse event.Org: Institute of Oncology Angel H Roffo, Tel Aviv Sourasky Medical Center,
Abstract
Efficacy and safety of mecapegfilgrastim in preventing neutropenia during concurrent chemoradiotherapy.Org: The First Affiliated Hospital of Air Force Military Medical University, Affiliated Hospital of Yangzhou University, Taixing People's Hospital, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology,
Abstract
Impact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer.Org: Yale University School of Medicine, Yale University, Yale Center for Analytical Sciences, Yale School of Medicine,
Abstract
Romiplostim for chemotherapy induced thrombocytopenia in solid tumors: A meta-analysis.Org: Pennsylvania Hospital, Alvin and Lois Lapidus Cancer Institute/Sinai Hospital of Baltimore,
Abstract
The efficacy and safety of ruxolitinib as an add-on therapy to corticosteroids for patients with severe checkpoint inhibitor pneumonitis.Org: Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijng, China, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China,
Abstract
Quantifying the risk of hypocalcemia in individuals treated with cabozantinib.Org: Stony Brook University Hospital - Cancer Center,
Abstract
Beyond the “teachable moment”: Smoking cessation during cancer treatment remains challenging despite high motivation to quit.Org: James P. Wilmot Cancer Center - Pluta, University of Rochester Medical Center, Rochester, NY,
Abstract
The survival benefits and the risk of severe renal injury of immune checkpoint inhibitors in patients with cancer: The real-world evidence from the National Clinical Cohort Collaborative (N3C).Org: Department of Biostatistics and Health Data Science at Indiana University School of Medicine, Indianapolis, IN, Biostatistics, Indiana University School of Medicine, Indianapolis, IN, Palila Software LLC, Reno, NV, Indiana University School of Medicine, Indianapolis, IN, Indiana University, Indianapolis, IN,
Abstract
Assessing our adherence to bone protection standards in metastatic prostate cancer in the largest Irish center: Are we falling behind?Org: xx,
Abstract
Trilaciclib use for prevention of hematological adverse events in chemotherapy: A meta-analysis of real-world studies and clinical trials.Org: Corewell Health System - Beaumont University Hospital, William Beaumont University Hospital, M Abdur Rahim Medical College, JCCR,
Abstract
Effectiveness and toxicity of multidisciplinary treatment of head and neck cancer among people with HIV: Real-world evidence from a tertiary cancer center in Brazil.Org: Instituto do Câncer do Estado de São Paulo (ICESP), Universidade de São Paulo, São Paulo, Brazil, Instituto do Cancer do Estado de Sao Paulo ICESP, Universidade de Sao Paulo,
Abstract
Optimizing patient (pt) care through pt-focused resources to prevent and manage hand-foot skin reaction (HFSR).Org: Bayer, Whippany, NJ, NJ, Sao Paulo (Brazil), Brazil,
Abstract
Can vitamin D deficiency be considered a risk factor be considered a risk factor in luminal breast cancer?Org: Clinical Analysis Service, Hospital Infanta Elena,
Abstract
Recommendations for the assessment of glomerular filtration rate in patients with cancer: A position statement and systematic review on behalf of the American Society of Onco-Nephrology (ASON).Org: The University of Texas Health Sciences Center at Houston, Tufts Medical Center (Cancer Center),
Abstract
Safety and efficacy of PEG-rhG-CSF as primary prophylaxis against neutropenia induced by combination chemotherapy regimens involving oral chemotherapy agents in gastrointestinal cancer patients: A prospective, exploratory, non-randomized controlled study.Org: Graduate School of Shanxi Medical University, First Hospital of Shanxi Medical University, Luzhou District People's Hospital, Changzhi City,
Abstract
Immune checkpoint inhibitors (ICI): From cancer killers to electrolyte disruptors.Org: SUNY Upstate Medical University,
Abstract
Effect of probiotics on quality of life for patients with cancer undergoing immunotherapy.Org: Hospital Ángeles Puebla, Puebla, Mexico, Hospital Ángeles Puebla, Puebla, PU, Mexico,
Abstract
Immune-related adverse events associated with nivolumab: Analysis of the FAERS database in the United States.Org: Shaanxi Province,
Abstract
Disparities in the prevalence of febrile neutropenia in patients hospitalized with lung cancer: An observational study.Org: Wyckoff Heights Medical Center, Nuvance Health/Vassar Brothers Medical Center, Lake Erie College of Osteopathic Medicine, State University of New York, Upstate Medical University, University of Missouri-Columbia, School of Medicine,
Abstract
Association between immunotherapy and hypothyroidism in a Latin American population: An analytical study of cases and controls from 2019 to 2023.Org: Hospital Fundación Santa Fe de Bogotá, Hospital Universitario Fundación Santa Fe de Bogotá,
Abstract
Safety and efficacy of interleukin-6 blockade for immune-related adverse events: A systematic review and meta-analysis.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, University of Toronto,
Abstract
Preventing 5-fluorouracil-induced ischemic events in very high-risk cardiac patients: A retrospective cohort analysis (SQCCCRC protocol).Org: Oman,
Abstract
Metabolic changes due to dexamethasone premedication in patients with breast cancer.Org: ICESP,
Abstract
Preventive effect of naldemedine for opioid-induced constipation in patients with cancer starting opioids: A multicenter, double-blinded, randomized, placebo-controlled, phase 3 trial.Org: Department of Palliative and Supportive Care, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, University of Tsukuba Hospital, Tsukuba, Japan, International University of Health and Welfare Narita Hospital, Narita, Japan, Third Department of Internal Medicine, University of Toyama, Toyama, Toyama-ken, Japan, Department of Data Management, Japanese Organisation for Research and Treatment of Cancer (JORTC) Data Center, Tokyo, Japan,